<SEC-DOCUMENT>0001387131-19-005935.txt : 20190809
<SEC-HEADER>0001387131-19-005935.hdr.sgml : 20190809
<ACCEPTANCE-DATETIME>20190809150028
ACCESSION NUMBER:		0001387131-19-005935
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190809
DATE AS OF CHANGE:		20190809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		191012698

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_063019.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:txmd="http://therapeuticsmd.com/20190630" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>TherapeuticsMD, Inc. - 25743 - 2019</title></head>
<body>
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20190101to20190630"  id="Fdei_EntityCentralIndexKey_From2019-01-01to2019-03-31">0000025743</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20190101to20190630"  id="Fdei_AmendmentFlag_From2019-01-01to2019-03-31">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20190101to20190630"  id="Fdei_CurrentFiscalYearEndDate_From2019-01-01to2019-03-31">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20190101to20190630"  id="Fdei_DocumentFiscalPeriodFocus_From2019-01-01to2019-03-31">Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="C_20190101to20190630"  id="Fdei_DocumentFiscalYearFocus_From2019-01-01to2019-03-31">2019</ix:nonNumeric></ix:hidden>
<ix:references>
      <link:schemaRef xlink:type="simple" xlink:href="txmd-20190630.xsd"/>
      </ix:references><ix:resources><xbrli:context id="AsOf2017-12-31"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-31"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-31_us-gaap_CommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-05-01_us-gaap_SecuredDebtMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-05-01</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:KnightTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-3120181231_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_EquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="AsOf2019-04-24_us-gaap_SubsequentEventMember_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to2018063020180101to20180630_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk7Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630txmdPrescriptionVitaminsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_0_1"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_0_1_2"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_txmd_OutsideConsultant2Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_us-gaap_DirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_us-gaap_EmployeeStockOptionMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_usgaapSupplierConcentrationRiskMember_srtMajorCustomersAxis_txmdOnerMajorCustomersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:OnerMajorCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180401to20180630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180401to20180630txmdPrescriptionVitaminsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180401to20180630usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180401to20180630usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>
        <xbrli:context id="C_20180401to20180630usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>
	        <xbrli:context id="C_20190401to20190630_EmployeeStockOptionMember"><xbrli:entity>
		      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
		        <xbrli:startDate>2019-04-01</xbrli:startDate>
		        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>

        <xbrli:context id="C_20180401to20180630usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180401to20180630usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>
        <xbrli:context id="C_20180101to20180630_WarrantMember"><xbrli:entity>
	      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
	        <xbrli:startDate>2018-01-01</xbrli:startDate>
	        <xbrli:endDate>2018-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>

        <xbrli:context id="C_20180630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20180630_txmd_OutsideConsultant2Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181212to2018121320181212to20181213_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-12-12</xbrli:startDate>
        <xbrli:endDate>2018-12-13</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-01-01</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to2019063020190101to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to2019063020190101to20190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentTwoMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630txmdImvexxyTmMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyTmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630txmdPrescriptionVitaminsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_0_1"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierConcentrationRisk4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_0_1_2_3"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_srtProductOrServiceAxis_txmdBijuvaMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_srt_MinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_txmd_OutsideConsultant2Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_us-gaap_DirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_us-gaap_RestrictedStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_us-gaap_WarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByBenchmarkAxis_usgaap_SalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaap_CustomerConcentrationRiskMember_srtRangeAxis_srt_MinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk2Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskOneMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierConcentrationRiskOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskTwoMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierConcentrationRiskTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_usgaap_SupplierConcentrationRiskMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190101to20190630_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to20190630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to20190630txmdImvexxyTmMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyTmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to20190630txmdPrescriptionVitaminsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to20190630usgaapRestrictedStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>

        <xbrli:context id="C_20190401to20190630usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>


        <xbrli:context id="C_20190401to20190630_srtProductOrServiceAxis_txmdBijuvaMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context>
        <xbrli:context id="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190401to20190630_usgaapVariableRateAxis_usgaapBaseRateMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents16Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents16Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context>

        <xbrli:context id="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents10Member"><xbrli:entity>
	      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents10Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
	        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context>

        <xbrli:context id="C_2019063020190630_usgaapLongtermDebtTypeAxis_usgaapLineOfCreditMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_usgaapPlanNameAxis_txmdNonQualified2012StockIncentivePlanMember_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_2019063020190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentThreeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630txmdHormoneTherapyDrugCandidatePatentsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630txmdMultipleTrademarksForVitaminsSupplementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapFurnitureAndFixturesMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630usgaapSoftwareAndSoftwareDevelopmentCostsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_0_1"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_0_1_2"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmdDebtTrancheAxis_txmdTrancheOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_LongTermIncentiveCompensationPlan2009Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_NonQualified2012StockIncentivePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_OutsideConsultant2Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_Patents11Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents11Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_Patents1Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_Patents6Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_txmd_Patents9Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapCreditFacilityAxis_usgaapSecuredDebtMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFiveMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFourMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodOneMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodThreeMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents2Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents3Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents4Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents5Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents7Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents8Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents8Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapPlanNameAxis_txmdPlan2019Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche2Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:Tranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche3Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:Tranche3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_usgaapVariableRateAxis_usgaapBaseRateMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20190802"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-08-02</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-03-31"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-03-31_us-gaap_CommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-04-29to2018-05-01_us-gaap_SecuredDebtMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-04-29</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-07-29to2018-07-30_custom_CouncilLicenseAgreement1Member"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-07-29</xbrli:startDate>
        <xbrli:endDate>2018-07-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2018-08-04to2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:KnightTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-08-04</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentThreeMember_srt_MinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember_srt_MaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
</ix:resources></ix:header></div>

<div>

<div>

<div style="margin-top:12pt;margin-bottom:3pt;font-family:Times New Roman, Times, Serif;text-align:left">

<div style="font:1pt Times New Roman, Times, Serif;border-top:Black 4pt solid;border-bottom:Black 1pt solid;width:100%">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:14pt">

<div style="display:inline;font-weight:bold">UNITED STATES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:14pt">

<div style="display:inline;font-weight:bold">SECURITIES AND EXCHANGE COMMISSION</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:12pt">

<div style="display:inline;font-weight:bold">WASHINGTON, D.C. 20549</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:16pt">

<div style="display: inline; font-weight: bold; text-align: center">FORM <ix:nonNumeric id="Fxbrl_20190801154039407" name="dei:DocumentType" contextRef="C_20190101to20190630">10-Q</ix:nonNumeric></div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(Mark One)</div></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:0;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.5in;text-align:left;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190801162509962" name="dei:DocumentQuarterlyReport" contextRef="C_20190101to20190630" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:12pt">
        <div style="display:inline;font-weight:bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT</div></div></div>
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:12pt">
        <div style="display:inline;font-weight:bold">OF 1934</div></div></div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:0;margin-left:0.5in;text-indent:0in;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:0;margin-left:0.5in;text-indent:0in;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">For the quarterly period ended <ix:nonNumeric id="Fxbrl_20190801154344415" name="dei:DocumentPeriodEndDate" contextRef="C_20190101to20190630" format="ixt:datemonthdayyearen">June 30, 2019</ix:nonNumeric></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">or</div></div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:0;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.5in;text-align:left;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190801172622096" name="dei:DocumentTransitionReport" contextRef="C_20190101to20190630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:12pt">
        <div style="display:inline;font-weight:bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT</div></div></div>
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:12pt">
        <div style="display:inline;font-weight:bold">OF 1934</div></div></div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">For the transition period from________ to ___________</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Commission File No.

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline"><ix:nonNumeric id="Fxbrl_20190801154207811" name="dei:EntityFileNumber" contextRef="C_20190101to20190630">001-00100</ix:nonNumeric></div></div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:18pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline"><ix:nonNumeric id="Fxbrl_20190801154227247" name="dei:EntityRegistrantName" contextRef="C_20190101to20190630">THERAPEUTICSMD, INC.</ix:nonNumeric></div></div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(Exact Name of Registrant as Specified in Its Charter)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="width:22%;text-align:center;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:8%;text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold"><ix:nonNumeric id="Fxbrl_20190801154257252" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20190101to20190630" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></div></div></td>
    <td style="width:22%;text-align:center;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:18%;text-align:center;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold"><ix:nonNumeric id="Fxbrl_20190801154316019" name="dei:EntityTaxIdentificationNumber" contextRef="C_20190101to20190630">87-0233535</ix:nonNumeric></div></div></td>
    <td style="width:19%;text-align:center;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td colspan="3" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(State or Other Jurisdiction of Incorporation or Organization)</div></td>
    <td colspan="3" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(I.R.S. Employer Identification No.)</div></td></tr></tbody>
</table>

<div style="margin:0;font-family:Times New Roman, Times, Serif">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;width:60%;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold"><ix:nonNumeric id="Fxbrl_20190801154409917" name="dei:EntityAddressAddressLine1" contextRef="C_20190101to20190630">6800 Broken Sound Parkway NW</ix:nonNumeric>,<ix:nonNumeric id="Fxbrl_20190801154425351" name="dei:EntityAddressAddressLine2" contextRef="C_20190101to20190630">Third Floor</ix:nonNumeric>&#160;,<ix:nonNumeric id="Fxbrl_20190801154439559" name="dei:EntityAddressCityOrTown" contextRef="C_20190101to20190630">Boca Raton</ix:nonNumeric>&#160;,<ix:nonNumeric id="Fxbrl_20190801154504285" name="dei:EntityAddressStateOrProvince" contextRef="C_20190101to20190630">FL</ix:nonNumeric></div></div></td>
    <td style="text-align:center;width:18%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;border-bottom:Black 1pt solid;width:4%;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold"><ix:nonNumeric id="Fxbrl_20190801154553567" name="dei:EntityAddressPostalZipCode" contextRef="C_20190101to20190630" format="ixt:numdotdecimal">33487</ix:nonNumeric></div></div></td>
    <td style="text-align:center;width:18%;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(Address of Principal Executive Offices)</div></td>
    <td colspan="3" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(Zip Code)</div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:1.5in">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonNumeric id="Fxbrl_20190801154612345" name="dei:CityAreaCode" contextRef="C_20190101to20190630">561</ix:nonNumeric>&#8212;<ix:nonNumeric id="Fxbrl_20190801154628961" name="dei:LocalPhoneNumber" contextRef="C_20190101to20190630">961-1900</ix:nonNumeric></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(Registrant&#8217;s telephone number, including area code)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">N/A</div></div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Securities registered pursuant to Section 12(b) of the Act:</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
        <tbody>
<tr style="font-family:Times New Roman, Times, Serif">
    <td style="width:40%;border-top:Black 1pt solid;border-bottom:Black 1pt solid;border-left:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Title of Each Class</div></td>
    <td style="width:15%;border:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">Trading Symbol</div></div></td>
    <td style="width:45%;border-top:Black 1pt solid;border-right:Black 1pt solid;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">Name of Each Exchange on Which Registered</div></div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="border-bottom:Black 1pt solid;border-left:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonNumeric id="Fxbrl_20190801154655095" name="dei:Security12bTitle" contextRef="C_20190101to20190630">Common Stock, par value $0.001 per share</ix:nonNumeric></div></td>
    <td style="border-bottom:Black 1pt solid;border-left:Black 1pt solid;text-align:center;border-right:Black 1pt solid;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190801154711447" name="dei:TradingSymbol" contextRef="C_20190101to20190630">TXMD</ix:nonNumeric></td>
    <td style="border-bottom:Black 1pt solid;text-align:center;border-right:Black 1pt solid;font-family:Times New Roman, Times, Serif">The <ix:nonNumeric id="Fxbrl_20190801154731063" name="dei:SecurityExchangeName" contextRef="C_20190101to20190630" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric>&#160;Stock
    Market LLC</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.<ix:nonNumeric id="Fxbrl_20190808000421567" name="dei:EntityCurrentReportingStatus" contextRef="C_20190101to20190630">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No &#9744;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).<ix:nonNumeric id="Fxbrl_20190808000456320" name="dei:EntityInteractiveDataCurrent" contextRef="C_20190101to20190630">Yes</ix:nonNumeric>&#160; &#9746;&#160;No &#9744;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act (Check one):</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font:10pt Times New Roman, Times, Serif;width:80%;margin:auto">
        <tbody>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="width:30%;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font:10pt Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190808000617327" name="dei:EntityFilerCategory" contextRef="C_20190101to20190630" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric>&#160;&#9746;</div></td>
    <td style="width:20%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:30%;font-family:Times New Roman, Times, Serif">Accelerated filer &#9744;</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font:10pt Times New Roman, Times, Serif">Non-accelerated filer &#9744;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">Smaller reporting company<ix:nonNumeric id="Fxbrl_20190801155144509" name="dei:EntitySmallBusiness" contextRef="C_20190101to20190630" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font:10pt Times New Roman, Times, Serif">Emerging growth company<ix:nonNumeric id="Fxbrl_20190801155209319" name="dei:EntityEmergingGrowthCompany" contextRef="C_20190101to20190630" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:5in">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No&#160;<ix:nonNumeric id="Fxbrl_20190801155844967" name="dei:EntityShellCompany" contextRef="C_20190101to20190630" format="ixt:booleanfalse">&#9746;</ix:nonNumeric></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The number of shares outstanding of the
registrant&#8217;s common stock, par value $0.001 per share, as of August 2, 2019 was <ix:nonFraction id="Fxbrl_20190801155021947" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20190802" unitRef="Shares" scale="3" decimals="-3" format="ixt:numdotdecimal">241,221,840</ix:nonFraction>&#160;.</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-weight:bold">&#160;</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:3pt;font-family:Times New Roman, Times, Serif;text-align:left">

<div style="font:1pt Times New Roman, Times, Serif;border-top:Black 1pt solid;border-bottom:Black 4pt solid;width:100%">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-weight:bold">&#160;</div></div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">&#160;</div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div></div>

<div style="margin:0;font-family:Times New Roman, Times, Serif">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">INDEX</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;width:10%;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;width:82%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;width:8%;border-bottom:Black 1pt solid;font:10pt Times New Roman, Times, Serif;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">Page</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="2" style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#part1" style="-sec-extract:exhibit">PART I - FINANCIAL INFORMATION</a></div></div></td>
    <td style="white-space:nowrap;text-align:center;font-family:Times New Roman, Times, Serif">3</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#item1" style="-sec-extract:exhibit">Item. 1</a></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#item1" style="-sec-extract:exhibit">Financial Statements</a></div></td>
    <td style="white-space:nowrap;text-align:center;font-family:Times New Roman, Times, Serif">3</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#txmd10qa001" style="-sec-extract:exhibit">Consolidated Balance Sheets as of June 30, 2019 (Unaudited) and December 31, 2018</a></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">3</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#txmd10qa002" style="-sec-extract:exhibit">Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2019 (Unaudited) and 2018 (Unaudited)</a></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">4</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#txmd10qa003" style="-sec-extract:exhibit">Consolidated Statements of Stockholders&#8217; Equity for the Three and Six Months Ended June 30, 2019 (Unaudited) and 2018 (Unaudited)</a></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">5</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#txmd10qa004" style="-sec-extract:exhibit">Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2019 (Unaudited) and 2018 (Unaudited)</a></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">6</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif"><a href="#txmd10qa005" style="-sec-extract:exhibit">Notes to Unaudited Consolidated Financial Statements</a></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">7</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;vertical-align:top;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa006" style="-sec-extract:exhibit">Item 2.</a></div></div></td>
    <td style="vertical-align:bottom;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa006" style="-sec-extract:exhibit">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div></td>
    <td style="white-space:nowrap;vertical-align:bottom;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">28</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa007" style="-sec-extract:exhibit">Item 3.</a></div></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa007" style="-sec-extract:exhibit">Quantitative and Qualitative Disclosures about Market Risk</a></div></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">43</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa008" style="-sec-extract:exhibit">Item 4.</a></div></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa008" style="-sec-extract:exhibit">Controls and Procedures</a></div></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">43</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="2" style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa009" style="-sec-extract:exhibit">Part II - OTHER INFORMATION</a></div></div></td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa010" style="-sec-extract:exhibit">Item 1.</a></div></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa010" style="-sec-extract:exhibit">Legal Proceedings</a></div></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">44</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa011" style="-sec-extract:exhibit">Item 1A.</a></div></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa011" style="-sec-extract:exhibit">Risk Factors</a></div></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">44</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa012" style="-sec-extract:exhibit">Item 6.</a></div></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold"><a href="#txmd10qa012" style="-sec-extract:exhibit">Exhibits</a></div></div></td>
    <td style="white-space:nowrap;text-align:center;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">45</div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>&#160;

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">2</div></div>&#160;

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div><a id="part1"></a> <a id="item1"></a>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:100%;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="2" style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">PART I - FINANCIAL INFORMATION</div></div></td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;width:10%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;width:82%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;width:8%;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Item. 1</div></div></td>
    <td style="white-space:nowrap;font:10pt Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Financial Statements</div></div></td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="white-space:nowrap;padding-left:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="white-space:nowrap;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold"><a id="txmd10qa001"></a>CONSOLIDATED BALANCE SHEETS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align:center;font-family:Times New Roman, Times, Serif">(Unaudited)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="8" style="text-align:center;font-family:Times New Roman, Times, Serif">ASSETS</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Current Assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:68%;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Cash</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:13%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F486" name="us-gaap:Cash" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">182,846,301</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:13%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F490" name="us-gaap:Cash" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">161,613,077</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Accounts receivable, net of allowance for doubtful accounts&#160;of $<ix:nonFraction id="Fxbrl_20190801160142324" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">764,102</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190801160154492" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">596,602</ix:nonFraction>&#160;, respectively</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F496" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">18,383,012</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F500" name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">11,063,821</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Inventory</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F506" name="us-gaap:InventoryNet" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,494,440</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F510" name="us-gaap:InventoryNet" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,267,670</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Other current assets</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F516" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,739,048</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F520" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">10,834,693</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total current assets</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F526" name="us-gaap:AssetsCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">216,462,801</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F530" name="us-gaap:AssetsCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">186,779,261</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Fixed assets, net</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F546" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,432,137</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F550" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">472,683</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Other Assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 9pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">License rights</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F576" name="txmd:LicenseRights" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F580" name="txmd:LicenseRights" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Intangible assets, net</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804111216876" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,688,114</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F590" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,092,679</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Other assets</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F596" name="us-gaap:OtherAssets" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,635,227</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F600" name="us-gaap:OtherAssets" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">324,855</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Security deposit</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F606" name="us-gaap:DepositsAssetsNoncurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">334,866</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font:bold 9pt Times New Roman, Times, Serif;padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F610" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">314,446</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total other assets</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F616" name="us-gaap:AssetsNoncurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">28,658,207</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F620" name="us-gaap:AssetsNoncurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">24,731,980</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Total assets</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F626" name="us-gaap:Assets" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">246,553,145</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F630" name="us-gaap:Assets" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">211,983,924</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td colspan="8" style="text-align:center;font-family:Times New Roman, Times, Serif">&#160;LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Current Liabilities:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Accounts payable</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F659" name="us-gaap:AccountsPayableCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">19,499,238</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F663" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">22,743,841</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Other current liabilities</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F669" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">22,376,617</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F673" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">18,334,948</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total current liabilities</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F679" name="us-gaap:LiabilitiesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">41,875,855</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F683" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">41,078,789</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Long-Term Liabilities:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Long-term debt</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F709" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">194,095,220</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F713" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">73,381,014</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Operating lease liability</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F719" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,488,101</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total liabilities</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F729" name="us-gaap:Liabilities" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">238,459,176</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F733" name="us-gaap:Liabilities" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">114,459,803</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Commitments and Contingencies- See Note 15</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Stockholders&#8217; Equity:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Preferred stock - par value $<ix:nonFraction id="Fxbrl_201908011602580120" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2018-12-31" unitRef="USDPShares" scale="0" decimals="3"><ix:nonFraction id="Fxbrl_20190801160258012" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_20190630" unitRef="USDPShares" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction>&#160;;<ix:nonFraction id="Fxbrl_201908011603370650" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2018-12-31" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190801160337065" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; no shares issued and outstanding</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801180633653" name="us-gaap:PreferredStockValue" contextRef="C_20190630" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801180647605" name="us-gaap:PreferredStockValue" contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true"></ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Common stock - par value $<ix:nonFraction id="Fxbrl_201908011604407860" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF"><ix:nonFraction id="Fxbrl_20190801160440786" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20190630" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction></ix:nonFraction>&#160;;<ix:nonFraction id="Fxbrl_201908011605137050" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2018-12-31" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190801160513705" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">350,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_201908011606050430" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190801160605043" name="us-gaap:CommonStockSharesIssued" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">241,221,840</ix:nonFraction></ix:nonFraction>and<ix:nonFraction id="Fxbrl_201908011607024580" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190801160702458" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2018-12-31" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">240,462,439</ix:nonFraction></ix:nonFraction>&#160;issued and outstanding, respectively</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801160744089" name="us-gaap:CommonStockValue" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">241,222</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801160754449" name="us-gaap:CommonStockValue" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">240,463</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Additional paid-in capital</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F809" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">621,871,919</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F813" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">616,559,938</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Accumulated deficit</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F819" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">614,019,172</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F823" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">519,276,280</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total stockholders&#8217; equity</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F829" name="us-gaap:StockholdersEquity" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">8,093,969</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F833" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">97,524,121</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Total liabilities and stockholders&#8217; equity</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F839" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">246,553,145</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F843" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">211,983,924</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">The accompanying footnotes are an integral part of these consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">3</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold"><a id="txmd10qa002"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">(Unaudited)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three Months Ended</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30 ,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30 ,</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:40%;text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Revenues, net</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F938" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,078,865</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F942" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,763,010</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F946" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">10,025,516</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F950" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,536,402</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Cost of goods sold</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F974" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,248,860</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F978" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">454,161</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F982" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,011,687</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F986" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,087,784</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Gross profit</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1010" name="us-gaap:GrossProfit" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,830,005</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1014" name="us-gaap:GrossProfit" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,308,849</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1018" name="us-gaap:GrossProfit" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">8,013,829</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1022" name="us-gaap:GrossProfit" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,448,618</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Operating expenses:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Sales, general, and administrative</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1064" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">41,387,451</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1068" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">29,466,770</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1072" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">76,251,533</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1076" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">50,224,007</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Research and development</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1082" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,964,368</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1086" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,798,380</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1090" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">11,282,250</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1094" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">13,837,677</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Depreciation and amortization</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1100" name="us-gaap:DepreciationAndAmortization" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">115,059</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1104" name="us-gaap:DepreciationAndAmortization" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">65,603</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1108" name="us-gaap:DepreciationAndAmortization" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">221,997</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1112" name="us-gaap:DepreciationAndAmortization" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">125,224</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total operating expenses</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1118" name="us-gaap:OperatingExpenses" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">46,466,878</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1122" name="us-gaap:OperatingExpenses" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">36,330,753</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1126" name="us-gaap:OperatingExpenses" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">87,755,780</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1130" name="us-gaap:OperatingExpenses" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">64,186,908</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Operating loss</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1154" name="us-gaap:OperatingIncomeLoss" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">41,636,873</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1158" name="us-gaap:OperatingIncomeLoss" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">33,021,904</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1162" name="us-gaap:OperatingIncomeLoss" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">79,741,951</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1166" name="us-gaap:OperatingIncomeLoss" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">57,738,290</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Other (expense) income</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Loss on extinguishment of debt</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801160938478" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">10,057,632</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161417958" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">10,057,632</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Miscellaneous income</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1226" name="us-gaap:OtherNonoperatingIncome" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">486,597</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1230" name="us-gaap:OtherNonoperatingIncome" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">334,238</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1234" name="us-gaap:OtherNonoperatingIncome" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,175,318</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1238" name="us-gaap:OtherNonoperatingIncome" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">648,795</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Interest expense</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1244" name="us-gaap:InterestExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,028,609</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161549851" name="us-gaap:InterestExpense" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">531,382</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1252" name="us-gaap:InterestExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,118,627</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161609705" name="us-gaap:InterestExpense" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">531,382</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Total other (expense) income</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1262" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">13,599,644</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1266" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">197,144</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1270" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">15,000,941</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1274" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">117,413</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Loss before income taxes</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1298" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">55,236,517</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1302" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">33,219,048</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1306" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">94,742,892</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1310" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">57,620,877</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Provision for income taxes</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2.5pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1370" name="us-gaap:NetIncomeLoss" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">55,236,517</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1374" name="us-gaap:NetIncomeLoss" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">33,219,048</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1378" name="us-gaap:NetIncomeLoss" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">94,742,892</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1382" name="us-gaap:NetIncomeLoss" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">57,620,877</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Loss per share, basic and diluted:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2.5pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Net loss per share, basic and diluted</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161446762" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_20190401to20190630" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-">0.23</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161456274" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_20180401to20180630" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-">0.15</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161506216" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_20190101to20190630" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-">0.39</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2.5pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2.5pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2.5pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161526286" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_20180101to20180630" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal" sign="-">0.27</ix:nonFraction></td>
    <td style="padding-bottom:2.5pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Weighted average number of common shares outstanding, basic and diluted</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1478" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_20190401to20190630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">241,221,840</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1482" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_20180401to20180630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">216,640,186</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1486" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_20190101to20190630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">241,114,532</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1490" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_20180101to20180630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">216,583,067</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">The accompanying footnotes are an integral part of these consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">4</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold"><a id="txmd10qa003"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Additional</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Common Stock</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Paid in</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Shares</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Capital</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Deficit</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Total</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:25%;font-weight:bold;font-family:Times New Roman, Times, Serif">Balance, December 31, 2017</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1622" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">216,429,642</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1626" name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">216,430</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1630" name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">516,351,405</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1634" name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">386,659,120</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1638" name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">129,908,715</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Shares issued for exercise of options, net</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1644" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">154,632</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1648" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">154</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1652" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">43,902</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808232157473" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-01to2018-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">44,056</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808225858347" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,751,358</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808225752717" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-01to2018-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,751,358</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1700" name="us-gaap:NetIncomeLoss" contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">24,401,829</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1704" name="us-gaap:NetIncomeLoss" contextRef="From2018-01-01to2018-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">24,401,829</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">Balance, March 31, 2018</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1732" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">216,584,274</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1736" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">216,584</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1740" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">518,146,665</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1744" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">411,060,949</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1748" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">107,302,300</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Shares issued for exercise of options, net</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1776" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20180401to20180630usgaapCommonStockMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">249,785</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1780" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20180401to20180630usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">250</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1784" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20180401to20180630usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,084,689</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1792" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,084,939</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1806" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20180401to20180630usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,377,082</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1814" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,377,082</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1832" name="us-gaap:NetIncomeLoss" contextRef="C_20180401to20180630usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">33,219,048</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1836" name="us-gaap:NetIncomeLoss" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">33,219,048</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;padding-bottom:2pt;font-family:Times New Roman, Times, Serif">Balance, June 30, 2018</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1864" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">216,834,059</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1868" name="us-gaap:StockholdersEquity" contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">216,834</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1872" name="us-gaap:StockholdersEquity" contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">521,608,436</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F1876" name="us-gaap:StockholdersEquity" contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">444,279,997</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F1880" name="us-gaap:StockholdersEquity" contextRef="C_20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">77,545,273</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">Balance, December 31, 2018</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163539302" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">240,462,439</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163822002" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">240,463</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163851129" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">616,559,938</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164011931" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">519,276,280</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164029485" name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">97,524,121</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Shares issued for exercise of options and warrants, net</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801165118177" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">759,401</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801165149019" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">759</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801165219477" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">99,348</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801165244147" name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-01to2019-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">100,107</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164851065" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,575,369</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164913277" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,575,369</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164549687" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">39,506,375</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164617937" name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">39,506,375</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">Balance, March 31, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163717618" name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">241,221,840</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164123338" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">241,222</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164215295" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">619,234,655</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164255203" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">558,782,655</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164326605" name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">60,693,222</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164958800" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,637,264</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801165012723" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,637,264</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164715597" name="us-gaap:NetIncomeLoss" contextRef="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">55,236,517</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164733240" name="us-gaap:NetIncomeLoss" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">55,236,517</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;padding-bottom:2pt;font-family:Times New Roman, Times, Serif">Balance, June 30, 2019</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163753847" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20190630usgaapCommonStockMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">241,221,840</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164141732" name="us-gaap:StockholdersEquity" contextRef="C_20190630usgaapCommonStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">241,222</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164351020" name="us-gaap:StockholdersEquity" contextRef="C_20190630usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">621,871,919</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801164411546" name="us-gaap:StockholdersEquity" contextRef="C_20190630usgaapRetainedEarningsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">614,019,172</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801164441008" name="us-gaap:StockholdersEquity" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">8,093,969</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">The accompanying footnotes are an integral part of these consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">5</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold"><a id="txmd10qa004"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">(Unaudited)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30 ,</div></td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:70%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801161859370" name="us-gaap:NetIncomeLoss" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">94,742,892</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190809000639608" name="us-gaap:NetIncomeLoss" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">57,620,877</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Depreciation of fixed assets</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2217" name="us-gaap:Depreciation" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">133,049</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2221" name="us-gaap:Depreciation" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">79,201</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Amortization of intangible assets</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2227" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">88,948</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2231" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">46,023</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Write off of patent and trademark cost</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163351469" name="us-gaap:OtherNoncashExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">78,864</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Non-cash operating lease expense</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2247" name="txmd:NoncashOperatingLeaseExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">443,734</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Provision for doubtful accounts</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2257" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">167,500</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2261" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">38,024</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Loss on extinguishment of debt</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162552686" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">10,057,632</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2277" name="us-gaap:ShareBasedCompensation" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,224,212</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2281" name="us-gaap:ShareBasedCompensation" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,128,440</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Amortization of deferred financing fees</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162001756" name="us-gaap:AmortizationOfFinancingCosts" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">316,880</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162013848" name="us-gaap:AmortizationOfFinancingCosts" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">30,155</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.5in;font-family:Times New Roman, Times, Serif">Changes in operating assets and liabilities:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.625in;font-family:Times New Roman, Times, Serif">Accounts receivable</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2307" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,486,691</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2311" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,335,209</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.625in;font-family:Times New Roman, Times, Serif">Inventory</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2317" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,226,770</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2321" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">395,219</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.625in;font-family:Times New Roman, Times, Serif">Other current assets</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2327" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">1,710,697</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2331" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">2,539,394</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.625in;font-family:Times New Roman, Times, Serif">Accounts payable</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2337" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">3,244,603</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2341" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,329,560</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.625in;font-family:Times New Roman, Times, Serif">Accrued expenses and other liabilities</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162118384" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,801,717</ix:nonFraction></td>
    <td style="text-align:left;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162130810" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">561,615</ix:nonFraction></td>
    <td style="text-align:left;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Net cash used in operating activities</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2367" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">88,677,723</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2371" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">44,598,893</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Patent costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2397" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">763,247</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2401" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">434,677</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Purchase of fixed assets</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2407" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,092,504</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2411" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">45,720</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Payment of security deposit</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801162311377" name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">20,420</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2421" name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">11,486</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Net cash used in investing activities</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2437" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">1,876,171</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F2441" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">491,883</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-weight:bold;text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Proceeds from exercise of options and warrants</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163205366" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">100,107</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162728552" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,128,996</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Repayment of the Credit Agreement</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801162858927" name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">81,660,719</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Proceeds from the Financing Agreement</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162939771" name="us-gaap:ProceedsFromOtherDebt" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801162949944" name="us-gaap:ProceedsFromOtherDebt" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">Payment of deferred financing fees</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801163043487" name="us-gaap:PaymentsOfFinancingCosts" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">6,652,270</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190801163056042" name="us-gaap:PaymentsOfFinancingCosts" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">3,786,918</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-weight:bold;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Net cash provided by financing activities</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2517" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">111,787,118</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2521" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">72,342,078</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Increase in cash</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163238216" name="us-gaap:CashPeriodIncreaseDecrease" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">21,233,224</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801163252494" name="us-gaap:CashPeriodIncreaseDecrease" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">27,251,302</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Cash, beginning of period</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2547" name="us-gaap:Cash" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">161,613,077</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2551" name="us-gaap:Cash" contextRef="AsOf2017-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">127,135,628</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Cash, end of period</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2557" name="us-gaap:Cash" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">182,846,301</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2561" name="us-gaap:Cash" contextRef="C_20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">154,386,930</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td colspan="8" style="text-align:center;font-family:Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Cash paid for interest</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190801161933980" name="us-gaap:InterestPaidNet" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,989,570</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Cash paid for income taxes</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin-top:0;text-align:center;margin-bottom:0;font-family:Times New Roman, Times, Serif">&#160;</div>

<div style="margin-top:0;text-align:center;margin-bottom:0;font-family:Times New Roman, Times, Serif">

<div style="font-family:Times New Roman,Times,serif;display:inline">

<div style="font-size:10px;display:inline">The accompanying footnotes are an integral part of these consolidated financial statements.</div></div></div>

<div style="margin-top:0;text-align:center;margin-bottom:0;font-family:Times New Roman, Times, Serif">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">6</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="margin:0;font-family:Times New Roman, Times, Serif">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold"><a id="txmd10qa005"></a>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190709101414998" name="us-gaap:NatureOfOperations" contextRef="C_20190101to20190630" escape="true" continuedAt="Fxbrl_20190709101414998_1">

<div style="display: inline; text-decoration: underline; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; THE COMPANY</b></span></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">TherapeuticsMD, Inc., a Nevada
corporation, or TherapeuticsMD or the Company, has <ix:nonFraction id="Fxbrl_20190802171029422" name="txmd:NumberOfSubsidiares" contextRef="C_20190630" unitRef="Pure" scale="0" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction>&#160;wholly
owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada
corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context
otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#8220;our
company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Nature of Business</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We are a women&#8217;s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#8217;s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD<sup>&#174;</sup> and BocaGreenMD<sup>&#174;</sup> brands.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">With our SYMBODA&#8482; technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During 2018 , U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our FDA-approved product, IMVEXXY&#174; (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched BIJUVA&#174;, our hormone therapy combination of bio-identical 17 &#223;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. We are also focused on commercialization activities necessary for launch of ANNOVERA&#8482; (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In addition, on July 30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. On June 6, 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">7</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="Fxbrl_20190709101414998_1"></ix:continuation><ix:nonNumeric id="F599c2581-9c46-11e9-a255-0d2e847c7ff2" name="txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c2581-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Interim Financial Statements</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period in the future.</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Recently Issued Accounting Pronouncements</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating the effect of this guidance on our disclosures.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In June 2018, the FASB issued ASU 2018 -07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In February 2016, the FASB issued ASU 2016 -02 , Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018 -11 , Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016 -02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018 -11 and we recorded a $<ix:nonFraction id="Fxbrl_20190801165600395" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20190101" unitRef="USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction> million right of use asset and a $<ix:nonFraction id="Fxbrl_20190801165629829" name="us-gaap:OperatingLeaseLiability" contextRef="C_20190101" unitRef="USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.1</ix:nonFraction> million liability related to adoption of this standard. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess ( 1 ) whether existing or expired contracts contain leases, ( 2 ) lease classification for any existing or expired leases, and ( 3 ) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">8</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c2581-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</div></ix:continuation><ix:nonNumeric id="F599c2582-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c2582-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190801165719609" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Fair Value of Financial Instruments</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820,

<div style="display:inline;font-style:italic">Fair Value Measurements.</div>&#160;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 1</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 2</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 3</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#8217;s impairment test on an annual basis.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190801165757102" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display: inline; text-decoration:underline"> Trade Accounts Receivable and Allowance for Doubtful Accounts<br /><br />Trade accounts receivable are customer obligations due
under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an
allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and
existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.<div>&#160;</div></div></div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">9</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div> <ix:continuation id="F599c2582-9c46-11e9-a255-0d2e847c7ff2_1" continuedAt="F599c2582-9c46-11e9-a255-0d2e847c7ff2_2">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190801165842808" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="Fxbrl_20190801165842808_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Revenue Recognition</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#8220;completed&#8221; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Prescription Products</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on&#160;consignment,&#160;revenue&#160;is generally recognized when the prescription is filled.&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</div></ix:nonNumeric> </ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">10</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c2582-9c46-11e9-a255-0d2e847c7ff2_2" continuedAt="F599c2582-9c46-11e9-a255-0d2e847c7ff2_3"> <ix:continuation id="Fxbrl_20190801165842808_1" continuedAt="Fxbrl_20190801165842808_2">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of<ix:nonNumeric id="Fxbrl_20190808010302031" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts" contextRef="C_20190101to20190630_srt_MinimumMember" format="ixt-sec:durwordsen">
six&#160;months</ix:nonNumeric>&#160;prior to and up to <ix:nonNumeric id="Fxbrl_20190807122414745" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts" contextRef="C_20190101to20190630_srtRangeAxis_srtMaximumMember" format="ixt-sec:durmonth">12</ix:nonNumeric>&#160;months
following product expiration. Our prescription products currently have a shelf life of <ix:nonNumeric id="Fxbrl_20190807122517919" name="txmd:ShelfLifeOfPrescriptionProducts" contextRef="C_20190101to20190630" format="ixt-sec:durmonth">24</ix:nonNumeric>&#160;months
from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use
history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for
which the right of return exists but for which we currently do not have history of product returns, we estimate returns based
on available industry data, our own sales information and our visibility into the inventory remaining in the distribution
channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information
from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current
liabilities on the consolidated balance sheet.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.</div></ix:continuation> </ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">11</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c2582-9c46-11e9-a255-0d2e847c7ff2_3" continuedAt="F599c2582-9c46-11e9-a255-0d2e847c7ff2_4"> <ix:continuation id="Fxbrl_20190801165842808_2">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible&#160;enrolled patients do not pay more than $<ix:nonFraction id="Fxbrl_20190807122651310" name="txmd:EnrolledPatients" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">35</ix:nonFraction>&#160;for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Disaggregation of revenue</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190801170017507" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Three Months</div></div>
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Ended June 30,</div></div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Six Months<br />Ended June 30</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif">Prescription vitamins</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2840" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190401to20190630txmdPrescriptionVitaminsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,822,872</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2844" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20180401to20180630txmdPrescriptionVitaminsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,763,010</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2848" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190101to20190630txmdPrescriptionVitaminsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,758,844</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2852" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20180101to20180630txmdPrescriptionVitaminsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,536,402</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">IMVEXXY</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2858" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190401to20190630txmdImvexxyTmMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,121,711</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2866" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190101to20190630txmdImvexxyTmMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,132,390</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">BIJUVA</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808142038661" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190401to20190630_srtProductOrServiceAxis_txmdBijuvaMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">134,282</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808142112181" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190101to20190630_srtProductOrServiceAxis_txmdBijuvaMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">134,282</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Net revenue</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2894" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,078,865</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2898" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,763,010</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2902" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">10,025,516</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F2906" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,536,402</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div></ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190801165906669" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20190101to20190630" escape="true" continuedAt="Fxbrl_20190801165906669_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Share-Based Compensation</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur.</div></ix:nonNumeric> </ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">12</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div> <ix:continuation id="F599c2582-9c46-11e9-a255-0d2e847c7ff2_4" continuedAt="F599c2582-9c46-11e9-a255-0d2e847c7ff2_5"> <ix:continuation id="Fxbrl_20190801165906669_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190801165929160" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Research and Development Expenses</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Research and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;D expenses include professional research and advice regarding R&amp;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div><ix:nonNumeric id="Fxbrl_20190801165950011" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Segment Reporting</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">13</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c2582-9c46-11e9-a255-0d2e847c7ff2_5"></ix:continuation><ix:nonNumeric id="F599c2583-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:InventoryDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">
<div style="display:inline;font-weight:bold">
<div style="display:inline;text-decoration:underline">NOTE 4 &#8211; INVENTORY</div>
</div>
</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<ix:nonNumeric id="Fxbrl_20190801170052657" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="C_20190101to20190630" escape="true">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Inventory consists of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
	<tbody>
		<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">June 30,<br />
			2019</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">December 31,<br />
			2018</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
			<td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Finished product</td>
			<td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F2975" name="us-gaap:InventoryFinishedGoods" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,382,969</ix:nonFraction>
			</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F2979" name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,908,958</ix:nonFraction>
			</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;font-family:Times New Roman, Times, Serif">Work in process</td>
			<td style="font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F2985" name="us-gaap:InventoryWorkInProcess" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">439,993</ix:nonFraction>
			</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F2989" name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">339,312</ix:nonFraction>
			</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Raw material</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F2995" name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,671,478</ix:nonFraction>
			</td>
			<td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F2999" name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">19,400</ix:nonFraction>
			</td>
			<td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
			<td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL INVENTORY</td>
			<td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F3005" name="us-gaap:InventoryNet" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,494,440</ix:nonFraction>
			</td>
			<td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">
			<ix:nonFraction id="F3009" name="us-gaap:InventoryNet" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,267,670</ix:nonFraction>
			</td>
			<td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
	</tbody>

</table>
</ix:nonNumeric>
</ix:nonNumeric>
<ix:nonNumeric id="F599c2584-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:OtherCurrentAssetsTextBlock" contextRef="C_20190101to20190630" escape="true"><div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 5 &#8211; OTHER CURRENT ASSETS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190801170126948" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Other current assets consist of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br />2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br />2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Prepaid sales and marketing costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3041" name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,568,100</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3045" name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,148,789</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Deferred financing fees (Note 9)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802171741106" name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">550,757</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802171758580" name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,898,074</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Prepaid insurance</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3061" name="us-gaap:PrepaidInsurance" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">686,891</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3065" name="us-gaap:PrepaidInsurance" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">790,465</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Other prepaid costs</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3071" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,933,300</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3075" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,997,365</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3081" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">7,739,048</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3085" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">10,834,693</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table></ix:nonNumeric></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">&#160;</div></div></div><ix:nonNumeric id="Fxbrl_20190801170203300" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 6 &#8211; FIXED ASSETS, NET</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190801170246097" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Fixed assets, net consist of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br />2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br />2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Accounting system</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3117" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20190630usgaapSoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">301,096</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802171912175" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301,096</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Equipment</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3127" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20190630usgaapEquipmentMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">581,150</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3131" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_EquipmentMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">490,576</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Furniture and fixtures</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3137" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20190630usgaapFurnitureAndFixturesMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">940,963</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3141" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">116,542</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Computer hardware</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3147" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20190630usgaapComputerEquipmentMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">220,820</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3151" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">80,211</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Leasehold improvements</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3157" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20190630usgaapLeaseholdImprovementsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">74,788</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3161" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">37,888</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802171944119" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,118,817</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802172038860" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,026,313</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Accumulated depreciation</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3177" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">686,680</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3181" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">553,630</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL FIXED ASSETS, NET</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3187" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,432,137</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3191" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">472,683</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Depreciation expense for the three months ended June 30, 2019 and 2018 was $<ix:nonFraction id="Fxbrl_20190801170328497" name="us-gaap:Depreciation" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">66,556</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190801170341018" name="us-gaap:Depreciation" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">40,777</ix:nonFraction>&#160;, respectively, and for the six months ended June 30, 2019 and 2018 was $<ix:nonFraction id="Fxbrl_20190801170355146" name="us-gaap:Depreciation" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">133,049</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190801170409094" name="us-gaap:Depreciation" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">79,201</ix:nonFraction>&#160;, respectively.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">14</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div><ix:nonNumeric id="F599c4c91-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 7 &#8211; INTANGIBLE ASSETS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190804141249795" name="txmd:ScheduleOfIntangibleAssetsTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>&#160; &#160; &#160; &#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Gross Carrying Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Net<br />Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted-Average<br />Remaining Amortization Period (yrs.)</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3274" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,962,563</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3278" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">370,338</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3282" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,592,225</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190802123211924" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="C_20190101to20190630_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt-sec:duryear">13.5</ix:nonNumeric></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3292" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_20190630txmdHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,833,584</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3300" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_20190630txmdHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,833,584</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Multiple trademarks</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3329" name="us-gaap:IndefiniteLivedTrademarks" contextRef="C_20190630txmdMultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">262,305</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3337" name="us-gaap:IndefiniteLivedTrademarks" contextRef="C_20190630txmdMultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">262,305</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">indefinite</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802121900481" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,058,452</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190802121951031" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">370,338</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802121916123" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,688,114</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">&#160;</div>&#160;&#160; &#160; &#160; &#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Gross Carrying Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Net<br />Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted-Average<br />Remaining Amortization Period (yrs.)</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3426" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">31,951</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3430" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">10,484</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3434" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">21,467</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#160;<ix:nonNumeric id="Fxbrl_20190807105637186" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="From2018-01-01to2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt-sec:duryear">10.75</ix:nonNumeric></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Development costs of corporate website</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3444" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">91,743</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3448" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">91,743</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3463" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,234,129</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3467" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">282,485</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3471" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,951,644</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190807105737177" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="From2018-01-01to2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear">14</ix:nonNumeric></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3481" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,855,279</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3489" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,855,279</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Multiple trademarks</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3518" name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">264,289</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3526" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">264,289</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">indefinite</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802122754480" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,477,391</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190802122828042" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">384,712</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802122809838" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,092,679</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately<ix:nonNumeric id="Fxbrl_20190802123459138" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_20190101to20190630_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear">20</ix:nonNumeric>&#160;years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30, 2019, we wrote off $<ix:nonFraction id="Fxbrl_20190807192021078" name="txmd:IntangibleWrittenOfff" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">78,864</ix:nonFraction>&#160;in costs related to trademarks and patents, including the net carrying amount of the OPERA patent.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">15</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_1" continuedAt="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_2">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we had&#160;<ix:nonFraction id="Fxbrl_20190717154044672" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents5Member" unitRef="Pure" decimals="INF" format="ixt:numdotdecimal">26</ix:nonFraction>&#160;issued domestic, or U.S., patents and&#160;<ix:nonFraction id="Fxbrl_20190717154636576" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents3Member" unitRef="Pure" decimals="INF" format="ixt:numdotdecimal">27</ix:nonFraction>&#160;issued foreign patents, including:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190802124143640" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_txmd_Patents1Member" unitRef="Pure" decimals="INF" format="ixt:numdotdecimal">12 </ix:nonFraction>domestic patents and&#160;<ix:nonFraction id="Fxbrl_20190802124306426" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_txmd_Patents6Member" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction>&#160;foreign patents that relate to BIJUVA as well as three domestic patents that relate to non-approved doses of BIJUVA. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804123843106" name="txmd:NumberOfIssuedPatents" contextRef="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents10Member" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">Four </ix:nonFraction>foreign
    patents that relate to our progesterone-only candidate, which are owned by us. The foreign patents will expire no earlier
    than 2033. In addition, we have pending patent applications with respect to our progesterone-only candidate in the U.S.,
    Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804124145396" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents4Member" unitRef="Pure" scale="0" decimals="0" format="ixt-sec:numwordsen">Five</ix:nonFraction>&#160;
    domestic patents (three utility and two design) and <ix:nonFraction id="Fxbrl_20190804124254828" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents7Member" unitRef="Pure" decimals="INF" format="ixt:numdotdecimal">13</ix:nonFraction>&#160;foreign
    patents (three utility and ten design) that relate to IMVEXXY. These patents establish an important intellectual property
    foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents
    will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain
    jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent
    applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New
    Zealand, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804124529586" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_txmd_Patents11Member" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">One </ix:nonFraction>domestic
    utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035.
    We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil,
    Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804124716143" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents2Member" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">One </ix:nonFraction>domestic utility patent and&#160;<ix:nonFraction id="Fxbrl_20190804124625652" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents8Member" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction>&#160;foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South Africa;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804130031224" name="txmd:NumberOfIssuedPatents" contextRef="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents16Member" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">One </ix:nonFraction>domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804125148646" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="Pure" decimals="INF" format="ixt-sec:numwordsen">One </ix:nonFraction>domestic
    utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031;
    and</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808002720029" name="txmd:NumberOfIssuedPatents" contextRef="C_20190630_txmd_Patents9Member" unitRef="Pure" scale="0" decimals="0" format="ixt-sec:numwordsen">Two</ix:nonFraction>&#160;domestic utilitypatents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:continuation>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">16</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div> <ix:continuation id="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_2" continuedAt="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_3">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Amortization expense was $<ix:nonFraction id="F3596_40444" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">48,503</ix:nonFraction>&#160;and $<ix:nonFraction id="F3596_21197" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">24,826</ix:nonFraction>&#160;for the three months ended June 30, 2019 and 2018, respectively and $<ix:nonFraction id="Fxbrl_20190808133831216" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">88,948</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190808133843387" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">46,023</ix:nonFraction>&#160;for the six months ended June 30, 2019 and 2018, respectively. Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190801170551044" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>&#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:25%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Year Ending December 31,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Estimated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2019(6 months)</div></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3647" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">96,008</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2020</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3655" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">196,017</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2021</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3663" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">196,017</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3671" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">196,017</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2023</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3679" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">196,017</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">License Agreement with the Population Council</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On July 30, 2018, we entered into the Council License Agreement to commercialize in the U.S. ANNOVERA. We currently estimate that ANNOVERA will be commercially available as early as the third quarter of 2019 with a planned full commercial launch by the first quarter of 2020.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Under the terms of the Council License
Agreement, we paid the Population Council a milestone payment of $<ix:nonFraction id="Fxbrl_20190804130506978" name="txmd:MilestonePaymentsUponFDAApproval" contextRef="C_20190630_0_1" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>&#160;within
30 days following approval by the FDA of the NDA for ANNOVERA and will be required to pay the Population Council
$<ix:nonFraction id="Fxbrl_20190804130557953" name="txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch" contextRef="C_20190630_0_1" unitRef="USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>&#160;within
30 days following the release of the first commercial batch of ANNOVERA. The Population Council is also eligible to receive
milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for marketing expenses
related to the commercialization of ANNOVERA. The milestone payment of $<ix:nonFraction id="Fxbrl_20190804130700619" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2018-07-29to2018-07-30_custom_CouncilLicenseAgreement1Member" unitRef="USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>&#160;upon
the FDA&#8217;s approval of ANNOVERA in the third quarter of 2018 was recorded as a finite-lived intangible asset in the
consolidated balance sheet and will be amortized on a straight-line basis once it becomes available for use which is expected
to be upon release of first commercial batch of ANNOVERA. In addition, we are required to pay the Population Council, on a
quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its
affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $<ix:nonFraction id="Fxbrl_20190804130903166" name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="C_20190101to20190630_0_1_2_3" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>&#160;,
a royalty of <ix:nonFraction id="Fxbrl_20190804135026954" name="txmd:RoyaltyPercent" contextRef="C_20190630_0_1_2" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction>&#160;%
of net sales; (ii) for annual net sales greater than $<ix:nonFraction id="Fxbrl_20190804131343634" name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="C_20190101to2019063020190101to20190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentTwoMember_srtRangeAxis_srtMinimumMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>&#160;and
less than or equal to $<ix:nonFraction id="Fxbrl_20190804131533195" name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember_srt_MaximumMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction>&#160;,
a royalty of <ix:nonFraction id="Fxbrl_20190804135436155" name="txmd:RoyaltyPercent" contextRef="AsOf2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction>&#160;%
of such net sales; and (iii) for net sales greater than $<ix:nonFraction id="Fxbrl_20190804142227168" name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentThreeMember_srt_MinimumMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction>&#160;,
a royalty of <ix:nonFraction id="Fxbrl_20190804135254055" name="txmd:RoyaltyPercent" contextRef="C_2019063020190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentThreeMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction>&#160;%
of such net sales. The annual royalty rate will be reduced to <ix:nonFraction id="Fxbrl_20190804142328368" name="txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction>&#160;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to <ix:nonFraction id="Fxbrl_20190804142405118" name="txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction>&#160;%
of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will be offset against
royalties or other payments owed by us to the Population Council under the Council License Agreement. We and the Population
Council have agreed to form a joint product committee responsible for overseeing activities under the Council License
Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system,
subject to oversight and decisions made by the joint product committee. The Council License Agreement includes exclusive
rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the
Population Council.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:continuation>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">17</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_3" continuedAt="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_4">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We assess our intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">License Agreement with Knight Therapeutics Inc.</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased<ix:nonFraction id="F3717_3921568" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-08-04to2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">3,921,568</ix:nonFraction>&#160;shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $<ix:nonFraction id="F3717_510" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">5.10</ix:nonFraction>&#160;, for proceeds of $<ix:nonFraction id="Fxbrl_20190804141542003" name="txmd:ProceedsFromIssuanceOfCommonStock1" contextRef="From2018-08-04to2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>&#160;, on August 6, 2018.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">License Agreement with Theramex</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On June 6, 2019, we entered into an
exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical
company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and
Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR<ix:nonFraction id="Fxbrl_20190806103115224" name="txmd:CashUpfrontPaymentDue" contextRef="C_20190630" unitRef="EUR" scale="6" decimals="-6" format="ixt:numdotdecimal">14</ix:nonFraction>&#160;million
in cash as an upfront fee on August 5, 2019. Within thirty days of signing License Agreement, we are required to provide
Theramex the regulatory materials and clinical data that are necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. The revenue related to fees received by us will
be recognized once our performance obligations have been satisfied. We are eligible to receive additional milestone payments
comprised of (i) up to an aggregate of EUR <ix:nonFraction id="Fxbrl_20190806103209638" name="txmd:RegulatoryMilestonePaymentDue" contextRef="C_20190630" unitRef="EUR" scale="6" decimals="-6" format="ixt:numdotdecimal">2</ix:nonFraction>&#160;million
in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii)
up to an aggregate of EUR <ix:nonFraction id="Fxbrl_20190806103247860" name="txmd:SalesMilestonePayments" contextRef="C_20190630" unitRef="EUR" scale="6" decimals="-5" format="ixt:numdotdecimal">27.5</ix:nonFraction>&#160;million
in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net
sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR <ix:nonFraction id="Fxbrl_20190806103601794" name="txmd:AnnualNetSalesMilestones" contextRef="C_2019063020190630_srtRangeAxis_srtMinimumMember" unitRef="EUR" scale="6" decimals="-6" format="ixt:numdotdecimal">25</ix:nonFraction>&#160;million
to EUR<ix:nonFraction id="Fxbrl_20190806103638864" name="txmd:AnnualNetSalesMilestones" contextRef="C_2019063020190630_srtRangeAxis_srtMaximumMember" unitRef="EUR" scale="6" decimals="-6" format="ixt:numdotdecimal">100</ix:nonFraction>&#160;million.
We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will
be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense
its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the
License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for
regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate
the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material
breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy
or other related matters.</div></ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">18</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c91-9c46-11e9-a255-0d2e847c7ff2_4"></ix:continuation><ix:nonNumeric id="Fxbrl_20190807231825954" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_20190101to20190630" escape="true">

<div>

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</div></div></div><br />&#160;</div><ix:nonNumeric id="Fxbrl_20190804122919023" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other current liabilities consist of the following:</div>&#160;

<table cellpadding="5" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;border:Black 1pt solid;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">June 30,<br />2019</div></div></td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">December 31,<br />2018</div></div></td>
    <td style="padding-bottom:1pt">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued payroll, bonuses and commission costs</div></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="width:12%;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804120835764" name="us-gaap:AccruedSalariesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,115,082</ix:nonFraction></div></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="width:12%;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804120758347" name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,854,002</ix:nonFraction></div></td>
    <td style="width:1%;text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Allowance for coupons and returns</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804120937701" name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,340,450</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804120951637" name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,294,120</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued sales and marketing costs</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121324224" name="us-gaap:AccruedMarketingCostsCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,107,696</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121342898" name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,288,028</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued compensated absences</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121423708" name="us-gaap:AccruedVacationCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,492,131</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121443614" name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,178,110</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Allowance for wholesale distributor fees</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121511313" name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,077,444</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121522690" name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">792,891</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued legal and accounting expense</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121550288" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">367,898</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121603320" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">385,824</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued research and development</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121632291" name="txmd:AccruedResearchAndDevelopment" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,402,600</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121647645" name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">388,675</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Operating lease liability</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121708681" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,187,029</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued rent</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121736431" name="us-gaap:AccruedRentCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">365,155</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued rebates</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121800231" name="txmd:AccruedRebates" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,251,047</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121811739" name="txmd:AccruedRebates" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">412,570</ix:nonFraction></div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other accrued expenses</div></td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121848974" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">35,240</ix:nonFraction></div></td>
    <td style="padding-bottom:1pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121915102" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">375,573</ix:nonFraction></div></td>
    <td style="padding-bottom:1pt;text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">TOTAL OTHER CURRENT LIABILITIES</div></td>
    <td style="padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="border-bottom:Black 2pt double;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121939658" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">22,376,617</ix:nonFraction></div></td>
    <td style="padding-bottom:2pt;text-align:left">&#160;</td>
    <td style="padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="border-bottom:Black 2pt double;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190804121953819" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">18,334,948</ix:nonFraction></div></td>
    <td style="padding-bottom:2pt;text-align:left">&#160;</td></tr></tbody>
</table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F599c4c93-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:LongTermDebtTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c4c93-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 9 &#8211; DEBT</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On April 24, 2019, we entered into a
Financing Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the
Administrative Agent, various lenders from time to time party thereto, and certain of the Company&#8217;s subsidiaries party
thereto from time to time as guarantors, which provides us with a $<ix:nonFraction id="Fxbrl_20190806115642913" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_SubsequentEventMember_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">300,000,000</ix:nonFraction>&#160;first
lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in <ix:nonFraction id="Fxbrl_20190806115858351" name="txmd:NumberOfTranchesUnderTermLoanFacility" contextRef="AsOf2019-04-24_us-gaap_SubsequentEventMember_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember" unitRef="Pure" scale="0" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction>&#160;tranches:
(i) $<ix:nonFraction id="Fxbrl_20190806120120260" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_20190630_usgaapCreditFacilityAxis_usgaapSecuredDebtMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction>&#160;was
drawn upon entering into the Financing Agreement; (ii) $<ix:nonFraction id="Fxbrl_20190806140245643" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche2Member" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>&#160;will
be available to us upon the designation of our ANNOVERA product as a new category of birth control by the FDA on or prior to
December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $<ix:nonFraction id="Fxbrl_20190806140552675" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche3Member" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>&#160;will
be available to us upon our achieving $<ix:nonFraction id="Fxbrl_20190806140846968" name="us-gaap:Revenues" contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">11,000,000</ix:nonFraction>&#160;in
net revenues, as defined in the Financing Agreement, from our IMVEXXY, BIJUVA and ANNOVERA products for the fourth quarter of
2019 and satisfaction (or waiver) of other customary conditions precedent. Borrowings under the Facility accrue interest at
either (i)<ix:nonNumeric id="Fxbrl_20190806141031245" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">3-month
LIBOR plus<ix:nonFraction id="Fxbrl_20190806141104317" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.75</ix:nonFraction>%</ix:nonNumeric>,
subject to a LIBOR floor of <ix:nonFraction id="Fxbrl_20190806141145183" name="txmd:LiborFloorRate" contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.70</ix:nonFraction>%
or (ii) <ix:nonNumeric id="Fxbrl_20190806141606218" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="C_20190401to20190630_usgaapVariableRateAxis_usgaapBaseRateMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">the
prime rate plus<ix:nonFraction id="Fxbrl_20190807100635497" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="C_20190401to20190630_usgaapVariableRateAxis_usgaapBaseRateMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">6.75</ix:nonFraction></ix:nonNumeric>%,
subject to a prime rate floor of <ix:nonFraction id="Fxbrl_20190806142027954" name="txmd:PrimeRateFloor" contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_usgaapVariableRateAxis_usgaapBaseRateMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.20</ix:nonFraction>%,
as selected by us. Interest on amounts borrowed under the Facility will be payable quarterly. The outstanding principal
amount of the Facility is payable in four equal quarterly installments beginning on June 30, 2023, with the Facility maturing
on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a
prepayment fee on the principal amount being prepaid of (i)<ix:nonFraction id="Fxbrl_20190806142335695" name="txmd:PrepaymentPercentOfDebt" contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodOneMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:numdotdecimal">30.0</ix:nonFraction>%
for the first two years following the initial funding date of the applicable borrowing, (ii)<ix:nonFraction id="Fxbrl_20190806143104358" name="txmd:PrepaymentPercentOfDebt" contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodThreeMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.0</ix:nonFraction>%
for the third year following the initial funding date of the applicable borrowing, (iii)<ix:nonFraction id="Fxbrl_20190806143139553" name="txmd:PrepaymentPercentOfDebt" contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFourMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction>%
for the fourth year following the initial funding date of the applicable borrowing and (iv)<ix:nonFraction id="Fxbrl_20190806143201185" name="txmd:PrepaymentPercentOfDebt" contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFiveMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction>%
for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection
with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to <ix:nonFraction id="Fxbrl_20190806142419034" name="txmd:FacilityFeePaidPercent" contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="Pure" scale="-2" decimals="3">2.5</ix:nonFraction>%
of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings
under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in
addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and
covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i)
maintain a minimum unrestricted cash balance of $<ix:nonFraction id="Fxbrl_20190806143431403" name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">50,000,000</ix:nonFraction>,
which will increase to $<ix:nonFraction id="Fxbrl_20190806143639301" name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_srtRangeAxis_srtMaximumMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">60,000,000</ix:nonFraction>&#160;if
we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts
attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending
December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default
that are customary for financings of this type, including an event of default relating to a change of control of the Company.
Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations
under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the
Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject
to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all
existing and after-acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be
guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">19</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c93-9c46-11e9-a255-0d2e847c7ff2_1" continuedAt="F599c4c93-9c46-11e9-a255-0d2e847c7ff2_2">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $<ix:nonFraction id="Fxbrl_20190806115307416" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in three separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) o<ix:nonNumeric id="Fxbrl_20190806115359973" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="From2018-04-29to2018-05-01_us-gaap_SecuredDebtMember">ne-month LIBOR (subject to a LIBOR floor of<ix:nonFraction id="Fxbrl_20190806115447900" name="txmd:LiborFloor" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.50</ix:nonFraction>%) plus (ii)<ix:nonFraction id="Fxbrl_20190806115537636" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2018-04-29to2018-05-01_us-gaap_SecuredDebtMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.75</ix:nonFraction>% per annum</ix:nonNumeric>.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On April 24, 2019, we terminated
the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of
approximately $<ix:nonFraction id="Fxbrl_20190806112625196" name="txmd:RepaymentOfDebtWithNewCreditFacility" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">81,661,000</ix:nonFraction>&#160;was
used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of <ix:nonFraction id="Fxbrl_20190806111434846" name="txmd:PrepaymentFee" contextRef="C_20190401to20190630" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction>%,
a repayment fee of <ix:nonFraction id="Fxbrl_20190806111503891" name="txmd:RepaymentFeePercent" contextRef="C_20190401to20190630" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction>%
and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the
Credit Agreement, we recorded $<ix:nonFraction id="Fxbrl_20190806111625974" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal" sign="-">10,057,632</ix:nonFraction>&#160;in
loss on extinguishment of debt in the accompanying unaudited consolidated financial statements. Interest on amounts
borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the six months ending June 30, 2019
related to the Credit Agreement was $<ix:nonFraction id="Fxbrl_20190806112448419" name="us-gaap:InterestExpenseBorrowings" contextRef="C_20190101to20190630_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,816,747</ix:nonFraction>.
During the six months ended June 30, 2019, and prior to the repayment of the Credit Agreement, we amortized $<ix:nonFraction id="Fxbrl_20190806112550757" name="txmd:AmortizationOfDeferredFinancingFees" contextRef="C_20190101to20190630_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">120,146</ix:nonFraction>&#160;of
deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we had
$<ix:nonFraction id="Fxbrl_20190806110409454" name="us-gaap:LongTermDebt" contextRef="C_2019063020190630_usgaapLongtermDebtTypeAxis_usgaapLineOfCreditMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction>&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying unaudited
consolidated financial statements. We incurred $<ix:nonFraction id="Fxbrl_20190806110653599" name="txmd:DeferredFinancingFees" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,652,270</ix:nonFraction>&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees
related to Tranche 1 of $<ix:nonFraction id="Fxbrl_20190806110801800" name="txmd:DeferredFinancingFees" contextRef="C_20190630_txmdDebtTrancheAxis_txmdTrancheOneMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,101,513</ix:nonFraction>&#160;have
been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred
financing fees associated with unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones have
been met. As of June 30, 2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in other current
assets in the accompanying consolidated financial statements. During both the three and six months ended June 30, 2019, we
amortized $<ix:nonFraction id="Fxbrl_201908061111580110" name="txmd:AmortizationOfDeferredFinancingFees" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190806111158011" name="txmd:AmortizationOfDeferredFinancingFees" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">196,734</ix:nonFraction></ix:nonFraction>&#160;of
deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated financial
statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest
expense for both the three and six months ending June 30, 2019 was $<ix:nonFraction id="Fxbrl_201908061112342360" name="us-gaap:InterestExpenseBorrowings" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190806111234236" name="us-gaap:InterestExpenseBorrowings" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,985,000</ix:nonFraction></ix:nonFraction>.
The overall effective interest rate under the Financing Agreement was approximately <ix:nonFraction id="Fxbrl_20190806111331861" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="C_20190630" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction>%
as of June 30, 2019. As of June 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190807102918456" name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br />2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br />2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Financing Agreement</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190805184215513" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_2019063020190630_usgaapLongtermDebtTypeAxis_usgaapLineOfCreditMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Credit Agreement</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190806112137771" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2018-12-3120181231_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">75,000,000</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Debt discount and financing fees</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3932" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">5,904,780</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F3936" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,618,986</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL LONG-TERM DEBT</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3942" name="us-gaap:LongTermDebtNoncurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">194,095,220</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3946" name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">73,381,014</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">&#160;</div></div></ix:continuation>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">20</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c93-9c46-11e9-a255-0d2e847c7ff2_2"></ix:continuation><ix:nonNumeric id="F599c4c94-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 10&#8211; NET LOSS PER SHARE</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been antidilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190801170918904" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three and Six months ended</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:justify;font-family:Times New Roman, Times, Serif">Stock options</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F39950" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F3995" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190401to20190630_EmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">22,072,469</ix:nonFraction></ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F3999" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20180401to20180630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F3999_1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">25,210,899</ix:nonFraction></ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Warrants</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F40050" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190101to20190630_us-gaap_WarrantMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F4005" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190401to20190630usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">1,832,571</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F40090" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20180101to20180630_WarrantMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F4009" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20180401to20180630usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">3,007,571</ix:nonFraction></ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Restricted stock awards</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F40150" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190101to20190630_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F4015" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190401to20190630usgaapRestrictedStockMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">1,040,000</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190804144547868" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190401to20190630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190804144547868_1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20190101to20190630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">24,945,040</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_201908041446067970" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20180101to20180630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190804144606797" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20180401to20180630" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">28,218,470</ix:nonFraction></ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F599c4c95-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Preferred Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019, we had <ix:nonFraction id="Fxbrl_20190805172810515" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction>&#160;shares
of preferred stock, par value $0.001 per share, authorized for issuance, of which no shares of preferred stock were issued or
outstanding.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Common Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019, we had <ix:nonFraction id="Fxbrl_20190805172836945" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">350,000,000</ix:nonFraction>&#160;shares
of Common Stock authorized for issuance, of which <ix:nonFraction id="Fxbrl_201908051729050280" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fxbrl_20190805172905028" name="us-gaap:CommonStockSharesIssued" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">241,221,840</ix:nonFraction></ix:nonFraction>&#160;shares
of Common Stock were issued and outstanding.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Issuances During the Three and Six Months Ended June 30, 2019</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the three months ended June 30,
2019, no options to purchase shares of Common Stock were exercised. During the six months ended June 30, 2019, certain
individuals exercised stock options to purchase <ix:nonFraction id="Fxbrl_20190805183759077" name="txmd:NumberOfStockOptionsExercised" contextRef="C_20190101to20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">276,383</ix:nonFraction>&#160;shares
of Common Stock for $<ix:nonFraction id="Fxbrl_20190805183838429" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">100,107</ix:nonFraction>&#160;in
cash. Also, during the same period, stock options to purchase <ix:nonFraction id="Fxbrl_20190805183945484" name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="C_20190101to20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">12,097</ix:nonFraction>&#160;shares
of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <ix:nonFraction id="Fxbrl_20190805184045995" name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="C_20190101to20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">11,834</ix:nonFraction>&#160;shares
of Common Stock were issued.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Issuances During the Three and Six Months Ended June 30, 2018</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the three months ended June
30, 2018, certain individuals exercised stock options to purchase <ix:nonFraction id="Fxbrl_20190805173113057" name="txmd:NumberOfStockOptionsExercised" contextRef="C_20180401to20180630usgaapEmployeeStockOptionMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">249,785</ix:nonFraction>&#160;shares
of Common Stock for $<ix:nonFraction id="Fxbrl_20190805173020037" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20180401to20180630usgaapEmployeeStockOptionMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,084,939</ix:nonFraction>&#160;in
cash. During the six months ended June 30, 2018, certain individuals exercised stock options to purchase <ix:nonFraction id="Fxbrl_20190805173204963" name="txmd:NumberOfStockOptionsExercised" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">394,576</ix:nonFraction>&#160;shares
of Common Stock for $<ix:nonFraction id="Fxbrl_20190805173243759" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,128,996</ix:nonFraction>&#160;in
cash. Also, during the six months ended June 30, 2018, stock options to purchase <ix:nonFraction id="Fxbrl_20190805173329995" name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="C_20180101to20180630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction>&#160;shares
of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <ix:nonFraction id="Fxbrl_20190805173356488" name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="C_20180101to20180630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">9,841</ix:nonFraction>&#160;shares
of Common Stock were issued.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">21</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div> <ix:continuation id="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_1" continuedAt="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_2">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Warrants to Purchase Common Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we had
warrants outstanding to purchase an aggregate of <ix:nonFraction id="Fxbrl_20190805173454706" name="us-gaap:WarrantsAndRightsOutstanding" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,832,571</ix:nonFraction>&#160;shares
of Common Stock with a weighted-average contractual remaining life of approximately <ix:nonNumeric id="Fxbrl_20190805173534925" name="txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife" contextRef="C_20190101to20190630" format="ixt-sec:duryear">2.5</ix:nonNumeric>&#160;years,
and exercise prices ranging from $<ix:nonFraction id="Fxbrl_20190805174114177" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMinimumMember" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">0.24</ix:nonFraction>&#160;to
$<ix:nonFraction id="Fxbrl_20190805174204806" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMaximumMember" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">8.20</ix:nonFraction>&#160;per
share, resulting in a weighted average exercise price of $<ix:nonFraction id="Fxbrl_20190808171425198" name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="C_20190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember" unitRef="Shares" scale="0" decimals="2" format="ixt:numdotdecimal">2.62</ix:nonFraction>&#160;per
share.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the six months ended June
30, 2019, we granted warrants to purchase<ix:nonFraction id="Fxbrl_20190805174457582" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction>&#160;shares
of Common Stock to outside consultants at an exercise price of $<ix:nonFraction id="Fxbrl_20190805174556143" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20190630_txmd_OutsideConsultant2Member" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">5.63</ix:nonFraction>&#160;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of <ix:nonNumeric id="Fxbrl_20190805175101963" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" format="ixt-sec:duryear">5</ix:nonNumeric>&#160;years;
volatility of <ix:nonFraction id="Fxbrl_20190805175130289" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" unitRef="Pure" scale="-2" decimals="3" format="ixt:numdotdecimal">60.8</ix:nonFraction>&#160;%;
risk free rate of <ix:nonFraction id="Fxbrl_20190805175244651" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.52</ix:nonFraction>&#160;%;
and dividend yield of <ix:nonFraction id="Fxbrl_20190805175314443" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" unitRef="Pure" scale="-2" decimals="2">0</ix:nonFraction>&#160;%.
The grant date fair value of the warrants was $<ix:nonFraction id="Fxbrl_20190805175853010" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">3.00</ix:nonFraction>&#160;per
share. The warrants are vesting ratably over a 12-month period and have an expiration date of February 12, 2024. During
the six months ended June 30, 2018, we granted warrants to purchase<ix:nonFraction id="Fxbrl_20190805175348840" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">175,000</ix:nonFraction>&#160;shares
of Common Stock to outside consultants at an exercise price of $<ix:nonFraction id="Fxbrl_20190805175543966" name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="C_20180630_txmd_OutsideConsultant2Member" unitRef="Shares" scale="0" decimals="2" format="ixt:numdotdecimal">5.16</ix:nonFraction>&#160;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of <ix:nonNumeric id="Fxbrl_20190805175613902" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" format="ixt-sec:duryear">5</ix:nonNumeric>&#160;years;
volatility of <ix:nonFraction id="Fxbrl_20190805175644631" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" unitRef="Pure" scale="-2" decimals="3" format="ixt:numdotdecimal">62.1</ix:nonFraction>&#160;%;
risk free rate of <ix:nonFraction id="Fxbrl_20190805175712301" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.36</ix:nonFraction>&#160;%;
and dividend yield of <ix:nonFraction id="Fxbrl_20190805175738498" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction>&#160;%.
The grant date fair value of the warrants was $<ix:nonFraction id="Fxbrl_20190805175835321" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">2.79</ix:nonFraction>&#160;per
share. The warrants vest ratably over a 12-month period and have an expiration date of March 15, 2023.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the three months ended June 30, 2019 and 2018, we recorded $<ix:nonFraction id="Fxbrl_20190805175950990" name="us-gaap:ShareBasedCompensation" contextRef="C_20190401to20190630usgaapWarrantMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">56,172</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805180002541" name="us-gaap:ShareBasedCompensation" contextRef="C_20180401to20180630usgaapWarrantMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">164,840</ix:nonFraction>&#160;, respectively, and during the six months ended June 30, 2019 and 2018, we recorded $<ix:nonFraction id="Fxbrl_20190805180015882" name="us-gaap:ShareBasedCompensation" contextRef="C_20190101to20190630_us-gaap_WarrantMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">141,888</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805180027631" name="us-gaap:ShareBasedCompensation" contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">256,315</ix:nonFraction>&#160;, respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants. As of June 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants was approximately $<ix:nonFraction id="Fxbrl_20190805180129948" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">139,000</ix:nonFraction>&#160;, which is expected to be recognized over a weighted-average period of<ix:nonNumeric id="Fxbrl_20190805180158269" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20190101to20190630_us-gaap_WarrantMember" format="ixt-sec:durmonth">0.6</ix:nonNumeric>&#160;years.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><br />During the three months ended June 30, 2019 and 2018, no warrants to purchase shares of Common Stock were exercised.<br />&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the six months ended June
30, 2019, warrants to purchase <ix:nonFraction id="Fxbrl_20190805180458308" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">1,250,000</ix:nonFraction>&#160;shares
of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <ix:nonFraction id="Fxbrl_20190805180631338" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_20190101to20190630_us-gaap_WarrantMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">471,184</ix:nonFraction>&#160;shares
of Common Stock were issued. During the six months ended June 30, 2018, no warrants were exercised.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Options to Purchase Common Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In 2009, we adopted the 2009 Long Term
Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and
consultants of our company who are able to contribute towards the creation of or who have created stockholder value by
providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan
consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or
as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or
on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable
exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of
June 30, 2019, there were non-qualified stock options to purchase <ix:nonFraction id="Fxbrl_20190805180744758" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20190630_txmd_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">15,116,995</ix:nonFraction>&#160;shares
of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive
Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan.</div></ix:continuation>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">22</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_2" continuedAt="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_3">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In 2012, we adopted the 2012
Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to
serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants
and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as
described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors,
upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they
have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The
expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were non-qualified
stock options to purchase <ix:nonFraction id="Fxbrl_20190805180835817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20190630_txmd_NonQualified2012StockIncentivePlanMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">6,317,974</ix:nonFraction>&#160;shares
of Common Stock outstanding and <ix:nonFraction id="Fxbrl_20190805181146886" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_2019063020190630_usgaapPlanNameAxis_txmdNonQualified2012StockIncentivePlanMember_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">1,040,000</ix:nonFraction>&#160;restricted
stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan on June 20, 2019, no future awards may be
made under the 2012 Plan.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were<ix:nonFraction id="Fxbrl_20190805181537818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">16,812,383</ix:nonFraction>&#160;shares of Common Stock authorized for issuance thereunder, consisting of (i)<ix:nonFraction id="Fxbrl_20190805181808633" name="txmd:PlanAwardsNumberOfNewShares" contextRef="C_20190630" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">14,362,500</ix:nonFraction>&#160;new shares, (ii)<ix:nonFraction id="Fxbrl_20190805182031607" name="txmd:PlanAwardsNumberOfNewSharesUnallocated" contextRef="C_20190630_txmd_NonQualified2012StockIncentivePlanMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">2,393,833</ix:nonFraction>&#160;unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii)<ix:nonFraction id="Fxbrl_20190805182049312" name="txmd:PlanAwardsNumberOfNewSharesUnallocated" contextRef="C_20190630_txmd_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">56,050</ix:nonFraction>&#160;unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of June 30, 2019, there were non-qualified stock options to purchase&#160;<ix:nonFraction id="Fxbrl_20190809044255788" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20190630_usgaapPlanNameAxis_txmdPlan2019Member" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">637,500</ix:nonFraction>&#160;shares of Common Stock outstanding under the 2019 Plan.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2019 and 2018 are set forth in the table below.</div><ix:nonNumeric id="Fxbrl_20190801171005263" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:70%;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">
        <div style="display:inline;font-weight:bold">Six months ended</div></div>
        <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">
        <div style="display:inline;font-weight:bold">June 30,</div></div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:38%;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">2019</div></div></td>
    <td style="width:2%;text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">2018</div></div></td></tr>
<tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Risk-free interest rate</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190805170942669" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.19</ix:nonFraction>&#8212;<ix:nonFraction id="Fxbrl_20190805171121781" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.54</ix:nonFraction>&#160;%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190805171011725" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.38</ix:nonFraction>&#8212;<ix:nonFraction id="Fxbrl_20190805171145883" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.63</ix:nonFraction>&#160;%</div></td></tr>
<tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Volatility</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190805171220687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">61.25</ix:nonFraction>&#8212;<ix:nonFraction id="Fxbrl_20190805171309803" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4">61.85</ix:nonFraction>&#160;%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190805171244247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">61.82</ix:nonFraction>&#8212;<ix:nonFraction id="Fxbrl_20190805171331971" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4">64.04</ix:nonFraction>&#160;%</div></td></tr>
<tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Term (in years)</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonNumeric id="Fxbrl_20190805171411048" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20190101to2019063020190101to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric>&#8212;<ix:nonNumeric id="Fxbrl_20190805171817089" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20190101to20190630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonNumeric id="Fxbrl_20190805171725791" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.1</ix:nonNumeric>&#8212;<ix:nonNumeric id="Fxbrl_20190805171856652" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20180101to20180630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></div></td></tr>
<tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Dividend yield</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190805171938465" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction>%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonFraction id="Fxbrl_20190805171957655" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4">0.00</ix:nonFraction>%</div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div></ix:continuation>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">23</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_3" continuedAt="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_4">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div><ix:nonNumeric id="Fxbrl_20190801171035546" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:95%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Number of Shares Underlying Stock Options</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted Average Exercise Price</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted<br />Average<br />Remaining<br />Contractual<br />Life in Years</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Aggregate Intrinsic Value</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:39%;font-family:Times New Roman, Times, Serif">Balance at December 31, 2018</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4205" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">20,872,824</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4209" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">4.93</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190805172411252" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.94</ix:nonNumeric></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">12,239,876</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Granted</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4223" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">1,544,500</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4227" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">4.40</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Exercised</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F4241" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">288,480</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4245" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">0.35</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4253" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,315,238</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Expired/Forfeited</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="F4259" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">56,375</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4263" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">5.77</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">Balance at June 30, 2019</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4277" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">22,072,469</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4281" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">4.95</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190805172435417" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.80</ix:nonNumeric></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190805172516555" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,945,665</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Vested and Exercisable at June 30, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4295" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">17,125,888</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4299" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">4.79</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190805172621306" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">4.94</ix:nonNumeric></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190805172545599" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,945,665</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Unvested at June 30, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4313" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:numdotdecimal">4,946,581</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4317" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" contextRef="C_20190630usgaapEmployeeStockOptionMember" unitRef="USDPShares" decimals="INF" format="ixt:numdotdecimal">5.48</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonNumeric id="Fxbrl_20190805172648875" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">8.79</ix:nonNumeric></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">0</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019, our outstanding stock options had exercise prices ranging from $<ix:nonFraction id="Fxbrl_20190805182252672" name="txmd:OptionExercisePrices" contextRef="C_2019063020190630_srtRangeAxis_srtMinimumMember" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">0.10</ix:nonFraction>&#160;to $<ix:nonFraction id="Fxbrl_20190805182324264" name="txmd:OptionExercisePrices" contextRef="C_2019063020190630_srtRangeAxis_srtMaximumMember" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">8.92</ix:nonFraction>&#160;per share. The weighted average grant date fair value per share of options granted was $<ix:nonFraction id="Fxbrl_20190805182404023" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20190101to20190630" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">2.57</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805182415728" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20180101to20180630" unitRef="USDPShares" scale="0" decimals="2" format="ixt:numdotdecimal">3.15</ix:nonFraction>&#160;during the six months ended June 30, 2019 and 2018, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended June 30, 2019 and 2018 ($<ix:nonFraction id="Fxbrl_20190805182448003" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,230,829</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805182504198" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,212,241</ix:nonFraction>&#160;, respectively) and for the six months ended June 30, 2019 and 2018 ($<ix:nonFraction id="Fxbrl_20190805182522661" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,374,069</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805182537393" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20180101to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,872,125</ix:nonFraction>&#160;, respectively) is based on vested awards. At June 30, 2019, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $<ix:nonFraction id="Fxbrl_20190805182616429" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">11,606,000</ix:nonFraction>&#160;which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of<ix:nonNumeric id="Fxbrl_20190805182641826" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">2.1</ix:nonNumeric>&#160;years. No tax benefit was realized due to a continued pattern of operating losses.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Restricted Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On December 13, 2018, we granted <ix:nonFraction id="Fxbrl_20190805183011909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20181212to2018121320181212to20181213_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">1,040,000</ix:nonFraction>&#160;restricted
stock units to certain executive employees which will vest at the end of the third year. The grant date fair value
was $<ix:nonFraction id="Fxbrl_20190805183106717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20181212to2018121320181212to20181213_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USDPShares" scale="0" decimals="2">4.06</ix:nonFraction>&#160;per
unit. During the three and six months ended June 30, 2019 we recorded $<ix:nonFraction id="Fxbrl_20190805183224034" name="us-gaap:ShareBasedCompensation" contextRef="C_20190401to20190630usgaapRestrictedStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">350,263</ix:nonFraction>&#160;and
$<ix:nonFraction id="Fxbrl_20190805183245314" name="us-gaap:ShareBasedCompensation" contextRef="C_20190101to20190630_us-gaap_RestrictedStockMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">696,676</ix:nonFraction>&#160;,
respectively, in share-based compensation expense related to restricted stock units. At June 30, 2019, total
unrecognized estimated compensation expense related to unvested restricted stock units was approximately $<ix:nonFraction id="Fxbrl_20190805183345174" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_2019063020190630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,453,000</ix:nonFraction>&#160;,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of <ix:nonNumeric id="Fxbrl_20190805183446370" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20190101to20190630_us-gaap_RestrictedStockMember" format="ixt-sec:duryear">2.5</ix:nonNumeric>&#160;years.
At June 30, 2019,<ix:nonFraction id="Fxbrl_20190805183618631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_2019063020190630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember" unitRef="Shares" scale="0" decimals="0" format="ixt:numdotdecimal">1,040,000</ix:nonFraction>&#160;restricted
stock awards remained outstanding.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Cash-Settled Stock Appreciation Rights (SARs)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:continuation>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">24</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c4c95-9c46-11e9-a255-0d2e847c7ff2_4">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Cash settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, &#8220;Stock Compensation,&#8221; the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded liability was reversed and no cash payment was made.</div></ix:continuation><ix:nonNumeric id="F599c73a0-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><div style="display:inline;font-weight:bold"><div style="display:inline;text-decoration:underline">NOTE 12 &#8211; INCOME TAXES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Deferred income tax assets and liabilities
are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay
any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the six months ended June 30,
2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior years.
Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than
not&#8221; that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2019, we maintain
a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has
been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</div>


</ix:nonNumeric><ix:nonNumeric id="F599c73a1-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">
<div style="display:inline;font-weight:bold">
<div style="display:inline;text-decoration:underline">NOTE 13 &#8211; RELATED PARTIES</div>
</div>
</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of our company since July 2015. During the three months ended June 30, 2019 and 2018, we were billed by Catalent approximately $
<ix:nonFraction id="Fxbrl_20190804145609173" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">974,000</ix:nonFraction>
and $

<ix:nonFraction id="Fxbrl_20190804145633765" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="C_20180401to20180630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,266,000</ix:nonFraction>
, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. During the six months ended June 30, 2019 and 2018, we were billed by Catalent approximately $

<ix:nonFraction id="Fxbrl_20190804145242309" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="C_20190101to20190630_us-gaap_DirectorMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,371,000</ix:nonFraction>
and $

<ix:nonFraction id="Fxbrl_20190804145214901" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="C_20180101to20180630_us-gaap_DirectorMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,040,000</ix:nonFraction>
, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of June 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $

<ix:nonFraction id="Fxbrl_20190804145545029" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">243,000</ix:nonFraction>
and $

<ix:nonFraction id="F4824_88000" name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2018-12-31" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">88,000</ix:nonFraction>
, respectively.</div>
</ix:nonNumeric>
<ix:nonNumeric id="F599c73a2-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:ConcentrationRiskDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c73a2-9c46-11e9-a255-0d2e847c7ff2_1"><div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We purchase our prescription products
from several suppliers with approximately&#160;<ix:nonFraction id="Fxbrl_20190807094026692" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_usgaap_SupplierConcentrationRiskMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">14</ix:nonFraction>%,<ix:nonFraction id="Fxbrl_20190717170009193" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskOneMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">18</ix:nonFraction>%,<ix:nonFraction id="Fxbrl_20190717170114041" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskTwoMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">31</ix:nonFraction>%
and<ix:nonFraction id="Fxbrl_20190717170311759" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20190101to20190630_0_1" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">37</ix:nonFraction>%
of our purchases were supplied by four vendors each, respectively, during the six months ended June 30, 2019 and
approximately <ix:nonFraction id="Fxbrl_20190717170533812" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_usgaapSupplierConcentrationRiskMember_srtMajorCustomersAxis_txmdOnerMajorCustomersMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction>%
of our purchases were supplied from one vendor for the six months ended June 30, 2018.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We sell our prescription prenatal
vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that
generally sell products to retail pharmacies, hospitals, and other institutional customers. During the six months ended June
30, 2019, three customers each generated more than <ix:nonFraction id="Fxbrl_20190806100553131" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20190101to20190630_usgaapConcentrationRiskByBenchmarkAxis_usgaap_SalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaap_CustomerConcentrationRiskMember_srtRangeAxis_srt_MinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction>%
of our total revenues. During the six months ended June 30, 2018, four customers each generated more than <ix:nonFraction id="Fxbrl_20190806100218357" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20180101to20180630_0_1_2" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction>%
of our total revenues. Revenue generated from the three customers combined accounted for approximately <ix:nonFraction id="Fxbrl_20190717170949802" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20190101to20190630" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction>%
of our recognized revenue for the six months ended June 30, 2019 and revenue generated from the four customers combined
accounted for approximately<ix:nonFraction id="Fxbrl_20190717171256915" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20180101to20180630" unitRef="Pure" scale="-2" decimals="2" format="ixt:numdotdecimal">71</ix:nonFraction>%
of our recognized revenue for the six months ended June 30, 2018.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the six months ended June 30, 2019, &#160; Pillpack, Inc. accounted for approximately $<ix:nonFraction id="Fxbrl_20190806103954046" name="us-gaap:Revenues" contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk2Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,615,000</ix:nonFraction>of our revenue, AmerisourceBergen accounted for approximately $<ix:nonFraction id="Fxbrl_20190806105704728" name="us-gaap:Revenues" contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,365,000</ix:nonFraction>of our revenue and Cardinal Health accounted for approximately $<ix:nonFraction id="Fxbrl_20190806110304552" name="us-gaap:Revenues" contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,048,000</ix:nonFraction>of our revenue. During the six months ended June 30, 2018, PI Services generated approximately $<ix:nonFraction id="F4842_557000" name="us-gaap:Revenues" contextRef="C_20180101to2018063020180101to20180630_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk7Member" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">981,000</ix:nonFraction>of our revenue, Pillpack, Inc. generated approximately $<ix:nonFraction id="F4842_905000" name="us-gaap:Revenues" contextRef="C_20180101to20180630_0_1" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,088,000</ix:nonFraction>of our revenue, AmerisourceBergen generated approximately $<ix:nonFraction id="Fxbrl_20190806104425339" name="us-gaap:Revenues" contextRef="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,283,000</ix:nonFraction>of our revenue and Cardinal Health generated approximately $<ix:nonFraction id="Fxbrl_20190806104817562" name="us-gaap:Revenues" contextRef="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">971,000</ix:nonFraction>of our &#160;revenue.</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">25</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c73a2-9c46-11e9-a255-0d2e847c7ff2_1"></ix:continuation><ix:nonNumeric id="F599c73a3-9c46-11e9-a255-0d2e847c7ff2" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20190101to20190630" escape="true" continuedAt="F599c73a3-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which lease on 7,561 square feet commenced in 2018 and the lease on the remaining 48,651 square feet will commence sometime in the third quarter of 2019, or the full premises commencement date. The lease will expire 11 years after full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In addition, we will be entitled to reimbursement from the landlord of up to $<ix:nonFraction id="Fxbrl_20190805170823573" name="txmd:ReimbursementFromLandlordTenantImprovements" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,800,000</ix:nonFraction>&#160;for tenant improvements. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">26</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:6pt">

<div style="margin:0pt">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC. AND SUBSIDIARIES</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">

<div style="display:inline;font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div> <ix:continuation id="F599c73a3-9c46-11e9-a255-0d2e847c7ff2_1">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div><ix:nonNumeric id="Fxbrl_20190801171136670" name="txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Supplemental lease information as of June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use asset (included in Other assets)</td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190808003742416" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,316,436</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Short-term operating lease liability (included in Other current liabilities)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4427" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,187,029</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Long-term operating lease liability</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4433" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">2,488,101</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Weighted average remaining term</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><ix:nonNumeric id="Fxbrl_20190807110051339" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20190630" format="ixt-sec:duryear">5</ix:nonNumeric>Years</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Weighted average discount rate</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="Fxbrl_20190805170615555" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20190630" unitRef="Pure" scale="-2" decimals="4">8.25</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Supplemental cash flow information<br />for the six months ended June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4465" name="us-gaap:OperatingLeasePayments" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">564,092</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4471" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,760,171</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><ix:nonNumeric id="Fxbrl_20190801171204026" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20190101to20190630" escape="true">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Years Ending December 31,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2019 (6 months)</div></td>
    <td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4492" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">595,649</ix:nonFraction></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2020</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4498" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,292,914</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2021</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4504" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,135,467</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4510" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">172,651</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2023</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4516" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">176,968</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Thereafter</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4523" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">1,228,504</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Total undiscounted lease payments</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4530" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">4,602,153</ix:nonFraction></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Less: imputed interest</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(<ix:nonFraction id="Fxbrl_20190808143103920" name="txmd:LesseeOperatingLeaseLiabilityImputedInterestAmount" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">927,023</ix:nonFraction></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Present value of lease payments</div></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"><ix:nonFraction id="F4544" name="us-gaap:OperatingLeaseLiability" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">3,675,130</ix:nonFraction></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div></ix:nonNumeric>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we estimated undiscounted fixed future minimum rental commitments of approximately $<ix:nonFraction id="Fxbrl_20190805170238375" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">13,300,000</ix:nonFraction>&#160;and estimated undiscounted variable future minimum rental commitments of approximately $<ix:nonFraction id="Fxbrl_20190805170320093" name="txmd:OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum" contextRef="C_20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">6,400,000</ix:nonFraction>&#160;over the term of the lease related to the operating lease for the new corporate office that we entered into in October 2018 and an additional suite that we entered into in 2019 that had not commenced yet, as disclosed above. During the three and six months ended June 30, 2019, operating lease expense related to our real estate leases was approximately $<ix:nonFraction id="Fxbrl_20190805170357464" name="us-gaap:OperatingLeaseExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">295,000</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805170408954" name="us-gaap:OperatingLeaseExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">590,000</ix:nonFraction>&#160;, respectively, and variable lease expense was insignificant for the three and six months ended June 30, 2019. Rent expense totaled $<ix:nonFraction id="Fxbrl_20190805170527436" name="us-gaap:LeaseAndRentalExpense" contextRef="C_20190401to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">257,000</ix:nonFraction>&#160;and $<ix:nonFraction id="Fxbrl_20190805170544832" name="us-gaap:LeaseAndRentalExpense" contextRef="C_20190101to20190630" unitRef="USD" scale="0" decimals="0" format="ixt:numdotdecimal">515,000</ix:nonFraction>&#160;during the three and six months ended June 30, 2018, respectively.</div></ix:continuation>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-weight:bold"><a id="txmd10qa006"></a>Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">General</div></div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, or the SEC, on February 27, 2019, or our Annual Report, including the audited financial statements and notes included therein. The reported results will not necessarily reflect future results of operations or financial condition.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">In addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;should,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions and are based on assumptions and assessments made in light of management&#8217;s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our Annual Report, and include the following: our ability to maintain or increase sales of our approved products; our ability to develop and commercialize IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;</sup>, ANNOVERA&#8482; and our hormone therapy drug candidates and obtain additional financing necessary therefor; our commercialization, marketing and manufacturing capabilities and strategy for our approved products; the size of markets and the potential market opportunity for which our products are approved and our ability to penetrate such markets; the rate and degree of market acceptance of our products; the willingness of healthcare providers to prescribe and patients to use our products; our ability to obtain additional financing when needed; our competitive position and the success of competing products that are or become available for the indications that we are pursuing; our intellectual property position; whether we will be able to comply with the covenants and conditions under our term loan agreement; the length, cost and uncertain results of our clinical trials, the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the ability of our licensees to commercialize and distribute IMVEXXY and BIJUVA; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Throughout this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;TherapeuticsMD,&#8221; or &#8220;our company&#8221; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">28</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as IMVEXXY&#174;, BIJUVA&#174;&#160;and ANNOVERA&#8482; which are protected under applicable intellectual property laws and are the property of our company. This Quarterly Report on Form 10-Q also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this quarterly report may appear without the &#174;, &#8482; or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">Overview</div></div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We are a women&#8217;s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#8217;s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD<sup>&#174;</sup> and BocaGreenMD<sup>&#174;</sup> brands.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">With our SYMBODA&#8482; technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our commercialization plan allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our FDA approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved product BIJUVA, our hormone therapy combination of bio-identical 17&#223;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved by the FDA on October 28, 2018. We are also focused on commercialization activities necessary for launch of ANNOVERA (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our common stock, par value $0.001 per share, or the Common Stock, is traded on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC, or the Nasdaq, under the symbol &#8220;TXMD.&#8221; We maintain websites at

<div style="display:inline;text-decoration:underline">www.therapeuticsmd.com</div>&#160;as well as various product websites. The information contained on our websites or that can be accessed through our websites does not constitute part of this Quarterly Report on Form 10-Q.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">IMVEXXY</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">On May 30, 2018, we announced that the FDA had approved the 4 &#956;g and 10 &#956;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#956;g formulation of IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">29</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">On July 9, 2018, we launched IMVEXXY 10-&#956;g with our early experience program to a targeted sample of healthcare providers, or HCPs, throughout the U.S. The national launch of the 10-&#956;g dose of IMVEXXY began in August 2018, and the 4-&#956;g dose of IMVEXXY launched on September 13, 2018. Since FDA approval of our NDA for IMVEXXY, we have been focused on executing our launch plan. The key objectives of our launch plan include: (i) providing broad commercial access at the retail level and with commercial payers, (ii) increasing awareness and appreciation of the clinical and patient features of IMVEXXY amongst HCPs, (iii) designing and deploying our customer facing model, and (iv) developing our internal capabilities (for example, in the areas of finance, human resources, medical affairs, information technology, data analytics, pharmacovigilance capacity and compliance) to support our commercial-stage company. We have made progress in each of these key strategic areas:</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Commercial Access:</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Both the 4-&#956;g and 10-&#956;g doses of IMVEXXY are broadly available in major pharmacy chains in the U.S., as well as with our BIO-IGNITE&#8482; partners, via our third-party logistics and our distribution partners.</div></td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We have aggressively sought commercial payer coverage as many commercial payers employ &#8220;new-to-market blocks&#8221; for newly launched brands until the payers make a coverage decision based upon their internal review the product. As we seek to increase the number of lives covered by commercial payers, it is our objective to continue to seek unrestricted coverage that involves affordable access for patients.</div></td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Through June 30, 2019, we achieved unrestricted coverage with seven of the top ten commercial payers of VVA products and we continue to sign new agreements with payers to cover IMVEXXY.&#160; In addition, as of June 30, 2019, two of the top six Medicare Part D payers of VVA products were adjudicating IMVEXXY.</div></td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Beginning at launch, we instituted a patient education and affordability program that allows all eligible enrolled patients to receive IMVEXXY at a reasonable cost. When a product is not covered, the patient is responsible to pay the full price for the medication, which can significantly limit a patient&#8217;s ability to pay and subsequent utilization of the product. With our co-pay assistance program, eligible enrolled patients do not pay more than $35 for a prescription of IMVEXXY.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Brand Awareness and Adoption:</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">In addition to our focus on direct selling from our sales organization, we have executed a branded multichannel awareness campaign for HCPs leveraging digital, non-personal promotion and journal advertising and have already reached most of the active writing HCPs within the VVA category with IMVEXXY branded messages. The focus of our interactions with HCPs included: (i) introducing IMVEXXY and highlighting the unmet medical need that IMVEXXY can fulfill for many women, (ii) increasing awareness of the clinical data and patient features of IMVEXXY, and (iii) familiarizing HCPs with our patient support services for IMVEXXY. Based on our early sales effectiveness research, more than 90% of HCPs that responded to our surveys indicated that they have prescribed or intend to prescribe IMVEXXY. As of June 30, 2019, more than 13,000 HCPs had sent an IMVEXXY prescription to a pharmacy for at least one patient.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Patient Affordability and Adherence Programs:</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We believe the patient affordability and adherence programs that we created and piloted around our prescription prenatal vitamin business have the potential to improve patient compliance for IMVEXXY, compared to other products in the VVA category. We launched our patient affordability and adherence program for IMVEXXY to help patients manage out-of-pocket costs (eligible enrolled patients pay no more than $35 per prescription) and improve education regarding VVA and IMVEXXY with the goal of increasing patient adherence and compliance for an improved treatment experience. As of June 30, 2019, 93% of our total IMVEXXY fills have utilized the patient savings programs. We plan to launch print and digital direct-to-consumer marketing for IMVEXXY in the second half of 2019. As of June 30, 2019, we had approximately 70,700 patients who have received at least one paid IMVEXXY prescription filled at a pharmacy.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">30</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Customer Model:</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As of June 30, 2019, we had a sales force targeting approximately 200 territories, covering approximately 35,000 HCPs, and deploying a hybrid sales model that combines an internal sales leadership team with a fully dedicated contract sales force to call on our customer universe. Additionally, we have an internal sales team that calls on HCP&#8217;s that fall outside of our targeted territories. We have also deployed our Key Account Managers (KAMs) to engage with our BIO-IGNITE&#8482; partners.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Infrastructure:</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We continue to develop our internal capabilities and sales force to support the launch of IMVEXXY. We have launched KAMs to support our BIO-IGNITE partners and continue to build our internal capabilities to support both organizations, including compliance professionals and programs and key data support systems that provide real-time data for the sales force and KAMs.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Regulatory:</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As part of the FDA&#8217;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to also participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this study is underway, and we do not believe that the costs will be material. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#8217;s specifications, which we submitted to FDA.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">BIJUVA</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">On October 28, 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms, or VMS (commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have the same chemical and molecular structure as the hormones that are naturally produced in a woman&#8217;s body.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We launched BIJUVA on April 17, 2019 with a similar model to IMVEXXY. The key objectives of our launch plan include: (i) broad commercial access at the retail level and with commercial payers, (ii) increasing awareness and appreciation of the clinical and patient features of BIJUVA amongst HCPs, (iii) expanding and leveraging our existing customer facing model, and (iv) leverage our internal capabilities (for example, in the areas of finance, human resources, information technology, data analytics and compliance) to support the launch of BIJUVA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our focus is first on key OB/GYN targets, particularly those that have already adopted IMVEXXY, to deliver the core clinical messages as well as provide information on our patient affordability and adherence programs. In support of BIJUVA, our field force was expanded to approximately 200 territories. In addition, we continue to expand our BIO-IGNITE program throughout 2019 with a fuller expansion towards the end of 2019 when the six-month payer block for BIJUVA is expected to lift.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">31</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We launched our patient affordability and adherence program for BIJUVA, similar to IMVEXXY, to help patients manage out-of-pocket costs (eligible enrolled patients pay no more than $35 per prescription) and improve patient education with the goal of increasing patient adherence and compliance for an improved treatment experience. As of June 30, 2019, 87% of our total BIJUVA fills have utilized the patient savings programs. As of June 30, 2019, we have approximately 3,100 patients who have received at least one paid BIJUVA prescription filled at a pharmacy.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We believe that the successful launch of IMVEXXY allows us to leverage existing contracts with our third-party logistics partner and our distribution partners. We anticipate similar timing regarding payer coverage as we experienced with IMVEXXY as many commercial payers employ &#8220;new-to-market blocks&#8221; for newly launched brands until they have the opportunity to make a coverage decision based upon their internal review. However, our ability to leverage existing payer contracts by amending to include BIJUVA along with our recent experience with the payers may simplify the process. Through June 30, 2019, we achieved unrestricted coverage with two of the top ten commercial payers of VMS products and we continue to sign new agreements with payers to cover BIJUVA.&#160; In addition, as of June 30, 2019, one of the top six Medicare Part D payers of VMS products was adjudicating BIJUVA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">With the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this method and validation were completed and submitted to FDA as required in our approval.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">ANNOVERA</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">On July 30, 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a full year, which was approved by the FDA on August 10, 2018.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">ANNOVERA was classified by the FDA as a &#8220;new chemical entity,&#8221; or NCE, and thus has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone&#174;, or NES, and ethinyl estradiol, or EE. EE is an approved active ingredient in many marketed hormonal products. Segesterone acetate, a new chemical entity, is a potent progestin that is not active orally but is active when administered via non-oral routes such as vaginal rings, implants, and transdermal systems. NES has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, or OCs, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active ingredients (NES and EE). The claimed release rate of 150 &#956;g/day NES and 13/day &#956;g EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We&#160;have commenced and plan to continue to conduct pre-launch activities for ANNOVERA during the second half of 2019, with a full-scale launch planned for the first quarter of 2020. We intend to leverage our existing infrastructure, including our sales force, to commercialize ANNOVERA, together with our recently approved IMVEXXY and BIJUVA products. ANNOVERA will also follow the same commercialization model as IMVEXXY and BIJUVA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">32</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As part of the FDA&#8217;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to also participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#8217;s specifications, which we submitted to FDA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. A protocol submission for the study is due to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As of June 30, 2019, we had 27 issued foreign patents and 26 issued domestic or, U.S., patents, which included 15 domestic utility patents that relate to BIJUVA, five domestic utility patents that relate to IMVEXXY, which establish an important intellectual property foundation for IMVEXXY, one domestic utility patent that relates to a pipeline transdermal patch technology, one domestic utility patent that relates to our topical-cream candidates, one domestic utility patent that relates to a product candidate containing d-limonene, one domestic utility patent that relates to our OPERA&#174; information technology platform that we wrote off in the second quarter of 2019 as we no longer use the system, and two domestic utility patents that relate to TX-009HR, our progesterone and estradiol drug candidate.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;font-style:italic">Research and Development Expenses</div></div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">A portion of our operating expenses to date have been incurred in research and development activities.&#160; Research and development expenses relate primarily to the discovery and development of our drug candidates.&#160; Our business model is dependent upon our company continuing to conduct research and development.&#160; Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, and consultants that conduct our preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls capabilities, and costs associated with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred with respect to drug candidates that have not received Investigational New Drug application approval from the FDA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">33</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The following table indicates our research and development expense by project for the periods indicated:</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="width:80%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="5" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="5" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;width:32%;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">TX 001-HR (BIJUVA)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:9%;text-align:right;font-family:Times New Roman, Times, Serif">905</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:9%;text-align:right;font-family:Times New Roman, Times, Serif">2,062</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:9%;text-align:right;font-family:Times New Roman, Times, Serif">2,415</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:9%;text-align:right;font-family:Times New Roman, Times, Serif">5,415</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">TX 004-HR(IMVEXXY)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">577</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,758</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,342</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,158</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">ANNOVERA</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">840</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,714</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Other research and development</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">2,642</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">2,979</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">5,811</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">5,265</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Total</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,964</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">6,799</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">11,282</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">13,838</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Research and development expenditures will continue to be incurred as we develop our drug pipeline, continue stability testing and validation on our drugs, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on existing submissions.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The costs of clinical trials may vary significantly over the life of a project owing to a variety factors. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory testing, regulatory submission and response work. For a discussion of the nature of efforts, steps and costs necessary to complete these projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">Results of Operations</div></div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Three months ended June 30, 2019 compared with three months ended June 30, 2018</div></div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="width:70%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Change</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="9" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;width:31%;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Revenues, net</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">6,079</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">3,763</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">2,316</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Cost of goods sold</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,249</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">454</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">795</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Operating expenses</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">46,467</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">36,331</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">10,136</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.25in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Operating loss</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(41,637</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(33,022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(8,615</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Other expense, net</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(13,600</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(197</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(13,403</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;padding-left:0.125in;text-align:justify;text-indent:-0.125in;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(55,237</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(33,219</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(22,018</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr></tbody>
</table>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Revenues and Cost of Goods Sold</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Revenues for the three months ended June 30, 2019 increased approximately $2,316,000, or 62%, to approximately $6,079,000, compared with approximately $3,763,000 for the three months ended June 30, 2018. Revenues increased primarily due to sales of approximately $3,122,000 of IMVEXXY and approximately $134,000 of BIJUVA in the current period, partially offset by a decrease in prenatal vitamin sales of approximately $940,000. The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold as compared to the prior year. We launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. Since the launches, revenues related to our newly approved drugs have been greatly affected by the co-pay assistance programs that we introduced to launch IMVEXXY and BIJUVA, which allowed eligible enrolled patients to access the products at a reasonable cost of no more than $35 per prescription regardless of insurance coverage. We expect our revenues related to IMVEXXY and BIJUVA to improve as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY and BIJUVA prescriptions at pharmacies.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">34</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Cost of goods sold increased approximately $795,000, or 175%, to approximately $1,249,000 for the three months ended June 30, 2019, compared with approximately $454,000 for the three months ended June 30, 2018, primarily due to an increased number of units sold as well as a higher cost per unit following the launch of our drugs. Our gross margin was approximately 79% and 88% for the three-month periods ended June 30, 2019 and 2018, respectively, primarily due to the product mix related to our prenatal vitamins and our recently launched drugs.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Operating Expenses</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our principal operating costs include the following items as a percentage of total operating expenses.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-left:0.25in;width:96%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="width:74%;text-align:justify;font-family:Times New Roman, Times, Serif">Sales and marketing costs, excluding human resource costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:8%;text-align:right;font-family:Times New Roman, Times, Serif">45.1</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:8%;text-align:right;font-family:Times New Roman, Times, Serif">45.8</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Human resource related costs, including salaries, benefits and taxes</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">27.0</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">21.9</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Product research and development costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">10.7</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">18.7</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Professional fees and consulting costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">7.3</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.4</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Other operating expenses</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">9.9</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">8.2</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Operating expenses increased by approximately $10,136,000, or 28%, to approximately $46,467,000 for the three months ended June 30, 2019, from approximately $36,331,000 for the three months ended June 30, 2018 as a result of the following items:</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-left:0.25in;width:90%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Change</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="10" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="width:51%;text-align:justify;font-family:Times New Roman, Times, Serif">Sales and marketing, excluding human resources costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">20,978</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">16,623</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">4,355</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Human resource related costs, including salaries, benefits and taxes</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">12,546</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">7,968</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4,578</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Product research and development costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4,964</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">6,799</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(1,835</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Professional fees and consulting costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,391</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,966</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,425</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">Other operating expenses</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">4,588</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">2,975</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">1,613</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-align:justify;font-family:Times New Roman, Times, Serif">Total operating expenses</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">46,467</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">36,331</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">10,136</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Sales and marketing costs for the three months ended June 30, 2019 increased by approximately $4,355,000, or 26%, to approximately $20,978,000, compared with approximately $16,623,000 for the three months ended June 30, 2018, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, physician education and product samples, advertising and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue the launch of BIJUVA, prepare for the launch of ANNOVERA and continue to support our growing business and commercialization of our products.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">35</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">Human resource costs, including salaries, benefits and taxes, for the three months ended June 30, 2019 increased by approximately $4,578,000, or 57%, to approximately $12,546,000, compared with approximately $7,968,000 for the three months ended June 30, 2018, primarily as a result of an increase of approximately $4,190,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our drugs and an increase of approximately $388,000 in non-cash compensation expense included in this category related to employee stock based compensation during 2019 as compared to 2018.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Research and development costs for the three months ended June 30, 2019 decreased by approximately $1,835,000, or 27%, to approximately $4,964,000, compared with $6,799,000 for the three months ended June 30, 2018.&#160; Research and development costs include costs related to manufacturing validation and clinical trials, as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased primarily as a result of certain employees and activities that were previously classified as research and development being transferred to operations as they began to support commercial and launch efforts after the FDA approvals of IMVEXXY and BIJUVA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.75in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9675;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Since the project&#8217;s inception in February 2013, we have incurred approximately $129,602,000 in research and development costs with respect to BIJUVA.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.75in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9675;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Since the project&#8217;s inception in April 2013, we have incurred approximately $2,525,000 in research and development costs with respect to TX-002HR.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif;width:100%">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.75in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9675;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Since the project&#8217;s inception in August 2014, we have incurred approximately $47,081,000 in research and development costs with respect to IMVEXXY.</div></td></tr></tbody>
</table>

<div style="margin-bottom:0pt;margin-top:0pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">For a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Professional fees for the three months ended June 30, 2019 increased by approximately $1,425,000, or 72%, to approximately $3,391,000, compared with approximately $1,966,000 for the three months ended June 30, 2018, primarily as a result of increased recruiting and consulting fees.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">All other operating expense for the three months ended June 30, 2019 increased by approximately $1,613,000, or 54%, to approximately $4,588,000, compared with approximately $2,975,000 for the three months ended June 30, 2018, as a result of increased information technology, travel, dues and subscriptions, allowance for bad debt expense, insurance and other office expenses primarily to support commercialization of our new drugs.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Operating Loss</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As a result of the foregoing, our operating loss increased approximately $8,615,000, or 26%, to approximately $41,637,000 for the three months ended June 30, 2019, compared with approximately $33,022,000 for the three months ended June 30, 2018, primarily as a result of increased personnel costs, sales and marketing expenses to support commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, professional fees and other operating expenses, partially offset by an increase in revenue and a decrease in research and development costs.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA and ANNOVERA will be successful.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">36</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Other Expense</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other non-operating expense changed by approximately $13,403,000 to an expense of approximately $13,600,000 for the three months ended June 30, 2019 compared with an expense of approximately $197,000 for the three months ended June 30, 2018, primarily as a result of loss on extinguishment of debt and increased interest expense related to our debt.&#160; For more information regarding the refinancing of our credit facility during the quarter, see &#8220;&#8211; Liquidity and Capital Resources&#8221; below.&#160;&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Net Loss</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Because of the net effects of the foregoing, net loss increased approximately $22,018,000, or 66%, to approximately $55,237,000 for the three months ended June 30, 2019, compared with approximately $33,219,000 for the three months ended June 30, 2018. Net loss per share of Common Stock, basic and diluted, was ($0.23) and ($0.15) for the three months ended June 30, 2019 and 2018, respectively.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Six months ended June 30, 2019 compared with six months ended June 30, 2018</div></div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="width:70%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Change</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="9" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="width:31%;text-align:justify;font-family:Times New Roman, Times, Serif">Revenues, net</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">10,026</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">7,536</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">2,490</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Cost of goods sold</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,012</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,088</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">924</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">Operating expenses</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">87,756</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">64,186</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">23,570</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;text-align:justify;font-family:Times New Roman, Times, Serif">Operating loss</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(79,742</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(57,738</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(22,004</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">Other (expense) income, net</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(15,001</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">117</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(15,118</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-align:justify;font-family:Times New Roman, Times, Serif">Net loss</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(94,743</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(57,621</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(37,122</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr></tbody>
</table>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Revenues and Cost of Goods Sold</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Revenues for the six months ended June 30, 2019 increased approximately $2,490,000, or 33%, to approximately $10,026,000, compared with approximately $7,536,000 for the six months ended June 30, 2018. Revenues increased primarily due to sales of approximately $5,133,000 of IMVEXXY and approximately $134,000 of BIJUVA in the current period, partially offset by a decrease in prenatal vitamin sales of approximately $2,777,000. The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold as compared to the prior year. We launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. Since the launches, revenues related to our newly approved drugs have been greatly affected by the co-pay assistance programs that we introduced to launch IMVEXXY and BIJUVA, which allowed eligible patients to access the product at a reasonable cost of no more than $35 per prescription regardless of insurance coverage. We expect our revenues related to IMVEXXY and BIJUVA to improve as commercial and Medicare payer coverage increase, and plans complete the process needed to adjudicate IMVEXXY and BIJUVA prescriptions at pharmacies.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Cost of goods sold increased approximately $924,000, or 85%, to approximately $2,012,000 for the six months ended June 30, 2019, compared with approximately $1,088,000 for the six months ended June 30, 2018, primarily due to an increased number of units sold. Our gross margin was approximately 80% and 86% for the six-month periods ended June 30, 2019 and 2018, respectively, primarily due to the product mix related to our prenatal vitamins and our recently launched drugs.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">37</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Operating Expenses</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our principal operating costs include the following items as a percentage of total operating expenses.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-left:0.25in;width:96%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="width:78%;text-align:justify;font-family:Times New Roman, Times, Serif">Sales and marketing costs, excluding human resource costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:5%;text-align:right;font-family:Times New Roman, Times, Serif">43.3</td>
    <td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:5%;text-align:right;font-family:Times New Roman, Times, Serif">42.2</td>
    <td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Human resource related costs, including salaries, benefits and taxes</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">27.0</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">22.4</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Product research and development costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">12.9</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">21.6</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Professional fees and consulting costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">6.8</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.9</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Other operating expenses</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">10.0</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">7.9</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Operating expenses increased by approximately $23,570,000, or 37%, to approximately $87,756,000 for the six months ended June 30, 2019, from approximately $64,186,000 for the six months ended June 30, 2018 as a result of the following items:</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-left:0.25in;width:90%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Change</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="9" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="width:51%;text-align:justify;font-family:Times New Roman, Times, Serif">Sales and marketing, excluding human resources costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">37,991</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">27,118</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">10,873</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Human resource related costs, including salaries, benefits and taxes</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">23,655</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">14,385</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">9,270</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Product research and development costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">11,282</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">13,838</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(2,556</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Professional fees and consulting costs</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5,925</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,761</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,164</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">Other operating expenses</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">8,903</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">5,084</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">3,819</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-align:justify;font-family:Times New Roman, Times, Serif">Total operating expenses</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">87,756</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">64,186</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">23,570</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Sales and marketing costs for the six months ended June 30, 2019 increased by approximately $10,873,000, or 40%, to approximately $37,991,000, compared with approximately $27,118,000 for the six months ended June 30, 2018, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, physician education and product samples, advertising and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue the launch of BIJUVA, prepare for the launch of ANNOVERA, and continue to support our growing business and commercialization of our products.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Human resource costs, including salaries, benefits and taxes, for the six months ended June 30, 2019 increased by approximately $9,270,000, or 64%, to approximately $23,655,000, compared with approximately $14,385,000 for the six months ended June 30, 2018, as a result of an increase of approximately $8,019,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our drugs and an increase of approximately $1,251,000 in non-cash compensation expense included in this category related to employee stock based compensation during 2019 as compared to 2018.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Research and development costs for the six months ended June 30, 2019 decreased by approximately $2,556,000, or 18%, to approximately $11,282,000, compared with $13,838,000 for the six months ended June 30, 2018. Research and development costs included costs related to on-going stability and laboratory testing and clinical trials, as well as salaries, wages, noncash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased for the six months ended June 30, 2019 as compared to the prior period primarily as a result of the completion of the REPLENISH Trial for BIJUVA and FDA approval of IMVEXXY and BIJUVA, partially offset by scale-up and manufacturing activities for BIJUVA before FDA approval as well as increased pre-clinical work to support our product pipeline.&#160; Research and development costs also decreased as a result of certain employees and activities previously classified as research and development to be transferred to operations as they began to support commercial and launch efforts after FDA approvals of IMVEXXY and BIJUVA.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">38</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">For a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Professional fees for the six months ended June 30, 2019 increased by approximately $2,164,000, or 58%, to approximately $5,925,000, compared with approximately $3,761,000 for the six months ended June 30, 2018, primarily as a result of increased recruiting and consulting fees.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">All other operating expense for the six months ended June 30, 2019 increased by approximately $3,819,000, or 75%, to approximately $8,903,000, compared with approximately $5,084,000 for the six months ended June 30, 2018, as a result of increased information technology, travel, allowance for bad debt expense, insurance and other office expenses primarily to support commercialization of our new drugs.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Operating Loss</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As a result of the foregoing, our operating loss increased approximately $22,004,000, or 38%, to approximately $79,742,000 for the six months ended June 30, 2019, compared with approximately $57,738,000 for the six months ended June 30, 2018, primarily as a result of increased personnel costs, sales and marketing expenses to support commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, professional fees and other operating expenses, as well a decrease in revenue, partially offset by a decrease in research and development costs.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA and ANNOVERA will be successful.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Other (Expense) Income</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other non-operating (expense) income changed by approximately $15,118,000 to an expense of approximately $15,001,000 for the six months ended June 30, 2019 compared with an income of approximately $117,000 for the six months ended June 30, 2018, primarily as a result of loss on extinguishment of debt and increased interest expense related to our debt. For more information regarding the refinancing of our credit facility during the quarter, see &#8220;&#8211; Liquidity and Capital Resources&#8221; below.&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Net Loss</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Because of the net effects of the foregoing, net loss increased approximately $37,122,000, or 64%, to approximately $94,743,000 for the six months ended June 30, 2019, compared with approximately $57,621,000 for the six months ended June 30, 2018. Net loss per share of Common Stock, basic and diluted, was ($0.39) and ($0.27) for the six months ended June 30, 2019 and 2018, respectively.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">Liquidity and Capital Resources</div></div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;color:windowtext;font-family:Times New Roman, Times, Serif;font-size:10pt">We have funded our operations primarily through public offerings of our Common Stock and private placements of equity and debt securities. For</div>

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">the three years ended December 31, 2018, we received approximately $293,344,000 in net proceeds from the issuance of shares of our Common Stock. As of June 30, 2019, we had cash and cash equivalents totaling approximately $182,846,000, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">39</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our net days sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts, chargebacks and payment discounts divided by the average daily net revenues during the quarter. We also disclose gross DSO, which includes the calculation of gross accounts receivable divided by the average daily gross revenues to distributors during the quarter. For the three months ended June 30, 2019, our gross DSO was 65 days compared to 77 days for the three months ended December 31, 2018 and our net DSO was 275 days for the three months ended June 30, 2019 compared to 200 days for the three months ended December 31, 2018. Our net DSO was affected by extended terms and increased coupons and discounts given to our customers in connection with the launch of IMVEXXY and BIJUVA timing of cash receipts after June 30, 2019. Our gross DSO decreased due to consignment arrangements that we entered into in the second quarter of 2019. We anticipate that our DSO will fluctuate in the future based upon a variety of factors, including longer payment terms associated with the launch of IMVEXXY, BIJUVA and ANNOVERA and changes in the healthcare industry</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">On April 24, 2019, we entered into a Financing Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of the Company&#8217;s subsidiaries party thereto from time to time as guarantors, which provided us with a $300,000,000 first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $200,000,000 was drawn upon entering into the Financing Agreement; (ii) $50,000,000 will be available to us upon the designation of ANNOVERA as a new category of birth control by the FDA on or prior to December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $50,000,000 will be available to us upon our achieving $11,000,000 in net revenues from our IMVEXXY, BIJUVA and ANNOVERA products for the fourth quarter of 2019 and satisfaction (or waiver) of other customary conditions precedent. A portion of the initial tranche of borrowing under the Facility in the amount of approximately $81,661,000 was used to repay all amounts outstanding under our prior financing agreement with MidCap Financial Trust, or the MidCap Agreement. As a result of the termination of the MidCap Agreement, we recorded $10,057,632 in loss on extinguishment of debt in our unaudited consolidated financial statements. We believe that our existing cash and availability under the Facility will allow us to fund our operating plan through at least the next 12 months from the date of this Quarterly Report. However, if the commercialization of IMVEXXY, BIJUVA or ANNOVERA is delayed, our existing cash and availability under the Facility, if we are able to access such funds, may be insufficient to satisfy our liquidity requirements until we are able to commercialize IMVEXXY, BIJUVA and ANNOVERA and we may not be able to access funds under the Facility. If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing and other commercialization and pre-commercialization efforts and we may seek to sell additional equity or debt securities. Our ability to sell debt securities or obtain additional debt financing is restricted pursuant to the Financing Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, to the extent permitted under the Financing Agreement, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, certain of which are restricted under the Financing Agreement, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products, if permitted under the Financing Agreement. Additionally, we may have to grant licenses on terms that may not be favorable to us.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">40</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">License Agreement with Theramex</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0px;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On June 6, 2019, we entered into an exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR 14 million in cash as an upfront fee on August 5, 2019. Within thirty days of signing the License Agreement, we are required to provide Theramex with the regulatory materials and clinical data that are necessary for Theramex to obtain marketing authorizations and other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. The revenue related to fees received by us will be recognized once our performance obligations have been satisfied. We are eligible to receive additional milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.</div></div>

<div style="margin:0pt 0px;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0px;text-align:justify;text-indent:0.493in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive drugs. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0.7pt 0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Summary of (Uses) and Sources of Cash</div></div></div>

<div style="margin:0pt 0.7pt 0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="width:80%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Six Months Ended<br />June 30,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="5" style="border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">(000s)</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="width:54%;text-align:justify;font-family:Times New Roman, Times, Serif">Net cash used in operating activities</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">(88,678</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">(44,599</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:white;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Net cash used in investing activities</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(1,876</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(492</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="background-color:#cceeff;vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:12.6pt;text-align:justify;text-indent:-12.6pt;font-family:Times New Roman, Times, Serif">Net cash provided by financing activities</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">111,787</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">72,342</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-style:italic">Operating Activities</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The principal use of cash in operating activities for the six months ended June 30, 2019 was to fund our current expenses primarily related to supporting commercialization activities for IMVEXXY, BIJUVA and ANNOVERA, sales, marketing, scale-up and manufacturing activities and clinical development, adjusted for non-cash items. The increase of approximately $44,079,000 in cash used in operating activities for the six months ended June 30, 2019 compared with the comparable period in the prior year was due primarily to an increase in our net loss and changes in the components of working capital, partially offset by an increase in non-cash items.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0.7pt 0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-style:italic">Investing Activities</div></div></div>

<div style="margin:0pt 0.7pt 0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 5.05pt 0pt 0;text-align:justify;text-indent:38.45pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">An increase in spending on patent and trademarks resulted in an increase in cash used in investing activities for the six months ended June 30, 2019 compared with the same period in 2018.</div></div>

<div style="margin:0pt 5.05pt 0pt 0;text-align:justify;text-indent:38.45pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0.7pt 0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-style:italic">Financing Activities</div></div></div>

<div style="margin:0pt 0.7pt 0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0.7pt 0pt 0.5pt;text-align:justify;text-indent:35.5pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Financing activities represent the principal source of our cash flow. Our financing activities for the six months ended June 30, 2019 provided net cash of approximately $111,787,000 which consisted of the net funding from our Facility of approximately $193,348,000 and exercise of options and warrants to purchase Common Stock of approximately $100,000, partially offset by the repayment of our Credit Agreement of approximately $81,661,000. Our financing activities for the six months ended June 30, 2018 provided net cash of approximately $72,342,000, which consisted of the net funding from our Credit Agreement of approximately $71,213,000 and the exercise of options to purchase Common Stock of approximately $1,129,000.</div></div>

<div style="margin:0pt 0.7pt 0pt 0.5pt;text-align:justify;text-indent:35.5pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">41</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0.7pt 0pt 0.5pt;text-align:justify;text-indent:35.5pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">New Accounting Pronouncements</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="color:#252525;margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">In August 2018, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating the effect of this guidance on our disclosures.</div></div>

<div style="color:#252525;margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="color:#252525;margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements.</div></div>

<div style="color:#252525;margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $3.8 million right of use asset and a $4.1 million liability related to adoption of this standard. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">42</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold"><a id="txmd10qa007"></a>Item 3. Quantitative and Qualitative Disclosures about Market Risk</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. To minimize this risk, we intend to maintain an investment portfolio that may include cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">As of April 24, 2019, we repaid all amounts outstanding under the MidCap Agreement and became subject to market risk in connection with borrowings under the Financing Agreement. Amounts borrowed under the Financing Agreement will accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70% or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20%. Considering the total outstanding principal balance under the Financing Agreement of approximately $200,000,000 at June 30, 2019, a 1.0% change in interest rates would result in an impact to income before income taxes of approximately $2,000,000 per year.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold"><a id="txmd10qa008"></a>Item 4. Controls and Procedures</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Disclosure Controls and Procedures</div></div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within the time period specified in the SEC&#8217;s rules and forms and is accumulated and communicated to our principal executive officer and principal financial officer, as appropriate, in order to allow timely decisions in connection with required disclosure.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Evaluation of Disclosure Controls and Procedures</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">43</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font:10pt Times New Roman, Times, Serif">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;text-decoration:underline">Changes in Internal Controls</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">During the three months ended June 30, 2019, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold"><a id="txmd10qa009"></a>PART II - OTHER INFORMATION</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold"><a id="txmd10qa010"></a>Item 1. Legal Proceedings</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">We have been informed by the staff (&#8220;Staff&#8221;) of the Securities and Exchange Commission that the Staff is conducting a formal investigation concerning whether certain of our communications during 2017 regarding TX-004HR may have violated Regulation FD. We are cooperating with the Staff in connection with the investigation. Any determination that our actions violated Regulation FD could result in penalties or other remedies being imposed. While we believe that any such penalties and other remedies would be immaterial from a financial perspective, no assurance can be made about the ultimate outcome of the investigation, and there can be no assurance that any such penalties and remedies would not have a material adverse effect on our business.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">From time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding that we believe would have a material effect on our business or financial condition.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold"><a id="txmd10qa011"></a>Item 1A. Risk Factors</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">There have been no material changes to the risk factors previously disclosed in our Annual Report.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">44</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold"><a id="txmd10qa012"></a>Item 6. Exhibits</div></div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="margin-left:5.4pt;width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:10%;vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="border-bottom:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">Exhibit</div></div></div></td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:17%;font-family:Times New Roman, Times, Serif">
        <div style="border-bottom:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">Date</div></div></div></td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:69%;font-family:Times New Roman, Times, Serif">
        <div style="border-bottom:Black 0.5pt solid;font:10pt Times New Roman, Times, Serif;margin:0pt 0">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">Description</div></div></div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex10-1.htm">10.1*+</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">April 24, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC.</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex10-2.htm">10.2*+</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">April 24, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Pledge and Security Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc. and TPG Specialty Lending, Inc.</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex10-3.htm">10.3*+</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">June 6, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">License and Supply Agreement, by and between TherapeuticsMD, Inc. and Theramex HQ UK Limited.</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119003116/txmd-def14a_062019.htm#txmd-def14a_042919a215">10.4</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">June 20, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">TherapeuticsMD, Inc. 2019 Stock Incentive Plan (incorporated by reference to Annex A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 30, 2019).</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex31-1.htm">31.1*</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">August 9, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex31-2.htm">31.2*</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">August 9, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex32-1.htm">32.1**</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">August 9, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Section 1350 Certification of Chief Executive Officer</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"><a href="ex32-2.htm">32.2**</a></div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">August 9, 2019</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Section 1350 Certification of Chief Financial Officer</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">101.INS*</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">101.SCH*</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">XBRL Taxonomy Extension Schema Document</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">101.CAL*</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">XBRL Taxonomy Extension Calculation Linkbase Document</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">101.DEF*</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">XBRL Taxonomy Extension Definition Linkbase Instance Document</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">101.LAB*</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">XBRL Taxonomy Extension Label Linkbase Instance Document</div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">101.PRE*</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">XBRL Taxonomy Extension Presentation Linkbase Instance Document</div></td></tr>
<tr style="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <td style="vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">104*&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">n/a&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: justify; font-family: Times New Roman, Times, Serif">Cover Page Interactive Data File (formatted as Inline XBRL and Contained in Exhibit 101). &#160;</td></tr></tbody>
</table>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin-bottom:3pt;margin-top:3pt;font-family:Times New Roman, Times, Serif;text-align:left">

<div style="border-top:Black 1pt solid;font:1pt Times New Roman, Times, Serif;width:20%">&#160;</div></div>

<div style="margin:0pt 0;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0 0pt 0.5in;text-indent:-0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">* Filed herewith.</div></div>

<div style="margin:0pt 0 0pt 0.5in;text-indent:-0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">** Furnished herewith.</div></div>

<div style="margin:0pt 0 0pt 9pt;text-indent:-9pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">+ Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed.</div></div>

<div style="margin:0pt 0 0pt 9pt;text-indent:-9pt;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">45</div></div>

<div style="page-break-before:always;margin-top:6pt;margin-bottom:12pt">&#160;</div>

<div style="margin:0pt 0;text-align:center;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin:0pt 0;text-align:center;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">SIGNATURES</div></div></div>

<div style="margin:0pt 0;text-align:center;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div></div>

<div style="margin:0pt 0;text-align:justify;text-indent:0.5in;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">DATE: August 9, 2019</div></div>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#160;</div></div>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif;border-collapse:collapse">
        <tbody>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">THERAPEUTICSMD, INC.</div></td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="width:50%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:3%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:47%;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">By:</td>
    <td style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-style:italic">/s/ Robert G. Finizio</div></td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Robert G. Finizio</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Chief Executive Officer</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">(Principal Executive Officer)</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">By:</td>
    <td style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-style:italic">/s/ Daniel A. Cartwright</div></td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font:10pt Times New Roman, Times, Serif">Daniel A. Cartwright</div></td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font:10pt Times New Roman, Times, Serif">Chief Financial Officer</div></td></tr>
<tr style="vertical-align:top;text-align:left;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font:10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</div></td></tr></tbody>
</table>

<div style="margin:0pt 0;text-align:justify;font:10pt Times New Roman, Times, Serif">&#160;</div>

<div style="margin-top:12pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">46</div></div></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>FINANCING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Execution
Version</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dated
as of April 24, 2019</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">among</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERAPEUTICSMD,
INC.<BR>
as the Borrower,</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN
SUBSIDIARIES OF BORROWER<BR>
as Guarantors,</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VARIOUS
LENDERS FROM TIME TO TIME PARTY HERETO,</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AND</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG
SPECIALTY LENDING, INC.,<BR>
as Administrative Agent</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TABLE
OF CONTENTS</U></FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 0pt; padding-top: 0; padding-left: 0; border-bottom: Black 1pt solid"><B>P<FONT STYLE="text-transform: lowercase">age</FONT></B></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-top: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 0pt; padding-top: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    I DEFINITIONS AND INTERPRETATION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0pt; padding-left: 0; width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; width: 3%; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting and Other Terms</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation, etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time References</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    II LOANS</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>32</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term Loans</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of Debt; Register; Lenders&rsquo; Books and
Records; Notes</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion/Continuation</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.6&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Default Interest</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of Term Loans</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voluntary Prepayments and Commitment Reductions</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mandatory Prepayments</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Prepayments</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.12&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Provisions Regarding Payments</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.13&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ratable Sharing</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.14&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased Costs; Capital Adequacy</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.15&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes; Withholding, etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.16&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligation to Mitigate</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.17&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaulting Lenders</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.18&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal or Replacement of a Lender</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 2.19&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making or Maintaining LIBOR Rate Loans</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    III CONDITIONS PRECEDENT</B></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>50</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Date</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 3.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to Each Credit Extension</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    IV REPRESENTATIONS AND WARRANTIES</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>54</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization; Requisite Power and Authority; Qualification</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Stock and Ownership</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due Authorization</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental Consents</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.6&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Binding Obligation</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical Financial Statements</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Material Adverse Effect</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse Proceedings, etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Taxes</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.12&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties, Title</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.13&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.14&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0; width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Defaults</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.15&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.16&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental Regulation</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.17&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margin Stock</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.18&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.19&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Fees</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.20&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.21&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.22&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Statutes, etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.23&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.24&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.25&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Enterprise</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.26&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permits, Etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.27&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank Accounts and Securities Accounts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.28&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Interests</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.29&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PATRIOT ACT and FCPA</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.30&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managerial Assistance and Related Persons</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.31&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.32&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.33&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory Compliance</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.34&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Contracts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.35&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Regulatory Laws</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    V AFFIRMATIVE COVENANTS</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>64</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Other Reports</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existence</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Taxes and Claims</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance of Properties</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.6&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Books and Records; Inspections</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenders Meetings and Conference Calls</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Assurances</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.12&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control Agreements</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 5.13&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Closing Matters</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    VI NEGATIVE COVENANTS</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>72</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indebtedness</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liens</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Further Negative Pledges</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Junior Payments</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.6&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions on Subsidiary Distributions</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Covenants</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fundamental Changes; Disposition of Assets; Acquisitions</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposal of Subsidiary Interests</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales and Lease Backs</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.12&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with Shareholders and Affiliates</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.13&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0; width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct of Business</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.14&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes to Certain Agreements and Organizational Documents</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.15&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Methods</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.16&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit Accounts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.17&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments of Certain Indebtedness</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.18&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Terrorism Laws</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.19&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Corruption Laws</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 6.20&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real Property</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    VII GUARANTY</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>77</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guaranty of the Obligations</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contribution by Guarantors</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment by Guarantors</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability of Guarantors Absolute</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waivers by Guarantors</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.6&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guarantors&rsquo; Rights of Subrogation, Contribution,
etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subordination of Other Obligations</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing Guaranty</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority of Guarantors or Company</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Condition of Company</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bankruptcy, etc.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 7.12&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discharge of Guaranty Upon Sale of Guarantor</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    VIII EVENTS OF DEFAULT</B></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>82</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Events of Default</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remedies</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 8.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights Not Exclusive</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    IX ADMINISTRATIVE AGENT</B></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>85</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment of Administrative Agent</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Powers and Duties</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Immunity</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative Agent Entitled to Act as Lender</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenders&rsquo; Representations, Warranties and Acknowledgment</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.6&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right to Indemnity</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successor Administrative Agent</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral Documents and Guaranty</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agency for Perfection</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports and Other Information; Confidentiality; Disclaimers</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 9.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protective Advances</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-top: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
    X MISCELLANEOUS</B></FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>91</B></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.1&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.2&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.3&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.4&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set-Off</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.5&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments and Waivers</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.6&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successors and Assigns; Participations</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.7&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independence of Covenants</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.8&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival of Representations, Warranties and Agreements</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.9&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Waiver; Remedies Cumulative</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.10&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0; width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marshalling; Payments Set Aside</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.11&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.12&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations Several; Independent Nature of Lenders&rsquo;
Rights</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.13&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headings</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.14&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICABLE LAW</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.15&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT TO JURISDICTION</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.16&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAIVER OF JURY TRIAL</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.17&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.18&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Usury Savings Clause</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.19&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.20&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effectiveness</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 10.21&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0; padding-bottom: 0pt; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PATRIOT Act Notice</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21%; padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APPENDICES:</B></FONT></TD>
    <TD STYLE="width: 13%; padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</FONT></TD>
    <TD STYLE="width: 66%; padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Term Loan Commitments</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-2</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
    Draw A-1 Term Loan Commitments</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-3</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
    Draw A-2 Term Loan Commitments</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice
    Addresses</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCHEDULES:</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdictions
    of Organization and Qualification</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
    Stock and Ownership</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Real
    Property</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental
    Matters</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    Contracts</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23(b)-(c)</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    Property</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
    Accounts and Securities Accounts</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.34</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
    Contracts</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Post Closing Matters</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Indebtedness</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Liens</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Loans and Advances to Employees</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Investments</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Affiliate Transactions</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS:</B></FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
    Notice</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-2</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion/Continuation
    Notice</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    Certificate</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
    Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    Regarding Non-Bank Status</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing
    Date Certificate</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency
    Certificate</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><U>FINANCING
AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
FINANCING AGREEMENT, dated as of April 24, 2019, is entered into by and among THERAPEUTICSMD, INC., a Nevada Corporation (&ldquo;<U>Company</U>&rdquo;
or &ldquo;<U>Borrower</U>&rdquo;), and certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party hereto
and TPG SPECIALTY LENDING, INC., a Delaware corporation (&ldquo;<U>TSL</U>&rdquo;), as administrative agent for the Lenders (in
such capacity, &ldquo;<U>Administrative Agent</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><U>W
I T N E S E T H</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
capitalized terms used in these Recitals shall have the respective meanings set forth for such terms in <U>Section 1.1</U> hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Lenders have agreed to extend to Company (a) an initial term loan in an aggregate principal amount not exceeding $200,000,000
and (b) delayed draw term loans in an aggregate principal amount not exceeding $100,000,000, in each case the proceeds of which
will be used as described in <U>Section 2.2</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Company has agreed to secure all of its Obligations by granting to Administrative Agent, for the benefit of Secured Parties, a
first priority Lien on all of its assets (except as otherwise set forth in the Collateral Documents), including a pledge of all
of the Capital Stock of each of its Subsidiaries; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Guarantors have agreed to guarantee the obligations of Company hereunder and to secure their respective Obligations by granting
to Administrative Agent, for the benefit of Secured Parties, a first priority Lien on all of their respective assets (except as
otherwise set forth in the Collateral Documents), including a pledge of all of the Capital Stock of each of their respective Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
I</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
DEFINITIONS AND INTERPRETATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions.</U> The following terms
used herein, including in the preamble, recitals, exhibits and schedules hereto, shall have the following
meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Adjusted
LIBOR Rate</U>&rdquo; means, for any Interest Rate Determination Date with respect to an Interest Period for a LIBOR Rate Loan,
the greater of (a) the rate per annum obtained by dividing (i) (A) the rate per annum equal to the Intercontinental Exchange Benchmark
Administration Ltd. (or such other Person that takes over the administration of such rate) LIBOR Rate (&ldquo;<U>ICE LIBOR</U>&rdquo;),
as published by a nationally recognized service such as the Dow Jones Market Service (Telerate), Reuters or Bloomberg (or such
other commercially available source providing quotations of ICE LIBOR as may be reasonably designated by the Administrative Agent
from time to time), or a comparable or successor rate used generally in the market for syndicated commercial loans that has been
reasonably approved by the Administrative Agent in consultation with the Borrower (such rate, the &ldquo;<U>Alternate Benchmark
Rate</U>&rdquo;), at approximately 11:00 a.m., London time on the Interest Rate Determination Date, for Dollar deposits (for delivery
on the first day of such Interest Period) with a term equivalent to such Interest Period or (B) if such rate is not available
at such time for any reason, the rate per annum determined by the Administrative Agent to be the rate at which deposits in Dollars
for delivery on the first day of such Interest Period in same day funds in the approximate amount of the LIBOR Rate Loan being
made, continued or converted and with a term equivalent to such Interest Period would be offered to major banks in the London
interbank eurodollar market at their request at approximately 11:00 a.m. (London time) on the Interest Rate Determination Date,
by (ii) an amount equal to (A) one, minus (B) the Applicable Reserve Requirement, and (b) 2.70% per annum. Any such determination
of LIBOR shall be conclusive absent manifest error.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Administrative
Agent</U></FONT>&rdquo; has the meaning specified in the preamble hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Administrative
Agent&rsquo;s Account</U></FONT>&rdquo; means an account at a bank designated by Administrative Agent from time to time by written
notice to Borrower in accordance with <U>Section 10.1(a)</U> as the account into which the Loan Parties shall make all payments
to Administrative Agent under this Agreement and the other Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Adverse
Proceeding</U></FONT>&rdquo; means any action, suit, proceeding (whether administrative, judicial or otherwise), governmental
investigation or arbitration (whether or not purportedly on behalf of Borrower or any of its Subsidiaries) at law or in equity,
or before or by any Governmental Authority, domestic or foreign (including any Environmental Claims) or other regulatory body
or any mediator or arbitrator, whether pending or, to the knowledge of Borrower or any of its Subsidiaries, threatened in writing
against Borrower or any of its Subsidiaries or any property of Borrower or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Affected
Lender</U></FONT>&rdquo; has the meaning specified in <U>Section 2.19(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Affected
Loans</U></FONT>&rdquo; has the meaning specified in <U>Section 2.19(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Affiliate</U></FONT>&rdquo;
means, as applied to any Person, any other Person directly or indirectly controlling (including any member of the senior management
group of such Person), controlled by, or under common control with, that Person. For the purposes of this definition, &ldquo;control&rdquo;
(including, with correlative meanings, the terms &ldquo;controlling,&rdquo; &ldquo;controlled by&rdquo; and &ldquo;under common
control with&rdquo;), as applied to any Person, means the possession, directly or indirectly, of the power (a) to vote 10% or
more of the securities having ordinary voting power for the election of directors of such Person, or (b) to direct or cause the
direction of the management and policies of that Person, whether through the ownership of voting securities or by contract or
otherwise. Notwithstanding anything herein to the contrary, in no event shall Administrative Agent or any Lender or any of their
Affiliates or Related Funds be considered an &ldquo;Affiliate&rdquo; of any Loan Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Aggregate
Amounts Due</U></FONT>&rdquo; has the meaning specified in <U>Section 2.13</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Aggregate
Payments</U></FONT>&rdquo; has the meaning specified in <U>Section 7.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Agreement</U></FONT>&rdquo;
means this Financing Agreement and any annexes, exhibits and schedules attached hereto as it may be amended, supplemented or otherwise
modified from time to time in accordance with and subject to the terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Alternate
Benchmark Rate</U>&rdquo; has the meaning set forth in the definition of Adjusted LIBOR Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Annovera</U>&rdquo;
means (a) the ANNOVERA (segesterone acetate/ethinyl estradiol vaginal system) product approved for commercialization in the U.S.
as of the Closing Date and (b) any other vaginal system being developed or commercialized by the Company (or any Affiliate thereof
that is controlled by the Company), or any of its licensees or sub-licensees (now or in the future) (in the case of such licensees
or sub-licensees, solely with respect to development or commercialization pursuant to agreements with the Company or any of its
Subsidiaries) that contains segesterone acetate and/or ethinyl estradiol (and in the case of clause (a) and clause (b) above,
including any of their respective derivatives, polymorphs, isomers, prodrugs, metabolites, esters, salts and other forms, formulations,
and methods of delivery thereof), commercialized by the Company (or any Affiliate thereof that is controlled by the Company),
or any of its licensees or sub-licensees (now or in the future) (in the case of such licensees or sub-licensees, solely with respect
to development or commercialization pursuant to agreements with the Company or any of its Subsidiaries) in any country of the
world under any brand name for any indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Annovera
Agreement</U>&rdquo; means that certain License Agreement, dated July 30, 2018, between Company and The Population Council, Inc.,
as amended from time to time in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Annovera
Patents</U>&rdquo; means the U.S. and foreign patents and pending patent applications owned or in-licensed by Company or any of
its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development,
manufacture, use, or sale of Annovera.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Anti-Corruption
Laws</U>&rdquo; means all Requirements of Law concerning or relating to bribery or corruption, including, without limitation,
the United States Foreign Corrupt Practices Act of 1977, as amended, and the anti-bribery and anti-corruption laws and regulations
of those jurisdictions in which the Loan Parties do business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Anti-Terrorism
Laws</U></FONT>&rdquo; means any Requirement of Law relating to terrorism or money laundering, including, without limitation,
(a) the Money Laundering Control Act of 1986 (<I>i.e.</I>, 18 U.S.C. &sect;&sect; 1956 and 1957), (b) the Currency and Foreign
Transactions Reporting Act (31 U.S.C. &sect;&sect; 5311-5330 and 12 U.S.C. &sect;&sect; 1818(s), 1820(b) and 1951-1959) (the &ldquo;<FONT STYLE="font-weight: normal"><U>Bank
Secrecy Act</U></FONT>&rdquo;), (c) the USA Patriot Act, (d) the laws, regulations and Executive Orders administered by the United
States Department of the Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;<FONT STYLE="font-weight: normal"><U>OFAC</U></FONT>&rdquo;),
(e) the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010 and implementing regulations by the United States
Department of the Treasury, (f) any law prohibiting or directed against terrorist activities or the financing of terrorist activities
(<I>e.g.</I>, 18 U.S.C. &sect;&sect; 2339A and 2339B), or (g) any similar laws enacted in the United States or any other jurisdictions
in which the parties to this Agreement operate, as any of the foregoing laws may from time to time be amended, renewed, extended,
or replaced and all other present and future legal requirements of any Governmental Authority governing, addressing, relating
to, or attempting to eliminate, terrorist acts and acts of war and any regulations promulgated pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Margin</U>&rdquo; means (a) with respect to a Term Loan that is a LIBOR Rate Loan, 7.75% and (b) with respect to a Term Loan that
is a Base Rate Loan, 6.75%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Reserve Requirement</U>&rdquo; means, at any time, for any LIBOR Rate Loan, the maximum rate, expressed as a decimal, at which
reserves (including, without limitation, any basic marginal, special, supplemental, emergency or other reserves) are required
to be maintained with respect thereto against &ldquo;Eurocurrency liabilities&rdquo; (as such term is defined in Regulation D)
under regulations issued from time to time by the Board of Governors of the Federal Reserve System or other applicable banking
regulator having appropriate jurisdiction. Without limiting the effect of the foregoing, the Applicable Reserve Requirement shall
reflect any other reserves required to be maintained by such member banks with respect to (a) any category of liabilities which
includes deposits by reference to which the applicable Adjusted LIBOR Rate or any other interest rate of a Loan is to be determined,
or (b) any category of extensions of credit or other assets which include LIBOR Rate Loans. A LIBOR Rate Loan shall be deemed
to constitute Eurocurrency liabilities and as such shall be deemed subject to reserve requirements without benefits of credit
for proration, exceptions or offsets that may be available from time to time to the applicable Lender. The rate of interest on
LIBOR Rate Loans shall be adjusted automatically on and as of the effective date of any change in the Applicable Reserve Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Application
Event</U>&rdquo; means the (a) occurrence of an Event of Default and (b) the election by Administrative Agent or the Required
Lenders during the continuance of such Event of Default to require that payments and proceeds of Collateral be applied pursuant
to <U>Section 2.12(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Asset
Sale</U></FONT>&rdquo; means a sale, lease or sub lease (as lessor or sublessor), sale and leaseback, assignment, conveyance,
transfer, license or sublicense (including a Permitted Product Transaction) or other disposition to (other than to a Loan Party),
or any exchange of property with, any Person, in one transaction or a series of transactions, of all or any part of any Loan Party&rsquo;s
businesses, assets or properties of any kind, whether real, personal, or mixed and whether tangible or intangible, whether now
owned or hereafter acquired, including, without limitation, the Capital Stock of any Loan Party. For purposes of clarification,
&ldquo;Asset Sale&rdquo; shall include (a) the sale or other disposition for value of any contracts, (b) any disposition of property
through a &ldquo;plan of division&rdquo; under the Delaware Limited Liability Company Act or any comparable transaction under
any similar law, (c) the early termination or modification of any contract resulting in the receipt by any Loan Party of a cash
payment or other consideration in exchange for such event, (d) any sale of accounts (or any rights thereto (including, without
limitation, any rights to any residual payment stream with respect thereto)) by any Loan Party or Subsidiary of Borrower and (e)
any royalty monetization transaction with respect to licenses or sublicenses of the intellectual property owned or controlled
by the Company or any of its Subsidiaries, including but not limited to sales of royalty streams, royalty bonds and other royalty
financings, synthetic royalty and revenue interest transactions and hybrid monetization transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, none of the following items will be deemed to be an Asset Sale:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                         issuance of Capital Stock by a Subsidiary of the Company to the Company or to another
                                         Loan Party;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                         or transfer of Cash or Cash Equivalents in a manner that is not prohibited by the terms
                                         of this Agreement or the other Loan Documents;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         licensing or sublicensing of patents, trademarks, know-how or other intellectual property
                                         or general intangibles related thereto (in each case, other than a Permitted Product
                                         Transaction) in the ordinary course of business which do not materially interfere with
                                         the ordinary conduct of the business of the Company or any of its Subsidiaries (<I>provided
                                         </I>that any exclusive license of patents that effectively constitutes a transfer of
                                         the related patent shall be deemed to be an Asset Sale); and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         lease, assignment or sublease of any real or personal property (other than a Permitted
                                         Product Transaction) in the ordinary course of business which do not materially interfere
                                         with the ordinary conduct of the business of the Company or any of its Subsidiaries.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Assignment
Agreement</U></FONT>&rdquo; means an Assignment and Assumption Agreement substantially in the form of <U>Exhibit C</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Assignment
Letter</U>&rdquo; means that certain Assignment Side Letter, dated as of the date hereof, among Borrower, Administrative Agent
and Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Authorized
Officer</U></FONT>&rdquo; means, as applied to any Person, any individual holding the position of chairman of the board (if an
officer), chief executive officer, president or one of its vice presidents (or the equivalent thereof), and such Person&rsquo;s
chief financial officer or treasurer or other substantially comparable title.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Bankruptcy
Code</U></FONT>&rdquo; means Title 11 of the United States Code entitled &ldquo;Bankruptcy,&rdquo; as now and hereafter in effect,
or any successor statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Base
Rate</U>&rdquo; means, for any day, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the
Federal Funds Effective Rate in effect on such day <U>plus</U> &frac12; of 1%, (c) the Adjusted LIBOR Rate (which rate shall be
calculated based upon an Interest Period of three months and to be determined on a daily basis) <U>plus</U> 1%, and (d) 5.20%
per annum. Any change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBOR Rate shall be effective on the
effective day of such change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBOR Rate, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Base
Rate Loan</U>&rdquo; means a Loan bearing interest at a rate determined by reference to the Base Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Beneficiary</U></FONT>&rdquo;
means Administrative Agent and each Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bijuva</U>&rdquo;
means (a) the BIJUVA (estradiol and progesterone) product approved for commercialization in the U.S. as of the Closing Date, and
(b) any other product being developed or commercialized for the treatment of vasomotor symptoms by the Company (or any Affiliate
thereof that is controlled by the Company), or any of its licensees or sub-licensees (now or in the future) (in the case of such
licensees or sub-licensees, solely with respect to development or commercialization pursuant to agreements with the Company or
any of its Subsidiaries) that contains estradiol and progesterone (and in the case of clause (a) and clause (b) above, including
any of their respective derivatives, polymorphs, isomers, prodrugs, metabolites, esters, salts and other forms, formulations,
and methods of delivery thereof), commercialized in any country of the world under any brand name.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bijuva
Patents</U>&rdquo; means the U.S. and foreign patents and pending patent applications owned or in-licensed by Company or any of
its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development,
manufacture, use, or sale of Bijuva..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Blocked
Person</U></FONT>&rdquo; means any Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
is publicly identified (i) on the most current list of &ldquo;Specially Designated Nationals and Blocked Persons&rdquo; published
by OFAC or resides, is organized or chartered, or has a place of business in a country or territory subject to OFAC sanctions
or embargo program or (ii) as prohibited from doing business with the United States under the International Emergency Economic
Powers Act, the Trading With the Enemy Act, or any other Anti-Terrorism Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
is owned or controlled by, or that owns or controls, or that is acting for or on behalf of, any Person described in clause (a)
above;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;which
any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
is affiliated or associated with a Person described in clauses (a), (b) or (c) above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Board
of Directors</U></FONT>&rdquo; means, (a) with respect to any corporation, the board of directors of the corporation or any committee
thereof duly authorized to act on behalf of such board, (b) with respect to a partnership, the board of directors of the general
partner of the partnership, (c) with respect to a limited liability company, the managing member or members or any controlling
committee or board of directors of such company or the sole member or the managing member thereof, and (d) with respect to any
other Person, the board or committee of such Person serving a similar function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Borrower</U></FONT>&rdquo;
has the meaning specified in the preamble hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means (a) any day excluding Saturday, Sunday and any day which is a legal holiday under the laws of the State of
New York or is a day on which banking institutions located in either such state are authorized or required by law or other governmental
action to close, and (b) with respect to all notices, determinations, fundings and payments in connection with the Adjusted LIBOR
Rate or any LIBOR Rate Loans, the term &ldquo;Business Day&rdquo; shall mean any day which is a Business Day described in <U>clause
(a)</U> and which is also a day for trading by and between banks in Dollar deposits in the London interbank market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Capital
Lease</U></FONT>&rdquo; means, as applied to any Person, any lease of any property (whether real, personal or mixed) by that Person
(a) as lessee that, in conformity with GAAP as in effect on December 31, 2018, is or should be accounted for as a capital lease
on the balance sheet of that Person or (b) as lessee which is a transaction of a type commonly known as a &ldquo;synthetic lease&rdquo;
(i.e., a transaction that is treated as an operating lease for accounting purposes but with respect to which payments of rent
are intended to be treated as payments of principal and interest on a loan for federal income Tax purposes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Capital
Stock</U></FONT>&rdquo; means any and all shares, equity interests, economic participations or other equivalents (however designated)
of capital stock of a corporation, any and all equivalent ownership interests in a Person (other than a corporation), including,
without limitation, partnership interests and membership interests, and any and all warrants, rights or options to purchase or
other written arrangements or rights to acquire any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Cash</U></FONT>&rdquo;
means money, currency or a credit balance in any demand or Deposit Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Cash
Equivalents</U></FONT>&rdquo; means, as at any date of determination, (a) marketable securities (i) issued or directly and unconditionally
guaranteed as to interest and principal by the United States Government, or (ii) issued by any agency of the United States the
obligations of which are backed by the full faith and credit of the United States, in each case maturing within one year after
such date; (b) marketable direct obligations issued by any state of the United States of America or any political subdivision
of any such state or any public instrumentality thereof, in each case maturing within one year after such date and having, at
the time of the acquisition thereof, a rating of at least A 1 from S&amp;P or at least P 1 from Moody&rsquo;s; (c) commercial
paper maturing no more than one year from the date of creation thereof and having, at the time of the acquisition thereof, a rating
of at least A 1 from S&amp;P or at least P 1 from Moody&rsquo;s; (d) certificates of deposit or bankers&rsquo; acceptances maturing
within one year after such date and issued or accepted by any Lender or by any commercial bank organized under the laws of the
United States of America or any state thereof or the District of Columbia that (i) is at least &ldquo;adequately capitalized&rdquo;
(as defined in the regulations of its primary Federal banking regulator), and (ii) has Tier 1 capital (as defined in such regulations)
of not less than $100,000,000; and (e) shares of any money market mutual fund that (i) has substantially all of its assets invested
continuously in the types of investments referred to in <U>clauses (a)</U> and <U>(b)</U> above, (ii) has net assets of not less
than $500,000,000, and (iii) has the highest rating obtainable from either S&amp;P or Moody&rsquo;s.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Certificate
Regarding Non-Bank Status</U></FONT>&rdquo; means a certificate substantially in the form of <U>Exhibit D</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Change
of Control</U>&rdquo; means, at any time, any of the following occurrences:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Person or &ldquo;group&rdquo; (within the meaning of Rules 13d 3 and 13d 5 under the Exchange Act) (i) shall have acquired beneficial
ownership of 50.1% or more on a fully diluted basis of the voting interest in the Capital Stock of Borrower or (ii) shall have
obtained the power (whether or not exercised) to elect a majority of the members of the Board of Directors (or similar governing
body) of Borrower;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
pursuant to a transaction permitted by this Agreement, Borrower shall cease to beneficially own and control, directly or indirectly,
100% on a fully diluted basis of the economic and voting interest in the Capital Stock of each Loan Party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
majority of the seats (other than vacant seats) on the Board of Directors (or similar governing body) of Borrower cease to be
occupied by Persons who either (i) were members of the Board of Directors of Borrower on the Closing Date, or (ii) were nominated
for election by the Board of Directors of Borrower, a majority of whom were directors on the Closing Date or whose election or
nomination for election was previously approved by a majority of such directors; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
&ldquo;change of control&rdquo; or similar event shall occur under, and as defined in or set forth in the documents evidencing
or governing, (i) the Capital Stock of Borrower if, as a result of such change of control or similar event, Borrower is required
to make a payment of $5,000,000 or more or (ii) any Indebtedness in an individual principal amount of $5,000,000 or more owed
by Borrower or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Closing
Date</U></FONT>&rdquo; means the date on which the Initial Term Loans are made, which is April 24, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Closing
Date Certificate</U></FONT>&rdquo; means a Closing Date Certificate substantially in the form of <U>Exhibit E</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Collateral</U></FONT>&rdquo;
means, collectively, all of the real, personal and mixed property (including Capital Stock to the extent permitted under any Loan
Document) and all interests therein and proceeds thereof now owned or hereafter acquired by any Person upon which a Lien is granted
or purported to be granted by such Person pursuant to the Collateral Documents as security for the Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Collateral
Access Agreement</U></FONT>&rdquo; means a collateral access agreement in form and substance reasonably satisfactory to Administrative
Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Collateral
Documents</U></FONT>&rdquo; means the Pledge and Security Agreement, the Mortgages, the Collateral Access Agreements, if any,
any Control Agreement, and all other instruments, documents and agreements delivered by any Loan Party pursuant to this Agreement
or any of the other Loan Documents in order to grant to Administrative Agent, for the benefit of Secured Parties, a Lien on any
real, personal or mixed property of that Loan Party as security for the Obligations, in each case, as such Collateral Documents
may be amended or otherwise modified from time to time, in accordance with and subject to the terms and conditions hereof and
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commitment</U>&rdquo;
means the Term Loan Commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Commodity
Exchange Act</U></FONT>&rdquo; means the Commodity Exchange Act (7 U.S.C. &sect; 1 et seq.), as amended from time to time, and
any successor statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Company</U></FONT>&rdquo;
has the meaning specified in the preamble hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Compliance
Certificate</U></FONT>&rdquo; means a Compliance Certificate substantially in the form of <U>Exhibit B</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Connection
Income Taxes</U>&rdquo; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that
are franchise Taxes or branch profits Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Contractual
Obligation</U></FONT>&rdquo; means, as applied to any Person, any provision of any Security issued by that Person or of any indenture,
mortgage, deed of trust, contract, license, undertaking, agreement or other instrument to which that Person is a party or by which
it or any of its properties is bound or to which it or any of its properties is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Control
Agreement</U></FONT>&rdquo; means a control agreement, in form and substance reasonably satisfactory to Administrative Agent,
executed and delivered by Borrower or a Guarantor Subsidiary, Administrative Agent, and the applicable securities intermediary
(with respect to a Securities Account) or bank (with respect to a Deposit Account).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion/Continuation
Date</U>&rdquo; means the effective date of a continuation or conversion, as the case may be, as set forth in the applicable Conversion/Continuation
Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Conversion/Continuation
Notice</U>&rdquo; means a Conversion/Continuation Notice substantially in the form of <U>Exhibit A-2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Controlled
Investment Affiliate</U>&rdquo; means, as to any Person, any other Person that (a) directly or indirectly, is in control of, is
controlled by, or is under common control with, such Person and (b) is organized by such Person primarily for the purpose of making
equity or debt investments in one or more companies. For purposes of this definition, &ldquo;control&rdquo; of a Person means
the power, directly or indirectly, to direct or cause the direction of the management and policies of such Person whether by contract
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Credit
Date</U>&rdquo; means the date of a Credit Extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Credit
Extension</U>&rdquo; means the making of a Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Debtor
Relief Law</U></FONT>&rdquo; means the Bankruptcy Code and any other liquidation, conservatorship, bankruptcy, assignment for
the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief law of
the United States or other applicable jurisdiction from time to time in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Declined
Proceeds</U></FONT>&rdquo; means the amount of Net Proceeds received in connection with a Waivable Mandatory Prepayment for which
a Lender has elected to waive its right to prepayment in accordance with <U>Section 2.11(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Default</U></FONT>&rdquo;
means a condition or event that, after notice or lapse of time or both, would constitute an Event of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Default
Excess</U></FONT>&rdquo; means, with respect to any Defaulting Lender, the excess, if any, of such Defaulting Lender&rsquo;s Pro
Rata Share of the aggregate outstanding principal amount of Term Loans of all Lenders (calculated as if all Defaulting Lenders
(other than such Defaulting Lender) had funded all of their respective Defaulted Loans) over the aggregate outstanding principal
amount of all Term Loans of such Defaulting Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Default
Period</U></FONT>&rdquo; means, with respect to any Defaulting Lender, the period commencing on the date of the applicable Funding
Default or violation of <U>Section 9.5(c)</U>, as applicable, and ending on the earliest of the following dates: (a) the date
on which all Commitments are cancelled or terminated and/or the Obligations are declared or become immediately due and payable,
in each case, in accordance with and subject to the terms and conditions of this Agreement, (b) the date on which (i) the Default
Excess with respect to such Defaulting Lender shall have been reduced to zero (whether by the funding by such Defaulting Lender
of any Defaulted Loans of such Defaulting Lender or by the non pro rata application of any voluntary or mandatory prepayments
of the Loans in accordance with and subject to the terms and conditions of <U>Section 2.9</U> or <U>Section 2.10</U> or by a combination
thereof), and (ii) such Defaulting Lender shall have delivered to Company and Administrative Agent a written reaffirmation of
its intention to honor its obligations hereunder with respect to its Commitments, (c) the date on which Company, Administrative
Agent and Required Lenders waive all Funding Defaults of such Defaulting Lender in writing and (d) if such Defaulting Lender is
a Defaulting Lender solely due to a violation of <U>Section 9.5(c)</U>, the date on which Administrative Agent shall have waived
all violations of <U>Section 9.5(c)</U> by such Defaulting Lender in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Defaulted
Loan</U></FONT>&rdquo; has the meaning specified in <U>Section 2.17</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Defaulting
Lender</U></FONT>&rdquo; has the meaning specified in <U>Section 2.17</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Default
Rate</U></FONT>&rdquo; means any interest payable pursuant to <U>Section 2.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw A-1 <FONT STYLE="font-weight: normal">Term Loan</FONT></U>&rdquo; means the Term Loan funded after the Closing Date pursuant
to <U>Section 2.1(a)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw A-1 Term <FONT STYLE="font-weight: normal">Loan Commitment</FONT></U>&rdquo; means the commitment of a Lender to make or
otherwise fund the Delayed Draw Term Loan and &ldquo;Delayed Draw A-1 Term Loan Commitments&rdquo; means such commitments of all
such Lenders in the aggregate. The amount of each Lender&rsquo;s Delayed Draw A-1 Term Loan Commitment, if any, is set forth on
<U>Appendix A-3</U> or in the applicable Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and
conditions hereof. The aggregate amount of the Delayed Draw A-1 Term Loan Commitments as of the Closing Date is $50,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw A-2 <FONT STYLE="font-weight: normal">Term Loan</FONT></U>&rdquo; means the Term Loan funded after the Closing Date pursuant
to <U>Section 2.1(a)(iii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw A-2 Term <FONT STYLE="font-weight: normal">Loan Commitment</FONT></U>&rdquo; means the commitment of a Lender to make or
otherwise fund the Delayed Draw Term Loan and &ldquo;Delayed Draw A-2 Term Loan Commitments&rdquo; means such commitments of all
such Lenders in the aggregate. The amount of each Lender&rsquo;s Delayed Draw A-2 Term Loan Commitment, if any, is set forth on
<U>Appendix A-4</U> or in the applicable Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and
conditions hereof. The aggregate amount of the Delayed Draw A-2 Term Loan Commitments as of the Closing Date is $50,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw <FONT STYLE="font-weight: normal">Term Loan</FONT></U>&rdquo; means, collectively, the Delayed Draw A-1 Term Loan and the
Delayed Draw A-2 Term Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw Term <FONT STYLE="font-weight: normal">Loan Commitment</FONT></U>&rdquo; means, collectively, the Delayed Draw A-1 Term Loan
Commitment and the Delayed Draw A-2 Term Loan Commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw Term Loan Commitment Period</U>&rdquo; means the time period commencing on the Closing Date through and including the Delayed
Draw Term Loan Commitment Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Delayed
Draw Commitment Termination Date</U>&rdquo; means the earliest to occur of (a) the date the Term Loan Commitments are permanently
reduced to zero in accordance with and pursuant to <U>Section 2.12(b)</U> or <U>2.13</U>, (b) the date of the termination of the
Term Loan Commitments in accordance with and pursuant to <U>Section 8.1</U>, (c) solely in the case of the Delayed Draw A-1 Term
Loan Commitment, January 23, 2020 (or such later date as may be consented to by the Required Lenders in their sole discretion)
and (d) solely in the case of the Delayed Draw A-2 Term Loan Commitment, March 31, 2020 (or such later date as may be consented
to by the Required Lenders in their sole discretion).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Deposit
Account</U></FONT>&rdquo; means a demand, time, savings, passbook or like account with a bank, savings and loan association, credit
union or like organization, other than an account evidenced by a negotiable certificate of deposit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disputes</U>&rdquo;
has the meaning set forth in <U>Section 4.23(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Disqualified
Capital Stock</U></FONT>&rdquo; means any Capital Stock that, by its terms (or by the terms of any security or other Capital Stock
into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition, (a) matures or
is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (b) is redeemable at the option of the holder thereof,
in whole or in part, (c) provides for the scheduled payments of dividends or distributions in cash, or (d) is convertible into
or exchangeable for (i) Indebtedness or (ii) any other Capital Stock that would constitute Disqualified Capital Stock, in each
case of clauses (a) through (d), prior to the date that is 91 days after the Term Loan Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disqualified
Institution</U>&rdquo; means (a) any Person designated by Borrower as a &ldquo;Disqualified Institution&rdquo; by written notice
delivered to Administrative Agent prior to the Closing Date and consented to by Administrative Agent and the named Affiliates
of each such Person which are clearly identifiable as such on the basis of each such Affiliate&rsquo;s name, (b) those Persons
that are competitors of any Loan Party or any Subsidiary thereof, and its named Affiliates, in each case to the extent identified
by Borrower to Administrative Agent in writing prior to the Closing Date and consented to by the Administrative Agent, and the
named Affiliates of each such Person which are clearly identifiable as such on the basis of such Affiliate&rsquo;s name or (c)
any other Person as Borrower and Administrative Agent shall mutually agree after the Closing Date; <U>provided</U>, that (x) the
Persons described in clause (b) above shall not include any Person that is engaged in making, purchasing, holding or otherwise
investing in commercial loans and similar extensions of credit in the ordinary course of business and (y) &ldquo;Disqualified
Institution&rdquo; shall exclude any Person that Borrower has designated as no longer being a &ldquo;Disqualified Institution&rdquo;
by written notice delivered to Administrative Agent from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Dollars</U></FONT>&rdquo;
and the sign &ldquo;<FONT STYLE="font-weight: normal"><U>$</U></FONT>&rdquo; mean the lawful money of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Eligible
Assignee</U></FONT>&rdquo; means (a) any Lender, any Affiliate of any Lender and any Related Fund (any two or more Related Funds
being treated as a single Eligible Assignee for all purposes hereof), (b) any commercial bank, insurance company, investment or
mutual fund or other entity that is an &ldquo;<FONT STYLE="font-weight: normal"><U>accredited investor</U></FONT>&rdquo; (as defined
in Regulation D under the Securities Act) and which other entity extends credit or buys loans as one of its or its Affiliates&rsquo;
businesses, and (c) any other Person (other than a natural Person); <U>provided</U>, (i) neither Borrower nor any Affiliate of
Borrower shall, in any event, be an Eligible Assignee, (ii) no Person owning or controlling any trade debt or Indebtedness of
any Loan Party (other than the Obligations) or any Capital Stock of any Loan Party (in each case, unless approved by Administrative
Agent) shall, in any event, be an Eligible Assignee and (iii) no Disqualified Institution shall be an Eligible Assignee so long
as no Event of Default has occurred and is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Employee
Benefit Plan</U>&rdquo; means any &ldquo;employee benefit plan&rdquo; as defined in Section 3(3) of ERISA which is or was sponsored,
maintained or contributed to by, or required to be contributed by, Borrower, any of its Subsidiaries or any of their respective
ERISA Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Environmental
Claim</U>&rdquo; means any complaint, summons, citation, investigation, notice, directive, notice of violation, order, claim,
demand, action, litigation, judicial or administrative proceeding, judgment, letter or other communication from any Governmental
Authority or any other Person, involving (a) any actual or alleged violation of any Environmental Law; (b) any Hazardous Material
or any actual or alleged Hazardous Materials Activity; (c) injury to the environment, natural resource, any Person (including
wrongful death) or property (real or personal) in connection with Hazardous Materials or actual or alleged violations of Environmental
Laws; or (d) actual or alleged Releases or threatened Releases of Hazardous Materials either (i) on, at or migrating from any
assets, properties or businesses currently or formerly owned or operated by any Loan Party or any of its Subsidiaries or any predecessor
in interest, (ii) from adjoining properties or businesses, or (iii) onto any facilities which received Hazardous Materials generated
by any Loan Party or any of its Subsidiaries or any predecessor in interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Environmental
Laws</U>&rdquo; means any and all current or future foreign or domestic, federal or state (or any subdivision of either of them),
statutes, ordinances, orders, rules, regulations, judgments, decrees, permits, licenses or binding determinations of any Governmental
Authorizations, or any other requirements of Governmental Authorities relating to (a) the manufacture, generation, use, storage,
transportation, treatment, disposal or Release of Hazardous Materials; or (b) occupational safety and health, industrial hygiene,
land use or the protection of the environment, human, plant or animal health or welfare.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Environmental
Liabilities and Costs</U>&rdquo; means all liabilities, monetary obligations, losses (including monies paid in settlement), damages,
punitive damages, natural resources damages, consequential damages, treble damages, costs and expenses (including all reasonable
fees, disbursements and expenses of counsel, experts and consultants and costs of investigations and feasibility studies), fines,
penalties, sanctions and interest incurred in connection with any Remedial Action, any Environmental Claim, or any other claim
or demand by any Governmental Authority or any Person that relates to any actual or alleged violation of Environmental Laws, actual
or alleged exposure or threatened exposure to Hazardous Materials, or any actual or alleged Release or threatened Release of Hazardous
Materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Environmental
Lien</U>&rdquo; means any Lien in favor of any Governmental Authority for Environmental Liabilities and Costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Equity
Issuance</U>&rdquo; means, without duplication, either (a) the sale or issuance by Borrower of any shares of its Capital Stock
or (b) the receipt by Borrower of any cash capital contributions in respect of Capital Stock of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended from time to time, and any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>ERISA
Affiliate</U>&rdquo; means, as applied to any Person, (a) any corporation which is a member of a controlled group of corporations
within the meaning of Section 414(b) of the Internal Revenue Code of which that Person is a member; (b) any trade or business
(whether or not incorporated) which is a member of a group of trades or businesses under common control within the meaning of
Section 414(c) of the Internal Revenue Code of which that Person is a member; and (c) any member of an affiliated service group
within the meaning of Section 414(m) or (o) of the Internal Revenue Code of which that Person, any corporation described in <U>clause
(a)</U> above or any trade or business described in <U>clause (b)</U> above is a member.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>ERISA
Event</U>&rdquo; means (a) a &ldquo;reportable event&rdquo; within the meaning of Section 4043 of ERISA and the regulations issued
thereunder with respect to any Pension Plan (excluding those for which the provision for thirty day notice to the PBGC has been
waived by regulation); (b) the failure to meet the minimum funding standard of Section 412 of the Internal Revenue Code with respect
to any Pension Plan (whether or not waived in accordance with Section 412(d) of the Internal Revenue Code) or the failure to make
by its due date a required installment under Section 412(m) of the Internal Revenue Code with respect to any Pension Plan or the
failure to make any required contribution to a Multiemployer Plan; (c) the provision by the administrator of any Pension Plan
pursuant to Section 4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in Section
4041(c) of ERISA; (d) [reserved]; (e) the institution by the PBGC of proceedings to terminate any Pension Plan, or the occurrence
of any event or condition which might constitute grounds under ERISA for the termination of, or the appointment of a trustee to
administer, any Pension Plan; (f) the imposition of liability on Borrower, any of its Subsidiaries or any of their respective
ERISA Affiliates pursuant to Section 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (g)
the withdrawal of Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates in a complete or partial withdrawal
(within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefor,
or the receipt by Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of notice from any Multiemployer
Plan that it is in insolvency pursuant to Section 4245 of ERISA, or that it intends to terminate or has terminated under Section
4041A or 4042 of ERISA; (h) [reserved]; (i) the assertion of a material claim (other than routine claims for benefits) against
any Employee Benefit Plan other than a Multiemployer Plan or the assets thereof, or against Borrower, any of its Subsidiaries
or any of their respective ERISA Affiliates in connection with any Employee Benefit Plan; (j) receipt from the Internal Revenue
Service of notice of the failure of any Pension Plan (or any other Employee Benefit Plan intended to be qualified under Section
401(a) of the Internal Revenue Code) to qualify under Section 401(a) of the Internal Revenue Code, or the failure of any trust
forming part of any Pension Plan to qualify for exemption from taxation under Section 501(a) of the Internal Revenue Code; or
(k) the imposition of a Lien pursuant to Section 401(a)(29) or 412(n) of the Internal Revenue Code or pursuant to ERISA with respect
to any Pension Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Event
of Default</U></FONT>&rdquo; means each of the conditions or events set forth in <U>Section 8.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Exchange
Act</U></FONT>&rdquo; means the Securities Exchange Act of 1934, as amended from time to time, and any successor statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;</I><U>Excluded
Account</U><I>&rdquo;</I> means (i) Deposit Accounts and Securities Accounts the balance of which consists exclusively of (a)
withheld income Taxes and federal, state or local employment Taxes in such amounts as are required to be paid to the Internal
Revenue Service or state or local government agencies within the following two months with respect to employees of the Company
or any of its Subsidiaries, and (b) any payroll accounts, health care reimbursement accounts and employee benefits accounts, including
any accounts containing amounts required to be paid over to an employee benefit plan pursuant to DOL Reg. Sec. 2510.3-102 on behalf
of or for the benefit of employees of the Company or any of its Subsidiaries, (ii) all segregated Deposit Accounts constituting
(and the balance of which consists solely of funds set aside in connection with) tax accounts, fiduciary accounts and trust accounts
and (iii) any Deposit Accounts and Securities Accounts, amounts on deposit in which do not exceed $100,000 individually or $500,000
in the aggregate at any one time or (iv) any Deposit Accounts that contain accounts receivable arising from any Governmental Payor
where Administrative Agent may not under applicable Law obtain a security interest in or lien on such Deposit Account receiving
the proceeds of such accounts receivable; <U>provided</U>, that amounts in such Deposit Account referred to in this subclause
(iv) are automatically transferred on each Business Day into a Deposit Account that is not an Excluded Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Excluded
Taxes</U>&rdquo; has the meaning specified in <U>Section 2.15(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Existing
Indebtedness</U>&rdquo; means Indebtedness and other obligations outstanding under that certain Credit and Security Agreement,
dated as of May 1, 2018, between the Loan Parties, MidCap Financial Trust, as agent, and the lenders from time to time party thereto,
as amended prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Extraordinary
Receipts</U>&rdquo; means any cash received by Borrower or any of its Subsidiaries not in the ordinary course of business (and
not consisting of proceeds described in <U>Section 2.10(a)</U> or <U>(b)</U> hereof), including, without limitation, (a) foreign,
United States, state or local Tax refunds, (b) pension plan reversions, (c) judgments, proceeds of settlements or other consideration
of any kind in connection with any cause of action (including, without limitation, infringement proceeds, breach of contract claims,
damages (including treble damages), settlement amounts and other payments) received by Company from any of its existing or future
licensees under any license or settlement agreement or recovered by Company, in each case, pursuant to any enforcement of any
of the Product Patents or any license agreement relating thereto against third parties), and (d) condemnation awards (and payments
in lieu thereof), (e) indemnity payments not received in the ordinary course of business, and (f) any purchase price adjustment
received in connection with any purchase agreement entered into in connection with the acquisition by a Loan Party of (i) any
Capital Stock of another Person or (ii) all or substantially all of the assets of another Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Facility
Fee</U>&rdquo; has the meaning set forth in the Fee Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Fair
Share</U></FONT>&rdquo; has the meaning specified in <U>Section 7.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FASB
ASC</U>&rdquo; means the Accounting Standards Codification of the Financial Accounting Standards Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>FATCA</U></FONT>&rdquo;
means Sections 1471 through 1474 of the Internal Revenue Code, in effect as of the date of this Agreement (or any amended or successor
version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or
official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code and
any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention
among Governmental Authorities and implementing such Sections of the Internal Revenue Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>FDA</U></FONT>&rdquo;
means the U.S. Food and Drug Administration or any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>FDA
Laws</U></FONT>&rdquo; means all applicable statutes, rules, regulations, standards, guidelines, policies and orders and Requirements
of Law administered, implemented, enforced or issued by FDA or any comparable Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Federal
Funds Effective Rate</U>&rdquo; means for any day, the rate per annum (expressed, as a decimal, rounded upwards, if necessary,
to the next higher 1/100 of 1%) equal to the weighted average of the rates on overnight Federal funds transactions with members
of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal Reserve Bank of New York
on the Business Day next succeeding such day; <U>provided</U>, if such day is not a Business Day, the Federal Funds Rate for such
day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Federal
Healthcare Program Laws</U></FONT>&rdquo; means collectively, federal Medicare or federal or state Medicaid statutes, Sections
1128, 1128A, 1128B, 1128C or 1877 of the SSA (42 U.S.C. &sect;&sect; 1320a-7, 1320a-7a, 1320a-7b, 1320a-7c and 1395nn), the federal
TRICARE statute (10 U.S.C. &sect; 1071 et seq.), the civil False Claims Act of 1863 (31 U.S.C. &sect; 3729 et seq.), criminal
false claims statutes (e.g., 18 U.S.C. &sect;&sect; 287 and 1001), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. &sect;
3801 et seq.), HIPAA, or related regulations or other Requirements of Law that directly or indirectly govern the health care industry,
programs of Governmental Authorities related to healthcare, health care professionals or other health care participants, or relationships
among health care providers, suppliers, distributors, manufacturers and patients, and the pricing, sale and reimbursement of health
care items or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Fee
Letter</U>&rdquo; means the letter agreement, dated as of the Closing Date, between Company and Administrative Agent, as amended,
amended and restated, supplemented or otherwise modified from time to time in accordance with and subject to the terms and conditions
hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Financial
Officer Certification</U></FONT>&rdquo; means, with respect to the financial statements for which such certification is required,
the certification of the chief financial officer of Borrower that such financial statements fairly present, in all material respects,
the financial condition of Borrower and its Subsidiaries as at the dates indicated and the results of their operations and their
cash flows for the periods indicated, subject to changes resulting from audit and normal year-end adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Fiscal
Quarter</U></FONT>&rdquo; means a fiscal quarter of any Fiscal Year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Fiscal
Year</U></FONT>&rdquo; means the fiscal year of Borrower and its Subsidiaries ending on December 31 of each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Flood
Hazard Property</U>&rdquo; means any real property subject to a mortgage in favor of Administrative Agent, for the benefit of
the Secured Parties, and located in an area designated by the Federal Emergency Management Agency as having special flood or mud
slide hazards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Flow
of Funds Agreement</U>&rdquo; means that certain Flow of Funds Agreement, dated as of the Closing Date, executed by each Loan
Party, the Administrative Agent, each Lender and any other person party thereto, in form and substance reasonably satisfactory
to the Administrative Agent, in connection with the disbursement of Loan proceeds in accordance with <U>Section 2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Foreign
Official</U></FONT>&rdquo; means any officer or employee of a non-U.S. government or any department, agency, or instrumentality
thereof, or of a public international organization, or any person acting in an official capacity for or on behalf of any such
government or department, agency, or instrumentality, or for or on behalf of any such public international organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Funding
Default</U>&rdquo; has the meaning specified in <U>Section 2.17</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Funding
Notice</U></FONT>&rdquo; means a notice substantially in the form of <U>Exhibit A-1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>GAAP</U></FONT>&rdquo;
means, subject to the limitations on the application thereof set forth in <U>Section 1.2</U>, United States generally accepted
accounting principles in effect as of the date of determination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Governmental
Authority</U></FONT>&rdquo; means any federal, state, municipal, national or other government, governmental department, commission,
board, bureau, court, agency or instrumentality or political subdivision thereof or any entity or officer exercising executive,
legislative, judicial, regulatory or administrative functions of or pertaining to any government or any court, in each case whether
associated with a state of the United States, the United States, or a foreign entity or government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Governmental
Authorization</U></FONT>&rdquo; means any permit, license, authorization, plan, directive, consent order or consent decree of
or from any Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Governmental
Payor</U>&rdquo; means Medicare, Medicaid, TRICARE, CHAMPVA, any state health plan adopted pursuant to Title XIX of the Social
Security Act, any other state or federal health care program and any other Governmental Authority which maintains a payment or
reimbursement program, and in which any Loan Party or Subsidiary thereof directly participates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Grantor</U></FONT>&rdquo;
has the meaning specified in the Pledge and Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Guaranteed
Obligations</U></FONT>&rdquo; has the meaning specified in <U>Section 7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt; font: normal 9pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Guarantor</U></FONT>&rdquo;
means, subject to <U>Section 5.10</U>, each Subsidiary of Borrower and each other Person which guarantees, pursuant to <U>Article
VII</U> or otherwise, all or any part of the Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Guarantor
Subsidiary</U>&rdquo; means each Guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Guaranty</U></FONT>&rdquo;
means (a) the guaranty of each Guarantor set forth in <U>Article VII</U> and (b) each other guaranty, in form and substance reasonably
satisfactory to Administrative Agent, made by any other Guarantor for the benefit of the Secured Parties guaranteeing all or part
of the Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Hazardous
Materials</U>&rdquo; means, regardless of amount or quantity, (a) any element, compound or chemical that is defined, listed or
otherwise classified as a contaminant, pollutant, toxic pollutant, toxic or hazardous substance, extremely hazardous substance
or chemical, hazardous waste, special waste, or solid waste under Environmental Laws or that is likely to cause immediately, or
at some future time, harm to or have an adverse effect on, the environment or risk to human health or safety, including, without
limitation, any pollutant, contaminant, waste, hazardous waste, toxic substance or dangerous good which is defined or identified
in any Environmental Law and which is present in the environment in such quantity or state that it contravenes any Environmental
Law; (b) petroleum and its refined products; (c) polychlorinated biphenyls; (d) any substance exhibiting a hazardous waste characteristic,
including, without limitation, corrosivity, ignitability, toxicity or reactivity as well as any radioactive or explosive materials;
(e) any raw materials, building components (including, without limitation, asbestos-containing materials) and manufactured products
containing hazardous substances listed or classified as such under Environmental Laws; and (f) any substance or materials that
are otherwise regulated under Environmental Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Hazardous
Materials Activity</U>&rdquo; means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous
Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, Release, threatened Release,
discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal,
disposition or handling of any Hazardous Materials, and any corrective action or response action with respect to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Highest
Lawful Rate</U></FONT>&rdquo; means the maximum lawful interest rate, if any, that at any time or from time to time may be contracted
for, charged, or received under the laws applicable to any Lender which are presently in effect or, to the extent allowed by law,
under such applicable laws which may hereafter be in effect and which allow a higher maximum non-usurious interest rate than applicable
laws now allow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>HIPAA</U></FONT>&rdquo;
means the Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical
Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009), and other state or local laws regulating the privacy
and/or security of patient-identifying health care information, including with respect to notification of breach of privacy or
security of such information,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Historical
Financial Statements</U></FONT>&rdquo; means as of the Closing Date, (a) the audited consolidated financial statements of Borrower
and its Subsidiaries, for the Fiscal Year ended December 31, 2018 consisting of consolidated balance sheets and the related consolidated
statements of income, stockholders&rsquo; equity and cash flows for such Fiscal Year, and (b) the internally prepared, unaudited
consolidated financial statements of Borrower and its Subsidiaries for each fiscal month ended January 31, 2019, February 28,
2019 and March 31, 2019, consisting of a consolidated balance sheet and the related consolidated statements of income and cash
flows for such fiscal month, in the case of <U>clauses (a)</U> and <U>(b)</U>, certified by the chief financial officer of Borrower
that they fairly present, in all material respects, the financial condition of Borrower and its Subsidiaries as at the dates indicated
and the results of their operations and their cash flows for the periods indicated, subject, if applicable, to changes resulting
from audit and normal year-end adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Imvexxy</U>&rdquo;
means (a) the IMVEXXY (estradiol vaginal inserts) product approved for commercialization in the U.S. as of the Closing Date, and
(b) any other vaginal product being developed or commercialized for the treatment of vaginal atrophy by the Company (or any Affiliate
thereof that is controlled by the Company), or any of its licensees or sub-licensees (now or in the future) (in the case of such
licensees or sub-licensees, solely with respect to development or commercialization pursuant to agreements with the Company or
any of its Subsidiaries) that contains estradiol as the sole active ingredient (and in the case of clause (a) and clause (b) above,
including any of their respective derivatives, polymorphs, isomers, prodrugs, metabolites, esters, salts and other forms, formulations,
and methods of delivery thereof), commercialized in any country of the world under any brand name.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Imvexxy
Patents</U>&rdquo; means the U.S. and foreign patents and pending patent applications owned or in-licensed by Company or any of
its Subsidiaries, now or in the future, that relate to, or otherwise may be useful in connection with, the research, development,
manufacture, use, or sale of Imvexxy..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Increased
Cost Lenders</U>&rdquo; has the meaning specified in <U>Section 2.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Indebtedness</U></FONT>&rdquo;
means, as applied to any Person, without duplication, (a) all indebtedness for borrowed money; (b) that portion of obligations
with respect to Capital Leases that is properly classified as a liability on a balance sheet in conformity with GAAP as in effect
on December 31, 2018; (c) all obligations of such Person evidenced by notes, bonds or similar instruments or upon which interest
payments are customarily paid and all obligations in respect of notes payable and drafts accepted representing extensions of credit
whether or not representing obligations for borrowed money; (d) any obligation owed for all or any part of the deferred purchase
price of property or services, including any earn-outs or other deferred payment obligations in connection with an acquisition
(excluding (i) trade payables incurred in the ordinary course of business and repayable in accordance with customary trade terms
and (ii) accruals for payroll and other liabilities accrued in the ordinary course of business), in each case, if such obligation
or earn-outs are classified as a liability on the balance sheet of such Person in accordance with GAAP; (e) all obligations created
or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person; (f)
all indebtedness secured by any Lien on any property or asset owned or held by that Person regardless of whether the indebtedness
secured thereby shall have been assumed by that Person or is non-recourse to the credit of that Person; (g) the face amount of
any letter of credit or letter of guaranty issued, bankers&rsquo; acceptances facilities, surety bonds and similar credit transactions
issued for the account of that Person or as to which that Person is otherwise liable for reimbursement of drawings; (h) the direct
or indirect guaranty, endorsement (otherwise than for collection or deposit in the ordinary course of business), co-making, discounting
with recourse or sale with recourse by such Person of the obligation of another; (i) any guarantee of such Person the primary
purpose or intent of which is to provide assurance to an obligee that the obligation of the obligor thereof will be paid or discharged;
(j) any liability of such Person for an obligation of another through any agreement (contingent or otherwise) (i) to purchase,
repurchase or otherwise acquire such obligation or any security therefor, or to provide funds for the payment or discharge of
such obligation (whether in the form of loans, advances, stock purchases, or capital contributions or otherwise) or (ii) to maintain
the solvency or any balance sheet item, level of income or financial condition of another if, in the case of any agreement described
under <U>subclauses (i)</U> or <U>(ii)</U> of this <U>clause (j)</U>, the primary purpose or intent thereof is as described in
<U>clause (i)</U> above; and (k) all obligations of such Person in respect of any exchange traded or over the counter derivative
transaction, including, without limitation, any Interest Rate Agreement, whether entered into for hedging or speculative purposes
and (l) Disqualified Capital Stock. The Indebtedness of any Person shall include the Indebtedness of any partnership or joint
venture in which such Person is a general partner or joint venturer, unless such Indebtedness is expressly non-recourse to such
Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Liabilities</U>&rdquo; means, collectively, any and all liabilities (including Environmental Liabilities and Costs), obligations,
losses, damages (including natural resource damages), penalties, claims (including Environmental Claims), costs (including the
costs of any investigation, study, sampling, testing, abatement, cleanup, removal, remediation or other response action necessary
to remove, remediate, clean up or abate any Hazardous Materials Activity), expenses and disbursements of any kind or nature whatsoever
(including the reasonable and documented out-of-pocket fees and disbursements of counsel for Indemnitees in connection with any
investigative, administrative or judicial proceeding commenced or threatened by any Person, whether or not any such Indemnitee
shall be designated as a party or a potential party thereto, and any fees or expenses incurred by Indemnitees in enforcing this
indemnity), whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules
or regulations (including securities and commercial laws, statutes, rules or regulations and Environmental Laws), on common law
or equitable cause or on contract or otherwise, that may be imposed on, incurred by, or asserted in writing against any such Indemnitee,
in any manner relating to or arising out of (a) this Agreement or the other Loan Documents or the transactions contemplated hereby
or thereby (including the Lenders&rsquo; agreement to make Credit Extensions or the use or intended use of the proceeds thereof,
or any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the
Collateral or the enforcement of the Guaranty)); (b) the statements contained in the proposal letter delivered by any Lender to
Company prior to the Closing Date with respect to the transactions contemplated by this Agreement; or (c) any Environmental Claim
or any Hazardous Materials Activity relating to or arising from, directly or indirectly, any past or present activity, operation,
land ownership, or practice of Borrower or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Indemnified
Taxes</U></FONT>&rdquo; means (a) Taxes (other than Excluded Taxes) imposed on or with respect to any payment made by or on account
of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in clause (a), Other
Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Indemnitee</U></FONT>&rdquo;
has the meaning specified in <U>Section 10.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Indemnitee
Agent Party</U></FONT>&rdquo; has the meaning specified in <U>Section 9.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Initial
<FONT STYLE="font-weight: normal">Term Loan</FONT></U>&rdquo; means the Term Loan funded on the Closing Date pursuant to <U>Section
2.1(a)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Initial
<FONT STYLE="font-weight: normal">Term Loan Commitment</FONT></U>&rdquo; means the commitment of a Lender to make or otherwise
fund the Initial Term Loan and &ldquo;Initial Term Loan Commitments&rdquo; means such commitments of all such Lenders in the aggregate.
The amount of each Lender&rsquo;s Initial Term Loan Commitment, if any, is set forth on <U>Appendix A-1</U> or in the applicable
Assignment Agreement, subject to any adjustment or reduction pursuant to the terms and conditions hereof. The aggregate amount
of the Initial Term Loan Commitments as of the Closing Date is $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Insolvency
Proceeding</U></FONT>&rdquo; means any proceeding commenced by or against any Person under any provision of any Debtor Relief
Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Intercompany
Subordination Agreement</U></FONT>&rdquo; means that certain Intercompany Subordination Agreement, dated as of the date hereof,
made by the Loan Parties and their Subsidiaries in favor of Administrative Agent for the benefit of the Secured Parties in form
and substance satisfactory to Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Interest
Payment Date</U>&rdquo; means (a) with respect to any Base Rate Loan, the last Business Day of each Fiscal Quarter, commencing
on the first such date to occur after the Closing Date; (b) with respect to any LIBOR Rate Loan, (i) the last Business Day of
each Fiscal Quarter, commencing on the first such date to occur after the Closing Date and (ii) the last day of each Interest
Period applicable to such Loan; and (c) with respect to each Loan, the final maturity date of the Loans (whether by scheduled
maturity, acceleration or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<U>Interest
Period</U>&rdquo; means, in connection with a LIBOR Rate Loan, an interest period of three months (a) initially, commencing on
the Credit Date or Conversion/Continuation Date thereof, as the case may be; and (b) thereafter, commencing on the day on which
the immediately preceding Interest Period expires; <U>provided</U>, (i) if an Interest Period would otherwise expire on a day
that is not a Business Day, such Interest Period shall expire on the next succeeding Business Day unless no further Business Day
occurs in such month, in which case such Interest Period shall expire on the immediately preceding Business Day; (ii) any Interest
Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day
in the calendar month at the end of such Interest Period) shall, subject to <U>clauses (b)(iii)</U> and <U>(b)(iv)</U> of this
definition, end on the last Business Day of a calendar month; and (iii) no Interest Period with respect to any portion of any
Term Loan shall extend beyond Term Loan Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Interest
Rate Agreement</U></FONT>&rdquo; means any interest rate swap agreement, interest rate cap agreement, interest rate collar agreement,
interest rate hedging agreement or other similar agreement or arrangement, each of which is (a) for the purpose of hedging the
interest rate exposure associated with Borrower&rsquo;s and its Subsidiaries&rsquo; operations, (b) approved by Administrative
Agent, and (c) not for speculative purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Interest
Rate Determination Date</U>&rdquo; means, with respect to any Interest Period, the date that is two Business Days prior to the
first day of such Interest Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Internal
Revenue Code</U></FONT>&rdquo; means the Internal Revenue Code of 1986, as amended to the date hereof and from time to time hereafter,
and any successor statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Investment</U></FONT>&rdquo;
means (a) any direct or indirect purchase or other acquisition by Borrower or any of its Subsidiaries of, or of a beneficial interest
in, any of the securities or Capital Stock or all or substantially all of the assets of any other Person (or of any division or
business line of such other Person); (b) any direct or indirect redemption, retirement, purchase or other acquisition for value,
by any Subsidiary of Borrower from any Person, of any Capital Stock of such Person; (c) any direct or indirect loan, advance or
capital contributions by Borrower or any of its Subsidiaries to any other Person, including all indebtedness and accounts receivable
from that other Person that are not current assets or did not arise from sales to that other Person in the ordinary course of
business; and (d) any direct or indirect Guarantee of any obligations of any other Person. The amount of any Investment shall
be the original cost of such Investment plus the cost of all additions thereto, without any adjustments for increases or decreases
in value, or write ups, write downs or write offs with respect to such Investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Joint
Venture</U></FONT>&rdquo; means a joint venture, partnership or other similar arrangement, whether in corporate, partnership or
other legal form; <U>provided</U>, in no event shall any corporate Subsidiary of any Person be considered to be a Joint Venture
to which such Person is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Lender</U></FONT>&rdquo;
means each lender listed on the signature pages hereto as a Lender, and any other Person that becomes a party hereto in accordance
with and subject to the terms and conditions hereof pursuant to an Assignment Agreement other than any Person that ceases to be
a party hereto pursuant to any Assignment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<FONT STYLE="font-weight: normal"><U>Liabilities</U></FONT>&rdquo;
means all claims, actions, suits, judgments, damages, losses, liability, obligations, responsibilities, fines, penalties, sanctions,
costs, fees, Taxes, commissions, charges, disbursements and expenses, in each case of any kind or nature (including interest accrued
thereon or as a result thereto and fees, charges and disbursements of financial, legal and other advisors and consultants), whether
joint or several, whether or not indirect, contingent, consequential, actual, punitive, treble or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>LIBOR
Rate Loan</U>&rdquo; means a Loan bearing interest at a rate determined by reference to the Adjusted LIBOR Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Lien</U></FONT>&rdquo;
means (a) any lien, mortgage, pledge, assignment, hypothec, deed of trust, security interest, charge or encumbrance of any kind
(including any agreement to give any of the foregoing, any conditional sale or other title retention agreement, and any lease
in the nature thereof) and any option, trust or other preferential arrangement having the practical effect of any of the foregoing,
and (b) in the case of securities or Capital Stock, any purchase option, call or similar right of a third party with respect to
such securities or Capital Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Loan</U></FONT>&rdquo;
means any Term Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Loan
Account</U></FONT>&rdquo; means an account maintained hereunder by Administrative Agent on its books of account at the Payment
Office, and with respect to Company, in which it will be charged with the Term Loan made to, and all other Obligations incurred
by the Loan Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Loan
Document</U></FONT>&rdquo; means any of this Agreement, the Notes, if any, the Collateral Documents, the Fee Letter, the Flow
of Funds Agreement, any Guaranty, the Intercompany Subordination Agreement, and all other material documents, instruments or agreements
executed and delivered by a Loan Party for the benefit of Administrative Agent or any Lender in connection herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Loan
Party</U></FONT>&rdquo; means Company or any Guarantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Loan
Party Partner</U></FONT>&rdquo; has the meaning set forth in <U>Section 4.33(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Margin
Stock</U></FONT>&rdquo; has the meaning specified in Regulation U of the Board of Governors of the Federal Reserve System as in
effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Material
Adverse Effect</U></FONT>&rdquo; means a material adverse effect on (a) the business operations, properties, assets, condition
(financial or otherwise) or liabilities of Borrower and its Subsidiaries taken as a whole; (b) the ability of any Loan Party to
fully and timely perform its obligations under any Loan Document to which it is a party; (c) the legality, validity, binding effect,
or enforceability against a Loan Party of a Loan Document to which it is a party; (d) the Collateral or the validity, perfection
or priority of Administrative Agent&rsquo;s Liens on the Collateral except as expressly permitted in the Collateral Documents;
(e) the rights, remedies and benefits available to, or conferred upon, Administrative Agent and any Lender or any other Secured
Party under any Loan Document; (f) any Product; and (g) the Product Patents for a particular Product (taken as a whole); or (h)
any Registration by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Material
Contract</U></FONT>&rdquo; means any contract or other written arrangement to which Borrower or any of its Subsidiaries is a party
(other than the Loan Documents), now or in the future, for which breach, non-performance, cancellation or failure to renew would
reasonably be expected to have a Material Adverse Effect, which, as of the Closing Date, are those contracts and arrangements
listed on <U>Schedule 4.15</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Material
Regulatory Liabilities</U></FONT>&rdquo; means (a)(i) any Liabilities arising from the violation of FDA Laws, Public Health Laws,
Federal Health Care Program Laws, and other applicable comparable Requirements of Law, or the terms, conditions of or requirements
applicable to any Registrations (including costs of actions required under applicable Requirements of Law, including FDA Laws
and Federal Health Care Program Laws, or necessary to remedy any violation of any terms or conditions applicable to any Registrations),
including, but not limited to, withdrawal of approval, recall, revocation, suspension, import detention and seizure of any Product,
and (ii) any loss of recurring annual revenues as a result of any loss, suspension or limitation of any Registrations, which,
in the case of the foregoing clauses (i) and (ii), exceed $1,000,000, individually or in the aggregate, or (b) any Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Moody&rsquo;s</U></FONT>&rdquo;
means Moody&rsquo;s Investor Services, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Mortgage</U>&rdquo;
means a mortgage, deed of trust or deed to secure debt, in form and substance satisfactory to Administrative Agent, made by a
Loan Party in favor of Administrative Agent for the benefit of the Secured Parties, securing the Obligations and delivered to
Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Multiemployer
Plan</U>&rdquo; means any Employee Benefit Plan which is a &ldquo;multiemployer plan&rdquo; as defined in Section 3(37) of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Net
Proceeds</U></FONT>&rdquo; means (a) with respect to any Asset Sale, an amount equal to: (i) all Cash payments received by Borrower
or any of its Subsidiaries from such Asset Sale, <U>minus</U> (ii) any bona fide costs or expenses incurred in connection with
such Asset Sale that are properly attributable to such Asset Sale to the extent paid or payable to non-Affiliates, including (A)
income or gains Taxes payable by the seller as a result of any gain recognized in connection with such Asset Sale during the Tax
period the sale occurs, (B) payment of the outstanding principal amount of, premium or penalty, if any, and interest on any Indebtedness
(other than the Loans) that is secured by a Lien on the stock or assets in question and that is required to be repaid under the
terms thereof as a result of such Asset Sale, (C) a reasonable reserve for any indemnification payments (fixed or contingent)
attributable to seller&rsquo;s indemnities and representations and warranties to purchaser in respect of such Asset Sale undertaken
by Borrower or any of its Subsidiaries in connection with such Asset Sale , and (D) any reasonable and documented out-of-pocket
fees or expenses incurred in connection therewith; <U>provided</U> that upon release of any such reserve, the amount released
shall be considered Net Proceeds; and (b) with respect to any insurance, condemnation, taking or other casualty proceeds, an amount
equal to: (i) any Cash payments or proceeds received by Borrower or any of its Subsidiaries (A) under any casualty or business
interruption insurance policies in respect of any covered loss thereunder, or (B) as a result of the condemnation or taking of
any assets of Borrower or any of its Subsidiaries by any Person pursuant to the power of eminent domain, condemnation or otherwise,
or pursuant to a sale of any such assets to a purchaser with such power under threat of such a taking, <U>minus</U> (ii) (A) any
actual costs or expenses incurred by Borrower or any of its Subsidiaries in connection with the adjustment or settlement of any
claims of Borrower or such Subsidiary in respect thereof, and (B) any bona fide costs or expenses incurred in connection with
any sale of such assets as referred to in <U>clause (b)(i)(B)</U> of this definition to the extent paid or payable to non-Affiliates,
including income Taxes payable as a result of any gain recognized in connection therewith and properly attributable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Non-US
Lender</U></FONT>&rdquo; has the meaning specified in <U>Section 2.15(e)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Note</U></FONT>&rdquo;
means a promissory note evidencing the Initial Term Loan or a Delayed Draw Term Loan, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Notice</U>&rdquo;
means a Funding Notice or a Conversion/Continuation Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Obligations</U></FONT>&rdquo;
means all obligations of every nature of each Loan Party and its Subsidiaries from time to time owed to the Administrative Agent
(including former Administrative Agents), the Lenders or any of them, under any Loan Document, whether for principal, interest
(including interest which, but for the filing of a petition in bankruptcy with respect to such Loan Party, would have accrued
on any Obligation, whether or not a claim is allowed against such Loan Party for such interest in the related bankruptcy proceeding),
the Prepayment Premium (if any), fees, expenses, indemnification or otherwise and whether primary, secondary, direct, indirect,
contingent, fixed or otherwise (including obligations of performance).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>OFAC</U></FONT>&rdquo;
has the meaning specified in the definition of &ldquo;Anti-Terrorism Laws&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>OFAC
Sanctions Programs</U></FONT>&rdquo; means (a) the Requirements of Law and Executive Orders administered by OFAC, including but
not limited to, Executive Order No. 13224, and (b) the list of Specially Designated Nationals and Blocked Persons administered
by OFAC, in each case, as renewed, extended, amended, or replaced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Organizational
Documents</U></FONT>&rdquo; means (a) with respect to any corporation, its certificate or articles of incorporation or organization,
as amended, and its by-laws, as amended, (b) with respect to any limited partnership, its certificate of limited partnership,
as amended, and its partnership agreement, as amended, (c) with respect to any general partnership, its partnership agreement,
as amended, and (d) with respect to any limited liability company, its articles of organization, as amended, and its operating
agreement, as amended. In the event any term or condition of this Agreement or any other Loan Document requires any Organizational
Document to be certified by a secretary of state or similar governmental official, the reference to any such &ldquo;Organizational
Document&rdquo; shall only be to a document of a type customarily certified by such governmental official.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Other
Connection Taxes</U>&rdquo; has the meaning specified therefor in <U>Section 2.15(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Other
Taxes</U></FONT>&rdquo; has the meaning specified in <U>Section 2.15(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Participant
Register</U></FONT>&rdquo; has the meaning specified in <U>Section 10.6(h)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>PATRIOT
Act</U></FONT>&rdquo; has the meaning specified in <U>Section 4.29</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Payment
Office</U>&rdquo; means Administrative Agent&rsquo;s office located at 888 7th Avenue, 35th Floor New York, New York 10106, or
such other office or offices of Administrative Agent as may be designated in writing from time to time by Administrative Agent
to Collateral Agent and Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>PBGC</U></FONT>&rdquo;
means the Pension Benefit Guaranty Corporation or any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Pension
Plan</U></FONT>&rdquo; means any Employee Benefit Plan, other than a Multiemployer Plan, which is subject to Section 412 of the
Internal Revenue Code or Section 302 of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Perfection
Certificate</U></FONT>&rdquo; means a certificate in form reasonably satisfactory to Administrative Agent that provides information
with respect to the assets of each Loan Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Acquisition</U>&rdquo; means any acquisition by Company or any of its wholly owned Guarantor Subsidiaries, whether by purchase,
merger or otherwise, of all or substantially all of the assets of, all of the Capital Stock of, or a business line or unit or
a division of, any Person; <U>provided</U>,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;immediately
prior to, and after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or would result
therefrom;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable laws and
in conformity with all applicable Governmental Authorizations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of the acquisition of Capital Stock, all of the Capital Stock (except for any such securities in the nature of directors&rsquo;
qualifying shares required pursuant to applicable law) acquired or otherwise issued by such Person or any newly formed Guarantor
Subsidiary of Company in connection with such acquisition shall be owned 100% by Company or a Guarantor Subsidiary thereof, and
Company shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of Company, each of the actions
set forth in <U>Section 5.10</U> and/or <U>Section 5.11</U>, as applicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower
and its Subsidiaries shall be in compliance with the covenants set forth in <U>Section 6.8</U> on a pro forma basis after giving
effect to such acquisition as of the last day of the Fiscal Quarter most recently ended;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
shall have delivered to Administrative Agent at least 10 days (or such shorter period as agreed to by Administrative Agent in
writing) prior to such proposed acquisition, such information and documents that Administrative Agent may reasonably request,
including, without limitation, financial information with respect to such acquired assets and drafts of the respective acquisition
agreements related thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the acquisition shall have been approved by the Board of Directors or other governing body or
controlling Person of the Person acquired or the Person from whom such assets or division is acquired; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
total consideration (excluding any portion thereof paid with proceeds of an Equity Issuance) paid in connection with all such
acquisitions consummated since the Closing Date shall not exceed $50,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Permitted
Indebtedness</U></FONT>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted
Intercompany Investments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
incurred by Borrower or any of its Subsidiaries arising from agreements providing for indemnification or from guaranties or letters
of credit, surety bonds or performance bonds securing the performance of Company or any such Subsidiary pursuant to such agreements,
in connection with Permitted Acquisitions or Asset Sales permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
which may be deemed to exist pursuant to any guaranties, performance, surety, statutory, appeal or similar obligations incurred
in the ordinary course of business and Indebtedness constituting guaranties in the ordinary course of business of the obligations
of suppliers, customers, franchisees and licensees of Borrower and its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
in respect of netting services, overdraft protections and otherwise in connection with deposit accounts;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
described in <U>Schedule 6.1</U>, and any Permitted Refinancing Indebtedness in respect of such Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
in an aggregate amount not to exceed at any time $1,000,000 with respect to (i) Capital Leases and (ii) purchase money Indebtedness
(including any Indebtedness acquired in connection with a Permitted Acquisition); <U>provided</U> that any such Indebtedness shall
be secured only by the asset subject to such Capital Lease or by the asset acquired in connection with the incurrence of such
Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, so long as the amount of such
Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance
for the period in which such Indebtedness is incurred and such Indebtedness is outstanding only during such period;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;contingent
liabilities in respect of any indemnification obligation, adjustment of purchase price, non-compete, or similar obligation of
any Loan Party incurred in connection with the consummation of one or more Permitted Acquisitions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
of a Person whose assets or Capital Stock are acquired by the Borrower or any of its Subsidiaries in a Permitted Acquisition in
an aggregate amount not to exceed $1,000,000 at any one time outstanding; <U>provided</U>, that such Indebtedness (i) is either
purchase money Indebtedness or a Capital Lease with respect to equipment or mortgage financing with respect to a facility, (ii)
was in existence prior to the date of such Permitted Acquisition, and (iii) was not incurred in connection with, or in contemplation
of, such Permitted Acquisition;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unsecured
Indebtedness owing to the seller party to a Permitted Acquisition that is incurred by the applicable Loan Party in connection
with the consummation of one or more Permitted Acquisitions so long as (i) the aggregate principal amount for all such Indebtedness
does not exceed $10,000,000 at any one time outstanding, and (ii) such Indebtedness is subordinated to the Obligations on terms
and conditions reasonably acceptable to the Administrative Agent, and (iii) such Indebtedness is otherwise on terms and conditions
(including all economic terms and the absence of covenants) reasonably acceptable to the Administrative Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other
Indebtedness of Borrower and its Subsidiaries, which is unsecured and subordinated to the Obligations in a manner satisfactory
to Administrative Agent in an aggregate amount not to exceed at any time $5,000,000; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
incurred in the ordinary course of business in connection with workers&rsquo; compensation, unemployment insurance and other types
of social security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government
contracts, trade contracts, performance and return of money bonds and other similar obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Intercompany Investments</U>&rdquo; means Investments by (a) a Loan Party to or in another Loan Party, (b) a Subsidiary that is
not a Loan Party to or in another Subsidiary that is not a Loan Party, and (c) a Subsidiary that is not a Loan Party to or in
a Loan Party, so long as, in the case of a loan or an advance, the parties thereto are party to an Intercompany Subordination
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Permitted
Investments</U></FONT>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments
in Cash and Cash Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;equity
Investments owned as of the Closing Date in any Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted
Intercompany Investments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;loans
and advances to employees of Borrower and its Subsidiaries (i) made in the ordinary course of business, and (ii) any refinancings
of such loans after the Closing Date, in each case, in an aggregate amount not to exceed $1,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted
Acquisitions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments
described in <U>Schedule 6.7</U> as of the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant
of trade credit in the ordinary course of business or received in compromise or resolution of (A) obligations of trade creditors
or customers that were incurred in the ordinary course of business of the Company or any of its Subsidiaries, including pursuant
to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any trade creditor or customer; or (B)
litigation, arbitration or other disputes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;loans
and advances by Borrower or any of its Subsidiaries in lieu of, and not in excess of the amount of (after giving effect to any
other such loans or advances or Restricted Junior Payments in respect thereof), Restricted Junior Payments to the extent permitted
to be made to Borrower or any of its Subsidiaries in accordance with <U>Section 6.5(a)</U>, <U>(b)</U> or <U>(c)</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;so
long as no Event of Default has occurred and is continuing or would result therefrom, other Investments (other than any Investment
constituting a disposition or contribution of the Products or the Product Patents) in an aggregate amount not to exceed $10,000,000
at any time outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Permitted
Liens</U></FONT>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
in favor of Administrative Agent for the benefit of Secured Parties granted pursuant to any Loan Document;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
for Taxes if obligations with respect to such Taxes are being contested in good faith by appropriate proceedings promptly instituted
and diligently conducted and reserves required by GAAP have been made, so long as the aggregate amount of such Taxes does not
exceed $1,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;statutory
Liens of landlords, banks (and rights of set off), of carriers, warehousemen, mechanics, repairmen, workmen and materialmen, and
other Liens imposed by law (other than any such Lien imposed pursuant to Section 401 (a)(29) or 412(n) of the Internal Revenue
Code or by ERISA), in each case incurred in the ordinary course of business for amounts not yet overdue;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
incurred in the ordinary course of business in connection with workers&rsquo; compensation, unemployment insurance and other types
of social security, or to secure the performance of tenders, statutory obligations, surety and appeal bonds, bids, leases, government
contracts, trade contracts, performance and return of money bonds and other similar obligations, so long as no foreclosure, sale
or similar proceedings have been commenced with respect to any portion of the Collateral on account thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;easements,
rights of way, restrictions, encroachments, and other minor defects or irregularities in title, in each case which do not and
will not interfere in any material respect with the ordinary conduct of the business of Borrower or any of its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
interest or title of a lessor or sublessor under any lease of real estate permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
solely on any cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any letter of intent
or purchase agreement permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;purported
Liens evidenced by the filing of precautionary UCC financing statements relating solely to operating leases entered into in the
ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with
the importation of goods;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
zoning or similar law or right reserved to or vested in any governmental office or agency to control or regulate the use of any
real property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
described in <U>Schedule 6.2</U>; <U>provided</U> that any such Lien shall only secure the Indebtedness that it secures on the
Closing Date and any Permitted Refinancing Indebtedness in respect thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
securing Capital Leases or purchase money Indebtedness permitted pursuant to <U>clause (g)</U> of the definition of Permitted
Indebtedness; <U>provided</U>, any such Lien shall encumber only the asset subject to such Capital Lease or the asset acquired
with the proceeds of such Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
granted in the ordinary course of business on the unearned portion of insurance premiums securing the financing of insurance premiums
to the extent the financing is permitted under the definition of Permitted Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
assumed by Borrower and its Subsidiaries in connection with a Permitted Acquisition that secure Indebtedness permitted by clause
(j) of the definition of Permitted Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other
Liens incurred in the ordinary course of business of the Company or any Subsidiary of the Company with respect to obligations
that do not exceed $1,000,000 at any one time outstanding;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
securing any judgments, writs or warrants of attachment or similar process not constituting an Event of Default under <U>Section
8.1(h)</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens
that are contractual rights of setoff relating to purchase orders entered into with customers, vendors or suppliers of such Person
in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Product Transaction</U>&rdquo; means a transaction that includes the granting of a license or sublicense of any rights under any
Product Patents or Registrations pursuant to a Product Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Permitted
Refinancing Indebtedness</U>&rdquo; means any Indebtedness of the Company or any of its Subsidiaries issued in exchange for, or
the net proceeds of which are used to renew, refund, refinance, replace, defease or discharge other Indebtedness of the Company
or any of its Subsidiaries; <I>provided </I>that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness does not exceed the principal amount
(or accreted value, if applicable) of the Indebtedness renewed, refunded, refinanced, replaced, defeased or discharged (plus all
accrued interest on the Indebtedness and the amount of all fees and expenses, including premiums, incurred in connection therewith);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Permitted Refinancing Indebtedness has a final maturity date later than the final maturity date of, and has a Weighted Average
Life to Maturity equal to or greater than the Weighted Average Life to Maturity of, the Indebtedness being renewed, refunded,
refinanced, replaced, defeased or discharged;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the Indebtedness being renewed, refunded, refinanced, replaced, defeased or discharged is subordinated in right of payment to
the Obligations, such Permitted Refinancing Indebtedness is subordinated in right of payment to, the Obligations on terms at least
as favorable to the Administrative Agent and the Lenders as those contained in the documentation governing the Indebtedness being
renewed, refunded, refinanced, replaced, defeased or discharged; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Indebtedness is incurred either by the Company or by the Subsidiary who is the obligor on the Indebtedness being renewed, refunded,
refinanced, replaced, defeased or discharged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Person</U></FONT>&rdquo;
means and includes natural persons, corporations, limited partnerships, general partnerships, limited liability companies, limited
liability partnerships, joint stock companies, Joint Ventures, associations, companies, trusts, banks, trust companies, land trusts,
business trusts or other organizations, whether or not legal entities, and Governmental Authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Pledge
and Security Agreement</U></FONT>&rdquo; means the Pledge and Security Agreement executed by Grantors in favor of Administrative
Agent for the benefit of the Secured Parties, as it may be amended, supplemented or otherwise modified from time to time in accordance
with and subject to the terms and conditions hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Prepayment
Premium</U></FONT>&rdquo; has the meaning specified in the Fee letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prime
Rate</U>&rdquo; means the rate of interest quoted in <I>The Wall Street Journal</I>, Money Rates Section as the Prime Rate (currently
defined as the base rate on corporate loans posted by at least 75% of the nation&rsquo;s thirty (30) largest banks), as in effect
from time to time. The Prime Rate is a reference rate and does not necessarily represent the lowest or best rate actually charged
to any customer. Any Agent or any other Lender may make commercial loans or other loans at rates of interest at, above or below
the Prime Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Principal
Office</U></FONT>&rdquo; means, for Administrative Agent, such Person&rsquo;s &ldquo;Principal Office&rdquo; as set forth on <U>Appendix
B</U>, or such other office as such Person may from time to time designate in writing in accordance with <U>Section 10.1</U> to
Company and each Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Products</U></FONT>&rdquo;
means Annovera, Bijuva and Imvexxy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Product
Agreement</U>&rdquo; means any agreement entered into between Company or any of its Subsidiaries with another Person that includes
the granting of a license or sublicense of any rights under any Product Patents or Registrations that allows such Person to develop
or commercialize a Product outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Product
Patents</U>&rdquo; means the Annovera Patents, Bijuva Patents and Imvexxy Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Product
Revenue</U>&rdquo; means, for any period, (a) the consolidated gross revenues of Borrower and its Subsidiaries generated solely
through the commercial sale of Products by Borrower and its Subsidiaries during such period, less, without duplication, (b)(i)
trade, quantity and cash discounts allowed by Borrower, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustments
and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for
shipping or other distribution expenses, (iv) set-offs and counterclaims, and (v) any other similar and customary deductions used
by Borrower in determining net revenues, all, in respect of (a) and (b), as determined in accordance with GAAP and calculated
on a basis consistent with the Historical Financial Statements delivered to Administrative Agent prior to the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pro
Rata Share</U>&rdquo; means, with respect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
(i) a Lender&rsquo;s obligation to make the Initial Term Loan and such Lender&rsquo;s right to receive payment of the Facility
Fee in respect thereof, the percentage obtained by dividing (A) such Lender&rsquo;s Initial Term Loan Commitment by (B) the Total
Initial Term Loan Commitment; (ii) a Lender&rsquo;s obligation to make a Delayed Draw A-1 Term Loan and such Lender&rsquo;s right
to receive payment of the Facility Fee in respect thereof, the percentage obtained by dividing (A) such Lender&rsquo;s Delayed
Draw A-1 Term Loan Commitment by (B) the aggregate amount of the Lenders&rsquo; Delayed Draw A-1 Term Loan Commitments; and (iii)
a Lender&rsquo;s obligation to make a Delayed Draw A-2 Term Loan and such Lender&rsquo;s right to receive payment of the Facility
Fee in respect thereof, the percentage obtained by dividing (A) such Lender&rsquo;s Delayed Draw A-1 Term Loan Commitment by (B)
the aggregate amount of the Lenders&rsquo; Delayed Draw A-2 Term Loan Commitments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
a Lender&rsquo;s right to receive payments of interest, fees (other than the Facility Fee) and principal with respect to a Term
Loan, the percentage obtained by dividing (i) the aggregate unpaid principal amount of such Lender&rsquo;s portion of the Term
Loan, by (ii) the aggregate unpaid principal amount of the Term Loan; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
all other matters the percentage obtained by dividing (i) the sum of such Lender&rsquo;s Delayed Draw Term Loan Commitment and
the unpaid principal amount of such Lender&rsquo;s portion of the Term Loan, by (ii) the sum of the Total Delayed Draw Term Loan
Commitment and the aggregate unpaid principal amount of the Term Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Protective
Advances</U>&rdquo; has the meaning specified in <U>Section 9.11</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Public
Health Laws</U></FONT>&rdquo; means all Requirements of Law relating to the procurement, development, clinical and non-clinical
evaluation, product approval or licensure, manufacture, production, analysis, distribution, dispensing, importation, exportation,
use, handling, quality, sale, labeling, promotion, or post market requirements of any drug, biologic or other product (including,
without limitation, any ingredient or component of the foregoing products) subject to regulation under the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. et seq.) and the Public Health Service Act (42 U.S.C. et seq.), including without limitation the regulations
promulgated by the FDA at Title 21 of the Code of Federal Regulations and guidance, compliance policies and other guidelines issued
by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Qualified
Cash</U></FONT>&rdquo; means, as of any date of determination, the amount of unrestricted Cash and Cash Equivalents (other than
restrictions created by the Collateral Documents) of the Loan Parties that is in Deposit Accounts or in Securities Accounts, or
any combination thereof, which such Deposit Account or Securities Account is subject to a Control Agreement and is maintained
by a branch office of the bank or securities intermediary located within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Recipient</U>&rdquo;
means Administrative Agent or any Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Register</U></FONT>&rdquo;
has the meaning specified in <U>Section 2.3(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Registrations</U></FONT>&rdquo;
shall mean authorizations, approvals, licenses, permits, certificates, or exemptions of or issued by any Governmental Authority
(including pre-market approval applications, pre-market notifications, investigational new drug applications, product recertifications,
manufacturing approvals and authorizations, pricing and reimbursement approvals, labeling approvals or their foreign equivalent),
and all applications for any of the foregoing, that are required for the research, development, manufacture, commercialization,
distribution, marketing, storage, transportation, pricing, Government Authority reimbursement, use and sale of Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Regulation
D</U></FONT>&rdquo; means Regulation D of the Board of Governors of the Federal Reserve System, as in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Regulatory
Action</U></FONT>&rdquo; means an administrative or regulatory enforcement action, proceeding or investigation, warning letter,
untitled letter, Form 483 inspectional observations or other notice of violation letter, recall, seizure, Section 305 notice or
other similar written communication, or consent decree, issued by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Reinvestment
Amounts</U>&rdquo; has the meaning specified term in <U>Section 2.10(a)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Related
Fund</U></FONT>&rdquo; means, with respect to any Lender that is an investment fund, any other investment fund that invests in
commercial loans and that is managed or advised by the same investment advisor as such Lender or by an Affiliate of such investment
advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Release</U>&rdquo;
means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping,
leaching or migration of any Hazardous Material into the indoor or outdoor environment (including the abandonment or disposal
of any barrels, containers or other closed receptacles containing any Hazardous Material), including the movement of any Hazardous
Material through the air, soil, surface water or groundwater.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Remedial
Action</U>&rdquo; means all actions taken to (a) correct or address any actual or threatened non-compliance with Environmental
Law, (b) clean up, remove, remediate, contain, treat, monitor, assess, evaluate or in any other way address Hazardous Materials
in the indoor or outdoor environment; (c) prevent or minimize a Release or threatened Release of Hazardous Materials so they do
not migrate or endanger or threaten to endanger public health or welfare or the indoor or outdoor environment; (d) perform pre-remedial
studies and investigations and post-remedial operation and maintenance activities; or (e) perform any other actions authorized
or required by Environmental Law or Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Replacement
Lender</U></FONT>&rdquo; has the meaning specified in <U>Section 2.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Required
Lenders</U></FONT>&rdquo; means Lenders whose Pro Rata Share (calculated in accordance with clause (c) of the definition thereof)
aggregate at least 50.1%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Required
Prepayment Date</U></FONT>&rdquo; has the meaning specified in <U>Section 2.11(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Requirements
of Law</U></FONT>&rdquo; means, with respect to any Person, collectively, the common law and all federal, state, provincial, local,
foreign, multinational or international laws, statutes, codes, treaties, standards, rules and regulations, guidelines, ordinances,
orders, judgments, writs, injunctions, decrees (including administrative or judicial precedents or authorities) and the interpretation
or administration thereof by, and other determinations, directives, requirements or requests of, any Governmental Authority, in
each case having appropriate jurisdiction over and that are applicable to or binding upon such Person or any of its property or
to which such Person or any of its property is subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Restricted
Junior Payment</U></FONT>&rdquo; means (a) any dividend or other distribution, direct or indirect, on account of any shares of
any class of Capital Stock of Borrower now or hereafter outstanding, except a dividend payable solely in shares of Capital Stock
to the holders of that class, together with any payment or distribution pursuant to a &ldquo;plan of division&rdquo; under the
Delaware Limited Liability Act or any comparable transaction under any similar law; (b) any redemption, retirement, sinking fund
or similar payment, purchase or other acquisition for value, direct or indirect, of any shares of any class of Capital Stock of
Borrower or any of its Subsidiaries that is not a Loan Party now or hereafter outstanding; (c) any payment made to retire, or
to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Capital Stock
of Borrower or any of its Subsidiaries that is not a Loan Party now or hereafter outstanding and (d) any payment or prepayment
of principal of, premium, if any, or interest on, or redemption, purchase, retirement, defeasance (including in substance or legal
defeasance), sinking fund or similar payment with respect to, any subordinated Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>S&amp;P</U></FONT>&rdquo;
means Standard &amp; Poor&rsquo;s Ratings Group, a division of The McGraw Hill Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Secured
Parties</U></FONT>&rdquo; has the meaning assigned to that term in the Pledge and Security Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Securities
Account</U></FONT>&rdquo; means a securities account (as defined in the UCC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Securities
Act</U></FONT>&rdquo; means the Securities Act of 1933, as amended from time to time, and any successor statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Solvent</U></FONT>&rdquo;
means, with respect to any Loan Party, that as of the date of determination, both (a)(i) the sum of such Loan Party&rsquo;s debt
(including contingent liabilities) does not exceed the present fair saleable value of such Loan Party&rsquo;s present assets;
(ii) such Loan Party&rsquo;s capital is not unreasonably small in relation to its business as contemplated on the Closing Date
or with respect to any transaction contemplated or undertaken after the Closing Date; and (iii) such Person has not incurred and
does not intend to incur, debts beyond its ability to pay such debts as they become due (whether at maturity or otherwise); and
(b) such Person is &ldquo;<FONT STYLE="font-weight: normal"><U>solvent</U></FONT>&rdquo; within the meaning given that term and
similar terms under applicable laws relating to fraudulent transfers and conveyances. For purposes of this definition, the amount
of any contingent liability at any time shall be computed as the amount that, in light of all of the facts and circumstances existing
at such time, represents the amount that can reasonably be expected to become an actual or matured liability (irrespective of
whether such contingent liabilities meet the criteria for accrual under Statement of Financial Accounting Standard No. 5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Specified
Deposit Accounts</U>&rdquo; means each Deposit Account (other than any Excluded Account) of the Loan Parties held at Bank of America,
N.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Specified
Product Component</U>&rdquo; means that portion of each of Annovera, Bijuva and Imvexxy described in clause (a) of each definition
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Subsidiary</U></FONT>&rdquo;
means, with respect to any Person, any corporation, partnership, limited liability company, association, joint venture or other
business entity of which more than 50% of the total voting power of shares of stock or other ownership interests entitled (without
regard to the occurrence of any contingency) to vote in the election of the Person or Persons (whether directors, managers, trustees
or other Persons performing similar functions) having the power to direct or cause the direction of the management and policies
thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of
that Person or a combination thereof; <U>provided</U>, in determining the percentage of ownership interests of any Person controlled
by another Person, no ownership interest in the nature of a &ldquo;qualifying share&rdquo; of the former Person shall be deemed
to be outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Tax</U></FONT>&rdquo;
means any present or future tax, levy, impost, duty, assessment, charge, fee, deduction or withholding (including backup withholding),
imposed by any Governmental Authority, including all interest, penalties, additions to tax or other liabilities with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Term
Loan</U></FONT>&rdquo; means, collectively, the Initial Term Loan and each Delayed Draw Term Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Term
Loan Commitment</U></FONT>&rdquo; means, collectively, the Initial Term Loan Commitment and the Delayed Draw Term Loan Commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Term
Loan Maturity Date</U></FONT>&rdquo; means the earlier of (a) March 31, 2024 and (b) the date that the Term Loan shall become
due and payable in full hereunder, whether by acceleration or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Terminated
Lender</U></FONT>&rdquo; has the meaning specified in <U>Section 2.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Total
Delayed Draw Term Loan Commitment</U>&rdquo; means the sum of the amounts of the Lenders&rsquo; Delayed Draw Term Loan Commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Total
Initial Term Loan Commitment</U>&rdquo; means the sum of the amounts of the Lenders&rsquo; Initial Term Loan Commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Transaction
Costs</U></FONT>&rdquo; means the reasonable and documented fees, costs and expenses payable by Borrower or any of its Subsidiaries
on or before the Closing Date in connection with the transactions contemplated by the Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Type
of Loan</U>&rdquo; means with respect to any Term Loan, a Base Rate Loan or a LIBOR Rate Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>UCC</U></FONT>&rdquo;
means the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>U.S.</U>&rdquo;
or &ldquo;<U>United States</U>&rdquo; means the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal"><U>Waivable
Mandatory Prepayment</U></FONT>&rdquo; has the meaning specified in <U>Section 2.11(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Weighted
Average Life to Maturity</U>&rdquo; means, when applied to any Indebtedness at any date, the number of years obtained by dividing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
sum of the products obtained by multiplying (a) the amount of each then remaining installment, sinking fund, serial maturity or
other required payments of principal, including payment at final maturity, in respect of the Indebtedness, by (b) the number of
years (calculated to the nearest one-twelfth) that will elapse between such date and the making of such payment; by</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
then outstanding principal amount of such Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accounting and Other Terms.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise expressly provided herein, all accounting terms not otherwise defined herein shall have the meanings assigned to
them in conformity with GAAP. Financial statements and other information required to be delivered by Borrower to Lenders pursuant
to Sections <U>5.1(b)</U> and <U>5.1(c)</U> shall be prepared in accordance with GAAP as in effect at the time of such preparation
(and delivered together with any reconciliation statements provided for in <U>Section 5.1(f)</U>, if applicable). Subject to the
foregoing, calculations in connection with the definitions, covenants and other provisions hereof shall utilize accounting principles
and policies in conformity with those used to prepare the Historical Financial Statements. Notwithstanding the foregoing, or anything
else to the contrary in this Agreement or in any other Loan Document to the contrary for purposes of determining compliance with
any covenant (including the computation of any financial covenant) contained herein, Indebtedness of Borrower and its Subsidiaries
shall be deemed to be carried at 100% of the outstanding principal amount thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
terms used in this Agreement which are defined in Article 8 or Article 9 of the UCC as in effect from time to time in the State
of New York and which are not otherwise defined herein shall have the same meanings herein as set forth therein, <U>provided</U>
that terms used herein which are defined in the UCC as in effect in the State of New York on the date hereof shall continue to
have the same meaning notwithstanding any replacement or amendment of such statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of determining compliance with any incurrence or expenditure tests set forth in this Agreement, any amounts so incurred
or expended (to the extent incurred or expended in a currency other than Dollars ($)) shall be converted into Dollars on the basis
of the exchange rates (as shown on the Bloomberg currency page for such currency or, if the same does not provide such exchange
rate, by reference to such other recognized and publicly available service for displaying exchange rates as may be reasonably
selected by Administrative Agent or, in the event no such service is available, on such other basis as is reasonably satisfactory
to Administrative Agent) as in effect on the date of such incurrence or expenditure under any provision of any such Section that
has an aggregate Dollar limitation provided for therein (and to the extent the respective incurrence or expenditure test regulates
the aggregate amount outstanding at any time and it is expressed in terms of Dollars, all outstanding amounts originally incurred
or spent in currencies other than Dollars shall be converted into Dollars on the basis of the exchange rates (as shown on the
Bloomberg currency page for such currency or, if the same does not provide such exchange rate, by reference to such other recognized
and publicly available service for displaying exchange rates as may be reasonably selected by Administrative Agent or, in the
event no such service is available, on such other basis as is reasonably satisfactory to Administrative Agent) as in effect on
the date of any new incurrence or expenditures made under any provision of any such Section that regulates the Dollar amount outstanding
at any time).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Interpretation, etc.</U> Any of the
terms defined herein may, unless the context otherwise requires, be used in the singular or the plural, depending on the reference.
References herein to any Section, Appendix, Schedule or Exhibit shall be to a Section, an Appendix, a Schedule or an Exhibit,
as the case may be, hereof unless otherwise specifically provided. The use herein of the word &ldquo;include&rdquo; or &ldquo;including,&rdquo;
when following any general statement, term or matter, shall not be construed to limit such statement, term or matter to the specific
items or matters set forth immediately following such word or to similar items or matters, whether or not no limiting language
(such as &ldquo;without limitation&rdquo; or &ldquo;but not limited to&rdquo; or words of similar import) is used with reference
thereto, but rather shall be deemed to refer to all other items or matters that fall within the broadest possible scope of such
general statement, term or matter. The words &ldquo;asset&rdquo; and &ldquo;property&rdquo; shall be construed to have the same
meaning and effect and to refer to any right or interest in or to assets and properties of any kind whatsoever, whether real,
personal or mixed and whether tangible or intangible. Any reference herein or in any other Loan Document to the satisfaction,
repayment, or payment in full of the Obligations or Guaranteed Obligations shall mean the payment or repayment in full in immediately
available funds of (i) the principal amount of, and interest accrued and unpaid with respect to, all outstanding Loans, together
with the payment of any premium applicable to the repayment of the Loans, including any Prepayment Premium, (ii) all costs, expenses,
or indemnities payable pursuant to <U>Section 10.2</U> or Section <U>10.3</U> of this Agreement that have accrued and are unpaid
regardless of whether demand has been made therefor and (iii) all fees, charges, expense reimbursement and other Obligations that
have accrued hereunder or under any other Loan Document and are unpaid and are payable hereunder and (b) the receipt by Administrative
Agent of cash collateral from any Loan Party in order to secure any other contingent Obligations for which a claim or demand for
payment has been made on or prior to such time or in respect of matters or circumstances known to an Agent or a Lender at such
time that are reasonably expected to result in any loss, cost, damage, or expense (including attorneys&rsquo; fees and legal expenses),
such cash collateral to be in such amount as Agents reasonably determine is appropriate to secure such contingent Obligations.
Notwithstanding anything in the Agreement to the contrary, (A) the Dodd-Frank Wall Street Reform and Consumer Protection Act and
all requests, rules, guidelines or directives thereunder or issued in connection therewith and (B) all requests, rules, guidelines
or directives concerning capital adequacy promulgated by the Bank for International Settlements, the Basel Committee on Banking
Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities shall, in each case,
be deemed to be enacted, adopted, issued, phased in or effective after the date of this Agreement regardless of the date enacted,
adopted, issued, phased in or effective. Unless the context requires otherwise (a) any definition of or reference to any Loan
Document, agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements
or modifications set forth in any Loan Document) and (b) any reference to any law or regulation shall (i) include all statutory
and regulatory provisions consolidating, amending, replacing or interpreting or supplementing such law or regulation, and (ii)
unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time. This <U>Section
1.3</U> shall apply, <I>mutatis mutandis</I>, to all Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Time
References.</U> Unless otherwise indicated herein, all references to time of day refer to Central Standard Time or Central
daylight saving time, as in effect in Dallas, Texas on such day. For purposes of the computation of a period of time from a
specified date to a later specified date, the word &ldquo;from&rdquo; means &ldquo;from and including&rdquo; and the words
&ldquo;to&rdquo; and &ldquo;until&rdquo; each means &ldquo;to but excluding&rdquo;; <U>provided</U>, <U>however</U>, that
with respect to a computation of fees or interest payable to Administrative Agent or any Lender, such period shall in any
event consist of at least one full day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
II</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
LOANS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Term
Loans.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Loan
Commitment</U>. Subject to the terms and conditions hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
Lender severally agrees to make, on the Closing Date, an Initial Term Loan to Company in an amount equal to such Lender&rsquo;s
Initial Term Loan Commitment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
Lender severally agrees to make, after the Closing Date and at any time prior to the Delayed Draw Term Loan Commitment Termination
Date, a Delayed Draw A-1 Term Loan to Company in an aggregate amount equal to such Lender&rsquo;s Delayed Draw A-1 Term Loan Commitment;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
Lender severally agrees to make, after the Closing Date and at any time prior to the Delayed Draw Term Loan Commitment Termination
Date, a Delayed Draw A-2 Term Loan to Company in an aggregate amount equal to such Lender&rsquo;s Delayed Draw A-2 Term Loan Commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
may make only one borrowing under the Initial Term Loan Commitment which shall be on the Closing Date. Any amount borrowed under
this <U>Section 2.1(a)</U> and subsequently repaid or prepaid may not be reborrowed. Subject to <U>Section 2.9</U>, all amounts
owed hereunder with respect to the Term Loan shall be paid in full no later than the Term Loan Maturity Date. Each Lender&rsquo;s
Initial Term Loan Commitment shall terminate immediately and without further action on the Closing Date after giving effect to
the funding of such Lender&rsquo;s Initial Term Loan Commitment on such date in an amount equal to such Lender&rsquo;s Pro Rata
Share (calculated in accordance with clause (a)(i) of the definition thereof) of such funded Initial Term Loan. Each Lender&rsquo;s
Delayed Draw A-1 Term Loan Commitment shall be permanently reduced immediately and without further action upon the funding of
each Delayed Draw A-1 Term Loan after the Closing Date in an amount equal to such Lender&rsquo;s Pro Rata Share (calculated in
accordance with clause (a)(ii) of the definition thereof) of such funded Delayed Draw A-1 Term Loan. Each Lender&rsquo;s Delayed
Draw A-1 Term Loan Commitment shall terminate immediately and without further action on the earlier to occur of (i) the Term Loan
Maturity Date and (ii) the applicable Delayed Draw Term Loan Commitment Termination Date after giving effect to the funding of
such Lender&rsquo;s Delayed Draw A-1 Term Loan Commitment, if any, on such date. Each Lender&rsquo;s Delayed Draw A-2 Term Loan
Commitment shall be permanently reduced immediately and without further action upon the funding of each Delayed Draw A-2 Term
Loan after the Closing Date in an amount equal to such Lender&rsquo;s Pro Rata Share (calculated in accordance with clause (a)(iii)
of the definition thereof) of such funded Delayed Draw A-2 Term Loan. Each Lender&rsquo;s Delayed Draw A-2 Term Loan Commitment
shall terminate immediately and without further action on the earlier to occur of (i) the Term Loan Maturity Date and (ii) the
applicable Delayed Draw Term Loan Commitment Termination Date after giving effect to the funding of such Lender&rsquo;s Delayed
Draw A-2 Term Loan Commitment, if any, on such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Borrowing
Mechanics for Term Loans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
shall deliver to Administrative Agent a fully executed Funding Notice no later than three Business Days prior to the Closing Date
(or such shorter period permitted by Administrative Agent), with respect to Term Loans made on the Closing Date. Following the
Closing Date (and subject to the conditions set forth in <U>Section 3.2</U>), whenever Company desires that Lenders make a Delayed
Draw Term Loan, Company shall deliver to Administrative Agent a fully executed and delivered Funding Notice at least 15 Business
Days in advance of the proposed Credit Date (or such shorter period consented to by Administrative Agent). Except as otherwise
provided herein, a Funding Notice for a Term Loan that is a LIBOR Rate Loan shall be irrevocable on and after the related Interest
Rate Determination Date, and Company shall be bound to make a borrowing in accordance therewith. Promptly upon receipt by Administrative
Agent of any such Funding Notice, Administrative Agent shall notify each Lender of the proposed borrowing. Administrative Agent
and Lenders (A) may act without liability upon the basis of written or facsimile notice believed by Administrative Agent in good
faith to be from Company (or from any Authorized Officer thereof designated in writing purportedly from Company to Administrative
Agent), (B) shall be entitled to rely conclusively on any Authorized Officer&rsquo;s authority to request a Term Loan on behalf
of Company until Administrative Agent receives written notice to the contrary, and (C) shall have no duty to verify the authenticity
of the signature appearing on any written Funding Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender shall make its Initial Term Loan available to Administrative Agent not later than 12:00 p.m. on the applicable Credit Date,
by wire transfer of same day funds in Dollars, at Administrative Agent&rsquo;s Principal Office. Upon satisfaction or waiver of
the conditions precedent specified herein, Administrative Agent shall make the proceeds of the Term Loans available to Company
on the applicable Credit Date by causing an amount of same day funds in Dollars equal to the proceeds of all such Loans received
by Administrative Agent from Lenders to be credited to the account of Company at Administrative Agent&rsquo;s Principal Office
or to such other account as may be designated in writing to Administrative Agent by Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Delayed Draw Term Loan Commitment Period, drawings under the (i) Delayed Draw A-1 Term Loan Commitment shall be (A) made on
not more than 1 date and (B) made in an aggregate amount not exceeding $50,000,000 and (ii) Delayed Draw A-2 Term Loan Commitment
shall be (A) made on not more than 1 date and (B) made in an aggregate amount not exceeding $50,000,000, and in each case for
clauses (i) and (ii) shall be subject to the satisfaction of the conditions set forth in <U>Section 3.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pro
Rata Shares; Availability of Funds</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Pro
Rata Shares</U>. All Loans shall be made by Lenders simultaneously and proportionately to their respective Pro Rata Shares, it
being understood that no Lender shall be responsible for any default by any other Lender in such other Lender&rsquo;s obligation
to make a Loan requested hereunder nor shall any Term Loan Commitment of any Lender be increased or decreased as a result of a
default by any other Lender in such other Lender&rsquo;s obligation to make a Loan requested hereunder or purchase a participation
required hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Availability
of Funds</U>. Unless Administrative Agent shall have been notified by any Lender prior to the applicable Credit Date that such
Lender does not intend to make available to Administrative Agent the amount of such Lender&rsquo;s Loan requested on such Credit
Date, Administrative Agent may assume that such Lender has made such amount available to Administrative Agent on such Credit Date
and Administrative Agent may, in its sole discretion, but shall not be obligated to, make available to Company a corresponding
amount on such Credit Date. If such corresponding amount is not in fact made available to Administrative Agent by such Lender,
Administrative Agent shall be entitled to recover such corresponding amount on demand from such Lender together with interest
thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the customary rate
set by Administrative Agent for the correction of errors among banks for three Business Days and thereafter at the Base Rate.
If such Lender does not pay such corresponding amount forthwith upon Administrative Agent&rsquo;s demand therefor, Administrative
Agent shall promptly notify Company and Company shall immediately pay such corresponding amount to Administrative Agent together
with interest thereon, for each day from such Credit Date until the date such amount is paid to Administrative Agent, at the rate
payable hereunder for Base Rate Loans for such Class of Loans. Nothing in this <U>Section 2.1(d)(ii)</U> shall be deemed to relieve
any Lender from its obligation to fulfill its Term Loan Commitments hereunder or to prejudice any rights that Company may have
against any Lender as a result of any default by such Lender hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Use
of Proceeds.</U> The proceeds of the Term Loans made on and after the Closing Date shall be applied by Company for working capital,
capital expenditures and general corporate purposes of Borrower and its Subsidiaries. No portion of the proceeds of the Term Loan
shall be used in any manner that causes or might cause such Credit Extension or the application of such proceeds to violate Regulation
T, Regulation U or Regulation X of the Board of Governors of the Federal Reserve System or any other regulation thereof or to
violate the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Evidence of Debt; Register; Lenders&rsquo;
Books and Records; Notes.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lenders&rsquo;
Evidence of Debt</U>. Each Lender shall maintain on its internal records an account or accounts evidencing the Obligations of
Company to such Lender, including the amounts of the Term Loans made by it and each repayment and prepayment in respect thereof.
Any such recordation shall be conclusive and binding on Company, absent manifest error; <U>provided</U>, that the failure to make
any such recordation, or any error in such recordation, shall not affect Company&rsquo;s Obligations in respect of any Term Loans;
and <U>provided further</U>, in the event of any inconsistency between the Register and any Lender&rsquo;s records, the recordations
in the Register shall govern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Register</U>.
Administrative Agent shall maintain at its Principal Office a register for the recordation of the names and addresses of
Lenders and the principal amount of the Term Loans (and stated interest therein) of each Lender from time to time (the
&ldquo;<FONT STYLE="font-weight: normal"><U>Register</U></FONT>&rdquo;). The Register shall be available for inspection by
Company at any reasonable time and from time to time upon reasonable prior notice, and Administrative Agent shall notify
Company in writing following any updates to the Register made from time to time. Administrative Agent shall record in the
Register the Term Loans, and each repayment or prepayment in respect of the principal amount of the Term Loans, and any such
recordation shall be conclusive (absent manifest error) and binding on Company and each Lender, and Company, <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Administrative
Agent and Lenders shall treat each Person whose name is recorded in the Register pursuant to and in accordance with the terms
and conditions hereof as a Lender hereunder for any purposes of this Agreement; <U>provided</U>, failure to make any such recordation,
or any error in such recordation, or any failure to provide notice of any updates to the Register, shall not affect Company&rsquo;s
Obligations in respect of any Term Loan. Company hereby designates the entity serving as Administrative Agent to serve as Company&rsquo;s
non-fiduciary agent solely for purposes of maintaining the Register as provided in this <U>Section 2.3</U>, and Company hereby
agrees that, to the extent such entity serves in such capacity, the entity serving as Administrative Agent and its officers, directors,
employees, agents and affiliates shall constitute &ldquo;<FONT STYLE="font-weight: normal"><U>Indemnitees.&rdquo;</U></FONT></FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notes</U>.
If so requested by any Lender by written notice to Company (with a copy to Administrative Agent) at least two Business Days prior
to the Closing Date, or at any time thereafter, Company shall execute and deliver to such Lender (and/or, if applicable and if
so specified in such notice, to any Person who is an assignee of such Lender pursuant to <U>Section 10.6</U>) on the Closing Date
(or, if such notice is delivered after the Closing Date, promptly after Company&rsquo;s receipt of such notice) a Note or Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Interest.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise set forth herein, each Loan shall bear interest on the unpaid principal <U>amount</U> thereof from the date made
through repayment (whether by acceleration or otherwise) thereof as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
a Base Rate Loan, at the Base Rate <U>plus</U> the Applicable Margin; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
a LIBOR Rate Loan, at the Adjusted LIBOR Rate <U>plus</U> the Applicable Margin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
basis for determining the rate of interest with respect to any Loan, and the Interest Period with respect to any LIBOR Rate Loan,
shall be selected by Company and notified to Administrative Agent and Lenders pursuant to the applicable Funding Notice or Conversion/Continuation
Notice, as the case may be. If on any day a Loan is outstanding with respect to which a Funding Notice or Conversion/Continuation
Notice has not been delivered to Administrative Agent in accordance with the terms hereof specifying the applicable basis for
determining the rate of interest, then for that day such Loan shall be a Base Rate Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with LIBOR Rate Loans there shall be no more than five Interest Periods outstanding at any time. In the event Company
fails to specify between a Base Rate Loan or a LIBOR Rate Loan in the applicable Funding Notice or Conversion/Continuation Notice,
such Loan (if outstanding as a LIBOR Rate Loan) will be automatically converted into a Base Rate Loan on the last day of the then
current Interest Period for such Loan (or if outstanding as a Base Rate Loan will remain as, or (if not then outstanding) will
be made as, a Base Rate Loan). In the event Company fails to specify an Interest Period for any LIBOR Rate Loan in the applicable
Funding Notice or Conversion/Continuation Notice, Company shall be deemed to have selected an Interest Period of three months.
At any time that a Default or an Event of Default has occurred and is continuing, Company no longer shall have the option to request
that any portion of the Loans be a LIBOR Rate Loan and such LIBOR Rate Loans shall automatically convert to Base Rate Loans on
the last day of the then current Interest Period. As soon as practicable after 10:00 a.m. (New York City time) on each Interest
Rate Determination Date, Administrative Agent shall determine (which determination shall, absent manifest error, be final, conclusive
and binding upon all parties) the interest rate that shall apply to the LIBOR Rate Loans for which an interest rate is then being
determined for the applicable Interest Period and shall promptly give notice thereof (in writing) to Company and each Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
payable hereunder shall be computed on the basis of a 360 day year, in each case for the actual number of days elapsed in the
period during which it accrues. In computing interest on any Loan, the date of the making of such Loan or the first day of an
Interest Period applicable to such Loan or, with respect to a Base Rate Loan being converted from a LIBOR Rate Loan, the date
of conversion of such LIBOR Rate Loan to such Base Rate Loan, as the case may be, shall be included, and the date of payment of
such Loan or the expiration date of an Interest Period applicable to such Loan or, with respect to a Base Rate Loan being converted
to a LIBOR Rate Loan, the date of conversion of such Base Rate Loan to such LIBOR Rate Loan, as the case may be, shall be excluded;
<U>provided</U>, if a Loan is repaid on the same day on which it is made, one day's interest shall be paid on that Loan.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise set forth herein, interest on each Term Loan shall be payable in cash and in arrears (i) on each Interest Payment
Date; (ii) upon any prepayment of that Term Loan, whether voluntary or mandatory, to the extent accrued on the amount being prepaid;
and (iii) at maturity, including final maturity.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion/Continuation.</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to <U>Section 2.17</U> and so long as no Default or Event of Default shall have occurred and then be continuing, Company shall
have the option:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
convert at any time all or any part of any Term Loan equal to $5,000,000 and integral multiples of $1,000,000 in excess of that
amount from one Type of Loan to another Type of Loan; <U>provided</U>, a LIBOR Rate Loan may only be converted on the expiration
of the Interest Period applicable to such LIBOR Rate Loan unless Company shall pay all amounts due under <U>Section 2.17</U> in
connection with any such conversion; or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
the expiration of any Interest Period applicable to any LIBOR Rate Loan, to continue all or any portion of such Loan equal to
$5,000,000 and integral multiples of $1,000,000 in excess of that amount as a LIBOR Rate Loan.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
shall deliver a Conversion/Continuation Notice to Administrative Agent no later than 10:00 a.m. (New York City time) at least
one Business Day in advance of the proposed conversion date (in the case of a conversion to a Base Rate Loan) and at least three
Business Days in advance of the proposed conversion/continuation date (in the case of a conversion to, or a continuation of, a
LIBOR Rate Loan). Except as otherwise provided herein, a Conversion/Continuation Notice for conversion to, or continuation of,
any LIBOR Rate Loans shall be irrevocable on and after the related Interest Rate Determination Date, and Company shall be bound
to effect a conversion or continuation in accordance therewith.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Default
Interest</U>. Upon Company's receipt of written notice thereof from Administrative Agent following the occurrence and during the
continuance of an Event of Default, the principal amount of all Term Loans outstanding and, to the extent permitted by applicable
law, any accrued and unpaid interest payments on the Term Loans or any fees or other amounts owed hereunder (including any Prepayment
Premium, if applicable), shall from and after the first date of the occurrence of such Event of Default bear interest (including
post petition interest in any proceeding under the Bankruptcy Code or other applicable bankruptcy laws) payable on demand at a
rate that is 2.0% per annum in excess of the interest rate otherwise payable hereunder with respect to the Term Loans. All interest
payable at the Default Rate shall be payable in cash on demand. Payment or acceptance of the Default Rate of interest provided
for in this <U>Section 2.6</U> is not a permitted alternative to timely payment and shall not constitute a waiver of any Default
or Event of Default or otherwise prejudice or limit any rights or remedies of Administrative Agent or any Lender.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fees</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
agrees to pay to Administrative Agent all fees payable by it in the Fee Letter in the amounts and at the times specified therein.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
fees referred to in <U>Section 2.7(a)</U> shall be calculated on the basis of a 360 day year and the actual number of days elapsed.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repayment of Term Loans</U>. Commencing on June 30, 2023
and on the last day of each Fiscal Quarter ending thereafter, the Borrower shall repay the principal amount of the Term Loan in
an amount equal to 25.0% of the aggregate principal balance of the Term Loan on June 30, 2023, which payments shall be applied
as follows: (a) <U>first</U>, the principal of the Initial Term Loan until paid in full, (b) <U>second</U>, the principal of the
Delayed Draw A-1 Term Loan until paid in full and (c) <U>third</U>, the principal of the Delayed Draw A-2 Term Loan until paid
in full. Notwithstanding the foregoing, the Term Loan, together with all other amounts owed hereunder with respect thereto, shall
be paid in full no later than the Term Loan Maturity Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;<U>Voluntary Prepayments and Commitment Reductions</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voluntary
Prepayments</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the Fee Letter, Company may prepay at any time the Term Loan on any Business Day in whole or in part (together
with any amounts due pursuant to <U>Section 2.19(c)</U>), in an aggregate minimum amount of $5,000,000 and integral multiples
of $1,000,000 in excess of that amount.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
such prepayments shall be made (A) upon not less than one Business Day's prior written notice in the case of Base Rate Loans and
(B) upon not less than three Business Days' prior written notice in the case of LIBOR Rate Loans, in each case given to Administrative
Agent by 3:00 p.m. on the date required (and Administrative Agent will promptly transmit such notice to each Lender). Upon the
giving of any such notice, the principal amount of the Term Loans specified in such notice shall become due and payable on the
prepayment date specified therein. Any such voluntary prepayment shall be applied to the Term Loans as directed by the Borrower.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voluntary
Commitment Reductions</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
may, upon not less than three Business Days' prior written to Administrative Agent (which original written notice Administrative
Agent will promptly transmit to each applicable Lender), at any time and from time to time terminate in whole or permanently reduce
in part any unused portion of the Delayed Draw Term Loan Commitments; <U>provided</U>, any such partial reduction of the Delayed
Draw Term Loan Commitments shall be in an aggregate minimum amount of $5,000,000 and integral multiples of $1,000,000 in excess
of that amount.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company's
notice to Administrative Agent shall designate (A) the date (which shall be a Business Day) of such termination or reduction and
the amount of any partial reduction and (B) whether such termination or reduction is for the Delayed Draw A-1 Term Loan Commitment
and/or the Delayed Draw A-2 Term Loan Commitment, and such termination or reduction of the Delayed Draw Term Loan Commitments
shall be effective on the date specified in Company's notice and shall reduce the Delayed Draw Term Loan of each Lender proportionately
to its Pro Rata Share thereof.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory Prepayments</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Asset
Sales</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
later than the fifth Business Day following the date of receipt by any Loan Party of any Net Proceeds from one or more Asset Sales
constituting a Permitted Product Transaction in excess of $40,000,000 in the aggregate for all such Permitted Product Transactions,
Company shall prepay the Term Loan as set forth in <U>Section 2.11(a)</U> in an aggregate amount equal to such Net Proceeds in
excess of $40,000,000.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
later than the fifth Business Day following the date of receipt by any Loan Party of any Net Proceeds from Asset Sales in excess
of $5,000,000 in the aggregate in any Fiscal Year that do not constitute a Permitted Product Transaction, Company shall prepay
the Term Loans set forth in <U>Section 2.11(a)</U> in an aggregate amount equal to such Net Proceeds in excess of $5,000,000 in
such Fiscal Year; <U>provided</U>, so long as (i) no Default or Event of Default shall have occurred and be continuing, (ii) Company
has delivered Administrative Agent prior written notice of Company's intention to apply such monies (the &ldquo;<U>Reinvestment
Amounts</U>&rdquo;) to reinvest in or to the costs of purchase of other assets used or useful in the business of the Loan Parties
including capital expenditures, (iii) the monies are held in a Deposit Account subject to a Control Agreement, and (iv) the Loan
Parties complete such reinvestment or purchase within 365 days after the initial receipt of such monies, the Loan Parties shall
have the option to apply such monies to the reinvestment in or the costs of purchase of other assets used or useful in the business
of the Loan Parties (including capital expenditures) unless and to the extent that such applicable period shall have expired without
such reinvestment or purchase being made or completed, in which case, any such amounts not so used to reinvest or purchase shall
be paid to Administrative Agent and applied in accordance with <U>Section 2.11(a)</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
contained in this <U>Section 2.10(a)</U>&nbsp;shall permit Borrower or any of its Subsidiaries to sell or otherwise dispose of
any assets other than in accordance with <U>Section 6.9</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance/Condemnation
Proceeds</U>. No later than the fifth Business Day following the date of receipt by any Loan Party, or Administrative Agent as
loss payee, of any Net Proceeds from insurance or any condemnation, taking or other casualty in excess of $5,000,000 in the aggregate
in any Fiscal Year, Company shall prepay the Term Loan in an aggregate amount equal to such Net Proceeds in excess of $5,000,000
in the aggregate in any Fiscal Year; <U>provided</U>, (i) so long as no Default or Event of Default shall have occurred and be
continuing, (ii) Company has delivered Administrative Agent prior written notice of Company's intention to apply the Reinvestment
Amounts to reinvest in or the costs of purchase of other assets used or useful in the business of the Loan Parties (including
capital expenditures), (iii) the monies are held in a Deposit Account subject to a Control Agreement, and (iv)&nbsp;the Loan Parties
complete such reinvestment or purchase within 365 days after the initial receipt of such monies, the Loan Parties shall have the
option to apply such monies to the reinvestment in or costs of purchase of other assets used or useful in the business of the
Loan Parties (including capital expenditures) unless and to the extent that such applicable period shall have expired without
such reinvestment or purchase being made or completed, in which case, any such amounts not so used to reinvest or purchase shall
be paid to Administrative Agent and applied in accordance with <U>Section 2.11(a)</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance
of Debt</U>. On the date of receipt by Borrower or any of its Subsidiaries of any Cash proceeds from the incurrence of any Indebtedness
of Borrower or any of its Subsidiaries (in each case, other than with respect to any Indebtedness permitted to be incurred pursuant
to <U>Section 6.1</U>), Company shall prepay the Term Loans as set forth in <U>Section 2.11(a)</U> in an aggregate amount equal
to 100% of such proceeds, net of underwriting discounts and commissions and other reasonable costs and expenses associated therewith,
in each case, paid to non-Affiliates, including reasonable legal fees and expenses.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Extraordinary
Receipts</U>. On the date of receipt by Borrower or any of its Subsidiaries of any Extraordinary Receipts in excess of $5,000,000
in the aggregate in any Fiscal Year, Company shall prepay the Terms Loan as set forth in <U>Section 2.11(a)</U> in the amount
of such Extraordinary Receipts in excess of $5,000,000.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Prepayment
Certificate</U>. Concurrently with any prepayment of the Term Loan pursuant to <U>Section 2.10(a)</U> through <U>Section 2.10(d)</U>,
Company shall deliver to Administrative Agent a certificate of an Authorized Officer demonstrating the calculation of the amount
of the applicable net proceeds and compensation owing to Lenders pursuant to the Fee Letter, if any, as the case may be. In the
event that Company shall subsequently determine that the actual amount received exceeded the amount set forth in such certificate,
Company shall promptly make an additional prepayment of the Loans, and Company shall concurrently therewith deliver to Administrative
Agent a certificate of an Authorized Officer demonstrating the derivation of such excess.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Application
of Prepayments</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Prepayments of Term Loans</U>. Except in connection with any Waivable Mandatory Prepayment provided for in <U>Section 2.11(b)</U>,
so long as no Application Event has occurred and is continuing, any mandatory prepayment of any Loan pursuant to <U>Section 2.10</U>,
in each case, shall be applied as follows:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">first,
<FONT STYLE="font-style: normal">to prepay accrued and unpaid interest on the Term Loan;</FONT></FONT></P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">second,
<FONT STYLE="font-style: normal">to pay any Prepayment Premium payable thereon; and</FONT></FONT></P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third,
<FONT STYLE="font-style: normal">to prepay (A) <U>first</U>, the principal of the Initial Term Loan to the installments thereof
on a pro rata basis until paid in full, (B) <U>second</U>, the principal of the Delayed Draw A-1 Term Loan to the installments
thereof on a pro rata basis until paid in full and (C) <U>third</U>, the principal of the Delayed Draw A-2 Term Loan to the installments
thereof on a pro rata basis until paid in full.</FONT></FONT></P>

<P STYLE="font: italic 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waivable
Mandatory Prepayment</U>. Anything contained herein to the contrary notwithstanding, in the event Company is required to make
any mandatory prepayment (a &ldquo;<FONT STYLE="font-weight: normal"><U>Waivable Mandatory Prepayment</U></FONT>&rdquo;) of the
Term Loans pursuant to <U>Section 2.8</U> and <U>Section 2.10</U>, not less than three Business Days prior to the date (the &ldquo;<FONT STYLE="font-weight: normal"><U>Required
Prepayment Date</U></FONT>&rdquo;) on which Company is required to make such Waivable Mandatory Prepayment, Company shall notify
Administrative Agent of the amount of such prepayment, and Administrative Agent will promptly thereafter notify each Lender holding
an outstanding Term Loan of the amount of such Lender's Pro Rata Share of such Waivable Mandatory Prepayment and such Lender's
option to refuse such amount. Each such Lender may exercise such option by giving written notice to Company and Administrative
Agent of its election to do so on or before the first Business Day prior to the Required Prepayment Date (it being understood
that any Lender which does not notify Company and Administrative Agent of its election to exercise such option on or before the
first Business Day prior to the Required Prepayment Date shall be deemed to have elected, as of such date, not to exercise such
option). On the Required Prepayment Date, Company shall pay to Administrative Agent the amount of the Waivable Mandatory Prepayment,
which amount shall be applied (i) in an amount equal to that pro rata portion of the Waivable Mandatory Prepayment payable to
those Lenders that have elected not to exercise such option, to prepay the Term Loans of such Lenders (which prepayment shall
be applied in accordance with <U>Section 2.11(a)</U>), and (ii) to the extent of any excess, to Company for working capital and
general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time an Application Event has occurred and is continuing, all payments shall be applied pursuant to <U>Section 2.12(f)</U>.
Nothing contained herein shall modify the provisions of <U>Section 2.12(b)</U> regarding the requirement that all prepayments
be accompanied by accrued interest on the principal amount being prepaid to the date of such prepayment and any applicable Prepayment
Premium, or any requirement otherwise contained herein to pay all other amounts as the same become due and payable in accordance
with and subject to the terms and conditions herein.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General
Provisions Regarding Payments</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
payments by Company of principal, interest, fees and other Obligations shall be made in Dollars in immediately available funds,
without defense, recoupment, setoff or counterclaim, free of any restriction or condition, and delivered to Administrative Agent,
for the account of Lenders, not later than 3:00 p.m. to Administrative Agent's Account; funds received by Administrative Agent
after that time on such due date shall be deemed to have been paid by Company on the next Business Day unless otherwise consented
to by Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
payments in respect of the principal amount of any Term Loan shall be accompanied by payment of accrued and unpaid interest on
the principal amount being repaid or prepaid, any applicable Prepayment Premium and all other amounts due and payable hereunder
with respect to the principal amount being repaid or prepaid.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent shall promptly distribute to each Lender at such address as such Lender shall indicate in writing, such Lender's applicable
Pro Rata Share of all payments and prepayments of principal and interest due hereunder, together with all other amounts due with
respect thereto, including, without limitation, all fees payable with respect thereto, to the extent received by Administrative
Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the provisos set forth in the definition of &ldquo;Interest Period&rdquo;, whenever any payment to be made hereunder shall
be stated to be due on a day that is not a Business Day, such payment shall be made on the next succeeding Business Day and such
extension of time shall be included in the computation of the payment of interest hereunder or of the commitment fees hereunder.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative
Agent shall deem any payment by or on behalf of Company hereunder that is not made in same day funds prior to 3:00 p.m. to be
a non-conforming payment. Any such payment shall not be deemed to have been received by Administrative Agent until the later of
(i) the time such funds become available funds, and (ii)&nbsp;the applicable next Business Day. Administrative Agent shall give
prompt telephonic notice to Company and each applicable Lender (confirmed in writing) if any payment is non-conforming. Any non-conforming
payment may constitute or become a Default or Event of Default in accordance with and subject to the terms and conditions of <U>Section
8.1(a)</U>. Interest shall continue to accrue on any principal as to which a non-conforming payment is made until such funds become
available funds (but in no event less than the period from the date of such payment to the next succeeding applicable Business
Day) at the Default Rate determined pursuant to <U>Section 2.6</U> from the date such amount was due and payable until the date
such amount is paid in full.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time an Application Event has occurred and is continuing, or the maturity of the Obligations shall have been accelerated pursuant
to <U>Section 8.1</U>, all payments or proceeds received by Administrative Agent hereunder or under any Collateral Document in
respect of any of the Obligations, including, but not limited to all proceeds received by Administrative Agent in respect of any
sale, any collection from, or other realization upon all or any part of the Collateral, shall be applied in full or in part as
follows:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>first</I>,
ratably to pay the Obligations in respect of any fees (other than any Prepayment Premium), expense reimbursements, indemnities
and other amounts then due and payable to the Administrative Agent until paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>second</I>,
ratably to pay interest then due and payable in respect of Protective Advances until paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>third</I>,
ratably to pay principal of Protective Advances then due and payable until paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>fourth</I>,
ratably to pay the Obligations in respect of any fees (other than any Prepayment Premium) and indemnities then due and payable
to the Lenders with a Term Loan Commitment until paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>fifth</I>,
ratably to pay interest then due and payable in respect of the Term Loan until paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>sixth</I>,
ratably to pay (A) <U>first</U>, the principal of the Initial Term Loan until paid in full, (B) <U>second</U>, the principal of
the Delayed Draw A-1 Term Loan until paid in full and (C) <U>third</U>, the principal of the Delayed Draw A-2 Term Loan until
paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>seventh</I>,
ratably to pay the Obligations in respect of any Prepayment Premium then due and payable to the Lenders with a Term Loan Commitment
until paid in full;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>eighth</I>,
to the ratable payment of all other Obligations then due and payable until paid in full; and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ninth</I>,
to Company or as otherwise directed by applicable law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of <U>Section 2.12(f)</U> (other than <U>clause eighth</U>, of <U>Section 2.12(f)</U>), &ldquo;paid in full&rdquo; means
payment in cash of all amounts due and payable under the Loan Documents in accordance with and subject to the terms and conditions
thereof, including loan fees, service fees, professional fees, interest (and specifically including interest accrued after the
commencement of any Insolvency Proceeding), default interest, interest on interest, and expense reimbursements, whether or not
same would be or is allowed or disallowed in whole or in part in any Insolvency Proceeding.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a direct conflict between the priority provisions of <U>Section 2.12(f) </U>and other provisions contained in any
other Loan Document, it is the intention of the parties hereto that both such priority provisions in such documents shall be read
together and construed, to the fullest extent possible, to be in concert with each other. In the event of any actual, irreconcilable
conflict that cannot be resolved as aforesaid, the terms and provisions of <U>Section 2.12(f)</U> shall control and govern.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower
hereby authorizes Administrative Agent to charge Company's accounts with Administrative Agent or any of its Affiliates in order
to cause timely payment to be made to Administrative Agent of all principal, interest, fees and expenses due hereunder (subject
to sufficient funds being available in its accounts for that purpose). The Lenders and Company also hereby authorize Administrative
Agent to, and Administrative Agent may, from time to time upon prior notice to Company, charge the Loan Account with any amount
due and payable by Company under any Loan Document. Each of the Lenders and Company agrees that Administrative Agent shall have
the right to make such charges whether or not any Default or Event of Default shall have occurred and be continuing or whether
any of the conditions precedent in <U>Section 3.2</U> have been satisfied. Any amount charged to the Loan Account shall be deemed
a Loan hereunder made by the Lenders to Company, funded by Administrative Agent on behalf of the Lenders and subject to <U>Section
2.2</U>. The Lenders and Company confirm that any charges which Administrative Agent may so make to the Loan Account as herein
provided will be made as an accommodation to Company and solely at Administrative Agent's discretion, provided that Administrative
Agent shall from time to time upon the request of Collateral Agent, charge the Loan Account of Company with any amount due and
payable under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding the foregoing provisions hereof, if any Conversion/Continuation Notice is withdrawn as to any Affected Lender
or if any Affected Lender makes Base Rate Loans in lieu of its Pro Rata Share of any LIBOR Rate Loans, Administrative Agent shall
give effect thereto in apportioning payments received thereafter.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ratable Sharing</U>. Lenders hereby agree among themselves
that, except as otherwise provided in the Collateral Documents with respect to amounts realized from the exercise of rights with
respect to Liens on the Collateral, if any of them shall, whether by voluntary payment (other than a voluntary prepayment of Term
Loans made and applied in accordance with the terms hereof), through the exercise of any right of set off or banker's lien, by
counterclaim or cross action or by the enforcement of any right under the Loan Documents or otherwise, or as adequate protection
of a deposit treated as cash collateral under the Bankruptcy Code, receive payment or reduction of a proportion of the aggregate
amount of principal, interest, fees and other amounts then due and owing to such Lender hereunder or under the other Loan Documents
(collectively, the &ldquo;<FONT STYLE="font-weight: normal"><U>Aggregate Amounts Due</U></FONT>&rdquo; to such Lender) which is
greater than the proportion received by any other Lender in respect of the Aggregate Amounts Due to such other Lender having Term
Loans, then the Lender receiving such proportionately greater payment shall (a) notify Administrative Agent and each other Lender
of the receipt of such payment and (b) apply a portion of such payment to purchase participations (which it shall be deemed to
have purchased from each seller of a participation simultaneously upon the receipt by such seller of its portion of such payment)
in the Aggregate Amounts Due to the other Lenders so that all such recoveries of Aggregate Amounts Due shall be shared by all
Lenders having Term Loans in proportion to the Aggregate Amounts Due to them; <U>provided</U>, if all or part of such proportionately
greater payment received by such purchasing Lender is thereafter recovered from such Lender upon the bankruptcy or reorganization
of Company or otherwise, those purchases shall be rescinded and the purchase prices paid for such participations shall be returned
to such purchasing Lender ratably to the extent of such recovery, but without interest. Company expressly consents to the foregoing
arrangement and agrees that any holder of a participation so purchased may exercise any and all rights of banker's lien, set off
or counterclaim with respect to any and all monies owing by Company to that holder with respect thereto as fully as if that holder
were owed the amount of the participation held by that holder.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Increased
Costs; Capital Adequacy</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
For Increased Costs and Taxes</U>. Subject to the provisions of <U>Section 2.15</U> (which shall be controlling with respect to
the matters covered thereby), in the event that any Lender shall determine (which determination shall, absent manifest error,
be final and conclusive and binding upon all parties hereto) that any law, treaty or governmental rule, regulation or order, or
any change therein or in the interpretation, administration or application thereof (including the introduction of any new law,
treaty or governmental rule, regulation or order) by any Governmental Authority having appropriate jurisdiction, or any determination
of a court or Governmental Authority having appropriate jurisdiction, in each case that becomes effective after the date hereof,
or compliance by such Lender with any guideline, request or directive issued or made after the date hereof by any central bank
or other governmental or quasi-Governmental Authority (whether or not having the force of law): (i) subjects such Recipient (or
its applicable lending office) to any additional Tax (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii)-(iv)
of the definition of Excluded Taxes and (C) Connection Income Taxes) with respect to this Agreement or any of the other Loan Documents
or any of its obligations hereunder or thereunder or any payments to such Lender (or its applicable lending office) of principal,
interest, fees or any other amount payable hereunder; (ii) imposes, modifies or holds applicable any reserve (including any marginal,
emergency, supplemental, special or other reserve), special deposit, compulsory loan, FDIC insurance or similar requirement against
assets held by, or deposits or other liabilities in or for the account of, or advances or loans by, or other credit extended by,
or any other acquisition of funds by, any office of such Lender (other than any such reserve or other requirements with respect
to LIBOR Rate Loans that are reflected in the definition of Adjusted LIBOR Rate); or (iii) imposes any other condition (other
than with respect to a Tax matter) on or affecting such Lender (or its applicable lending office) or its obligations hereunder
or the London interbank market; and the result of any of the foregoing is to increase the cost to such Lender or such other Recipient
of agreeing to make, making or maintaining Loans hereunder or to reduce any amount received or receivable by such Lender or such
other Recipient (or its applicable lending office) with respect thereto; then, in any such case, Company shall promptly pay to
such Lender or such other Recipient, upon receipt of the statement referred to in the next sentence, such additional amount or
amounts (in the form of an increased rate of, or a different method of calculating, interest or otherwise as such Lender in its
sole discretion shall determine) as may be necessary to compensate such Lender or such other Recipient for any such increased
cost or reduction in amounts received or receivable hereunder. Such Lender or such other Recipient shall deliver to Company (with
a copy to Administrative Agent) a written statement, setting forth in reasonable detail the basis for calculating the additional
amounts owed to such Lender or such other Recipient under this <U>Section 2.14(a)</U>, which statement shall be conclusive and
binding upon all parties hereto absent manifest error.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capital
Adequacy Adjustment</U>. In the event that any Lender shall have determined that the adoption, effectiveness, phase in or applicability
after the Closing Date of any law, rule or regulation (or any provision thereof) regarding capital adequacy, or any change therein
or in the interpretation or administration thereof by any Governmental Authority, central bank or comparable agency charged with
the interpretation or administration thereof, in each case, having appropriate jurisdiction or compliance by any Lender (or its
applicable lending office) with any guideline, request or directive regarding capital adequacy (whether or not having the force
of law) of any such Governmental Authority, central bank or comparable agency, has or would have the effect of reducing the rate
of return on the capital of such Lender or any corporation controlling such Lender as a consequence of, or with reference to,
such Lender's Term Loans or other obligations hereunder with respect to the Term Loan to a level below that which such Lender
or such controlling corporation could have achieved but for such adoption, effectiveness, phase in, applicability, change or compliance
(taking into consideration the policies of such Lender or such controlling corporation with regard to capital adequacy), then
from time to time, within five Business Days after receipt by Company from such Lender of the statement referred to in the next
sentence, Company shall pay to such Lender such additional amount or amounts as will compensate such Lender or such controlling
corporation on an after Tax basis for such reduction. Such Lender shall deliver to Company (with a copy to Administrative Agent)
in accordance with <U>Section 10.1</U> a written statement, setting forth in reasonable detail the basis for calculating the additional
amounts owed to Lender under this <U>Section 2.14(b)</U>, which statement shall be conclusive and binding upon all parties hereto
absent manifest error.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Taxes;
Withholding, etc.</U>&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purpose of this Section, the term &ldquo;applicable law&rdquo; includes FATCA.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding
of Taxes</U>. All sums payable by or on account of any Obligation of any Loan Party hereunder and under the other Loan Documents
shall (except to the extent required by applicable law) be paid free and clear of, and without any deduction or withholding on
account of, any Tax, other than, to the extent required by applicable law, any of the following Taxes imposed on or with respect
to a Recipient or required to be withheld or deducted from a payment to a Recipient: (i) Taxes imposed on or measured by the Recipient's
net income (however denominated), franchise Taxes, and branch profits Taxes, imposed on the Recipient, in each case, (A) by the
jurisdiction (or any political subdivision thereof) under the laws of which such Recipient is organized or in which its principal
office is located or, in the case of any Lender, in which its applicable lending office is located or (B) as the result of any
other present or former connection between such Recipient and the jurisdiction imposing such Tax, other than connections arising
from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received
or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document (&ldquo;<U>Other
Connection Taxes</U>&rdquo;), (ii)&nbsp;in the case of a Lender, United States federal income withholding Taxes imposed on amounts
payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law
in effect on the date on which such Lender becomes a party hereto (other than pursuant to an assignment request by the Company
under <U>Section 2.18</U>) or such Lender changes its lending office, except that this <U>clause (ii)</U> shall not apply to the
extent that, pursuant to this <U>Section 2.15</U> amounts with respect to such Taxes were payable either to such Lender's assignor
immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii)
Taxes attributable to such recipient Lender's failure to comply with <U>Section 2.15(e)</U> and (iv) withholding Taxes imposed
under FATCA (all such Taxes described in clauses (i)-(iv) above, collectively or individually, &ldquo;<U>Excluded Taxes</U>&rdquo;).
If any Loan Party or any other Person is required by law to make any deduction or withholding on account of any Indemnified Tax
from any sum paid or payable by or on account of any obligation of any Loan Party to Administrative Agent or any Lender under
any of the Loan Documents: (1) Company shall notify Administrative Agent of any such requirement or any change in any such requirement
as soon as Company becomes aware of it; (2)&nbsp;Company shall pay any such Tax in accordance with applicable law, such payment
to be made (if the liability to pay is imposed on any Loan Party) for its own account or (if that liability is imposed on Administrative
Agent or such Lender, as the case may be) on behalf of and in the name of Administrative Agent or such Lender; (3) the sum payable
by such Loan Party shall be increased to the extent necessary to ensure that, after the making of that deduction, withholding
or payment (including such deductions or withholdings applicable to additional sums payable under this Section), Administrative
Agent or such Lender, as the case may be, receives on the due date a net sum equal to what it would have received had no such
deduction, withholding or payment been required or made; and (4) within thirty days after paying any sum from which it is required
by law to make any deduction or withholding, Company shall deliver to Administrative Agent evidence satisfactory to the other
affected parties of such deduction, withholding or payment and of the remittance thereof to the relevant taxing or other authority.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Taxes</U>. The Loan Parties shall pay to the relevant Governmental Authorities any present or future stamp, court, intangible,
recording, filing or similar Taxes or documentary Taxes or any other excise or property Taxes that arise from any payment made
hereunder or from the execution, delivery or registration, performance or enforcement of, or from the receipt or perfection of
a security interest under or otherwise with respect to, this Agreement or any other Loan Document (&ldquo;<FONT STYLE="font-weight: normal"><U>Other
Taxes</U></FONT>&rdquo;), provided that the definition of &ldquo;Other Taxes&rdquo; shall exclude Taxes that are Other Connection
Taxes imposed with respect to an assignment (other than an assignment made pursuant to <U>Section 2.18</U>). Within thirty days
after paying any such Other Taxes, each Loan Party shall deliver to Administrative Agent and any Lender evidence satisfactory
to Administrative Agent and Lenders that such Other Taxes have been paid to the relevant Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Indemnification</U>. The Loan Parties hereby jointly and severally indemnify and agree to hold Administrative Agent and Lender
harmless from and against all Indemnified Taxes (including, without limitation, Indemnified Taxes imposed or asserted on or attributable
to any amounts payable under this <U>Section 2.15</U>) paid by Administrative Agent or Lender or required to be withheld or deducted
from a payment to Administrative Agent or such Lender and any reasonable expenses arising therefrom or with respect thereto, whether
or not such Indemnified Taxes were correctly or legally asserted. Such indemnification shall be paid within ten days from the
date on which Administrative Agent or Lender makes written demand therefor specifying in reasonable detail the nature and amount
of such Indemnified Taxes and such written demand shall be conclusive absent manifest error.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Evidence
of Exemption From or Reduction of U.S. Withholding Tax</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments under any Loan Document
shall deliver to Company and Administrative Agent, at the time or times reasonably requested by Company or Administrative Agent,
properly completed and executed documentation reasonably requested by Company or Administrative Agent as will permit such payments
to be made without, or at a reduced rate, of withholding. In addition, any Lender, if reasonably requested by Company or Administrative
Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by Company or Administrative
Agent to enable them to determine whether such Lender is subject to backup withholding or information reporting requirements.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document
that is not a United States person (as such term is defined in Section 7701(a)(30) of the Internal Revenue Code) for United States
federal income tax purposes (a &ldquo;<FONT STYLE="font-weight: normal"><U>Non-US Lender</U></FONT>&rdquo;) shall deliver to Administrative
Agent and Company, on or about the Closing Date (in the case of each Lender listed on the signature pages hereof on the Closing
Date) or on or about the date such Person becomes a Lender hereunder, and at such other times as may be necessary in the determination
of Administrative Agent or Company (in its reasonable exercise of its discretion), (i) two original copies of Internal Revenue
Service Form W-8IMY (with appropriate attachments), W-8BEN, W-8BEN-E or W-8ECI (or any successor forms), as applicable, properly
completed and duly executed by such Lender to establish that such Lender is not subject to, or eligible for a reduction of, deduction
or withholding of United States federal income Tax with respect to any payments to such Lender of principal, interest, fees or
other amounts payable under any of the Loan Documents, and (ii) if such Lender is claiming exemption from United States federal
income Tax under Section 871(h) or 881(c) of the Internal Revenue Code, a Certificate Regarding Non-Bank Status (to the effect
that such Non-US Lender is not a &ldquo;bank&rdquo; within the meaning of Section 881(c)(3)(A) of the Internal Revenue Code, a
&ldquo;10 percent shareholder&rdquo; of the Borrower within the meaning of Section 871(h)(3)(B) of the Internal Revenue Code,
or a &ldquo;controlled foreign corporation&rdquo; described in Section 881(c)(3)(C) of the Internal Revenue Code), properly completed
and duly executed by such Lender. Each Lender required to deliver any forms or certificates with respect to United States federal
income Tax withholding matters pursuant to this <U>Section 2.15(e)</U> hereby agrees, from time to time after the initial delivery
by such Lender of such forms or certificates, whenever a lapse in time or change in circumstances renders such forms or certificates
obsolete or inaccurate in any material respect, that such Lender shall deliver to Administrative Agent and Company, two new original
copies of Internal Revenue Service Form W-8IMY (with appropriate attachments thereto), W-8BEN, W-8BEN-E or W-8ECI, as applicable,
and, if applicable, a Certificate Regarding Non-Bank Status (or any successor forms), and other supplementary documentation reasonably
requested by Borrower or Administrative Agent, as the case may be, properly completed and duly executed by such Lender, or notify
Administrative Agent and Company of its legal inability to deliver any such forms or certificates. Notwithstanding the above,
a Non-US Lender shall not be required to deliver any form pursuant to <U>Section 2.15(e)(ii)</U> that such Non-US Lender is not
legally able to deliver.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a payment made to a Lender under any Loan Document would be subject to United States federal withholding Tax imposed by FATCA
if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section
1471(b) or 1472(b) of the Internal Revenue Code, as applicable), such Lender shall deliver to Company and Administrative Agent
at the time or times prescribed by law and at such time or times reasonably requested by Company or Administrative Agent such
documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Internal Revenue Code)
and such additional documentation reasonably requested by Company or Administrative Agent as may be necessary for Company and
Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender's
obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this
<U>Section 2.15(e)(iii)</U>, FATCA shall include any amendments made to FATCA after the date of this Agreement. Notwithstanding
the above, a Lender shall not be required to deliver any form or other form of documentation pursuant to this <U>Section 2.15(e)(iii)
</U>that such Non-US Lender is not legally able to deliver.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender that is a United States person (as such term is defined in Section 7701(a)(30) of the Internal Revenue Code) for United
States federal income Tax purposes shall deliver to Administrative Agent and Company, on or about the Closing Date (in the case
of each such Lender listed on the signature pages hereof on the Closing Date) or on or about the date such Person becomes a Lender
hereunder, and at such other times as may be necessary in the determination of Administrative Agent or Company (in its reasonable
exercise of its discretion), two original copies of Internal Revenue Service Form W-9 (or any successor forms) properly completed
and duly executed by such Lender to establish that such Lender is not subject to United States backup withholding Taxes with respect
to any payments to such Lender of principal, interest, fees or other amounts payable under any of the Loan Documents.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Treatment
of Certain Refunds</U>. If a recipient determines in its discretion exercised in good faith that it has received a refund of any
Taxes (including any Tax credit in lieu of a refund) that were indemnified by any Loan Party or with respect to which a Loan Party
paid additional amounts pursuant to this Section, it shall pay the amount equal to such refund to the applicable Loan Party (but
only to the extent of indemnity payments or additional amounts actually paid by such Loan Party with respect to the Taxes giving
rise to the refund), net of all out-of-pocket expenses (including Taxes) incurred by such recipient and without interest (other
than interest paid by the relevant Governmental Authority with respect to such refund). Loan Parties shall, upon request by the
recipient, repay to the recipient such amount paid over to such Loan Party (plus any penalties, interest or other charges imposed
by the relevant Governmental Authority) if the recipient is required to repay such refund to the Governmental Authority. Notwithstanding
anything herein to the contrary, no recipient shall be required to pay any amount to a Loan Party if such payment would place
it in a less favorable net after-Tax position than it would have been in if the Tax subject to indemnification and giving rise
to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with
respect to such Tax had never been paid. In no event shall Administrative Agent or any Lender be required to make its Tax returns
(or any other information relating to its Taxes that it deems confidential) available to any Loan Party.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Survival</U>.
Each party's obligations under this <U>Section 2.15</U> shall survive the resignation or replacement of Administrative Agent or
any assignment of rights by or replacement of a Lender, the termination of the Loan or Commitment, and the repayment, satisfaction,
discharge or full payment of any obligations under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Obligation
to Mitigate</U>. Each Lender agrees that after the officer of such Lender responsible for administering its Term Loans becomes
aware of the occurrence of an event or the existence of a condition that would cause such Lender to become an Affected Lender
or that would entitle such Lender to receive payments under <U>Section 2.13</U>, <U>2.14</U>, <U>2.15</U> or <U>2.19</U>, it will,
to the extent not inconsistent with the internal policies of such Lender and any applicable legal or regulatory restrictions,
and to the extent it would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous
to such Lender, use reasonable efforts to (a)&nbsp;make, issue, fund or maintain its Credit Extensions, including any Affected
Loans, through another office of such Lender, or (b) take such other measures as such Lender may deem reasonable, if as a result
thereof the circumstances which would cause such Lender to be an Affected Lender would cease to exist or the additional amounts
which would otherwise be required to be paid to such Lender pursuant to <U>Section 2.13</U>, <U>2.14</U>, <U>2.15</U> or <U>2.19
</U>would be materially reduced and if, as determined by such Lender in its sole discretion exercised in good faith, the making,
issuing, funding or maintaining of such Term Loans through such other office or in accordance with such other measures, as the
case may be, would not otherwise adversely affect such Term Loans or the interests of such Lender; <U>provided</U>, such Lender
will not be obligated to utilize such other office pursuant to this <U>Section 2.16</U> unless Company agrees to pay all reasonable
incremental expenses incurred by such Lender as a result of utilizing such other office as described above. A certificate as to
the amount of any such expenses payable by Company pursuant to this <U>Section 2.16</U> (setting forth in reasonable detail the
basis for requesting such amount) submitted by such Lender to Company (with a copy to Administrative Agent) shall be conclusive
absent manifest error.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Defaulting
Lenders</U>. Anything contained herein to the contrary notwithstanding, in the event that any Lender violates any provision of
<U>Section 9.5(c)</U>, or, other than at the direction or request of any regulatory agency or authority having appropriate jurisdiction,
defaults (in each case, a &ldquo;<FONT STYLE="font-weight: normal"><U>Defaulting Lender</U></FONT>&rdquo;) in its obligation to
fund (a &ldquo;<U>Funding Default</U>&rdquo;) a Term Loan (in each case, a &ldquo;<U>Defaulted Loan</U>&rdquo;), then (a) during
any Default Period with respect to such Defaulting Lender, such Defaulting Lender shall be deemed not to be a &ldquo;Lender&rdquo;
for purposes of voting on any matters (including the granting of any consents or waivers) with respect to any of the Loan Documents;
and (b) to the extent permitted by applicable law, until such time as the Default Excess, if any, with respect to such Defaulting
Lender shall have been reduced to zero, (i) any voluntary prepayment of the Term Loans shall, if Administrative Agent so directs
at the time of making such voluntary prepayment, be applied to Term Loans of other Lenders as if such Defaulting Lender had no
Term Loans outstanding and the outstanding Term Loans of such Defaulting Lender were zero, and (ii) any mandatory prepayment of
the Term Loans shall, if Administrative Agent so directs at the time of making such mandatory prepayment, be applied to the Term
Loans of other Lenders (but not to the Term Loans of such Defaulting Lender) as if such Defaulting Lender had funded all Defaulted
Loans of such Defaulting Lender, it being understood and agreed that Company shall be entitled to retain any portion of any mandatory
prepayment of the Term Loans that is not paid to such Defaulting Lender solely as a result of the operation of the provisions
of this <U>clause (b)</U>. No Term Loan Commitment of any Lender shall be increased or otherwise affected, and, except as otherwise
expressly provided in this <U>Section 2.17</U>, performance by Company of its obligations hereunder and the other Loan Documents
shall not be excused or otherwise modified as a result of any Funding Default or the operation of this <U>Section 2.17</U>. The
rights and remedies against a Defaulting Lender under this <U>Section 2.17</U> are in addition to other rights and remedies which
Company may have against such Defaulting Lender with respect to any Funding Default and which Administrative Agent or any Lender
may have against such Defaulting Lender with respect to any Funding Default or violation of <U>Section 9.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Removal
or Replacement of a Lender</U>. Anything contained herein to the contrary notwithstanding, in the event that: (a) (i) any Lender
(an &ldquo;<FONT STYLE="font-weight: normal"><U>Increased Cost Lender</U></FONT>&rdquo;) shall give notice to Company that such
Lender is an Affected Lender or that such Lender is entitled to receive payments under <U>Section 2.14</U>, <U>2.15</U> or <U>2.16</U>,
(ii) the circumstances which have caused such Lender to be an Affected Lender or which entitle such Lender to receive such payments
shall remain in effect, and (iii) such Lender shall fail to withdraw such notice within five Business Days after Company's request
for such withdrawal; or (b) (i) any Lender shall become a Defaulting Lender, (ii) the Default Period for such Defaulting Lender
shall remain in effect, and (iii) such Defaulting Lender shall fail to cure the default as a result of which it has become a Defaulting
Lender within five Business Days after Company's request that it cure such default; or (c) in connection with any proposed amendment,
modification, termination, waiver or consent with respect to any of the provisions hereof as contemplated by <U>Section 10.5(b)</U>,
the consent of Administrative Agent and Required Lenders shall have been obtained but the consent of one or more of such other
Lenders (each a &ldquo;<FONT STYLE="font-weight: normal"><U>Non-Consenting Lender</U></FONT>&rdquo;) whose consent is required
shall not have been obtained; then, with respect to each such Increased Cost Lender, Defaulting Lender or Non-Consenting Lender
(the &ldquo;<FONT STYLE="font-weight: normal"><U>Terminated Lender</U></FONT>&rdquo;), Administrative Agent may (which, in the
case of an Increased-Cost Lender, only after receiving written request from Company to remove such Increased-Cost Lender), by
giving written notice to Company and any Terminated Lender of its election to do so, elect to cause such Terminated Lender (and
such Terminated Lender hereby irrevocably agrees) to assign its outstanding Term Loans in full to one or more Eligible Assignees
(each a &ldquo;<FONT STYLE="font-weight: normal"><U>Replacement Lender</U></FONT>&rdquo;) in accordance with the provisions of
<U>Section 10.6</U> and Terminated Lender shall pay any fees payable thereunder in connection with such assignment; <U>provided</U>,
(1) on the date of such assignment, the Replacement Lender shall pay to Terminated Lender an amount equal to the sum of (A) an
amount equal to the principal of, and all accrued interest on, all outstanding Loans of the Terminated Lender and (B) an amount
equal to all accrued, but theretofore unpaid fees owing to such Terminated Lender pursuant to <U>Section 2.7</U> (except for any
Prepayment Premium (as defined in the Fee Letter)); (2) on the date of such assignment, Company shall pay any amounts payable
to such Terminated Lender pursuant to <U>Section 2.14</U> or <U>2.15</U> (except for any Prepayment Premium (as defined in the
Fee Letter)); and (3) in the event such Terminated Lender is a Non-Consenting Lender, each Replacement Lender shall consent, at
the time of such assignment, to each matter in respect of which such Terminated Lender was a Non-Consenting Lender. Upon the prepayment
of all amounts owing to any Terminated Lender, such Terminated Lender shall no longer constitute a &ldquo;Lender&rdquo; for purposes
hereof; <U>provided</U>, any rights of such Terminated Lender to indemnification hereunder shall survive as to such Terminated
Lender.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Making
or Maintaining LIBOR Rate Loans</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inability
to Determine Applicable Interest Rate</U>. In the event that Administrative Agent shall have made good faith efforts to implement
an Alternate Benchmark Rate and Administrative Agent shall have reasonably determined (which determination shall be final and
conclusive and binding upon all parties hereto), on any Interest Rate Determination Date with respect to any LIBOR Rate Loans,
that by reason of circumstances affecting the London interbank market adequate and fair means do not exist for ascertaining the
interest rate applicable to such LIBOR Rate Loans on the basis provided for in the definition of Adjusted LIBOR Rate, Administrative
Agent shall on such date give notice (by facsimile or by telephone confirmed in writing) in accordance with <U>Section 10.1</U>
of this Agreement to Company and each Lender of such determination, whereupon (i) no Loans may be made as, or converted to, LIBOR
Rate Loans until such time as Administrative Agent notifies Company and Lenders that the circumstances giving rise to such notice
no longer exist, and (ii) any Funding Notice or Conversion/Continuation Notice given by Company with respect to the Loans in respect
of which such determination was made shall be deemed to be rescinded by Company.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Illegality
or Impracticability of LIBOR Rate Loans</U>. In the event that on any date any Lender shall have reasonably determined (which
determination shall be final and conclusive and binding upon all parties hereto but shall be made only after consultation with
Company and Administrative Agent) that the making, maintaining or continuation of its LIBOR Rate Loans (i) has become unlawful
as a result of compliance by such Lender in good faith with any law, treaty, governmental rule, regulation, guideline or order
(or would conflict with any such treaty, governmental rule, regulation, guideline or order not having the force of law even though
the failure to comply therewith would not be unlawful), or (ii) has become impracticable, as a result of contingencies occurring
after the date hereof which materially and adversely affect the London interbank market or the position of such Lender in that
market, then, and in any such event, such Lender shall be an &ldquo;<U>Affected Lender</U>&rdquo; and it shall on that day give
notice (by facsimile or by telephone confirmed in writing) in accordance with <U>Section 10.1</U> of this Agreement to Company
and Administrative Agent of such determination (which notice Administrative Agent shall promptly transmit to each other Lender).
Thereafter (A) the obligation of the Affected Lender to make Loans as, or to convert Loans to, LIBOR Rate Loans shall be suspended
until such notice shall be withdrawn by the Affected Lender, (B) to the extent such determination by the Affected Lender relates
to a LIBOR Rate Loan then being requested by Company pursuant to a Funding Notice or a Conversion/Continuation Notice, the Affected
Lender shall make such Loan as (or continue such Loan as or convert such Loan to, as the case may be) a Base Rate Loan, (C) the
Affected Lender's obligation to maintain its outstanding LIBOR Rate Loans (the &ldquo;<U>Affected Loans</U>&rdquo;) shall be terminated
at the earlier to occur of the expiration of the Interest Period then in effect with respect to the Affected Loans or when required
by law, and (D) the Affected Loans shall automatically convert into Base Rate Loans on the date of such termination. Notwithstanding
the foregoing, to the extent a determination by an Affected Lender as described above relates to a LIBOR Rate Loan then being
requested by Company pursuant to a Funding Notice or a Conversion/Continuation Notice, Company shall have the option, subject
to the provisions of <U>Section 2.19(c)</U>, to rescind such Funding Notice or Conversion/Continuation Notice as to all Lenders
by giving written notice to Administrative Agent of such rescission on the date on which the Affected Lender gives notice of its
determination as described above (which notice of rescission Administrative Agent shall promptly transmit to each other Lender).
Except as provided in the immediately preceding sentence, nothing in this <U>Section 2.19(b)</U> shall affect the obligation of
any Lender other than an Affected Lender to make or maintain Loans as, or to convert Loans to, LIBOR Rate Loans in accordance
with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation
for Breakage or Non-Commencement of Interest Periods</U>. Company shall compensate each Lender, upon written request by such Lender
(which request shall set forth the basis for requesting such amounts), for all reasonable losses, expenses and liabilities (including
any interest paid or calculated to be due and payable by such Lender to lenders of funds borrowed by it to make or carry its LIBOR
Rate Loans and any loss, expense or liability sustained by such Lender in connection with the liquidation or re-employment of
such funds but excluding loss of anticipated profits) which such Lender may sustain: (i) if for any reason (other than a default
by such Lender) a borrowing of any LIBOR Rate Loan does not occur on a date specified therefor in a Funding Notice, or a conversion
to or continuation of any LIBOR Rate Loan does not occur on a date specified therefor in a Conversion/Continuation Notice; (ii)
if any prepayment or other principal payment of, or any conversion of, any of its LIBOR Rate Loans occurs on any day other than
the last day of an Interest Period applicable to that Loan (whether voluntary, mandatory, automatic, by reason of acceleration,
or otherwise); or (iii) if any prepayment of any of its LIBOR Rate Loans is not made on any date specified in a notice of prepayment
given by Company.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Booking
of LIBOR Rate Loans</U>. Any Lender may make, carry or transfer LIBOR Rate Loans at, to, or for the account of any of its branch
offices or the office of an Affiliate of such Lender.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Assumptions
Concerning Funding of LIBOR Rate Loans</U>. Calculation of all amounts payable to a Lender under this <U>Section 2.19</U> and
under <U>Section 2.14</U> shall be made as though such Lender had actually funded each of its relevant LIBOR Rate Loans through
the purchase of a LIBOR deposit bearing interest at the rate obtained pursuant to <U>clause (a)(i)</U> of the definition of Adjusted
LIBOR Rate in an amount equal to the amount of such LIBOR Rate Loan and having a maturity comparable to the relevant Interest
Period and through the transfer of such LIBOR deposit from an offshore office of such Lender to a domestic office of such Lender
in the United States of America; <U>provided</U>, <U>however</U>, each Lender may fund each of its LIBOR Rate Loans in any manner
it sees fit and the foregoing assumptions shall be utilized only for the purposes of calculating amounts payable under this <U>Section
2.19</U> and under <U>Section 2.14</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Provisions with Respect to LIBOR</U>. If prior to the commencement of any Interest Period for any LIBOR Rate Loan,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Administrative Agent shall have reasonably determined that adequate and reasonable means do not exist for ascertaining LIBOR for
such Interest Period, including, without limitation, because the Administrative Agent reasonably determines that either inadequate
or insufficient quotations of the London interbank offered rate exist or the use of &ldquo;LIBOR&rdquo; has been discontinued
(any determination of Administrative Agent to be conclusive and binding absent manifest error), or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Administrative Agent shall have received notice from the Required Lenders that LIBOR does not adequately and fairly reflect the
cost to such Lenders of making, funding or maintaining their LIBOR Rate Loans for such Interest Period,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">then
the Administrative Agent shall give written notice to Borrower and to the Lenders as soon as practicable thereafter. Until the
Administrative Agent shall notify Borrower and the Lenders that the circumstances giving rise to such notice no longer exist,
(A) the obligations of the Lenders to make LIBOR Rate Loans, or to continue or convert outstanding Loans as or into LIBOR Rate
Loans, shall be suspended and (B) all such affected Loans shall be converted into Base Rate Loans on the last day of the then
current Interest Period applicable thereto.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
III</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
CONDITIONS PRECEDENT</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing
Date</U>. The obligation of each Lender to make a Credit Extension on the Closing Date is subject to the satisfaction, or waiver
in accordance with <U>Section 10.5</U>, of the following conditions on or before the Closing Date:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Loan
Documents</U>. Administrative Agent shall have received copies of each Loan Document originally executed and delivered by each
applicable Loan Party for each Lender party to this Agreement on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organizational
Documents; Incumbency</U>. Administrative Agent shall have received a Secretary's Certificate for each Loan Party attaching (i)
copies of each Organizational Document of such Loan Party and, to the extent applicable, certified as of a recent date by the
appropriate governmental official, each dated the Closing Date or a recent date prior thereto; (ii) signature and incumbency certificates
of the officers of such Person executing the Loan Documents to which it is a party; (iii) resolutions of the Board of Directors
or similar governing body of such Loan Party approving and authorizing the execution, delivery and performance of this Agreement
and the other Loan Documents to which it is a party or by which it or its assets may be bound as of the Closing Date, certified
as of the Closing Date by its secretary or an assistant secretary (or other duly authorized officer) as being in full force and
effect without modification or amendment; (iv) a good standing certificate from the applicable Governmental Authority (A) of such
Loan Party's jurisdiction of incorporation, organization or formation and (B) in each jurisdiction in which it is qualified as
a foreign corporation or other entity to do business (solely in the case of this subclause (B), except in jurisdictions where
the failure to be so qualified or in good standing has not had, and would not be reasonably expected to have, a Material Adverse
Effect), each dated a recent date prior to the Closing Date; and (v) such other documents as Administrative Agent may reasonably
request.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organizational
and Capital Structure</U>. The organizational structure and capital structure of Borrower and its Subsidiaries shall be as set
forth on <U>Schedule 4.2</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sources
and Uses</U>. On or prior to the Closing Date, Company shall have delivered to Administrative Agent Company's reasonable best
estimate of all sources and uses of Cash and other proceeds of Term Loans on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governmental
Authorizations and Consents</U>. Each Loan Party shall have obtained all Governmental Authorizations and all consents of other
Persons, in each case that are necessary in connection with the transactions contemplated by the Loan Documents and each of the
foregoing shall be in full force and effect and in form and substance reasonably satisfactory to Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Personal Property Collateral</U>. In order to create in favor of Administrative Agent, for the benefit of Secured Parties,
a valid, perfected first priority security interest (subject to any exceptions permitted in the Collateral Documents) in the personal
property Collateral, Administrative Agent shall have received:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence
reasonably satisfactory to Administrative Agent of the compliance by each Loan Party of their obligations under the Pledge and
Security Agreement and the other Collateral Documents (including, without limitation, their obligations to authorize or execute,
as the case may be as required under the applicable Collateral Documents, and deliver UCC financing statements, originals of securities
(including stock certificates, if any, representing pledged Capital Stock along with appropriate endorsements), instruments and
chattel paper, and any agreements governing deposit and/or securities accounts as provided therein and a duly executed authorization
to pre-file UCC-1 financing statements which is effective as of the Closing Date), together with appropriate financing statements
on Form UCC-1 in form for filing in such office or offices as may be necessary or, in the reasonable discretion of Administrative
Agent, desirable to perfect the security interests purported to be created by each Pledge and Security Agreement and (B) evidence
reasonably satisfactory to Administrative Agent of filing of such UCC-1 financing statements; <U>provided</U>, that such evidence
of filing will not require the receipt on the Closing Date of certified copies of the filed UCC-1 financing statements;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
completed Perfection Certificate dated the Closing Date and executed by an Authorized Officer of each Loan Party, together with
all attachments contemplated thereby, including the results of a recent search, by a Person satisfactory to Administrative Agent,
of all effective UCC financing statements (or equivalent filings) made with respect to any assets or property of any Loan Party
in the jurisdictions specified in the Perfection Certificate, together with copies of all such filings disclosed by such search;
and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evidence
that each Loan Party shall have taken or caused to be taken any other action, executed and delivered or caused to be executed
and delivered any other agreement, document and instrument (including, without limitation, evidence that Bank of America, N.A.
has agreed to the forms of, and is prepared to sign on or promptly after the Closing Date, one or more Control Agreements in respect
of the Specified Deposit Accounts) and made or caused to be made any other filing and recording reasonably required by Administrative
Agent, in each case, to the extent required by, and subject to the terms and conditions of, the Pledge and Security Agreement
or any other Collateral Document in effect on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial
Statements</U>. Lenders shall have received from Borrower (i) the Historical Financial Statements (it being agreed that the financial
statement for the month ended March 31, 2019 shall, if not available prior to the Closing Date, be delivered to Administrative
Agent promptly upon it becoming available after the Closing Date) and (ii) pro forma consolidated balance sheets of Borrower and
its Subsidiaries as at the Closing Date, and reflecting the transactions contemplated by the Loan Documents to occur on or prior
to the Closing Date, which pro forma financial statements shall be in form and substance reasonably satisfactory to Administrative
Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Evidence
of Insurance</U>. Administrative Agent shall have received a certificate from Company's insurance broker or other evidence reasonably
satisfactory to it that all insurance required to be maintained pursuant to <U>Section 5.5</U> is in full force and effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Opinions of Counsel to Loan Parties</U>. The
Administrative Agent and its counsel shall have received copies of originally executed written opinions of DLA Piper LLP (US),
counsel for Loan Parties, and such other applicable counsel for Loan Parties, dated as of the Closing Date and otherwise in form
and substance reasonably satisfactory to Administrative Agent (and each Loan Party hereby instructs each such counsel to deliver
such opinions to Administrative Agent and Lenders).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Fees</U>. Substantially contemporaneously with the initial funding of the Term Loan on the Closing Date, Company shall have
paid to Administrative Agent, the fees and expenses then due and payable pursuant to <U>Section 2.7</U> and <U>Section 10.2</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Solvency
Certificate</U>. On the Closing Date, Administrative Agent shall have received a Solvency Certificate of the chief financial officer
(or other substantially similar title) of Borrower substantially in the form of <U>Exhibit F</U>, dated as of the Closing Date
and addressed to Administrative Agent and Lenders.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing Date Certificate</U>. Company shall
have delivered to Administrative Agent an originally executed copy of the Closing Date Certificate, together with copies of all
attachments thereto.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Litigation</U>. There shall not exist any action, suit, investigation, litigation or proceeding or other legal or regulatory developments
(including any Regulatory Action), pending or threatened in any court or before any arbitrator or Governmental Authority that
singly or in the aggregate, would have a Material Adverse Effect or would result in any Material Regulatory Liability.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Minimum
Qualified Cash</U>. Administrative Agent shall have received evidence reasonably satisfactory to it that the Company shall have
unrestricted Cash and Cash Equivalents (other than restrictions created by the Collateral Documents) of at least $50,000,000 immediately
after giving effect to any Credit Extensions to be made on the Closing Date, including the payment of all Transaction Costs required
to be paid in Cash on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Effect</U>. Since December 31, 2018, no event, circumstance or change shall have occurred that has caused or
has resulted in, either in any case or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Completion
of Proceedings</U>. All partnership, corporate and other proceedings taken or to be taken in connection with the transactions
contemplated hereby and all documents incidental thereto not previously found reasonably acceptable by Administrative Agent and
its counsel and communicated in writing to the Loan Parties and their counsel as such shall be reasonably satisfactory in form
and substance to Administrative Agent and such counsel.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Regulations</U>. Administrative Agent shall have received all documentation and other information reasonably requested that is
required by bank regulatory authorities under applicable &ldquo;know-your-customer&rdquo; and anti-money laundering rules and
regulations, including the Patriot Act, and all such documentation and other information shall be in form and substance reasonably
satisfactory to the Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Funding
Notice</U>. Administrative Agent shall have received a fully executed and delivered Funding Notice.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties</U>. The representations and warranties contained herein and in each other Loan Document or certificate delivered
to Administrative Agent or any Lender pursuant hereto or thereto on or prior to the date hereof shall be true and correct in all
material respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already
are qualified or modified as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof, which
representations and warranties shall be true and correct in all respects subject to such qualification) on and as the date hereof
to the same extent as though made on and as of that date, except to the extent such representations and warranties specifically
relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material
respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are
qualified or modified as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof, which representations
and warranties shall be true and correct in all respects subject to such qualification) on and as of such earlier date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Default or Event of Default</U>. No event shall have occurred and be continuing or would result from the consummation of the transactions
contemplated herein that would constitute an Event of Default or a Default.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Contravention</U>. The making of the Term Loan shall not contravene any law, rule or regulation of any Governmental Authority
having appropriate jurisdiction over the Administrative Agent or any Lender that is applicable to Administrative Agent or any
Lender.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Existing
Indebtedness</U>. Substantially contemporaneously with the initial funding of the Term Loan on the Closing Date, Borrower and
its Subsidiaries shall have (i) repaid in full all Existing Indebtedness, (ii) terminated any commitments to lend or make other
extensions of credit thereunder, and (iii) delivered to Administrative Agent all documents or instruments necessary to release
all Liens securing Existing Indebtedness or other obligations of Borrower and its Subsidiaries thereunder being repaid on the
Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registrations</U>.
All Registrations from the FDA in respect of the Products shall be valid and subsisting and in full force and effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender, by delivering its signature page to this Agreement and funding the Term Loan on the Closing Date, shall be deemed to have
acknowledged receipt of, and consented to and approved, each Loan Document and each other document, instrument or agreement required
to be approved by Administrative Agent, Required Lenders and/or Lenders, as applicable, on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions
to Each Credit Extension</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
Precedent</U>. The obligation of each Lender to make any Loan on any date following the Closing Date is subject to the satisfaction,
or waiver in accordance with <U>Section 10.5</U>, of the following conditions precedent:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent shall have received a fully executed and delivered Funding Notice;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of such Credit Date, the representations and warranties contained herein and in each other Loan Document or certificate delivered
to any Agent or any Lender pursuant hereto or thereto on or prior to the Credit Date shall be true and correct in all material
respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are
qualified or modified as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof, which representations
and warranties shall be true and correct in all respects subject to such qualification) on and as of that Credit Date to the same
extent as though made on and as of that date, except to the extent such representations and warranties specifically relate to
an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (except
that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) on and as of such earlier date;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of such Credit Date, no event shall have occurred and be continuing or would result from the consummation of the applicable Credit
Extension that would constitute an Event of Default or a Default;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent shall have received evidence reasonably satisfactory to it that the Company shall have unrestricted Cash and Cash Equivalents
(other than restrictions created by the Collateral Documents) of at least $60,000,000 immediately after giving effect to any Credit
Extensions to be made on such Credit Date;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solely
in respect of any Delayed Draw A-1 Term Loan, Company shall have delivered, on or prior to December 31, 2019, evidence demonstrating
[***]; and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solely
in respect of any Delayed Draw A-2 Term Loan, the Chief Financial Officer of Company shall have delivered a certificate (together
with such other evidence as is reasonably requested by Administrative Agent) representing and warranting, and otherwise demonstrating
to the reasonable satisfaction of Administrative Agent, that the Product Revenue for the Fiscal Quarter ending December 31, 2019
is greater than $11,000,000.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
Any Notice shall be executed by an Authorized Officer of Company in a writing delivered to Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
IV</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to induce Agents and Lenders to enter into this Agreement and to make each Credit Extension to be made thereby, each Loan
Party represents and warrants to each Agent and Lender, on the Closing Date and on each Credit Date, that the following statements
are true and correct:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organization;
Requisite Power and Authority; Qualification</U>. Each of Borrower and its Subsidiaries (a) is duly organized, validly existing
and in good standing under the laws of its jurisdiction of organization as identified in <U>Schedule 4.1</U>, (b) has all requisite
corporate power and authority to own and operate its properties, to carry on its business as now conducted and as proposed to
be conducted, to enter into the Loan Documents to which it is a party and to carry out the transactions contemplated thereby and,
in the case of Company, to make the borrowings hereunder, and (c) is qualified to do business and in good standing in every jurisdiction
wherever necessary to carry out its business and operations, except in jurisdictions where the failure to be so qualified or in
good standing has not had, and would not be reasonably expected to have, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;<U>Capital Stock and Ownership</U>. The Capital Stock of
each of Borrower and its Subsidiaries has been duly authorized and validly issued and, if applicable, is fully paid and non-assessable.
Except as set forth on <U>Schedule 4.2</U>, as of the date hereof, there is no existing option, warrant, call, right, commitment
or other agreement to which Borrower or any of its Subsidiaries is a party requiring, and there is no membership interest or other
Capital Stock of Borrower or any of its Subsidiaries outstanding which upon conversion or exchange would require, the issuance
by Borrower or any of its Subsidiaries of any additional membership interests or other Capital Stock of Borrower or any of its
Subsidiaries or other securities convertible into, exchangeable for or evidencing the right to subscribe for or purchase, a membership
interest or other Capital Stock of Borrower or any of its Subsidiaries. <U>Schedule 4.2</U> correctly sets forth the ownership
interest of Borrower and each of its Subsidiaries in their respective Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Due
Authorization</U>. The execution, delivery and performance of the Loan Documents have been duly authorized by all necessary corporate
or limited liability, as applicable, action on the part of each Loan Party that is a party thereto.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Conflict</U>. The execution, delivery and performance by Loan Parties of the Loan Documents to which they are parties and the
consummation of the transactions contemplated by the Loan Documents do not and will not (a) violate any provision of any law or
any governmental rule or regulation of any Governmental Authority that is applicable to Borrower or any of its Subsidiaries, any
of the Organizational Documents of Borrower or any of its Subsidiaries, or any order, judgment or decree of any court or other
agency of government of any Governmental Authority that is binding on Borrower or any of its Subsidiaries; (b)&nbsp;conflict with,
result in a breach of or constitute (with due notice or lapse of time or both) a default under any material Contractual Obligation
of Borrower or any of its Subsidiaries; (c) result in or require the creation or imposition of any Lien upon any of the properties
or assets of Borrower or any of its Subsidiaries (other than any Liens created under any of the Loan Documents in favor of Administrative
Agent, on behalf of Secured Parties); (d) result in any default, non-compliance, suspension revocation, impairment, forfeiture
or non-renewal of any material permit, license, authorization or approval of any Governmental Authority having appropriate jurisdiction
that is applicable to its operations or any of its properties; or (e) require any approval or consents of stockholders, members
or partners of Borrower or any of its Subsidiaries, except for such approvals or consents which will be obtained on or before
the Closing Date and disclosed in writing to Lenders.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Governmental Consents</U>. The execution, delivery and
performance by Loan Parties of the Loan Documents to which they are parties and the consummation of the transactions contemplated
by the Loan Documents do not and will not require any registration with, consent or approval of, or notice to, or other action
to, with or by, any Governmental Authority except for filings and recordings with respect to the Collateral to be made, or otherwise
delivered to Administrative Agent for filing and/or recordation, as of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Binding Obligation</U>. Each Loan Document has been duly
executed and delivered by each Loan Party that is a party thereto and is the legally valid and binding obligation of such Loan
Party, enforceable against such Loan Party in accordance with its respective terms, except as may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or limiting creditors' rights generally or by equitable principles relating
to enforceability.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Historical
Financial Statements</U>. The Historical Financial Statements were prepared in conformity with GAAP and fairly present, in all
material respects, the financial position, on a consolidated basis, of the Persons described in such financial statements as at
the respective dates thereof and the results of operations and cash flows, on a consolidated basis, of the entities described
therein for each of the periods then ended, subject, in the case of any such unaudited financial statements, to changes resulting
from audit and normal year end adjustments. As of the Closing Date, neither Borrower nor any of its Subsidiaries has any contingent
liability or liability for taxes, long term lease or unusual forward or long term commitment that is not reflected in the Historical
Financial Statements or the notes thereto and which in any such case is material in relation to the business, operations, properties,
assets, condition (financial or otherwise) or prospects of Borrower and any of its Subsidiaries taken as a whole.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Material Adverse Effect</U>. Since December 31, 2018, no event, circumstance or change has occurred or has resulted in, either
in any case or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adverse
Proceedings, etc</U>. As of the Closing Date, there are no Adverse Proceedings that (a) relate to any Loan Document or the transactions
contemplated hereby or thereby or (b) individually or in the aggregate, could materially impair the Administrative Agent's security
interest in the Collateral, the Borrower's and its Subsidiaries' respective rights, powers or remedies with respect to applicable
Products or would otherwise reasonably be expected to have a Material Adverse Effect. Neither Borrower nor any of its Subsidiaries
is in violation of or in default with respect to any final judgments, writs, injunctions, decrees, rules, laws or regulations
of any Governmental Authority having appropriate jurisdiction except to the extent such violation or default could not reasonably
be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment
of Taxes</U>. Except as otherwise permitted under <U>Section 5.3</U>, all U.S. federal and material state and local income tax
returns and other material reports of Borrower and its Subsidiaries required to be filed by any of them have been timely filed,
all such tax returns are true, complete and correct in all material respects, and all U.S. federal and material state and local
Taxes shown as due and payable on such tax returns and all assessments, fees and other governmental charges upon Borrower and
its Subsidiaries and upon their respective properties, assets, income, businesses and franchises which are due and payable have
been paid when due and payable. Borrower knows of no proposed Tax assessment against Borrower or any of its Subsidiaries which
is not being actively contested by Borrower or such Subsidiary in good faith and by appropriate proceedings; <U>provided</U>,
such reserves or other appropriate provisions, if any, as shall be required in conformity with GAAP shall have been made or provided
therefor.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Properties,
Title</U>. Each of Borrower and its Subsidiaries has (a) good, sufficient, marketable and legal title to (in the case of fee interests
in real property), (b) valid leasehold interests in (in the case of leasehold interests in real or personal property), and (c)
good and valid title to (in the case of all other personal property), all of their respective properties and assets reflected
in their respective Historical Financial Statements referred to in <U>Section 4.7</U> and in the most recent financial statements
delivered pursuant to <U>Section 5.1</U>, in each case except for (i) assets disposed of since the date of such financial statements
in the ordinary course of business or as otherwise permitted under <U>Section 6.9</U> or (ii)&nbsp;defects in title or interests
which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. All such properties
and assets are in working order and condition, ordinary wear and tear excepted, and except as permitted by this Agreement or any
of the Collateral Documents, all such non-leasehold properties and assets are free and clear of Liens. As of the Closing Date,
<U>Schedule 4.12</U> contains a true, accurate and complete list of all real property owned or leased by Borrower and its Subsidiaries
or where Collateral or books and records are located.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><U>Section
4.13</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Matters</U>. In each case of the following sub-clauses (a)-(d), except as any such failure or exception to the applicable representation
and warranty would not reasonably be expected to result in a Material Adverse Effect:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Environmental Claim has been asserted against any Loan Party or any predecessor in interest nor has any Loan Party received notice
of any threatened or pending Environmental Claim against Loan Party or any predecessor in interest.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been no Release of Hazardous Materials and there are no Hazardous Materials present in violation of Environmental Law at any
of the properties currently owned or operated by any Loan Party.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operation of the business of, and each of the properties owned or operated by, each Loan Party are in compliance with all Environmental
Laws.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Loan Party holds and is in compliance Governmental Authorizations required under any Environmental Laws in connection with the
operations carried on by it and the properties owned or operated by it.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Defaults</U>. Neither Borrower nor any of its Subsidiaries (a) is in default in the performance, observance or fulfillment of
any of the obligations, covenants or conditions contained in any of its Contractual Obligations, and (b) no condition exists which,
with the giving of notice or the lapse of time or both, could constitute such a default, except , in each case of the foregoing
subclauses (a)-(b), where the consequences, direct or indirect, of such default or defaults, if any, could not reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
Contracts</U>. <FONT STYLE="color: #010000"></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: #010000">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Schedule 4.15</U> contains
a true, correct and complete list of all the Material Contracts in effect on the Closing Date, which Material Contracts,
together with any updates provided pursuant to <U>Section 5.1(l)</U>, are in full force and effect and no defaults givng any
party thereto the right to terminate such Material Contract currently exist thereunder (other than as described in <U>Schedule
4.15</U> or in such updates).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described in <U>Schedule 4.15</U>, each Material Contract is a legal, valid and binding obligation of Borrower, its Subsidiaries
and, to the knowledge of Borrower, each other party thereto, is enforceable in accordance with its terms and is in full force
and effect, subject bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors' rights and to general equity principles. Neither the Borrower nor its Subsidiaries, nor to
the knowledge of the Authorized Officers of Borrower or its Subsidiaries, any other party to any Material Contract, is or was
in material breach or default, under the terms of any Material Contract, and no condition existed or exists which, with the giving
of notice or the lapse of time or both, could constitute a material breach or default by Borrower or any of its Subsidiaries thereunder.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governmental
Regulation</U>. Neither Borrower nor any of its Subsidiaries is subject to regulation under the Public Utility Holding Company
Act of 2005, the Federal Power Act or the Investment Company Act of 1940 or under any other federal or state statute or regulation
which may limit its ability to incur Indebtedness or which may otherwise render all or any portion of the Obligations unenforceable.
Neither Borrower nor any of its Subsidiaries is required to register as a &ldquo;registered investment company&rdquo; or a company
&ldquo;controlled&rdquo; by a &ldquo;registered investment company&rdquo; or a &ldquo;principal underwriter&rdquo; of a &ldquo;registered
investment company&rdquo; as such terms are defined in the Investment Company Act of 1940.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Margin
Stock</U>. Neither Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the
business of extending credit for the purpose of purchasing or carrying any Margin Stock. No part of the proceeds of the Term Loans
made to such Loan Party will be used to purchase or carry any such Margin Stock or to extend credit to others for the purpose
of purchasing or carrying any such Margin Stock or for any purpose that violates, or is inconsistent with, the provisions of Regulation
T, U or X of the Board of Governors of the Federal Reserve System.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employee
Benefit Plans</U>. No ERISA Event has occurred or is reasonably expected to occur that would reasonably be expected to result
in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
Fees</U>. No broker's or finder's fee or commission will be payable with respect hereto or any of the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Solvency</U>.
The Loan Parties, on a consolidated basis, are and, upon the incurrence of the Credit Extension by the applicable Loan Party on
the Closing Date and on each date on which this representation and warranty is made, will be, Solvent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>[Reserved]</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
with Statutes, etc</U>. Each of Borrower and its Subsidiaries is in compliance with (i) its Organizational Documents and (ii)
all applicable laws, statutes, regulations and orders of, and all applicable restrictions imposed by, all Governmental Authorities
having appropriate jurisdiction, in respect of the conduct of its business and the ownership of its property, except such non-compliance
that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual
Property</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Borrower and its Subsidiaries own, or hold licenses in, all trademarks, trade secrets, trade names, copyrights, patents, and
licenses that are necessary to the conduct of its business as currently conducted.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule
4.23(b)</U> sets forth a true, correct and complete listing in all material respects of all U.S. and foreign Product Patents as
of the Closing Date, and identifies the owner of each such Product Patent and the Product to which such Product Patent relates.
As of the Closing Date and except as identified in <U>Schedule 4.23(b)</U>, (i) the owner listed on <U>Schedule 4.23(b)</U> for
each Product Patent is the exclusive owner of such patent/application and no Third Party has any right, title, interest or ownership
claim in such Product Patent, (ii) to the best of Borrower's and its Subsidiaries' knowledge, the Product Patents are valid, subsisting,
and enforceable; (iii)&nbsp;except for those patent applications that that are abandoned or lapse, in the case of provisional
patent applications, in the due course of patent prosecution and in accordance with the reasonable business judgment of the Company
and its subsidiaries in executing a comprehensive patent strategy designed to maximize and maintain exclusivity of the Products,
none of the Product Patents have lapsed or been abandoned, cancelled or expired; (iv) Company has taken commercially reasonable
steps to maintain such Product Patents, including by timely filing fees and responses; (v) each individual associated with the
filing and prosecution of the Product Patents, including the named inventors, has complied in all material respects with all applicable
duties of candor and good faith in dealing with any patent office, including the USPTO, in those jurisdictions where such duties
exist.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Closing Date, <U>Schedule 4.23(c)</U> sets forth a true, correct and complete listing, under separate headings, of all
material written Contractual Obligations (i) under which Company or its Subsidiaries uses or licenses any Product Patents that
any other Person owns, or owes any royalties or other payments to any Person for the use of any Product Patents, (ii) under which
Company or its Subsidiaries have granted any Person any right or interest in any Product Patents, and (iii) that otherwise limit
the Company or its Subsidiaries' use of or rights in the Product Patents (including co-existence agreements and covenants not
to sue). Company may update this list to add additional licenses, so long as such amendment occurs by written notice to Administrative
Agent, and subject to Company's obligations and restrictions under this Agreement.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no opposition, interference, reexamination, derivation or other post-grant proceeding, injunction, claim, suit, action, subpoena,
hearing, inquiry, investigation (by the International Trade Commission or otherwise), complaint, arbitration, mediation, demand,
decree or other dispute, disagreement, proceeding or claim (collectively, &ldquo;<U>Disputes</U>&rdquo;) that is pending or currently
threatened in writing, that challenges the scope, validity, enforceability, ownership, or inventorship of the Product Patents.
Company and its Subsidiaries have not received any written notice that there is any, and to the knowledge of the Authorized Officers
of the Borrower and its Subsidiaries there is no, Person who is or claims to be an inventor under any of the Product Patents who
is not a named inventor thereof.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of Borrower's knowledge, there is no past, pending or threatened, and no event has occurred or circumstance exists that
(with or without notice or lapse of time, or both) could reasonably be expected to give rise to or serve as a basis for any, action,
suit, or proceeding, or any investigation or written claim by any Person that claims or alleges that the manufacture, use, marketing,
sale, offer for sale, importation or distribution of any Product, once marketed, does or could infringe on any patent or other
intellectual property rights of any other Person or constitute misappropriation of any other Person's trade secrets or other intellectual
property rights anywhere in the world.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance</U>.
Each of Borrower and its Subsidiaries (a)&nbsp;maintains insurance to such extent and against such risks, as is customary with
companies in the same or similar businesses, (b)&nbsp;is covered by workmen's compensation insurance in the amount required by
applicable law, (c) maintains commercial general liability insurance, which shall include product liability insurance, in the
amount customary with companies in the same or similar business against claims for personal injury or death on properties owned,
occupied or controlled by it, and (d) maintains such other insurance as may be required by any Governmental Authority. <U>Schedule
4.24</U> sets forth a list of all insurance maintained by each Loan Party on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Common
Enterprise</U>. Each Loan Party expects to derive benefit (and its Board of Directors or other governing body has determined that
it may reasonably be expected to derive benefit), directly and indirectly, from the credit extended by the Lenders to the Borrower
hereunder, both in their separate capacities and as members of a group of companies. Each Loan Party has determined that execution,
delivery, and performance of this Agreement and any other Loan Documents to be executed by such Loan Party is within its purpose,
will be of direct and indirect benefit to such Loan Party, and is in its best interest.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Permits,
Etc.</U> Each Loan Party has, and is in compliance with, all permits, licenses, authorizations, approvals, entitlements and accreditations
required by any Governmental Authority having appropriate jurisdiction for such Person to own, lease, manage or operate, or to
acquire, each business currently owned, leased, managed or operated, or to be acquired, by such Person, except for any such permits,
licenses, authroizations, approvals, entitlements and accreditations which, if not obtained, could not reasonably be expected
to have a Material Adverse Effect. No condition exists or event has occurred which, in itself or with the giving of notice or
lapse of time or both, would result in the suspension, revocation, impairment, forfeiture or non-renewal of any such permit, license,
authorization, approval, entitlement or accreditation, and there is no claim that any thereof is not in full force and effect,
except, in each case, to the extent any such condition, event or claim could not be reasonably be expected to have a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bank
Accounts and Securities Accounts</U>. <U>Schedule 4.27</U> sets forth a complete and accurate list in all material aspects as
of the Closing Date of all deposit, checking and other bank accounts, all securities and other accounts maintained with any broker
dealer and all other similar accounts maintained by each Loan Party, together with a description thereof in reasonable detail
(<U>i.e.</U>, the bank or broker dealer at which such deposit or other account is maintained and the account number and the purpose
thereof).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Security
Interests</U>. The Collateral Documents create in favor of Administrative Agent, for the benefit of Secured Parties, a legal,
valid and enforceable security interest in the Collateral secured thereby. Upon the filing of the UCC-1 financing statements described
in <U>Section 3.1(f)</U>, the posssession by the Administrative Agent of any certificated Capital Stock or instrument owned by
such Loan Party, the recording of the Collateral Assignments for Security referred to in each Pledge and Security Agreement in
the United States Patent and Trademark Office and the United States Copyright Office and the taking of all other actions required
by the Pledge and Security Agreement, as applicable, such security interests in and Liens on the Collateral granted thereby shall
be perfected, first priority (subject to any Permitted Liens) security interests, and no further recordings or filings are or
will be required in connection with the creation, perfection or enforcement of such security interests and Liens, other than (a)&nbsp;the
filing of continuation statements in accordance with applicable law, (b)&nbsp;the recording of the Collateral Assignments for
Security pursuant to each Pledge and Security Agreement in the United States Patent and Trademark Office and the United States
Copyright Office, as applicable, with respect to after-acquired U.S.&nbsp;patent and trademark applications and registrations
and U.S. copyrights, and (c) the recordation of appropriate evidence of the security interest in the appropriate foreign registry
with respect to all foreign intellectual property and all other recordings and filings required in any jurisdiction other than
the U.S. in order to create, register or perfect any such security interests, in each case, so long as Administrative Agent has
not required any Loan Party to create, register or perfect such security interests in accordance with <U>Section 5.11</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PATRIOT
ACT and FCPA</U>. To the extent applicable, each Loan Party is in compliance with (a) the laws, regulations and Executive Orders
administered by OFAC, and (b) the Bank Secrecy Act, as amended by the Uniting and Strengthening America by Providing Appropriate
Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT Act ) of 2001 (the &ldquo;<FONT STYLE="font-weight: normal"><U>PATRIOT
Act</U></FONT>&rdquo;). Neither the Loan Parties nor any of their officers, directors, employees, agents or shareholders acting
on the Loan Parties' behalf shall use the proceeds of the Loans to make any payments, directly or indirectly (including through
any third party intermediary), to any Foreign Official in violation of the United States Foreign Corrupt Practices Act of 1977,
as amended (the &ldquo;<FONT STYLE="font-weight: normal"><U>FCPA</U></FONT>&rdquo;). None of the Loan Parties nor any Affiliates
of any Loan Parties that are controlled by the Loan Parties, is in violation of any Anti-Terrorism Law or engages in or conspires
to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of
the Anti-Terrorism Laws. None of the Loan Parties, nor any Affiliates of any Loan Parties that are controlled by the Loan Parties,
or their respective agents acting or benefiting in any capacity in connection with the Loans or other transactions hereunder,
is a Blocked Person. None of the Loan Parties, nor any of their agents acting in any capacity in connection with the Loans or
other transactions hereunder (A) conducts any business or engages in making or receiving any contribution of funds, goods or services
to or for the benefit of any Blocked Person, or (B) deals in, or otherwise engages in any transaction relating to, any property
or interests in property blocked pursuant to any OFAC Sanctions Programs.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Managerial
Assistance and Related Persons</U>. Each Loan Party represents and warrants that (a) TSL has offered to make available to each
of them &ldquo;significant managerial assistance&rdquo; (as defined in Section 2(a)(47) of the Investment Company Act of 1940)
and, to the extent any Loan Party accepts such offer from TSL, the scope, terms and conditions of such significant managerial
assistance are set forth in a separate agreement between such Loan Party and TSL and (b)&nbsp;it is not a &ldquo;person&rdquo;
related to TSL as described in Section 57(b) or 57(e) of the Investment Company Act of 1940.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclosure</U>.
No representation or warranty of any Loan Party contained in any Loan Document or in any other documents, certificates or written
statements made or furnished to Lenders by or on behalf of Borrower or any of its Subsidiaries for use in connection with the
transactions contemplated hereby when taken as a whole contains any untrue statement of a material fact or omits to state a material
fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances in which
the same were made. Notwithstanding anything to the contrary in the foregoing, it is hereby understood and agreed by each party
to this Agreement that any projections, budgets, estimates, pro forma financial information, any other forward-looking statements
or information of a general economic or industry nature contained in such materials are based upon good faith estimates and assumptions
believed by Company to be reasonable at the time made, it being recognized by Lenders that such projections, budgets, estimates,
pro forma financial information and forward looking statements are not to be viewed as facts and that actual results during the
period or periods covered by any such projections, budgets, estimates, pro forma financial information and forward looking statements
may differ from the projected results and such differences may be material. There are no facts known (or which should upon the
reasonable exercise of diligence be known) to any Authorized Officer of the Company (other than matters of a general economic
nature) that, individually or in the aggregate, are material and pertinent in the transactions contemplated hereby or the Products
that have not been disclosed herein or in such other documents, certificates and statements furnished to Lenders for use in connection
with the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Use
of Proceeds</U>. The proceeds of the Term Loan shall be applied by Company for working capital, capital expenditures, and general
corporate purposes of Borrower and its Subsidiaries. No portion of the proceeds of any Credit Extension shall be used in any manner
that causes or might cause such Credit Extension or the application of such proceeds to violate Regulation T, Regulation U or
Regulation X of the Board of Governors of the Federal Reserve System or any other regulation thereof or to violate the Exchange
Act.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory
Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Borrower and its Subsidiaries have all Registrations from the FDA, comparable foreign counterparts or any other Governmental
Authority required to conduct their respective businesses as currently conducted, except where the failure to have all such Registrations
would not reasonably be expected to, individually or in the aggregate, result in Material Regulatory Liabilities. Each of such
Registrations is valid and subsisting in full force and effect. To the knowledge of Borrower and its Subsidiaries, neither the
FDA nor any comparable Governmental Authority is considering limiting, suspending, or revoking such Registrations or changing
the marketing classification or labeling of any Products under such Registrations. To the knowledge of the Borrower and its Subsidiaries,
there is no false or materially misleading information or significant omission in any Product application or other notification,
submission or report to the FDA or any comparable Governmental Authority that was not corrected by subsequent submission, and
all such applications, notifications, submissions and reports provided by Borrower and its Subsidiaries were true, complete, and
correct in all material respects as of the date of submission to FDA or any comparable Governmental Authority. Borrower and its
Subsidiaries have not failed to fulfill and perform their material obligations which are due under each such Registration, and,
no event has occurred or condition or state of facts exists which would constitute a breach or default under any such Registration,
in each case that would reasonably be expected to cause the revocation, termination or suspension or material limitation of any
such Registration. To the knowledge of the Borrower and its Subsidiaries, any third party that develops, researches, manufactures,
commercializes, distributes, sells or markets Products pursuant to an agreement with Borrower or its Subsidiaries (a &ldquo;<FONT STYLE="font-weight: normal"><U>Loan
Party Partner</U></FONT>&rdquo;) is in compliance with all Registrations from the FDA and any comparable Governmental Authority
insofar as they pertain to Products, and each such Loan Party Partner is in compliance with applicable Public Health Laws, except
where the failure to so be in compliance would not reasonably be expected to, individually or in the aggregate, result in Material
Regulatory Liabilities</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Borrower and its Subsidiaries is in compliance, and has been in compliance, with all Public Health Laws, except to the extent
that any such non-compliance, individually or in the aggregate, could not reasonably be expected to result in Material Regulatory
Liabilities.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent applicable, all products designed, developed, investigated, manufactured, prepared, assembled, packaged, tested, labeled,
distributed, sold, marketed or delivered by or on behalf of Borrower or any of its Subsidiaries, that are subject to the jurisdiction
of the FDA have been and are being designed, developed, investigated, manufactured, prepared, assembled, packaged, tested, labeled,
distributed, sold, marketed or delivered in compliance in all material respects with the Public Health Laws. To the knowledge
of Borrower and its Subsidiaries, there are no defects in the design or technology embodied in any Products that are reasonably
expected to prevent the safe and effective performance of any such Product for its intended use (other than such limitations specified
in the applicable package insert), except for such defects that would not reasonably be expected to, individually or in the aggregate,
result in Material Regulatory Liabilities or other Liabilities. None of the Products has been the subject of any products liability
or warranty action against Borrower or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Borrower nor any of its Subsidiaries is currently subject to any material obligation arising pursuant to a Regulatory Action and,
to the knowledge of Borrower and its Subsidiaries, no such material obligation or Regulatory Action has been threatened by a Governmental
Authority in writing. In addition, and without limitation on the foregoing, except as set forth on <U>Schedule&nbsp;4.33(d)</U>
neither Borrower nor any of its Subsidiaries has received any written notice or communication from the FDA, comparable foreign
counterparts or any other Governmental Authority alleging material non-compliance with any Public Health Law or comparable foreign
laws.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth on <U>Schedule 4.33(e)</U>, (i) neither Borrower nor any of its Subsidiaries has received any written notice or communication
from the FDA or any other Governmental Authority alleging material noncompliance with any Public Health Law, including without
limitation any Form FDA 483, notice of inspectional observation, notice of adverse finding, notice of violation, warning letters,
untitled letters or other notices from the FDA and (ii) to the knowledge of Borrower and its Subsidiaries, no Loan Party Partner
has received any written notice or communication from the FDA or any other Governmental Authority alleging material noncompliance
with any Public Health Law, including without limitation any Form FDA 483, notice of inspectional observation, notice of adverse
finding, notice of violation, warning letters, untitled letters or other notices from the FDA relating to such Loan Party Partner's
work for Borrower or such Subsidiary. No Product has been seized, withdrawn, recalled, detained, or subject to a suspension (other
than in the ordinary course of business) of research, manufacturing, distribution or commercialization activity. Neither Borrower
nor any of its Subsidiaries is aware of any facts or circumstances that are reasonably likely to result in any recall of any Product.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Government
Contracts</U>. Except as set forth on Schedule 4.34 as of the Closing Date hereof, neither Borrower nor any of its Subsidiaries
is a party to any contract or agreement with any Governmental Authority and none of Borrower's or such Subsidiary's accounts receivables
or other rights to receive payment are subject to the Federal Assignment of Claims Act (31 U.S.C. Section 3727) or any similar
state, county or municipal law.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Health
Care Regulatory Laws</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of Borrower and its Subsidiaries, nor, to their knowledge, any officer, director, managing employee or agent (as those terms are
defined in 42 C.F.R. &sect; 1001.1001) thereof, is a party to, or bound by, any written order, individual integrity agreement,
corporate integrity agreement or other formal written agreement with any Governmental Authority concerning their compliance with
Federal Health Care Program Laws.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of Borrower and its Subsidiaries, nor any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R.
&sect; 1001.1001) thereof, nor to the knowledge of Borrower and its Subsidiaries, any Loan Party Partner: (i) has been charged
with or convicted of any criminal offense relating to the delivery of an item or service under any Federal Health Care Program;
(ii)&nbsp;has had a civil monetary penalty assessed against it, him or her under Section 1128A of the SSA; (iii) has been listed
on the U.S. General Services Administration published list of parties excluded from federal procurement programs and non-procurement
programs; or (iv) to the knowledge of Borrower and its Subsidiaries, is the target or subject of any current or potential investigation
relating to any of the foregoing or any Federal Health Care Program-related offense. None of Borrower and its Subsidiaries, nor
any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R. &sect;&nbsp;1001.1001) thereof, nor
any Loan Party Partner, has been debarred, excluded, disqualified or suspended from participation in any Federal Health Care Program
or under any FDA Laws (including 21 U.S.C. &sect;&nbsp;335a).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of Borrower and its Subsidiaries, nor any officer, director, managing employee or agent (as those terms are defined in 42 C.F.R.
&sect; 1001.1001) thereof, nor to the knowledge of Borrower and its Subsidiaries, any Loan Party Partner, has engaged in any activity
that is in material violation of any Federal Health Care Program Laws, including the following:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">knowingly
and willfully making or causing to be made a false statement or representation of a material fact in any application for any benefit
or payment;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">knowingly
and willfully making or causing to be made a false statement or representation of a material fact for use in determining rights
to any benefit or payment;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">knowingly
and willfully soliciting or receiving any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly
or covertly, in cash or kind (1) in return for referring an individual to a person for the furnishing or arranging for the furnishing
of any item or service for which payment may be made in whole or in part under any Federal Health Care Program; or (2) in return
for purchasing, leasing, or ordering, or arranging, or arranging for or recommending purchasing, leasing, or ordering any good,
facility, service or item for which payment may be made in whole or in part under any Federal Health Care Program in violation
of 42 U.S.C. Section 1320a-7b(b); or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">knowingly
and willfully offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or
covertly, in cash or in kind, to any person to induce such person (1) to refer an individual to a person for the furnishing or
arranging for the furnishing of any item or service for which payment may be made in whole or in part under a Federal Health Care
Program; or (2) to purchase, lease, order or arrange for or recommend purchasing, leasing or ordering any good, facility, service
or item for which payment may be made in whole or in part under a Federal Health Care Program in violation of 42 U.S.C. Section
1320a-7b(b).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the knowledge of Borrower and its Subsidiaries, no person has filed or has threatened to file against Borrower or any of its Subsidiaries,
an action relating to any FDA Law, Public Health Law or Federal Health Care Program Law under any whistleblower statute, including
without limitation, under the False Claims Act of 1863 (31 U.S.C. &sect; 3729 et seq.).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Borrower and its Subsidiaries is in compliance in all material respects with HIPAA, and the provisions of all business associate
agreements (as such term is defined by HIPAA) to which it is a party, and has implemented reasonably adequate policies, procedures
and training designed to assure continued compliance and to detect non-compliance, except where the failure to implement such
policies, procedures, and training would not reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
V</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
AFFIRMATIVE COVENANTS</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Loan Party covenants and agrees that, so long as any Commitment is in effect and until payment in full of all Obligations (other
than any such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of
all Obligations), each Loan Party shall perform, and shall cause each of its Subsidiaries to perform, all covenants in this <U>Article
V</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial
Statements and Other Reports</U>. Unless otherwise provided below, Borrower will deliver to Administrative Agent (for delivery
to the Lenders):</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cash
Reports</U>. Promptly, but in any event within 5 Business Days, after the end of each fiscal month of the Company, a report (which
report may consist of bank statements) of the current Cash and Cash Equivalent balances (including the balances in each Deposit
Account of each Loan Party) of the Company and its Subsidiaries, which report shall identify (i) unrestricted (other than restrictions
created by the Collateral Documents) and restricted Cash and Cash Equivalents and (ii) those accounts that constitute Qualified
Cash; <U>provided</U>, that at any time the current Cash and Cash Equivalent balances of the Company and its Subsidiaries is less
than $75,000,000, Administrative Agent may request at any time, and the Company shall promptly provide, a report of at least 95%
of the current Cash and Cash Equivalent balances of the Company and its Subsidiaries, which report shall identify unrestricted
(other than restrictions created by the Collateral Documents) and restricted Cash and Cash Equivalents (or, if greater, all Cash
and Cash Equivalent balances required to satisfy the covenant set forth in <U>Section 6.8</U>).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Quarterly
Financial Statements</U>. As soon as available, and in any event (i) within 45 days after the end of the first three Fiscal Quarters
of each Fiscal Year and (ii) within 60 days after the end of the fourth Fiscal Quarter of each Fiscal Year, the consolidated balance
sheets of Borrower and its Subsidiaries as at the end of such Fiscal Quarter and the related consolidated statements of income,
statements of income and cash flows of Borrower and its Subsidiaries for such Fiscal Quarter, setting forth in each case in comparative
form the corresponding figures for the corresponding periods of the previous Fiscal Year, all in reasonable detail, together with
a Financial Officer Certification with respect thereto;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Annual
Financial Statements</U>. As soon as available, and in any event within 120 days after the end of each Fiscal Year, (i) the consolidated
balance sheets of Borrower and its Subsidiaries as at the end of such Fiscal Year and the related consolidated statements of income,
stockholders' equity and cash flows of Borrower and its Subsidiaries for such Fiscal Year, setting forth in each case in comparative
form the corresponding figures for the previous Fiscal Year, in reasonable detail, together with a Financial Officer Certification
with respect thereto; and (ii) with respect to such consolidated financial statements a report thereon of Grant Thornton LLP or
other independent certified public accountants of recognized national standing selected by Borrower, and reasonably satisfactory
to Administrative Agent (which report shall be unqualified as to going concern and scope of audit (other than with respect to
or resulting from an upcoming maturity of Indebtedness), and shall state that such consolidated financial statements fairly present,
in all material respects, the consolidated financial position of Borrower and its Subsidiaries as at the dates indicated and the
results of their operations and their cash flows for the periods indicated in conformity with GAAP);</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
Certificate</U>. Together with each delivery of financial statements of Borrower and its Subsidiaries pursuant to <U>Section 5.1(b)
</U>or <U>Section 5.1(c)</U>, a duly executed and completed Compliance Certificate;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, the obligations in paragraphs (b), (c) and (d) of this <U>Section 5.1</U> may be satisfied with respect to financial
information of Borrower and its Subsidiaries by furnishing Borrower's Form 10-K or 10-Q, as applicable, filed with the SEC; provided
that, to the extent such information is in lieu of information required to be provided under <U>Section 5.1(c)</U>, such materials
are accompanied by an opinion of Grant Thornton LLP or other independent certified public accountants of recognized national standing
selected by Borrower, and reasonably satisfactory to Administrative Agent, which opinion shall meet the standards set forth in
<U>Section 5.1(c)</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Product
Information</U>. As soon as available, and in any event within 45 days after the end of each Fiscal Quarter of each Fiscal Year
(including the fourth Fiscal Quarter of any Fiscal Year), a description of (i) the aggregate number of Product units sold by the
Loan Parties and the gross and net revenues with respect thereto presented on a monthly basis and (ii) the number of Product units
sold by VitaCare Prescription Services, Inc. and the gross and net revenues with respect thereto presented on a monthly basis.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Statements
of Reconciliation after Change in Accounting Principles</U>. If, as a result of any change in accounting principles and policies
from those used in the preparation of the Historical Financial Statements, the information contained in the consolidated financial
statements of Borrower and its Subsidiaries delivered pursuant to <U>Section 5.1(b)</U> or <U>Section 5.1(c)</U> (to the extent
such information is applicable to the calculation of Product Revenue for purposes of determining the Borrower's compliance with
<U>Section 6.8(b)</U>) will differ in any material respect from the consolidated financial statements that would have been delivered
pursuant to such subdivisions had no such change in accounting principles and policies been made, then, together with the first
delivery of such financial statements after such change, one or more statements of reconciliation for all such prior financial
statements in form and substance satisfactory to Administrative Agent;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
of Default</U>. Promptly (but in any event within five (5) Business Days) upon any Authorized Officer of Borrower obtaining knowledge
(i) of any condition or event that constitutes a Default or an Event of Default or that written notice has been given to Borrower
with respect thereto; (ii) that any Person has given any written notice to Borrower or any of its Subsidiaries or taken any other
action which is reasonably likely to cause an Event of Default to occur pursuant to <U>Section 8.1(b)</U> of this Agreement; or
(iii) of the occurrence of any event or change that has caused or resulted in any case or in the aggregate, a Material Adverse
Effect or Material Regulatory Liabilities, a certificate of its Authorized Officers specifying the nature and period of existence
of such condition, event or change, or specifying the notice given and action taken by any such Person and the nature of such
claimed Event of Default, Default, default, event or condition, and what action Company has taken, is taking and proposes to take
with respect thereto;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
of Litigation</U>. Promptly (but in any event within five (5) Business Days) upon any Authorized Officer of Company obtaining
knowledge of (i) the institution of, or non-frivolous written threat of, any Adverse Proceeding or (ii) any material development
in any Adverse Proceeding that, in the case of either <U>clause (i)</U> or <U>(ii)</U> which relates to the Products, the Collateral
or the Material Contracts or which could reasonably be expected to result in Material Regulatory Liabilities, or which seeks to
enjoin or otherwise prevent the consummation of, or to recover any damages or obtain relief as a result of, the transactions contemplated
hereby, written notice thereof together with such other information as may be reasonably available to Company to enable Lenders
and their counsel to evaluate such matters;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ERISA</U>.
Promptly (but in any event within five (5) Business Days) upon becoming aware of the occurrence of or forthcoming occurrence of
any ERISA Event that would reasonably be expected to result in a material Liability to a Loan Party, a written notice specifying
the nature thereof, what action a Loan Party or any ERISA Affiliate has taken, is taking or proposes to take with respect thereto
and, when known, any action taken or threatened by the Internal Revenue Service, the Department of Labor or the PBGC with respect
thereto;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance
Report</U>. As soon as practicable and in any event within 30 days after the end of each Fiscal Year, a report in form and substance
reasonably satisfactory to Administrative Agent outlining all material changes in insurance coverage maintained as of the date
of such report by Borrower and its Subsidiaries compared to the last day of the prior Fiscal Year, and any material changes to
the insurance coverage planned to be maintained by Borrower and its Subsidiaries in the immediately succeeding Fiscal Year;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory
and Product Notices</U>. Each Loan Party shall promptly (but in any event within five (5) Business Days) after the receipt or
occurrence thereof notify Administrative Agent of:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
written notice received by Borrower or its Subsidiaries alleging potential or actual material violations of any Public Health
Law by Borrower or its Subsidiaries,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
written notice that the FDA (or international equivalent) is limiting, suspending or revoking any Registration,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
written notice that Borrower or its Subsidiaries has become subject to any Regulatory Action (other than any inspection or investigation
in the ordinary course of business),</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
exclusion or debarment from any governmental health care program or debarment or disqualification by FDA of Borrower or its Subsidiaries
or its or their Authorized Officers,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
written notice addressed to Borrower or any Subsidiary that a Borrower or any Subsidiary, or any of their licensees or sublicensees
(including licensees or sublicensees under the Product Agreements), is being investigated or is the subject of any allegation
of potential or actual violations of any Federal Health Care Program Laws, in each case, which could reasonably be expected to
result in a Material Adverse Effect,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
written notice that any Product of Borrower or its Subsidiaries has been seized, withdrawn, recalled, detained, or subject to
a suspension of manufacturing, or the commencement of any proceedings in the United States by a Governmental Authority having
appropriate jurisdiction seeking the withdrawal, recall, suspension, import detention, or seizure of any Product or Products are
pending or threatened in writing against Borrower or its Subsidiaries, or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changing
the market classification or labeling of the Products of Borrower and its Subsidiaries under any such Registration in a manner
materially adverse to Borrower and its Subsidiaries,</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except,
in each case of (i) through (vii) above, where such action would not reasonably be expected to have, either individually or in
the aggregate, Material Regulatory Liabilities;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
Regarding Material Contracts</U>. Promptly (but in any event within five (5) Business Days) (i) after a Loan Party or a Subsidiary
of a Loan Party receives a written notice of default or event of default under any Material Contract giving any party thereto
the right to terminate such Material Contract, (ii) after Loan Party or a Subsidiary of a Loan Party receives or otherwise becomes
aware of any (A) any dispute, purchase price adjustment, indemnity claim, exercise of rights of set-off or deduction (in each
case, not in the ordinary course of business) or (B) litigation (including litigation threatened in writing), in each case for
clauses (A) and (B) under or with respect any Material Contract, and (iii) after a new Material Contract is entered into, in each
case of clauses (i) through (iii), furnish a written statement describing such event, with copies of such notices or new contracts
together with all reasonably pertinent detail and information relating thereto, delivered to Administrative Agent, and an explanation
of any actions being taken with respect thereto;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Information
Regarding Collateral</U>. Company will furnish to Administrative Agent prior written notice of any change (a) in any Loan Party's
legal name or (b)&nbsp;in any Loan Party's corporate identity or corporate structure. Company agrees not to effect or permit any
change referred to in the preceding sentence unless all filings have been made under the UCC that are required in order for Administrative
Agent to continue at all times following such change to have a valid, legal and perfected security interest in all the Collateral
in which a security interest may be perfected by the filing of a UCC-1 in the state of organization or formation of the Company
or such applicable Guarantor and for such Collateral at all times following such change to have a valid, legal and perfected security
interest as contemplated in the Collateral Documents. Company also agrees promptly to notify Administrative Agent if any material
portion of the Collateral is damaged or destroyed;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Annual
Collateral Verification</U>. Each year, at the time of delivery of annual financial statements with respect to the preceding Fiscal
Year pursuant to <U>Section 5.1(c)</U>, Company shall deliver to Administrative Agent an Officer's Certificate either confirming
that there has been no change in such information since the date of the Perfection Certificate delivered on the Closing Date or
the date of the most recent certificate delivered pursuant to this <U>Section 5.1(n)</U> and/or identifying such changes;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Products</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly,
but in any event within five (5) Business Days after the receipt by the Company or any of its Subsidiaries or any Authorized Officer
thereof obtaining knowledge of the occurrence thereof, notice of:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.4in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granting
any sublicenses under any Product Agreement;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.4in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.4in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entering
into any new Product Agreement (to the extent permitted under this Agreement); and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.4in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.4in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
material communications with the FDA that could reasonably be expected to result in a Material Adverse Effect; and</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quarterly,
in connection with the delivery of the Compliance Certificate required by <U>Section 5.1(d)</U>, copies of royalty reports received
for such quarter pursuant to any Product Agreement;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory
Documentation</U>. Company shall be responsible for, and shall maintain, with respect to each Product, all submissions to Governmental
Authorities relating to the Products, including clinical studies, tests and biostudies, including all Product non-disclosure agreements,
and the drug master files, as well as all correspondence with Governmental Authorities with respect thereto (including Registrations
and licenses and regulatory drug lists, and any amendments or supplements thereto). Concurrent with the delivery of a Compliance
Certificate following the end of each Fiscal Quarter in accordance with Section 5.1(d) and promptly following Administrative Agent's
reasonable request from time to time, Company shall promptly provide to Administrative Agent copies of any and all regulatory
filings submitted to any such Governmental Authorities and material correspondence sent to or received from Governmental Authorities,
in each case, with respect to the Products;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Maintenance
of Product Patents</U>. Company shall take all commercially reasonable steps to maintain the Product Patents, including by timely
filing fees and responses with the United States Patent and Trademark Office or any applicable foreign counterpart. Company shall
provide prompt written notice to Administrative Agent of any material occurrences with respect to any Product Patents, and, upon
Administrative Agent's request from time to time, shall promptly provide Administrative Agent with complete and correct copies
of any material correspondence sent by Company to or received from the United States Patent and Trademark Office or any applicable
foreign counterpart with respect to any Product Patent;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Information</U>. (A) Promptly upon their becoming available and in any event within five (5) Business Days of Borrower's receipt
thereof, copies of (i) all reports and all registration statements and prospectuses, if any, filed by Borrower or any of its Subsidiaries
with the Securities and Exchange Commission or any similar governmental or private regulatory authority and which is not otherwise
publicly available, and (ii) all amendments, waivers, consents, notices of default and reservations of rights with respect to
and received by Borrower or its Subsidiaries from any holder of its Indebtedness having a principal amount greater than $5,000,000,
(B) subject to any applicable confidentiality restrictions or restrictions under applicable law, promptly after submission to
any Governmental Authority, all documents and information furnished to such Governmental Authority in connection with any investigation
of any Loan Party (other than a routine inquiry), and (C) such other information and data with respect to Borrower or any of its
Subsidiaries as from time to time may be reasonably requested by Administrative Agent in writing in accordance with <U>Section
10.1</U> of this Agreement.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Existence</U>.
Except as otherwise permitted under <U>Section 6.9</U>, each Loan Party will, and will cause each of Borrower's Subsidiaries to,
at all times preserve and keep in full force and effect its existence and all rights and Governmental Authorizations, qualifications,
franchises, licenses and permits material to its business and to conduct its business in each jurisdiction in which its business
is conducted, except, in each case, which such failure to do so would not, either individually or in the aggregate, be reasonably
expected to result in a Material Adverse Effect; <U>provided</U>, no Loan Party or any of Borrower's Subsidiaries shall be required
to preserve any such existence, right or Governmental Authorizations, qualifications, franchise, licenses and permits if such
Person's Board of Directors (or similar governing body) shall determine that the preservation thereof is no longer desirable in
the conduct of the business of such Person, and that the loss thereof is not disadvantageous in any material respect to such Person
or to Lenders.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment
of Taxes and Claims</U>. Each Loan Party will, and will cause each of Borrower's Subsidiaries to, (a) file all Tax returns required
to be filed by Borrower or any of its Subsidiaries and (b) pay (i) all Taxes exceeding $500,000 imposed upon it or any of its
properties or assets or in respect of any of its income, businesses or franchises before any penalty or fine accrues thereon and
(ii) all claims (including claims for labor, services, materials and supplies) for sums that have become due and payable and that
by law have or may become a Lien upon any of its properties or assets prior to the time when any penalty or fine shall be incurred
with respect thereto; <U>provided</U>, no such Tax or claim need be paid if it is being contested in good faith by appropriate
proceedings promptly instituted and diligently conducted, so long as (a)&nbsp;adequate reserve or other appropriate provision,
as shall be required in conformity with GAAP shall have been made therefor, and (b) in the case of a Tax or claim which has or
may become a Lien against any of the Collateral, such contest proceedings conclusively operate to stay imposition of any penalty,
fine or Lien resulting from the non-payment thereof. No Loan Party will, nor will it permit any of Borrower's Subsidiaries to,
file or consent to the filing of any consolidated income tax return with any Person (other than Borrower or its Subsidiaries).</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Maintenance
of Properties</U>. Each Loan Party will, and will cause each of Borrower's Subsidiaries to (a) maintain or cause to be maintained
in good repair, working order and condition, ordinary wear and tear excepted, all properties used or useful in the business of
Borrower and its Subsidiaries and from time to time will make or cause to be made all appropriate repairs, renewals and replacements
thereof, except, in each case, to the extent any such failure to maintain would not reasonably be expected to have a Material
Adverse Effect, and (b) comply at all times with the provisions of all material leases to which it is a party as lessee or under
which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder, except, in each case, to the extent
any such failure to comply could not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Parties will maintain or cause to be maintained, with financially sound and reputable insurers, (i) business interruption
insurance reasonably satisfactory to Administrative Agent, and (ii) casualty insurance, such commercial general liability insurance,
third party property damage insurance or such other insurance with respect to liabilities, losses or damage in respect of the
assets, properties and businesses of the Loan Parties as may customarily be carried or maintained under similar circumstances
by Persons of established reputation engaged in similar businesses, in each case in such amounts (giving effect to self-insurance),
with such deductibles, covering such risks and otherwise on such terms and conditions as shall be customary for such Persons.
Each such commercial general policy of insurance shall (1) name Administrative Agent, on behalf of Lenders as an additional insured
thereunder as its interests may appear, and (2) in the case of each property insurance policy, contain a loss payable clause or
endorsement, satisfactory in form and substance to Administrative Agent, that names Administrative Agent, on behalf of Secured
Parties as the loss payee thereunder. If any Loan Party or any of its Subsidiaries fails to maintain such insurance, Administrative
Agent may, upon prior written notice to Company, arrange for such insurance, but at Company's expense and without any responsibility
on Administrative Agent's part for obtaining the insurance, the solvency of the insurance companies, the adequacy of the coverage,
or the collection of claims. Upon the occurrence and during the continuance of an Event of Default, Administrative Agent shall
have the sole right, in the name of the Lenders, any Loan Party and its Subsidiaries, to file claims under any insurance policies,
to receive, receipt and give acquittance for any payments that may be payable thereunder, and to execute any and all endorsements,
receipts, releases, assignments, reassignments or other documents that may be necessary to effect the collection, compromise or
settlement of any claims under any such insurance policies.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the insurance policies required to be maintained under this <U>Section 5.5</U> shall provide for at least thirty (30) days'
prior written notice to Administrative Agent of the cancellation or substantial modification thereof. Receipt of such notice shall
entitle Administrative Agent (but Administrative Agent shall not be obligated), upon prior written notice to the Loan Parties,
to renew any such policies, cause the coverages and amounts thereof to be maintained at levels required pursuant to this <U>Section
5.5</U> or otherwise to obtain similar insurance in place of such policies, in each case at the expense of the Loan Parties and
to the extent the Loan Parties have not so renewed such policies or obtained similar insurance in place therefor.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Books
and Records; Inspections</U>. Each Loan Party will, and will cause each of Borrower's Subsidiaries to, (a) maintain at all times
at the chief executive office of Borrower copies of all material books and records of Borrower and its Subsidiaries, (b) keep
adequate books of record and account in which full, true and correct entries in all material respects are made of all dealings
and transactions in relation to its business and activities and (c)&nbsp;permit any representatives designated by Administrative
Agent or any Lender (including employees of Administrative Agent, any Lender or any consultants, auditors, accountants, lawyers
and appraisers retained by Administrative Agent) to visit any of the properties of any Loan Party and any of Borrower's Subsidiaries
to inspect, copy and take extracts from its and their financial and accounting records, all upon reasonable notice and at such
reasonable times during normal business hours (so long as no Default or Event of Default has occurred and is continuing) and as
often as may reasonably be requested; provided that, excluding any such visits and inspections during the occurrence and continuation
of an Event of Default, only the Administrative Agent on behalf of the Lenders may exercise rights of the Administrative Agent
and the Lenders under this <U>Section 5.6</U> and the Administrative Agent shall not, absent the occurrence and continuance of
an Event of Default, exercise such rights more often than one time during any calendar year. The Loan Parties agree to pay the
reasonable and documented out-of-pocket costs and expenses incurred by the examiner in connection therewith. Notwithstanding anything
to the contrary in this <U>Section 5.6</U>, none of the Loan Parties or any of their Subsidiaries will be required to disclose
or permit the inspection or discussion of, any document, information or other matter (i) in respect of which disclosure to the
Agents or any Lender (or their respective representatives) is prohibited by applicable law or Contractual Obligations that (A)
are owed to any Person that is not an Affiliate of Borrower or its Subsidiaries that is controlled by Borrower or its Subsidiaries
pursuant to a binding agreement to which Borrower or its Subsidiaries are a party and (B) that have not been waived by such Person
following the use by Borrower or its Subsidiaries of commercailly reasonable efforts to obtain such waiver or (ii) that is subject
to attorney client or similar privilege or constitutes attorney work product.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lenders
Meetings and Conference Calls</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
will, upon the request of Administrative Agent or Required Lenders, participate in a meeting of Administrative Agent and Lenders
once during each Fiscal Year to be held at Company's corporate offices (or at such other location as may be agreed to by Company
and Administrative Agent) at such time as may be agreed to by Borrower and Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
10 Business Days after delivery of financial statements and other information required to be delivered pursuant to <U>Section
5.1(b)</U>, Borrower shall, upon request by the Administrative Agent, cause its chief financial officer or other Authorized Officers
to participate in a conference call with Administrative Agent and all Lenders who choose to participate in such conference call,
during which conference call the chief financial officer or such Authorized Officer shall review the financial condition of Borrower
and its Subsidiaries and such other matters as Administrative Agent or any Lender may reasonably request in a reasonable time
period in advance of such conference call.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
with Laws</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Loan Party will comply, and shall cause each of Borrower's Subsidiaries, to comply, with the requirements of all applicable laws,
rules, regulations and orders of any Governmental Authority (including all Environmental Laws), in each case, non-compliance with
which could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
limiting the generality of the foregoing, each Loan Party shall, and shall cause each of Borrower's Subsidiaries to, comply with
all FDA Laws and Public Health Laws, and with all applicable Federal Health Care Program Laws, in each case, except where the
failure to comply would not reasonably be expected to result, either individually or in the aggregate, in Material Regulatory
Liabilities. All Products developed, manufactured, tested, investigated, distributed or marketed by or on behalf of the Loan Parties
and Borrower's Subsidiaries that are subject to the jurisdiction of the FDA or any comparable Governmental Authority have been
and shall be developed, tested, manufactured, investigated, distributed and marketed in compliance with the FDA Laws and any other
Requirement of Law, including, without limitation, pre-market notification, good manufacturing practices, labeling, advertising,
record-keeping, and adverse event reporting, in each case, except where the failure to comply would not reasonably be expected
to result, either individually or in the aggregate, in Material Regulatory Liabilities.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Environmental</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Loan Party shall (i) keep its owned real property free of any Environmental Liens; (ii) maintain and comply in all material respects
with all Governmental Authorizations required under applicable Environmental Laws, except as any such failure which could not
reasonably be expected to result in a Material Adverse Effect; and (iii) take all steps to prevent any Release of Hazardous Materials
from any property owned or operated by any Loan Party, except as any such failure would not reasonably be expected to result in
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Parties shall promptly (but in any event within ten (10) Business Days) (i) notify Administrative Agent in writing (A) of
any material Environmental Claims asserted against or material Environmental Liabilities and Costs of any Loan Party, and (B)
any notice of Environmental Lien filed against any owned real property, and (ii) provide such other documents and information
as reasonably requested by Administrative Agent in relation to any matter pursuant to this <U>Section 5.9(b)</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiaries</U>.
In the event that any Person becomes a Subsidiary of Company, Company (including pursuant to a Permitted Acquisition) shall (a)
within 10 Business Days of such Person becoming a Subsidiary (or such later time as is consented to by Administrative Agent) cause
such Subsidiary to become a Guarantor hereunder and a Grantor under the Pledge and Security Agreement by executing and delivering
to Administrative Agent a Counterpart Agreement, and (b) take all such actions and execute and deliver, or cause to be executed
and delivered, all such documents, instruments, agreements, and certificates as are similar to those described in <U>Sections
3.1(b)</U>, <U>3.1(f)</U> and <U>3.1(i)</U>. With respect to each such Subsidiary, Company shall send to Administrative Agent
written notice within 10 Business Days of such Person becoming a Subsidiary (or such later time as is consented to by Administrative
Agent) setting forth with respect to such Person (i) the date on which such Person became a Subsidiary of Company, and (ii) all
of the data required to be set forth in <U>Schedules 4.1</U> and <U>4.2</U> with respect to all Subsidiaries of Company; <U>provided</U>,
such written notice shall be deemed to supplement <U>Schedules 4.1</U> and <U>4.2</U> for all purposes hereof.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further
Assurances</U>. At any time or from time to time upon the written request of Administrative Agent, each Loan Party will, at its
expense, promptly execute, acknowledge and deliver such further documents and do such other acts and things within its control
as Administrative Agent may reasonably request in order to effect fully the purposes of the Loan Documents, including providing
Lenders with any information reasonably requested pursuant to <U>Section 10.21</U>. In furtherance and not in limitation of the
foregoing, each Loan Party shall take such actions as Administrative Agent may reasonably request from time to time to ensure
that the Obligations are guaranteed by the Guarantors and are secured by substantially all of the assets of Borrower's Subsidiaries
and all of the outstanding Capital Stock of Borrower's Subsidiaries, to the extent permitted under any Loan Document. Notwithstanding
anything to the contrary in the foregoing or anywhere else in this Agreement or in any other Loan Document, unless requested by
the Administrative Agent in its reasonable discretion, none of the Loan Parties or any of their Subsidiaries shall be required,
nor shall the Administrative Agent or any Lender be authorized, to take any action with respect to any assets or property of any
Loan Party located outside of the United States.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Control
Agreements</U>. Each of Borrower and each Guarantor Subsidiary shall hold all of its cash and Cash Equivalents in a Deposit Account
or Securities Account (other than any Excluded Accounts) subject to a Control Agreement. All such Control Agreements shall provide
for &ldquo;springing&rdquo; cash dominion with respect to each such account that is not an Excluded Account, including each disbursement
account. With respect to each Control Agreement providing for &ldquo;springing&rdquo; cash dominion, Administrative Agent will
not deliver to the relevant depository institution a notice or other instruction which provides for exclusive control over such
account by Administrative Agent until an Event of Default has occurred and is continuing.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Closing
Matters</U>. Company shall, and shall cause each of the Loan Parties to, satisfy the requirements set forth on <U>Schedule 5.13
</U>on or before the date specified for such requirement or such later date as is consented to by Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
VI</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
NEGATIVE COVENANTS</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Loan Party covenants and agrees that, so long as any Commitment is in effect and until payment in full of all Obligations (other
than any such contingent obligations or liabilities hereunder that by the express terms thereof survive such payment in full of
all Obligations), such Loan Party shall perform, and shall cause each of its Subsidiaries to perform, all covenants in this <U>Article
VI</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indebtedness</U>.
No Loan Party shall, nor shall it permit any of Borrower's Subsidiaries to, directly or indirectly, create, incur, assume or guaranty,
or otherwise become or remain directly or indirectly liable with respect to any Indebtedness, in each case, except Permitted Indebtedness.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liens</U>.
No Loan Party shall, nor shall it permit any of its Subsidiaries to, directly or indirectly, create, incur, assume or permit to
exist any Lien on or with respect to any property or asset of any kind (including any document or instrument in respect of goods
or accounts receivable) of Borrower or any of its Subsidiaries, whether now owned or hereafter acquired, or any income or profits
therefrom, or file or permit the filing of, or permit to remain in effect, any financing statement or other similar notice of
any Lien with respect to any such property, asset, income or profits under the UCC of any State or under any similar recording
or notice statute, in each case, except Permitted Liens.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
Contracts</U>. None of Borrower or any of its Subsidiaries shall agree to any set-off, counterclaim or other deduction under or
with respect to any Material Contract, other than any such set-off, counterclaim or other deduction that is in the ordinary course
of business and is explicitly required or permitted by the terms of such Material Contract as in effect on the date hereof or
as amended from time to time in accordance with the terms hereof. Borrower and its Subsidiaries shall not materially breach any
Material Contract or otherwise default under any Material Contract in such a manner as could reasonably be expected to give rise
to a termination right of any other party to such Material Contract.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Further Negative Pledges</U>. Except with respect to (a) specific property encumbered to secure payment of particular Indebtedness
or to be sold pursuant to an executed agreement with respect to an Asset Sale permitted under <U>Section 6.9</U> and (b) restrictions
by reason of customary provisions restricting assignments, subletting or other transfers contained in leases, licenses and similar
agreements entered into in the ordinary course of business (provided that such restrictions are limited to the property or assets
secured by such Liens or the property or assets subject to such leases, licenses or similar agreements, as the case may be) no
Loan Party nor any of Borrower's Subsidiaries shall enter into any agreement prohibiting the creation or assumption of any Lien
upon any of its properties or assets, whether now owned or hereafter acquired, in each case, except Permitted Liens.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restricted
Junior Payments</U>. No Loan Party shall, nor shall it permit any of its Subsidiaries through any manner or means or through any
other Person to, directly or indirectly, declare, order, pay, make or set apart, or agree to declare, order, pay, make or set
apart, any sum for any Restricted Junior Payment, in each case, except for:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cashless
repurchases of Capital Stock in the ordinary course of business in Borrower or any Subsidiary thereof deemed to occur upon exercise
of stock options or warrants if such Capital Stock represents a portion of the exercise price of such options or warrants;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
Loan Party may make Restricted Junior Payments in the form of its payment in cash to the relevant Governmental Authority of any
Taxes payable as a result of the vesting of Capital Stock in connection with equity-based compensation plans; <U>provided</U>,
the aggregate amount of all such Restricted Junior Payments shall not exceed $10,000,000 during the term of this Agreement; or</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
may make payments of cash in lieu of fractional shares in connection with stock dividends, splits or combinations or conversions
or exercises of convertible securities.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restrictions
on Subsidiary Distributions</U>. Except as provided herein, no Loan Party shall, nor shall it permit any of Borrower's Subsidiaries
to, create or otherwise cause or suffer to exist or become effective any consensual encumbrance or restriction of any kind, in
each case, except for Permitted Liens, on the ability of any Subsidiary of Company to (a) pay dividends or make any other distributions
on any of such Subsidiary's Capital Stock owned by Company or any other Subsidiary of Company, (b) repay or prepay any Indebtedness
owed by such Subsidiary to Company or any other Subsidiary of Company, (c) make loans or advances to Company or any other Subsidiary
of Company, or (d) transfer any of its property or assets to Company or any other Subsidiary of Company other than restrictions
(i) in agreements evidencing purchase money Indebtedness permitted by <U>clause (g)</U> of the definition of Permitted Indebtedness
that impose restrictions on the property so acquired, (ii) by reason of customary provisions restricting assignments, subletting
or other transfers contained in leases, licenses, joint venture agreements and similar agreements entered into in the ordinary
course of business, and (iii)&nbsp;that are or were created by virtue of any transfer of, agreement to transfer or option or right
with respect to any property, assets or Capital Stock not otherwise prohibited under this Agreement. No Loan Party shall, nor
shall it permit its Subsidiaries to, enter into any Contractual Obligations which would prohibit a Subsidiary of Borrower from
being a Loan Party.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investments</U>.
Borrower shall not, nor shall it permit any of its Subsidiaries to, directly or indirectly, make or own any Investment in any
Person, including without limitation any Joint Venture, except Permitted Investments. Notwithstanding the foregoing, in no event
shall any Loan Party make any Investment which results in or facilitates in any manner any Restricted Junior Payment not otherwise
permitted under the terms of <U>Section 6.5</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial
Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Minimum
Qualified Cash</U>. At all times, Borrower shall not permit Qualified Cash to be less than (a) $50,000,000 during the period commencing
on the Closing Date to (but not including) the Credit Date in respect of the first Delayed Draw Term Loan made hereunder and (b)&nbsp;$60,000,000
thereafter.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Minimum
Revenue</U>. Borrower shall not permit Product Revenue for any Fiscal Quarter set forth below to be less than the amount set forth
opposite such Fiscal Quarter:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 40%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; border-bottom: Black 2pt double; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
    Quarter <BR>
Ending</B></FONT></TD>
    <TD STYLE="width: 57%; border-bottom: Black 2pt double; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    Revenue</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2020</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 40%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; border-bottom: Black 2pt double; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fiscal
    Quarter <BR>
Ending</B></FONT></TD>
    <TD STYLE="width: 57%; border-bottom: Black 2pt double; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product
    Revenue</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</FONT></TD>
    <TD STYLE="text-align: justify; width: 57%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2022 and
    each Fiscal Quarter thereafter</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fundamental
Changes; Disposition of Assets; Acquisitions</U>. No Loan Party shall, nor shall it permit any of Borrower's Subsidiaries to,
enter into any transaction of merger or consolidation, or liquidate, wind up or dissolve itself (or suffer any liquidation or
dissolution), including by means of a &ldquo;plan of division&rdquo; under the Delaware Limited Liability Company Act or any comparable
transaction under any similar law, or convey, sell, lease or sub lease (as lessor or sublessor), exchange, transfer or otherwise
dispose of, or otherwise enter into or consummate any Asset Sale, in one transaction or a series of transactions, all or any part
of its business, assets or property of any kind whatsoever (including, without limitation, any Product (including, without limitation,
any intellectual property rights related thereto) and any Product Agreement (including, without limitation, any of Company's rights
thereunder)), whether real, personal or mixed and whether tangible or intangible, whether now owned or hereafter acquired, or
acquire by purchase or otherwise (other than purchases or other acquisitions of inventory, materials and equipment and Capital
Expenditures in the ordinary course of business) the business, property or fixed assets of, or stock or other evidence of beneficial
ownership of, any Person or any division or line of business or other business unit of any Person, except:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
Subsidiary of Borrower may be merged with or into Company or any Guarantor Subsidiary, or be liquidated, wound up or dissolved,
or all or any part of its business, property or assets may be conveyed, sold, leased, transferred or otherwise disposed of, in
one transaction or a series of transactions, to Company or any Guarantor Subsidiary; <U>provided</U>, in the case of such a merger,
Company or such Guarantor Subsidiary, as applicable shall be the continuing or surviving Person. Notwithstanding anything herein
to the contrary, neither Borrower nor any of its Subsidiaries shall divide or enter into any plan of division pursuant to Section
18-217 of the Delaware Limited Liability Company Act (or any similar statute or provision under applicable law);</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset
Sales (other than (i) subject to <U>Section 6.9(d)</U>, those constituting Permitted Product Transactions and (ii) any other Asset
Sale in respect of the Products or the Product Patents) in any Fiscal Year, the proceeds of which are less than $10,000,000 with
respect to any single Asset Sale or series of related Asset Sales made within the same Fiscal Year; <U>provided</U> (A) the consideration
received for such assets shall be in an amount at least equal to the fair market value thereof (determined in good faith by officers
of Company or the Board of Directors of Company (or similar governing body)), (B) no less than 85% thereof shall be paid in Cash,
and (C) if and to the extent required by <U>Section 2.10(a)(ii)</U>, the Net Proceeds thereof shall be applied as required by
<U>Section 2.10(a)(ii)</U>;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted
Acquisitions and other Permitted Investments;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset
Sales constituting Permitted Product Transactions; <U>provided</U> that (i) no Event of Default shall have occurred and be continuing
or would result therefrom (it being understood that this clause (i) shall not prohibit the continued performance by any Loan Party
in the ordinary course of business under contracts entered into prior to the occurrence of any such Event of Default) and (ii)
the Net Proceeds thereof shall be applied as and to the extent required by <U>Section 2.10(a)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
or any Subsidiary thereof may sell inventory and immaterial assets in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispositions
of obsolete or worn out, retired or surplus property, whether now owned or hereafter acquired, in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
or any Subsidiary thereof may surrender or waive contractual rights and settle or waive contractual or litigation claims in the
ordinary course of business; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
sale or discount with recourse of accounts receivable arising in the ordinary course of business in connection with the compromise
or collection thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.10 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disposal
of Subsidiary Interests</U>. Except for any sale of all of its interests in the Capital Stock of any of its Subsidiaries in compliance
with the provisions of <U>Section 6.9</U>, no Loan Party shall, nor shall it permit any of Borrower&rsquo;s Subsidiaries to, (a)
directly or indirectly sell, assign, pledge or otherwise encumber or dispose of any Capital Stock of any of its Subsidiaries,
except to qualify directors if required by applicable law; or (b) permit any of its Subsidiaries directly or indirectly to sell,
assign, pledge or otherwise encumber or dispose of any Capital Stock of any of its Subsidiaries, except to another Loan Party
(subject to the restrictions on such disposition otherwise imposed hereunder), or to qualify directors if required by applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.11 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sales and
Lease Backs</U>. No Loan Party shall, nor shall it permit any of Borrower&rsquo;s Subsidiaries to, directly or indirectly, become
or remain liable as lessee or as a guarantor or other surety with respect to any lease of any property (whether real, personal
or mixed), whether now owned or hereafter acquired, which such Loan Party (a) has sold or transferred or is to sell or to transfer
to any other Person (other than Borrower or any of its Subsidiaries) or (b) intends to use for substantially the same purpose
as any other property which has been or is to be sold or transferred by such Loan Party to any Person (other than Borrower or
any of its Subsidiaries) in connection with such lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.12 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
with Shareholders and Affiliates</U>. No Loan Party shall, nor shall it permit any of Borrower&rsquo;s Subsidiaries to, directly
or indirectly, enter into or permit to exist any transaction (including the purchase, sale, lease or exchange of any property
or the rendering of any service) with any Affiliate of Borrower or of any such holder; <U>provided</U>, that the Loan Parties
and Borrower&rsquo;s Subsidiaries may enter into or permit to exist any such transaction if both Administrative Agent has consented
thereto in writing prior to the consummation thereof and the terms of such transaction are not less favorable to Borrower or that
Subsidiary, as the case may be, than those that might be obtained at the time from a Person who is not such a holder or Affiliate;
further, <U>provided</U>, <U>further</U>, that the foregoing restrictions shall not apply to any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
transaction among the Loan Parties expressly permitted hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
and customary fees paid to members of the Board of Directors (or similar governing body) of Borrower and its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
arrangements for officers and other employees of Borrower and its Subsidiaries entered into in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
transaction between a Loan Party and any direct or indirect holder of not more than 20% of any class of Capital Stock of Borrower
so long as (i) such transaction is between a Loan Party and a federally regulated financial institution which occurs on an arm&rsquo;s
length basis in the ordinary course such Loan Party&rsquo;s business consistent with past practice, (ii) such transaction involves
the ordinary course financial services provided by such financial institution to such Loan Party, excluding any loan or other
form of Indebtedness which is not Permitted Indebtedness, and (iii) such transaction is not otherwise prohibited under the terms
of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
described in <U>Schedule 6.12</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conduct
of Business</U>. From and after the Closing Date, no Loan Party shall, nor shall it permit any of its Subsidiaries to, engage
in any business other than the businesses engaged in by such Loan Party on the Closing Date (or any other business reasonably
related thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.14 &nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Changes to Certain
Agreements and Organizational Documents</U>. No Loan Party shall (i) amend or permit any amendments to any Loan Party&rsquo;s
Organizational Documents, including, without limitation, any amendment, modification or change to any of Loan Party&rsquo;s Organizational
Documents to effect a division or plan of division pursuant to Section 18-217 of the Delaware Limited Liability Company Act (or
any similar statute or provision under applicable law); or (ii) amend or permit any amendments by any Loan Parties to, or terminate
or waive any provision of, any Material Contract if such amendment, termination, or waiver would be materially adverse to Administrative
Agent or the Lenders (it being understood that any amendment to a Material Contract to permit set-off or other deduction of amounts
payable thereunder (other than any set-off or other deduction in the ordinary course of business that does not increase the obligations
of a Loan Party) shall be deemed to be materially adverse to the Administrative Agent and the Lenders).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.15 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accounting
Methods</U>. The Loan Parties will not and will not permit any of their Subsidiaries to modify or change its fiscal year or its
method of accounting (other than as may be required to conform to GAAP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.16 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deposit
Accounts</U>. No Loan Party shall establish or maintain a Deposit Account (other than an Excluded Account) or a Securities Account
that is not subject to a Control Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.17 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prepayments
of Certain Indebtedness</U>. No Loan Party shall, directly or indirectly, voluntarily purchase, redeem, defease or prepay any
principal of, premium, if any, interest or other amount payable in respect of any Indebtedness prior to its scheduled maturity,
other than (a) the Obligations and (b) Indebtedness secured by a Permitted Lien if the asset securing such Indebtedness has been
sold or otherwise disposed of in accordance with <U>Section 6.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.18 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Anti-Terrorism
Laws</U>. None of the Loan Parties (nor any of their Affiliates that are controlled by the Loan Parties) or agents shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
any business or engage in any transaction or dealing with any Blocked Person, including the making or receiving any contribution
of funds, goods or services to or for the benefit of any Blocked Person,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deal
in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to the OFAC Sanctions
Programs or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate,
any of the prohibitions set forth in the OFAC Sanctions Programs, the USA PATRIOT Act or any other Anti-Terrorism Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall deliver to the Lenders any certification or other evidence requested from time to time by any Lender in its sole
discretion, confirming the Company&rsquo;s compliance with this <U>Section 6.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.19 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Anti-Corruption
Laws</U>. No Loan Party shall use, or permit any of its Subsidiaries to use, directly or indirectly, any of the proceeds of any
Loan for the purpose of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else
of value, to any Person in violation of any Anti-Corruption Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.20 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Real
Property</U>. None of the Borrower or any of its Subsidiaries shall own any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
VII</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
GUARANTY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.1 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Guaranty
of the Obligations</U>. Subject to the provisions of <U>Section 7.2</U>, Guarantors jointly and severally hereby irrevocably and
unconditionally guaranty for the ratable benefit of the Beneficiaries the due and punctual payment in full of all Obligations
when the same shall become due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise
(including amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code,
11 U.S.C. &sect; 362(a)) (collectively, the &ldquo;<FONT STYLE="font-weight: normal"><U>Guaranteed Obligations</U></FONT>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.2 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution
by Guarantors</U>. All Guarantors desire to allocate among themselves, in a fair and equitable manner, their obligations arising
under this Guaranty. Accordingly, in the event any payment or distribution is made on any date by a Guarantor under this Guaranty
such that its Aggregate Payments exceeds its Fair Share as of such date, such Guarantor shall be entitled to a contribution from
each of the other Guarantors in an amount sufficient to cause each Guarantor&rsquo;s Aggregate Payments to equal its Fair Share
as of such date. &ldquo;<FONT STYLE="font-weight: normal"><U>Fair Share</U></FONT>&rdquo; means, with respect to any Guarantor
as of any date of determination, an amount equal to (a) the ratio of (i) the Fair Share Contribution Amount with respect to such
Guarantor, to (ii) the aggregate of the Fair Share Contribution Amounts with respect to all Guarantors multiplied by, (b) the
aggregate amount paid or distributed on or before such date by all Guarantors under this Guaranty in respect of the obligations
Guaranteed. &ldquo;<FONT STYLE="font-weight: normal"><U>Fair Share Contribution Amount</U></FONT>&rdquo; means, with respect to
any Guarantor as of any date of determination, the maximum aggregate amount of the obligations of such Guarantor under this Guaranty
that would not render its obligations hereunder subject to avoidance as a fraudulent transfer or conveyance under Section 548
of Title 11 of the United States Code or any comparable applicable provisions of state law; <U>provided</U>, solely for purposes
of calculating the &ldquo;<FONT STYLE="font-weight: normal"><U>Fair Share Contribution Amount</U></FONT>&rdquo; with respect to
any Guarantor for purposes of this <U>Section 7.2</U>, any assets or liabilities of such Guarantor arising by virtue of any rights
to subrogation, reimbursement or indemnification or any rights to or obligations of contribution hereunder shall not be considered
as assets or liabilities of such Guarantor. &ldquo;<FONT STYLE="font-weight: normal"><U>Aggregate Payments</U></FONT>&rdquo; means,
with respect to any Guarantor as of any date of determination, an amount equal to (A) the aggregate amount of all payments and
distributions made on or before such date by such Guarantor in respect of this Guaranty (including, without limitation, in respect
of this <U>Section 7.2</U>), <U>minus</U> (B) the aggregate amount of all payments received on or before such date by such Guarantor
from the other Guarantors as contributions under this <U>Section 7.2</U>. The amounts payable as contributions hereunder shall
be determined as of the date on which the related payment or distribution is made by the applicable Guarantor. The allocation
among Guarantors of their obligations as set forth in this <U>Section 7.2</U> shall not be construed in any way to limit the liability
of any Guarantor hereunder. Each Guarantor is a third party beneficiary to the contribution agreement set forth in this <U>Section
7.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.3 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
by Guarantors</U>. Subject to <U>Section 7.2</U>, Guarantors hereby jointly and severally agree, in furtherance of the foregoing
and not in limitation of any other right which any Beneficiary may have at law or in equity against any Guarantor by virtue hereof,
that upon the failure of Company to pay any of the Guaranteed Obligations when and as the same shall become due, whether at stated
maturity, by required prepayment, declaration, acceleration, demand or otherwise (including amounts that would become due but
for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C. &sect; 362(a)), Guarantors will
upon demand pay, or cause to be paid, in Cash, to Administrative Agent for the ratable benefit of Beneficiaries, an amount equal
to the sum of the unpaid principal amount of all Guaranteed Obligations then due as aforesaid, accrued and unpaid interest on
such Guaranteed Obligations (including interest which, but for Company&rsquo;s becoming the subject of a case under the Bankruptcy
Code, would have accrued on such Guaranteed Obligations, whether or not a claim is allowed against Company for such interest in
the related bankruptcy case) and all other Guaranteed Obligations then owed to Beneficiaries as aforesaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.4 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liability
of Guarantors Absolute</U>. Each Guarantor agrees that its obligations hereunder are irrevocable, absolute, independent and unconditional
and shall not be affected by any circumstance which constitutes a legal or equitable discharge of a guarantor or surety other
than payment in full of the Guaranteed Obligations. In furtherance of the foregoing and without limiting the generality thereof,
each Guarantor agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
Guaranty is a guaranty of payment when due and not of collectability. This Guaranty is a primary obligation of each Guarantor
and not merely a contract of surety;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent may enforce this Guaranty upon the occurrence of an Event of Default notwithstanding the existence of any dispute between
Company and any Beneficiary with respect to the existence of such Event of Default;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
obligations of each Guarantor hereunder are independent of the obligations of Company and the obligations of any other guarantor
(including any other Guarantor) of the obligations of Company, and a separate action or actions may be brought and prosecuted
against such Guarantor whether or not any action is brought against Company or any of such other guarantors and whether or not
Company is joined in any such action or actions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
by any Guarantor of a portion, but not all, of the Guaranteed Obligations shall in no way limit, affect, modify or abridge any
Guarantor&rsquo;s liability for any portion of the Guaranteed Obligations which has not been paid. Without limiting the generality
of the foregoing, if Administrative Agent is awarded a judgment in any suit brought to enforce any Guarantor&rsquo;s covenant
to pay a portion of the Guaranteed Obligations, such judgment shall not be deemed to release such Guarantor from its covenant
to pay the portion of the Guaranteed Obligations that is not the subject of such suit, and such judgment shall not, except to
the extent satisfied by such Guarantor, limit, affect, modify or abridge any other Guarantor&rsquo;s liability hereunder in respect
of the Guaranteed Obligations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
Beneficiary, upon such terms as it deems appropriate, without notice or demand and without affecting the validity or enforceability
hereof or giving rise to any reduction, limitation, impairment, discharge or termination of any Guarantor&rsquo;s liability hereunder,
from time to time may (i) renew, extend, accelerate, increase the rate of interest on, or otherwise change the time, place, manner
or terms of payment of the Guaranteed Obligations; (ii) settle, compromise, release or discharge, or accept or refuse any offer
of performance with respect to, or substitutions for, the Guaranteed Obligations or any agreement relating thereto and/or subordinate
the payment of the same to the payment of any other obligations; (iii) request and accept other guaranties of the Guaranteed Obligations
and take and hold security for the payment hereof or the Guaranteed Obligations; (iv) release, surrender, exchange, substitute,
compromise, settle, rescind, waive, alter, subordinate or modify, with or without consideration, any security for payment of the
Guaranteed Obligations, any other guaranties of the Guaranteed Obligations, or any other obligation of any Person (including any
other Guarantor) with respect to the Guaranteed Obligations; (v) enforce and apply any security now or hereafter held by or for
the benefit of such Beneficiary in respect hereof or the Guaranteed Obligations and direct the order or manner of sale thereof,
or exercise any other right or remedy that such Beneficiary may have against any such security, in each case as such Beneficiary
in its discretion may determine consistent herewith and any applicable security agreement, including foreclosure on any such security
pursuant to one or more judicial or non-judicial sales, whether or not every aspect of any such sale is commercially reasonable,
and even though such action operates to impair or extinguish any right of reimbursement or subrogation or other right or remedy
of any Guarantor against Company or any security for the Guaranteed Obligations; and (vi) exercise any other rights available
to it under the Loan Documents; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
Guaranty and the obligations of Guarantors hereunder shall be valid and enforceable and shall not be subject to any reduction,
limitation, impairment, discharge or termination for any reason (other than payment in full of the Guaranteed Obligations), including
the occurrence of any of the following, whether or not any Guarantor shall have had notice or knowledge of any of them: (i) any
failure or omission to assert or enforce or agreement or election not to assert or enforce, or the stay or enjoining, by order
of court, by operation of law or otherwise, of the exercise or enforcement of, any claim or demand or any right, power or remedy
(whether arising under the Loan Documents, at law, in equity or otherwise) with respect to the Guaranteed Obligations or any agreement
relating thereto, or with respect to any other guaranty of or security for the payment of the Guaranteed Obligations; (ii) any
rescission, waiver, amendment or modification of, or any consent to departure from, any of the terms or provisions (including
provisions relating to events of default) hereof, any of the other Loan Documents or any agreement or instrument executed pursuant
thereto, or of any other guaranty or security for the Guaranteed Obligations, in each case whether or not in accordance with the
terms hereof or such Loan Document or any agreement relating to such other guaranty or security; (iii) the Guaranteed Obligations,
or any agreement relating thereto, at any time being found to be illegal, invalid or unenforceable in any respect; (iv) the application
of payments received from any source (other than payments received pursuant to the other Loan Documents or from the proceeds of
any security for the Guaranteed Obligations, except to the extent such security also serves as collateral for indebtedness other
than the Guaranteed Obligations) to the payment of indebtedness other than the Guaranteed Obligations, even though any Beneficiary
might have elected to apply such payment to any part or all of the Guaranteed Obligations; (v) any Beneficiary&rsquo;s consent
to the change, reorganization or termination of the corporate structure or existence of Borrower or any of its Subsidiaries and
to any corresponding restructuring of the Guaranteed Obligations; (vi) any failure to perfect or continue perfection of a security
interest in any collateral which secures any of the Guaranteed Obligations; (vii) any defenses, set offs or counterclaims which
Company may allege or assert against any Beneficiary in respect of the Guaranteed Obligations, including failure of consideration,
breach of warranty, payment, statute of frauds, statute of limitations, accord and satisfaction and usury; and (viii) any other
act or thing or omission, or delay to do any other act or thing, which may or might in any manner or to any extent vary the risk
of any Guarantor as an obligor in respect of the Guaranteed Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.5 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers
by Guarantors</U>. Each Guarantor hereby waives, for the benefit of Beneficiaries: (a) any right to require any Beneficiary, as
a condition of payment or performance by such Guarantor, to (i) proceed against Company, any other guarantor (including any other
Guarantor) of the Guaranteed Obligations or any other Person, (ii) proceed against or exhaust any security held from Company,
any such other guarantor or any other Person, (iii) proceed against or have resort to any balance of any Deposit Account or credit
on the books of any Beneficiary in favor of Company or any other Person, or (iv) pursue any other remedy in the power of any Beneficiary
whatsoever; (b) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of Company
or any other Guarantor including any defense based on or arising out of the lack of validity or the unenforceability of the Guaranteed
Obligations or any agreement or instrument relating thereto or by reason of the cessation of the liability of Company or any other
Guarantor from any cause other than payment in full of the Guaranteed Obligations; (c) any defense based upon any statute or rule
of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than
that of the principal; (d) any defense based upon any Beneficiary&rsquo;s errors or omissions in the administration of the Guaranteed
Obligations, except behavior which amounts to bad faith; (e) (i) any principles or provisions of law, statutory or otherwise,
which are or might be in conflict with the terms hereof and any legal or equitable discharge of such Guarantor&rsquo;s obligations
hereunder, (ii) the benefit of any statute of limitations affecting such Guarantor&rsquo;s liability hereunder or the enforcement
hereof, (iii) any rights to set offs, recoupments and counterclaims, and (iv) promptness, diligence and any requirement that any
Beneficiary protect, secure, perfect or insure any security interest or lien or any property subject thereto; (f) notices, demands,
presentments, protests, notices of protest, notices of dishonor and notices of any action or inaction, including acceptance hereof,
notices of default hereunder or any agreement or instrument related thereto, notices of any renewal, extension or modification
of the Guaranteed Obligations or any agreement related thereto, notices of any extension of credit to Company and notices of any
of the matters referred to in <U>Section 7.4</U> and any right to consent to any thereof; and (g) any defenses or benefits that
may be derived from or afforded by law which limit the liability of or exonerate guarantors or sureties, or which may conflict
with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.6 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Guarantors&rsquo;
Rights of Subrogation, Contribution, etc.</U> Until the Guaranteed Obligations shall have been indefeasibly paid in full and the
Delayed Draw Term Loan Commitments have been terminated, each Guarantor hereby waives any claim, right or remedy, direct or indirect,
that such Guarantor now has or may hereafter have against Company or any other Guarantor or any of its assets in connection with
this Guaranty or the performance by such Guarantor of its obligations hereunder, in each case whether such claim, right or remedy
arises in equity, under contract, by statute, under common law or otherwise and including without limitation (a) any right of
subrogation, reimbursement or indemnification that such Guarantor now has or may hereafter have against Company with respect to
the Guaranteed Obligations, (b) any right to enforce, or to participate in, any claim, right or remedy that any Beneficiary now
has or may hereafter have against Company, and (c) any benefit of, and any right to participate in, any collateral or security
now or hereafter held by any Beneficiary. In addition, until the Guaranteed Obligations shall have been indefeasibly paid in full
and the Delayed Draw Term Loan Commitments have been terminated, each Guarantor shall withhold exercise of any right of contribution
such Guarantor may have against any other guarantor (including any other Guarantor) of the Guaranteed Obligations, including,
without limitation, any such right of contribution as contemplated by <U>Section 7.2</U>. Each Guarantor further agrees that,
to the extent the waiver or agreement to withhold the exercise of its rights of subrogation, reimbursement, indemnification and
contribution as set forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, any rights
of subrogation, reimbursement or indemnification such Guarantor may have against Company or against any collateral or security,
and any rights of contribution such Guarantor may have against any such other guarantor, shall be junior and subordinate to any
rights any Beneficiary may have against Company, to all right, title and interest any Beneficiary may have in any such collateral
or security, and to any right any Beneficiary may have against such other guarantor. If any amount shall be paid to any Guarantor
on account of any such subrogation, reimbursement, indemnification or contribution rights at any time when all Guaranteed Obligations
shall not have been finally and indefeasibly paid in full, such amount shall be held in trust for Administrative Agent on behalf
of Beneficiaries and shall forthwith be paid over to Administrative Agent for the benefit of Beneficiaries to be credited and
applied against the Guaranteed Obligations, whether matured or unmatured, in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.7 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subordination
of Other Obligations</U>. Any Indebtedness of Company or any Guarantor now or hereafter held by any Guarantor is hereby subordinated
in right of payment to the Guaranteed Obligations, and any such indebtedness collected or received by such Guarantor after an
Event of Default has occurred and is continuing shall be held in trust for Administrative Agent on behalf of Beneficiaries and
shall forthwith be paid over to Administrative Agent for the benefit of Beneficiaries to be credited and applied against the Guaranteed
Obligations but without affecting, impairing or limiting in any manner the liability of such Guarantor under any other provision
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.8 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuing
Guaranty</U>. This Guaranty is a continuing guaranty and shall remain in effect until all of the Guaranteed Obligations shall
have been indefeasibly paid in full and the Delayed Draw Term Loan Commitments have been terminated. Each Guarantor hereby irrevocably
waives any right to revoke this Guaranty as to future transactions giving rise to any Guaranteed Obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.9 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority
of Guarantors or Company</U>. It is not necessary for any Beneficiary to inquire into the capacity or powers of any Guarantor
or Company or the officers, directors or agents acting or purporting to act on behalf of any of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.10 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Condition of Company</U>. Any Credit Extension may be made to Company or continued from time to time without notice to or authorization
from any Guarantor regardless of the financial or other condition of Company at the time of any such grant or continuation is
entered into, as the case may be. No Beneficiary shall have any obligation to disclose or discuss with any Guarantor its assessment,
or any Guarantor&rsquo;s assessment, of the financial condition of Company. Each Guarantor has adequate means to obtain information
from Company on a continuing basis concerning the financial condition of Company and its ability to perform its obligations under
the Loan Documents, and each Guarantor assumes the responsibility for being and keeping informed of the financial condition of
Company and of all circumstances bearing upon the risk of non-payment of the Guaranteed Obligations. Each Guarantor hereby waives
and relinquishes any duty on the part of any Beneficiary to disclose any matter, fact or thing relating to the business, operations
or conditions of Company now known or hereafter known by any Beneficiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.11 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bankruptcy,
etc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as any Guaranteed Obligations remain outstanding, no Guarantor shall, without the prior written consent of Administrative
Agent acting pursuant to the instructions of Required Lenders, commence or join with any other Person in commencing any bankruptcy,
reorganization or insolvency case or proceeding of or against Company or any other Guarantor. The obligations of Guarantors hereunder
shall not be reduced, limited, impaired, discharged, deferred, suspended or terminated by any case or proceeding, voluntary or
involuntary, involving the bankruptcy, insolvency, receivership, reorganization, liquidation or arrangement of Company or any
other Guarantor or by any defense which Company or any other Guarantor may have by reason of the order, decree or decision of
any court or administrative body resulting from any such proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Guarantor acknowledges and agrees that any interest on any portion of the Guaranteed Obligations which accrues after the commencement
of any case or proceeding referred to in <U>clause (a)</U> above (or, if interest on any portion of the Guaranteed Obligations
ceases to accrue by operation of law by reason of the commencement of such case or proceeding, such interest as would have accrued
on such portion of the Guaranteed Obligations if such case or proceeding had not been commenced) shall be included in the Guaranteed
Obligations because it is the intention of Guarantors and Beneficiaries that the Guaranteed Obligations which are guaranteed by
Guarantors pursuant hereto should be determined without regard to any rule of law or order which may relieve Company of any portion
of such Guaranteed Obligations. Guarantors will permit any trustee in bankruptcy, receiver, debtor in possession, assignee for
the benefit of creditors or similar person to pay Administrative Agent, or allow the claim of Administrative Agent in respect
of, any such interest accruing after the date on which such case or proceeding is commenced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that all or any portion of the Guaranteed Obligations are paid by Company, the obligations of Guarantors hereunder shall
continue and remain in full force and effect or be reinstated, as the case may be, in the event that all or any part of such payment(s)
are rescinded or recovered directly or indirectly from any Beneficiary as a preference, fraudulent transfer or otherwise, and
any such payments which are so rescinded or recovered shall constitute Guaranteed Obligations for all purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.12 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;<U>Discharge of
Guaranty Upon Sale of Guarantor</U>. If all of the Capital Stock of any Guarantor or any of its successors in interest hereunder
shall be sold or otherwise disposed of (including by merger or consolidation) in accordance with the terms and conditions hereof,
the Guaranty of such Guarantor or such successor in interest, as the case may be, hereunder shall automatically be discharged
and released without any further action by any Beneficiary or any other Person effective as of the time of such sale or disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
VIII</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
EVENTS OF DEFAULT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
8.1 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events
of Default</U>. If any one or more of the following conditions or events shall occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Failure
to Make Payments When Due</U>. Failure by Company to pay (i) the principal of and premium, if any, on any Term Loan whether at
stated maturity, by acceleration or otherwise; (ii) when due any installment of principal of any Term Loan, by notice of voluntary
prepayment, by mandatory prepayment or otherwise; or (iii) within three (3) Business Days when due any interest on any Term Loan
or any fee or any other amount due hereunder; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Default
in Other Agreements</U>. (i) Failure of any Loan Party or any of Borrower&rsquo;s Subsidiaries to pay when due any principal of
or interest on or any other amount payable in respect of one or more items of Indebtedness (other than Indebtedness referred to
in <U>Section 8.1(a)</U>) in an individual principal amount of $5,000,000 or more or with an aggregate principal amount of $5,000,000
or more, in each case beyond the grace or cure period, if any, provided therefor; or (ii) breach or default by any Loan Party
with respect to any other material term of (A) one or more items of Indebtedness in the individual or aggregate principal amounts
referred to in <U>clause (i)</U> above, or (B) any loan agreement, mortgage, indenture or other agreement relating to such item(s)
of Indebtedness referred to in clause (i) above, in each case beyond the grace or cure period, if any, provided therefor, if the
effect of such breach or default is to cause, or to permit the holder or holders of that Indebtedness (or a trustee on behalf
of such holder or holders), to cause, that Indebtedness to become or be declared due and payable (or subject to a compulsory repurchase
or redeemable) or to require the prepayment, redemption, repurchase or defeasance of, or to cause Borrower or any of Borrower&rsquo;s
Subsidiaries to make any offer to prepay, redeem, repurchase or defease such Indebtedness, prior to its stated maturity or the
stated maturity of any underlying obligation, as the case may be; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Breach
of Covenants</U>. Failure of any Loan Party to perform or comply with any term or condition contained in (i) <U>Section 2.2</U>,
<U>Section 5.1(a)-(m)</U>, <U>Section 5.1(o)-(r)</U>, <U>Section 5.2</U>, <U>Section 5.3</U>, <U>Section 5.5</U>, <U>Section 5.8</U>,
<U>Section 5.9</U>, <U>Section 5.12</U>, <U>Section 5.13</U> or <U>Article VI</U> or (ii) Section 5.4, Section 5.6, <U>Section
5.7</U>, <U>Section 5.10</U> or <U>Section 5.11</U>, and, solely in the case of this clause (ii), such failure shall continue
unremedied for 10 Business Days following notice of such failure; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Breach
of Representations, etc.</U> Any representation, warranty, certification or other statement made or deemed made by any Loan Party
in any Loan Document or in any statement or certificate at any time given by any Loan Party or any of Borrower&rsquo;s Subsidiaries
in writing pursuant hereto or thereto or in connection herewith or therewith shall be false in any material respect (except that
such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified
as to &ldquo;materiality&rdquo; or &ldquo;Material Adverse Effect&rdquo; in the text thereof, which representations and warranties
shall be true and correct in all respects subject to such qualification) as of the date made or deemed made; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Defaults Under Loan Documents</U>. Any Loan Party shall default in the performance of or compliance with any term contained herein
or any of the other Loan Documents, other than any such term referred to in any other Section of this <U>Section 8.1</U>, and
such default shall not have been remedied or waived within thirty days after the earlier of (i) an Authorized Officer of such
Loan Party becoming aware of such default, or (ii) receipt by Company of written notice from Administrative Agent of such default;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Involuntary
Bankruptcy; Appointment of Receiver, etc.</U> (i) A court of competent jurisdiction shall enter a decree or order for relief in
respect of Borrower or any of its Subsidiaries in an involuntary case under the Bankruptcy Code or under any other applicable
bankruptcy, insolvency or similar law now or hereafter in effect, which decree or order is not stayed; or any other similar relief
shall be granted under any applicable federal or state law; or (ii) an involuntary case shall be commenced against Borrower or
any of its Subsidiaries under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now or hereafter
in effect; or a decree or order of a court having jurisdiction in the premises for the appointment of a receiver, liquidator,
sequestrator, trustee, custodian or other officer having similar powers over Borrower or any of its Subsidiaries, or over all
or a substantial part of its property, shall have been entered; or there shall have occurred the involuntary appointment of an
interim receiver, trustee or other custodian of Borrowers or any of its Subsidiaries for all or a substantial part of its property;
or a warrant of attachment, execution or similar process shall have been issued against any substantial part of the property of
Borrower or any of its Subsidiaries, and any such event described in the foregoing <U>clause (i)</U> or <U>(ii)</U> shall continue
for sixty days without having been dismissed, bonded or discharged; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Voluntary
Bankruptcy; Appointment of Receiver, etc.</U> (i) Borrower or any of its Subsidiaries shall have an order for relief entered with
respect to it or shall commence a voluntary case under the Bankruptcy Code or under any other applicable bankruptcy, insolvency
or similar law now or hereafter in effect, or shall consent to the entry of an order for relief in an involuntary case, or to
the conversion of an involuntary case to a voluntary case, under any such law, or shall consent to the appointment of or taking
possession by a receiver, trustee or other custodian for all or a substantial part of its property; or Borrower or any of its
Subsidiaries shall make any assignment for the benefit of creditors; or (ii) Borrower or any of its Subsidiaries shall be unable,
or shall fail generally, or shall admit in writing its inability, to pay its debts as such debts become due; or the Board of Directors
(or similar governing body) of Borrower or any of its Subsidiaries shall adopt any resolution or otherwise authorize any action
to approve any of the actions referred to herein; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Judgments
and Attachments</U>. Any money judgment, writ or warrant of attachment or similar process involving (i) in any individual case
an amount in excess of $5,000,000 or (ii) in the aggregate at any time an amount in excess of $5,000,000 (in either case to the
extent not adequately covered by insurance as to which a solvent and unaffiliated insurance company has not denied coverage) shall
be entered or filed against Borrower or any of its Subsidiaries or any of their respective assets and shall remain undischarged,
unvacated, unbonded or unstayed for a period of sixty days (or in any event later than five days prior to the date of any proposed
sale thereunder); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Dissolution</U>.
Any order, judgment or decree by a Governmental Authority having appropriate jurisdiction shall be entered against any Loan Party
or any of its Subsidiaries decreeing the dissolution or split up of such Loan Party or any of its Subsidiaries and such order
shall remain undischarged or unstayed for a period in excess of forty-five days; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Change
of Control</U>. A Change of Control shall occur; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Guaranties,
Collateral Documents and other Loan Documents</U>. At any time after the execution and delivery thereof, (i) the Guaranty for
any reason, other than the satisfaction in full of all Obligations, shall cease to be in full force and effect (other than in
accordance with its terms) or shall be declared to be null and void or any Guarantor shall repudiate its obligations thereunder,
(ii) this Agreement or any Collateral Document ceases to be in full force and effect (other than by reason of a release of Collateral
in accordance with the terms hereof or thereof or the satisfaction in full of the Obligations in accordance with the terms hereof)
or shall be declared null and void, or Administrative Agent shall not have or shall cease to have a valid and perfected Lien in
any Collateral purported to be covered by the Collateral Documents with the priority required by the relevant Collateral Document,
in each case for any reason other than the failure of Administrative Agent or any Secured Party to take any action within its
control, or (iii) any Loan Party shall contest the validity or enforceability of any Loan Document in writing or deny in writing
that it has any further liability, including with respect to future advances by Lenders, under any Loan Document to which it is
a party; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Proceedings</U>.
The indictment of any Loan Party or any of its Subsidiaries under any criminal statute, or commencement of criminal or civil proceedings
against any Loan Party or any of its Subsidiaries pursuant to which statute or proceedings the penalties or remedies sought or
available include forfeiture to any Governmental Authority of any material portion of the property of such Person; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ERISA</U>.
The imposition of a Lien pursuant to the Internal Revenue Code or ERISA on any Loan Party with respect to any Pension Plan or
Multiemployer Plan; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
Contracts</U>. The termination of any Material Contract by Company or any other party thereto unless such Material Contract is
contemporaneously replaced by or substituted with a substantially similar contract (i) with another Person who is not a Loan Party
and (ii) containing terms and conditions that (A) taken as a whole are substantially similar to or better than the terms and conditions
of the terminated Material Contract or any other similar Material Contract then in existence or (B) are reasonably acceptable
to Administrative Agent; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cessation
of Development or Commercialization</U>. At any time prior to February 15, 2021, Borrower ceases using commercially reasonable
efforts to develop or commercialize any Specified Product Component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
8.2 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
Upon the occurrence and during the continuance of any Event of Default, Administrative Agent shall at the request of the Required
Lenders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">declare
all or any portion of the unpaid principal amount of all outstanding Term Loans, all interest accrued and unpaid thereon, and
all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable; without presentment,
demand, protest or other notice of any kind, all of which are hereby expressly waived by each Loan Party; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
on behalf of themselves and the Lenders all rights and remedies available to them and the Lenders under the Loan Documents or
applicable law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U>,
that upon the occurrence of any event specified in <U>Section 8.1(f)</U> or <U>(g)</U> above, the unpaid principal amount of all
outstanding Term Loans and all interest and other amounts as aforesaid shall automatically become due and payable without further
act of Administrative Agent or any Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
8.3 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rights Not Exclusive</U>. The rights provided
for in this Agreement and the other Loan Documents are cumulative and are not exclusive of any other rights, powers, privileges
or remedies provided by law or in equity, or under any other instrument, document or agreement now existing or hereafter arising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
IX</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
ADMINISTRATIVE AGENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.1 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Appointment
of Administrative Agent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TSL
is hereby appointed Administrative Agent hereunder and under the other Loan Documents and each Lender hereby authorizes TSL, in
such capacity, to act as its agent in accordance with the terms hereof and the other Loan Documents to perform, exercise and enforce
any and all other rights and remedies of the Lenders with respect to the Loan Parties, the Obligations or otherwise related to
any of same to the extent reasonably incidental to the exercise by Administrative Agent of the rights and remedies specifically
authorized to be exercised by Administrative Agent by the terms of this Agreement or any other Loan Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent hereby agrees to act upon the express conditions contained herein and the other Loan Documents, as applicable. The provisions
of this <U>Article IX</U> are solely for the benefit of Administrative Agent and Lenders and no Loan Party shall have any rights
as a third party beneficiary of any of the provisions thereof. In performing its functions and duties hereunder, Administrative
Agent shall act solely as an agent of Lenders and does not assume and shall not be deemed to have assumed any obligation towards
or relationship of agency or trust with or for Borrower or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.2 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Powers
and Duties</U>. Each Lender irrevocably authorizes Administrative Agent to take such action on such Lender&rsquo;s behalf and
to exercise such powers, rights and remedies hereunder and under the other Loan Documents as are specifically delegated or granted
to Administrative Agent by the terms hereof and thereof, together with such powers, rights and remedies as are reasonably incidental
thereto. Administrative Agent shall have only those duties and responsibilities that are expressly specified herein and the other
Loan Documents. Administrative Agent may exercise such powers, rights and remedies and perform such duties by or through its agents
or employees Administrative Agent shall not have, by reason hereof or any of the other Loan Documents, a fiduciary relationship
in respect of any Lender; and nothing herein or any of the other Loan Documents, expressed or implied, is intended to or shall
be so construed as to impose upon Administrative Agent any obligations in respect hereof or any of the other Loan Documents except
as expressly set forth herein or therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.3 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General Immunity</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
Responsibility for Certain Matters</U>. Administrative Agent shall not be responsible to any Lender for the execution, effectiveness,
genuineness, validity, enforceability, collectability or sufficiency hereof or any other Loan Document or for any representations,
warranties, recitals or statements made herein or therein or made in any written or oral statements or in any financial or other
statements, instruments, reports or certificates or any other documents furnished or made by Administrative Agent to Lenders or
by or on behalf of any Loan Party to Administrative Agent or any Lender in connection with the Loan Documents and the transactions
contemplated thereby or for the financial condition or business affairs of any Loan Party or any other Person liable for the payment
of any Obligations, nor shall Administrative Agent be required to ascertain or inquire as to the performance or observance of
any of the terms, conditions, provisions, covenants or agreements contained in any of the Loan Documents or as to the use of the
proceeds of the Loans or as to the existence or possible existence of any Event of Default or Default or to make any disclosures
with respect to the foregoing. Anything contained herein to the contrary notwithstanding, Administrative Agent shall not have
any liability arising from confirmations of the amount of outstanding Term Loans or the component amounts thereof. In addition,
Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor
or enforce, compliance with the provisions hereof relating to Disqualified Institutions. Without limiting the generality of the
foregoing, Administrative Agent shall not &lrm;(x) be obligated to ascertain, monitor or inquire as to whether any Lender or participant
or prospective Lender or participant is a Disqualified Institution or (y) have any liability with respect to or arising out of
any assignment or participation of loans, or disclosure of confidential information, to, or the restrictions on any exercise of
rights or remedies of, any Disqualified Institution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exculpatory
Provisions</U>. Neither Administrative Agent nor any of its officers, partners, directors, employees or agents shall be liable
to Lenders for any action taken or omitted by Administrative Agent under or in connection with any of the Loan Documents except
to the extent caused by Administrative Agent&rsquo;s gross negligence or willful misconduct, as determined by a court of competent
jurisdiction in a final, non-appealable order. Administrative Agent shall be entitled to refrain from any act or the taking of
any action (including the failure to take an action) in connection herewith or any of the other Loan Documents or from the exercise
of any power, discretion or authority vested in it hereunder or thereunder unless and until Administrative Agent shall have received
instructions in respect thereof from Required Lenders (or such other Lenders as may be required to give such instructions under
<U>Section 10.5</U>) and, upon receipt of such instructions from Required Lenders (or such other Lenders, as the case may be),
Administrative Agent shall be entitled to act or (where so instructed) refrain from acting, or to exercise such power, discretion
or authority, in accordance with such instructions. Without prejudice to the generality of the foregoing, (i) Administrative Agent
shall be entitled to rely, and shall be fully protected in relying, upon any communication, instrument or document believed by
it to be genuine and correct and to have been signed or sent by the proper Person or Persons, and shall be entitled to rely and
shall be protected in relying on opinions and judgments of attorneys (who may be attorneys for Borrower and its Subsidiaries),
accountants, experts and other professional advisors selected by it; and (ii) no Lender shall have any right of action whatsoever
against Administrative Agent as a result of Administrative Agent acting or (where so instructed) refraining from acting hereunder
or any of the other Loan Documents in accordance with the instructions of Required Lenders (or such other Lenders as may be required
to give such instructions under <U>Section 10.5</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
of Default</U>. Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event
of Default, except with respect to Events of Default in the payment of principal, interest and fees required to be paid to Administrative
Agent for the account of the Lenders, unless Administrative Agent shall have received written notice from a Lender or the Loan
Party referring to this Agreement, describing such Default or Event of Default and stating that such notice is a &ldquo;notice
of default.&rdquo; Administrative Agent will notify the Lenders of its receipt of any such notice. Administrative Agent shall
take such action with respect to any such Default or Event of Default as may be directed by the Required Lenders in accordance
with <U>Article VIII</U>; <U>provided</U>, <U>however</U>, that unless and until Administrative Agent has received any such direction,
Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to
such Default or Event of Default as it shall deem advisable or in the best interest of the Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.4 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Administrative
Agent Entitled to Act as Lender</U>. The agency hereby created shall in no way impair or affect any of the rights and powers of,
or impose any duties or obligations upon, Administrative Agent in its individual capacity as a Lender hereunder. With respect
to its participation in the Term Loans, Administrative Agent shall have the same rights and powers hereunder as any other Lender
and may exercise the same as if it were not performing the duties and functions delegated to it hereunder, and the term &ldquo;Lender&rdquo;
shall, unless the context clearly otherwise indicates, include Administrative Agent in its individual capacity. Administrative
Agent and its Affiliates may accept deposits from, lend money to, own securities of, and generally engage in any kind of banking,
trust, financial advisory or other business with Borrower or any of its Affiliates as if it were not performing the duties specified
herein, and may accept fees and other consideration from Company for services in connection herewith and otherwise without having
to account for the same to Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.5 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lenders&rsquo;
Representations, Warranties and Acknowledgment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender represents and warrants that it has made its own independent investigation of the financial condition and affairs of Borrower
and its Subsidiaries in connection with Credit Extensions hereunder and that it has made and shall continue to make its own appraisal
of the creditworthiness of Borrower and its Subsidiaries. Administrative Agent shall not have any duty or responsibility, either
initially or on a continuing basis, to make any such investigation or any such appraisal on behalf of Lenders or to provide any
Lender with any credit or other information with respect thereto, whether coming into its possession before the making of the
Term Loans or at any time or times thereafter, and Administrative Agent shall not have any responsibility with respect to the
accuracy of or the completeness of any information provided to Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender, by delivering its signature page to this Agreement and funding its Term Loan on the Closing Date, shall be deemed to have
acknowledged receipt of, and consented to and approved, each Loan Document and each other document required to be approved by
Administrative Agent, Required Lenders or Lenders, as applicable on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender (i) represents and warrants that as of the Closing Date neither such Lender nor its Affiliates or Related Funds owns or
controls, or owns or controls any Person owning or controlling, any trade debt or Indebtedness of any Loan Party other than the
Obligations or any Capital Stock of any Loan Party and (ii) covenants and agrees that from and after the Closing Date neither
such Lender nor its Affiliates and Related Funds shall purchase any trade debt or Indebtedness of any Loan Party other than the
Obligations or Capital Stock described in <U>clause (i)</U> above without the prior written consent of Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.6 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
to Indemnity</U>. EACH LENDER, IN PROPORTION TO ITS PRO RATA SHARE, SEVERALLY AGREES TO INDEMNIFY ADMINISTRATIVE AGENT, ITS AFFILIATES
AND ITS RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, MEMBERS, INVESTORS, ADVISORS, PARTNERS, EMPLOYEES AND AGENTS OF ADMINISTRATIVE
AGENT (EACH, AN &ldquo;<FONT STYLE="font-weight: normal"><U>INDEMNITEE AGENT PARTY</U></FONT>&rdquo;), TO THE EXTENT THAT SUCH
INDEMNITEE AGENT PARTY SHALL NOT HAVE BEEN REIMBURSED BY ANY LOAN PARTY, FOR AND AGAINST ANY AND ALL LIABILITIES, OBLIGATIONS,
LOSSES, DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES (INCLUDING COUNSEL FEES AND DISBURSEMENTS) OR DISBURSEMENTS
OF ANY KIND OR NATURE WHATSOEVER WHICH MAY BE IMPOSED ON, INCURRED BY OR ASSERTED AGAINST SUCH INDEMNITEE AGENT PARTY IN EXERCISING
ITS POWERS, RIGHTS AND REMEDIES OR PERFORMING ITS DUTIES HEREUNDER OR UNDER THE OTHER LOAN DOCUMENTS OR OTHERWISE IN ITS CAPACITY
AS SUCH INDEMNITEE AGENT PARTY IN ANY WAY RELATING TO OR ARISING OUT OF THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS, <B>IN ALL
CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART, OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH
INDEMNITEE AGENT PARTY</B>; <U>PROVIDED</U>, NO LENDER SHALL BE LIABLE FOR ANY PORTION OF SUCH LIABILITIES, OBLIGATIONS, LOSSES,
DAMAGES, PENALTIES, ACTIONS, JUDGMENTS, SUITS, COSTS, EXPENSES OR DISBURSEMENTS RESULTING FROM SUCH INDEMNITEE AGENT PARTY&rsquo;S
GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL, NON-APPEALABLE ORDER. IF
ANY INDEMNITY FURNISHED TO ANY INDEMNITEE AGENT PARTY FOR ANY PURPOSE SHALL, IN THE OPINION OF SUCH INDEMNITEE AGENT PARTY, BE
INSUFFICIENT OR BECOME IMPAIRED, SUCH INDEMNITEE AGENT PARTY MAY CALL FOR ADDITIONAL INDEMNITY AND CEASE, OR NOT COMMENCE, TO
DO THE ACTS INDEMNIFIED AGAINST UNTIL SUCH ADDITIONAL INDEMNITY IS FURNISHED; <U>PROVIDED</U>, IN NO EVENT SHALL THIS SENTENCE
REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION, LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT,
SUIT, COST, EXPENSE OR DISBURSEMENT IN EXCESS OF SUCH LENDER&rsquo;S PRO RATA SHARE THEREOF; AND <U>PROVIDED FURTHER</U>, THIS
SENTENCE SHALL NOT BE DEEMED TO REQUIRE ANY LENDER TO INDEMNIFY ANY INDEMNITEE AGENT PARTY AGAINST ANY LIABILITY, OBLIGATION,
LOSS, DAMAGE, PENALTY, ACTION, JUDGMENT, SUIT, COST, EXPENSE OR DISBURSEMENT DESCRIBED IN THE PROVISO IN THE IMMEDIATELY PRECEDING
SENTENCE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Successor Administrative Agent</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent may resign at any time by giving thirty days&rsquo; (or such shorter period as shall be agreed by the Required Lenders)
prior written notice thereof to Lenders and Company. Upon any such notice of resignation, Required Lenders shall have the right,
upon five Business Days&rsquo; notice to Company, to appoint a successor Administrative Agent. If no successor shall have been
so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative
Agent gives notice of its resignation, then the retiring Administrative Agent may, on behalf of the Lenders appoint a successor
Administrative Agent from among the Lenders. Upon the acceptance of any appointment as Administrative Agent hereunder by a successor
Administrative Agent that successor Administrative Agent shall thereupon succeed to and become vested with all the rights, powers,
privileges and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall promptly (i) transfer
to such successor Administrative Agent all sums, securities or Capital Stock and other items of Collateral held under the Collateral
Documents, together with all records and other documents necessary or appropriate in connection with the performance of the duties
of the successor Administrative Agent under the Loan Documents, and (ii) execute and deliver to such successor Administrative
Agent such amendments to financing statements, and take such other actions, as may be necessary or appropriate in connection with
the assignment to such successor Administrative Agent of the security interests created under the Collateral Documents, whereupon
such retiring Administrative Agent shall be discharged from its duties and obligations hereunder. After any retiring Administrative
Agent&rsquo;s resignation hereunder as Administrative Agent, the provisions of this <U>Article IX</U> shall inure to its benefit
as to any actions taken or omitted to be taken by it while it was Administrative Agent hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, Administrative Agent may assign its rights and duties as Administrative Agent, as applicable,
hereunder to an Affiliate of TSL without the prior written consent of, or prior written notice to, Company or the Lenders; <U>provided
</U>that Company and the Lenders may deem and treat such assigning Administrative Agent as Administrative Agent for all purposes
hereof, unless and until such assigning Administrative Agent provides written notice to Company and the Lenders of such assignment.
Upon such assignment such Affiliate shall succeed to and become vested with all rights, powers, privileges and duties as Administrative
Agent hereunder and under the other Loan Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent may perform any and all of its duties and exercise its rights and powers under this Agreement or under any other Loan Document
by or through any one or more sub-agents appointed by Administrative Agent. Administrative Agent and any such sub-agent may perform
any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory, indemnification
and other provisions of <U>Section 9.3</U>, <U>Section 9.6</U> and of this <U>Section 9.7</U> shall apply to any of the Affiliates
of Administrative Agent and shall apply to their respective activities in connection with the syndication of the credit facilities
provided for herein as well as activities as Administrative Agent. All of the rights, benefits and privileges (including the exculpatory
and indemnification provisions) of <U>Section 9.3</U>, <U>Section 9.6</U> and of this <U>Section 9.7</U> shall apply to any such
sub-agent and to the Affiliates of any such sub-agent, and shall apply to their respective activities as sub-agent as if such
sub-agent and Affiliates were named herein. Notwithstanding anything herein to the contrary, with respect to each sub-agent appointed
by Administrative Agent, (i) such sub-agent shall be a third party beneficiary under this Agreement with respect to all such rights,
benefits and privileges (including exculpatory and rights to indemnification) and shall have all of the rights, benefits and privileges
of a third party beneficiary, including an independent right of action to enforce such rights, benefits and privileges (including
exculpatory rights and rights to indemnification) directly, without the consent or joinder of any other Person, against any or
all of the Loan Parties and the Lenders, (ii) such rights, benefits and privileges (including exculpatory rights and rights to
indemnification) shall not be modified or amended without the consent of such sub-agent, and (iii) such sub-agent shall only have
obligations to Administrative Agent and not to any Loan Party, Lender or any other Person and no Loan Party, Lender or any other
Person shall have the rights, directly or indirectly, as a third party beneficiary or otherwise, against such sub-agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.8 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Collateral
Documents and Guaranty</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Administrative
Agent under Collateral Documents and Guaranty</U>. Each Lender hereby further authorizes Administrative Agent on behalf of and
for the benefit of Lenders, to be the agent for and representative of Lenders with respect to the Guaranty, the Collateral and
the Collateral Documents. Subject to <U>Section 10.5</U>, without further written consent or authorization from Lenders, Administrative
Agent may execute any documents or instruments necessary to (i) release any Lien encumbering any item of Collateral that is the
subject of a sale or other disposition of assets permitted hereby or to which Required Lenders (or such other Lenders as may be
required to give such consent under <U>Section 10.5</U>) have otherwise consented, or (ii) release any Guarantor from the Guaranty
pursuant to <U>Section 7.12</U> or with respect to which Required Lenders (or such other Lenders as may be required to give such
consent under <U>Section 10.5</U>) have otherwise consented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Right
to Realize on Collateral and Enforce Guaranty</U>. Anything contained in any of the Loan Documents to the contrary notwithstanding,
Company, Administrative Agent and each Lender hereby agree that (i) no Lender shall have any right individually to realize upon
any of the Collateral or to enforce the Guaranty, it being understood and agreed that all powers, rights and remedies hereunder
may be exercised solely by Administrative Agent, on behalf of Lenders in accordance with the terms hereof and all powers, rights
and remedies under the Collateral Documents may be exercised solely by Administrative Agent, and (ii) in the event of a foreclosure
by Administrative Agent on any of the Collateral pursuant to a public or private sale or any sale of the Collateral in a case
under the Bankruptcy Code, Administrative Agent or any Lender may be the purchaser of any or all of such Collateral at any such
sale and Administrative Agent, as agent for and representative of Secured Parties (but not any Lender or Lenders in its or their
respective individual capacities unless Required Lenders shall otherwise agree in writing) shall be entitled, for the purpose
of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such public
sale, to use and apply any of the Obligations as a credit on account of the purchase price for any collateral payable by Administrative
Agent at such sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.9 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agency
for Perfection</U>. Administrative Agent and each Lender hereby appoints each other Lender as agent and bailee for the purpose
of perfection the security interests in and liens upon the Collateral in assets which, in accordance with Article 9 of the UCC,
can be perfected only by possession or control (or where the security interest of a secured party with possession or control has
priority over the security interest of another secured party) and Administrative Agent and each Lender hereby acknowledges that
it holds possession of or otherwise controls any such Collateral for the benefit of the Lenders as secured party. Should any Lender
obtain possession or control of any such Collateral, such Lender shall notify Administrative Agent thereof, and, promptly upon
Administrative Agent&rsquo;s request therefore shall deliver such Collateral to Administrative Agent or in accordance with Administrative
Agent&rsquo;s instructions. In addition, Administrative Agent shall also have the power and authority hereunder to appoint such
other sub-agents as may be necessary or required under applicable state law or otherwise to perform its duties and enforce its
rights with respect to the Collateral and under the Loan Documents. Each Loan Party by its execution and delivery of this Agreement
hereby consents to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.10 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reports
and Other Information; Confidentiality; Disclaimers</U>. By becoming a party to this Agreement, each Lender:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
deemed to have requested that Administrative Agent furnish such Lender or Administrative Agent, promptly after it becomes available,
a copy of each field audit or examination report with respect to Borrower or its Subsidiaries (each a &ldquo;<FONT STYLE="font-weight: normal"><U>Report</U></FONT>&rdquo;
and collectively, &ldquo;<FONT STYLE="font-weight: normal"><U>Reports</U></FONT>&rdquo;) prepared by or at the request of Administrative
Agent, and Administrative Agent shall so furnish each Lender with such Reports,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expressly
agrees and acknowledges that Administrative Agent does not (i) make any representation or warranty as to the accuracy of any Report,
and (ii) shall not be liable for any information contained in any Report,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expressly
agrees and acknowledges that the Reports are not comprehensive audits or examinations, that Administrative Agent or other party
performing any audit or examination will inspect only specific information regarding Borrower and its Subsidiaries and will rely
significantly upon Borrower&rsquo; and its Subsidiaries&rsquo; books and records, as well as on representations of such Person&rsquo;s
personnel,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agrees
to keep all Reports and other material, non-public information regarding Borrower and its Subsidiaries and their operations, assets,
and existing and contemplated business plans in a confidential manner in accordance with <U>Section 10.17</U>, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without
limiting the generality of any other indemnification provision contained in this Agreement, agrees: (i) to hold Administrative
Agent and any other Lender preparing a Report harmless from any action the indemnifying Lender may take or fail to take or any
conclusion the indemnifying Lender may reach or draw from any Report in connection with any loans or other credit accommodations
that the indemnifying Lender has made or may make to Company, or the indemnifying Lender&rsquo;s participation in, or the indemnifying
Lender&rsquo;s purchase of, a loan or loans of Company, and (ii) to pay and protect, and indemnify, defend and hold Administrative
Agent, and any such other Lender preparing a Report harmless from and against, the claims, actions, proceedings, damages, costs,
expenses, and other amounts (including, attorneys&rsquo; fees and costs) incurred by Administrative Agent and any such other Lender
or Agent preparing a Report as the direct or indirect result of any third parties who might obtain all or part of any Report through
the indemnifying Lender or Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing: (x) any Lender may from time to time request of Administrative Agent in writing that Administrative
Agent provide to such Lender a copy of any report or document provided by Borrower or its Subsidiaries to Administrative Agent
that has not been contemporaneously provided by Borrower or such Subsidiary to such Lender, and, upon receipt of such request,
Administrative Agent promptly shall provide a copy of same to such Lender, (y) to the extent that Administrative Agent is entitled,
under any provision of the Loan Documents, to request additional reports or information from Borrower or its Subsidiaries, any
Lender may, from time to time, reasonably request Administrative Agent to exercise such right as specified in such Lender&rsquo;s
notice to Administrative Agent, whereupon Administrative Agent promptly shall request of Company the additional reports or information
reasonably specified by such Lender, and, upon receipt thereof from Company or such Subsidiary, Administrative Agent promptly
shall provide a copy of same to such Lender, and (z) any time that Administrative Agent renders to Company a statement regarding
the Loan Account, Administrative Agent shall send a copy of such statement to each Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
9.11 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Protective
Advances</U>. Subject to the limitations set forth below, Administrative Agent is authorized by Company and the Lenders, from
time to time in Administrative Agent&rsquo;s sole discretion (but Administrative Agent shall have absolutely no obligation to),
to make disbursements or advances to Company, which Administrative Agent, in its sole discretion, deems necessary or desirable
(i) to preserve or protect the Collateral, or any portion thereof, (ii) to enhance the likelihood of, or maximize the amount of,
repayment of the Loans and other Obligations, or (iii) to pay any other amount chargeable to or required to be paid by Company
pursuant to the terms of this Agreement and the other Loan Documents, including, without limitation, payments of principal, interest,
fees and reimbursable expenses (any of such Loans are in this clause (c) referred to as &ldquo;<U>Protective Advances</U>&rdquo;);
<U>provided,</U> that Administrative Agent shall not make any Protective Advance (other than with respect to the payment of payroll,
insurance premiums and rent or leased properties) unless an Event of Default has occurred and is continuing or Borrower has consented
to the making of such Protective Advance. Protective Advances may be made even if the conditions precedent set forth in <U>Article
III</U> have not been satisfied. The interest rate on all Protective Advances shall be at the Base Rate plus the Applicable Margin
for Term Loans. Each Protective Advance shall be secured by the Liens in favor of Collateral Agent in and to the Collateral and
shall constitute Obligations hereunder. The Protective Advances shall constitute Obligations hereunder which may be charged to
the Loan Account in accordance with <U>Section 2.12(i)</U>. Company shall pay the unpaid principal amount and all unpaid and accrued
interest of each Protective Advance on the earlier of the Term Loan Maturity Date and the date on which demand for payment is
made by the Administrative Agent. Administrative Agent shall notify each Lender and Company in writing in advance of each such
Protective Advance, which notice shall (y) include a description of the purpose of such Protective Advance and (z) indicate the
date on or after which such Protective Advance may be made. Without limitation to its obligations pursuant to <U>Section 9.6,
</U>each Lender agrees that it shall make available to Administrative Agent, upon such Agent&rsquo;s demand, in Dollars in immediately
available funds, the amount equal to such Lender&rsquo;s Pro Rata Share of each such Protective Advance. If such funds are not
made available to Administrative Agent by such Lender, Administrative Agent shall be entitled to recover such funds on demand
from such Lender, together with interest thereon for each day from the date such payment was due until the date such amount is
paid to Administrative Agent, at the Federal Funds Rate for three Business Days and thereafter at the Base Rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Article
X</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.1 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices
Generally</U>. Unless otherwise specifically provided herein, any notice or other communication herein required or permitted to
be given to a Loan Party, Administrative Agent, shall be sent to such Person&rsquo;s address as set forth on <U>Appendix B</U>
or in the other relevant Loan Document, and in the case of any Lender, the address as indicated on Appendix B or otherwise indicated
to Administrative Agent in writing. Each notice hereunder shall be in writing and may be personally served or sent by United States
certified mail, return receipt, or courier service and shall be deemed to have been given when delivered in person or by certified
mail or courier service and signed for against receipt thereof; <U>provided</U>, no notice to Administrative Agent shall be effective
until received by Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Electronic
Communications</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent and Company may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications
pursuant to procedures approved by it and agreed to in writing within a reasonable time prior to such delivery of such notice
and other communications; <U>provided</U> that approval of such procedures may be limited to particular notices or communications.
Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including
e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, <U>provided</U> that the
foregoing shall not apply to notices to any Lender pursuant to <U>Article II</U> if such Lender has notified the Administrative
Agent that it is incapable of receiving notices under such Article by electronic communication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the foregoing clause (i), (A) notices and other communications sent to an e-mail address shall be deemed received upon the
sender&rsquo;s receipt of an acknowledgement from the intended recipient (such as by the &ldquo;return receipt requested&rdquo;
function, as available, return e-mail or other written acknowledgement), and (B) notices or communications to Lenders posted to
an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address
as described in the foregoing <U>clause (A)</U>, of notification that such notice or communication is available and identifying
the website address therefor; <U>provided</U> that, for both <U>clauses (A)</U> and <U>(B)</U> above, if such notice, email or
other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed
to have been sent at the opening of business on the next Business Day for the recipient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.2 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
Subject to <U>Section 5.6</U>, whether or not the transactions contemplated hereby shall be consummated, Company agrees to pay
promptly (a) all of Administrative Agent&rsquo;s actual and reasonable out-of-pocket costs and expenses of preparation of the
Loan Documents and any consents, amendments, waivers or other modifications thereto; (b) all the reasonable and documented out-of-pocket
fees, expenses and disbursements of counsel to Administrative Agent in connection with the negotiation, preparation, execution
and administration of the Loan Documents and any consents, amendments, waivers or other modifications thereto and any other documents
or matters requested by Company; (c) all the actual documented costs and reasonable expenses of creating and perfecting Liens
in favor of Administrative Agent, for the benefit of Secured Parties, including filing and recording fees, expenses and taxes,
stamp or documentary taxes, search fees, title insurance premiums and reasonable fees, expenses and disbursements of counsel to
Administrative Agent and of counsel providing any opinions that Administrative Agent or Required Lenders may request in respect
of the Collateral or the Liens created pursuant to the Collateral Documents; (d) all of Administrative Agent &lsquo;s actual documented
costs and reasonable and documented out-of-pocket fees, expenses for, and disbursements of any of Administrative Agent&rsquo;s
auditors, accountants, or consultants, and all reasonable and documented out-of-pocket attorneys&rsquo; fees (including expenses
and disbursements of outside counsel) incurred by Administrative Agent; (e) all the actual documented costs and reasonable and
documented expenses (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any appraisers,
consultants, advisors and agents employed or retained by Administrative Agent and its counsel) in connection with the custody
or preservation of any of the Collateral; (f) all the actual documented costs and reasonable and documented out-of-pocket expenses
of Administrative Agent and Lenders in connection with the attendance at any meetings in connection with this Agreement and the
other Loan Documents (including the meetings referred to in <U>Section 5.7</U>; (g) all other actual and reasonable and documented
out-of-pocket costs and expenses incurred by Administrative Agent in connection with the syndication of the Loans and Commitments
and the negotiation, preparation and execution of the Loan Documents and any consents, amendments, waivers or other modifications
thereto and the transactions contemplated thereby; and (h) after the occurrence and continuance of a Default or an Event of Default,
all costs and expenses, including reasonable attorneys&rsquo; fees (including allocated costs of internal counsel) and costs of
settlement, incurred by Administrative Agent and Lenders in enforcing any Obligations of or in collecting any payments due from
any Loan Party hereunder or under the other Loan Documents by reason of such Default or Event of Default (including in connection
with the sale of, collection from, or other realization upon any of the Collateral or the enforcement of the Guaranty) or in connection
with any refinancing or restructuring of the credit arrangements provided hereunder in the nature of a &ldquo;work out&rdquo;
or pursuant to any insolvency or bankruptcy cases or proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.3 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
ADDITION TO THE PAYMENT OF EXPENSES PURSUANT TO <U>SECTION 10.2</U>, WHETHER OR NOT THE TRANSACTIONS CONTEMPLATED HEREBY SHALL
BE CONSUMMATED, EACH LOAN PARTY AGREES TO DEFEND (SUBJECT TO INDEMNITEES&rsquo; SELECTION OF COUNSEL), INDEMNIFY, PAY AND HOLD
HARMLESS, ADMINISTRATIVE AGENT AND LENDER, THEIR AFFILIATES AND THEIR RESPECTIVE OFFICERS, PARTNERS, DIRECTORS, TRUSTEES, MEMBERS,
INVESTORS, ADVISORS, PARTNERS, EMPLOYEES AND AGENTS OF ADMINISTRATIVE AGENT AND EACH LENDER (EACH, AN &ldquo;<FONT STYLE="font-weight: normal"><U>INDEMNITEE</U></FONT>&rdquo;),
FROM AND AGAINST ANY AND ALL INDEMNIFIED LIABILITIES, <B>IN ALL CASES, WHETHER OR NOT CAUSED BY OR ARISING, IN WHOLE OR IN PART,
OUT OF THE COMPARATIVE, CONTRIBUTORY, OR SOLE NEGLIGENCE OF SUCH INDEMNITEE</B>; <U>PROVIDED</U>, NO LOAN PARTY SHALL HAVE ANY
OBLIGATION TO ANY INDEMNITEE HEREUNDER WITH RESPECT TO (I) ANY INDEMNIFIED LIABILITIES TO THE EXTENT SUCH INDEMNIFIED LIABILITIES
ARISE FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, AS DETERMINED BY A COURT OF COMPETENT JURISDICTION IN A FINAL ORDER SUBJECT
TO NO FURTHER APPEAL, OF THAT INDEMNITEE OR ANY OF ITS AFFILIATES OR (II) ANY SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES RELATING
TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR ARISING OUT OF ITS ACTIVITIES IN CONNECTION HEREWITH OR THEREWITH (WHETHER BEFORE
OR AFTER THE CLOSING DATE). TO THE EXTENT THAT THE UNDERTAKINGS TO DEFEND, INDEMNIFY, PAY AND HOLD HARMLESS SET FORTH IN THIS
<U>SECTION 10.3</U> MAY BE UNENFORCEABLE IN WHOLE OR IN PART BECAUSE THEY ARE VIOLATIVE OF ANY LAW OR PUBLIC POLICY, THE APPLICABLE
LOAN PARTY SHALL CONTRIBUTE THE MAXIMUM PORTION THAT IT IS PERMITTED TO PAY AND SATISFY UNDER APPLICABLE LAW TO THE PAYMENT AND
SATISFACTION OF ALL INDEMNIFIED LIABILITIES INCURRED BY INDEMNITEES OR ANY OF THEM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted by applicable law, no Loan Party shall assert, and each Loan Party hereby waives, any claim against Lenders,
Administrative Agent and their respective Affiliates, directors, employees, attorneys or agents, on any theory of liability, for
special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor
is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with, as a result
of, or in any way related to, this Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby
or referred to herein or therein, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof
or any act or omission or event occurring in connection therewith, and Company hereby waives, releases and agrees not to sue upon
any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.4 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Set-Off</U>.
In addition to any rights now or hereafter granted under applicable law and not by way of limitation of any such rights, upon
the occurrence of any Event of Default each Lender, and their respective Affiliates is hereby authorized by each Loan Party at
any time or from time to time subject to the consent of Administrative Agent (such consent not to be unreasonably withheld or
delayed), without notice to any Loan Party or to any other Person (other than Administrative Agent), any such notice being hereby
expressly waived, to set off and to appropriate and to apply any and all deposits (general or special, including Indebtedness
evidenced by certificates of deposit, whether matured or unmatured, but not including trust accounts (in whatever currency)) and
any other Indebtedness at any time held or owing by such Lender to or for the credit or the account of any Loan Party (in whatever
currency) against and on account of the obligations and liabilities of any Loan Party to such Lender hereunder, the participations
under the other Loan Documents, including all claims of any nature or description arising out of or connected hereto, or with
any other Loan Document, irrespective of whether or not (a) such Lender shall have made any demand hereunder, (b) the principal
of or the interest on the Term Loans or any other amounts due hereunder shall have become due and payable pursuant to <U>Article
II</U> and although such obligations and liabilities, or any of them, may be contingent or unmatured or (c) such obligation or
liability is owed to a branch or office of such Lender different from the branch or office holding such deposit or obligation
or such Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.5 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
and Waivers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Required
Lenders&rsquo; Consent</U>. Subject to <U>Section 10.5(b)</U> and <U>10.5(b)(i)</U>, no amendment, modification, termination or
waiver of any provision of the Loan Documents, or consent to any departure by any Loan Party therefrom, shall in any event be
effective without the written concurrence of the Borrower, Administrative Agent and the Required Lenders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Affected
Lenders&rsquo; Consent</U>. Without the written consent of each Lender (other than a Defaulting Lender) that would be affected
thereby, no amendment, modification, termination, or consent shall be effective if the effect thereof would:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extend
the scheduled final maturity of any Loan or Note;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">waive,
reduce or postpone any scheduled repayment (but not prepayment);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
the rate of interest on any Loan (other than any waiver of any increase in the interest rate applicable to any Loan pursuant to
<U>Section 2.6</U>) or any fee payable hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extend
the time for payment of any such interest or fees;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
the principal amount of any Loan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend,
modify, terminate or waive any provision of this <U>Section 10.5(b)</U> or <U>Section 10.5(b)(i)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend
the definition of &ldquo;Required Lenders&rdquo; or &ldquo;Pro Rata Share&rdquo;;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">release
all or substantially all of the Collateral or all or substantially all of the Guarantors from the Guaranty except as expressly
provided in the Loan Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subordinate
any of the Obligations or any Lien created by this Agreement or any other Loan Document; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
to the assignment or transfer by any Loan Party of any of its rights and obligations under any Loan Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
Consents</U>. No amendment, modification, termination or waiver of any provision of the Loan Documents, or consent to any departure
by any Loan Party therefrom, shall amend, modify, terminate or waive any provision of <U>Article IX</U> as the same applies to
Administrative agent, or any other provision hereof as the same applies to the rights or obligations of Administrative Agent,
in each case without the consent of Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Execution
of Amendments, etc.</U> Administrative Agent may, but shall have no obligation to, with the concurrence of any Lender, execute
amendments, modifications, waivers or consents on behalf of such Lender. Any waiver or consent shall be effective only in the
specific instance and for the specific purpose for which it was given. No notice to or demand on any Loan Party in any case shall
entitle any Loan Party to any other or further notice or demand in similar or other circumstances. Any amendment, modification,
termination, waiver or consent effected in accordance with this <U>Section 10.5</U> shall be binding upon each Lender at the time
outstanding, each future Lender and, if signed by a Loan Party, on such Loan Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.6 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns; Participations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Generally</U>.
This Agreement shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure
to the benefit of the parties hereto and the successors and permitted assigns of Lenders. No Loan Party&rsquo;s rights or obligations
hereunder nor any interest therein may be assigned or delegated by any Loan Party without the prior written consent of all Lenders.
Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto,
Indemnitee Agent Parties under <U>Section 9.6</U>, Indemnitees under <U>Section 10.3</U>, their respective successors and assigns
permitted hereby and, to the extent expressly contemplated hereby, Affiliates of each of the Administrative Agent and Lenders)
any legal or equitable right, remedy or claim under or by reason of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Register</U>.
Company, Administrative Agent and Lenders shall deem and treat the Persons listed as Lenders in the Register as the holders and
owners of the corresponding Commitments and Loans listed therein for all purposes hereof, and no assignment or transfer of any
such Commitment or Loan shall be effective, in each case, unless and until an Assignment Agreement effecting the assignment or
transfer thereof shall have been delivered to and accepted by Administrative Agent and recorded in the Register as provided in
<U>Section 10.6(e)</U>. Prior to such recordation, all amounts owed with respect to the applicable Commitment or Loan shall be
owed to the Lender listed in the Register as the owner thereof, and any request, authority or consent of any Person who, at the
time of making such request or giving such authority or consent, is listed in the Register as a Lender shall be conclusive and
binding on any subsequent holder, assignee or transferee of the corresponding Commitments or Loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Right
to Assign</U>. Each Lender shall have the right at any time to sell, assign or transfer all or a portion of its rights and obligations
under this Agreement, including, without limitation, all or a portion of its Commitment or Loans owing to it or other Obligations
(<U>provided</U>, <U>however</U>, that each such assignment shall be of a uniform, and not varying, percentage of all rights and
obligations under and in respect of any Loan and any related Commitments):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
any Person meeting the criteria of <U>clause (a)</U> of the definition of the term of &ldquo;<FONT STYLE="font-weight: normal"><U>Eligible
Assignee</U></FONT>&rdquo; upon the giving of notice to Company and Administrative Agent in accordance with <U>Section 10.1</U>
of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
any Person otherwise constituting an Eligible Assignee with the consent of Administrative Agent and subject to the terms of the
Assignment Letter; <U>provided</U>, each such assignment pursuant to this <U>Section 10.6(c)(ii)</U> shall be in an aggregate
amount of not less than $1,000,000 (or such lesser amount as may be agreed to by Company and Administrative Agent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics</U>.
The assigning Lender and the permitted assignee thereof shall execute and deliver to Administrative Agent (i) an Assignment Agreement,
together with such forms or certificates with respect to United States federal income Tax withholding matters pursuant to <U>Section
2.15(e)</U> as if such assignee were a Lender, and (ii) a joinder to the Assignment Letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
of Assignment</U>. Upon its receipt and acceptance of a duly executed and completed Assignment Agreement, any forms or certificates
required by this Agreement in connection therewith, Administrative Agent shall record the information contained in such Assignment
Agreement in the Register, shall give written notice thereof to Company promptly (and in any event, within 30 days upon Administrative
Agent&rsquo;s receipt and acceptance thereof; <U>provided</U>, such assignment shall be effective upon receipt and acceptance
by Administrative Agent notwithstanding whether Administrative Agent delivers notice thereof to Company) and shall maintain a
copy of such Assignment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
and Warranties of Assignee</U>. Each Lender, upon execution and delivery hereof or upon executing and delivering an Assignment
Agreement, as the case may be, represents and warrants as of the Closing Date or as of the applicable Effective Date (as defined
in the applicable Assignment Agreement) that (i) it is an Eligible Assignee; (ii) it has experience and expertise in the making
of or investing in commitments or loans such as the applicable Commitments or Loans, as the case may be; (iii) it will make or
invest in, as the case may be, its Commitments or Loans for its own account in the ordinary course of its business and without
a view to distribution of such Commitments or Loans within the meaning of the Securities Act or the Exchange Act or other federal
securities laws; (iv) such Lender does not own or control, or own or control any Person owning or controlling, any trade debt
or Indebtedness of any Loan Party other than the Obligations or any Capital Stock of any Loan Party; and (v) the representations
and warranties set forth in <U>Section 9.5</U> of this Agreement are true and correct with respect to such Lender as of the Closing
Date or such applicable Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect
of Assignment</U>. Subject to the terms and conditions of this <U>Section 10.6</U>, as of the later (i) of the &ldquo;Effective
Date&rdquo; specified in the applicable Assignment Agreement or (ii) the date such assignment is recorded in the Register: (A)
the permitted assignee thereunder shall have the rights and obligations of a &ldquo;Lender&rdquo; hereunder to the extent such
rights and obligations hereunder have been properly assigned to it pursuant to such Assignment Agreement and shall thereafter
be a party hereto and a &ldquo;Lender&rdquo; for all purposes hereof; (B) the assigning Lender thereunder shall, to the extent
that rights and obligations hereunder have been assigned thereby pursuant to such Assignment Agreement, relinquish its rights
(other than any rights which survive the termination hereof under <U>Section 10.8</U>) and be released from its obligations hereunder
(and, in the case of an Assignment Agreement covering all or the remaining portion of an assigning Lender&rsquo;s rights and obligations
hereunder, such Lender shall cease to be a party hereto; <U>provided</U>, anything contained in any of the Loan Documents to the
contrary notwithstanding, such assigning Lender shall continue to be entitled to the benefit of all indemnities hereunder as specified
herein with respect to matters arising out of the prior involvement of such assigning Lender as a Lender hereunder); (C) the Commitments
shall be modified to reflect the Commitment of such assignee and any Commitment of such assigning Lender, if any; and (D) if any
such assignment occurs after the issuance of any Note hereunder, the assigning Lender shall, upon the effectiveness of such assignment
or as promptly thereafter as practicable, surrender its applicable Notes to Administrative Agent for cancellation, and thereupon
Company shall issue and deliver new Notes, if so requested in writing by the assignee and/or assigning Lender, to such assignee
and/or to such assigning Lender, with appropriate insertions, to reflect the new Commitments and/or outstanding Loans of the assignee
and/or the assigning Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Participations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Lender shall have the right at any time, without the consent of, or notice to the Borrower, to sell one or more participations
to any Person (other than Borrower, any of its Subsidiaries or any of its Affiliates) in all or any part of its Commitments, Loans
or in any other Obligation. The holder of any such participation, other than an Affiliate of the Lender granting such participation,
shall not be entitled to require such Lender to take or omit to take any action hereunder except with respect to any amendment,
modification or waiver that would (i) extend the final scheduled maturity of any Term Loan or Note in which such participant is
participating, or reduce the rate or extend the time of payment of interest or fees thereon (except in connection with a waiver
of applicability of any post default increase in interest rates) or reduce the principal amount thereof, or increase the amount
of the participant&rsquo;s participation over the amount thereof then in effect (it being understood that a waiver of any Default
or Event of Default or of a mandatory reduction in the Commitment shall not constitute a change in the terms of such participation,
and that an increase in any Commitment or Loan shall be permitted without the consent of any participant if the participant&rsquo;s
participation is not increased as a result thereof), (ii) consent to the assignment or transfer by any Loan Party of any of its
rights and obligations under this Agreement, or (iii) release all or substantially all of the Collateral under the Collateral
Documents or all or substantially all of the Guarantors from the Guaranty (in each case, except as expressly provided in the Loan
Documents) supporting the Loans hereunder in which such participant is participating. Company agrees that each participant shall
be entitled to the benefits of <U>Sections 2.14</U>, <U>2.15</U> and <U>2.19(c)</U> to the same extent as if it were a Lender
and had acquired its interest by assignment pursuant to <U>Section 10.6(c)</U>; <U>provided</U>, a participant that would be a
Non-US Lender if it were a Lender shall not be entitled to the benefits of <U>Section 2.15</U> unless, at the time such participant
is claiming such benefits, Company is notified of the participation sold to such participant and such participant agrees, for
the benefit of Company, to comply with <U>Section 2.15</U> as though it were a Lender. To the extent permitted by law, each participant
also shall be entitled to the benefits of <U>Section 10.4</U> as though it were a Lender, provided such Participant agrees to
be subject to <U>Section 2.13</U> as though it were a Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any Lender sells participations in its Commitments, Loans or in any other Obligation hereunder in accordance with
and subject to the terms and conditions of the foregoing subclause (i), such Lender shall, acting solely for this purpose as a
non-fiduciary agent of Company, maintain a register on which it enters the name of all participants in the Commitments, Loans
or Obligations held by it and the principal amount (and stated interest thereon) of the portion of such Commitments, Loans or
Obligations which are the subject of the participation (the &ldquo;<FONT STYLE="font-weight: normal"><U>Participant Register</U></FONT>&rdquo;).
A Commitment, Loan or Obligation hereunder may be participate in whole or in part only by registration of such participation on
the Participant Register (and each Note shall expressly so provide). The Participant Register shall be available for inspection
by Company at any reasonable time and from time to time upon reasonable prior notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
Other Assignments</U>. In addition to any other assignment permitted pursuant to this <U>Section 10.6</U>, any Lender or Agent
may assign, pledge and/or grant a security interest in, all or any portion of its Loans, the other Obligations owed by or to such
Lender, and its Notes, if any, to secure obligations of such Lender or Agent or any of its Affiliates to any Person providing
any loan, letter of credit or other extension of credit or financial arrangement to or for the account of such Lender or Agent
or any of its Affiliates and any agent, trustee or representative of such Person (without the consent of, or notice to, or any
other action by, any other party hereto), including, without limitation, any Federal Reserve Bank as collateral security pursuant
to Regulation A of the Board of Governors of the Federal Reserve System and any operating circular issued by such Federal Reserve
Bank; <U>provided</U>, no Lender or Agent, as between Company and such Lender or Agent, shall be relieved of any of its obligations
hereunder as a result of any such assignment and pledge; <U>provided further</U>, in no event shall such Person, agent, trustee
or representative of such Person or the applicable Federal Reserve Bank be considered to be a &ldquo;Lender&rdquo; or &ldquo;Agent&rdquo;
or be entitled to require the assigning Lender or Agent to take or omit to take any action hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.7 </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independence
of Covenants</U>. All covenants hereunder shall be given independent effect so that if a particular action or condition is not
permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within the limitations
of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.8 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival
of Representations, Warranties and Agreements</U>. All representations, warranties and agreements made herein shall survive the
execution and delivery hereof and the making of any Credit Extension. Notwithstanding anything herein or implied by law to the
contrary, the agreements of each Loan Party set forth in <U>Sections</U>,<U>2.14</U>, <U>2.15</U>, <U>2.19(c)</U>, <U>10.2</U>,
<U>10.3</U>, <U>10.4</U>, and <U>10.10</U> and the agreements of Lenders set forth in <U>Section 2.13</U>, <U>9.3(b)</U> and <U>9.6
</U>shall survive the payment of the Term Loans and the termination hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.9 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No Waiver;
Remedies Cumulative</U>. No failure or delay on the part of Administrative Agent or any Lender in the exercise of any power, right
or privilege hereunder or under any other Loan Document shall impair such power, right or privilege or be construed to be a waiver
of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other power, right or privilege. The rights, powers and remedies given to Administrative
Agent and each Lender hereby are cumulative and shall be in addition to and independent of all rights, powers and remedies existing
by virtue of any statute or rule of law or in any of the other Loan Documents. Any forbearance or failure to exercise, and any
delay in exercising, any right, power or remedy hereunder shall not impair any such right, power or remedy or be construed to
be a waiver thereof, nor shall it preclude the further exercise of any such right, power or remedy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.10 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;<U>Marshalling;
Payments Set Aside</U>. Neither Administrative Agent nor any Lender shall be under any obligation to marshal any assets in favor
of any Loan Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any Loan Party
makes a payment or payments to Administrative Agent or Lenders (or to Administrative Agent, on behalf of Lenders), or Administrative
Agent or Lenders enforce any security interests or exercise their rights of setoff, and such payment or payments or the proceeds
of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set
aside and/or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, any other state or federal
law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part thereof originally intended
to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in full force
and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.11 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>Severability</U>.
In case any provision in or obligation hereunder or any Note or other Loan Document shall be invalid, illegal or unenforceable
in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision
or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.12 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<U>Obligations Several; Independent
Nature of Lenders&rsquo; Rights</U>. The obligations of Lenders hereunder are several and no Lender shall be responsible for the
obligations or Commitment of any other Lender hereunder. Nothing contained herein or in any other Loan Document, and no action
taken by Lenders pursuant hereto or thereto, shall be deemed to constitute Lenders as a partnership, an association, a joint venture
or any other kind of entity. The amounts payable at any time hereunder to each Lender shall be a separate and independent debt,
and, subject to <U>Section 9.8</U>, each Lender shall be entitled to protect and enforce its rights arising under this Agreement
and the other Loan Documents and it shall not be necessary for any other Lender to be joined as an additional party in any proceeding
for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.13 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>Headings</U>. Section
headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose
or be given any substantive effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.14 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<U>APPLICABLE LAW</U>. THIS
AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.15 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>CONSENT TO JURISDICTION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALL
JUDICIAL PROCEEDINGS BROUGHT AGAINST ANY LOAN PARTY ARISING OUT OF OR RELATING HERETO OR ANY OTHER LOAN DOCUMENT, OR ANY OF THE
OBLIGATIONS, MAY BE BROUGHT IN ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE, COUNTY AND CITY OF NEW YORK.
BY EXECUTING AND DELIVERING THIS AGREEMENT, EACH PARTY HERETO IRREVOCABLY (I) ACCEPTS GENERALLY AND UNCONDITIONALLY THE NON-EXCLUSIVE
JURISDICTION AND VENUE OF SUCH COURTS; (II) WAIVES ANY DEFENSE OF FORUM NON CONVENIENS; (III) AGREES THAT SERVICE OF ALL PROCESS
IN ANY SUCH PROCEEDING IN ANY SUCH COURT MAY BE MADE BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE APPLICABLE
PARTY AT ITS ADDRESS PROVIDED IN ACCORDANCE WITH <U>SECTION 10.1</U> IS SUFFICIENT TO CONFER PERSONAL JURISDICTION OVER THE APPLICABLE
PARTY IN ANY SUCH PROCEEDING IN ANY SUCH COURT, AND OTHERWISE CONSTITUTES EFFECTIVE AND BINDING SERVICE IN EVERY RESPECT; AND
(IV) AGREES THAT ADMINSTRATIVE AGENT AND LENDERS RETAIN THE RIGHT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO
BRING PROCEEDINGS AGAINST ANY LOAN PARTY IN THE COURTS OF ANY OTHER JURISDICTION IF REQUIRED BY LAW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EACH
PARTY HEREBY AGREES THAT PROCESS MAY BE SERVED ON IT BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO THE ADDRESSES PERTAINING
TO IT AS SPECIFIED IN <U>SECTION 10.1</U>. ANY AND ALL SERVICE OF PROCESS AND ANY OTHER NOTICE IN ANY SUCH ACTION, SUIT OR PROCEEDING
SHALL BE EFFECTIVE AGAINST ANY SUCH PARTY IF GIVEN BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, OR BY ANY OTHER
MEANS OR MAIL WHICH REQUIRES A SIGNED RECEIPT, POSTAGE PREPAID, MAILED AS PROVIDED ABOVE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.16 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;<U>WAIVER OF JURY TRIAL</U>.
EACH OF THE PARTIES HERETO HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED
UPON OR ARISING HEREUNDER OR UNDER ANY OF THE OTHER LOAN DOCUMENTS OR ANY DEALINGS BETWEEN THEM RELATING TO THE SUBJECT MATTER
OF THIS LOAN TRANSACTION OR THE LENDER/BORROWER RELATIONSHIP THAT IS BEING ESTABLISHED. THE SCOPE OF THIS WAIVER IS INTENDED TO
BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION,
INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. EACH PARTY HERETO
ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON
THIS WAIVER IN ENTERING INTO THIS AGREEMENT, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN ITS RELATED FUTURE DEALINGS.
EACH PARTY HERETO FURTHER WARRANTS AND REPRESENTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT
IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING (OTHER THAN BY A MUTUAL WRITTEN WAIVER SPECIFICALLY REFERRING TO THIS <U>SECTION
10.16</U> AND EXECUTED BY EACH OF THE PARTIES HERETO), AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS
OR MODIFICATIONS HERETO OR ANY OF THE OTHER LOAN DOCUMENTS OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE LOANS MADE
HEREUNDER. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.17 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
Administrative Agent and Lender shall hold all non-public information (whether delivered prior to or after the Closing Date) regarding
Company and its Subsidiaries and their businesses identified as such by Company (or in the case of information which has not been
identified by Company as confidential, is similar to other information which has been idenfied as confidential and which is readily
identifiable as confidential) and obtained by such Lender from Company or its Subsidiaries pursuant to the requirements hereof
in accordance with such Lender&rsquo;s customary procedures for handling confidential information of such nature, it being understood
and agreed by Company that, in any event, Administrative Agent or Lender may make (i) disclosures of such information to Affiliates
of Administrative Agent or Lender and to their agents, advisors, directors and shareholders (and to other persons authorized by
a Lender or Agent to organize, present or disseminate such information in connection with disclosures otherwise made in accordance
with this <U>Section 10.17</U>), (ii) disclosures of such information reasonably required by any bona fide or potential assignee,
transferee or participant in connection with the contemplated assignment, transfer or participation by any such Lender of any
Loans or any participations therein, (iii) disclosure to any rating agency when required by it, (iv) disclosure to any Lender&rsquo;s
financing sources, <U>provided </U>that prior to any disclosure, such financing source is informed of the confidential nature
of the information, (v) disclosures of such information to any actual or potential investors and partners of Administrative Agent
any Lender or their Affiliates, <U>provided</U> that prior to any disclosure, such investor or partner is informed of the confidential
nature of the information, (vi) disclosures in connection with the exercise of any remedies hereunder or under any other Loan
Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder
or thereunder and (vii) disclosure required or requested in connection with any public filings, whether pursuant to any securities
laws or regulations or rules promulgated therefor (including the Investment Company Act of 1940 or otherwise) or representative
thereof or by the National Association of Insurance Commissioners (and any successor thereto) or pursuant to legal or judicial
process; <U>provided</U>, unless specifically prohibited by applicable law or court order, Administrative Agent and Lender shall
make reasonable efforts to notify Company of any request by any Governmental Authority or representative thereof (other than any
such request in connection with any examination of the financial condition or other routine examination of such Lender by such
Governmental Authority) for disclosure of any such non-public information prior to disclosure of such information and shall cooperate
with any efforts of Company to seek confidential treatment of such information. Notwithstanding anything to the contrary set forth
herein, each party (and each of their respective employees, representatives or other agents) may disclose to any and all persons,
without limitations of any kind, the tax treatment and tax structure of the transactions contemplated by this Agreement and all
materials of any kind (including opinions and other tax analyses) that are provided to any such party relating to such tax treatment
and tax structure. However, any information relating to the tax treatment or tax structure shall remain subject to the confidentiality
provisions hereof (and the foregoing sentence shall not apply) to the extent reasonably necessary to enable the parties hereto,
their respective Affiliates, and their and their respective Affiliates&rsquo; directors and employees to comply with applicable
securities laws. For this purpose, &ldquo;tax treatment&rdquo; and &ldquo;tax structure&rdquo; mean any facts relevant to the
federal income tax treatment of the transactions contemplated by this Agreement but does not include information relating to the
identity of any of the parties hereto or any of their respective Affiliates or the parties to a transaction. Notwithstanding the
foregoing, on or after the Closing Date, Administrative Agent and any Lender may, at its own expense, issue news releases and
publish &ldquo;tombstone&rdquo; advertisements and other announcements relating to this transaction in newspapers, trade journals
and other appropriate media (which may include use of logos of one or more of the Loan Parties) (collectively, &ldquo;<U>Trade
Announcements</U>&rdquo;). No Loan Party shall permit any of its Affiliates to, issue any Trade Announcement, press release or
other public disclosure using the name, logo or otherwise referring to Administrative Agent, any Lender or any of its Affiliates
without the consent of Administrative Agent or such Lender, except to the extent required to do so under applicable Requirements
of Law and then, if practicable, only after consulting with Administrative Agent or such Lender. The obligations of confidentiality
set forth in this <U>Section 10.17</U> shall survive until the date that is [***] years following the termination of this Agreement;
<U>provided</U>, that notwithstanding the foregoing, such obligations of confidentiality shall survive until the date that is
[***] years following the Closing Date in respect of (a) [***] and (b) [***]. Any information that remains subject to the confidentiality
obligations of this <U>Section 10.17</U> that is held by Administrative Agent or any Lender as of the date of the expiration of
the applicable periods set forth in the preceding sentence shall thereafter be promptly destroyed by Administrative Agent or such
Lender; <U>provided</U>, that any such information that is required to be held by Administrative Agent or such Lender following
the expiration of the applicable period set forth in the preceding sentence shall continue to be subject to the confidentiality
obligations set forth in this <U>Section 10.17</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.18 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>Usury Savings Clause</U>.
Notwithstanding any other provision herein, the aggregate interest rate charged or agreed to be paid with respect to any of the
Obligations, including all charges or fees in connection therewith deemed in the nature of interest under applicable law shall
not exceed the Highest Lawful Rate. If the rate of interest (determined without regard to the preceding sentence) under this Agreement
at any time exceeds the Highest Lawful Rate, the outstanding amount of the Loans made hereunder shall bear interest at the Highest
Lawful Rate until the total amount of interest due hereunder equals the amount of interest which would have been due hereunder
if the stated rates of interest set forth in this Agreement had at all times been in effect. In addition, if when the Loans made
hereunder are repaid in full the total interest due hereunder (taking into account the increase provided for above) is less than
the total amount of interest which would have been due hereunder if the stated rates of interest set forth in this Agreement had
at all times been in effect, then to the extent permitted by law, Company shall pay to Administrative Agent an amount equal to
the difference between the amount of interest paid and the amount of interest which would have been paid if the Highest Lawful
Rate had at all times been in effect. Notwithstanding the foregoing, it is the intention of Lenders and Company to conform strictly
to any applicable usury laws. Accordingly, if any Lender contracts for, charges, or receives any consideration which constitutes
interest in excess of the Highest Lawful Rate, then any such excess shall be cancelled automatically and, if previously paid,
shall at such Lender&rsquo;s option be applied to the outstanding amount of the Loans made hereunder or be refunded to Company.
In determining whether the interest contracted for, charged, or received by Administrative Agent or a Lender exceeds the Highest
Lawful Rate, such Person may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as
an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize,
prorate, allocate, and spread in equal or unequal parts the total amount of interest, throughout the contemplated term of the
Obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.19 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an
original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart
of this Agreement by telecopier or electronic mail shall be equally as effective as delivery of an original executed counterpart
of this Agreement. Any party delivering an executed counterpart of this Agreement by telecopier or electronic mail also shall
deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not
affect the validity, enforceability, and binding effect of this Agreement. The foregoing shall apply to each other Loan Document
<I>mutatis mutandis</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.20 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>Effectiveness</U>.
This Agreement shall become effective upon the execution of a counterpart hereof by each of the parties hereto and receipt by
Company and Administrative Agent of written notification of such execution and authorization of delivery thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
10.21 </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;<U>PATRIOT Act Notice</U>.
Each Lender and Agent (for itself and not on behalf of any Lender) hereby notifies the Loan Parties that pursuant to the requirements
of the PATRIOT Act, it may be required to obtain, verify and record information that identifies each Loan Party, which information
includes the name and address of the Loan Parties and other information that will allow such Lender or Agent, as applicable, to
identify the Loan Parties in accordance with the PATRIOT Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Remainder
of page intentionally left blank]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Value: 75 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers
thereunto duly authorized as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERAPEUTICSMD,
    INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
                                         Chief Financial Officer and Treasurer</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">VITAMEDMD, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel Cartwright</FONT></TD>
    <TD STYLE="text-align: justify; width: 16%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BOCAGREENMD, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel Cartwright</FONT></TD>
    <TD STYLE="text-align: justify; width: 16%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">VITACARE PRESCRIPTION SERVICES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel Cartwright</FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer and Assistant Treasurer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG
    SPECIALTY LENDING, INC.,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                    Administrative Agent and Lender</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Easterly</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.55in; text-align: justify"></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua Easterly</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.55in; text-align: justify"></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP
    IV TALENTS, LLC,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                    Lender</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Vice President</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO
    TALENTS, LLC,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                    Lender</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Joshua Peck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.55in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Vice President</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
A-1<BR>
TO FINANCING AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Initial
Term Loan Commitment</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Lender</U></B></FONT></TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Initial
    Term Loan Commitment</U></B></FONT></TD>
    <TD STYLE="width: 19%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Pro
    Rata Share</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG Specialty Lending,
    Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP IV Talents,
    LLC</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO Talents, LLC</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$200,000,000.00</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
A-2<BR>
TO FINANCING AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delayed
Draw A-1 Term Loan Commitments</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Lender</U></B></FONT></TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delayed
    Draw A-1 Term Loan Commitment</U></B></FONT></TD>
    <TD STYLE="width: 19%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Pro
    Rata Share</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG Specialty Lending,
    Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP IV Talents,
    LLC</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO Talents, LLC</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$50,000,000.00</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
A-3<BR>
TO FINANCING AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delayed
Draw A-2 Term Loan Commitments</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Lender</U></B></FONT></TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delayed
    Draw A-2 Term Loan Commitment</U></B></FONT></TD>
    <TD STYLE="width: 19%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Pro
    Rata Share</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG Specialty Lending,
    Inc.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP IV Talents,
    LLC</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO Talents, LLC</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$50,000,000.00</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDIX
B<BR>
TO FINANCING AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
Addresses</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERAPEUTICSMD,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
Broken Sound Parkway NW<BR>
Third Floor<BR>
Boca Raton, FL 33487<BR>
Attention: Daniel Cartwright, Chief Financial Officer<BR>
Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VITAMEDMD,
LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOCAGREENMD,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VITACARE
PRESCRIPTION SERVICES, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
Broken Sound Parkway NW<BR>
Third Floor<BR>
Boca Raton, FL 33487<BR>
Attention: Daniel Cartwright, Chief Financial Officer<BR>
Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
each case, with a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DLA
Piper LLP<BR>
200 South Biscayne Boulevard<BR>
Suite 2500<BR>
Miami, FL 33131<BR>
Attention: Joshua M. Samek<BR>
Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">APPENDIX B</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG
SPECIALTY LENDING, INC., as</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent and a Lender</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
Agent&rsquo;s Principal Office:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">888
7th Avenue, 35th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10106<BR>
Attention: Parker Hooper<BR>
Facsimile: [***]<BR>
Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schulte
Roth &amp; Zabel LLP<BR>
919 Third Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022<BR>
Attention: Frederic L. Ragucci<BR>
Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP
IV TALENTS, LLC and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO
TALENTS, LLC<BR>
as Lenders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]<BR>
Attention: TSSPOps<BR>
Facsimile: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schulte
Roth &amp; Zabel LLP<BR>
919 Third Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022<BR>
Attention: Frederic L. Ragucci<BR>
Email: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">APPENDIX B</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule
5.13</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Closing
Matters</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
later than the date that is 5 Business Days after the Closing Date, the Loan Parties shall have (a) delivered to Administrative
Agent evidence that VitaMedMD LLC has irrevocably opted into Article 8 of the UCC and caused the membership interests therein
to be deemed to be securities for purposes of Article 8 of the UCC, (b) caused such membership interests to be certificated and
(c) delivered such certificated securities (along with appropriate instruments of transfer) to Administrative Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">APPENDIX B</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<FONT STYLE="text-transform: uppercase"><B><U>Organization</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid; text-align: center; vertical-align: middle; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <U>Borrower or Guarantor</U></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: middle; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <U>State of Organization</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VitaMedMD
    LLC</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BocaGreenMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VitaCare
    Prescription Services, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florida</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Capital
Stock and Ownership</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
                                         Options, Warrants, Calls, Rights, Commitments or Other Agreements Issued by Borrower:<SUP>1</SUP></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2009
                                         Long Term Incentive Compensation Plan, as amended</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                         Outstanding: 15,128,745</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                         Available: 44,300</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
                                         and Restated 2012 Stock Incentive Plan</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                         Outstanding: 7,358,974</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                         Available: 2,392,833</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants:
                                         1,832,571</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational
                                         and Capital Structure:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="4" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid; text-align: center; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <U>Borrower or Guarantor</U></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <U>Capitalization</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publicly
    Held</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VitaMedMD
    LLC</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    &ndash; TherapeuticsMD, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BocaGreenMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    &ndash; TherapeuticsMD, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VitaCare
    Prescription Services, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    &ndash; TherapeuticsMD, Inc.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
As of March 31, 2019.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.12</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
<FONT STYLE="text-transform: uppercase"><B><U>Properties; title</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: middle; width: 34%; border: Black 1pt solid; text-align: center; padding-top: 8pt; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <U>Borrower or Guarantor</U></FONT></TD>
    <TD STYLE="vertical-align: middle; width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 8pt; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <U>Location</U></FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 8pt; padding-bottom: 8pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Leasehold
                                         or Fee</U></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
                                         Broken Sound Parkway NW, <BR>
                                         Suite 100</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
        Raton, FL 33487</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
                                         Broken Sound Parkway NW, <BR>
                                         Suite 125</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
        Raton, FL 33487</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
    Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
                                         Broken Sound Parkway NW, <BR>
                                         Suite 150</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
        Raton, FL 33487</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
                                         Inc. (Lessor);</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VitaMedMD
        LLC (books and <BR>
        records); BocaGreenMD, Inc. <BR>
        (books and records)</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
                                         Broken Sound Parkway NW, <BR>
                                         Suite 300</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
        Raton, FL 33487</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
    Inc. (Lessor); <BR>
    VitaCare Prescription Services, <BR>
    Inc. (books and records)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">951
                                         Yamato Road</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
        Raton, FL 33487</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.15</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="text-transform: uppercase"><B><U>material contracts</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.23(b)-(c)</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>intellectual property</U></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>23</SUP></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRODUCT
PATENTS</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issued
Patents:</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 4%; border: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,577,716</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">System
    and Method of Ongoing Evaluation Reporting and Analysis</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/17/09</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/05/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,633,178</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/21/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,846,648</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/30/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,846,649</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/30/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,933,059</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/13/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,987,237</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,987,238</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,993,548</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,993,549</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/31/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,006,222</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/14/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,012,434</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,114,145</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/25/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,114,146</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/25/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
Borrower is the holder of all intellectual property unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
Key: pink - Imvexxy, purple - Bijuva, blue &ndash; Annovera.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 4%; border: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,180,091</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/20/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/10/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,248,136</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/12/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/02/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,289,382</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/17/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/22/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,296,780*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Process
    for Alkynylating 16-Substituted-17-Keto Steroids</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/29/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,301,920</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/15/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/05/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D801,518</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/31/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,931,349</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/03/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,052,386</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/21/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,098,894</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/16/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,206,932</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/19/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,258,630</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/17/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89459</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/17/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">366507</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/12/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2012340589</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/25/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013211876</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/25/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013277236</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013277234</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/10/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX
    358440 B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/03/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166,044</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/17/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">002916247-0001</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/10/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">* Licensed patent or patent application.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 4%; border: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">302015005859-5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/30/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6285866</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6298460</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX
    50237 B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/19/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-2015-0065043</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/06/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101179</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/10/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A2015/01935</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/16/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015/00211</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/27/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015/00212</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/26/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6334519</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/11/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6342334</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/25/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6342389</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/25/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6397402</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/07/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013277235</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013277233</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/13/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1624393</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/18/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2861234B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2806742B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pending
Patent Applications:</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/104,101</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120140124442</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,856,520</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12850845.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017-173842</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2014/006256</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/090,493</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/04/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20140101244</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/17/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017206262</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/20/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120140319103</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,876,977</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13806855.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236358</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017-176379</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2015-7001189</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2014/015898</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015100533</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/999,040</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/512,046</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/10/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20150101608</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015264003</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112016
    027359 1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,947,767</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15727528.0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">248985</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016-565647</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2016-7032773</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2016/014281</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016143081</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016/07541</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/832,757</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/064788</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/832,750</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/244,020</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/09/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/355,532</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/15/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62/822,609</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/22/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/649,818</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/17/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017208300</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120140319146</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,876,968</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13807188.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236359</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2015-7001193</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2018/009466</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015100531</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014/09278</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018-162966</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/521,230</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20140103975</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014349132</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120160090080</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,926,342</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14862905.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">245139</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016-516086</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2016-7010901</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2016/005092</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016118396</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016/01933</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/521,002</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/372,385</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2016/065466</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20160103768</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016366200</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120180114839</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,007,636</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16873806.0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19122548.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/17/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259884</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018-529574</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2018-7019331</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2018/006882</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">743229</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NZ</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018121094</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018/03804</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62/680,715</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Formulations and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/06/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/893,542**</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/893,550**</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/975,733</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/975,723</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/781,840</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/06/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/004,338</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2018/36790</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/006,721</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/12/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/037,452</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/17/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018222947</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120140318379</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,876,964</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2014/015900</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2018/009467</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/454,898</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations Having a Desirable PK Profile</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/09/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20150100920</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Compositions</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015237243</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120160225708</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,942,568</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15768772.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">247828</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">** Application contains allowable subject matter and a patent will issue in due course.</P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016-557059</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2016-7029519</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2016/011706</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016136666</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016/06309</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/273,955</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progesterone
    Formulations Having a Desirable PK Profile</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/12/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">104.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/125,201</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/07/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P20150102431</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015296609</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112016
    029338 0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,951,284</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15827543.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">248984</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">111.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016-571728</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2017-7002451</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2016/013693</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016141135</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016/07317</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/420,019</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">118.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">119.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">120.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/217,301</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formulations
    for Solubilizing Hormones</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/22/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR112014
    018439 9</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,861,346</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">123.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2014/009093</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">124.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/843,362</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/15/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">125.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1120140318247</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">126.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,876,947</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13807463.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">128.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2014/015897</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">129.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015/00210</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transdermal
    Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/475,052</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">131.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/025211</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">132.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20170100832</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017239679</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">134.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120180698776</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">135.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,019,375</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17776724.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">137.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">261924</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">138.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018-550593</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">139.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2018-7031666</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">140.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2018/011706</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">141.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">746686</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NZ</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">142.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018133921</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">143.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018/06413</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/475,068</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Pharmaceutical Composition in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">145.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20170100831</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">146.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/025220</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">147.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/473,742</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">148.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/359,839</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/20/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">149.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/024955</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/901,467</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/21/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">151.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20170100830</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">152.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017239645</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR1120180701998</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">154.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,020,153</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">155.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17776645.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">261930</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018-550564</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2018-7031878</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">159.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/A/2018/011705</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">160.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">746682</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NZ</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">161.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018133932</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">162.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018/06414</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">163.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/US2017/024994</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">164.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20170100829</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steroid
    Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">165.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">166.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(217,217,217)">
    <TD STYLE="width: 6%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">167.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">168.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="background-color: Blue">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">169.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)(i)</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
has licensed certain Product Patents and is obligated to pay royalties and other payments pursuant to that certain License Agreement,
dated July 30, 2018, between Borrower and The Population Council, Inc.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)(ii)</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
has licensed certain Product Patents pursuant to that certain License and Supply Agreement, dated July 30, 2018, as amended, between
Borrower and Knight Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)(iii)</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the contracts in (c)(i) and (c)(ii) listed above, none.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Schedule
4.24</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>insurance</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company is covered by general liability and certain other insurance in the amounts and
                                         coverage limits as set forth in the certificate attached hereto as <U>Annex A</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company is covered by workmen&rsquo;s compensation insurance in the amounts and coverage
                                         limits as set forth in the certificate attached hereto as <U>Annex B</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.24</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
4.24</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
B</U></B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Schedule
4.27</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>bank accounts and securities accounts</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 25%; border: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company</U></FONT></TD>
    <TD STYLE="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bank
    or Broker</U></FONT></TD>
    <TD STYLE="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address</U></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Account
    No.</U></FONT></TD>
    <TD STYLE="width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Account
    Type</U></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 5.4pt; padding-bottom: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Schedule
4.33(d)-(e)</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>regulatory compliance</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Schedule
4.34</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>GOVERNMENT CONTRACTS</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
6.1</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>permitted indebtedness</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Schedule
6.2</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>permitted liens</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
6.7</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>permitted investments</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
6.12</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><BR>
<FONT STYLE="text-transform: uppercase"><B><U>Transactions with Shareholders and Affiliates</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None.</B></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<DESCRIPTION>PLEDGE AND SECURITY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</A>&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Execution
Version</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLEDGE
AND SECURITY AGREEMENT</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dated
as of April 24, 2019</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">among</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EACH
OF THE GRANTORS PARTY HERETO</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG
SPECIALTY LENDING, INC.,</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
Administrative Agent</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"> </P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="width: 90%; text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    1. DEFINITIONS; GRANT OF SECURITY</FONT></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&nbsp;&nbsp;&nbsp;General
    Definitions</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&nbsp;&nbsp;&nbsp;Definitions;
    Interpretation</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    2. GRANT OF SECURITY</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&nbsp;&nbsp;&nbsp;Grant
    of Security</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&nbsp;&nbsp;&nbsp;Certain
    Limited Exclusions</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    3. SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&nbsp;&nbsp;&nbsp;Security
    for Obligations</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;Continuing
    Liability Under Collateral</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    4. REPRESENTATIONS AND WARRANTIES AND COVENANTS</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;Generally</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;[Reserved]</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;Receivables</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&nbsp;&nbsp;&nbsp;Investment
    Related Property</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&nbsp;&nbsp;&nbsp;Material
    Contracts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&nbsp;&nbsp;&nbsp;Letter
    of Credit Rights</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7&nbsp;&nbsp;&nbsp;Intellectual
    Property</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&nbsp;&nbsp;&nbsp;Commercial
    Tort Claims</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    5. ACCESS; RIGHT OF INSPECTION AND FURTHER ASSURANCES; ADDITIONAL GRANTORS</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;&nbsp;&nbsp;[Reserved]</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;&nbsp;&nbsp;Further
    Assurances</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&nbsp;&nbsp;&nbsp;Additional
    Grantors</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    6. ADMINISTRATIVE AGENT APPOINTED ATTORNEY-IN-FACT</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&nbsp;&nbsp;&nbsp;Power
    of Attorney</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 12pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&nbsp;&nbsp;&nbsp;No
    Duty on the Part of Administrative Agent or Secured Parties</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    7. REMEDIES.</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1&nbsp;&nbsp;&nbsp;Generally</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2&nbsp;&nbsp;&nbsp;Application
    of Proceeds</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3&nbsp;&nbsp;&nbsp;Sales
    on Credit</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4&nbsp;&nbsp;&nbsp;Deposit
    Accounts</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5&nbsp;&nbsp;&nbsp;Investment
    Related Property</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6&nbsp;&nbsp;&nbsp;Intellectual
    Property</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7&nbsp;&nbsp;&nbsp;Cash
    Proceeds</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-left: 1in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0in">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    8. [RESERVED]</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    9. CONTINUING SECURITY INTEREST; TRANSFER OF TERM LOANS</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    10. STANDARD OF CARE; ADMINISTRATIVE AGENT MAY PERFORM</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 11pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -1in; padding-top: 0in; padding-bottom: 0pt; padding-left: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
    11. MISCELLANEOUS</FONT></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedules</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
4.1 &mdash; GENERAL INFORMATION</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
4.4 &mdash; INVESTMENT RELATED PROPERTY</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
4.5 &mdash; MATERIAL CONTRACTS</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
4.6 &mdash; DESCRIPTION OF LETTERS OF CREDIT</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
4.7 &mdash; INTELLECTUAL PROPERTY - EXCEPTIONS</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
4.8 &mdash; COMMERCIAL TORT CLAIMS</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibits</U></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A &mdash; PLEDGE SUPPLEMENT</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
B &mdash; TRADEMARK SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
C &mdash; COPYRIGHT SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
D &mdash; PATENT SECURITY AGREEMENT</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"> <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
PLEDGE AND SECURITY AGREEMENT, dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time
to time in accordance with and subject to the terms and conditions hereof, this &ldquo;<B>Agreement</B>&rdquo;), among <B>EACH OF
THE UNDERSIGNED</B>, whether as an original signatory hereto or as an Additional Grantor (as herein defined) (each, a &ldquo;<B>Grantor</B>&rdquo;),
and TPG Specialty Lending, Inc., as administrative agent for the Secured Parties (as herein defined) (in such capacity as administrative
agent, the &ldquo;<B>Administrative Agent</B>&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RECITALS:</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
reference is made to that certain Financing Agreement, dated as of the date hereof (as it may be amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Financing Agreement</B>&rdquo;), by and among <FONT STYLE="text-transform: uppercase">THERAPEUTICSMD,
INC., </FONT>a Nevada corporation, as borrower (&ldquo;<B>Company</B>&rdquo; or &ldquo;<B>Borrower</B>&rdquo;), and certain Subsidiaries
of the Borrower, as Guarantors, the Lenders from time to time party thereto and the Administrative Agent;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
in consideration of the extensions of credit and other accommodations of Lenders as set forth in the Financing Agreement, each
Grantor has agreed to secure such Grantor&rsquo;s obligations under the Loan Documents as set forth herein;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
each Grantor (other than Borrower) is a direct or indirect domestic Subsidiary of Borrower;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
each Grantor will directly or indirectly obtain benefits from the Financing Agreement and, accordingly, desires to execute this
Agreement in order to induce the Lenders to extend credit pursuant to the Financing Agreement and other Loan Documents; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises and the agreements, provisions and covenants herein contained, each Grantor and
the Administrative Agent agree as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
1. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS; GRANT OF SECURITY.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>1.1</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
                                         Definitions. </B>In this Agreement, the following terms shall have the following meanings:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Account
Debtor</B>&rdquo; shall mean each Person (or any successor or assign of such Person) who is obligated with respect to a Receivable
or any Supporting Obligation related thereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Accounts</B>&rdquo;
shall mean all &ldquo;accounts&rdquo; as defined in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Additional
Grantors</B>&rdquo; shall have the meaning assigned in <U>Section 5.3</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Agreement</B>&rdquo;
shall have the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Assigned
Agreements</B>&rdquo; shall mean all agreements and contracts to which such Grantor is a party as of the date hereof, or to which
such Grantor becomes a party after the date hereof, including, without limitation, each Material Contract, as each such agreement
may be amended, supplemented or otherwise modified from time to time.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Borrower</B>&rdquo;
has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Cash
Proceeds</B>&rdquo; shall have the meaning assigned in <U>Section 7.7</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Chattel
Paper</B>&rdquo; shall mean all &ldquo;chattel paper&rdquo; as defined in Article 9 of the UCC, including, without limitation, &ldquo;electronic
chattel paper&rdquo; or &ldquo;tangible chattel paper&rdquo;, as each term is defined in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Collateral</B>&rdquo;
shall have the meaning assigned in <U>Section 2.1</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Collateral
Records</B>&rdquo; shall mean books, records, ledger cards, files, correspondence, customer lists, blueprints, technical specifications,
manuals, computer software, computer printouts, tapes, disks and related data processing software and similar items that at any
time evidence or contain information relating to any of the Collateral or are otherwise necessary or helpful in the collection
thereof or realization thereupon.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Collateral
Support</B>&rdquo; shall mean all personal property assigned, hypothecated or otherwise securing any Collateral and shall include
any security agreement or other agreement granting a lien or security interest in such real or personal property.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Commercial
Tort Claims</B>&rdquo; shall mean all &ldquo;commercial tort claims&rdquo; as defined in Article 9 of the UCC, including, without
limitation, all commercial tort claims listed on <U>Schedule4.8</U> (as such schedule may be amended or supplemented from time
to time).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Commodities
Accounts</B>&rdquo; (i) shall mean all &ldquo;commodity accounts&rdquo; as defined in Article 9 of the UCC and (ii) shall include,
without limitation, all of the accounts listed on <U>Schedule&nbsp;4.4</U> under the heading &ldquo;Commodities Accounts&rdquo;
(as such schedule may be amended or supplemented from time to time).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Copyright
Licenses</B>&rdquo; shall mean any and all agreements providing for the granting of any right in or to Copyrights (whether such
Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in <U>Schedule 4.7(B)</U>
(as such schedule may be amended or supplemented from time to time).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Copyrights</B>&rdquo;
shall mean all United States, and foreign copyrights (including Community designs), including but not limited to copyrights in
software and databases, and all Mask Works (as defined under 17 U.S.C. 901 of the U.S. Copyright Act), whether registered or unregistered,
and, with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation,
the registrations and applications referred to in <U>Schedule&nbsp;4.7(A)</U> (as such schedule may be amended or supplemented
from time to time), (ii) all extensions and renewals thereof, (iii) all rights corresponding thereto throughout the world, (iv)
all rights to sue for past, present and future infringements thereof, and (v) all Proceeds of the foregoing, including, without
limitation, licenses, royalties, income, payments, claims, damages and proceeds of suit.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Documents</B>&rdquo;
shall mean all &ldquo;documents&rdquo; as defined in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Equipment</B>&rdquo;
shall mean: (i) all &ldquo;equipment&rdquo; as defined in Article 9 of the UCC, (ii) all machinery, manufacturing equipment, data
processing equipment, computers, office equipment, furnishings, furniture, appliances, fixtures and tools (in each case, regardless
of whether characterized as equipment under the UCC) and (iii) all accessions or additions thereto, all parts thereof, whether
or not at any time of determination incorporated or installed therein or attached thereto, and all replacements therefor, wherever
located, now or hereafter existing, including any fixtures.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Financing
Agreement</B>&rdquo; shall have the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>General
Intangibles</B>&rdquo; (i) shall mean all &ldquo;general intangibles&rdquo; as defined in Article 9 of the UCC, including &ldquo;payment
intangibles&rdquo; also as defined in Article 9 of the UCC and (ii) shall include, without limitation, all interest rate or currency
protection or hedging arrangements, all tax refunds, licenses, permits, concessions and authorizations, all Assigned Agreements
and all Intellectual Property (in each case, regardless of whether characterized as general intangibles under the UCC).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Goods</B>&rdquo;
(i) shall mean all &ldquo;goods&rdquo; as defined in Article 9 of the UCC and (ii) shall include, without limitation, all Inventory
and Equipment (in each case, regardless of whether characterized as goods under the UCC).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Grantors</B>&rdquo;
shall have the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Indemnitee</B>&rdquo;
shall mean the Administrative Agent, and its Affiliates&rsquo; officers, partners, directors, trustees, employees, agents.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Instruments</B>&rdquo;
shall mean all &ldquo;instruments&rdquo; as defined in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Insurance</B>&rdquo;
shall mean all insurance policies covering any or all of the Collateral (regardless of whether the Administrative Agent is the
loss payee thereof).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Intellectual
Property</B>&rdquo; shall mean, collectively, the Copyrights, the Copyright Licenses, the Patents, the Patent Licenses, the Trademarks,
the Trademark Licenses, the Trade Secrets, and the Trade Secret Licenses.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Inventory</B>&rdquo;
shall mean (i) all &ldquo;inventory&rdquo; as defined in Article 9 of the UCC and (ii) all goods held for sale or lease or to be
furnished under contracts of service or so leased or furnished, all raw materials, work in process, finished goods, and materials
used or consumed in the manufacture, packing, shipping, advertising, selling, leasing, furnishing or production of such inventory
or otherwise used or consumed in any Grantor&rsquo;s business; all goods in which any Grantor has an interest in mass or a joint or
other interest or right of any kind; and all goods which are returned to or repossessed by any Grantor, all computer programs
embedded in any goods and all accessions thereto and products thereof (in each case, regardless of whether characterized as inventory
under the UCC).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investment
Accounts</B>&rdquo; shall mean the Administrative Agent&rsquo;s Account, Securities Accounts, Commodities Accounts and Deposit Accounts.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Investment
Related Property</B>&rdquo; shall mean: (i) all &ldquo;investment property&rdquo; (as such term is defined in Article 9 of the UCC)
and (ii) all of the following (regardless of whether classified as investment property under the UCC): all Pledged Equity Interests,
Pledged Debt, the Investment Accounts and certificates of deposit.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Letter
of Credit Right</B>&rdquo; shall mean &ldquo;letter-of-credit right&rdquo; as defined in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Money</B>&rdquo;
shall mean &ldquo;money&rdquo; as defined in the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Non-Assignable
Contract&rdquo; </B>shall mean any agreement, contract or license to which any Grantor is a party that by its terms purports to
restrict or prevent the assignment or granting of a security interest therein (either by its terms or by any federal or state
statutory prohibition or otherwise irrespective of whether such prohibition or restriction is enforceable under Section 9-406
through 409 of the UCC).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Patent
Licenses</B>&rdquo; shall mean all agreements providing for the granting of any right in or to Patents (whether such Grantor is
licensee or licensor thereunder).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Patents</B>&rdquo;
shall mean all United States and foreign patents and certificates of invention and applications for any of the foregoing, including,
but not limited to: (i) each patent and patent application referred to in <U>Schedule 4.7(C)</U> hereto (as such schedule may
be amended or supplemented from time to time) and including but not limited to the Annovera Patents, Bijuva Patents and Imvexxy
Patents, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof,
(iii) all rights corresponding thereto throughout the world, (iv) all inventions and improvements described therein, (v) all rights
to sue for past, present and future infringements thereof, (vi) all licenses, claims, damages, and proceeds of suit arising therefrom,
and (vii) all Proceeds of the foregoing, including, without limitation, licenses, royalties, income, payments, claims, damages,
and proceeds of suit.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledge
Supplement</B>&rdquo; shall mean any supplement to this agreement in substantially the form of <U>Exhibit A</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledged
Debt</B>&rdquo; shall mean all Indebtedness owed to such Grantor, including, without limitation, all Indebtedness described on
<U>Schedule 4.4(A)</U> under the heading &ldquo;Pledged Debt&rdquo; (as such schedule may be amended or supplemented from time to
time), issued by the obligors named therein, the instruments evidencing such Indebtedness, and all interest, cash, instruments
and other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for
any or all of such Indebtedness.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledged
Equity Interests</B>&rdquo; shall mean all Pledged Stock, Pledged LLC Interests, Pledged Partnership Interests and Pledged Trust
Interests.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledged
LLC Interests</B>&rdquo; shall mean all interests in any limited liability company including, without limitation, all limited liability
company interests listed on <U>Schedule 4.4(A)</U> under the heading &ldquo;Pledged LLC Interests&rdquo; (as such schedule may be
amended or supplemented from time to time) and the certificates, if any, representing such limited liability company interests
and any interest of such Grantor on the books and records of such limited liability company or on the books and records of any
securities intermediary pertaining to such interest and all dividends, distributions, cash, warrants, rights, options, instruments,
securities and other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in
exchange for any or all of such limited liability company interests.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledged
Partnership Interests</B>&rdquo; shall mean all interests in any general partnership, limited partnership, limited liability partnership
or other partnership including, without limitation, all partnership interests listed on <U>Schedule 4.4(A)</U> under the heading
&ldquo;Pledged Partnership Interests&rdquo; (as such schedule may be amended or supplemented from time to time) and the certificates,
if any, representing such partnership interests and any interest of such Grantor on the books and records of such partnership
or on the books and records of any securities intermediary pertaining to such interest and all dividends, distributions, cash,
warrants, rights, options, instruments, securities and other property or proceeds from time to time received, receivable or otherwise
distributed in respect of or in exchange for any or all of such partnership interests.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledged
Stock</B>&rdquo; shall mean all shares of capital stock owned by such Grantor, including, without limitation, all shares of capital
stock described on <U>Schedule 4.4(A)</U> under the heading &ldquo;Pledged Stock&rdquo; (as such schedule may be amended or supplemented
from time to time), and the certificates, if any, representing such shares and any interest of such Grantor in the entries on
the books of the issuer of such shares or on the books of any securities intermediary pertaining to such shares, and all dividends,
distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from time to time received,
receivable or otherwise distributed in respect of or in exchange for any or all of such shares.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pledged
Trust Interests</B>&rdquo; shall mean all interests in a Delaware business trust or other trust including, without limitation,
all trust interests listed on <U>Schedule 4.4(A)</U> under the heading &ldquo;Pledged Trust Interests&rdquo; (as such schedule may
be amended or supplemented from time to time) and the certificates, if any, representing such trust interests and any interest
of such Grantor on the books and records of such trust or on the books and records of any securities intermediary pertaining to
such interest and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or
proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such trust
interests.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Proceeds</B>&rdquo;
shall mean: (i) all &ldquo;proceeds&rdquo; as defined in Article 9 of the UCC, (ii) payments or distributions made with respect
to any Investment Related Property and (iii) whatever is receivable or received when Collateral or proceeds are sold, exchanged,
collected or otherwise disposed of, whether such disposition is voluntary or involuntary.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Receivables</B>&rdquo;
shall mean all rights to payment, whether or not earned by performance, with respect to (i) goods or other property sold, leased,
licensed, assigned or otherwise disposed of and (ii) services rendered or to be rendered, in each case, including, without limitation,
all such rights constituting or evidenced by any Account, Chattel Paper, Instrument, General Intangible or Investment Related
Property, together with all of Grantor&rsquo;s rights, if any, in any goods or other property giving rise to such right to payment and
all Collateral Support and Supporting Obligations related thereto and all Receivables Records.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Receivables
Records</B>&rdquo; shall mean (i) all copies of all documents, instruments or other writings or electronic records or other Records
evidencing the Receivables, (ii) all books, correspondence, credit or other files, Records, ledger sheets or cards, invoices,
and other papers relating to Receivables, including, without limitation, all tapes, cards, computer tapes, computer discs, computer
runs, record keeping systems and other papers and documents relating to the Receivables, whether in the possession or under the
control of Grantor or any computer bureau or agent from time to time acting for Grantor or otherwise, (iii) all evidences of the
filing of financing statements and the registration of other instruments in connection therewith, and amendments, supplements
or other modifications thereto, notices to other creditors or secured parties, and certificates, acknowledgments, or other writings,
including, without limitation, lien search reports, from filing or other registration officers, (iv) all credit information, reports
and memoranda relating thereto and (v) all other written or otherwise documented forms of information related in any way to the
foregoing or any Receivable.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Record</B>&rdquo;
shall have the meaning specified in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Secured
Obligations</B>&rdquo; shall have the meaning assigned in <U>Section 3.1</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Secured
Parties</B>&rdquo; shall mean the Administrative Agent and the Lenders and shall include, without limitation, any former Administrative
Agent or Lender to the extent that any Obligations owing to such Person were incurred while such Person was an Administrative
Agent or Lender and such Obligations have not been paid or satisfied in full.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Accounts</B>&rdquo; (i) shall mean all &ldquo;securities accounts&rdquo; as defined in Article 8 of the UCC and (ii) shall include,
without limitation, all of the accounts listed on Schedule 4.4(A) under the heading &ldquo;Securities Accounts&rdquo; (as such schedule
may be amended or supplemented from time to time).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Supporting
Obligation</B>&rdquo; shall mean all &ldquo;supporting obligations&rdquo; as defined in Article 9 of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trademark
Licenses</B>&rdquo; shall mean any and all agreements providing for the granting of any right in or to Trademarks (whether such
Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in <U>Schedule 4.7(F)</U>
(as such schedule may be amended or supplemented from time to time).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trademarks</B>&rdquo;
shall mean all United States, and foreign trademarks, trade names, corporate names, company names, business names, fictitious
business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers,
designs and general intangibles of a like nature, all registrations and applications for any of the foregoing including, but not
limited to: (i) the registrations and applications referred to in <U>Schedule 4.7(E)</U> (as such schedule may be amended or supplemented
from time to time), (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected
with the use of and symbolized by the foregoing, (iv) the right to sue for past, present and future infringement or dilution of
any of the foregoing or for any injury to goodwill, and (v) all Proceeds of the foregoing, including, without limitation, licenses,
royalties, income, payments, claims, damages, and proceeds of suit.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trade
Secret Licenses</B>&rdquo; shall mean any and all agreements providing for the granting of any right in or to Trade Secrets (whether
such Grantor is licensee or licensor thereunder) including, without limitation, each agreement referred to in <U>Schedule 4.7(G)
</U>(as such schedule may be amended or supplemented from time to time).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trade
Secrets</B>&rdquo; shall mean all trade secrets and all other confidential or proprietary information and know-how protectable
by applicable law, whether or not such Trade Secret has been reduced to a writing or other tangible form, including all documents
and things embodying, incorporating, or referring in any way to such Trade Secret, including but not limited to: (i) the right
to sue for past, present and future misappropriation or other violation of any Trade Secret, and (ii) all Proceeds of the foregoing,
including, without limitation, licenses, royalties, income, payments, claims, damages, and proceeds of suit.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>UCC</B>&rdquo;
shall mean the Uniform Commercial Code as in effect from time to time in the State of New York or, when the context implies, the
Uniform Commercial Code as in effect from time to time in any other applicable jurisdiction.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>United
States</B>&rdquo; shall mean the United States of America.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions; Interpretation. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
capitalized terms used herein (including the preamble and recitals hereto) and not otherwise defined herein shall have the meanings
ascribed thereto in the Financing Agreement or, if not defined therein, in the UCC. References to &ldquo;Sections,&rdquo; &ldquo;Exhibits&rdquo;
and &ldquo;Schedules&rdquo; shall be to Sections, Exhibits and Schedules, as the case may be, of this Agreement unless otherwise
specifically provided. Section headings in this Agreement are included herein for convenience of reference only and shall not
constitute a part of this Agreement for any other purpose or be given any substantive effect. Any of the terms defined herein
may, unless the context otherwise requires, be used in the singular or the plural, depending on the reference. The use herein
of the word &ldquo;include&rdquo; or &ldquo;including&rdquo;, when following any general statement, term or matter, shall not be construed
to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar
items or matters, whether or not nonlimiting language (such as &ldquo;without limitation&rdquo; or &ldquo;but not limited to&rdquo;
or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters
that fall within the broadest possible scope of such general statement, term or matter. If any conflict or inconsistency exists
between this Agreement and the Financing Agreement, the Financing Agreement shall govern. All references herein to provisions
of the UCC shall include all successor provisions under any subsequent version or amendment to any Article of the UCC.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
2. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANT OF SECURITY.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant of Security. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subject
to Section 2.2, each Grantor hereby grants to the Administrative Agent a security interest in and continuing Lien on all of such
Grantor&rsquo;s right, title and interest in, to and under all personal property of such Grantor including, but not limited to the following,
in each case whether now owned or existing or hereafter acquired or arising and wherever located (all of which being hereinafter
collectively referred to as the &ldquo;<B>Collateral</B>&rdquo; and excluding, for the avoidance of doubt, any Excluded Assets (as
defined below)): </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chattel
Paper;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Documents;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General
Intangibles;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goods;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Instruments;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual
Property;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment
Related Property;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Letter
of Credit Rights;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money
(including, for the avoidance of doubt, Money in the Administrative Agent&rsquo;s Account);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables
and Receivable Records;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial
Tort Claims described on <U>Schedule 4.8</U> and as supplemented by any written notification given by a Grantor to Administrative
Agent pursuant to <U>Section 4.8</U>;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the extent not otherwise included above, all Collateral Records, Collateral Support and Supporting Obligations relating to any
of the foregoing;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the extent not covered by the preceding clauses of this <U>Section 2.1</U>, all other tangible and intangible personal property
of such Grantor (whether or not subject to the UCC), including, without limitation, all bank and other accounts and all cash and
all investments therein, all proceeds, products, offspring, accessions, rents, profits, income, benefits, substitutions and replacements
of and to any of the property of such Grantor described in the preceding clauses of this <U>Section 2.1</U> hereof (including,
without limitation, any proceeds of insurance thereon and all causes of action, claims and warranties now or hereafter held by
such Grantor in respect of any of the items listed above), and all books, correspondence, files and other Records, including,
without limitation, all tapes, disks, cards, software, data and computer programs in the possession or under the control of such
Grantor or any other Person from time to time acting for such Grantor that at any time evidence or contain information relating
to any of the property described in the preceding clauses of this <U>Section 2</U> hereof or are otherwise necessary or helpful
in the collection or realization thereof; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the extent not otherwise included above, all Proceeds, products, accessions, rents and profits of or in respect of any of the
foregoing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 74pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Limited Exclusions. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notwithstanding
anything herein or in any other Loan Document to the contrary, in no event shall the Collateral include or the security interest
granted under <U>Section 2.1</U> hereof attach to or shall any perfection requirements be required with respect to (a) any of
such Grantor&rsquo;s right, title or interest in any license, contract, lease or agreement to which such Grantor is a party or any of
its right, title or interest thereunder to the extent, but only to the extent, that such a grant would, under the express terms
of such license, contract, lease or agreement result in a breach of the terms of, constitute a default under or create a right
of termination in favor of any party thereto (other than any Grantor) such license, contract, lease or agreement (other than to
the extent that any such term (A) has been waived or (B) would be rendered ineffective pursuant to Sections 9-406, 9-408, 9-409
of the UCC or other applicable provisions of the UCC of any relevant jurisdiction or any other applicable law (including the Bankruptcy
Code) or principles of equity); <U>provided</U>, that (x) immediately upon the ineffectiveness, lapse, termination or waiver of
any such provision, the Collateral shall include, and such Grantor shall be deemed to have granted a security interest in, all
such right, title and interest as if such provision had never been in effect and (y) the foregoing exclusion shall in no way be
construed so as to limit, impair or otherwise affect the Administrative Agent&rsquo;s unconditional continuing security interest in
and liens upon any rights or interests of a Grantor in or to (1)&nbsp;monies due or to become due under or in connection with
any such license, contract, lease or agreement, or (2)&nbsp;any proceeds from the sale, license, lease, or other dispositions
of any such license, contract, lease or agreement); (b) any intent-to-use United States trademark applications for which an amendment
to allege use or statement of use has not been filed under 15 U.S.C. &sect; 1051(c) or 15 U.S.C. &sect;1051(d), respectively,
or if filed, has not been deemed in conformance with 15 U.S.C. &sect;1051(a) or examined and accepted, respectively, by the United
States Patent and Trademark Office, <U>provided</U> that upon such filing and acceptance, such intent-to-use applications shall
be included in the definition of Collateral; (c) any Excluded Account; (d) those assets as to which the Administrative Agent reasonably
determines that the costs of obtaining such security interests in such assets or perfection thereof are excessive in relation
to the benefit to the Administrative Agent and the Lenders of the security to be afforded thereby; (e) motor vehicles, airplanes
and other assets subject to certificates of title to the extent (i) a lien therein cannot be perfected by the filing of UCC financing
statements and (ii) the aggregate fair market value of all such assets is less than $250,000; (f) letter of credit rights less
than $250,000 in the aggregate, to the extent a lien therein cannot be perfected by the filing of UCC financing statements, and
Commercial Tort Claims less than $250,000 in the aggregate; (g) any governmental licenses or state or local franchises, charters
and authorizations to the extent a security interest is prohibited or restricted thereby after giving effect to the applicable
anti-assignment provisions of applicable law (including the UCC), other than proceeds and receivables thereof, the assignment
of which is expressly deemed effective under applicable law notwithstanding such prohibition, and (h) assets which a pledge thereof
or a security interest therein is prohibited by applicable law (including the UCC), other than proceeds and receivables thereof,
the assignment of which is expressly deemed effective under applicable law notwithstanding such prohibition (the property referred
to in this Section 2.2 being collectively referred to as &ldquo;<B>Excluded Assets</B>&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
3. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY FOR OBLIGATIONS; GRANTORS REMAIN
LIABLE.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security for Obligations. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Agreement secures, and the Collateral is collateral security for, the prompt and complete payment or performance in full when
due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise (including the payment
of amounts that would become due but for the operation of the automatic stay under Section 362(a) of the Bankruptcy Code, 11 U.S.C.
&sect;362(a) (and any successor provision thereof)), of all Obligations with respect to every Grantor, in each case, in accordance
with and subject to the terms and conditions of the Financing Agreement (the &ldquo;<B>Secured Obligations</B>&rdquo;).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing Liability Under Collateral.
</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notwithstanding anything herein to the contrary, (i) each Grantor
shall remain liable for all obligations under the Collateral and nothing contained herein is intended or shall be a delegation
of duties to the Administrative Agent or any Secured Party, (ii) each Grantor shall remain liable under each of the agreements
included in the Collateral, including, without limitation, any agreements relating to Pledged Partnership Interests or Pledged
LLC Interests, to perform all of the obligations undertaken by it thereunder all in accordance with and pursuant to the terms
and provisions thereof and neither the Administrative Agent nor any Secured Party shall have any obligation or liability under
any of such agreements by reason of or arising out of this Agreement or any other document related thereto nor shall the Administrative
Agent nor any Secured Party have any obligation to make any inquiry as to the nature or sufficiency of any payment received by
it or have any obligation to take any action to collect or enforce any rights under any agreement included in the Collateral,
including, without limitation, any agreements relating to Pledged Partnership Interests or Pledged LLC Interests, and (iii) the
exercise by the Administrative Agent of any of its rights hereunder shall not release any Grantor from any of its duties or obligations
under the contracts and agreements included in the Collateral.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
4. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS AND WARRANTIES AND COVENANTS.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
hereby represents and warrants that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it owns the Collateral purported to be owned
by it or otherwise has the rights it purports to have in each item of Collateral and, as to all Collateral whether now existing
or hereafter acquired, will continue to own or have such rights in each item of the Collateral, in each case free and clear of
any and all Liens, rights or claims of all other Persons, in each case other than Permitted Liens;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has indicated on <U>Schedule 4.1(A)</U> (as
such schedule may be amended or supplemented from time to time): (w) the type of organization of such Grantor, (x) the jurisdiction
of organization of such Grantor, (y) its organizational identification number and (z) the jurisdiction where the chief executive
office or its sole place of business is located;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, the full legal name of
such Grantor is as set forth on <U>Schedule 4.1(A)</U> and it has not done in the last five (5) years, and does not do, business
under any other name (including any trade-name or fictitious business name) except for those names set forth on <U>Schedule 4.1(B)</U>;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, except as provided on
<U>Schedule 4.1(C)</U>, it has not changed its name, jurisdiction of organization, chief executive office or sole place of business
or its corporate structure in any way (<I>e.g.</I>, by merger, consolidation, change in corporate form or otherwise) within the
past five (5) years;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has not within the last five (5) years become
bound (whether as a result of merger or otherwise) as debtor under a security agreement entered into by another Person, which
has not heretofore been terminated or which does not relate to Permitted Indebtedness;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[reserved];</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u) upon the filing of all UCC financing statements
naming each Grantor as &ldquo;debtor&rdquo; and the Administrative Agent as &ldquo;secured party&rdquo; and describing the Collateral
in the filing offices set forth opposite such Grantor&rsquo;s name on <U>Schedule 4.1(E)</U> hereof (as such schedule may be amended
or supplemented from time to time) and other filings delivered by each Grantor, (v) upon delivery of all Instruments, Chattel
Paper and certificated Pledged Equity Interests and Pledged Debt, (w) upon sufficient identification of Commercial Tort Claims,
(x) upon execution of a control agreement establishing the Administrative Agent&rsquo;s &ldquo;control&rdquo; (within the meaning of Section
8-106, 9-106 or 9-104 of the UCC, as applicable) with respect to any Investment Account, (y) upon consent of the issuer with respect
to Letter of Credit Rights, and (z) to the extent not subject to Article 9 of the UCC, upon recordation of the security interests
granted hereunder in Patents, Trademarks and Copyrights in the applicable intellectual property registries, including but not
limited to the United States Patent and Trademark Office and the United States Copyright Office, the security interests in the
Collateral granted to the Administrative Agent hereunder constitute valid and perfected first priority (subject in priority only
to the Permitted Liens that, pursuant to the definition of the term &ldquo;Permitted Liens&rdquo;, are (i) prior to the Liens in
favor of the Administrative Agent by operation of law or (ii) not prohibited from being prior to the Liens in favor of the Administrative
Agent) Liens (subject to Permitted Liens) on all of the Collateral;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantially contemporaneously with the initial
funding of the Term Loan on the Closing Date, all actions and consents, including all filings, notices, registrations and recordings
necessary or, in the reasonable discretion of the Administrative Agent, desirable for the exercise by the Administrative Agent
of the voting or other rights provided for in this Agreement or the exercise of remedies in respect of the Collateral have been
made or obtained;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other than the financing statements filed in
favor of the Administrative Agent, no effective UCC financing statement, fixture filing or other instrument similar in effect
in the United States under any applicable law covering all or any part of the Collateral is on file in any filing or recording
office in the United States except for financing statements filed in connection with Permitted Liens;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no authorization, approval or other action by,
and no notice to or filing with, any Governmental Authority or regulatory body is required for either (i) the pledge or grant
by any Grantor of the Liens purported to be created in favor of the Administrative Agent hereunder or (ii) the exercise by Administrative
Agent of any rights or remedies in respect of any Collateral (whether specifically granted or created hereunder or created or
provided for by applicable law), except (A) for the filings contemplated by clause (vii) above and (B) as may be required, in
connection with the disposition of any Investment Related Property, by laws generally affecting the offering and sale of Capital
Stock;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all information supplied by any Grantor with
respect to any of the Collateral (in each case taken as a whole with respect to any particular Collateral) is accurate and complete
in all material respects (it being understood and agreed by each party to this Agreement that any projections, budgets, estimates,
pro forma financial information, any other forward-looking statements or information of a general economic or industry nature
contained in such materials are based upon good faith estimates and assumptions believed by such Grantor to be reasonable at the
time made, it being recognized by Administrative Agent and Lenders that such projections, budgets, estimates, pro forma financial
information and forward looking statements are not to be viewed as facts and that actual results during the period or periods
covered by any such projections, budgets, estimates, pro forma financial information and forward looking statements may differ
from the projected results, and such differences may be material);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none of the Collateral constitutes, or is the
Proceeds of, &ldquo;farm products&rdquo; (as defined in the UCC);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it does not own any &ldquo;as extracted collateral&rdquo;
(as defined in the UCC) or any timber to be cut;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such Grantor has not become bound as a debtor,
either by contract or by operation of law, by a security agreement previously entered into by another Person (other than a security
agreement related to any Permitted Indebtedness); and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, such Grantor has been
duly organized as an entity of the type as set forth opposite such Grantor&rsquo;s name on <U>Schedule 4.1(A</U>) solely under the laws
of the jurisdiction as set forth opposite such Grantor&rsquo;s name on <U>Schedule 4.1(A)</U> and remains duly existing as such.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except for the security interest created by this
Agreement, it shall not create or suffer to exist any Lien upon or with respect to any of the Collateral, except Permitted Liens,
and such Grantor shall defend the Collateral against all Persons at any time claiming any interest therein;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall not produce, use or permit any Collateral
to be used unlawfully or in violation of any provision of this Agreement or in violation in any material respect of any applicable
statute, regulation or ordinance or any policy of insurance covering the Collateral;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall not change such Grantor&rsquo;s legal name,
legal identity, corporate structure (e.g., by merger, consolidation, change in corporate form or otherwise) sole place of business,
chief executive office, type of organization or jurisdiction of organization unless it shall have (a) notified the Administrative
Agent thereof in writing at least five (5) Business Days prior to (or such shorter period acceptable to Administrative Agent in
its sole discretion) any such change or establishment, identifying such new proposed name, identity, corporate structure, sole
place of business, chief executive office or jurisdiction of organization and providing such other information in connection therewith
as the Administrative Agent may reasonably request and (b) taken all actions necessary to maintain the continuous validity, perfection
and the same or better priority of the Administrative Agent&rsquo;s security interest in the Collateral intended to be granted and agreed
to hereby;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[reserved];</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to Section 5.3 of the Financing Agreement,
it shall pay promptly when due all property and other taxes, assessments and governmental charges or levies imposed upon, and
all claims (including claims for labor, materials and supplies) against, the Collateral;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall not take or (to the extent in its control)
permit any action which could materially impair the Administrative Agent&rsquo;s rights in the Collateral; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall not sell, transfer or assign (by operation
of law or otherwise) any Collateral except as otherwise in accordance with the Financing Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
represents and warrants that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Receivable (a) is and will be the legal,
valid and binding obligation of the Account Debtor in respect thereof, representing an unsatisfied obligation of such Account
Debtor and (b) is and will be enforceable in accordance with its terms and will be in compliance in all material respects with
all applicable laws, whether federal, state, local or foreign (except as may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws relating to or limiting creditors&rsquo; rights generally or by equitable principles relating to enforceability);</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none of the Account Debtors in respect of any
Receivable that constitutes Collateral is the government of the United States, any agency or instrumentality thereof, any state
or municipality or any foreign sovereign; and no Receivable requires the consent of the Account Debtor in respect thereof in connection
with the pledge hereunder, except any consent which has been obtained; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no Receivable is evidenced by, or constitutes,
an Instrument or Chattel Paper which has not been delivered to, or otherwise subjected to the control of, the Administrative Agent
to the extent required by, and in accordance with <U>Section 4.3(c)</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>: Each Grantor
hereby covenants and agrees that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall keep and maintain at its own cost and
expense reasonably satisfactory and complete records of the Receivables in all material respects, including, but not limited to,
copies of all documentation with respect to all Receivables and records of all material dealings therewith;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall mark conspicuously, in form and manner
reasonably satisfactory to the Administrative Agent, all Chattel Paper and Instruments with an appropriate reference to the fact
that the Administrative Agent has a security interest therein;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall perform in all material respects all
of its obligations with respect to the Receivables;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except as otherwise provided in this subsection,
each Grantor shall use commercially reasonable efforts to continue to collect all amounts due or to become due to such Grantor
under the Receivables and any Supporting Obligation and diligently exercise each material right it may have under any Receivable
any Supporting Obligation or Collateral Support, in each case, at its own expense, and in connection with such collections and
exercise, if an Event of Default has occurred and is continuing, such Grantor shall use commercially reasonable efforts to take
such action as such Grantor or the Administrative Agent may deem necessary. Notwithstanding the foregoing, the Administrative
Agent shall have the right at any time following the occurrence and during the continuation of an Event of Default to notify,
or require any Grantor to notify, any Account Debtor of the Administrative Agent&rsquo;s security interest in the Receivables and any
Supporting Obligation and, in addition, at any time following the occurrence and during the continuation of an Event of Default,
the Administrative Agent may: (1) direct the Account Debtors under any Receivables to make payment of all amounts due or to become
due to such Grantor thereunder directly to the Administrative Agent; (2)&nbsp;notify, or require any Grantor to notify, each Person
maintaining a lockbox or similar arrangement to which Account Debtors under any Receivables have been directed to make payment
to remit all amounts representing collections on checks and other payment items from time to time sent to or deposited in such
lockbox or other arrangement directly to the Administrative Agent; and (3) enforce, at the expense of such Grantor, collection
of any such Receivables and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the same
extent as such Grantor might have done. If the Administrative Agent notifies any Grantor that it has elected to collect the Receivables
in accordance with and subject to the preceding sentence, any payments of Receivables received by such Grantor shall be forthwith
(and in any event within two (2) Business Days) deposited by such Grantor in the exact form received, duly indorsed by such Grantor
to the Administrative Agent if required, in the Administrative Agent&rsquo;s Account, and until so turned over, all amounts and proceeds
(including checks and other instruments) received by such Grantor in respect of the Receivables, any Supporting Obligation or
Collateral Support shall be received in trust for the benefit of the Administrative Agent hereunder and shall be segregated from
other funds of such Grantor and such Grantor shall not adjust, settle or compromise the amount or payment of any Receivable, or
release wholly or partly any Account Debtor or obligor thereof, or allow any credit or discount thereon; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall use its commercially reasonable efforts
to keep in full force and effect any Supporting Obligation or Collateral Support relating to any Receivable.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delivery and Control of Receivables</U>.
</B>With respect to any Receivable that evidences an amount greater than $250,000 and that is evidenced by, or constitutes, Chattel
Paper or Instruments, each Grantor shall cause each originally executed copy thereof to be delivered to the Administrative Agent
(or its agent or designee) appropriately indorsed to the Administrative Agent or indorsed in blank: (i) with respect to any such
Receivables in existence on the date hereof, on or prior to the date hereof and (ii) with respect to any such Receivables hereafter
arising, within thirty (30) days of such Grantor acquiring rights therein. With respect to any Receivable that evidences an amount
greater than $250,000 and that would constitute &ldquo;electronic chattel paper&rdquo; under Article 9 of the UCC, each Grantor
shall take all steps necessary to give the Administrative Agent control over such Receivables (within the meaning of Section 9-105
of the UCC): (i) with respect to any such Receivables in existence on the date hereof, on or prior to the date hereof and (ii)
with respect to any such Receivables hereafter arising, within thirty&nbsp;(30) days of such Grantor acquiring rights therein.
Any Receivable not otherwise required to be delivered or subjected to the control of the Administrative Agent in accordance with
this <U>subsection (c)</U> shall be delivered or subjected to such control upon written request of the Administrative Agent at
any time following the occurrence and during the continuance of an Event of Default.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Related Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
                                         Related Property Generally</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event it acquires rights in any Investment
Related Property after the date hereof, it shall deliver to the Administrative Agent a completed Pledge Supplement, substantially
in the form of <U>Exhibit A</U> attached hereto, together with all Supplements to Schedules thereto, reflecting such new Investment
Related Property and all other Investment Related Property; notwithstanding the foregoing, it is understood and agreed that the
security interest of the Administrative Agent shall attach to all Investment Related Property immediately upon any Grantor&rsquo;s acquisition
of rights therein and shall not be affected by the failure of any Grantor to deliver a supplement to <U>Schedule 4.4</U> as required
hereby;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event such Grantor receives any dividends,
economic interest or distributions on any Investment Related Property, or any securities or other property upon the merger, consolidation,
liquidation or dissolution of any issuer of any Investment Related Property, then (a)&nbsp;such dividends, interest or distributions
and securities or other property shall be included in the definition of Collateral without further action and (b) such Grantor
shall promptly take all steps, if any, necessary to ensure the validity, perfection, priority and, if applicable, control of the
Administrative Agent over such Investment Related Property to the extent required by this Agreement (including, without limitation,
delivery thereof to the Administrative Agent) and pending any such action such Grantor shall be deemed to hold such dividends,
interest, distributions, securities or other property in trust for the benefit of the Administrative Agent and shall segregate
such dividends, distributions, Capital Stock or other property from all other property of such Grantor; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Grantor consents to the grant by each other
Grantor of a Security Interest in all Investment Related Property to the Administrative Agent.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery and Control</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Grantor agrees that with respect to any
Investment Related Property in which it currently has rights it shall comply with the provisions of this <U>Section 4.4.1(b)</U>
on or before the Closing Date and with respect to any Investment Related Property hereafter acquired by such Grantor it shall
comply with the provisions of this <U>Section 4.4.1(b)</U> immediately upon acquiring rights therein, in each case in form and
substance reasonably satisfactory to the Administrative Agent. With respect to any Investment Related Property evidencing an amount
greater than $250,000 that is represented by a certificate or that is an &ldquo;instrument&rdquo; (other than any Investment Related
Property credited to a Securities Account) it shall cause such certificate or instrument to be delivered to the Administrative
Agent, indorsed in blank by an &ldquo;effective indorsement&rdquo; (as defined in Section 8-107 of the UCC), regardless of whether
such certificate constitutes a &ldquo;certificated security&rdquo; for purposes of the UCC. With respect to any Investment Related
Property that is an &ldquo;uncertificated security&rdquo; for purposes of the UCC (other than any &ldquo;uncertificated securities&rdquo;
credited to a Securities Account or any &ldquo;uncertificated securities&rdquo; which are General Intangibles), it shall cause
the issuer of such uncertificated security to either (i) register the Administrative Agent as the registered owner thereof on
the books and records of the issuer or (ii) execute an agreement in form and substance reasonably satisfactory to the Administrative
Agent, pursuant to which such issuer agrees to comply with the Administrative Agent&rsquo;s instructions with respect to such uncertificated
security without further consent by such Grantor.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, if any issuer of any Investment Related Property is located in a jurisdiction outside of the United
States, upon the request of the Administrative Agent, each Grantor shall take such additional actions, including, without limitation,
causing the issuer to register the pledge on its books and records or making such filings or recordings, in each case as may be
necessary or advisable, under the laws of such issuer&rsquo;s jurisdiction to insure the validity, perfection and priority of the security
interest of the Administrative Agent, subject to Permitted Liens. Upon the occurrence and during the continuance of an Event of
Default, the Administrative Agent shall have the right, without notice to any Grantor, to transfer all or any portion of the Investment
Related Property to its name or the name of its nominee or agent. In addition, the Administrative Agent shall have the right at
any time following the occurrence and during the continuance of an Event of Default, without notice to any Grantor, to exchange
any certificates or instruments representing any Investment Related Property for certificates or instruments of smaller or larger
denominations.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Voting and Distributions</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So long as no Event of Default shall have occurred
and be continuing:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except
                                         as otherwise provided under the covenants and agreements relating to investment related
                                         property in this Agreement or elsewhere herein or in the Financing Agreement, each Grantor
                                         shall be entitled to exercise or refrain from exercising any and all voting and other
                                         consensual rights pertaining to the Investment Related Property or any part thereof for
                                         any purpose not inconsistent with the terms of this Agreement or the Financing Agreement;
                                         <U>provided</U>, no Grantor shall exercise or refrain from exercising any such right
                                         if the Administrative Agent shall have notified such Grantor that, in the Administrative
                                         Agent&rsquo;s reasonable discretion, such action would have a Material Adverse Effect on the
                                         value of the Investment Related Property or any part thereof; it being understood, however,
                                         that neither the voting by such Grantor of any Pledged Stock for, or such Grantor&rsquo;s consent
                                         to, the election of directors (or similar governing body) at a regularly scheduled annual
                                         or other meeting of stockholders or with respect to incidental matters at any such meeting,
                                         nor such Grantor&rsquo;s consent to or approval of any action otherwise permitted under this
                                         Agreement and the Financing Agreement, shall be deemed inconsistent with the terms of
                                         this Agreement or the Financing Agreement within the meaning of this <U>Section 4.4.1(c)(i)(1)</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the occurrence and during the continuation
of an Event of Default:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                         rights of each Grantor to exercise or refrain from exercising the voting and other consensual
                                         rights which it would otherwise be entitled to exercise pursuant hereto shall cease and
                                         all such rights shall thereupon become vested in the Administrative Agent who shall thereupon
                                         have the sole right to exercise such voting and other consensual rights; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                         order to permit the Administrative Agent to exercise the voting and other consensual
                                         rights which it may be entitled to exercise pursuant hereto and to receive all dividends
                                         and other distributions which it may be entitled to receive hereunder: (A) each Grantor
                                         shall promptly execute and deliver (or cause to be executed and delivered) to the Administrative
                                         Agent all proxies, dividend payment orders and other instruments as the Administrative
                                         Agent may from time to time reasonably request and (B) each Grantor acknowledges that
                                         the Administrative Agent may utilize the power of attorney set forth in <U>Section 6.1</U>.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledged
                                         Equity Interests</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
hereby represents and warrants, that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, <U>Schedule 4.4(A)</U>
sets forth under the headings &ldquo;Pledged Stock, &ldquo;Pledged LLC Interests,&rdquo; &ldquo;Pledged Partnership Interests&rdquo;
and &ldquo;Pledged Trust Interests,&rdquo; respectively, all of the Pledged Stock, Pledged LLC Interests, Pledged Partnership Interests
and Pledged Trust Interests owned by any Grantor and such Pledged Equity Interests constitute the percentage of issued and outstanding
shares of stock, percentage of membership interests, percentage of partnership interests or percentage of beneficial interest
of the respective issuers thereof indicated on such Schedule;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, except as set forth on
<U>Schedule 4.4(B)</U>, it has not acquired any equity interests of another entity or substantially all the assets of another
entity within the past five (5) years;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it is the record and beneficial owner of the
Pledged Equity Interests free of all Liens, rights or claims of other Persons other than Permitted Liens and, as of the date hereof,
except as set forth on Schedule 4.2 to the Financing Agreement, there are no outstanding warrants, options or other rights to
purchase, or shareholder, voting trust or similar agreements outstanding with respect to, or property that is convertible into,
or that requires the issuance or sale of, any Pledged Equity Interests;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without limiting the generality of <U>Section
4.1(a)(v)</U>, no consent of any Person including any other general or limited partner, any other member of a limited liability
company, any other shareholder or any other trust beneficiary is necessary in connection with the creation, perfection or first
priority status of the security interest of the Administrative Agent in any Pledged Equity Interests (subject to any Permitted
Liens) or the exercise by the Administrative Agent of the voting or other rights provided for in this Agreement or the exercise
of remedies in respect thereof;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none of the Pledged LLC Interests nor Pledged
Partnership Interests are or represent interests in issuers that: (a) are registered as investment companies or (b) are dealt
in or traded on securities exchanges or markets; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none of the Pledged LLC Interests and Pledged
Partnership Interests are or represent interests in issuers that have opted to be treated as securities under the uniform commercial
code of any jurisdiction.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without the prior written consent of the Administrative
Agent, it shall not vote to enable or take any other action to: (a) amend or terminate any partnership agreement, limited liability
company agreement, certificate of incorporation, by-laws or other organizational documents in any way that materially adversely
affects the validity, perfection or priority of the Administrative Agent&rsquo;s security interest in such applicable Pledged Stock,
Pledged LLC Interests, Pledged Partnership Interests and Pledged Trust Interests, (b) permit any issuer of any Pledged Equity
Interest to issue any additional stock, partnership interests, limited liability company interests or other equity interests of
any nature or to issue securities convertible into or granting the right of purchase or exchange for any stock or other equity
interest of any nature of such issuer, (c) other than as permitted under the Financing Agreement, permit any issuer of any Pledged
Equity Interest to dispose of all or a material portion of their assets, (d) waive any default under or breach of any material
terms of organizational document relating to the issuer of any Pledged Equity Interest or the material terms of any Pledged Debt,
or (e) cause any issuer of any Pledged Partnership Interests or Pledged LLC Interests which are not securities (for purposes of
the UCC) on the date hereof to elect or otherwise take any action to cause such Pledged Partnership Interests or Pledged LLC Interests
to be treated as securities for purposes of the UCC; <U>provided</U>, <U>however</U>, notwithstanding the foregoing, if any issuer
of any Pledged Partnership Interests or Pledged LLC Interests takes any such action in violation of the foregoing in this <U>clause
(b)(i)(e)</U>, such Grantor shall promptly notify the Administrative Agent in writing of any such election or action and, in such
event, shall take all steps necessary to establish the Administrative Agent&rsquo;s &ldquo;control&rdquo; thereof;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall comply in all material respects with
all of its obligations under any partnership agreement or limited liability company agreement relating to Pledged Partnership
Interests or Pledged LLC Interests and shall use commercially reasonable efforts to enforce all of its rights with respect to
any Investment Related Property;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except as permitted by the Financing Agreement,
without the prior written consent of the Administrative Agent, it shall not permit any issuer of any Pledged Equity Interest to
merge or consolidate unless (i) such issuer creates a security interest that is perfected by a filed financing statement (that
is not effective solely under section 9-508 of the UCC) in collateral in which such new debtor has or acquires rights, and (ii)
all the outstanding capital stock or other equity interests of the surviving or resulting corporation, limited liability company,
partnership or other entity is, upon such merger or consolidation, pledged hereunder in accordance with the terms hereof and no
cash, securities or other property is distributed in respect of the outstanding equity interests of any other constituent Grantor;
and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Grantor consents to the grant by each other
Grantor of a security interest in all Investment Related Property to the Administrative Agent and, without limiting the foregoing,
consents to the transfer at any time following the occurrence and continuance of an Event of Default of any Pledged Partnership
Interest and any Pledged LLC Interest to the Administrative Agent or its nominee and to the substitution of the Administrative
Agent or its nominee as a partner in any partnership or as a member in any limited liability company with all the rights and powers
related thereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledged
                                         Debt</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
hereby represents and warrants that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, <U>Schedule 4.4</U> sets
forth under the heading &ldquo;Pledged Debt&rdquo; all of the Pledged Debt owned by any Grantor and all of such Pledged Debt has
been duly authorized or issued, and delivered and is the legal, valid and binding obligation of the issuers thereof (except as
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&rsquo; rights
generally or by equitable principles relating to enforceability) and is not in default in any material respect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall notify the Administrative Agent of any
default under any Pledged Debt that has caused, either in any individual case or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
                                         Accounts</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
hereby represents and warrants that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, <U>Schedule 4.4</U> hereto
sets forth under the headings &ldquo;Securities Accounts&rdquo; and &ldquo;Commodities Accounts,&rdquo; respectively, all of the Securities
Accounts and Commodities Accounts in which each Grantor has an interest. Each Grantor is the sole entitlement holder of each such
Securities Account and Commodity Account, and such Grantor has not consented to, and is not otherwise aware of, any Person (other
than the Administrative Agent pursuant hereto) having &ldquo;control&rdquo; (within the meanings of Sections 8-106 and 9-106 of
the UCC) over, or any other interest in, any such Securities Account or Commodity Account or securities or other property credited
thereto, in each case, except for any applicable depositary bank or institution holding such Securities Account or Commodity Account
on behalf of such Grantor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of the date hereof, <U>Schedule 4.4</U> hereto
sets forth under the headings &ldquo;Deposit Accounts&rdquo; all of the Deposit Accounts owned by each Grantor. Each Grantor is
the sole account holder of each such Deposit Account and such Grantor has not consented to, and is not otherwise aware of, any
Person (other than the Administrative Agent pursuant hereto) having either sole dominion and control (within the meaning of common
law) or &ldquo;control&rdquo; (within the meanings of Section 9-104 of the UCC) over, or any other interest in, any such Deposit
Account or any money or other property deposited therein, in each case, except for any applicable depositary bank or institution
holding such Deposit Account on behalf of such Grantor; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Grantor has taken all actions necessary,
including those specified in <U>Section 4.4.4(b)</U>, to: (a) establish Administrative Agent&rsquo;s &ldquo;control&rdquo; (within the
meanings of Sections 8-106 and 9-106 of the UCC) over any portion of the Investment Related Property constituting Certificated
Securities, Securities Accounts, Securities Entitlements or Commodities Accounts (each as defined in the UCC); (b) establish the
Administrative Agent&rsquo;s &ldquo;control&rdquo; (within the meaning of Section 9-104 of the UCC) over all Deposit Accounts (other than
Excluded Accounts); and (c) deliver all Instruments evidencing obligations in an amount greater than $250,000 to the Administrative
Agent.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenant and Agreement</U>. Each Grantor hereby
covenants and agrees with the Administrative Agent and each other Secured Party that it shall not close or terminate any Investment
Account without the prior consent of the Administrative Agent and unless a successor or replacement account has been established
with the consent of the Administrative Agent with respect to which successor or replacement account a control agreement has been
entered into by the appropriate Grantor, Administrative Agent and securities intermediary or depository institution at which such
successor or replacement account is to be maintained in accordance with the provisions of <U>Section 4.4.4(c)</U>.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery and Control</U></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to any Investment Related Property
consisting of Securities Accounts or Securities Entitlements, it shall cause the securities intermediary maintaining such Securities
Account or Securities Entitlement to enter into an agreement, in form and substance reasonably satisfactory to the Administrative
Agent, pursuant to which, subject to the terms and conditions thereof, it shall agree to comply with the Administrative Agent&rsquo;s
&ldquo;entitlement orders&rdquo; without further consent by such Grantor. With respect to any Investment Related Property that is
a &ldquo;Deposit Account&rdquo; (other than any Excluded Account) it shall cause the depositary institution maintaining such account
to enter into an agreement, in form and substance reasonably satisfactory to the Administrative Agent, pursuant to which, and
subject to the terms and conditions thereof, the Administrative Agent shall have control over such Deposit Account (within the
meaning of the common law) and &ldquo;control&rdquo; (within the meaning of Section 9-104 of the UCC) over such Deposit Account.
At all times prior to the occurrence and continuance of an Event of Default, the Grantors shall have full access to the cash on
deposit in such Deposit Accounts, and the Administrative Agent agrees not to deliver a control notice or take any other action
to control such Deposit Accounts unless and until an Event of Default has occurred and is continuing. Upon the occurrence of an
Event of Default, with respect to any Deposit Account (other than an Excluded Account) subject to a Control Agreement, the Administrative
Agent may give instructions and directions to such bank or depositary institution to wire all amounts on deposit in such Deposit
Account each Business Day to the Administrative Agent&rsquo;s Account. Each Grantor shall have entered into such control agreement or
agreements with respect to: (i) any Securities Accounts, Securities Entitlements or Deposit Accounts (other than any Excluded
Accounts) that exist on the Closing Date, as of or prior to the Closing Date (except as otherwise agreed to by the Administrative
Agent in writing) and (ii) any Securities Accounts or Securities Entitlements evidencing an amount greater than $250,000 or Deposit
Accounts (other than any Excluded Accounts) that are created or acquired after the Closing Date, as of or prior to the deposit
or transfer of any such Securities Entitlements or funds, whether constituting moneys or investments, into such Securities Accounts
or such Deposit Accounts.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
hereby represents and warrants that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule 4.5</U> (as such schedule may be
amended or supplemented from time to time) sets forth all of the Material Contracts to which such Grantor has rights; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Material Contracts, true and complete copies
(including any amendments or supplements thereof) of which have been furnished to the Administrative Agent, to such Grantor&rsquo;s
knowledge, have been duly authorized, executed and delivered by all parties thereto, are in full force and effect and are binding
upon and enforceable against all parties thereto in accordance with their respective terms (except as may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&rsquo; rights generally or by equitable principles
relating to enforceability). There exists no default under any Material Contract by any party thereto giving any party thereto
the right to terminate such Material Contract and neither such Grantor, nor to its knowledge, any other Person party thereto is
likely to become in default thereunder and no Person party thereto has any defenses, counterclaims or right of set-off with respect
to any Material Contract (except as provided under such Material Contract.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in addition to any rights under the Section of
this Agreement relating to Receivables, after the occurrence and during the continuance of an Event of Default, the Administrative
Agent may at any time notify, or require any Grantor to so notify, the counterparty on any Material Contract of the security interest
of the Administrative Agent therein. In addition, after the occurrence and during the continuance of an Event of Default, the
Administrative Agent may upon written notice to the applicable Grantor, notify, or require any Grantor to notify, the counterparty
to make all payments under the Material Contracts required to be paid to such Grantor directly to the Administrative Agent;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall perform in all material respects all
of its obligations with respect to the Material Contracts;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall promptly and diligently use commercially
reasonable efforts to exercise each material right (except the right of termination) it may have under any Material Contract,
any Supporting Obligation or Collateral Support, in each case, at its own expense, and in connection with such collections and
exercise after the occurrence and during the continuance of an Event of Default, such Grantor shall take such action as such Grantor
or the Administrative Agent may deem necessary or, in the Administrative Agent&rsquo;s reasonable discretion, advisable;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall use commercially reasonable efforts
to keep in full force and effect any Supporting Obligation or Collateral Support relating to any Material Contract.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter of Credit Rights</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. Each Grantor
hereby represents and warrants that all material letters of credit to which such Grantor has rights is listed on <U>Schedule 4.6
</U>(as such schedule may be amended or supplemented from time to time) hereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that with respect to any material letter of credit hereafter arising it shall obtain the consent of
the issuer thereof to the assignment of the proceeds of the letter of credit to the Administrative Agent and shall deliver to
the Administrative Agent a completed Pledge Supplement, substantially in the form of <U>Exhibit A</U> attached hereto, together
with all Supplements to Schedules thereto.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. As of
the date hereof, except as disclosed in <U>Schedule 4.7(H)</U>, each Grantor hereby represents and warrants that:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Schedule 4.7</U> sets forth a true and complete
list of (1) all United States, state and foreign registrations of and applications for Patents, Trademarks, and Copyrights owned
by each Grantor, including but not limited to the Annovera Patents, the Bijuva Patents and the Imvexxy Patents and (2) all Patent
Licenses, Trademark Licenses, Trade Secret Licenses and Copyright Licenses to which a Grantor is a party and which are material
to the business of such Grantor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it is the sole and exclusive owner of the entire
right, title, and interest in and to all Intellectual Property listed on <U>Schedule 4.7</U>, and owns or has the valid right
to use all other Intellectual Property material to or necessary to conduct its business, free and clear of all Liens, claims,
encumbrances and licenses, in each case except for Permitted Liens and the licenses set forth on <U>Schedule 4.7(B)</U>, <U>(D)</U>,
<U>(F)</U> and <U>(G)</U>;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all Intellectual Property is subsisting and has
not been adjudged invalid or unenforceable, in whole or in part, and each Grantor has performed all acts and has paid all renewal,
maintenance, and other fees and taxes required to maintain each and every material registration and application of Copyrights,
Patents and Trademarks in full force and effect;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the best of such Grantor&rsquo;s knowledge,
all Intellectual Property is valid and enforceable; no holding, decision, or judgment has been rendered in any action or proceeding
before any court or administrative authority challenging the validity of, such Grantor&rsquo;s right to register, or such Grantor&rsquo;s
rights to own or use, any Intellectual Property and no such action or proceeding is pending or, to the best of such Grantor&rsquo;s
knowledge, threatened;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all registrations and applications for Copyrights,
Patents and Trademarks are standing in the name of each Grantor, and none of the Trademarks, Patents, Copyrights or Trade Secrets
has been licensed by any Grantor to any Affiliate or third party, except as disclosed in <U>Schedule 4.7(B)</U>, <U>(D)</U>, <U>(F)
</U>or <U>(G)</U>;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;each
Grantor has been using commercially reasonable statutory notice of registration in connection with its use of registered Trademarks,
commercially reasonable marking practices in connection with the use of Patents, and commercially reasonable notice of copyright
in connection with the publication of Copyrights material to the business of such Grantor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Grantor uses commercially reasonable standards
of quality in the manufacture, distribution, and sale of all products sold and in the provision of all services rendered under
or in connection with all Trademark Collateral and has taken all action necessary to insure that all licensees of the Trademark
Collateral owned by such Grantor use such commercially reasonable standards of quality;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the best of such Grantor&rsquo;s knowledge,
the conduct of such Grantor&rsquo;s business does not infringe upon or otherwise violate any trademark, patent, copyright, trade secret
or other intellectual property right owned or controlled by a third party; no claim has been made that the use of any Intellectual
Property owned or used by Grantor (or any of its respective licensees) violates the asserted rights of any third party;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the best of each Grantor&rsquo;s knowledge, no third
party is infringing upon or otherwise violating any rights in any Intellectual Property owned or used by such Grantor, or any
of its respective licensees;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Grantor has taken reasonable steps to maintain
the confidentiality of and otherwise protect and enforce its rights in all trade secrets owned by such Grantor that are necessary
in the business of such Grantor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no settlement or consents, covenants not to sue,
nonassertion assurances, or releases have been entered into by Grantor or to which Grantor is bound that adversely affect Grantor&rsquo;s
rights to own or use any Intellectual Property set forth in Schedule 4.7;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Grantor has not made a previous assignment,
sale, transfer or agreement constituting a present or future assignment, sale, transfer or agreement of any Intellectual Property
set forth in Schedule 4.7 that has not been terminated or released. There is no effective financing statement on file or recorded
in any public office in the United States, granting a security interest in or otherwise encumbering any part of the Intellectual
Property, other than in favor of the Administrative Agent.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall not do any act or omit to do any act
whereby any of the Intellectual Property which is material to the business of Grantor may lapse, or become abandoned, dedicated
to the public, or unenforceable, or which would adversely affect the validity, grant, or enforceability of the security interest
granted therein;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall not, with respect to any Trademarks
which are material to the business of any Grantor, cease the use of any of such Trademarks or fail to maintain the level of the
quality of products sold and services rendered under any of such Trademark at a level at least substantially consistent with the
quality of such products and services as of the date hereof, and each Grantor shall take all steps necessary to insure that licensees
of such Trademarks use such consistent standards of quality;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall, within thirty (30) days of the creation
or acquisition of any Copyrightable work which is material to the business of Grantor, apply to register the Copyright in the
United States Copyright Office;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall promptly notify the Administrative Agent
if it knows or has reason to know that all or part of any Annovera Patent, Bijuva Patent, Imvexxy Patent, or any item of the Intellectual
Property that is material to the business of any Grantor may become (a) abandoned or dedicated to the public or placed in the
public domain, except at the end of the natural term of any of the aforementioned patents, (b) invalid or unenforceable, or (c)
subject to any adverse determination or development (including the institution of proceedings) in any action or proceeding in
the United States Patent and Trademark Office, the United States Copyright Office, any state registry, any foreign counterpart
of the foregoing, or any court;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall take all reasonable steps in the United
States Patent and Trademark Office, the United States Copyright Office, any state registry or any foreign counterpart of the foregoing,
to pursue any application and maintain any registration of each Trademark, Patent, and Copyright that is owned by any Grantor
and material to its business which is now or shall become included in the Intellectual Property including, but not limited to,
those items on <U>Schedule 4.7(A)</U>, <U>(C)</U> and <U>(E)</U>;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event that any material Intellectual Property
owned by or exclusively licensed to any Grantor is infringed, misappropriated, or diluted by a third party, such Grantor shall
promptly take all reasonable actions to stop such infringement, misappropriation, or dilution and protect its rights in such Intellectual
Property including, but not limited to, the initiation of a suit for injunctive relief and to recover damages;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall promptly (but in no event more than
forty-five (45) days after any Grantor obtains knowledge thereof) report to the Administrative Agent (i) the filing of any application
to register any material Intellectual Property with the United States Patent and Trademark Office or the United States Copyright
Office (whether such application is filed by such Grantor or through any agent, employee, licensee, or designee thereof) and (ii)
the registration of any such material Intellectual Property by any such office, in each case by executing and delivering to the
Administrative Agent a completed Pledge Supplement, substantially in the form of <U>Exhibit A</U> attached hereto, together with
all Supplements to Schedules thereto;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall, promptly upon the reasonable request
of the Administrative Agent, execute and deliver to the Administrative Agent any document required to acknowledge, confirm, register,
record, or perfect, in each case, to the extent required by this Agreement, the Administrative Agent&rsquo;s interest in any part of
the Intellectual Property, whether now owned or hereafter acquired;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except with the prior consent of the Administrative
Agent or as permitted under the Financing Agreement, each Grantor shall not execute, and there will not be on file in any public
office in the United States, any financing statement or other document or instruments, except financing statements or other documents
or instruments filed or to be filed in favor of the Administrative Agent and each Grantor shall not sell, assign, transfer, license,
grant any option, or create or suffer to exist any Lien upon or with respect to the Intellectual Property, except for Permitted
Liens and the Lien created by and under this Agreement and the other Loan Documents;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall hereafter use commercially reasonable
efforts so as not to permit the inclusion in any contract to which it hereafter becomes a party of any provision that could or
might in any way materially impair or prevent the creation of a security interest in, or the assignment of, such Grantor&rsquo;s rights
and interests in any property included within the definitions of any Intellectual Property acquired under such contracts;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall take reasonable steps to maintain the
confidentiality of, and otherwise protect and enforce its rights in, the Intellectual Property that is necessary in the conduct
of such Grantor&rsquo;s business, including, as applicable (A) protecting the secrecy and confidentiality of its confidential information
and Trade Secrets by having and enforcing a policy requiring all current employees, consultants, licensees, vendors and contractors
with access to such information to execute appropriate confidentiality agreements and (B) taking actions reasonably necessary
to ensure that no Trade Secret falls into the public domain;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall use proper statutory notice in connection
with its use of any of the Intellectual Property; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it shall continue to collect, at its own expense,
all amounts due or to become due to such Grantor in respect of the Intellectual Property or any portion thereof. In connection
with such collections, each Grantor may take (and, at the Administrative Agent&rsquo;s reasonable direction, shall take) such action
as such Grantor or the Administrative Agent may deem reasonably necessary to enforce collection of such amounts. Notwithstanding
the foregoing, the Administrative Agent shall have the right at any time following the occurrence and during the continuance of
an Event of Default, to notify, or require any Grantor to notify, any obligors with respect to any such amounts of the existence
of the security interest created hereby.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.8<FONT STYLE="font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial Tort Claims</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties</U>. As of
the date hereof, each Grantor hereby represents and warrants that <U>Schedule 4.8</U> sets forth all Commercial Tort Claims of
each Grantor in a stated amount greater than $250,000; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants and Agreements</U>. Each Grantor
hereby covenants and agrees that with respect to any Commercial Tort Claim in a stated amount greater than $250,000 hereafter
arising it shall deliver to the Administrative Agent a completed Pledge Supplement, substantially in the form of <U>Exhibit A
</U>attached hereto, together with all Supplements to Schedules thereto, identifying such new Commercial Tort Claims.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 40pt; text-indent: -40pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
5. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCESS; RIGHT OF INSPECTION AND FURTHER ASSURANCES;
ADDITIONAL GRANTORS.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved].</FONT></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Assurances</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Grantor agrees that from time to time, at
the expense of such Grantor, that it shall promptly execute and deliver all further instruments and documents, and take all further
action, that may be necessary, or that the Administrative Agent may reasonably request, in order to create and/or maintain the
validity, perfection or priority of and protect any security interest granted hereby or to enable the Administrative Agent to
exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the
foregoing, each Grantor shall:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">file such financing or continuation statements,
or amendments thereto, and execute and deliver such other agreements, instruments, endorsements, powers of attorney or notices,
as may be necessary or desirable, or as the Administrative Agent may reasonably request, in order to perfect and preserve the
security interests granted or purported to be granted hereby;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to <U>Section 5.2(c)</U>, take all actions
necessary to ensure the recordation of appropriate evidence of the Liens and security interest granted hereunder in the Intellectual
Property with any intellectual property registry in which said Intellectual Property is registered or in which an application
for registration is pending including, without limitation, the United States Patent and Trademark Office, the United States Copyright
Office, the various Secretaries of State, and the foreign counterparts on any of the foregoing; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the Administrative Agent&rsquo;s reasonable written
request, appear in and defend any action or proceeding that may affect such Grantor&rsquo;s title to or the Administrative Agent&rsquo;s security
interest in all or any part of the Collateral.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to <U>Section 5.2(c)</U>, Each Grantor
hereby authorizes the Administrative Agent to file a Record or Records, including, without limitation, financing or continuation
statements, and amendments thereto, in any jurisdictions and with any filing offices as are necessary or, in the Administrative
Agent&rsquo;s reasonable discretion, advisable to perfect the security interest granted to the Administrative Agent herein. Such
financing statements may describe the Collateral in the same manner as described herein or may contain an indication or description
of collateral that describes such property in any other manner as the Administrative Agent may determine, in its sole discretion,
is necessary, advisable or prudent to ensure the perfection of the security interest in the Collateral granted to the Administrative
Agent herein, including, without limitation, describing such property as &ldquo;all assets&rdquo; or &ldquo;all personal property,
whether now owned or hereafter acquired.&rdquo; Each Grantor shall furnish to the Administrative Agent from time to time statements
and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral as the
Administrative Agent may reasonably request in writing, all in reasonable detail.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything to the contrary in this
Agreement or in any other Loan Document, unless requested by the Administrative Agent in its reasonable discretion, none of the
Grantors or any of their Subsidiaries shall be required, nor shall the Administrative Agent or any Lender be authorized, to take
any action with respect to any assets or property of any Grantor located outside of the United States.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Grantors</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
From time to time subsequent to the date hereof, additional Persons may become parties hereto as additional Grantors (each, an
&ldquo;<B>Additional Grantor</B>&rdquo;), by executing a Counterpart Agreement. Upon delivery of any such counterpart agreement
to the Administrative Agent, notice of which is hereby waived by Grantors, each Additional Grantor shall be a Grantor and shall
be as fully a party hereto as if Additional Grantor were an original signatory hereto. Each Grantor expressly agrees that its
obligations arising hereunder shall not be affected or diminished by the addition or release of any other Grantor hereunder, nor
by any election of Administrative Agent not to cause any Subsidiary of Borrower to become an Additional Grantor hereunder. This
Agreement shall be fully effective as to any Grantor that is or becomes a party hereto regardless of whether any other Person
becomes or fails to become or ceases to be a Grantor hereunder. For the avoidance of doubt, unless requested by the Administrative
Agent in its sole discretion, no Foreign Subsidiary of Borrower shall be a Grantor or otherwise be required to pledge its assets.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
6. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMINISTRATIVE AGENT APPOINTED ATTORNEY-IN-FACT.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
Grantor hereby irrevocably appoints the Administrative Agent (such appointment being coupled with an interest) as such Grantor&rsquo;s
attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor, the Administrative
Agent or otherwise, from time to time in the Administrative Agent&rsquo;s discretion to take any action and to execute any instrument
that the Administrative Agent may deem reasonably necessary to accomplish the purposes of this Agreement, including, without limitation,
the following:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon the occurrence and during the continuance
of any Event of Default, to obtain and adjust insurance required to be maintained by such Grantor or paid to the Administrative
Agent pursuant to the Financing Agreement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon the occurrence and during the continuance
of any Event of Default, to ask for, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for
moneys due and to become due under or in respect of any of the Collateral;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon the occurrence and during the continuance
of any Event of Default, to receive, endorse and collect any drafts or other instruments, documents and chattel paper in connection
with clause (b) above;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon the occurrence and during the continuance
of any Event of Default, to file any claims or take any action or institute any proceedings that the Administrative Agent may
deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Administrative
Agent with respect to any of the Collateral;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to prepare and file any UCC financing statements
against such Grantor as debtor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to prepare, sign, and file for recordation in
any intellectual property registry, appropriate evidence of the lien and security interest granted herein in the Intellectual
Property in the name of such Grantor as debtor;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to take or cause to be taken all actions necessary
to perform or comply or cause performance or compliance with the terms of this Agreement, including, without limitation, access
to pay or discharge taxes or Liens (other than Permitted Liens) levied or placed upon or threatened against the Collateral, the
legality or validity thereof and the amounts necessary to discharge the same to be determined by the Administrative Agent in its
reasonable discretion, any such payments made by the Administrative Agent to become obligations of such Grantor to the Administrative
Agent, due and payable immediately without demand; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon the occurrence and during the continuance
of any Event of Default, generally to sell, transfer, pledge, make any agreement with respect to or otherwise deal with any of
the Collateral as fully and completely as though the Administrative Agent were the absolute owner thereof for all purposes, and
to do, at the Administrative Agent&rsquo;s option and such Grantor&rsquo;s expense, at any time or from time to time, all acts and things
that the Administrative Agent deems reasonably necessary to protect, preserve or realize upon the Collateral and the Administrative
Agent&rsquo;s security interest therein in order to effect the intent of this Agreement, all as fully and effectively as such Grantor
might do.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Duty on the Part of Administrative
Agent or Secured Parties. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The powers conferred on the Administrative
Agent hereunder are solely to protect the interests of the Secured Parties in the Collateral and shall not impose any duty upon
the Administrative Agent or any Secured Party to exercise any such powers. The Administrative Agent and the Secured Parties shall
be accountable only for amounts that they actually receive as a result of the exercise of such powers, and neither they nor any
of their officers, directors, employees or agents shall be responsible to any Grantor for any act or failure to act hereunder,
except for their own (or any of their respective Affiliate&rsquo;s) gross negligence or willful misconduct.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
7. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REMEDIES.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
If any Event of Default shall have occurred and be continuing the Administrative Agent shall have the following rights and remedies:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Administrative Agent may exercise in respect
of the Collateral, in addition to all other rights and remedies provided for herein or otherwise available to it at law or in
equity, all the rights and remedies of the Administrative Agent on default under the UCC (whether or not the UCC applies to the
affected Collateral) to collect, enforce or satisfy any Secured Obligations then owing, whether by acceleration or otherwise,
and also may pursue any of the following separately, successively or simultaneously:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require any Grantor to, and each Grantor hereby
agrees that it shall at its expense and promptly upon request of the Administrative Agent forthwith, assemble all or part of the
Collateral as directed by the Administrative Agent and make it available to the Administrative Agent at a place to be designated
by the Administrative Agent that is reasonably convenient to both parties;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter onto the property where any Collateral
is located and take possession thereof with or without judicial process;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior to the disposition of the Collateral, store,
process, repair or recondition the Collateral or otherwise prepare the Collateral for disposition in any manner to the extent
the Administrative Agent deems appropriate; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without notice except as specified below or under
the UCC, sell, assign, lease, license (on an exclusive or nonexclusive basis) or otherwise dispose of the Collateral or any part
thereof in one or more parcels at public or private sale, at any of the Administrative Agent&rsquo;s offices or elsewhere, for cash,
on credit or for future delivery, at such time or times and at such price or prices and upon such other terms as the Administrative
Agent may deem commercially reasonable.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Administrative Agent or any Secured Party
may be the purchaser of any or all of the Collateral at any public or private (to the extent to the portion of the Collateral
being privately sold is of a kind that is customarily sold on a recognized market or the subject of widely distributed standard
price quotations) sale in accordance with the UCC and the Administrative Agent, as Administrative Agent for and representative
of the Secured Parties, shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for
all or any portion of the Collateral sold at any such sale made in accordance with the UCC, to use and apply any of the Secured
Obligations as a credit on account of the purchase price for any Collateral payable by the Administrative Agent at such sale.
Each purchaser at any such sale shall hold the property sold absolutely free from any claim or right on the part of any Grantor,
and each Grantor hereby waives (to the extent permitted by applicable law) all rights of redemption, stay and/or appraisal which
it now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted. Each Grantor
agrees that, to the extent notice of sale shall be required by law, at least ten (10) days&rsquo; notice to such Grantor of the time
and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification.
The Administrative Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been given.
The Administrative Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed
therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor
agrees that it would not be commercially unreasonable for the Administrative Agent to dispose of the Collateral or any portion
thereof by using Internet sites that provide for the auction of assets of the types included in the Collateral or that have the
reasonable capability of doing so, or that match buyers and sellers of assets. Each Grantor hereby waives any claims against the
Administrative Agent arising by reason of the fact that the price at which any Collateral may have been sold at such a private
sale was less than the price which might have been obtained at a public sale, even if the Administrative Agent accepts the first
offer received and does not offer such Collateral to more than one offeree. If the proceeds of any sale or other disposition of
the Collateral are insufficient to pay all the Secured Obligations, Grantors shall be liable for the deficiency and the fees of
any attorneys employed by the Administrative Agent to collect such deficiency. Each Grantor further agrees that a breach of any
of the covenants contained in this Section will cause irreparable injury to the Administrative Agent, that the Administrative
Agent has no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained in
this Section shall be specifically enforceable against such Grantor, and such Grantor hereby waives and agrees not to assert any
defenses against an action for specific performance of such covenants except for a defense that no default has occurred giving
rise to the Secured Obligations becoming due and payable prior to their stated maturities. Nothing in this Section shall in any
way alter the rights of the Administrative Agent hereunder.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Administrative Agent may sell the Collateral
without giving any warranties as to the Collateral. The Administrative Agent may specifically disclaim or modify any warranties
of title or the like. This procedure will not be considered to adversely affect the commercial reasonableness of any sale of the
Collateral.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Administrative Agent shall have no obligation
to marshal any of the Collateral.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Administrative Agent may: (1)&nbsp;direct
the Account Debtors under any Receivables to make payment of all amounts due or to become due to such Grantor thereunder directly
to the Administrative Agent; (2)&nbsp;notify, or require any Grantor to notify, each Person maintaining a lockbox or similar arrangement
to which Account Debtors under any Receivables have been directed to make payment to remit all amounts representing collections
on checks and other payment items from time to time sent to or deposited in such lockbox or other arrangement directly to the
Administrative Agent; and (3)&nbsp;enforce, at the expense of such Grantor, collection of any such Receivables and to adjust,
settle or compromise the amount or payment thereof, in the same manner and to the same extent as such Grantor might have done.
If the Administrative Agent notifies any Grantor that it has elected to collect the Receivables in accordance with the preceding
sentence, any payments of Receivables received by such Grantor shall be forthwith (and in any event within two (2) Business Days)
deposited by such Grantor in the exact form received, duly indorsed by such Grantor to the Administrative Agent if required, in
the Administrative Agent&rsquo;s Account maintained under the sole dominion and control of the Administrative Agent, and until so turned
over, all amounts and proceeds (including checks and other instruments) received by such Grantor in respect of the Receivables,
any Supporting Obligation or Collateral Support shall be received in trust for the benefit of the Administrative Agent hereunder
and shall be segregated from other funds of such Grantor and such Grantor shall not adjust, settle or compromise the amount or
payment of any Receivable, or release wholly or partly any Account Debtor or obligor thereof, or allow any credit or discount
thereon</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Administrative Agent may exercise control
over any Investment Accounts, whether or not such Investment Accounts are created before or after the Closing Date. The Administrative
Agent shall have the right, without notice to any Grantor, to transfer all or any portion of the Investment Related Property to
its name or the name of its nominee or agent. In addition, the Administrative Agent shall have the right at any time, without
notice to any Grantor, to exchange any certificates or instruments representing any Investment Related Property for certificates
or instruments of smaller or larger denominations.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to any Deposit Account (other than
an Excluded Account), the Administrative Agent may give instructions and directions to such bank or depositary institution to
wire all amounts on deposit in such Deposit Account each Business Day to the Administrative Agent&rsquo;s Account. All amounts received
or deposited into the Administrative Agent&rsquo;s Account after the occurrence of an Event of Default shall be applied to the payment
of the outstanding Obligations in accordance with the Financing Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Application of Proceeds. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Except
as expressly provided elsewhere in this Agreement, all proceeds received by the Administrative Agent in respect of any sale, any
collection from, or other realization upon all or any part of the Collateral shall be applied in full or in part by the Administrative
Agent against the Secured Obligations as set forth in Section 2.11(a) of the Financing Agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales on Credit. </FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
Administrative Agent sells any of the Collateral upon credit, Grantor will be credited only with payments actually made by purchaser
and received by Administrative Agent and applied to indebtedness of the purchaser. In the event the purchaser fails to pay for
the Collateral, Administrative Agent may resell the Collateral and Grantor shall be credited with proceeds of the sale.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposit Accounts</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any Event of Default shall have occurred and be continuing, the Administrative Agent may apply the balance from any Deposit Account
or instruct the bank at which any Deposit Account is maintained to pay the balance of any Deposit Account to or for the benefit
of the Administrative Agent.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Related Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Grantor recognizes that, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws,
the Administrative Agent may be compelled, with respect to any sale of all or any part of the Investment Related Property conducted
without prior registration or qualification of such Investment Related Property under the Securities Act and/or such state securities
laws, to limit purchasers to those who will agree, among other things, to acquire the Investment Related Property for their own
account, for investment and not with a view to the distribution or resale thereof. Each Grantor acknowledges that any such private
sale may be at prices and on terms less favorable than those obtainable through a public sale without such restrictions (including
a public offering made pursuant to a registration statement under the Securities Act) and, notwithstanding such circumstances,
each Grantor agrees that any such private sale shall be deemed to have been made in a commercially reasonable manner and that
the Administrative Agent shall have no obligation to engage in public sales and no obligation to delay the sale of any Investment
Related Property for the period of time necessary to permit the issuer thereof to register it for a form of public sale requiring
registration under the Securities Act or under applicable state securities laws, even if such issuer would, or should, agree to
so register it. If the Administrative Agent determines to exercise its right to sell any or all of the Investment Related Property,
upon written request, each Grantor shall and shall cause each issuer of any Pledged Stock to be sold hereunder, each partnership
and each limited liability company from time to time to furnish to the Administrative Agent all such information as the Administrative
Agent may request in order to determine the number and nature of interest, shares or other instruments included in the Investment
Related Property which may be sold by the Administrative Agent in exempt transactions under the Securities Act and the rules and
regulations of the Capital Stock and Exchange Commission thereunder, as the same are from time to time in effect.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anything contained herein to the contrary notwithstanding,
upon the occurrence and during the continuation of an Event of Default:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Administrative Agent shall have the right
(but not the obligation) to bring suit or otherwise commence any action or proceeding in the name of any Grantor, the Administrative
Agent or otherwise, in the Administrative Agent&rsquo;s sole discretion, to enforce any Intellectual Property, in which event such Grantor
shall, at the request of the Administrative Agent, do any and all lawful acts and execute any and all documents required by the
Administrative Agent in aid of such enforcement and such Grantor shall promptly, upon demand, reimburse and indemnify the Administrative
Agent as provided in <U>Section 10</U> hereof in connection with the exercise of its rights under this Section, and, to the extent
that the Administrative Agent shall elect not to bring suit to enforce any Intellectual Property as provided in this Section,
each Grantor agrees to use all reasonable measures, whether by action, suit, proceeding or otherwise, to prevent the infringement
or other violation of any of such Grantor&rsquo;s rights in the Intellectual Property by others and for that purpose agrees to diligently
maintain any action, suit or proceeding against any Person so infringing as shall be necessary to prevent such infringement or
violation;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon written demand from the Administrative Agent,
each Grantor shall grant, assign, convey or otherwise transfer to the Administrative Agent or such Administrative Agent&rsquo;s designee
all of such Grantor&rsquo;s right, title and interest in and to the Intellectual Property and shall execute and deliver to the Administrative
Agent such documents as are necessary or appropriate to carry out the intent and purposes of this Agreement;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each Grantor agrees that such an assignment and/or
recording shall be applied to reduce the Secured Obligations outstanding only to the extent that the Administrative Agent (or
any Secured Party) receives cash proceeds in respect of the sale of, or other realization upon, the Intellectual Property;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">within five (5) Business Days after written notice
from the Administrative Agent, each Grantor shall make reasonable efforts to make available to the Administrative Agent, to the
extent within such Grantor&rsquo;s power and authority, such personnel in such Grantor&rsquo;s employ on the date of such Event of Default
as the Administrative Agent may reasonably designate, by name, title or job responsibility, to permit such Grantor to continue,
directly or indirectly, to produce, advertise and sell the products and services sold or delivered by such Grantor under or in
connection with the Trademarks, Trademark Licenses, such persons to be available to perform their prior functions on the Administrative
Agent&rsquo;s behalf and to be compensated by the Administrative Agent at such Grantor&rsquo;s expense on a per diem, pro-rata basis consistent
with the salary and benefit structure applicable to each as of the date of such Event of Default; and</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Administrative Agent shall have the right
to notify, or require each Grantor to notify, any obligors with respect to amounts due or to become due to such Grantor in respect
of the Intellectual Property, of the existence of the security interest created herein, to direct such obligors to make payment
of all such amounts directly to the Administrative Agent, and, upon such notification and at the expense of such Grantor, to enforce
collection of any such amounts and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the
same extent as such Grantor might have done;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                         amounts and proceeds (including checks and other instruments) received by Grantor in
                                         respect of amounts due to such Grantor in respect of the Collateral or any portion thereof
                                         shall be received in trust for the benefit of the Administrative Agent hereunder, shall
                                         be segregated from other funds of such Grantor and shall be forthwith paid over or delivered
                                         to the Administrative Agent in the same form as so received (with any necessary endorsement)
                                         to be held as cash Collateral and applied as provided by <U>Section 7.7</U> hereof; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grantor
                                         shall not adjust, settle or compromise the amount or payment of any such amount or release
                                         wholly or partly any obligor with respect thereto or allow any credit or discount thereon.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If (i) an Event of Default shall have occurred
and, by reason of cure, waiver, modification, amendment or otherwise, no longer be continuing, (ii) no other Event of Default
shall have occurred and be continuing, (iii) an assignment or other transfer to the Administrative Agent of any rights, title
and interests in and to the Intellectual Property shall have been previously made and shall have become absolute and effective,
and (iv) the Secured Obligations shall not have become immediately due and payable, upon the written request of any Grantor, the
Administrative Agent shall promptly execute and deliver to such Grantor, at such Grantor&rsquo;s sole cost and expense, such assignments
or other transfer as may be necessary to reassign to such Grantor any such rights, title and interests as may have been assigned
to the Administrative Agent as aforesaid, subject to any disposition thereof that may have been made by the Administrative Agent;
<U>provided</U> that after giving effect to such reassignment, the Administrative Agent&rsquo;s security interest granted pursuant hereto,
as well as all other rights and remedies of the Administrative Agent granted hereunder, shall continue to be in full force and
effect; and <U>provided further</U>, the rights, title and interests so reassigned shall be free and clear of any other Liens
granted by or on behalf of the Administrative Agent and the Secured Parties.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely for the purpose of enabling the Administrative
Agent to exercise rights and remedies under this <U>Section 7</U> and at such time as the Administrative Agent shall be lawfully
entitled to exercise such rights and remedies, each Grantor hereby grants to the Administrative Agent, to the extent it has the
right to do so, an irrevocable, nonexclusive license (exercisable without payment of royalty or other compensation to such Grantor),
subject, in the case of Trademarks, to sufficient rights to quality control and inspection in favor of such Grantor to avoid the
risk of invalidation of said Trademarks, to use, operate under, license, or sublicense any Intellectual Property now owned or
hereafter acquired by such Grantor, and wherever the same may be located.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Proceeds</FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
In addition to the rights of the Administrative Agent specified in <U>Section 4.3</U> with respect to payments of Receivables,
upon the occurrence and during the continuance of any Event of Default, all proceeds of any Collateral received by any Grantor
consisting of cash, checks and other non-cash items (&ldquo;<B>Cash Proceeds</B>&rdquo;) shall be held by such Grantor in trust
for the Administrative Agent, segregated from other funds of such Grantor, and shall, forthwith upon receipt by such Grantor (and,
in any event, within two&nbsp;(2) Business Days of receipt thereof), be turned over to the Administrative Agent in the exact form
received by such Grantor (duly indorsed by such Grantor to the Administrative Agent, if required) and deposited into the Administrative
Agent&rsquo;s Account; and any such Cash Proceeds received by the Administrative Agent (whether from a Grantor or otherwise) shall be
applied by the Administrative Agent against the Secured Obligations in accordance with Section 2.11(a) of the Financing Agreement.
Subject to <U>Section 4.3</U>, any Cash Proceeds received by the Administrative Agent (whether from a Grantor or otherwise): (i)
at any time that no Event of Default shall have occurred and be continuing, shall be returned to the Grantor and (ii)&nbsp;if
an Event of Default shall have occurred and be continuing, may, in the sole discretion of the Administrative Agent, (A) be held
by the Administrative Agent for the ratable benefit of the Secured Parties, as collateral security for the Secured Obligations
(whether matured or unmatured) and/or (B) then or at any time thereafter may be applied by the Administrative Agent against the
Secured Obligations then due and owing.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
8. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED].</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
9. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTINUING SECURITY INTEREST; TRANSFER OF
TERM LOANS.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall create a continuing security interest in the Collateral and shall remain in full force and effect until the payment
in full of all Secured Obligations (other than any such contingent obligations or liabilities hereunder or under the Financing
Agreement that by the express terms thereof survive such payment in full of all Secured Obligations) and be binding upon each
Grantor, its successors and assigns, and inure, together with the rights and remedies of the Administrative Agent hereunder, to
the benefit of the Administrative Agent and its successors, permitted transferees and permitted assigns. Without limiting the
generality of the foregoing, but subject to the terms and conditions of the Financing Agreement, any Lender may assign or otherwise
transfer the Term Loan held by it to any other Person, and such other Person shall thereupon become vested with all the benefits
in respect thereof granted to Lenders herein or otherwise. Upon the payment in full of all Secured Obligations (other than any
such contingent obligations or liabilities hereunder or under the Financing Agreement that by the express terms thereof survive
such payment in full of all Secured Obligations), the security interest granted hereby shall automatically terminate hereunder
and of record and all rights to the Collateral shall revert to Grantors. Upon any such termination the Administrative Agent shall,
at Grantors&rsquo; expense, execute and deliver to Grantors or otherwise authorize the filing of such documents, agreements and instruments
as Grantors shall reasonably request, including financing statement amendments to evidence such termination. Upon any disposition
of property permitted by the Financing Agreement, the Liens granted herein shall be deemed to be automatically released and such
property shall automatically revert to the applicable Grantor (or such other applicable Person) with no further action on the
part of any Person. The Administrative Agent shall, at Grantor&rsquo;s expense, execute and deliver or otherwise authorize the filing
of such documents, agreements and instruments as Grantors shall reasonably request, in form and substance reasonably satisfactory
to the Administrative Agent, including financing statement amendments to evidence such release.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
10. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STANDARD OF CARE.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
powers conferred on the Administrative Agent hereunder are solely to protect its interest in the Collateral and shall not impose
any duty upon it to exercise any such powers. Except for the exercise of reasonable care in the custody of any Collateral in its
possession and the accounting for moneys actually received by it hereunder, the Administrative Agent shall have no duty as to
any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining
to any Collateral. The Administrative Agent shall be deemed to have exercised reasonable care in the custody and preservation
of Collateral in its possession if such Collateral is accorded treatment substantially equal to that which the Administrative
Agent accords its own property. Neither the Administrative Agent nor any of its directors, officers, employees or agents shall
be liable for failure to demand, collect or realize upon all or any part of the Collateral or for any delay in doing so or shall
be under any obligation to sell or otherwise dispose of any Collateral upon the request of any Grantor or otherwise.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">Section
11. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS.</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice required or permitted to be given under this Agreement shall be given in accordance with Section 10.1 of the Financing
Agreement. No failure or delay on the part of the Administrative Agent in the exercise of any power, right or privilege hereunder
or under any other Loan Document shall impair such power, right or privilege or be construed to be a waiver of any default or
acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other power, right or privilege. All rights and remedies existing under this Agreement and the other
Loan Documents are cumulative to, and not exclusive of, any rights or remedies otherwise available. In case any provision in or
obligation under this Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability
of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way
be affected or impaired thereby. All covenants hereunder shall be given independent effect so that if a particular action or condition
is not permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within
the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken
or condition exists. This Agreement shall be binding upon and inure to the benefit of the Administrative Agent and Grantors and
their respective successors and permitted assigns. No Grantor shall, without the prior written consent of the Administrative Agent
given in accordance with the Financing Agreement, assign any right, duty or obligation hereunder. This Agreement and the other
Loan Documents embody the entire agreement and understanding between Grantors and the Administrative Agent and supersede all prior
agreements and understandings between such parties relating to the subject matter hereof and thereof. Accordingly, the Loan Documents
may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties. There are no unwritten
oral agreements between the parties. This Agreement may be executed in one or more counterparts and by different parties hereto
in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts
together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts
and attached to a single counterpart so that all signature pages are physically attached to the same document. Delivery of an
executed counterpart of this Agreement by facsimile or electronic mail shall be equally effective as delivery of an original executed
counterpart.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTIONS
10.5 (AMENDMENTS AND WAIVERS), 10.14 (APPLICABLE LAW), 10.15 (CONSENT TO JURISDICTION) and 10.16 (WAIVER OF JURY TRIAL) OF THE
FINANCING AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE, <I>MUTATIS MUTANDIS</I>. </B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, each Grantor and the Administrative Agent have caused this Agreement to be duly executed and delivered by their
respective officers thereunto duly authorized as of the date first written above.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTRORS:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THERAPEUTICSMD, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daniel
    Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer and
    Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VITAMEDMD, LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daniel
    Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer and
    Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCAGREENMD, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daniel
    Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer and
    Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VITACARE PRESCRIPTION SERVICES,
    INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daniel
    Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Daniel Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer and
    Assistant Treasurer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page to Pledge and Security Agreement]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>





<!-- Field: Page; Sequence: 38; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TPG SPECIALTY LENDING, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as the Administrative Agent</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joshua
    Easterly</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua Easterly</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[Signature
Page to Pledge and Security Agreement]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE 4.1<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>GENERAL INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">Full Legal Name, Type of Organization, Jurisdiction of Organization, Chief Executive Office/Sole
Place of Business and Organizational Identification Number of each Grantor:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid">Full
Legal<BR>
Name</P></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid">Type
of<BR>
Organization</P></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid">Jurisdiction
of<BR>
Organization</P></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid">Chief
Executive<BR>
Office/Sole Place of Business</P></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1pt solid">Organization
I.D.#</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">TherapeuticsMD, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Corporation</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">6800 Broken Sound Parkway NW, Suite 300, Boca Raton, Palm Beach County, FL 33487</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">20101548400</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">VitaMedMD LLC</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Limited Liability Company</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">See above.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">4546519</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">BocaGreenMD, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Corporation</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">See above.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">NV20121021440</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">VitaCare Prescription Services, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Corporation</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Florida</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">See above.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">P15000042489</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: left">Other Names (including any Trade-Name or Fictitious Business Name) under which each Grantor has conducted
business for the past five (5) years:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; text-align: left; padding-left: 1in"><FONT STYLE="font-size: 10pt"><U>Full Legal Name</U></FONT></TD>
    <TD STYLE="width: 62%; text-align: left"><FONT STYLE="font-size: 10pt"><U>Trade Name or Fictitious Business Name</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-left: 1in"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: left">Changes in Name, Jurisdiction of Organization, Chief Executive Office or Sole Place of Business and
Corporate Structure within past five (5) years:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 37%; text-align: left; padding-left: 0.55in"><FONT STYLE="font-size: 10pt"><U>Name of Grantor</U></FONT></TD>
    <TD STYLE="width: 31%; text-align: left"><FONT STYLE="font-size: 10pt"><U>Date of Change</U></FONT></TD>
    <TD STYLE="width: 32%; text-align: left"><FONT STYLE="font-size: 10pt"><U>Description of Change</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-left: 0.55in"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: left">[Reserved]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: left">Financing Statements:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; border: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><U>Name of Grantor</U></FONT></TD>
    <TD STYLE="width: 62%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><U>Filing Jurisdiction(s)</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">TherapeuticsMD, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Nevada, UCC #2018015124-8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">VitaMedMD LLC</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Delaware, UCC #20183582687</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">BocaGreenMD, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Nevada, UCC #2018015125-0</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">VitaCare Prescription Services, Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Florida, UCC #201805366147</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.1 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE 4.4<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INVESTMENT RELATED PROPERTY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: left">Pledged Stock:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Stock</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="width: 9%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class of Stock</B></FONT></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certificated</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Y/N)</B></P></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Stock</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Certificate</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="width: 7%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Par</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Value</B></FONT></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Pledged</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Stock</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Outstanding Stock of the Stock Issuer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">TherapeuticsMD, Inc.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">BocaGreenMD, Inc.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Common </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Yes </FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No. 1</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$0.001</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1,000</FONT></TD>
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">TherapeuticsMD, Inc.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">VitaCare Prescription Services, Inc.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Common </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Yes </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No. 1</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">$0.01</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">1,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pledged LLC Interests:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Limited</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Liability</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certificated</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Y/N)</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certificate</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>No. (if any)</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of Pledged Units</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Outstanding LLC Interests of the Limited Liability Company</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">TherapeuticsMD, Inc.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">VitaMedMD LLC</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pledged Partnership Interests:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Partnership</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Type of Partnership Interests (e.g., general or limited)</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certificated</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Y/N)</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certificate No.</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(if any)</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Outstanding Partnership Interests of the Partnership</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pledged Trust Interests:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trust</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class of Trust</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Interests</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certificated</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Y/N)</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Certificate No.</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(if any)</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Outstanding Trust Interests of the Trust</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.4 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pledged Debt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 17%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Original Principal</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Outstanding Principal Balance</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Issue Date</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Maturity Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Securities Account:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 25%; border: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of Securities Intermediary</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Account Number</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Account Name</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Commodities Accounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 25%; border: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Name of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Commodities Intermediary</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Account Number</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Account Name</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deposit Accounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 25%; border: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Name of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Depositary Bank</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Account Number</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><B>Account Name</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: left"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 34%; border: black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Name of Grantor</FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Date of Acquisition</FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Description of Acquisition</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: left"></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 48%; border: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Name of Grantor</FONT></TD>
    <TD STYLE="width: 52%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 2pt"><FONT STYLE="font-size: 10pt">Name of Issuer of Pledged LLC</FONT><BR>
<FONT STYLE="font-size: 10pt">Interest/Pledged Partnership Interest</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 2pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.4 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE 4.5<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>MATERIAL CONTRACTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><U>Name of Grantor</U></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><U>Description of Material Contract</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.5 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE 4.6<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>DESCRIPTION OF LETTERS OF CREDIT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><U>Name of Grantor</U></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt"><U>Description of Letters of Credit</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt">None.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.6 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right">SCHEDULE 4.7<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B><U>INTELLECTUAL PROPERTY -
EXCEPTIONS</U><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1<FONT STYLE="text-transform: uppercase">2</FONT></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(A)</TD><TD STYLE="text-align: justify">Copyrights</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(B)</TD><TD STYLE="text-align: justify">Copyright Licenses</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(C)</TD><TD STYLE="text-align: justify">Patents</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Issued Patents:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 4%; border: Black 1pt solid; text-align: center; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Patent Number</B></FONT></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Filing Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Issue Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,577,716</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">System and Method of Ongoing Evaluation Reporting and Analysis</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/17/09</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/05/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,633,178</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/21/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,846,648</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/30/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,846,649</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/30/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,933,059</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/13/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,987,237</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,987,238</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,993,548</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/31/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8,993,549</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/31/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,006,222</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/14/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Borrower is the holder of all intellectual property unless otherwise indicated.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
Key: pink - Imvexxy, purple - Bijuva, blue &ndash; Annovera.</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 4%; border: Black 1pt solid; text-align: center; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Patent Number</B></FONT></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Filing Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Issue Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 4%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 14%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,012,434</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; width: 43%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 13%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/06/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 13%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 13%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,114,145</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/25/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,114,146</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/03/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/25/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,180,091</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/20/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/10/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,248,136</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/12/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/02/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,289,382</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/17/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/22/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">17. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,296,780*<FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><SUP></SUP></FONT></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Process for Alkynylating 16-Substituted-17-Keto Steroids</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/19/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/29/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">18. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,301,920</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/15/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/05/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">19. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">D801,518</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/31/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9,931,349</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/03/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">21. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10,052,386</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/11/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/21/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">22. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10,098,894</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/16/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">23. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10,206,932</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/19/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">24. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10,258,630</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/17/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">25. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">89459</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/17/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">26. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">366507</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/12/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">27. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2012340589</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/25/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">28. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2013211876</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/25/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">29. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2013277236</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/03/17 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">* Licensed
patent or patent application.</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 4%; border: Black 1pt solid; text-align: center; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Patent Number</B></FONT></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Filing Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Issue Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 4%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">30. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 14%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2013277234</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; width: 43%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 13%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 13%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/10/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; width: 13%; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">31. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX 358440 B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/03/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">32. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">166,044</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/17/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/16/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">33. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">002916247-0001</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/10/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">34. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">302015005859-5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/30/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">35. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6285866</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">36. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6298460</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">37. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX 50237 B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/19/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">38. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">30-2015-0065043</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/06/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">39. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">101179</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/10/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">40. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">A2015/01935</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/16/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">41. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015/00211</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/27/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">42. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015/00212</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/26/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">43. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6334519</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/11/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">44. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6342334</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/25/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">45. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6342389</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/25/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">46. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6397402</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/07/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">47. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2013277235</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">48. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2013277233</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/13/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">49. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1624393</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Pharmaceutical Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/18/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">50. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2861234B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">51. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2806742B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Pending Patent Applications:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/104,101</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/16/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120140124442</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,856,520</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12850845.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2017-173842</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/a/2014/006256</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/090,493</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/04/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20140101244</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/17/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2017206262</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/20/17 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120140319103</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">11. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,876,977</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13806855.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">236358</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2017-176379</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2015-7001189</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/a/2014/015898</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">17. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015100533</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">18. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/999,040</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/16/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">19. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14/512,046</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/10/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20150101608</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">21. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015264003</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">22. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR112016 027359 1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">23. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,947,767</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">24. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15727528.0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">25. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">248985</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">26. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016-565647</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">27. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2016-7032773</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">28. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/a/2016/014281</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">29. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016143081</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">30. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016/07541</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">31. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/832,757</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">32. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2017/064788</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">33. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/832,750</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">34. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/244,020</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/09/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">35. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/355,532</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/15/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">36. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">62/822,609</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Natural Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/22/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">37. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14/649,818</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/17/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">38. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2017208300</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">39. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120140319146</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">40. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,876,968</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">41. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13807188.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">42. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">236359</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">43. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2015-7001193</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">44. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2018/009466</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">45. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015100531</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">46. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2014/09278</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">47. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018-162966</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Soluble Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">48. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14/521,230</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">49. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20140103975</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">50. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2014349132</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">51. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120160090080</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">52. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,926,342</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">53. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14862905.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">54. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">245139</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">55. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016-516086</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">56. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2016-7010901</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">57. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2016/005092</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">58. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016118396</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">59. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016/01933</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">60. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">14/521,002</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">61. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/372,385</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">62. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2016/065466</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">63. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20160103768</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">64. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016366200</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">65. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120180114839</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">66. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">3,007,636</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">67. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16873806.0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">68. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">19122548.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/17/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">HK</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">69. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">259884</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">70. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018-529574</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">71. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2018-7019331</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">72. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2018/006882</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">73. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">743229</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">NZ</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">74. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018121094</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">75. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018/03804</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">76. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">62/680,715</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Formulations and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/06/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">77. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/893,542**<FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><SUP>4</SUP></FONT></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">78. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/893,550**</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">79. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/975,733</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">80. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/975,723</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">05/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">81. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/781,840</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/06/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">82. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/004,338</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/08/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">83. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2018/36790</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/08/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(255,153,204)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">84. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/006,721</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Vaginal Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/12/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">85. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/037,452</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/17/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">86. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018222947</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">87. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120140318379</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">88. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,876,964</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">89. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/a/2014/015900</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">90. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/a/2018/009467</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">91. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/454,898</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations Having a Desirable PK Profile</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/09/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">92. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20150100920</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Compositions</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">93. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015237243</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">94. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120160225708</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">95. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,942,568</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">** Application
contains allowable subject matter and a patent will issue in due course.</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">96. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15768772.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">97. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">247828</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">98. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016-557059</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">99. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2016-7029519</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">100. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2016/011706</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">101. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016136666</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">102. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016/06309</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,153,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">103. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/273,955</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Progesterone Formulations Having a Desirable PK Profile</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/12/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">104. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/125,201</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">09/07/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">105. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">P20150102431</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">106. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015296609</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">107. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR112016 029338 0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">108. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,951,284</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">109. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15827543.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">110. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">248984</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">111. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016-571728</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">112. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2017-7002451</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">113. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/a/2016/013693</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">114. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016141135</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">115. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2016/07317</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/29/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">116. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/420,019</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Cream</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">117. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">118. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">119. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">120. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/217,301</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Formulations for Solubilizing Hormones</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">07/22/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">121. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR112014 018439 9</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">122. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,861,346</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">123. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2014/009093</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">01/25/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">124. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13/843,362</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/15/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">125. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">1120140318247</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">126. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2,876,947</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">127. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">13807463.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">128. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2014/015897</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">129. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2015/00210</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Transdermal Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">130. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/475,052</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">131. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2017/025211</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">132. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20170100832</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">133. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2017239679</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">134. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120180698776</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">135. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">3,019,375</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">136. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">17776724.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">137. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">261924</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">138. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018-550593</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">139. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2018-7031666</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">140. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2018/011706</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">141. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">746686</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">NZ</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">142. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018133921</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">143. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018/06413</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">144. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/475,068</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Pharmaceutical Composition in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">145. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20170100831</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">146. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2017/025220</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">147. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/473,742</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">148. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">16/359,839</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/20/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">149. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2017/024955</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">150. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">15/901,467</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">02/21/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">151. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20170100830</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">152. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2017239645</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">153. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR1120180701998</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">154. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">3,020,153</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">155. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">17776645.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">156. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">261930</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">IL</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">157. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018-550564</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">158. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">10-2018-7031878</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">159. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX/A/2018/011705</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">160. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">746682</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">NZ</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">161. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018133932</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">162. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">2018/06414</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">163. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT/US2017/024994</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">03/30/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">164. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">20170100829</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">Steroid Hormone Compositions in Medium Chain Oils</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">04/03/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 6%; border: Black 1pt solid; padding-left: 0.3in; text-align: left; padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Application Date (mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt; width: 6%"><FONT STYLE="font-size: 10pt">165. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt; width: 15%">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt; width: 50%">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt; width: 15%">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt; width: 14%">[***]</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">166. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">167. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">168. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
<TR STYLE="background-color: rgb(0,204,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 0.3in; text-align: justify; text-indent: -0.25in; padding-top: 2pt; padding-bottom: 2pt"><FONT STYLE="font-size: 10pt">169. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5.4pt; padding-top: 2pt; padding-bottom: 2pt">[***]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(D)</TD><TD STYLE="text-align: justify">Patent Licenses</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Borrower has licensed certain Product
Patents and is obligated to pay royalties and other payments pursuant to that certain License Agreement, dated July 30, 2018, between
Borrower and The Population Council, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Borrower has licensed certain Product
Patents pursuant to that certain License and Supply Agreement, dated July 30, 2018, as amended, between Borrower and Knight Pharmaceuticals,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(E)</TD><TD STYLE="text-align: justify">Trademarks</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Registered Trademarks:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Registration Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trademark or Design</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Registration Date </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4430100</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">BOCAGREENMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">11/05/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4568945</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">BOCAGREENMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">07/15/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4607073</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">FEPLUS</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">09/16/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4581759</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">FOLMAX</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">08/05/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4271087</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102001.jpg" ALT="" STYLE="height: 55.5pt; width: 120pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">01/08/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">5602058</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">IMVEXXY</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">11/06/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4444914</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">PRENA1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">12/03/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4314431</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">REDICHEW</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">04/02/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4580454</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">08/05/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left; width: 5%"><FONT STYLE="font-size: 10pt">10. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left; width: 16%"><FONT STYLE="font-size: 10pt">013048871</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left; width: 50%"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left; width: 15%"><FONT STYLE="font-size: 10pt">11/26/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left; width: 14%"><FONT STYLE="font-size: 10pt">EU</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">11. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">5714724</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">THERAPEUTICSMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">10/31/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">12. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4580455</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">VITAMEDMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">08/05/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">13. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">3842265</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">VITAMEDMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">10/31/10</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">14. </FONT></TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">4271086</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102002.jpg" ALT="" STYLE="height: 55.5pt; width: 120pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">01/08/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">15. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">5028550</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">VITATRUE</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">08/23/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2pt 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Pending Trademark Applications or Pending
Designs:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Serial Number</B></FONT></TD>
    <TD STYLE="width: 51%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Pending Trademark or Design</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Filing Date </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">88229031</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102003.jpg" ALT="" STYLE="height: 48pt; width: 48pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/13/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87744084</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BIJUVA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">10/10/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87916151</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">DUENTICA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/10/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87327866</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">FLIRTAYIS</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">02/07/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87941900</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102004.jpg" ALT="" STYLE="height: 77px; width: 60px">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/30/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">6. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87941908</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102005.jpg" ALT="" STYLE="height: 54.75pt; width: 39pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/30/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">7. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">88125885</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102006.jpg" ALT="" STYLE="height: 76px; width: 35px">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">09/20/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">8. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">88125894</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102007.jpg" ALT="" STYLE="height: 56.25pt; width: 38.25pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">09/20/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Serial Number</B></FONT></TD>
    <TD STYLE="width: 51%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Pending Trademark or Design</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Filing Date </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 5%"><FONT STYLE="font-size: 10pt">9. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 15%"><FONT STYLE="font-size: 10pt">87916153</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 51%"><FONT STYLE="font-size: 10pt">OVANATA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 15%"><FONT STYLE="font-size: 10pt">05/10/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 14%"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">10. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87498387</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">SYMBODA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">06/20/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87916147</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">SYMEPTO</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/10/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87916140</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">VIEPA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/10/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">13. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87916139</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">XUBIVVA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/10/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">14. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87916136</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">YUTHENA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/10/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">15. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">88125949</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">YUVVEXY</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">09/20/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">16. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87126380</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102008.jpg" ALT="" STYLE="height: 55.5pt; width: 120pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/03/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">17. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87126398</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex102009.jpg" ALT="" STYLE="height: 55.5pt; width: 120pt"></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/03/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">18. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1947704</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BIJUVA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">02/22/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">19. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1947721</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JOYESTA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">02/22/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">CA</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SERVICE MARKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Registered Service Marks or Designs:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Registration Number</B></FONT></TD>
    <TD STYLE="width: 51%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Service Mark or Design</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Registration Date </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">5051435</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">VITAMOM</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">09/27/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Pending Service Mark Applications or Designs:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Serial Number</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Pending Service Mark or Design</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Filing Date </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87340782</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BIO-IGNITE</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">02/17/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">87398429</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">FOREVHER</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">04/04/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">88346838</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MENOCHOICE***</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">03/19/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">US</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(F)</TD><TD STYLE="text-align: justify">Trademark Licenses</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Borrower has licensed certain trademarks
under a June 13, 2014 Trademark License Agreement with Lang Pharma Nutrition, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(G)</TD><TD STYLE="text-align: justify">Trade Secret Licenses</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(H)</TD><TD STYLE="text-align: justify">Intellectual Property Exceptions</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">*** Also in International Class 09.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.7 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE 4.8<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMERCIAL TORT CLAIMS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><U>Name of Grantor</U></FONT></TD>
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt"><U>Commercial Tort Claims</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">SCHEDULE 4.8 - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT A<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PLEDGE SUPPLEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This PLEDGE SUPPLEMENT,
dated as of ________, 20__, is delivered by <B>[NAME OF GRANTOR]</B> a <B>[NAME OF STATE OF ORGANIZATION]</B> [entity type] (a
&ldquo;<B>Additional Grantor</B>&rdquo;) pursuant to the Pledge and Security Agreement, dated as of April 24, 2019 (as amended,
restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Security Agreement</B>&rdquo;), among the Grantors
party thereto from time to time, and TPG Specialty Lending, Inc., as the Administrative Agent. Capitalized terms used herein not
otherwise defined herein shall have the meanings ascribed thereto in the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional Grantor
acknowledges and agrees that such Additional Grantor shall be a &ldquo;Grantor&rdquo; for all purposes under the Security Agreement
and to be bound by the terms thereof, and hereby confirms the grant to the Administrative Agent set forth in the Security Agreement
of, and does hereby grant to the Administrative Agent, a security interest in all of Additional Grantor&rsquo;s right, title and
interest in and to all Collateral to secure the Secured Obligations. Additional Grantor represents and warrants that the attached
Supplements to Schedules accurately and completely set forth all additional information required pursuant to the Security Agreement
and hereby agrees that such Supplements to Schedules shall constitute part of the Schedules to the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
Additional Grantor has caused this Pledge Supplement to be duly executed and delivered by its duly authorized officer as of the
date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[NAME OF ADDITIONAL GRANTOR]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">EXHIBIT A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT B<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TRADEMARK SECURITY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This TRADEMARK SECURITY
AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), dated as of ________, 20__, is entered into by and among ______________, a ___________
(the &ldquo;<B>Grantor</B>&rdquo;) and TPG Specialty Lending, Inc. (the &ldquo;<B>Assignee</B>&rdquo;), as Administrative Agent
pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the
other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Security
Agreement</B>&rdquo;), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Financing Agreement</B>&rdquo;), between, among others, certain of the Grantor&rsquo;s
affiliates, the Assignee, and certain Lenders party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms not
otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to
the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the
federally registered Trademarks set forth on <U>Schedule A</U> hereto as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Grantor and the Assignee hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Security Interest</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the
Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor&rsquo;s
right, title and interest in, to and under the Trademarks, whether now owned or existing or at any time hereafter acquired or arising
and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated
maturity, by acceleration or otherwise) of the Grantor&rsquo;s Secured Obligations. For the purposes of this Agreement, &ldquo;Trademarks&rdquo;
means (i) all trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles,
service marks, logos, Internet domain names and other source or business identifiers, and all goodwill associated therewith, now
existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications in connection therewith,
in the United States Patent and Trademark Office or in any similar office or agency of the United States, and all common-law rights
related thereto, including, without limitation, any of the foregoing referred to on Schedule A hereto, and (ii) the right to obtain
all renewals thereof, <U>provided</U> that no United States intent-to-use trademark or service mark application shall be included
in the Trademarks to the extent that, and solely during the period in which, the grant of a security interest therein would impair
the validity or enforceability of such intent-to-use trademark or service mark application under Federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Schedule
A</U> hereto contains a true and accurate list of all of the Grantor&rsquo;s federally registered United States registrations and
applications for registration for the Trademarks (excluding Internet domain names) existing as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">EXHIBIT B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee
under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement,
the provisions of the Security Agreement shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Modifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement or any
provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing
Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement
without obtaining the Grantor&rsquo;s signature to such modification, to the extent that such modification constitutes an amendment
of Schedule A hereto, to add any right, title or interest in any Trademarks owned or subsequently acquired by the Grantor or to
delete any reference to any right, title or interest in any Trademarks in which the Grantor no longer has or claims any right,
title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably
required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any
Trademark to the security interests and perfection created or contemplated hereby or by the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may
be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and
all of said counterparts taken together shall be deemed to constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, each of the undersigned
has caused this Agreement to be duly executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNEE:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG SPECIALTY LENDING, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Assignee:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Options: NewSection; Value: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRANTOR:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Grantor:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Options: NewSection; Value: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE A<BR>
TO TRADEMARK SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule A to TRADEMARK SECURITY AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>U.S. Registered Trademarks</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; border: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Grantor</B></FONT></TD>
    <TD STYLE="width: 22%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Trademark Name</B></FONT></TD>
    <TD STYLE="width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD>
    <TD STYLE="width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Number</B></FONT></TD>
    <TD STYLE="width: 13%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Applications of Registration of Trademarks</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit B - A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT C<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COPYRIGHT SECURITY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This COPYRIGHT SECURITY
AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), dated as of ________, 20__, is entered into by and among ______________, a ___________
(the &ldquo;<B>Grantor</B>&rdquo;) and TPG Specialty Lending, Inc. (the &ldquo;<B>Assignee</B>&rdquo;), as Administrative Agent
pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the
other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Security
Agreement</B>&rdquo;), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Financing Agreement</B>&rdquo;), between, among others, certain of the Grantor&rsquo;s
affiliates, the Assignee, and certain Lenders party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms not
otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to
the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the
Copyrights and the applications and registrations set forth on Schedule A hereto as of the date hereof, and all proceeds thereof,
including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages
arising from past, present and future violations thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Grantor and the Assignee hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Security Interest</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the
Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor&rsquo;s
right, title and interest in, to and under the Copyrights, whether now owned or existing or at any time hereafter acquired or arising
and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated
maturity, by acceleration or otherwise) of the Grantor&rsquo;s Secured Obligations. For the purposes of this Agreement, &ldquo;Copyrights&rdquo;
means (i) all copyrights arising under the laws of the United States, any other country or any political subdivision thereof, whether
registered or unregistered and whether published or unpublished (including, without limitation, those listed on Schedule A), all
computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible property embodying
or incorporating any copyrights, all registrations and recordings thereof, and all applications in connection therewith, including,
without limitation, all registrations, recordings and applications in the United States Copyright Office, and (ii) the right to
obtain all renewals thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Schedule
A</U> hereto contains a true and accurate list of all of the Grantor&rsquo;s federally registered United States registrations and
applications for registration for the Copyrights existing as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit C - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee
under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement,
the provisions of the Security Agreement shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Modifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement or any
provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing
Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement
without obtaining the Grantor&rsquo;s signature to such modification, to the extent that such modification constitutes an amendment
of Schedule A hereto, to add any right, title or interest in any Copyrights owned or subsequently acquired by the Grantor or to
delete any reference to any right, title or interest in any Copyrights in which the Grantor no longer has or claims any right,
title or interest. The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably
required by the Assignee from time to time, to subject any such owned or subsequently acquired right, title or interest in any
Copyright to the security interests and perfection created or contemplated hereby or by the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may
be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and
all of said counterparts taken together shall be deemed to constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, each of the undersigned
has caused this Agreement to be duly executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNEE:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG SPECIALTY LENDING, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Assignee:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit C - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRANTOR:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Grantor:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit C - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE A<BR>
TO COPYRIGHT SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule A to COPYRIGHT SECURITY AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>U.S. Registered Copyrights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 22%; border: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Number</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Applications of Registration of Copyrights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 22%; border: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Owner</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Number</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit C-A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT D<BR>
TO PLEDGE AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PATENT SECURITY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This PATENT SECURITY
AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), dated as of ________, 20__, is entered into by and among ______________, a ___________
(the &ldquo;<B>Grantor</B>&rdquo;) and TPG Specialty Lending, Inc. (the &ldquo;<B>Assignee</B>&rdquo;), as Administrative Agent
pursuant to (i) that certain Pledge and Security Agreement, dated as of April 24, 2019, among the Assignee, the Grantor and the
other Grantors party thereto (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Security
Agreement</B>&rdquo;), and (ii) that certain Financing Agreement, dated as of April 24, 2019 (as amended, restated, supplemented
or otherwise modified from time to time, the &ldquo;<B>Financing Agreement</B>&rdquo;), between, among others, certain of the Grantor&rsquo;s
affiliates, the Assignee, and certain Lenders party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms not
otherwise defined herein have the respective meanings ascribed to them in the Security Agreement or the Financing Agreement, as
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to
the Security Agreement, the Grantor has granted in favor of the Assignee a security interest in certain Collateral, including the
federally registered Patents set forth on <U>Schedule A</U> hereto as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Grantor and the Assignee hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant
of Security Interest</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of the Security Agreement, to evidence further the security interest granted by the Grantor to the
Assignee pursuant to the Security Agreement, the Grantor hereby grants to the Assignee a security interest in all of the Grantor&rsquo;s
right, title and interest in, to and under the Patents, whether now owned or existing or at any time hereafter acquired or arising
and wherever located, as collateral security for the prompt and complete payment and performance when due (whether at the stated
maturity, by acceleration or otherwise) of the Grantor&rsquo;s Secured Obligations. For the purposes of this Agreement, &ldquo;Patents&rdquo;
means (i) all letters patent of the United States, all reissues and extensions thereof and all goodwill associated therewith, including,
without limitation, any of the foregoing referred to on Schedule A hereto, (ii) all applications for letters patent of the United
States, continuations and continuations-in-part thereof, including, without limitation, any of the foregoing referred to on Schedule
A hereto, and (iii) all rights to obtain any reissues or extensions of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Schedule
A</U> hereto contains a true and accurate list of all of the Grantor&rsquo;s federally registered United States registrations and
applications for registration for the Patents existing as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
security interest granted hereby is granted concurrently and in conjunction with the security interest granted to the Assignee
under the Security Agreement. In the event that any of the provisions of this Agreement are in conflict with the Security Agreement,
the provisions of the Security Agreement shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit D - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Modifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement or any
provision hereof may not be changed, waived, or terminated except in accordance with the amendment provisions of the Financing
Agreement. In connection with the foregoing, the Grantor authorizes the Assignee, upon notice to the Grantor, to modify this Agreement
without obtaining the Grantor&rsquo;s signature to such modification, to the extent that such modification constitutes an amendment
of Schedule A hereto, to add any right, title or interest in any Patents owned or subsequently acquired by the Grantor or to delete
any reference to any right, title or interest in any Patents in which the Grantor no longer has or claims any right, title or interest.
The Grantor additionally agrees to execute any additional agreement or amendment hereto as may be reasonably required by the Assignee
from time to time, to subject any such owned or subsequently acquired right, title or interest in any Patent to the security interests
and perfection created or contemplated hereby or by the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Law</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may
be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by telecopy), and
all of said counterparts taken together shall be deemed to constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, each of the undersigned
has caused this Agreement to be duly executed and delivered as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNEE:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG SPECIALTY LENDING, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Assignee:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GRANTOR:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit D -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 27%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Address of Grantor:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit D -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">SCHEDULE A<BR>
TO PATENT SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule A to PATENT SECURITY AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>U.S. Registered Patents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 22%; border: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Application Number</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Patent Number</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Registration Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Exhibit D-A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex10-3.htm
<DESCRIPTION>LICENSE AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font-size: 10pt"><A HREF="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</A><B></B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.3</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CERTAIN IDENTIFIED INFORMATION
HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY
DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TXMD
EXECUTION VERSION</FONT><FONT STYLE="font-size: 10pt"><BR>
<FONT STYLE="text-transform: uppercase">Dated: JUNE 6, 2019</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">License
and</FONT> <FONT STYLE="font-size: 10pt">SUPPLY AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">by and
between</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">TherapeuticsMD,
Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">and</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Theramex
HQ UK Limited</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">DATE:
June 6, 2019</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">1.</TD>
    <TD STYLE="width: 89%">Definitions; Construction</TD>
    <TD STYLE="width: 7%; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>2.</TD>
    <TD>Licenses, Commercialization, and Intellectual Property Rights</TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.</TD>
    <TD>Governance</TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>4.</TD>
    <TD>Trademarks and Packaging; Materials</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>5.</TD>
    <TD>Product Development and Marketing Authorizations</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>6.</TD>
    <TD>Performance of Manufacturing and Supply</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>7.</TD>
    <TD>Orders</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>8.</TD>
    <TD>Delivery; Review and Defective Product</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>9.</TD>
    <TD>Product Recall</TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.</TD>
    <TD>Fees and Payments</TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>11.</TD>
    <TD>Invoicing and Payment</TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>12.</TD>
    <TD>Books and Records; Audit Rights</TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>13.</TD>
    <TD>Representations, Warranties and Covenants</TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>14.</TD>
    <TD>Indemnification and Limitation of Liability</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>15.</TD>
    <TD>Force Majeure</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>16.</TD>
    <TD>Term and Termination.</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>17.</TD>
    <TD>Confidentiality</TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>18.</TD>
    <TD>Dispute Resolution</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>19.</TD>
    <TD>Insurance</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>20.</TD>
    <TD>Miscellaneous</TD>
    <TD STYLE="text-align: right">43</TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">License
and</FONT> <FONT STYLE="font-size: 10pt">SUPPLY AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
License and Supply Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made effective as of <B>June 6, 2019</B> (the &ldquo;<B>Effective
Date</B>&rdquo;) by and between TherapeuticsMD, Inc., a Nevada corporation, with a principal place of business located at 6800
Broken Sound Parkway NW, Boca Raton, FL 33487 (&ldquo;<B>TXMD</B>&rdquo;) and Theramex HQ UK Limited, a company formed under the
laws of England, with its principal place of business located at Sloane Square House, 1 Holbein Place, London SW1W 8NS United
Kingdon (&ldquo;<B>Licensee</B>&rdquo;). TXMD and Licensee are sometimes referred to herein individually as a &ldquo;<B>Party</B>&rdquo;
and collectively as the &ldquo;<B>Parties</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><U>Recitals</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>A.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">TXMD<FONT STYLE="background-color: white">&nbsp;is
                                         an innovative healthcare company focused on developing and commercializing products for
                                         women.</FONT></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>B.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                         has experience in all facets of commercializing pharmaceutical products in the Territory
                                         (as defined below), including applying for Marketing Approvals, distribution, marketing,
                                         and sales in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>C.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">TXMD&rsquo;s
                                         pipeline includes Bijuva&trade;, recently approved by the FDA for treatment of moderate-to-severe
                                         vasomotor symptoms (VMS) due to menopause, and Imvexxy&reg;, recently approved by the
                                         FDA for treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>D.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                         desires to secure necessary rights to Commercialize (as defined below) the Products (as
                                         defined below) in the Territory (as defined below) and, subject to the terms and conditions
                                         of this Agreement, TXMD desires to grant such rights to Commercialize the Products in
                                         the Territory and to Supply (as defined below) the Products to Licensee.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Now,
therefore</B></FONT><FONT STYLE="font-size: 10pt">, in consideration of the foregoing premises and the mutual promises, covenants
and conditions contained in this Agreement, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Definitions;
                                         Construction</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Definitions</U>. Unless
otherwise specifically provided in this Agreement, the following terms shall have the following meanings:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Accounting
Standards</B>&rdquo; means IFRS as generally and consistently applied throughout Licensee&rsquo;s organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Acknowledgement</B>&rdquo;
is defined in Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Actual
Product Fees</B>&rdquo; means the actual per unit COGS pricing multiplied by the number of Products ordered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;,
with respect to a Party, shall mean any Person that controls, is controlled by, or is under common control with that Party. For
the purpose of this definition, &ldquo;control&rdquo; means, direct or indirect, ownership of fifty percent (50%) or more of the
shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of
the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other
arrangement whereby the entity or person controls or has the right to control the board of directors or equivalent governing body
of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other
entity. For the avoidance of doubt, an entity that shares a common corporate parent with Party shall be considered an Affiliate
of such Party if such common parent controls, either directly or indirectly (i.e., through different tiers of ownership), both
the Party and the entity at issue. In the case of entities organized under the laws of certain countries, the maximum percentage
ownership permitted by law for a foreign investor may be less than fifty percent (50%), and in such case such lower percentage
shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and
policies of such entity. For the avoidance of doubt, when used in connection with Licensee, the term &ldquo;Affiliate&rdquo; shall
exclude: (i) any funds or vehicles (&ldquo;<B>CVC Funds</B>&rdquo;) advised by CVC Capital Partners Limited and/or its affiliates;
and (ii) any portfolio companies in which any CVC Fund holds an interest or investment from time to time (together with the CVC
Funds, the &ldquo;<B>Restricted Entities</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Applicable
Laws</B>&rdquo; means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of
any governmental authority or Regulatory Authority, domestic or foreign, that are applicable to the particular situation, obligation
or circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Background
IPR&rdquo; </B>is defined in Section 2.4.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Bankruptcy
Code</B>&rdquo; means Title 11, U.S. Code, as amended, or analogous provisions of Applicable Laws outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Batch</B>&rdquo;
means a defined quantity of Product that is Manufactured according to a single manufacturing order during the same cycle of Manufacture
and is intended to have been Manufactured in accordance with the Manufacturing Process and Product Specifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Business
Day</B>&rdquo; means any day other than a Saturday, a Sunday or a day on which commercial banks located in New York, New York
or London, England are authorized or required by Applicable Law to remain closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Calendar
Quarter</B>&rdquo; means the respective period of three consecutive calendar months ending March 31, June 30, September 30 and
December 31.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Calendar
Year</B>&rdquo; means each successive twelve (12) months commencing on January 1 and ending on December 31.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Certificate
of Analysis</B>&rdquo; means the certificate of analysis to accompany Product delivered to Licensee as set forth in the Quality
Technical Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Change
of Control</B>&rdquo; means, with respect to Licensee, a completed transaction where any of the following occurs upon closing
of the transaction: (a) any Third Party (or group of Third Parties acting in concert) becomes the beneficial owner, directly or
indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of Licensee normally entitled
to vote in elections of directors; (b) Licensee or its Affiliate consolidates with or merges into another corporation or entity,
or any corporation or entity consolidates with or merges into Licensee or its Affiliate, in either event pursuant to a transaction
in which more than fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled
to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of the total outstanding shares
of Licensee preceding such consolidation or merger; or (c) Licensee divests or otherwise conveys, transfers or leases all or substantially
all of its assets relating to a Product, to any Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Clinical
Data</B>&rdquo; means, with respect to a Clinical Trial for a pharmaceutical product, all data and results from the conduct of
such Clinical Trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Clinical
Trial</B>&rdquo; means a human clinical trial of Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>cGMP</B>&rdquo;
means the current Good Manufacturing Practices promulgated by the U.S. Food and Drug Administration, EMA or any other Regulatory
Authority in the Territory for the manufacture and testing of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>CMC</B>&rdquo;
or &ldquo;<B>CMC Information</B>&rdquo; means all product quality cGMP data related to the manufacturing of the Products including
characterization, stability, manufacturing process development, control methods and specifications, biopharmaceutical classification
and all relevant supporting data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>COGS</B>&rdquo;
means with respect to any Product supplied within the scope of this Agreement the unit cost of Manufacture consisting of (a) Direct
Material Costs, (b) Direct Operating Labor Costs and (c) Indirect Expenses (Indirect Expenses shall be billed separately), each
as defined below, all as fairly and reasonably attributable to Product within the scope of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)
&ldquo;<B>Direct Material Costs</B>&rdquo; means the cost of purchased materials used in the manufacture or packaging of Product,
including costs of Materials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)
&ldquo;<B>Direct Operating Labor Costs</B>&rdquo; means the personnel cost of employees directly employed in the manufacturing,
Packaging, quality testing or release of Product, including basic wages, labor and related payroll taxes and benefits; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)
&ldquo;<B>Indirect Expenses</B>&rdquo; means, collectively:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)
Costs of quality assurance activities (excluding labor costs) relating to Products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(ii)
Interim transportation, or any related transportation cost including tertiary packaging and storage of Product, as incurred or
spent in connection with this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iii)
Costs of Products as actually invoiced by Contract Manufacturers for applicable Products supplied to Licensee, including the benefit
of any price reductions, payment or terms discounts or other reimbursements, such as volume discounts, that may be applicable
to purchased Products);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(iv)
Costs associated with changes of the Product Specifications or the Manufacturing Process;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(v)
Costs and expenses relating to registration and maintenance of Drug Master Files; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(vi)
Product validation costs (including manufacturing, testing, and stability) for the Territory, Territory-specific testing requirements,
and annual stability testing for the Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Commercialization,</B>&rdquo;
with a correlative meaning for &ldquo;<B>Commercialize,</B>&rdquo; means all activities undertaken with respect to commercialization
of Product in the Territory, including activities relating to submitting Regulatory Materials for Marketing Authorization and
other Regulatory Approvals for Product in the Territory by using the Regulatory Materials, Regulatory Approvals, pricing and reimbursement
approvals, TXMD Clinical Data and related materials necessary, in each case as provided or licensed by TXMD to Licensee hereunder,
marketing, promoting, distributing, importing, exporting (to other countries in the Territory, if applicable), offering for sale
and/or selling Product. Commercialization does not include Development. For the avoidance of doubt, nothing in this definition
shall be interpreted to restrict Licensee&rsquo;s ability to use any information in support of obtaining any Marketing Authorization
for Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Commercialization
Field</B>&rdquo; means human use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Confidential
Information</B>&rdquo; means all confidential or proprietary information of a Party disclosed by or on behalf of the relevant
Party (whether through its representatives, counsel, directors, officers, employees, agents, subcontractors, or Affiliates (collectively,
the &ldquo;<B>Representatives</B>&rdquo;) to the other Party pursuant to this Agreement in written, oral or any other form (such
as by permitting examination of tangible items or viewing of premises); and which may include, but is not limited to, technical
data, trade secrets, know-how, intellectual property or other materials owned or controlled by Disclosing Party, including, but
not limited to, research, product plans, products, samples, specifications, service plans, services, customer lists, customers,
markets, software, developments, inventions, processes, formulas, chemical applications, laboratory instruments, laboratory methods
of analysis, interpretation of lab results, techniques, technology, manufacturing methods, equipment, designs, drawings, engineering,
marketing, distribution and sales methods and systems, sales and profit figures, pricing, finances and other business information,
and all analyses, compilations, studies or other materials prepared by Recipient containing or based in whole or in part upon
such information furnished to Recipient by Disclosing Party or its Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Contract
Manufacturers</B>&rdquo; means any Third Party engaged by TXMD to perform Manufacturing of Product on behalf of TXMD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Contract
Manufacturing Agreement(s)</B>&rdquo; means the agreement(s) between TXMD and Contract Manufacturers for the Manufacture of Product
or related services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Consulting
Rate</B>&rdquo; means a blended rate of EUR [***] per hour plus all Licensee pre-approved and reasonable travel and expenses incurred
by resources in performing any Project Services (following the exhaustion of any applicable Project Pool hours, at Licensee&rsquo;s
discretion). The Consulting Rate and categories of resources to which it is applicable, shall be periodically reviewed for appropriateness
by the Joint Steering Committee in consultation with the finance departments of each Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Control</B>&rdquo;
means, with respect to any material, information, or Intellectual Property Right, that a Party has the legal right or authority
(whether by ownership, license or otherwise), as of the Effective Date or during the Term, to grant to the other Party access
to, ownership of, or a license or sublicense (as applicable) under, such material, information, or Intellectual Property Right
on the terms and conditions set forth herein without violating the terms of any agreement or any other arrangement with any Third
Party or misappropriating the proprietary or trade secret information of a Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Cover</B>&rdquo;
or &ldquo;<B>Covering</B>&rdquo; means, with respect to a Patent Right or claim of a Patent Right and a Product, that, but for
the licenses granted in this Agreement, the making, use, sale, offer for sale or importation of the Product would infringe such
claim or Patent Right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Defective
Product</B>&rdquo; means Product that is damaged or defective when Licensee takes title to the Product pursuant to Section 8.1
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Develop</B>&rdquo;
or &ldquo;<B>Development</B>&rdquo; means all research and development activities for Product, including all such activities intended
to research, discover or develop and/or to support INDs, NDAs or other Marketing Approvals or other post-marketing requirements
for Product, including, without limitation, (a) toxicology, pre-clinical and clinical drug development activities, and (b) Clinical
Trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Diligent
Efforts</B>&rdquo; means with respect to Licensee&rsquo;s obligations under this Agreement, the level of efforts in carrying out
such obligation in a manner that is at least consistent with the efforts that a pharmaceutical company in a similar position as
Licensee typically devotes to a product of similar commercial and scientific potential at a similar stage in its lifecycle, taking
into consideration safety and efficacy, cost to develop, the competitiveness of alternative Third Party products, the likelihood
of receipt Marketing Authorization and other Regulatory Approvals, expected profitability, including the amounts of marketing
and promotional expenditures with respect to Product and all other relevant factors. Diligent Efforts requires, with respect to
a particular task or activity in Developing or Commercializing Product, that Licensee: (a) promptly assign responsibility for
such task or activity to specific individuals who are held accountable for progress and to monitor such progress on an on-going
basis; (b) set and consistently seek to achieve specific and meaningful objectives for carrying out such task or activity; and
(c) make and implement decisions and allocate resources designed to advance progress with respect to such objectives. Diligent
Efforts shall be determined individually with respect to appropriate and reasonably defined specific markets or groups of markets,
and it is understood that the level of Diligent Efforts required during any specific period may vary from country to country and
between different markets or groups of markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>&ldquo;Disclosing
Party</B>&rdquo; means the Party disclosing Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Dispute</B>&rdquo;
is defined in Section 18.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>DMF</B>&rdquo;
or &ldquo;<B>Drug Master File</B>&rdquo; means a <FONT STYLE="color: #333333; background-color: white">submission to a Regulatory
Authority that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing,
processing, packaging, and storing of one or more human drugs. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Effective
Date</B>&rdquo; means the date as set forth in the preamble to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>EMA</B>&rdquo;
means the European Medicines Agency, or any successor entity thereto performing substantially the same functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Exception
Notice</B>&rdquo; is defined in Section 8.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>EUR</B>&rdquo;
means Euros, the currency of the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>European
Union</B>&rdquo; means all of the European Union member states as of the applicable date during the Term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>FCPA</B>&rdquo;
is defined in Section 13.3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Firm
Commitment</B>&rdquo; is defined in Section 6.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>First
Commercial Sale</B>&rdquo; means, with respect to a Product in any country or jurisdiction in the Territory, the first sale by
Licensee to a Person of such Product for use in such country or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Force
Majeure</B>&rdquo; means an event which is beyond a non-performing Party&rsquo;s reasonable control, including an act of God,
strike, lock-out or other industrial/labor dispute (whether involving the workforce of the Party so prevented or of any other
Person), war, riot, civil commotion, terrorist act, malicious damage, epidemic, quarantine, fire, flood, storm or natural disaster.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Force
Majeure Party</B>&rdquo; means a Party prevented or delayed in its performance under this Agreement by an event of Force Majeure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Generic
Product</B>&rdquo; means any product containing the same active pharmaceutical ingredients as Product and that is submitted as
an Abbreviated New Drug Application (or the foreign jurisdiction equivalent) that refers or compares to Product as the reference
product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>ICC</B>&rdquo;
is defined in Section 18.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>IFRS</B>&rdquo;
means International Reporting Financial Standards promulgated by the International Accounting Standards Board, as amended, supplemented
or replaced from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>IND</B>&rdquo;
means an investigational new drug application for Product filed by TXMD with the U.S. Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Indemnified
Party</B>&rdquo; is defined in Section 14.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Indemnifying
Party</B>&rdquo; is defined in Section 14.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Indirect
Taxes</B>&rdquo; means value added taxes, sales taxes, consumption taxes and other similar taxes relating to sales or purchase
of goods and supply of services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Initial
Indication</B>&rdquo; means, with respect to a country or jurisdiction in the Territory, the first indication for which Licensee
pursues Marketing Authorization for a Product in such country or jurisdiction using the TXMD Clinical Data as the basis for obtaining
such Marketing Authorization. Upon the granting of the first such Marketing Authorization in such country or jurisdiction by the
applicable Regulatory Authority, the indication described in such Marketing Authorization for a Product in such country or jurisdiction
as specified in the applicable Product Labeling for such Product shall thereafter be the Initial Indication. As of the Effective
Date, the Initial Indication for the TX-001 Product is anticipated to be comprised of <FONT STYLE="background-color: white">hormone
replacement therapy for oestrogen deficiency symptons in post-menopausal women</FONT>. As of the Effective Date, the Initial Indication
for the TX-004 Product is anticipated to be comprised of the treatment of dyspareunia<FONT STYLE="background-color: white">, a
symptom of vulvar and vaginal atrophy, due to menopause.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Intellectual
Property Rights</B>&rdquo; means Know-How, Patent Rights, trademarks, service marks, trade names, design rights, copyright (including
rights in computer software) or any rights or property similar to any of the foregoing in any part of the world, whether registered
or not, together with the right to apply for the registration of any such rights, and all rights or forms of protection having
equivalent or similar effect, in any part of the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>IP
Improvement</B>&rdquo; means any invention, discovery, upgrading or modification and all other Intellectual Property Rights (whether
patentable or not) created by either Party or jointly by the Parties during the Term in performance of a Party&rsquo;s rights
or obligations under this Agreement, including any manufacturing processes, dosage forms, formulations or delivery systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Joint
Steering Committee</B>&rdquo; is defined in Section 3.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Know-How</B>&rdquo;
means all technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets,
specifications, designs, instructions, processes, formulae, materials, expertise and other technology applicable to compounds,
formulations, compositions, products or to their manufacture, development, registration, use or commercialization or methods of
assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising
them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical,
safety, quality control, manufacturing, preclinical and Clinical Data, instructions, processes, formulae, expertise and information,
Regulatory Materials and copies thereof, relevant to the development, manufacture, use or commercialization of and/or which may
be useful in studying, testing, development, production or formulation of products, or intermediates for the synthesis thereof.
Know-How includes any rights including trade secrets, copyright, database or design rights protecting such Know-How.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Licensee
Claims&rdquo; is defined in Section </B>14.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Licensee
Group</B>&rdquo; <B>is defined in Section</B> 14.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Licensee
Indemnitees</B>&rdquo; <B>is defined in Section</B> 14.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Lead
Time</B>&rdquo; means the agreed time it will take from the date TXMD acknowledges receipt of a Purchase Order from Licensee until
and including the date of delivery of Product EXW INCOTERMS (2010) by Third Party Manufacturer to Licensee. The Lead Time shall
be 150 days for launch quantities unless additional testing or validation studies are required and 120 days for subsequent orders
unless otherwise agreed to by the Parties in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Long
Term Forecast</B>&rdquo; <B>is defined in Section</B> 6.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Major
Countries</B>&rdquo; means the United Kingdom, France, Germany, Spain, Italy, Brazil, and Mexico.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Manufacture</B>&rdquo;
means the manufacture of a Product, including the compounding, filling, encapsulating, testing, and Packaging of Materials by
TXMD (or any of its permitted Affiliates or subcontractors) to manufacture and produce Product in accordance with the Manufacturing
Process and Product Specifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Manufacturing
Process</B>&rdquo; means any process (or step in any process) used or planned to be used to Manufacture a Product as further described
in the Product Specifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Marketing
Authorization</B>&rdquo; means the approval of a Product by the Regulatory Authority for Commercialization in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Materials</B>&rdquo;
means raw materials, excipients, intermediates and laboratory reagents, packaging components and materials, devices, labels or
other materials used in the Supply of Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Milestone
Fees</B>&rdquo; means the fees payable by Licensee based on certain milestones, as specified in <U>Exhibit 2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Net
Sales</B>&rdquo; means, with respect to a particular time period, the total amounts invoiced by Licensee and its Affiliates to
Third Party purchasers (including wholesalers and non-Affiliate Sublicensees) in respect of sales of Product, less the following
deductions to the extent actually allowed to customers or incurred with respect to such sales:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">normal and customary trade, quantity or prompt settlement discounts off the invoiced
price, allowances and credits (other than price discounts granted at the time of invoicing which have already been included in
the gross amount invoiced);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">amounts repaid or credited because of rejections, returns, rebates, price adjustments
or allowances for damaged products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">rebates and similar payments made with respect to sales of Product paid for by any governmental
authority, chargeback payments, repayments and rebates (or the equivalent thereof) granted to or imposed by group purchasing organizations,
managed health care organizations or federal, state/provincial, local and other governments, including any or all of their regulatory
authorities, agencies, review boards or tribunals, or trade customers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">transportation costs, pre-wholesaling costs, distribution expenses, special packaging,
freight, postage, shipping, transportation and insurance charges directly allocated to Product, provided that such costs, expenses
and charges shall not exceed [***] percent ([***]%) of the invoiced amount of the Product, understanding in each case that such
costs, expenses and charges are on a pass-through basis without markup;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">sales, value-added (to the extent not refundable in accordance with applicable law excise
taxes, tariffs and duties, and other taxes directly related to the sale (but not including taxes assessed against the income derived
from such sale), Indirect Taxes, customs duties, customs levies and import fees imposed on the sale, importation, use or distribution
of Product;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">any other normal and customary deductions actually allowed to customers that are consistently
applied from time-to-time by Licensee in accordance with its Accounting Standards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">stocking allowances;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">amounts written off or not collected due to uncollectable invoiced amounts including
bad debts, in amounts consistent with Licensee&rsquo;s usual practice and with its Accounting Standards; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT><FONT STYLE="font-size: 10pt">any other payment which reduces gross revenue and is permitted to be deducted in calculating
net sales in accordance with IFRS, provided that any differences in the treatment of such other payment as determined under US
GAAP and IFRS shall be discussed by the JSC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Net Sales
shall be calculated using Licensee&rsquo;s internal audited system used to calculate and report net sales for all its products,
which at all times shall be in accordance with the Accounting Standards, as such Net Sales calculation may be adjusted for any
of the items (a) to (i) above that are not taken into account in such systems. Deductions pursuant to subsection (i) above shall
be taken in the Calendar Quarter in which such sales are no longer recorded as a receivable, and <I>provided that </I>if any amounts
of payment for such sales are subsequently received by Licensee (or its Affiliates), such amount shall be deemed &ldquo;Net Sales&rdquo;
in the period received. To the extent that Licensee (including its Affiliates, as applicable) provides to any Third Party purchaser
discounts or allowances that are applicable to and measured by purchases of a Product and one or more other products (such as
a &ldquo;bundled sale&rdquo; arrangement), such discounts and allowances shall be allocated between the products (for purposes
of the deductions used in calculating Net Sales as above) and such other products in a commercially reasonable manner that does
not unfairly or inappropriately bias the level of discounting against the Product (as compared to the other products), such allocation
to be determined in good faith by the Parties through the Joint Steering Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Net Sales
shall include the amount or fair market value of all consideration received by Licensee and its associated parties in respect
of sales of Product, whether such consideration is in cash, payment in kind, exchange, or other form. Net Sales shall not include
sales between or among Licensee or its Affiliates unless any such associated party is the end user, but shall include sales to
non-Affiliate Sublicensees. Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies
and procedures of Licensee, which shall at all times be in accordance with IFRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Package</B>&rdquo;
and &ldquo;<B>Packaging</B>&rdquo; means labelling, testing, inspecting, final finished packaging and packing of Product, or any
activity of a nature similar to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Paid
Estimated Product Fees</B>&rdquo; means fees paid by Licensee for Product ordered by Licensee in the Calendar Year or partial
Calendar Year based on the estimated COGS per unit fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Parties</B>&rdquo;
means TXMD and Licensee and &ldquo;<B>Party</B>&rdquo; means either TXMD or Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Patent
Rights</B>&rdquo; means patent applications and patents, inventors&rsquo; certificates, improvement patents, utility models and
patents of addition and administrative protection (such as pipeline protection) and all foreign counterparts of them in any and
all countries, and including any divisional applications and patents, refilings, renewals, continuations, continuations-in-part,
extensions (including patent term extensions), reissues, re-examinations, substitutions, confirmations, registrations, revalidation,
importation and additions, and any equivalents of or to any of the foregoing in any and all countries, as well as any supplementary
protection certificates and equivalent protection rights in respect of any of them in any and all countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
means an individual natural person, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation,
limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity
or organization, including a government or political subdivision, department or agency of a government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Pharmacovigilance
Agreement</B>&rdquo; means the pharmacovigilance agreement agreed between the Parties relating to Product, and any successor agreement
thereto to be executed within twelve (12) months of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>President</B>&rdquo;
is defined in Section 3.3.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Process</B>&rdquo;
or &ldquo;<B>Processing</B>&rdquo; means the compounding, filling, encapsulating, producing, testing and bulk packaging of Materials
into Product, in accordance with the Product Specifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Product</B>&rdquo;
means the (a) pharmaceutical product TX-001 and (b) the pharmaceutical product TX-004, each as further described in Appendix 1,
and all Product Improvements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Product
Improvements</B>&rdquo; means any improvements to a Product including with respect to any changes to the indications, dosage strengths,
reformulations, or line extensions of such Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Product
Labeling</B>&rdquo; means the approved Product label information as specified in the applicable Marketing Authorization for a
given country or jurisdiction in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Product
Specifications</B>&rdquo; means the finished product specifications for the Products as detailed in the Marketing Authorization
in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Project
Manager</B>&rdquo; is defined in Section 3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Project
Pool Hours</B>&rdquo; means an annual pool of [***] hours per Product provided to Licensee in each Calendar Year as a credit that
may be used solely for Project Services performed in such Calendar Year by Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Project
Services</B>&rdquo; means services relating to any activities that are required for the purposes of (i) introducing a new formulation
or dosage or type of packaging which are only to be utilized in the Territory, or (ii) ensuring that a Product meets Licensee
specific Product Specification requirements that are different from specifications in other territories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Project
Service Fees</B>&rdquo; is defined in Section 10.1.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Providing
Party</B>&rdquo; is defined in Section 17.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Purchase
Order</B>&rdquo; means a purchase order with a unique number issued by Licensee for such quantities of Product as Licensee commits
to purchase from Third Party Manufacturer through TXMD, with a statement of the date on which delivery of such shipment(s) shall
be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Quality
Technical Agreement</B>&rdquo; means the quality assurance agreement agreed between the Parties relating to Product, and any successor
agreement thereto to be executed within twelve (12) months from the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Receiving
Party</B>&rdquo; means the Party to whom Confidential Information is disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Regulatory
Approval</B>&rdquo; means, the Marketing Authorization and all other approvals (including supplements and amendments), licenses,
registrations and authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity, necessary for the clinical testing, manufacture, distribution, use and Commercialization
of Product in a given regulatory jurisdiction in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Regulatory
Authorities</B>&rdquo; means any applicable federal, national, regional, state, provincial or local regulatory agencies, departments,
commissions, councils or other government entities regulating or otherwise in the Territory having authority with respect to Product,
including the EMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Regulatory
Materials</B>&rdquo; means the regulatory applications, submissions, notifications, communications, correspondence, registrations,
applications for Marketing Authorizations and other Regulatory Approvals and other filings made to, received from or otherwise
conducted with the EMA or any other Regulatory Authority in the Territory that are necessary or reasonably desirable in order
to obtain or maintain the rights from the EMA or any such other Regulatory Authority to develop, manufacture, market, sell or
otherwise Commercialize Product in a particular country, territory or possession in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Representatives</B>&rdquo;
means, with respect to a Party, such Party&rsquo;s Affiliates and such Party&rsquo;s and its Affiliates&rsquo; respective directors,
officers, employees, agents and any other persons or entities (excluding the other Party or its Affiliates) who contribute to
the performance of such Party&rsquo;s obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Right
of Reference</B>&rdquo; means the &ldquo;right of reference&rdquo; defined in 21 CFR 314.3(b), or its equivalents outside the
United States, and shall in any event include the right to allow the applicable Regulatory Authority in the Territory or a country
in the Territory to have access to relevant information (by cross-reference, incorporation by reference or otherwise) contained
in Regulatory Materials (and any data contained therein) filed with such Regulatory Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Rolling
Forecast&rdquo; </B>is defined in Section 6.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Royalty
Payments</B>&rdquo; means the fees payable by Licensee pursuant to Section 10.1.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Sublicensee</B>&rdquo;
means a Third Party to which a Party has granted a sublicense under the licensed rights granted to such Party hereunder, to the
extent such sublicense grant is permitted and made in accordance with the terms thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Supply</B>&rdquo;
means the Manufacturing and/or Packaging of Product and all related tests, analysis and all other ancillary services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Taxes</B>&rdquo;
<B>is defined in Section</B> 10.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Term</B>&rdquo;
is defined in Section 16.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Territory</B>&rdquo;
means all countries of the world with the exception of the United States, Canada, and Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Third
Party</B>&rdquo; means any Person other than the Parties or their respective Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trademark</B>&rdquo;
means the BIJUVA and IMVEXXY trademarks, or, if it is not possible to obtain registration of these marks in the EU, then such
other trademarks as are selected in accordance with Section 4.1, but excluding the TX Trademark unless the EMA or any other Regulatory
Authority requires the listing of the TX Trademark on Product that is distributed or sold within the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TX
Trademark</B>&rdquo; means TherapeuticsMD, and any other TXMD trade name(s) and/or any trademark(s) used by TXMD to identify TXMD
as a company generally (as distinguished from any product-specific identifier(s)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TXMD
Claims</B>&rdquo; <B>is defined in Section</B> 14.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TXMD
Clinical Data</B>&rdquo; means all Clinical Data owned or Controlled by TXMD as of the Effective Date or during the Term for a
Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TXMD
Indemnitees</B>&rdquo; <B>is defined in Section</B> 14.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TXMD
Know-How</B>&rdquo; means all Know-How that is Controlled by TXMD or its Affiliates as of the Effective Date or during the Term,
to the extent necessary for the Manufacture, Development or Commercialization of Product within the Commercialization Field and/or
which is disclosed by TXMD hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TXMD
Patents</B>&rdquo; means (a) the Patent Rights specified on <U>Exhibit 1</U>, and (b) any and all Patent Rights that are Controlled
by TXMD as of the Effective Date or thereafter during the Term that Cover a Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>TXMD
Technology</B>&rdquo; means, collectively, the TXMD Patents, the TXMD Know-How, the TXMD Clinical Data and all IP Improvements
owned or Controlled by TXMD and all other intellectual property rights owned or Controlled by TXMD as of the Effective Date and
during the Term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>&ldquo;United
States</B>&rdquo; or &ldquo;<B>U.S.</B>&rdquo; means the United States of America and its possessions and territories, including
Puerto Rico, irrespective of the political status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>US
GAAP</B>&rdquo; means the then current generally accepted accounting principles in the United States as established by the Financial
Accounting Standards Board or any successor entity or other entity generally recognized as having the right to establish such
principles in the United States, in each case consistently applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&ldquo;<B>Valid
Claim</B>&rdquo; means (a) any claim of an issued and unexpired patent in a country that (i) has not been held permanently revoked,
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction, which decision is unappealable
or unappealed within the time allowed for appeal and (ii) has not been abandoned, disclaimed, denied or admitted to be invalid
or unenforceable or disclaimer; or (b) a claim of a pending patent application in such country that was filed and is being prosecuted
in good faith and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Construction</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the singular,
the use of any gender is applicable to all genders and the word &ldquo;or&rdquo; has the inclusive meaning represented by the
phrase &ldquo;and/or&rdquo;. Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers
to calendar days. The headings of this Agreement are for convenience of reference only and do not define, describe, extend or
limit the scope or intent of this Agreement or the scope or intent of any provision contained in this Agreement. The term &ldquo;including&rdquo;
or &ldquo;includes&rdquo; as used in this Agreement means including &ldquo;without limiting&rdquo; or &ldquo;without limitation.&rdquo;
The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>References to Recitals, Articles, Sections and Exhibits refer to the Recitals, Articles, Sections, or Exhibits of and to
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Exhibits (as amended from time to time by agreement of the Parties in writing) form part of this Agreement and have
the same force and effect as if expressly set forth in the body of the Agreement. Any reference to the Agreement includes the
Exhibits hereto and the Quality Technical Agreement. In the event of any conflict or inconsistency between the terms of the body
of this Agreement and any Exhibits, schedules, or addenda thereto, the terms of such Exhibits, schedules or addenda shall prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.2.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the foregoing, any varying or additional terms contained in any Purchase Order or other written order confirmation,
notification or document issued by either Party in relation to the subject matter hereof shall be of no effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp; </FONT>Licenses, Commercialization, and Intellectual Property Rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Commercialization License</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms and conditions of this Agreement, TXMD hereby grants to Licensee an exclusive, sublicensable (solely
in accordance with Section 2.1.4), revocable, royalty-bearing license during the Term to the TXMD Technology, solely to Commercialize
Product in the Commercialization Field solely in the Territory. For the avoidance of doubt, the foregoing license does not grant
Licensee the right to Manufacture Product in any location, to Commercialize Product outside of the Territory, or to Develop Product,
and all of such rights are reserved to TXMD, its Affiliates and Sublicensees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Negative Covenants</U>. Licensee shall not use any TXMD Technology for any purposes other than those purposes expressly
permitted in Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Trademark License</U>. Subject to the terms and conditions of this Agreement, TXMD hereby grants to Licensee a limited,
royalty-free, exclusive in the Territory, non-transferable, revocable license to use the Trademarks solely in connection with
the Commercialization of the Products in the Territory and Licensee&rsquo;s performance of its obligations under this Agreement.
For the avoidance of doubt, Licensee&rsquo;s use of the Trademarks is limited to use in association with the Products. Licensee
acknowledges that its use of the Trademarks pursuant to this Agreement shall inure to the benefit of TXMD or its Affiliates, and
TXMD and its applicable Affiliates shall own the goodwill created thereby. TXMD shall be responsible for registering and maintaining
the Trademarks in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sublicense Rights</U>. Licensee may sublicense the rights granted to Licensee by TXMD under this Agreement to
Affiliates and Third Parties in accordance with this Section 2.1.4; provided however that Licensee shall seek TXMD&rsquo;s prior
written consent, such consent not to be unreasonably withheld or delayed with respect to sublicenses to Third Parties. Any license
or sublicense granted by Licensee shall be consistent in all material respects with, and subject to, the terms of this Agreement.
Licensee shall send TXMD an executed copy of such license or sublicense entered into with Third Parties promptly, but in no case
later than thirty (30) days, after such license or sublicense is entered into by Licensee, and shall keep TXMD reasonably informed
with respect to any license or sublicense granted by it hereunder. Where such sublicenses grant rights which extend beyond the
Products (for example where other products are included) then the sublicense may be redacted appropriately. Licensee shall be
responsible and liable for the acts and omissions of its Affiliates, subcontractors and other Sublicensees performing Licensee&rsquo;s
rights or obligations under this Agreement on behalf of Licensee as if the same were performed by Licensee and no sublicense or
subcontract arrangement pursuant to this Section 2.1.4 shall relieve Licensee of any of its obligations under this Agreement.
Notwithstanding anything to the contrary in this Agreement, Licensee shall not sublicense the rights granted to Licensee by TXMD
under this Agreement to Third Parties with respect to Commercialization of Products in any of the Major Countries or Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;<B>&nbsp;&nbsp; </B></FONT><U>Commercialization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Diligent Efforts</U>. Licensee shall be solely responsible for all aspects of Commercialization of Product in the Territory,
including planning and implementation, distribution, marketing, sales, pricing, and returns and shall use Diligent Efforts to
Commercialize Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Marketing Plans</U>. Following the Effective Date and via the JSC, Licensee shall keep TXMD regularly and reasonably
informed of its general plans for Commercialization of Product in the Territory. Without limiting the generality of the foregoing,
by December 1 prior to each Calendar Year following First Commercial Sale, Licensee on an annual basis shall provide an outline
of the marketing strategy for Product by country in the upcoming Calendar Year, including details of attendance at major conferences,
organization of significant expert advisory panels, key positioning messages, significant medical educational programs, strategic
partners, and other similar information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;
</B></FONT><U>Diversion</U>. Licensee hereby covenants and agrees that neither it nor its Affiliates or Sublicensees shall,
either directly or indirectly, promote, market, or distribute or sell the Product in each case for or in respect of countries
that are outside of the Territory. As to all such countries outside of the Territory, Licensee and its Affiliates, Sublicensees
and distributors shall not, directly or indirectly, (a) engage in any advertising or promotional activities relating to Product
directed to customers located in such countries; and (b) solicit or fulfill any orders for Product from any prospective purchaser
or recipient located in such countries. Licensee further agrees that it shall refrain (and shall cause its Affiliates, distributors
or other Sublicensees to refrain) from any Commercialization activity which could reasonably be expected to have a material negative
impact upon Commercialization of Product outside of the Territory. If Licensee or its Affiliates, distributors or other Sublicensees
receives any order from a prospective purchaser located in a country outside of the Territory, Licensee shall, and shall cause
its Affiliates, Sublicensees or distributors to, promptly refer that order to TXMD or TXMD&rsquo;s designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Intellectual Property and IP Improvements</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pre-Existing IP</U>. Any Intellectual Property Rights, including for the avoidance of doubt, Patent Rights, Know-How,
results, data, inventions and information owned by either Party (or owned by a Third Party but which a Party has the right to
disclose or sub-license) prior to the Effective Date (&ldquo;<B>Background IPR</B>&rdquo;) shall remain the property of that Party
(or, as the case may be, such Third Party).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>IP Improvements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of IP Improvements</U>. Licensee shall promptly disclose to TXMD all material IP Improvements that Licensee&rsquo;s
management becomes aware of that are conceived, reduced to practice, or otherwise developed arising from Licensee&rsquo;s performance
of any Commercialization, Development or other activities hereunder performed by or on behalf of Licensee, its Affiliates, and
their Sublicensees. As part of such disclosures, Licensee shall include details of all patentable inventions which Licensee, its
Affiliates, and their Sublicensee may develop or discover during the Term as well as information relating to IP Improvements that
may be reasonably requested by TXMD (including for use by TXMD in accordance with its reserved rights or otherwise as permitted
pursuant to this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ownership</U>. TXMD shall have exclusive ownership of any IP Improvements. Licensee hereby unconditionally and irrevocably
assigns to TXMD all of Licensee&rsquo;s right, title, and interest in, to and under any and all IP Improvements and shall cause
all of its employees and contractors and other persons involved in the conception or development of any such Improvement to execute
agreements unconditionally and irrevocably assigning all of their rights to enable TXMD to obtain exclusive rights contemplated
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Further Assurances</U>. Each Party shall, at no cost to the other Party, perform (and shall cause its Affiliates and
Sublicensees to perform) all further acts and things and execute and deliver such further documents as may be necessary or as
the other Party may reasonably require to implement or give effect to this Agreement, including, with respect to execute all such
documents and do all such things as may be necessary to vest in TXMD the right, title and interest to such IP Improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Clinical Data; Rights of Reference</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.5.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TXMD Grant to Licensee</U>. Subject to the terms and conditions of this Agreement, TXMD hereby grants Licensee a Right
of Reference to any INDs, Regulatory Materials and TXMD Clinical Data in each case that are owned or Controlled by TXMD as of
the Effective Date and thereafter, in each case solely to the extent necessary for the Commercialization of Product under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.5.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cross-Reference Letter</U>. TXMD shall allow the EMA (if required) and all other applicable Regulatory Authorities in
the Territory to have access to information (by cross-reference, incorporation by reference or otherwise) contained in Regulatory
Materials owned or Controlled by TXMD as of the Effective Date and during the Term for Product to the extent necessary to effectuate
the Rights of Reference described above in Section 2.5.1 no later than thirty (30) days after written request by Licensee. TXMD
shall provide Licensee with a cross-reference letter or similar communication to the applicable Regulatory Authority to effectuate
the Right of Reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.5.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Clinical Studies</U>. Licensee is interested in participating in future clinicial studies which TXMD may
wish to conduct in order to expand the Initial Indication of the Products. Licensee would commit to contribute both financially
and using its technical expertise. The design and cost of any such studies would need to be mutually agreed between the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third Party Infringement of TXMD Technology</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification</U>. Each Party shall promptly notify the other Party in writing of any existing or threatened infringement
of the TXMD Patents, TXMD Know-How, or the Trademarks of which it becomes aware, and shall provide all evidence in such Party&rsquo;s
possession demonstrating such infringement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforcement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TXMD Right</U>. If a Third Party infringes or misappropriates any TXMD Patents, TXMD Know-How, or the Trademarks, in
each case in the Territory, TXMD shall have the first right, but not the obligation, to bring an appropriate suit or other action
against any Third Party in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Election of Enforcement Right</U>. TXMD shall have a period of ninety (90) days (or such shorter period as may be required
to avoid prejudice to any legal rights associated with such enforcement action) after the first notice pursuant to Section 2.6.2(a)
to elect to enforce the applicable TXMD Patents, TXMD Know-How, or Trademarks against such infringement in the Territory. If TXMD
elects to respond to any actual or threatened infringement by initiating a proceeding, TXMD shall use legal counsel of its choice
at its expense and shall have full control over the conduct of such proceeding. TXMD may settle or compromise any such proceeding
without the consent of Licensee; provided, however, that if such settlement adversely affects Licensee&rsquo;s rights under this
Agreement, or adversely affects Licensee&rsquo;s ability to Commercialize Product within the Territory, or requires Licensee to
admit wrongdoing, fault, or liability, then TXMD shall not settle or compromise any such proceeding without the consent of Licensee,
such consent not to be unreasonably withheld, conditioned, or delayed. In the event TXMD does not elect to initiate an enforcement
action and thereafter diligently prosecute a suit or action or otherwise cause the cessation of such infringement within such
ninety (90) day period, then Licensee shall have the right, but not the obligation, to commence suit or take action to enforce
the applicable TXMD Patents, TXMD Know-How, or Trademarks against such Third Party at its own costs and expenses in which case
Licensee shall have full control over the conduct of such proceeding and Licensee may settle or compromise any such proceeding
without the consent of TXMD; provided, however, that if such settlement adversely affects TXMD&rsquo;s Intellectual Property Rights
or its rights under this Agreement, or adversely affects TXMD&rsquo;s ability to Commercialize Product outside the Territory,
or requires TXMD to admit wrongdoing, fault, or liability, Licensee shall not settle or compromise any such proceeding without
the consent of TXMD, such consent not to be unreasonably withheld, conditioned, or delayed. Licensee shall be solely responsible
for any legal costs or damages awards made in any proceeding that is initiated by Licensee in the event that TXMD elects not to
respond to any actual or threatened infringement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reasonable Cooperation</U>. Each Party shall provide to the Party enforcing any such rights under this Section 2.6.2
reasonable assistance in such enforcement, at such enforcing Party&rsquo;s request and expense, including joining such action
as a party plaintiff if required by Applicable Law to pursue such action. The enforcing Party shall keep the other Party regularly
informed of the status and progress of such enforcement efforts and the Parties agree that, irrespective of which Party brings
an action pursuant to this Section 2.6.2, the Parties shall discuss and reasonably consider the views of the other Party in the
choice of counsel with respect to such action and strategic decisions and their implementation (including decisions regarding
defending against a claim, counterclaim or defense of invalidity or unenforceability of infringes any TXMD Patents, TXMD Know-How,
or the Trademarks) in connection with such action shall be managed by consensus of the Parties each acting reasonably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Separate Representation of Non-Enforcing Party</U>. The Party not bringing an enforcement action in the Licensed Territory
under this Section 2.6.2 shall be entitled to separate representation in such matter by counsel of its own choice and at its own
expense, but such Party shall at all times cooperate fully with the Party bringing such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Settlement</U>. Licensee may not settle an action it commences hereunder that admits any wrongdoing of TXMD without
TXMD&rsquo;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Costs and Proceeds</U>. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any monetary
award recovered from a Third Party in connection with any proceeding initiated to protect, maintain, defend, or enforce any intellectual
property rights in the Territory or recovered from a Third Party in connection with any proceeding initiated for infringement
or misappropriation of intellectual property rights in the Territory shall first be used to reimburse the Parties for any out-of-pocket
legal expenses relating to such proceeding and the balance being retained by the Party that brought and controlled such litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp; </FONT><U>Patent Prosecution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As between the Parties, TXMD, acting through outside patent counsel, shall have the sole right, but not the obligation
to prepare, file, prosecute (including without limitation conducting any interferences, oppositions, reissue proceedings, reexaminations
and patent term extensions) and maintain the TXMD Patents in the Territory. TXMD shall bear the cost and expense incurred in connection
with the preparation, filing, prosecution and maintenance of such TXMD Patents in the Territory. TXMD shall carry out any preparation,
filing, prosecution and maintenance of such TXMD Patents with commercially reasonable efforts. Licensee shall cooperate with TXMD
in the preparation, filing, prosecution and maintenance of such TXMD Patents, including by providing TXMD with data and other
information as appropriate and executing all necessary affidavits, assignments and other paperwork. TXMD shall copy Licensee on
all correspondence from and to any patent office relating to such TXMD Patents in a timely manner. For the purpose of this Section
2.7.1, &ldquo;prosecution&rdquo; shall include any patent interference, opposition, pre-issuance Third Party submission, ex parte
re-examination, post-grant review, inter partes review or other similar proceeding, appeals or petitions to any Board of Appeals
in a patent office, appeals to any court for any patent office decisions, reissue proceedings, and applications for patent term
extensions and the like.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>TXMD shall not abandon maintenance of any TXMD Patents in the Territory without notifying Licensee in a timely manner of
TXMD&rsquo;s intention and reason therefore and providing Licensee with reasonable opportunity to comment upon such abandonment
and to assume responsibility for maintenance of such patent rights. TXMD shall provide such notice at least thirty (30) days prior
to any payment due date, or any other due date that requires action, in connection with such TXMD Patent. In the event that TXMD
abandons maintenance of any or all TXMD Patents in the Territory, Licensee may assume maintenance for such patent in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Governance</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Project Managers</U>. Within thirty (30) days of the Effective Date, each Party shall appoint a representative having
a general understanding of pharmaceutical development and commercialization issues to act as its alliance manager under this Agreement
(&ldquo;<B>Project Manager</B>&rdquo;). The Project Managers shall be primarily responsible for facilitating the flow of information
and otherwise promoting communication, coordination and collaboration within and among the Joint Steering Committee and between
the Parties, providing a single point of <B>communication for seeking consensus both internally within the respective Party&rsquo;s
organization</B> and, together, regarding key strategy and planning issues, as appropriate, including facilitating review of external
corporate communications and raising cross-party or cross-functional disputes to the Joint Steering Committee in a timely manner.
Each Project Manager may also serve as a non-voting attendee of its respective Party to Joint Steering Committee meetings. Each
Party may replace its Project Manager upon notice to the other Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Project Management Meetings</U>. The Project Managers shall conduct sales and operation
planning meetings relating to Product in the Territory initially every ninety (90) days (or as otherwise reasonably requested
by either Party). The agenda of such meetings may include: (a) market intelligence; (b) Supply capability; (c) regulatory changes;
(d) long term forecasts; (e) capacity planning; or (f) such other topics that either Party may raise for discussion in connection
with its obligations under this Agreement. Meetings may be conducted by telephone, video conference, or in-person, as mutually
agreed by the Project Managers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Joint Steering Committee Formation; Purpose</U></B>. Within thirty (30) days from the Effective Date, the Parties
shall establish a committee (the &ldquo;<B>Joint Steering Committee</B>&rdquo;), which shall consist of two (2) representatives
of each Party, including: senior members of each Party&rsquo;s teams. The purpose of the Joint Steering Committee shall be to
keep the Parties advised and coordinated with respect to activities relating to Product and to perform such other functions as
may be mutually agreed by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Joint Steering Committee Meetings</U></B>. The Joint Steering Committee shall hold meetings no less frequently than
every Calendar Quarter. Each Party shall be entitled to call an extraordinary meeting of the Joint Steering Committee where it
reasonably believes that a meeting is called for with regard to a matter of material importance that cannot be delayed until the
next scheduled quarterly meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Location of Meetings; Attendees</U></B>. The Joint Steering Committee may meet via teleconference, video-conference,
or in-person, as mutually agreed by the Parties, provided that at least one Joint Steering Committee meeting per calendar year
would be held in person at a location to be agreed. The Joint Steering Committee may invite other personnel of the Parties to
attend meetings of the Joint Steering as appropriate, after giving notice to the other Party. The Joint Steering Committee shall
be dissolved upon the termination or expiration of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Decision Making</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the other applicable provisions of this Agreement, the Joint Steering Committee shall act and make decisions
only by unanimous vote, with each Party having one (1) vote. If the Joint Steering Committee is unable to reach unanimous agreement
on a matter before it for decision or action, for a period in excess of fifteen&nbsp;(15) days after written request by a Party,
the matter shall be referred to the President of the Parties for discussion and resolution. As of the Effective Date, the President
of TXMD is John Milligan and the Chief Executive Officer of Licensee is Anish Mehta.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, after referral by the Joint Steering Committee, the President and CEO of the Parties have not reached agreement on
the matter within fifteen (15) days after referral to the President and CEO, then: (i) Licensee shall have the right to make the
final decision on such matters that relate solely to or would have a material impact on the Commercialization of Product in the
Territory, (ii) TXMD shall have the right to make the final decision on such matters that would have a material adverse impact
on TXMD&rsquo;s rights in the United States, and (iii) TXMD shall have the right to make the final determination with respect
to all other matters; provided that in each case each Party shall act in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.3.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Authority</U></B>. The Joint Steering Committee shall have only the powers assigned expressly to it in this Article
3 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Costs</U>. TXMD and Licensee each shall bear all expenses incurred
by TXMD and Licensee, as applicable, of its employees related to meetings between the Parties, unless otherwise mutually
agreed by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Trademarks and Packaging; Materials</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Branding</U>. All Packaging shall be branded with the Trademark associated with each Product. All Trademarks, and all
goodwill relating thereto, shall be solely and exclusively owned by TXMD and its Affiliates, as applicable. TXMD will use all
reasonable commercial efforts to obtain registration of BIJUVA and IMVEXXY as a Community trade mark and as a UK trade mark as
soon as practicable after the Effective Date. If the BIJUVA or IMVEXXY filing is unsuccessful then the Parties will discuss in
good faith and agree upon an alternative mark which they consider will be effective in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Packaging Artwork</U>. Licensee shall be responsible for artwork and design for the packaging and labelling in the Territory,
which Licensee shall ensure complies with all applicable Marketing Authorizations. Licensee shall be entitled to have its trade-marks
displayed on the packaging for the Products. The Products shall also include the language &ldquo;distributed by Theramex HQ UK
Limited&rdquo; or such other equivalent in English and any other language as may be required under Applicable Law for the Territory.
The language may alternatively reference one of Licensee&rsquo;s Affiliates in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>TXMD Materials</U>. TXMD shall use the Licensee&rsquo;s Long Term Forecasts, Rolling Forecasts, Purchase Orders and
Firm Commitments, as defined in Sections 6 and 7, to order Materials to support manufacture of Product for Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Product Development and Marketing Authorizations</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Regulatory
Materials and Marketing Authorizations in the Territory</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Materials and Obligations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Licensee Diligent Efforts</U>. Licensee shall, in compliance with Applicable Laws in the Territory, prepare and file
the appropriate Regulatory Materials and use Diligent Efforts to file the submission for the applicable Marketing Authorizations
for [***] in [***]. Other than with respect to [***], the Parties will agree when and where to submit applications for [***] based
on the approvability of the dossier, market size and opportunity. With respect to [***], Licensee shall have a period of [***]
from the receipt of Regulatory Materials delivered pursuant to Section 5.1.1(b) to file the submission for the applicable Marketing
Authorizations for [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TXMD Regulatory Materials; Knowledge Transfer</U>. Within thirty (30) days following the Effective Date, TXMD shall
provide Licensee with copies of all completed Regulatory Materials and Clinical Data as submitted by or on behalf of TXMD to the
EMA or any other applicable Regulatory Authority that are in TXMD&rsquo;s or its Affiliates Control as of the Effective Date and
that are necessary for Licensee to obtain Marketing Authorizations and other applicable Regulatory Approvals for Commercializing
the Products in the Territory. Upon request from Licensee, TXMD shall provide any further documentation in TXMD&rsquo;s or its
Affiliates&rsquo; Control during the Term that is mutually agreed by the Parties acting in good faith to be necessary to support
obtaining Marketing Authorizations and other applicable Regulatory Approvals required to Commercialize the Products in the Territory.
Within the same timeframe, TXMD will provide Licensee with the most recent draft of its US Dossier in order that Licensee can
adapt it for filing in the Territory. TXMD may not have Control over its Contract Manufacturer&rsquo;s DMF and nothing herein
shall be construed to require TXMD to provide such DMF to Licensee. However, TXMD will ensure that Licensee has access to the
open part of any such DMF and that its Contract Manufacturer will provide a Letter of Access to the closed part of the DMF so
the Marketing Authorization application can proceed. All such Regulatory Materials and Clinical Data shall be deemed Confidential
Information of TXMD. TXMD shall provide to Licensee reasonable knowledge transfer and support services relating to Licensee&rsquo;s
use of any Regulatory Materials or Clinical Data provided by TXMD for used solely for the purposes permitted hereunder. For the
avoidance of doubt, Licensee shall be responsible for any modifications to or translation of TXMD-provided Regulatory Materials
or Clinical Data for use in Licensee&rsquo;s Regulatory Material filings in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cost</U>. All costs and expenses required for Licensee to prepare any and all such regulatory submissions in the Territory
shall be borne solely by Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filing Party</U>. Subject to Section 16.6 below, all Regulatory Materials and applications for Marketing Authorizations
and other Regulatory Approvals filed with the EMA and other applicable Regulatory Authorities in the Territory shall be held in
Licensee&rsquo;s name; provided that Licensee shall discuss and collaborate with TXMD on any Regulatory Materials or any application
for a Marketing Authorization or other Regulatory Approval in the Territory for the Products. Licensee will advise TXMD on the
most appropriate filing strategy in the Territory and the Parties will cooperate in order to arrange pre-submission meetings and
obtain a slot for filing as soon as practicable following the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Variations.</U> TXMD will assist Licensee with renewals, variations or updates of the Marketing Authorisations which
are required by Licensee or the Regulatory Authorities from time to time and promptly do all acts and execute all documents required
in order to carry out these activities. Actual and direct costs relating to variations etc. will be allocated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">TXMD
shall reimburse Licensee for any fees payable to the Regulatory Authority resulting from: (i) changes requested by TXMD; and (ii)
changes requested by its Contract Manufacturers (e.g. variations which are required due to the establishment, maintenance and
improvement of GMP-related activities or other aspects of the manufacturing process);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Licensee
shall bear all regulatory costs resulting from (i) changes required by Licensee, and (ii) changes required by competent authorities
relating to the Commercialization of the Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reporting and Review</U>. Licensee shall provide TXMD with copies of all Marketing Authorizations and other Regulatory
Approvals that it receives for the Products in the Territory, within fifteen (15) days of receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Steering Committee Review</U>. If TXMD believes that Licensee or its Affiliates or Sublicensees, as the case may be,
is taking or intends to take any action with respect to a Marketing Authorization or other Regulatory Approval that TXMD believes
may have an adverse impact upon the potential sales of Product outside of the Territory or the regulatory status of Product, TXMD
shall have such issue addressed by the Joint Steering Committee as described in Section 3.3.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adverse Event Reporting and Safety Data Exchange</U>. Licensee shall be responsible for the monitoring of all adverse
events and filing of all required reports in the Territory relating to Product throughout the Term. Licensee shall promptly notify
TXMD, in accordance with Applicable Laws and the requirements of the EMA and any other applicable Regulatory Authority, if it
becomes aware of any adverse event relating to Product in the Territory, including, without limitation, any event which (a) raises
any material concerns regarding the safety or efficacy of Product; (b) indicates or suggests a potential material liability of
either Party to Third Parties in connection with Product; (c) is reasonably likely to lead to a recall or market withdrawal of
Product; or (d) relates to expedited and periodic reports of adverse events with respect to Product, or to Product complaints,
and which may have a material impact on the Marketing Authorization or any other Regulatory Approval for Product or the continued
Commercialization of Product. TXMD contracts with a third party pharmacovigilance vendor. Licensee shall report any adverse events
to the third-party pharmacovigilance vendor in the vendor defined format, with a copy also sent to TXMD. TXMD will continue to
hold the Global Safety Database and the Parties will enter into a Pharmacovigilance Agreement clarifying their respective obligations
within six (6) months of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Regulatory Authority Communications Received by a Party</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. Without limiting the generality of the foregoing, each Party shall keep the other Party informed, in a
timely manner compliant with the reporting requirements of the EMA and all other applicable Regulatory Authorities in the Territory,
of notification of any action by, or notification or other information which it receives (directly or indirectly) from, the EMA
or any such other Regulatory Authority in the Territory which (a) raises any material concerns regarding the safety or efficacy
of Product; (b) indicates or suggests a potential material liability of either Party to Third Parties in connection with Product;
(c) poses a significant risk of leading to a recall or market withdrawal of Product; or (d) relates to expedited and periodic
reports of adverse events with respect to Product, or to Product complaints, and which may have a material impact on any Marketing
Authorization or other Regulatory Approvals for a Product or the continued Commercialization of a Product in the Territory. The
other Party shall fully cooperate with and assist such Party in complying with regulatory obligations and communications, including
by providing to such Party, within two (2) Business Days after a request, such information and documentation in the other Party&rsquo;s
possession as may be necessary or helpful for the Party to prepare a response to an inquiry from the EMA or any other applicable
Regulatory Authority with respect to Product. If Licensee is required to respond to any Regulatory Authority in the Territory,
Licensee shall use Diligent Efforts to discuss and collaborate with TXMD before responding. Licensee shall also provide TXMD in
a timely manner with a copy of all correspondence received from the EMA or any other applicable Regulatory Authority specifically
regarding the matters referred to above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Disclosures</U>. Licensee shall promptly (in all events, within 48 hours of receipt) disclose to TXMD the
following regulatory information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Actions</U>. All material information in Licensee&rsquo;s possession and Control pertaining to actions taken
by the EMA or any other applicable Regulatory Authority in the Territory in connection with Product including any notice, audit
notice, notice of initiation by the EMA or any such other Regulatory Authority of any investigation, inspection, detention, seizure
or injunction concerning Product, notice of violation letter (i.e., an untitled letter), warning letter, service of process or
other inquiry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Non-Compliance</U>. All Information pertaining to notices from the EMA or any other applicable Regulatory
Authority in the Territory of non-compliance with Applicable Laws in connection with Product, including receipt of a warning letter
or other notice of alleged non-compliance from the EMA or any such other Regulatory Authority relating to Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extra-territorial Disclosures</U>. TXMD will inform Licensee in a timely fashion of any communications of which it becomes
aware from regulatory authorities outside the Territory which may have a material bearing on the Commercialization of Product
in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Performance of Manufacturing and Supply</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Background; TXMD Responsibilities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Licensee acknowledges that as of the Effective Date, TXMD is utilizing a Contract Manufacturer to Manufacture the Products
both for TXMD&rsquo;s purposes outside of the Territory and to fulfill TXMD&rsquo;s obligations to Manufacture and supply Product
to Licensee under this Agreement. During the Term of the Agreement, the Parties shall discuss in good faith aligning the time
frames described in Article 6, Article 7 and Article 8 with TXMD&rsquo;s corresponding Manufacturing and supply time frames under
which TXMD is subject to with respect to such Contract Manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>TXMD shall perform Supply and Manufacturing service in accordance with professional standards and shall Supply Product
according to this Agreement. Notwithstanding the foregoing, if there is a shortage of Product due to an operational failure at
TXMD&rsquo;s Manufacturing facility, the Supply will be apportioned between TXMD and Licensee based on a fair consideration of
all factors affecting individual markets of both Parties, including relative volumes of Product ordered. TXMD shall be responsible
for the safety, health and environmental aspects of all work performed by or on behalf of TXMD, excluding any issues to the extent
caused by the acts, omissions, or negligence of Licensee, its Affiliates, or Sublicensees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subcontracting</U>. TXMD shall be entitled to subcontract to a Contract Manufacturer or any other Third Party any or
all of its obligations to Manufacture and Supply Product for Licensee under this Agreement without Licensee&rsquo;s prior approval
provided always that TXMD will give Licensee at least [***] months&rsquo; prior notice of the appointment of any new Contract
Manufacturer and provide adequate assurances to Licensee that the new appointment will not have a material adverse impact on the
ability of TXMD to fulfil its obligations under this Section. TXMD must notify Licensee of any subcontracting with respect to
the Manufacture of Product and the Parties shall work together to determine what information Licensee would be required to report
to or file with the EMA or any other applicable Regulatory Authority in order to comply with any Applicable Law in the Territory
or any country or jurisdiction in the Territory and TXMD shall use commercially reasonable efforts to assist Licensee with Licensee&rsquo;s
compliance obligations under Applicable Law in the Territory as a result of such subcontracting, which shall include coordinating
with Licensee to carry out audits of the facilities on an annual basis. Any additional actual costs relating to the participation
and attendance of Licensee&rsquo;s representatives in such audits shall be borne by Licensee. No subcontracting pursuant to this
Section 6.2 shall relieve TXMD of any of its obligations, or Licensee of any of its rights, under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Quality</U>. Each Party shall comply with all of the provisions and requirements of the Quality Technical Agreement.
In the event of a discrepancy between the Quality Technical Agreement and this Agreement, the terms of the Quality Technical Agreement
shall control all quality matters and this Agreement shall control all other matters. The Parties will enter into the Quality
Technical Agreement within twelve (12) months of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>GMP</U>. All Manufacture and quality control operations by TXMD or its designee shall be in compliance with cGMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Long Term Forecasts</U>. On a date to be agreed upon by the Parties following the Effective Date, but in any event such
date to be no later than [***] months prior to estimated First Commercial Sale, and thereafter, prior to [***] of each Calendar
Year during the Term, Licensee shall submit to TXMD a good faith estimate of the quantities of Product that Licensee expects to
order from TXMD during the immediately following Calendar Year (&ldquo;<B>Long Term Forecast</B>&rdquo;). Subject to Section 6.6,
Long Term Forecasts shall be non-binding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rolling Forecast; Binding Firm Commitment</U>. On or before the [***] day of each Calendar Month, beginning at least
[***] months prior to the anticipated First Commercial Sale and continuing during the Term, Licensee shall submit to TXMD a good
faith estimate of its anticipated orders of Product, which shall be at a bulk SKU level, broken out on a month-by-month basis,
for the upcoming Calendar Month and the succeeding twelve (12) Calendar Months (each, a &ldquo;<B>Rolling Forecast</B>&rdquo;).
Months [***] of each Rolling Forecast shall be binding on Licensee with respect to the quantities specified therein and month
[***] shall be binding but may vary by +/-[***]% (&ldquo;<B>Firm Commitment</B>&rdquo;); provided that TXMD has first provided
Licensee with reasonable advance notice of its planned manufacture date for Product and may not be changed without TXMD&rsquo;s
written consent (which may be withheld in its sole discretion). The Rolling Forecast for the remaining [***] months shall not
be binding but shall be provided in good faith. For avoidance of doubt, TXMD hereby covenants to provide said reasonable advance
notice of its planned manufacture date for Product to Licensee during the Term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Forecasts Exceeding the Firm Commitment</U>. If Licensee requires more than the Firm Commitment, Licensee must provide
TXMD reasonable prior notice of the delivery date requested as described in Section 6.1.1 and TXMD shall inform Licensee of the
quantity of Product (if any) above the Firm Commitment that TXMD is able to Supply. TXMD shall not be obligated to supply Product
in excess of the Firm Commitment to Licensee unless agreed to by TXMD in its sole discretion, and TXMD shall not be liable for
any failure to supply Product to Licensee in excess of the Firm Commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Licensee Rights and Responsibilities. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.8.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Alternative Primary and Secondary Manufacturers</U>. Both Parties will use commercially reasonable efforts to identify
potentially more cost-effective alternative primary (API manufacture) and/or secondary (processing of API into finished product)
manufacturers for the Product for the Territory and with the written agreement of both Parties will collaborate so as to add such
manufacturers to the Marketing Authorization and use them to Manufacture Product for Licensee in the Territory and for TXMD outside
of the Territory. If the addition of such a manufacturer and use of such manufacturer to Manufacture Product is to the benefit
of only one of the Parties, then such Party shall bear the costs of qualification of such manufacturer. If the addition of such
a manufacturer and use of such manufacturer to Manufacture Product is to the benefit of both Parties, then the Parties shall share
the costs of qualification of such manufacturer in a reasonable and proportionate manner. Licensee will not source Product from
an alternative manufacturer without the prior written consent of TXMD and will coordinate with TXMD before initiating sourcing
of Product from any such alternative manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.8.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Primary and Secondary Packaging</U>. Licensee will be responsible for identifying and contracting with suitable primary
(blister) and secondary (outer packaging and inserts) packagers in order to convert bulk Product supplied by TXMD&rsquo;s Manufacturers
into finished product in final form and ready for sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Orders</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Purchase Orders</U>. Licensee shall submit (or shall have one of its Affiliates
submit) to TXMD a Purchase Order for Product to be delivered to Licensee within the agreed Lead Time. Within five (5) days following
receipt of a Purchase Order, TXMD shall provide a written acknowledgement (&ldquo;<B>Acknowledgement</B>&rdquo;) that it accepts
the Purchase Order. The Acknowledgement shall confirm the delivery date and TXMD shall deliver Product in accordance with the
Lead Time as may be superseded by the revised timeframes contemplated by 6.1.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Modifications; Changes to Purchase Orders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>TXMD shall use commercially reasonable efforts to comply with changes to Purchase Orders that Licensee may request but
shall not be liable for its inability to do so. Purchase Orders may be amended only by mutual agreement of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No change in any Purchase Order shall relieve Licensee of its responsibility to meet the Firm Commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Supply</U>. TXMD shall Supply or have Supplied the specified quantity of Product in accordance with the delivery terms
set forth in each Purchase Order, provided that (a) TXMD shall be considered to have completed its obligations to fulfill any
individual Purchase Order if it Supplies a quantity of Product that is within a plus or minus [***] per cent ([***]%) variance
from the applicable Purchase Order, and (b) Licensee shall only be required to pay for the amount of Product actually delivered
by TXMD to Licensee. Any such variance in quantity of Product delivered by TXMD shall not constitute a breach of this Agreement
by TXMD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Delivery; Review and Defective Product</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delivery Terms; Storage Fees</U>. The Contract Manufacturer shall deliver and Supply Product ordered by Licensee EXW
INCOTERMS 2010 and title to Product shall transfer directly from the Contract Manufacturer to Licensee. Product will be delivered
with a minimum shelf life of [***] months remaining (for Product with a shelf life of [***] months) at the time of delivery. If
a Batch is held by the Contract Manufacturer for investigation, up to two Batches per calendar year, Product with a shelf life
of [***] months will be delivered with a minimum remaining shelf life of [***] months. The Parties currently anticipate that TX-001
and TX-004 will each have a shelf life of [***] months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Release of Batches</U>. Product shall be accompanied by a Certificate of Analysis and a certificate of manufacturing
compliance, which may be contained in a single certification, and any other documentation as set forth in the Quality Technical
Agreement. Issuance of a Certificate of Analysis and any other documentation as set forth in the Quality Technical Agreement constitutes
release of a Batch to Licensee. Licensee is responsible for final release of Product to the market in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Review; Defects or Shortfalls</U>. If any shipment of Product delivered by TXMD contains a Defective Product or if there
is a shortfall of the amount of Product in such delivery at the time of delivery, then Licensee shall notify TXMD (a) within thirty
(30) days of receipt of the applicable Batch if such damage, defect or shortfall can be ascertained by the exercise of reasonable
diligence upon examination by Licensee on receipt of such shipment, or (b) within thirty (30) days after discovery of the same
if such damage, defect or shortfall cannot be ascertained by the exercise of reasonable diligence upon examination by Licensee
on receipt of such shipment (including non-conformities relating to stability). Licensee shall provide TXMD with a sample of any
Defective Product. If and to the extent that Licensee has failed to provide TXMD with a notice of any Defective Product (an &ldquo;<B>Exception
Notice</B>&rdquo;) and a sample thereof by the applicable time period specified above in this Section 8.3, the relevant Batch
shall be deemed to have been accepted by Licensee in satisfactory condition, without any damages, shortfalls or defects. If Licensee
determines that there is a shortfall in the quantity of any shipment of Product (from quantities specified in the relevant bill
of lading or other shipping documents), and it is determined that discrepancy existed at the time it was delivered to Licensee
from TXMD, then Licensee shall notify TXMD in writing as soon as reasonably possible, and TXMD shall either (i) make up the shortage;
or (ii) reimburse Licensee for the amounts paid for shortfall Product, in each case at Licensee&rsquo;s option within thirty (30)
days of such notification at no additional cost to Licensee, provided that in each case, the make up or reimbursement will be
applied to future Batch orders. The remedies of Licensee under this Section 8.3 with respect to any shortage shall be the exclusive
remedies of Licensee for any such shortage and in lieu of any and all other remedies of Licensee and, upon compliance with this
Section 8.3, TXMD shall not be in breach of this Agreement as a result of any such shortage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Discrepant Results</U>. If a dispute arises between the Parties as to any claimed damage or defect in Product or as
to any shortfall of Product delivered, which cannot be resolved by the Parties within twenty (20) days of a claim being notified
by Licensee to TXMD, either Party may require that the matter in dispute be referred to an independent expert (such as an independent
testing laboratory) nominated by agreement of the Parties or, failing agreement, appointed in accordance with the commercial arbitration
rules of the International Chamber of Commerce at the request of either Party. Such referral shall be solely for the purpose of
establishing whether or not there is any damage, defect or shortfall (as the case may be) in Product delivered by TXMD to Licensee.
Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by TXMD
if Product is a Defective Product attributable to Manufacturing, storage, shipping, or any other action by or on behalf of TXMD
that occurs prior to delivery of Product to Licensee, and by Licensee in all other circumstances. Licensee shall be apprised in
writing of all Defective Product investigations executed by TXMD, as well as final investigation outcome and conclusion(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remedies for TXMD-Attributable Defective Product</U>. If Product constitutes a Defective Product due to Manufacturing
by or on behalf of TXMD, TXMD shall at TXMD&rsquo;s option either: (a) replace the Defective Product with conforming Product,
at TXMD&rsquo;s expense; or (b) credit or refund to Licensee the amounts paid to TXMD by Licensee for such Defective Product,
or, if the invoice has not been paid, cancel the invoice. THE OBLIGATION TO REPLACE A DEFECTIVE PRODUCT OR CREDIT OR REFUND PAYMENTS
MADE BY LICENSEE FOR A DEFECTIVE PRODUCT ATTRIBUTABLE TO ERRORS OR DEFECTS IN MANUFACTURING BY OR ON BEHALF OF TXMD SHALL BE LICENSEE&rsquo;S
SOLE AND EXCLUSIVE REMEDY THIS AGREEMENT FOR SUCH DEFECTIVE PRODUCT AND IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED,
OR REMEDY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Late Delivery</U>. Where Product is delivered late then TXMD will pay a penalty equivalent to [***]% of the value of
the portion of the order which was delivered late for each month which elapses beyond the original delivery date appearing on
the Purchase Order but capped at a level of [***]%. Deliveries of Product may vary by up to plus or minus [***] ([***]) Business
Days from the delivery date specified in the related Purchase Order. Such variance in actual date of delivery shall not constitute
a breach of this Agreement by TXMD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Product Recall</B>. If Product is recalled in the Territory for any reason, then Licensee, as Marketing Authorisation holder
shall administer all aspects of the recall. Each Party shall notify the other in writing promptly, and in any event within one
(1) business day after determining that a recall is required, and shall consult with the other Party regarding appropriate courses
of action. Licensee shall have ultimate discretion over whether and under what circumstances to require the recall of Product
in the Territory. TXMD shall provide all assistance that Licensee reasonably requires in connection with any Product recalls,
including as required by any Regulatory Authorities or pursuant to Applicable Laws. In the event that a recall is necessary as
a result of any breaches of obligations, representations or warranties hereunder or negligence of either Party, that Party shall
be responsible for the proportionate share of such costs. In the event of a recall, the obligations of Licensee to Commercialise
a recalled Product in the Territory and of TXMD to supply such recalled Product pursuant to this Agreement shall be suspended
with immediate effect and such obligations shall only become enforceable again if the circumstances that caused the recall have
been resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Fees and Payments</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Milestone Fees; Product Pricing and Royalties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Milestone Fees</U>. Upon the achievement of each milestone specified in <U>Exhibit 2</U>, Licensee shall issue to TXMD
a written statement as to the achievement of the milestone and the associated Milestone Fees within twenty (20) days following
the end of the Calendar Quarter in which such milestone is achieved. Upon receipt of each such statement, TXMD shall submit an
invoice to Licensee for the associated Milestone Fees due under this Section 10.1.1, which shall be due and payable to TXMD in
accordance with Section 11.3. Milestone Fees shall be non-refundable, non-creditable and not subject to set-off, except as provided
in Section 8.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Product Prices</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Estimated COG Per Unit Pricing</U>. No later than [***] of each Calendar Year during the Term, TXMD shall inform Licensee
of the estimated COGS per unit price for each Product, as established based on the anticipated volume of purchases and structured
as a pass-through without mark-up. The initial estimated COGS per unit price as of the Effective Date for each Product is set
out in <U>Exhibit 3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payments before Delivery/Firm Commitments</U>. Licensee shall pay TXMD the estimated COGS per unit price for ordered
Products in accordance with Section 11.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Annual True-Up</U>. Within sixty (60) days following the completion of each Calendar Year or termination of this Agreement,
TXMD shall calculate and reconcile the Paid Estimated Product Fees versus the Actual Product Fees due for such period, issuing
either an invoice to Licensee if Paid Estimated Product Fees were less than Actual Product Fees and a credit or refund if Paid
Estimated Product Fees were greater than Actual Product Fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Royalties</U>. During the Term, Licensee shall pay royalties at a rate of [***] percent ([***]%) on Net Sales of Product
in the Territory (the &ldquo;<B>Royalty Payments</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Quarterly Sales and Royalty Reports</U>. Within thirty (30) days following the end of each Calendar Quarter following
the First Commercial Sale of each Product in the Territory, Licensee shall furnish to TXMD a quarterly written report showing
the Net Sales of Product sold by Licensee, its Affiliates and their Sublicensees, and the royalties due to TXMD on such Net Sales.
Upon receipt of the report and the royalty calculation, TXMD will issue an invoice for the Royalty Payments due under Section
10.1.3 for each Calendar Quarter, which shall be due and payable to TXMD in accordance with Section 11.3. Each royalty report
shall describe in reasonable detail (based upon the data then available to Licensee) the Net Sales of Product (including, without
limitation, the deductions specified in the Net Sales definition) and the calculation of Royalty Payments (including currency
conversion as described in Section 11.3) due for the relevant calendar quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Royalty Reduction</U>. On a country-by-country, Product-by-Product, jurisdiction-by-jurisdiction basis, in the event
that a Generic Product gains Marketing Authorization for Commercialization and has been granted an official reimbursement price
(if applicable) in any such country or jurisdiction in the Territory, then the royalty rates in Section 10.1.3 payable in respect
of Net Sales for the applicable Product in such country or jurisdiction shall be reduced by [***] ([***]) percent beginning in
the first Calendar Quarter after Licensee provides notice to TXMD and reasonably sufficient documentation that a Generic Product
gained Marketing Authorization for Commercialization and price approval in such country or jurisdiction in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Project Services; Cost of Changes</U>. All Project Services shall be chargeable on a time and materials basis in accordance
with the Consulting Rate, following utilization of any available Project Pool Hours (the &ldquo;<B>Project Service Fees</B>&rdquo;).
Project Pool Hours do not have any cash value and cannot be used to offset any other fees due under this Agreement. Additionally,
to the extent that TXMD incurs any costs or expenses arising from materials required to implement any change, TXMD shall be reimbursed
for such costs and expenses, provided that Licensee has pre-approved such costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>. All fees due under this Agreement are exclusive of all sales, use, transfer, excise, value added and other
direct taxes or Indirect Taxes applied to its (or its Affiliates&rsquo;) sale of Product or receipt of services (collectively,
&ldquo;<B>Taxes</B>&rdquo;), which, if payable, shall be borne and paid by Licensee (without any set-off, deduction or withholding
against any other amounts due hereunder), subject to the provision by TXMD of an appropriate invoice listing such Taxes. Licensee
shall provide TXMD with proof of export and any other related documentation required by tax or Regulatory Authorities. Licensee
shall make all payments to TXMD under this Agreement without deduction or withholding for Taxes except to the extent that any
such deduction or withholding is required by law in effect at the time of payment. Any Tax required to be withheld on amounts
payable by Licensee under this Agreement shall be timely paid by Licensee on behalf of TXMD to the appropriate governmental authority,
and Licensee shall furnish TXMD with the corresponding proof of payment of such tax, as may be required in order to enable TXMD
to request reimbursement or deduction of the withheld amount, or to otherwise comply with its duties. Licensee and TXMD agree
to cooperate to legally minimize and reduce such withholding Taxes and provide any information or documentation required by any
taxing authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Invoicing and Payment</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Invoices for Fees</U>. TXMD shall issue an invoice to Licensee for Project Service Fees or any other fees due under
this Agreement that are not Milestone Fees or Royalty Payments within ninety (90) days after the end of the calendar quarter during
which such services were provided or fees became payable under this Agreement. The invoice shall contain a reference identifying
this Agreement and the Project Services Fees or other fees payable. Payment of such invoices shall be made in accordance with
Section 11.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Invoices for Product</U>. TXMD shall issue an invoice to Licensee for Product (or in the absence of such invoice, procure
an invoice from its Contract Manufacturer) ninety (90) days or more after a Purchase Order has been placed for Product for a scheduled
delivery date. The invoice shall contain a reference identifying this Agreement and the Purchase Order number. Payment of such
invoices shall be made in accordance with Section 11.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment Terms</U>. Payment of invoices for Milestone Fees submitted pursuant to Section 10.1.1 and invoices for Royalty
Payments submitted pursuant to Section 10.1.3 shall be made by Licensee within thirty (30) days after receipt of the related invoice
by Licensee. Payment of uncontested amounts of an invoice for Product submitted pursuant to Section 11.2 (including, for example,
and without limitation, the estimated COGS per unit price for ordered Products) shall be made by Licensee within thirty (30) days
following the end of the month in which the invoice is issued. Payment of all other invoices submitted by either Party shall be
made within thirty (30) days of the month end following the date of invoice, unless any other payment terms are specified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Means of Payment; Currency</U>. All payments to be made by one Party to the other Party under this Agreement shall be
made in U.S. Dollars and by bank wire transfer in immediately available funds to such U.S. bank account as may be designated in
writing by a receiving Party from time to time. The rate of exchange to be used in computing any foreign currency to U.S. Dollars
shall be made at the rate of exchange published by Bloomberg, prevailing on to the last Business Day of the month preceding the
month in which any fees due under this Agreement accrue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Late Payments</U>. If payment of any amount is overdue, TXMD may charge interest on the overdue amount, from the due
date of payment until the date of actual payment, at the rate of [***] percent ([***]%) per month but capped at a level of [***]%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Suspension Right</U>. If TXMD provides notice to Licensee that it has failed to pay any undisputed amounts due hereunder
and Licensee failure to pay any such outstanding amount within thirty (30) days of notice of such outstanding, past due payment,
more than twice in any twelve (12) month period, then TXMD may, in addition to its rights as per Section 16.4.1, stop further
Supply of the Product until payment is made<I>. If TXMD elects to stop further Supply, TXMD shall use commercially reasonable
efforts to re-start Supply of Product after payment is made by Licensee.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Books and Records; Audit Rights</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maintained by TXMD</U>. TXMD shall maintain, or cause to be maintained, all records necessary to comply with all Applicable
Laws in the countries as to which Marketing Authorizations or other Regulatory Approvals have been granted relating to the Manufacturing
of Product; provided Licensee has previously notified TXMD in writing of any such records requirements which are more restrictive
than applicable U.S. law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maintained by Licensee</U>. Licensee shall maintain complete and accurate records of all of its Product sales in each
country in the Territory and payments hereunder in sufficient detail to permit TXMD to determine and confirm, using standard audit
practices, that Licensee is complying with its diligence commitments as set forth in this Agreement and that all applicable Milestone
Fees and Royalty Payments or other amounts are being paid to TXMD. All such records shall be maintained for at least five (5)
years or such longer period as may be required by Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Audit Rights; Costs</U>. Upon reasonable prior notice, each Party shall make such records available during regular business
hours for a period of three (3) years from the end of the Calendar Year in which such individual records were created, for examination
by the other Party and/or its representatives, for the sole purpose of verifying the accuracy of the reports furnished pursuant
to this Agreement. Any such auditor shall not disclose any Confidential Information, except to the extent such disclosure is necessary
to verify the accuracy of the reports furnished by a Party or the amount of payments due by it under this Agreement. Any amounts
shown to be owed but unpaid shall be paid within thirty (30) days from the auditor&rsquo;s report, plus interest (calculated at
the rate as set forth in Section 11.5) from the original due date. Any amounts shown to have been overpaid shall be refunded plus
interest at the rate set forth in Section 11.5, within thirty (30) days from the auditor&rsquo;s report. The Party carrying out
the audit shall bear the full cost of such audit unless such audit discloses an underpayment by the other Party of the amounts
actually owed during the applicable audited period of more than [***] percent ([***]%), in which case the audited Party shall
bear the reasonable cost of such audit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Representations, Warranties and Covenants</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mutual Representations and Warranties</U>. Each Party hereby represents, warrants, and covenants (as applicable)
to the other Party as of the Effective Date and during the Term, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction
in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and
assets and to carry on its business as it is now being conducted and as contemplated in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>It has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement
and the performance of its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding
obligation of such Party that is enforceable against it in accordance with its terms except to the extent enforceability is limited
by bankruptcy, insolvency or similar laws affecting creditors&rsquo; rights and remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>The performance of its obligations under this Agreement shall not conflict with its organizational documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>It has not entered into, and shall not during the term of this Agreement, enter into any material agreements or contracts
that would or do conflict with its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.1.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>It shall perform under this Agreement and operate its business in compliance with all Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Licensee Representations, Warranties and Covenants</U>. Licensee represents, warrants and covenants to TXMD:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Licensee has the corporate power and authority and the legal right to bind all Affiliates to perform any Licensee obligations
(to the extent performed by such Affiliates).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Licensee shall not, and shall cause its Affiliates and Sublicensees not to, (i) file an application for any Marketing Authorization
or other Regulatory Approval relating to any Generic Product; (ii) purchase or otherwise acquire any such rights in any Generic
Product and, to the extent that Licensee acquires such rights, it shall promptly divest the same, without prejudice to any rights
or remedies that TXMD may have; or (iii) manufacture for another party any Generic Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Licensee, its Affiliates and its Sublicensees, (a) are not under investigation by the EMA or any other Regulatory Authority
in the Territory for debarment or is not presently debarred (or subject to any similar penalty or restriction on its activities)
by the EMA or any such other Regulatory Authority in any country or jurisdiction in the Territory pursuant to Applicable Law or
by the rules and regulations of the EMA or any such other Regulatory Authority, and (b) have not received written notice from
the EMA or any such other Regulatory Authority in any country or jurisdiction in the Territory of a pending disqualification hearing
(or any similar hearing or proceeding) and has not been disqualified (or subject to any similar penalty or restriction on its
activities) by the EMA or such other Regulatory Authority in any country or jurisdiction in the Territory. If, during the Term,
Licensee, its Affiliates, or any of its Sublicensees (i) comes under investigation by the EMA or by any other Regulatory Authority
in any country or jurisdiction in the Territory for a debarment action or disqualification (or any similar penalty or restriction
on its activities), (ii) is debarred or disqualified (or any similar penalty or restriction on its activities is imposed), or
(iii) engages in any conduct or activity that could lead to any of the above-mentioned disqualification or debarment actions (or
any similar penalty or restriction on its activities), Licensee shall immediately notify TXMD of same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Anti-Corruption</U>. Each Party represents, warrants and covenants to the other as of the Effective Date and for the
Term that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>it shall not, and shall cause its Affiliates and Sublicensees not to offer, pay, request or accept any bribe, inducement,
kickback or facilitation payment, and shall not make or cause another to make any offer or payment to any individual or entity
for the purpose of influencing a decision for the benefit of the other Party. Without limiting the generality of the foregoing,
it shall, and shall ensure that its Affiliates and any Third Party contractors shall, comply with the United Stated Foreign Corrupt
Practices Act (including as it may be amended) (the &ldquo;<B>FCPA</B>&rdquo;), and any analogous laws or regulations existing
in the Territory or any country or region in the Territory, in connection with its performance under this Agreement. Neither Party
shall make any payment, either directly or indirectly, of money or other assets, including but not limited to compensation derived
from this Agreement, to government or political party officials,&nbsp;officials of international public organizations, candidates
for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing, that would constitute
violation of any law, rule or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Neither Party nor its Affiliates, Sublicensees, or their respective Representatives are: (a) listed on the Office of Foreign
Assets Control&rsquo;s (&ldquo;<B>OFAC</B>&rdquo;) &ldquo;Specially Designated National and Blocked Person List&rdquo; (&ldquo;<B>SDN
List</B>&rdquo;) or otherwise subject to any sanction administered by OFAC (&ldquo;<B>U.S. Economic Sanctions</B>&rdquo;) or (b)
owned, controlled by or acting on behalf of, directly or indirectly, any person, entity, or government listed on the SDN List
or otherwise subject to any U.S. Economic Sanction. Licensee, its Affiliates, Sublicensees, and their respective Representatives
have not and shall not engage directly or indirectly in any transaction that could potentially violate applicable U.S. Economic
Sanctions. Nothing in this Section 13.3.2 shall prevent Licensee or its Affiliates or Sublicensees from conducting business with
any person, entity, or government listed on the SDN List or otherwise subject to any U.S. Economic Sanction to the extent that
the conduct of such business does not violate Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>A Party&rsquo;s failure to abide by the provisions of this Section 13.3 shall be deemed a material breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TXMD Representations, Warranties and Covenants</U>. TXMD represents, warrants and covenants to Licensee as of the Effective
Date that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>TXMD Controls the TXMD Patents listed on Exhibit 1 and shall, during the Term, maintain Control of such TXMD Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>(i) TXMD has the right to grant to Licensee all the licenses and other rights herein; and (ii) TXMD has not granted any
license, right or interest in, to or under the TXMD Patents or TXMD Know-How to any Third Party with respect to Product, in each
case with respect to this clause (ii), in any way that would conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>To the knowledge of TXMD, there is no litigation pending against it that alleges that the Commercialisation of Product
within the Territory infringes, misappropriates or otherwise violates the intellectual property rights of a Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Prior to the Effective Date, TXMD has not received any written notice, claim or demand of any Third Party alleging that
the development, manufacture, use, or Commercialisation of Product infringes or misappropriates the intellectual property rights
of a Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>(i) none of the TXMD Patents is subject to any pending or threatened, re-examination, opposition, interference or litigation
proceedings and (ii) to TXMD&rsquo;s knowledge, the issued TXMD Patents are valid and enforceable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>There are no actual or pending, and to TXMD&rsquo;s knowledge, no alleged or threatened, adverse actions, suits, claims,
or formal governmental investigations, or settlements or judgments, involving Product by or against TXMD or any of its Affiliates
in or before any governmental authority. In particular, to its knowledge, there is no pending or threatened product liability
action involving the use or administration of Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">13.4.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>All preclinical and clinical trials of Product that have been conducted by or on behalf of TXMD that have been submitted
to any Regulatory Authority in connection with any Regulatory Documentation, have been conducted in compliance in all material
respects with Applicable Law, including Good Clinical Practices and good laboratory practices, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Representations or Warranties</U>. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES
WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF
OF EITHER PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED,
OTHER THAN THE EXPRESS WARRANTIES IN THIS ARTICLE 13.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Indemnification and Limitation of Liability</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification by TXMD</U>. TXMD shall defend, indemnify, and hold Licensee, its Affiliates and their respective officers,
directors, employees, and agents (the &ldquo;<B>Licensee Indemnitees</B>&rdquo;) harmless from and against any and all damages
or other amounts payable to a Third Party claimant, as well as any reasonable attorneys&rsquo; fees and costs of litigation incurred
by such Licensee Indemnitees, all to the extent resulting from claims, suits, proceedings, or causes of action brought by such
Third Party (collectively, &ldquo;<B>Licensee Claims</B>&rdquo;) to the extent that such Licensee Claims arise out of, are based
on, or result from (a) a material breach of any of TXMD&rsquo;s representations, warranties, covenants or obligations under the
Agreement; or (b) the willful misconduct or negligent acts or omissions of any member of TXMD or its Affiliates, or the officers,
directors, employees, or agents of TXMD relating to any obligations of TXMD or the exercise by TXMD of any of its rights hereunder.
The foregoing indemnity obligation shall not apply to the extent that the Licensee Indemnitees fail to comply with the indemnification
procedures set forth in Section 14.3 and TXMD&rsquo;s defense of the relevant Licensee Claims is prejudiced by such failure, or
to the extent that any Licensee Claim arises from, is based on, or results from (x) a material breach of any of Licensee&rsquo;s
representations, warranties, or obligations under the Agreement; or (y) the willful misconduct or negligent acts of any Licensee
Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification by Licensee</U>. Licensee shall defend, indemnify, and hold TXMD, its Affiliates and their respective
officers, directors, employees, and agents (the &ldquo;<B>TXMD Indemnitees</B>&rdquo;) harmless from and against any and all damages
or other amounts payable to a Third Party claimant, as well as any reasonable attorneys&rsquo; fees and costs of litigation incurred
by such TXMD Indemnitees, all to the extent resulting from claims, suits, proceedings, or causes of action brought by such Third
Party (collectively, &ldquo;<B>TXMD Claims</B>&rdquo;) to the extent that such TXMD Claims arise out of, are based on, or result
from (a) the storage, handling, or Commercialization of Product by Licensee or its Affiliates, or their respective Sublicensees
or distributors (the &ldquo;<B>Licensee Group</B>&rdquo;); (b) any material breach of this Agreement or of any of Licensee&rsquo;s
or its Affiliate&rsquo;s representations, warranties, covenants or obligations under the Agreement; (c) the willful misconduct
or negligent acts or omissions of Licensee or its Affiliates, or the officers, directors, employees, or agents of the Licensee
Group. The foregoing indemnity obligation shall not apply to the extent that the TXMD Indemnitees fail to comply with the indemnification
procedures set forth in Section 14.3 and Licensee&rsquo;s defense of the relevant TXMD Claims is prejudiced by such failure, or
to the extent that any TXMD Claim arises from, is based on, or results from (x) a material breach of any of TXMD&rsquo;s representations,
warranties, or obligations under the Agreement; or (y) the willful misconduct or negligent acts of any TXMD Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification Procedures</U>. The Party claiming indemnity under this Section 14 (the &ldquo;<B>Indemnified Party</B>&rdquo;)
shall give written notice to the Party from whom indemnity is being sought (the &ldquo;<B>Indemnifying Party</B>&rdquo;) promptly
after learning of such Claim. Failure to provide such notice which substantially prejudices the indemnifying Party&rsquo;s ability
to defend such claim or action may invalidate any obligation of indemnification. The Indemnified Party shall provide the Indemnifying
Party with reasonable assistance, at the Indemnifying Party&rsquo;s expense, in connection with the defense of the claim for which
indemnity is being sought. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing
at its sole expense; provided, however, that the Indemnifying Party shall have sole case management authority, including the right
to assume and conduct the defense of the claim with counsel of its choice. Neither Party may compromise or settle any matter without
the other Party&rsquo;s prior written consent, not to be unreasonably withheld, delayed or conditioned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL (INCLUDING LOST
PROFITS), INCIDENTAL, EXEMPLARY, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO THIS AGREEMENT, WHETHER IN CONTRACT,
WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY, OR OTHERWISE, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES, PROVIDED,
HOWEVER, THAT THE FOREGOING LIMITATIONS SHALL NOT APPLY TO (A) THE AMOUNTS EACH PARTY IS OBLIGATED TO PAY TO A THIRD PARTY AS
PART OF A THIRD PARTY CLAIM THAT IS THE SUBJECT OF AN INDEMNIFICATION OBLIGATION HEREUNDER, OR (B) DAMAGES ARISING FROM A PARTY&rsquo;S
GROSS NEGLIGENCE, WILLFUL OR INTENTIONAL MISCONDUCT, FRAUD OR BREACH OF THE LICENSE RESTRICTIONS, BREACH OF CONFIDENTIALITY OBLIGATIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Force Majeure</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Force Majeure Event; Excused Performance</U>. The Force Majeure Party shall, within five (5) days of the occurrence
of a Force Majeure event, give notice in writing to the other Party specifying the nature and extent of the event of Force Majeure,
its anticipated duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and Sections
15.2 and 15.3 below, the Force Majeure Party shall not be liable for delay in performance or for non-performance of its obligations
under this Agreement to the extent due to an event of Force Majeure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">15.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt"><U>Remediation</U>. The Force Majeure Party shall use all commercially reasonable
efforts to (a) bring the Force Majeure event to a close or (b) find a solution by which the Agreement may be performed despite
the continuation of the event of Force Majeure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination for Prolonged Force Majeure Event</U>. Notwithstanding the other provisions of this Section 15, if the Force
Majeure Party is prevented from performing its obligations due to a Force Majeure event for a continuous period in excess of one
hundred (100) days after the date of the occurrence of the Force Majeure event, and such failure to perform would constitute a
material breach of this Agreement in the absence of such Force Majeure event, unless the Parties agree otherwise, the other Party
may terminate this Agreement immediately by written notice to the Force Majeure Party, in which case neither Party shall have
any liability to the other except as provided in Section 16 and except for those rights and liabilities that accrued prior to
the date of termination. Termination shall be on a Product-by-Product and country-by-country basis where the Force Majeure event
affects only one Product or less than all countries in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Term and Termination.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. This Agreement shall commence on the Effective Date and shall remain in full force and effect unless and until
earlier terminated in accordance with this Article 16 (the &ldquo;<B>Term</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by TXMD</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>TXMD may terminate this Agreement upon written notice to Licensee if any of the following occur: (a) Licensee or any of
its Affiliates, directly or indirectly divert any Products for distribution or sale outside of the Territory, unless such diversion
is an isolated incident occurring not more than once in any twelve (12) month period and Licensee provides reasonable assurances
to TXMD that such diversion will not recur, or (b) if Licensee or its Affiliates commences any action or proceeding that challenges
the validity, enforceability or scope of any TXMD Patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>TXMD shall have the right to terminate this Agreement if Licensee does not file an application with the appropriate Regulatory
Authority for Marketing Authorization for [***] in [***] within [***] of the Effective Date. Notwithstanding the above, Licensee
shall not be deemed to have failed to meet its obligations under this Section 16.2.2 if Licensee requires information in order
to satisfy a filing requirement for the submission for the Marketing Authorization from the Regulatory Authority and TXMD has
failed to provide Licensee with such required documentation, and despite using commercially reasonable efforts to obtain such
information, Licensee has not been able to obtain such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>TXMD shall have the right to terminate this Agreement on a country-by-country and Product-by-Product basis if Licensee
fails to use Diligent Efforts to Commercialize the applicable Product in [***] for [***] after obtaining Marketing Authorization
for each such Major Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by Licensee</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Licensee may terminate this Agreement on thirty (30) days&rsquo; written notice if TXMD fails to meet its supply obligations
(with regard to amount or timeliness) on more than three consecutive occasions or more than four times in any twelve month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>On a country-by-country and Product-by-Product basis, Licensee may terminate this Agreement upon sixty (60) days&rsquo;
written notice to TXMD in the event that the applicable Regulatory Authority in the Territory informs Licensee or Licensee&rsquo;s
Affiliate or Sublicensee that such Product can no longer be Commercialized in such country as a result of a safety issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by Either Party</U>. In addition to any other provisions of this Agreement expressly providing for
termination of this Agreement, this Agreement may be terminated, in whole or in part, immediately by either Party upon notice
to the other Party:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>if the other Party is in material breach of this Agreement and such material breach is not cured within (i) sixty (60)
days after written notice thereof is delivered to the defaulting or breaching Party (thirty (30) days in the case of Licensee&rsquo;s
failure to pay any undisputed amounts due hereunder), or (ii) in the case of a breach that cannot be cured within sixty (60) days,
within a reasonable period not exceeding one hundred twenty (120) days after written notice thereof is delivered to the defaulting
or breaching Party; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>if the other Party (or Licensee&rsquo;s parent) shall file in any court or agency, pursuant to any statute or regulation
of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment
of a receiver or trustee of such other Party (or Licensee&rsquo;s parent) or of its assets, or if the other Party (or Licensee&rsquo;s
parent) proposes a written agreement of composition or extension of its debts, or if the other Party (or Licensee&rsquo;s parent)
shall be served with an involuntary petition against it, filed in an insolvency proceeding, and such petition shall not be dismissed
within sixty (60) days after the filing thereof, or if the other Party (or Licensee&rsquo;s parent) shall propose or be a party
to any dissolution or liquidation, or if the other Party (or Licensee&rsquo;s parent) shall make an assignment for the benefit
of its creditors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination</U>. Without prejudice to any other rights or remedies each Party may have, upon the expiration
or termination of this Agreement for any reason, Licensee shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.5.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>immediately pay all undisputed sums which are due and payable to TXMD under this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.5.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>immediately cease all use of any property of TXMD unless required for the continuation of any performance permitted hereunder,
including any of TXMD&rsquo;s Confidential Information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.5.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>be entitled to sell off any inventory of Product existing on the date such termination is effective for the six (6) month
period following the effective date of such termination, and thereafter shall return or destroy (at TXMD&rsquo;s cost) and for
a full refund all such remaining inventory in accordance with TXMD&rsquo;s written instruction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination Related to Licensee Events</U>. Upon the termination of this Agreement pursuant to Section 15.3
or Section 16, the following shall apply:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of License Rights</U>. All licenses granted to Licensee hereunder shall terminate immediately upon such
termination, except to the extent necessary for Licensee to exercise its obligation under Section <B>16.5.3</B>, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT><U>Step-In Rights</U>. Upon TXMD&rsquo;s written request:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable but in any event no more than ninety (90) days after such termination, Licensee shall perform all
reasonable steps required to file for the transfer of the Marketing Authorization and all other Regulatory Approvals to TXMD in
order to assign to TXMD all Regulatory Materials, marketing Authorizations and other Regulatory Approvals (including with respect
to all Regulatory Materials and all Clinical Data contained therein) owned or Controlled by Licensee for the Products; provided
that, for clarity, TXMD shall not exercise any rights under such assignment until such termination date. Licensee shall promptly
notify the EMA and any other applicable Regulatory Authority of such transfer and assignment in the customary manner;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>upon the effective date of such a termination, if requested by TXMD, Licensee shall provide reasonable transition services
according to a transition plan reasonably agreed to mutually by the Parties; provided that if Licensee terminated this Agreement,
in whole or in part (i.e., by country), due to TXMD&rsquo;s uncured material breach pursuant to Section 16.4.1 (following the
cure period specified therein) or pursuant to Section 16.3), the transition services provided under this Section 16.6.2 shall
be at TXMD&rsquo;s cost and expense; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event that Licensee or any of its Affiliates has one or more agreements with Third Parties with respect to the Commercialization
of the Products, at TXMD&rsquo;s request, Licensee shall use Diligent Efforts to assign or sublicense its rights under such agreement(s)
(solely to the extent such agreements pertain to the Products) to TXMD upon any such termination and TXMD shall assume all of
Licensee&rsquo;s obligations under such agreement(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Alternative to Termination Related to Supply Problems</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>In the event that Licensee has a right to terminate this Agreement pursuant to Section 16.3.1, Licensee shall have the
right, as an alternative to termination of this Agreement pursuant to Section 16.3.1, exercisable by written notice to TXMD, to
continue this Agreement in effect in accordance with this Section 16.7 (the &ldquo;Alternate Remedy&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>In the event that Licensee exercises the Alternate Remedy pursuant to this Section 16.7, Licensee shall have the right
to enter into a supply agreement directly with the Contract Manufacturer or with another Third Party supplier selected by Licensee
for the supply of Product in the Territory. Any Third Party supplier selected by Licensee shall be subject to the approval of
TXMD, which shall not be unreasonably withheld. Licensee shall provide a copy of the supply agreement with the Contract Manufacturer
or Third Party supplier to TXMD promptly after the supply agreement is executed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Licensee shall be responsible for adding any Third Party supplier to the Marketing Authorizations in the Territory and
shall be responsible for the costs incurred by Licensee to qualify any such Third Party supplier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Licensee shall ensure that the Contract Manufacturer or such Third Party supplier enters into confidentiality obligations
in respect of the Confidential Information which are no less onerous than those set out in this Agreement. In addition, the Contract
Manufacturer or such Third Party supplier shall covenant not to manufacture for Licensee or another party any Generic Product
during the term of such supply agreement. Licensee shall provide prompt written notice to TXMD of any breach by the Contract Manufacturer
or Third Party supplier of any of such confidentiality obligations or covenant relating to Generic Products and, at the request
of TXMD, shall use commercially reasonable efforts to enforce such confidentiality obligation or covenant at its cost. TXMD shall
be a third-party beneficiary of such confidentiality obligations and covenant and shall have the right to enforce such confidentiality
obligations and covenant directly against the Contract Manufacturer or Third Party supplier at its cost. Any recovery in an action
against the Contract Manufacturer or Third Party supplier by Licensee or TXMD for any such breach shall for the benefit TXMD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Commencing with the Calendar Quarter after the exercise of the Alternate Remedy, Licensee shall pay TXMD royalties pursuant
to Section 10.1.3 at a rate of [***] percent ([***]%) on Net Sales of Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Upon the exercise by Licensee of the Alternate Remedy, all obligations of TXMD under this Agreement with respect to the
manufacture and supply of Product shall terminate, including the obligations of TXMD under Section 4.3, Section 6, Section 7,
Section 8 and Section 9. TXMD shall have no liability or obligation under this Agreement or otherwise for Product supplied to
Licensee or its Sublicensees by the Contract Manufacturer or such Third Party supplier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>The exercise by Licensee of the Alternate Remedy in this Section 16.8 shall terminate any right of Licensee to terminate
this Agreement pursuant to Section 16.3.1 as a result of such supply failure and shall be the exclusive remedy of Licensee and
in lieu of any and all other remedies of Licensee under this Agreement or otherwise for any such supply failure by TXMD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">16.7.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Subject to this Section 16.7, the terms of this Agreement shall remain in full force and effect after the exercise by Licensee
of the Alternate Remedy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rights in Bankruptcy</U>. The Parties agree that all rights, powers and remedies of each of the Parties, respectively
provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter
existing at law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.9<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. The following provisions shall survive any expiration or early termination of this Agreement: Articles
1, 14, 17, 18, 20, Sections 2.3, 2.4.1, 8.3, 8.4, 8.5, 8.7, 9, 15.3, 16.6.2 (for the time periods described therein), 16.7, 16.8
and 16.9, and any other provisions of the Agreement required to give effect to their intent and meaning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Confidentiality</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nondisclosure</U>. Except as otherwise provided in this Agreement, any Confidential Information which is disclosed by
or on behalf of one Party to the other in connection with this Agreement shall remain the property of the Disclosing Party and
the Receiving Party undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>to use the Confidential Information solely and exclusively for the purposes of this Agreement, and not to use the Confidential
Information for any other purpose whatsoever, including the Development, Manufacture, marketing, sale or licensing of any process
or product or any other commercial purpose anywhere in the world, unless the Parties specify otherwise; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>to maintain the confidentiality of the Confidential Information and not to disclose it directly or indirectly to any other
Person (including any Restricted Entities), except as otherwise permitted pursuant to this Article 17; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>at the request of the Disclosing Party and/or upon termination of this Agreement, to return, delete or destroy all copies
of the Confidential Information, in whatever form it is held, provided that the Receiving Party may retain one (1) copy of the
Confidential Information for the sole purpose of determining its obligations under this Agreement but may make no further use
of such Confidential Information whatsoever. Notwithstanding the foregoing, Receiving Party may retain Confidential Information
on electronic backup systems to which access within the organization of Receiving Party or its Representatives, as the case may
be, is limited to purposes of backup and contingency planning. The return of any Confidential Information shall not relieve Receiving
Party of its obligation to maintain the confidentiality of the Confidential Information in accordance with the terms hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>not to copy or reproduce in any form or medium Confidential Information or any part thereof except as may be reasonably
necessary for or in connection with the purpose of this Agreement and that any such copies or reproductions shall be the property
of the Disclosing Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Permitted Recipients</U>. Notwithstanding Section 17.1, the Receiving Party may only disclose the Disclosing Party&rsquo;s
Confidential Information to its officers, employees, professional advisors and distributors and (with respect to TXMD only, Contract
Manufacturers or other TXMD Sublicensees or subcontractors but in the case of other TXMD Sublicensees subject to Licensee&rsquo;s
prior written consent which shall not be unreasonably withheld, delayed or conditioned) on a purely need to know basis to the
extent necessary or required for the purposes of carrying out their respective obligations under the Agreement and in order to
fulfill the purpose of this Agreement, provided that the Receiving Party shall ensure that, prior to such disclosure, each such
Person to whom Confidential Information is to be disclosed is made aware of the obligations contained in this Agreement, and adhere
to these terms as if it were a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure Required by Law</U>. Nothing in Section 17.1, shall preclude disclosure of any Confidential Information required
by any governmental, quasi-governmental or regulatory agency or authority or court entitled by law to disclosure of the same,
or which is required by law or the requirements of a national securities exchange or another similar regulatory body to be disclosed,
provided that the Receiving Party promptly notifies the Disclosing Party when such requirement to disclose has arisen to enable
the Disclosing Party to seek an appropriate protective order, to make known to the relevant agency, authority, court or securities
exchange the proprietary nature of the Confidential Information, and to make any applicable claim of confidentiality. The Receiving
Party agrees to co-operate in any action, which the Disclosing Party may decide to take. If the Receiving Party is required to
make a disclosure in accordance with this clause, it shall only make a disclosure to the extent to which it is obliged and any
such disclosed information shall remain Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exceptions</U>. The provisions of Section 17.1, shall not apply to any Confidential Information which the Receiving
Party can demonstrate, to the reasonable satisfaction of the Disclosing Party based on authenticated written records:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>was already in the possession of the Receiving Party or any of its Affiliates and at the Receiving Party&rsquo;s or any
of its Affiliates&rsquo; free use and disposal or in the public domain (through in each case no fault of the Receiving Party or
any of its Affiliates or no breach of this Agreement by the Receiving Party) prior to its disclosure by the Disclosing Party under
this Agreement as documented by the Receiving Party&rsquo;s written records; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>is purchased or otherwise legally acquired by the Receiving Party or any of its Affiliates at any time from a third Person
having and the right to disclose it; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>comes into the public domain, otherwise than through the fault of the Receiving Party or any of its Affiliates; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">17.4.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>is independently generated by the Receiving Party or any of its Affiliates without any recourse or reference to the Confidential
Information as documented by the Receiving Party&rsquo;s written records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The obligations of each Party in this Article 17 shall survive the termination of this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Publicity</U>. Subject to the special authorized disclosure provisions set forth in this Article 17), neither Party
shall disclose to any Third Party the nature of their relationship or the terms of this Agreement. If either Party desires to
make a public announcement concerning the terms of this Agreement, such Party shall give reasonable prior advance notice of the
proposed text of such announcement to the other Party for its prior review and approval (except as otherwise provided herein),
such approval not to be unreasonably withheld. A Party commenting on such a proposed press release shall provide its comments,
if any, within five (5) Business Days after receiving the press release for review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financings; Press Release</U>. Except as expressly provided in this Section 17, each Party agrees not to disclose any
terms of this Agreement to any third party without the prior written consent of the other Party (which shall not be unreasonably
withheld or delayed). Each Party (the &ldquo;<B>Providing Party</B>&rdquo;) may, however, provide a copy of this Agreement or
otherwise disclose its terms in connections with any financing transaction, provided that the person or entity to whom a copy
of this Agreement is provided or to whom the terms of this Agreement are disclosed is bound to the Providing Party by reasonable
confidentiality obligations, and provided further that the Providing Party is responsible for breaches or confidentiality hereunder
by such person or entity to whom a copy of this Agreement is provided or to whom the terms of this Agreement are disclosed. Notwithstanding
the foregoing and subject to Section 17.7, the Parties may issue a mutually agreed upon press release announcing the execution
of this Agreement and describing the relationship of the Parties under the Agreement. In addition, each Party may disclose to
third parties the information disclosed in such press release without the need for further approval by the other Party, and TXMD
may disclose to third parties (via press releases or otherwise) the achievement of any material milestones in connection with
this Agreement without prior approval by Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filing of Agreement with Regulatory Authority</U>. The Parties acknowledge that each Party (or its Affiliate) may at
some point in time be obligated to file a copy of this Agreement with the applicable governmental authorities having regulatory
authority over the securities of such Party (or such Affiliate) or the exchange thereof. In such an event, the Party obligated
to file the Agreement shall promptly inform the other Party thereof and shall use reasonable efforts to maintain the confidentiality
of the other Party&rsquo;s Confidential Information and terms of this Agreement in any such filing or disclosure. Prior to making
any such filing of a copy of this Agreement, the Parties shall negotiate in good faith to mutually agree on the provisions of
this Agreement for which the Parties shall seek confidential treatment, it being understood that if one Party determines to seek
confidential treatment for a provision for which the other Party does not, then the Parties shall use reasonable efforts in connection
with such filing to seek the confidential treatment of any such provision. The Parties shall cooperate, each at its own expense,
in such filing, including without limitation such confidential treatment request, and shall execute all documents reasonably required
in connection therewith. The Parties shall reasonably cooperate in responding promptly to any comments received from such Regulatory
Authority with respect to such filing in an effort to achieve confidential treatment of such redacted form; provided that a Party
shall be relieved of such obligation to seek confidential treatment for a provision requested by the other Party if such treatment
is not achieved after the first round of responses to comments from the requesting governmental authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Dispute Resolution</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disputes</U>. The Parties recognize that disputes or issues between the Parties as to certain matters may from time
to time arise during the Term concerning either Party&rsquo;s rights and/or obligations under this Agreement. It is the objective
of the Parties to establish procedures to facilitate the resolution of issues and disputes arising under this Agreement in an
expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow
the procedures set forth in this Article 18 to resolve any issue, dispute, controversy or claim arising out of, relating to or
in connection with any provision of this Agreement (a &ldquo;<B>Dispute</B>&rdquo;), if and when any such Dispute arises under
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Arising Between the Parties</U>. With respect to all Disputes arising between the Parties, including any alleged failure
to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, if the
Parties are unable to resolve such Dispute within thirty (30) days after such Dispute is first identified by either Party in writing
to the other, the Parties shall refer such Dispute to the senior executive officers for each Party for attempted resolution by
good faith negotiations within thirty (30) days after such notice is received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Binding Arbitration</U>. Any unresolved disputes between the Parties relating to, arising out of or in any way connected
with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether
before or after termination of this Agreement, shall be resolved by final and binding arbitration. Whenever a Party shall decide
to institute arbitration proceedings, it shall give written notice to that effect to the other Party. Arbitration shall be held
in London, United Kingdom according to the commercial rules of the International Chamber of Commerce (&ldquo;<B>ICC</B>&rdquo;).
The arbitration shall be conducted by a panel of three arbitrators appointed in accordance with ICC rules; provided that each
Party shall within thirty (30) days after the institution of the arbitration proceedings appoint an arbitrator, and such arbitrators
shall together, within thirty (30) days, select a third arbitrator as the chairman of the arbitration panel, each arbitrator shall
have significant experience in the pharmaceutical business. If the two initial arbitrators are unable to select a third arbitrator
within such thirty (30) day period, the third arbitrator shall be appointed in accordance with ICC rules. The arbitrators shall
render their opinion within thirty (30) days of the final arbitration hearing. Decisions of the panel of arbitrators shall be
final and binding on the Parties; provided, that the arbitrators shall have no authority to award damages that exceed the scope
of the limitations set forth in Section 14.4 above. Judgment on the award so rendered may be entered in any court of competent
jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Prevailing Party Costs and Fees</U>. The losing Party to the arbitration (if any) as determined by the arbitrators shall
reimburse the prevailing Party for it costs and expenses arising from the arbitration, including the ICC fees and reasonable attorneys&rsquo;
fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Injunctive Relief</U><B>.</B> Notwithstanding anything to the contrary herein, either Party may seek seeking a preliminary
injunction or temporary restraint order in order to prevent any irreparable harm from occurring, including preventing Confidential
Information from being disclosed without appropriate authorization under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>19.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Insurance</B>. Each Party shall procure and maintain insurance, including product liability insurance, adequate to cover
its obligations hereunder and which are consistent with this Agreement and with normal business practices in the Territory. It
is understood that such insurance shall not be construed to create a limit with respect to its indemnification obligations or
any other liabilities hereunder. Each Party shall provide written evidence of such insurance to the other Party prior to the occurrence
of the First Commercial Sale or as otherwise requested by such other Party. Notwithstanding the foregoing, Licensee shall have
the right to self-insure in order to fulfill its insurance obligations under this Section 19 and shall provide written confirmation
to TXMD of Licensee&rsquo;s decision to do so within thirty (30) days of receiving a written request from TXMD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Miscellaneous</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement shall be governed by and construed under the laws of State of Delaware, without giving
effect to the conflicts of laws provision thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice Requirements</U>. Any notice, request, demand, waiver, consent, approval or other communication permitted or
required under this Agreement shall be in writing and shall be delivered by hand or by internationally recognized overnight delivery
service that requires a signature for delivery and maintains records of such delivery, addressed to the Parties at the following
addresses specified in this Section 20.2 (or to such other addresses of which notice shall have been given in accordance with
this Section 20.1):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">If
                                         to TXMD:</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 85%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Therapeutics
                                         MD, Inc.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">6800 Broken Sound Parkway,
        NW</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">3<SUP>rd</SUP> Floor</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Boca Raton, FL 33487</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">USA</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attention: Legal Department</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">With a copy to:</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">King &amp; Spalding LLP</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">601 S. California Avenue</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Suite 100</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Palo Alto, CA 94304</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attention: Jack Capers</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Telephone: [***]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Fax: [***]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Email: [***]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">If
                                         to Licensee:</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Theramex
                                         HQ UK Limited</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Sloane Square House</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">1 Holbein Place</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">London</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">SW1W 8NS</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">United Kingdom</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attention: Chief Corporate
        Development Officer<BR>
        </FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">With a copy to:</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Legal Department</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Attention: General Counsel<BR>
        <BR>
        E-mail: [***]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">This
Section is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations
under the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Relationship of the Parties</U>. The status of a Party under this Agreement shall be that of an independent contractor.
Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency relationship between
the Parties or, except as otherwise expressly provided in this Agreement, as granting either Party the authority to bind or contract
any obligation in the name of or on the account of the other Party or to make any statements, representations, warranties or commitments
on behalf of the other Party. All persons employed by a Party shall be employees of such Party and not of the other Party and
all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.4<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">20.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent
of the other, such consent not to be unreasonably withheld, delayed, or conditioned, except that either Party may make such an
assignment without the other Party&rsquo;s consent in the event of a Change of Control or to a successor to all or substantially
all of the assets of the Party that are the subject of this Agreement or a purchaser of all or substantially all of the rights
to a Product as part of a divestiture, whether in a merger, sale of stock, sale of assets or other transaction. Any permitted
assignment shall be binding on the successors of the assigning Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">20.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Whether or not this Agreement is assigned pursuant to Section 20.4, the rights to Clinical Data, information, materials,
Patent Rights, Know-How or other intellectual property rights: (i) controlled by a Third Party permitted assignee of a Party or
any of its Affiliates that were controlled by such assignee or any of its Affiliates (and not such Party) immediately prior to
such assignment (other than as a result of a license or other grant of rights, covenant or assignment by such Party or its Affiliates
to, or for the benefit of, such Third Party); or (ii) controlled by any successor-in-interest of a Party as a result of a Change
of Control or any Person that becomes an Affiliate of a Party through any Change of Control of such Party, that were controlled
by such successor or Person (and not such Party) immediately prior to such Change of Control (other than as a result of a license
or other grant of rights, covenant or assignment by such Party or its other Affiliates to, or for the benefit of, such Person),
in each case ((i) and (ii)), shall be automatically excluded from the rights licensed or granted to the other Party under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">20.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
</FONT>Any assignment or attempted assignment by either Party in violation of the terms of this Section 20.4 shall be null, void
and of no legal effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.5<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. Except as otherwise expressly provided in Section 18.4, each Party shall pay the fees and expenses of
its respective lawyers and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution
and delivery of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.6<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver and Non-Exclusion of Remedies</U>. A Party&rsquo;s failure to enforce, at any time or for any period of time,
any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or
remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To
be effective any waiver must be in writing and signed by the waiving Party. All rights and remedies are cumulative and do not
exclude any other right or remedy provided by law or otherwise available. The acceptance by TXMD of any payment by Licensee hereunder
shall not operate as any waiver by TXMD of any right, power or remedy provided by law or under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.7<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would
render any provision in this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is
held to be invalid, illegal or unenforceable, in any respect, then such provision shall be given no effect by the Parties and
shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights or obligations of any
Party shall not be materially and adversely affected, all other provisions of this Agreement shall remain in full force and effect
and the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or
unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.8<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entirety</U>. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter
of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter
of the Agreement. Any amendment or modification of this Agreement must be in writing and signed by authorized representatives
of both Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.9<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Language</U>. This Agreement was prepared in the English language, which language shall govern the interpretation of,
and any dispute regarding, the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.10<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which is an original and all
of which taken together shall be deemed to constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[Signature
page follows.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
Agreement is executed by the authorized representatives of the Parties as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2"><B>THERAPEUTICSMD, INC.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
                                                                                 <TD COLSPAN="2" STYLE="text-align: justify"><B>THERAMEX HQ UK LIMITED</B></TD>
</TR>                                                                           <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: left; width: 45%">&nbsp;</TD><TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Daniel Cartwright </FONT></TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Anish Mehta</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">Signature</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD COLSPAN="2" STYLE="text-align: justify">Signature</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>Name:</TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Daniel Cartwright</FONT></TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify">Name:</TD>
                                                                                 <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">Anish Mehta</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%">Title:</TD><TD STYLE="text-align: left; border-bottom: Black 1pt solid; width: 46%">CFO</TD><TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify; width: 3%">Title:</TD>
                                                                                 <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; width: 46%">CEO</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify">&nbsp;</TD>
                                                                                 <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-top: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: italic 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-style: normal">[Signature
Page to License and Supply Agreement]</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Appendix
1<BR>
Product</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">TX-001: [***].<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">TX-004: [***].<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>1
</SUP></FONT><FONT STYLE="font-size: 10pt">The TX-001 Product does not include [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT><FONT STYLE="font-size: 10pt">The TX-004 Product does not include [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Exhibit
1<BR>
TXMD Patents<FONT STYLE="font-family: Times New Roman, Times, Serif"><B><SUP>3</SUP></B></FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt"><FONT STYLE="font-size: 10pt"><B>Issued Patents:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center; padding-top: 3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Patent</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center; padding-top: 3pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Filing Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center; padding-top: 3pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Issue Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center; padding-top: 3pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">89459</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">02/17/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">366507</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">01/12/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2012340589</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/25/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2013277236</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/03/17
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2013277234</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/10/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX
    358440 B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/03/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">002916247-0001</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">08/10/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">302015005859-5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">01/30/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">6285866</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">02/09/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX
    50237 B</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">07/19/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">30-2015-0065043</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/18/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">03/06/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">101179</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">01/10/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">A2015/01935</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/16/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2015/00211</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">07/27/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">6334519</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/11/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">6397402</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">09/07/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">1624393</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pharmaceutical
    Capsule</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12/21/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">01/18/19</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>3
</SUP></FONT><FONT STYLE="font-size: 10pt">Exhibit does not include TXMD IP rights in the U.S., Canada, or Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt"><FONT STYLE="font-size: 10pt"><B>Pending Patent Applications:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR1120140124442</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12850845.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2017-173842</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX/a/2014/006256</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11/21/12</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">20140101244</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">03/17/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2017206262</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">07/20/17
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR1120140319103</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">13806855.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2017-176379</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10-2015-7001189</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/a/2014/015898</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2015100533</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">20150101608</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2015264003</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">BR112016
    027359 1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">15727528.0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016-565647</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">18.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10-2016-7032773</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">19.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/a/2016/014281</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">20.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016143081</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">21.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016/07541</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">05/22/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">22.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">PCT/US2017/064788</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Natural
    Combination Hormone Replacement Formulations and Therapies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/05/17</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">23.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2017208300</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">24.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">BR1120140319146</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">25.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">13807188.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">26.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10-2015-7001193</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">27.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/A/2018/009466</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">28.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2015100531</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">29.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2014/09278</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">30.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2018-162966</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Soluble
    Estradiol Capsule for Vaginal Insertion</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">31.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">20140103975</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">32.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2014349132</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">33.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">BR1120160090080</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">34.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">14862905.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">35.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016-516086</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">36.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10-2016-7010901</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">37.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/A/2016/005092</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">38.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016118396</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">39.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016/01933</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10/22/14</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">40.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">PCT/US2016/065466</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">41.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">20160103768</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">42.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016366200</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">43.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">BR1120180114839</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">44.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">16873806.0</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">45.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2018-529574</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">46.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10-2018-7019331</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">47.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/A/2018/006882</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">48.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">743229</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">NZ</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">49.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2018121094</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">50.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2018/03804</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">12/07/16</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">51.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">PCT/US2018/36790</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Vaginal
    Inserted Estradiol Pharmaceutical Compositions and Methods</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/08/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">PCT</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">52.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2018222947</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">06/18/13</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">53.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/a/2018/009467</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">08/02/18</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">54.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">20150100920</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Compositions</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">55.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2015237243</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">AU</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">56.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">BR1120160225708</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">BR</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="width: 5%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></P></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Application</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>(mm/dd/yy)</B></FONT></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt; width: 5%"><FONT STYLE="font-size: 10pt">57.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt; width: 15%"><FONT STYLE="font-size: 10pt">15768772.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt; width: 50%"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt; width: 16%"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt; width: 14%"><FONT STYLE="font-size: 10pt">EP</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">58.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016-557059</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/24/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">JP</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">59.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">10-2016-7029519</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">KR</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">60.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">MX/A/2016/011706</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">MX</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">61.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016136666</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">RU</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">62.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT>&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">2016/06309</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Progesterone
    Formulations</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 3pt; padding-left: 5.4pt; padding-top: 3pt"><FONT STYLE="font-size: 10pt">03/27/15</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">ZA</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Exhibit
2<BR>
Milestone Fees</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Upfront
Payment</U></B>. Licensee shall pay TXMD a payment of  Fourteen Million Euros (&euro;14,000,000) within sixty (60) days after the
Effective Date. Notwithstanding anything to the contrary in the Agreement, this upfront payment is non-refundable,
non-creditable and not subject to set-off. A failure of Licensee to pay this upfront payment when due (i.e. upon receipt of
the corresponding invoice from TXMD) will be deemed to be a material breach of this Agreement by Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Milestones</U></B>. Licensee
shall make the following one-time, non-refundable, milestone payments to TXMD following the first achievement of each of the milestones
below with respect to the Products (and any Product Improvements) in accordance with Section 10.1.1 of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Regulatory
    Milestone</B></FONT></TD>
    <TD STYLE="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Milestone
    Fee</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Regulatory
    Approval for Commercialization of [***] in [***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&euro;[***]
    (in equal installments of &euro;[***] upon Regulatory Approval for Commercialization of [***]in [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Regulatory
    Approval for Commercialization of [***] in [***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&euro;[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.5in">
<tr style="vertical-align: top">
    <td style="width: 70%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt"><b>Sales Milestone for TX-001 and TX-004 Products</b></font></td>
    <td style="width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt"><b>Milestone Fee </b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">First attaining annual Net Sales of the TX-001 and TX-004 Products in the Territory of &euro;25,000,000 </font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">&euro;[***] </font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">First attaining annual Net Sales of the TX-001 and TX-004 Products in the Territory of &euro;[***]&nbsp;&nbsp;</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">&euro;[***]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">First attaining annual Net Sales of the TX-001 and TX-004 Products in the Territory of &euro;[***]&nbsp;&nbsp;</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">&euro;[***]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">First attaining annual Net Sales of the TX-001 and TX-004 Products in the Territory of &euro;100,000,000 </font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0in"><font style="font-size: 10pt">&euro;[***]</font></td></tr>
</table>


<p style="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated
COGS Per Unit Price as of Effective Date</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Bijuva&reg; 1mg/100mg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Unit</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Price
    per unit US$</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Current
    price</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1
    capsule (in bulk packaging)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]
    ([***] cents per capsule)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Pre-launch
    price</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1
    capsule (in bulk packaging)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]
    ([***] cents per capsule)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The current price will be reduced
to the future price as soon as [***]. Both Parties will use their best efforts to include the [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Imvexxy&reg;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Unit</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Price
    per unit US$</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Current
    price (4mcg dose)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1
    capsule (in bulk packaging)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]
    ([***] cents per capsule)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Current
    price (10mcg dose)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1
    capsule (in bulk packaging)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]
    ([***] cents per capsule)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit
4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Current
and Intended Suppliers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Estradiol Hemihydrate:</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border: Black 1pt solid; padding: 3pt 5.4pt; font-weight: bold"><FONT STYLE="font-size: 10pt">Item</FONT></TD>
    <TD STYLE="width: 61%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 5.4pt; font-weight: bold"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt"><B>Address
    Facility 1:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt"><B>Address
    Facility 2:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Contact Information:</B></FONT></P>
                                                                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Progesterone:</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border: black 1pt solid; padding-top: 2.85pt; padding-left: 4.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item</B></FONT></TD>
    <TD STYLE="width: 61%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.85pt; padding-left: 4.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-left: 4.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.75pt; padding-left: 4.95pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2.85pt; padding-left: 4.95pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address Facility:</B></FONT></P>
                                                                                                                                                       <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
                                                                                                                                                       <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.05pt; padding-right: 154.65pt; padding-left: 4.95pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-left: 4.95pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact Information:</B></FONT></P>
                                                                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.4pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-left: 4.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.85pt; padding-right: 18.15pt; padding-left: 5.05pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-left: 4.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address
    Facility:</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.05pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[***]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Drug Product Bijuva (Bulk)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Item</B></FONT></TD>
    <TD STYLE="width: 73%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Catalent
    Pharma Solutions, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Address:</B></FONT></P>
                                                                                                                                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                                                                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Item</B></FONT></TD>
    <TD STYLE="width: 73%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; width: 27%; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; width: 73%; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Address:</B></FONT></P>
                                                                                                                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Drug Product Imvexxy (Bulk)</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Item</B></FONT></TD>
    <TD STYLE="width: 73%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Catalent
    Pharma Solutions, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Address:</B></FONT></P>
                                                                                                                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                                                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>Company
    Name:</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Address:</B></FONT></P>
                                                                                                                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <div align="CENTER" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.1</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Robert G. Finizio, certify that:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 0.25in; text-align: justify;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">
                <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
                <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(c)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(d)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(5)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 0.25in; text-align: justify;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="padding-left: 12pt; width: 60%; vertical-align: top; text-align: justify; text-indent: -12pt;">
                <font style="font-size: 10pt;">August 9, 2019</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 40%; vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt;">
                <font style="font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Executive Officer</p>
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Executive Officer)</p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 47-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->47
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-2.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0;">&nbsp;</p>
    <div align="CENTER" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.2</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Daniel A. Cartwright, certify that:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 0.25in; text-align: justify;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(c)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(d)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.25in; text-align: justify;">
                <font style="font-size: 10pt;">(5)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="width: 0.25in; text-align: justify;">&nbsp;</td>
            <td style="width: 0.25in; vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(a)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
            </td>
        </tr>
        <tr>
            <td style="text-align: justify;">&nbsp;</td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">(b)</font>
            </td>
            <td style="vertical-align: top; text-align: justify;">
                <font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="padding-left: 12pt; width: 60%; vertical-align: top; text-align: justify; text-indent: -12pt;">
                <font style="font-size: 10pt;">August 9, 2019</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 40%; vertical-align: bottom; text-align: justify;">
                <font style="font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt;">
                <font style="font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr>
            <td style="vertical-align: top; text-align: justify;">&nbsp;</td>
            <td style="vertical-align: bottom;">
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer</p>
                <p style="margin: 0pt 0 0pt 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 48-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->48
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0;">&nbsp;</p>
    <div align="CENTER" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 32.1</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the quarterly period ended June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 45.8pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.5in;">(1)</td>
            <td style="text-align: justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.5in;">(2)</td>
            <td style="text-align: justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="width: 60%;">August 9, 2019</td>
            <td style="border-bottom: Black 1pt solid; width: 40%;"><i>/s/ Robert G. Finizio</i></td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td>&nbsp;</td>
            <td>Robert G. Finizio</td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td>&nbsp;</td>
            <td>Chief Executive Officer</td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td>&nbsp;</td>
            <td>(Principal Executive Officer)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 49-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->49
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-2.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : 1.1 -->
    <p style="margin: 0;">&nbsp;</p>
    <div align="CENTER" style="margin-bottom: 3pt; margin-top: 3pt;">
        <div style="border-top: Black 2px solid; width: 100%; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_063019.htm">TherapeuticsMD, Inc. 10-Q</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 32.2</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the quarterly period ended June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 45.8pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.5in;">(1)</td>
            <td style="text-align: justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.5in;">(2)</td>
            <td style="text-align: justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top; text-align: left;">
            <td style="width: 60%;">August 9, 2019</td>
            <td style="border-bottom: Black 1pt solid; width: 40%;"><i>/s/ Daniel A. Cartwright</i></td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td>&nbsp;</td>
            <td>Daniel A. Cartwright</td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td>&nbsp;</td>
            <td>Chief Financial Officer</td>
        </tr>
        <tr style="vertical-align: top; text-align: left;">
            <td>&nbsp;</td>
            <td>(Principal Financial and Accounting Officer)</td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 50-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->50
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex102001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M53S##U)*$97;/KBBFJQ.<]:=7&>B%%%% !1110 4444 %%%% !1110 4444
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M>A!&"",@@@@U^Q94'V-?(_[=WPIMK[PK:^/+2W\O4=-=+6]D3 \RV=]J%O\
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M?!#XI?$SXF:K=WTNB^*GM3HILM*N99)(P&EFW((\Q_O) !YFW.W(ZBM#7/\
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MP"."0<=*\S-)KV#2/J.$:-3^U(2:T2?Y'UU1117Q9_0(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QHT;J ?J*9]G
MB_NK^52=Z6G=HAPC+5HC\B/^XOY4>1'_ '%_[YJ3%&*.9A[.'8B\B+^XOY4>
M1%_<7\JFHHYF+V<.Q#Y$7]Q?RIZJ%^ZN*=2$T:L:C&.R'4444BPHHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex102002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", 0X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^F*_P"%754*    . !VIN:NVMR50FTH2:Y5T5^GFQ:***S.H**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex102003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "0 )$# 2(  A$! Q$!_\0
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M21]!71P2221*TL)B8]4+ D?EQ0U?<J,G%\T79DM%%%!(4444 %%%% !1110
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M#]!0!+1110 4444 %%%% !1110 4444 %%5KV^MM-LIKR\GC@MH5+R2R-A5
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MWTK18=%FF8122R7$4L90H<*%SV/5NA- '-?!S3?[2^*6BJPRD#O.WML0D?\
MCV*^PA7S)^SI9B7QS?W1'^HL& ^K.@_D#7TV* %HHHH **** "BBB@ HHHH
M**** /GW]HWQ%=)=Z7X<CD*6S1?:Y@#]\[BJ _3:Q_$>E<[\+/A _C"%=8UF
M26#2 Q6*-.'N".N#_"H/&>_(&.M=#^T?H4HN](\01J3$8S9RD?PD$NGY[G_*
MO:?"5M;V?A#1K>U $*64(3 Z_(.?QZT .T3PIH/AR!8M(TJUM0!C<B N?JQ^
M8_B:P?B?XWC\$>$I;F-E_M&Y)ALT//SXY8CT4<_7 [UVDCK%&TCL%102S$X
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M_P"^7Q_[/7T?7RA\![_^S_BA;V[Y7[7;RP'/'.-X!_[XKZOH **** "BBB@
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MQ]""<CO@4 =^#S2US_@OQ/;^,/"MEK, "M*F)8P?]7(.&7\^GMBN@H ****
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:WSRM_P "//X#BNBHH 3'-+110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex102004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G % # 2(  A$! Q$!_\0
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M*^=;.SN-1OH+*TB::YN)!'%&O5F/ %?3G@+X;7O@RQ;RM1LOM<^#/+]CWO\
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M &M\>M06#P%%IP)\[4+N.-.., [C_(?G7I&F6PLM)L[4# A@2/\ )0/Z444
+6J*** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex102005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "< &X# 2(  A$! Q$!_\0
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M=92 E[>,>X&W^54QIR/)BWFN(D'4B0U$HTRHQDTVMD=@WC&Z0[?(A=_10?\
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M#@/PQ_0_H:VJ4.W8=;5J?=?\.%%%%68A1110 4444 %%%% !63X@_P"/%/\
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/****HQ"BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex102006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !Q #0# 2(  A$! Q$!_\0
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,WUK7HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex102007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K $D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#SC@, X'RG
MDGD#D\Y]?:H5+EL,FXGYB6/4>_I3L!\G*Y'&3V.?YT*6P WWL=">>G>@:'85
MSDYRQX(SGKT]A3E5E_A  ! XSC([>M+%'YD@4 DGH.Y.>OTKUGP/X!MY;*/4
M=3C\PO\ -'&PX ]<5$I6-(0YCRV.%@0W(!ZCG Y_4TT1%4./O'DYXW?7TKZ,
MG\/Z>\/E_98MOIM%>:>,_"(L+:2]T^,83+/%C@CU_"I53N:NAI='G!R3QN..
M.G/?]*8@.W<"OMMZ?A59KQU?/3GG/>GP2^>NP$[N> <9_P *U3.=HL!TP$(
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)M4WEKZ4Q'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex102008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", 0X# 2(  A$! Q$!_\0
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M</$W]UQV/\^U?'9ZUO\ AW6==\&W=IK^GK(D$Y9,L"8;@*?FC;W'YCJ* /L
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D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex102009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex102009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ", 0X# 2(  A$! Q$!_\0
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MKFNF6E-([JCY</&/?4TQTI:**P.,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I,4M% 'E_Q+3&MV<G]ZV*_DQ_QKG?#]H;
M[Q#I]OC(,ZLW^ZIW'^5=/\3?^0CI_KY+_P Q4/PXL3-J]Q>D?+;Q[0?]IO\
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M/]!Z"M>PL+33;1+6RMHK>!/NQQK@"K6*;EI9;%RGIRQT7YB"G48HJ3,****
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>txmd-20190630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:txmd="http://therapeuticsmd.com/20190630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" targetNamespace="http://therapeuticsmd.com/20190630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
        <link:definition>0007 - Disclosure - THE COMPANY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
        <link:definition>0008 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
        <link:definition>0010 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
        <link:definition>0011 - Disclosure - OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" id="FixedAssetsNet">
        <link:definition>0012 - Disclosure - FIXED ASSETS, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>0013 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES" id="OTHERCURRENTLIABILITIES">
        <link:definition>0014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/Debt" id="Debt">
        <link:definition>0015 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>0016 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>0017 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0018 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
        <link:definition>0019 - Disclosure - RELATED PARTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
        <link:definition>0020 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0021 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0022 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
        <link:definition>0025 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
        <link:definition>0026 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
        <link:definition>0027 - Disclosure - FIXED ASSETS, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <link:definition>0028 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables" id="OTHERCURRENTLIABILITIESTables">
        <link:definition>0029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/DebtTables" id="DebtTables">
        <link:definition>0030 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>0031 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>0032 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>0033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/THECOMPANYDetails" id="THECOMPANYDetails">
        <link:definition>0034 - Disclosure - THE COMPANY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" id="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative">
        <link:definition>0035 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>0036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>0037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
        <link:definition>0038 - Disclosure - INVENTORY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
        <link:definition>0039 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" id="FixedAssetsNetDetails">
        <link:definition>0040 - Disclosure - FIXED ASSETS, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" id="FixedAssetsNetDetailsNarrative">
        <link:definition>0041 - Disclosure - FIXED ASSETS, NET (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
        <link:definition>0042 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
        <link:definition>0043 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
        <link:definition>0044 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails" id="OTHERCURRENTLIABILITIESDetails">
        <link:definition>0045 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/DebtDetails" id="DebtDetails">
        <link:definition>0046 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
        <link:definition>0047 - Disclosure - DEBT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
        <link:definition>0048 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>0049 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>0050 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>0051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/THECOMPANY" id="THECOMPANY">
        <link:definition>0052 - Disclosure - THE COMPANY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
        <link:definition>0053 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
        <link:definition>0054 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
        <link:definition>0055 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
        <link:definition>0056 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>0058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>0059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>0060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd"/>
  <element name="AccruedRebates" id="txmd_AccruedRebates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AccruedResearchAndDevelopment" id="txmd_AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AllowanceForWholesaleDistributorFeesCurrent" id="txmd_AllowanceForWholesaleDistributorFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmortizationOfDeferredFinancingFees" id="txmd_AmortizationOfDeferredFinancingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnoveraMember" id="txmd_AnnoveraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualNetSalesMilestones" id="txmd_AnnualNetSalesMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" id="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" id="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ApprovedHormoneTherapyDrugCandidatePatentsMember" id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BijuvaMember" id="txmd_BijuvaMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CapitalLeaseObligationsTerm" id="txmd_CapitalLeaseObligationsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashUpfrontPaymentDue" id="txmd_CashUpfrontPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CouncilLicenseAgreement1Member" id="txmd_CouncilLicenseAgreement1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerConcentrationRisk2Member" id="txmd_CustomerConcentrationRisk2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerConcentrationRisk3Member" id="txmd_CustomerConcentrationRisk3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerConcentrationRisk4Member" id="txmd_CustomerConcentrationRisk4Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerConcentrationRisk5Member" id="txmd_CustomerConcentrationRisk5Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerConcentrationRisk7Member" id="txmd_CustomerConcentrationRisk7Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DebtTrancheAxis" id="txmd_DebtTrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="DebtTrancheDomain" id="txmd_DebtTrancheDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DeferredFinancingFees" id="txmd_DeferredFinancingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DocumentAndEntityInformationAbstract" id="txmd_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EnrolledPatients" id="txmd_EnrolledPatients" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FacilityFeePaidPercent" id="txmd_FacilityFeePaidPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancingAgreementMember" id="txmd_FinancingAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FiveMajorCustomersMember" id="txmd_FiveMajorCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FourMajorCustomersMember" id="txmd_FourMajorCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="HormoneTherapyDrugCandidatePatentsMember" id="txmd_HormoneTherapyDrugCandidatePatentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ImvexxyTmMember" id="txmd_ImvexxyTmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IntangibleWrittenOfff" id="txmd_IntangibleWrittenOfff" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestonlyPeriodExtension" id="txmd_InterestonlyPeriodExtension" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="KnightTherapeuticsIncMember" id="txmd_KnightTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LesseeOperatingLeaseLiabilityImputedInterestAmount" id="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LiborFloor" id="txmd_LiborFloor" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiborFloorRate" id="txmd_LiborFloorRate" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseRights" id="txmd_LicenseRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LongTermIncentiveCompensationPlan2009Member" id="txmd_LongTermIncentiveCompensationPlan2009Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumCostsAndExpensesForPostApprovalStudyToBePaid" id="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MidCapAgreementMember" id="txmd_MidCapAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentsAfterReleaseOfFirstCommercialBatch" id="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MilestonePaymentsUponFDAApproval" id="txmd_MilestonePaymentsUponFDAApproval" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MinimumCashBalanceRequirementUnderCreditAgreement" id="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MultipleTrademarksForVitaminsSupplementsMember" id="txmd_MultipleTrademarksForVitaminsSupplementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetSalesAmountPerStepbasedRoyalty" id="txmd_NetSalesAmountPerStepbasedRoyalty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NewOperatingLeasesMember" id="txmd_NewOperatingLeasesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoncashOperatingLeaseExpense" id="txmd_NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonQualified2012StockIncentivePlanMember" id="txmd_NonQualified2012StockIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfInstallmentPayments" id="txmd_NumberOfInstallmentPayments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfIssuedPatents" id="txmd_NumberOfIssuedPatents" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockOptionsExercised" id="txmd_NumberOfStockOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfStockOptionsExercisedInCashlessExercise" id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSubsidiares" id="txmd_NumberOfSubsidiares" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfTranchesUnderTermLoanFacility" id="txmd_NumberOfTranchesUnderTermLoanFacility" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OnerMajorCustomersMember" id="txmd_OnerMajorCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum" id="txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="OptionExercisePrices" id="txmd_OptionExercisePrices" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherCurrentAssetsAbstract" id="txmd_OtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OutsideConsultant2Member" id="txmd_OutsideConsultant2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents10Member" id="txmd_Patents10Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents11Member" id="txmd_Patents11Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents15Member" id="txmd_Patents15Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents16Member" id="txmd_Patents16Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents1Member" id="txmd_Patents1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents2Member" id="txmd_Patents2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents3Member" id="txmd_Patents3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents4Member" id="txmd_Patents4Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents5Member" id="txmd_Patents5Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents6Member" id="txmd_Patents6Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents7Member" id="txmd_Patents7Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents8Member" id="txmd_Patents8Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Patents9Member" id="txmd_Patents9Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Plan2019Member" id="txmd_Plan2019Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlanAwardsNumberOfNewShares" id="txmd_PlanAwardsNumberOfNewShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlanAwardsNumberOfNewSharesUnallocated" id="txmd_PlanAwardsNumberOfNewSharesUnallocated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaidSalesAndMarketingCostsCurrent" id="txmd_PrepaidSalesAndMarketingCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PrepaymentFee" id="txmd_PrepaymentFee" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaymentFeeFifthYearFundingPercent" id="txmd_PrepaymentFeeFifthYearFundingPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaymentFeeForFirstTwoYearsFundingPercent" id="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaymentFeeFourthYearFundingPercent" id="txmd_PrepaymentFeeFourthYearFundingPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaymentFeeThirdYearFundingPercent" id="txmd_PrepaymentFeeThirdYearFundingPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrepaymentPercentOfDebt" id="txmd_PrepaymentPercentOfDebt" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrescriptionVitaminsMember" id="txmd_PrescriptionVitaminsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrimeRateFloor" id="txmd_PrimeRateFloor" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromIssuanceOfCommonStock1" id="txmd_ProceedsFromIssuanceOfCommonStock1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RegulatoryMilestonePaymentDue" id="txmd_RegulatoryMilestonePaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReimbursementFromLandlordTenantImprovements" id="txmd_ReimbursementFromLandlordTenantImprovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RepaymentFeePercent" id="txmd_RepaymentFeePercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RepaymentOfDebtWithNewCreditFacility" id="txmd_RepaymentOfDebtWithNewCreditFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReturnPeriodOfUnsalablePrescriptionProducts" id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RevenueRequirementToDrawOnTermLoan" id="txmd_RevenueRequirementToDrawOnTermLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercent" id="txmd_RoyaltyPercent" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyTierAxis" id="txmd_RoyaltyTierAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="RoyaltyTierDomain" id="txmd_RoyaltyTierDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesDiscountsReturnsAndAllowancesGoods1" id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SalesMilestonePayments" id="txmd_SalesMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ScheduleOfIntangibleAssetsTableTextBlock" id="txmd_ScheduleOfIntangibleAssetsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfSupplementalLeaseInformationAndCashFlowInformation" id="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShelfLifeOfPrescriptionProducts" id="txmd_ShelfLifeOfPrescriptionProducts" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StepBasedRoyaltyPaymentOneMember" id="txmd_StepBasedRoyaltyPaymentOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StepBasedRoyaltyPaymentThreeMember" id="txmd_StepBasedRoyaltyPaymentThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StepBasedRoyaltyPaymentTwoMember" id="txmd_StepBasedRoyaltyPaymentTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubscriptionAgreementMember" id="txmd_SubscriptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SummaryOfActivityUnder2009And2012PlansAbstract" id="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplierConcentrationRisk4Member" id="txmd_SupplierConcentrationRisk4Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplierConcentrationRiskOneMember" id="txmd_SupplierConcentrationRiskOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplierConcentrationRiskTwoMember" id="txmd_SupplierConcentrationRiskTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalMilestonesPayments" id="txmd_TotalMilestonesPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="Tranche2Member" id="txmd_Tranche2Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Tranche3Member" id="txmd_Tranche3Member" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TrancheOneMember" id="txmd_TrancheOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAbstract" id="txmd_WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndRightsWeightedAverageContractualRemainingLife" id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" id="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>txmd-20190630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedBalanceSheets" roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#InventoryDetails" roleURI="http://therapeuticsmd.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssetsDetails" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetDetails" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetails" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIESDetails" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtDetails" roleURI="http://therapeuticsmd.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#THECOMPANY" roleURI="http://therapeuticsmd.com/role/THECOMPANY"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#THECOMPANYDetails" roleURI="http://therapeuticsmd.com/role/THECOMPANYDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LicenseRights" xlink:label="loc_txmd_LicenseRights_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_InventoryNet_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_txmd_LicenseRights_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_OtherAssets_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_Liabilities_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_AccountsPayableCurrent_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_12" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_14" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_StockholdersEquity_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_PreferredStockValue_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_CommonStockValue_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_19" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_14"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1" xlink:to="loc_us-gaap_OtherNonoperatingIncome_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1" xlink:to="loc_us-gaap_InterestExpense_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5" xlink:to="loc_us-gaap_OperatingExpenses_5" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5" xlink:to="loc_us-gaap_DepreciationAndAmortization_7" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5" xlink:to="loc_us-gaap_GrossProfit_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_10" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_14" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmd_NoncashOperatingLeaseExpense_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherShortTermDebt_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_22"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_10" order="90" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_txmd_NoncashOperatingLeaseExpense_13" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_15" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_16" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_17" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_19" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_20" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" xlink:to="loc_us-gaap_RepaymentsOfOtherShortTermDebt_21" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_22" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryFinishedGoods_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryWorkInProcess_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidInsurance_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmd_AccruedResearchAndDevelopment_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AccruedRebates" xlink:label="loc_txmd_AccruedRebates_10"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_11"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedSalariesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedVacationCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_txmd_AccruedResearchAndDevelopment_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccruedRentCurrent_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_txmd_AccruedRebates_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0" xlink:to="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_11" order="100" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:label="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_8"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0" xlink:to="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_8" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/THECOMPANY"/>
  <calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/THECOMPANYDetails"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>txmd-20190630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DocumentAndEntityInformation" roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedBalanceSheets" roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#Company" roleURI="http://therapeuticsmd.com/role/Company"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#Inventory" roleURI="http://therapeuticsmd.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssets" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNet" roleURI="http://therapeuticsmd.com/role/FixedAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssets" roleURI="http://therapeuticsmd.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIES" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#Debt" roleURI="http://therapeuticsmd.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#NetLossPerShare" roleURI="http://therapeuticsmd.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquity" roleURI="http://therapeuticsmd.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IncomeTaxes" roleURI="http://therapeuticsmd.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#RelatedParties" roleURI="http://therapeuticsmd.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BusinessConcentrations" roleURI="http://therapeuticsmd.com/role/BusinessConcentrations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingencies" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SubsequentEvents" roleURI="http://therapeuticsmd.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#InventoryTables" roleURI="http://therapeuticsmd.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssetsTables" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetTables" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsTables" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIESTables" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtTables" roleURI="http://therapeuticsmd.com/role/DebtTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#NetLossPerShareTables" roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityTables" roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesTables" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#InventoryDetails" roleURI="http://therapeuticsmd.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssetsDetails" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetDetails" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetDetailsNarrative" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetails" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetails1" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIESDetails" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtDetails" roleURI="http://therapeuticsmd.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtDetailsNarrative" roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#NetLossPerShareDetails" roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetails" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetails1" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetailsNarrative1" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetailsNarrative2" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#RelatedPartiesDetailsNarrative" roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BusinessConcentrationsDetailsNarrative" roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#THECOMPANY" roleURI="http://therapeuticsmd.com/role/THECOMPANY"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#THECOMPANYDetails" roleURI="http://therapeuticsmd.com/role/THECOMPANYDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="80" use="optional"/>


  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="loc_us-gaap_NewAccountingPronouncementMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_1" xlink:to="loc_us-gaap_AccountingGuidanceMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_1" xlink:to="loc_us-gaap_NewAccountingPronouncementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_1" xlink:to="loc_us-gaap_AccountingGuidanceMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BijuvaMember" xlink:label="loc_txmd_BijuvaMember_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmd_PrescriptionVitaminsMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ImvexxyTmMember" xlink:label="loc_txmd_ImvexxyTmMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_ProductOrServiceAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_txmd_BijuvaMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_txmd_PrescriptionVitaminsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_txmd_ImvexxyTmMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ImvexxyTmMember" xlink:label="loc_txmd_ImvexxyTmMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_11"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmd_ShelfLifeOfPrescriptionProducts_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_13"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_EnrolledPatients" xlink:label="loc_txmd_EnrolledPatients_14"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_ProductOrServiceAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6" xlink:to="loc_srt_ProductsAndServicesDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6" xlink:to="loc_txmd_ImvexxyTmMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6" xlink:to="loc_srt_ProductsAndServicesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_ShelfLifeOfPrescriptionProducts_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NumberOfReportableSegments_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_EnrolledPatients_14" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4" order="30" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_4" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_EquipmentMember_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_ComputerEquipmentMember_7" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaap_IndefiniteLivedTrademarks_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_10"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaap_InternetDomainNamesMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6" xlink:to="loc_us-gaap_IndefiniteLivedTrademarks_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_10" order="30" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:to="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:to="loc_us-gaap_InternetDomainNamesMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_10" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_16" xlink:to="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_16" xlink:to="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_16" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_22" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyTierAxis" xlink:label="loc_txmd_RoyaltyTierAxis_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyTierDomain" xlink:label="loc_txmd_RoyaltyTierDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentOneMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentOneMember_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentThreeMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentThreeMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentTwoMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyTierDomain" xlink:label="loc_txmd_RoyaltyTierDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmd_CouncilLicenseAgreement1Member_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_11"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnoveraMember" xlink:label="loc_txmd_AnnoveraMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SubscriptionAgreementMember" xlink:label="loc_txmd_SubscriptionAgreementMember_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_24"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents5Member" xlink:label="loc_txmd_Patents5Member_25"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents3Member" xlink:label="loc_txmd_Patents3Member_26"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents1Member" xlink:label="loc_txmd_Patents1Member_27"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents6Member" xlink:label="loc_txmd_Patents6Member_28"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents4Member" xlink:label="loc_txmd_Patents4Member_29"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents7Member" xlink:label="loc_txmd_Patents7Member_30"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents2Member" xlink:label="loc_txmd_Patents2Member_31"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents8Member" xlink:label="loc_txmd_Patents8Member_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_33"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents11Member" xlink:label="loc_txmd_Patents11Member_34"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents9Member" xlink:label="loc_txmd_Patents9Member_35"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents10Member" xlink:label="loc_txmd_Patents10Member_36"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents15Member" xlink:label="loc_txmd_Patents15Member_37"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents16Member" xlink:label="loc_txmd_Patents16Member_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_42"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_KnightTherapeuticsIncMember" xlink:label="loc_txmd_KnightTherapeuticsIncMember_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_IntangibleWrittenOfff" xlink:label="loc_txmd_IntangibleWrittenOfff_47"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualNetSalesMilestones" xlink:label="loc_txmd_AnnualNetSalesMilestones_48"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SalesMilestonePayments" xlink:label="loc_txmd_SalesMilestonePayments_49"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RegulatoryMilestonePaymentDue" xlink:label="loc_txmd_RegulatoryMilestonePaymentDue_50"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_TotalMilestonesPayments" xlink:label="loc_txmd_TotalMilestonesPayments_51"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CashUpfrontPaymentDue" xlink:label="loc_txmd_CashUpfrontPaymentDue_52"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_53"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_54"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmd_NumberOfIssuedPatents_55"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MilestonePaymentsUponFDAApproval" xlink:label="loc_txmd_MilestonePaymentsUponFDAApproval_56"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_57"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_58"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmd_RoyaltyPercent_59"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_60"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ProceedsFromIssuanceOfCommonStock1" xlink:label="loc_txmd_ProceedsFromIssuanceOfCommonStock1_61"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_62"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmd_NetSalesAmountPerStepbasedRoyalty_63"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_64"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_65"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_66"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_txmd_RoyaltyTierAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmd_RoyaltyTierAxis_1" xlink:to="loc_txmd_RoyaltyTierDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_RoyaltyTierDomain_1" xlink:to="loc_txmd_StepBasedRoyaltyPaymentOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_RoyaltyTierDomain_1" xlink:to="loc_txmd_StepBasedRoyaltyPaymentThreeMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_RoyaltyTierDomain_1" xlink:to="loc_txmd_StepBasedRoyaltyPaymentTwoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_txmd_RoyaltyTierAxis_1" xlink:to="loc_txmd_RoyaltyTierDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" xlink:to="loc_txmd_CouncilLicenseAgreement1Member_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_srt_ProductOrServiceAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_11" xlink:to="loc_srt_ProductsAndServicesDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11" xlink:to="loc_txmd_AnnoveraMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_11" xlink:to="loc_srt_ProductsAndServicesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_srt_RangeAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MinimumMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_15" xlink:to="loc_srt_MaximumMember_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_15" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_txmd_SubscriptionAgreementMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents5Member_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents3Member_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents1Member_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents6Member_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents4Member_29" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents7Member_30" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents2Member_31" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents8Member_32" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_33" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents11Member_34" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents9Member_35" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents10Member_36" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents15Member_37" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_24" xlink:to="loc_txmd_Patents16Member_38" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_dei_LegalEntityAxis_42" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_42" xlink:to="loc_dei_EntityDomain_42" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42" xlink:to="loc_txmd_KnightTherapeuticsIncMember_42" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_42" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_IntangibleWrittenOfff_47" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_AnnualNetSalesMilestones_48" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_SalesMilestonePayments_49" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_RegulatoryMilestonePaymentDue_50" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_TotalMilestonesPayments_51" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_CashUpfrontPaymentDue_52" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_53" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_54" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_NumberOfIssuedPatents_55" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_MilestonePaymentsUponFDAApproval_56" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_57" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_58" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_RoyaltyPercent_59" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_60" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_ProceedsFromIssuanceOfCommonStock1_61" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_62" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_NetSalesAmountPerStepbasedRoyalty_63" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_64" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_65" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_66" order="200" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_us-gaap_LineOfCreditMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_us-gaap_UnsecuredDebtMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmd_MidCapAgreementMember_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmd_FinancingAgreementMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmd_DebtTrancheAxis_30"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmd_DebtTrancheDomain_30"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Tranche3Member" xlink:label="loc_txmd_Tranche3Member_30"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Tranche2Member" xlink:label="loc_txmd_Tranche2Member_31"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_TrancheOneMember" xlink:label="loc_txmd_TrancheOneMember_32"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmd_DebtTrancheDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentPercentOfDebt" xlink:label="loc_txmd_PrepaymentPercentOfDebt_42"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmd_PrimeRateFloor_43"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AmortizationOfDeferredFinancingFees" xlink:label="loc_txmd_AmortizationOfDeferredFinancingFees_44"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DeferredFinancingFees" xlink:label="loc_txmd_DeferredFinancingFees_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_46"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings_47"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_48"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_49"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmd_NumberOfTranchesUnderTermLoanFacility_51"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_52"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_53"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_54"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LiborFloor" xlink:label="loc_txmd_LiborFloor_55"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LiborFloorRate" xlink:label="loc_txmd_LiborFloorRate_56"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_InterestonlyPeriodExtension" xlink:label="loc_txmd_InterestonlyPeriodExtension_57"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_58"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_59"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RepaymentFeePercent" xlink:label="loc_txmd_RepaymentFeePercent_60"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFee" xlink:label="loc_txmd_PrepaymentFee_61"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmd_FacilityFeePaidPercent_62"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_63"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_64"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_65"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmd_RepaymentOfDebtWithNewCreditFacility_66"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_67"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_68"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_VariableRateAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_12" xlink:to="loc_us-gaap_VariableRateDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_12" xlink:to="loc_us-gaap_BaseRateMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_12" xlink:to="loc_us-gaap_VariableRateDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_txmd_MidCapAgreementMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" xlink:to="loc_txmd_FinancingAgreementMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_21" xlink:to="loc_us-gaap_SubsequentEventMember_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_21" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_CreditFacilityAxis_25" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_25" xlink:to="loc_us-gaap_CreditFacilityDomain_25" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_25" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_25" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_25" xlink:to="loc_us-gaap_SecuredDebtMember_26" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_25" xlink:to="loc_us-gaap_CreditFacilityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_txmd_DebtTrancheAxis_30" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmd_DebtTrancheAxis_30" xlink:to="loc_txmd_DebtTrancheDomain_30" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_DebtTrancheDomain_30" xlink:to="loc_txmd_Tranche3Member_30" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_DebtTrancheDomain_30" xlink:to="loc_txmd_Tranche2Member_31" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_DebtTrancheDomain_30" xlink:to="loc_txmd_TrancheOneMember_32" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_txmd_DebtTrancheAxis_30" xlink:to="loc_txmd_DebtTrancheDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_36" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_36" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_36" xlink:to="loc_us-gaap_LineOfCreditMember_36" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_36" xlink:to="loc_us-gaap_UnsecuredDebtMember_37" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_36" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_PrepaymentPercentOfDebt_42" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_PrimeRateFloor_43" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_AmortizationOfDeferredFinancingFees_44" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_DeferredFinancingFees_45" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_46" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestExpenseBorrowings_47" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Revenues_48" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_49" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_50" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_NumberOfTranchesUnderTermLoanFacility_51" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_52" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_53" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_54" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_LiborFloor_55" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_LiborFloorRate_56" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_InterestonlyPeriodExtension_57" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestExpenseDebt_58" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_59" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_RepaymentFeePercent_60" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_PrepaymentFee_61" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_FacilityFeePaidPercent_62" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_63" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_64" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_65" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_RepaymentOfDebtWithNewCreditFacility_66" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_67" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LongTermDebt_68" order="270" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:to="loc_us-gaap_RestrictedStockMember_3" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_18" order="80" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_28"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_19" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_6" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_28" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmd_NumberOfStockOptionsExercised_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_21"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CounterpartyNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_NumberOfStockOptionsExercised_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_21" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_22" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_23" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmd_OutsideConsultant2Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmd_WarrantsAbstract_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_15"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_21"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_txmd_OutsideConsultant2Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_us-gaap_WarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_VestingAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6" xlink:to="loc_us-gaap_VestingDomain_Default" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6" xlink:to="loc_us-gaap_VestingDomain_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_WarrantsAbstract_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensation_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_22" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_24" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_25" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_26" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_27" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_28" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_29" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_31" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmd_WarrantsAbstract_15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_32" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_34" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Plan2019Member" xlink:label="loc_txmd_Plan2019Member_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmd_NonQualified2012StockIncentivePlanMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmd_LongTermIncentiveCompensationPlan2009Member_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PlanAwardsNumberOfNewSharesUnallocated" xlink:label="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmd_PlanAwardsNumberOfNewShares_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OptionExercisePrices" xlink:label="loc_txmd_OptionExercisePrices_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_41"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_txmd_Plan2019Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_txmd_NonQualified2012StockIncentivePlanMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_txmd_LongTermIncentiveCompensationPlan2009Member_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_RestrictedStockMember_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_PlanAwardsNumberOfNewShares_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_OptionExercisePrices_25" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_27" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_28" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_30" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_34" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_35" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_36" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_37" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_38" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_39" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_41" order="220" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_srt_DirectorMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_7" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRiskOneMember" xlink:label="loc_txmd_SupplierConcentrationRiskOneMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRiskTwoMember" xlink:label="loc_txmd_SupplierConcentrationRiskTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRisk4Member" xlink:label="loc_txmd_SupplierConcentrationRisk4Member_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk7Member" xlink:label="loc_txmd_CustomerConcentrationRisk7Member_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmd_CustomerConcentrationRisk2Member_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmd_CustomerConcentrationRisk3Member_8"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmd_CustomerConcentrationRisk4Member_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk5Member" xlink:label="loc_txmd_CustomerConcentrationRisk5Member_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_14"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FourMajorCustomersMember" xlink:label="loc_txmd_FourMajorCustomersMember_14"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OnerMajorCustomersMember" xlink:label="loc_txmd_OnerMajorCustomersMember_15"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FiveMajorCustomersMember" xlink:label="loc_txmd_FiveMajorCustomersMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_30"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0" xlink:to="loc_us-gaap_ConcentrationRiskTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_SupplierConcentrationRiskOneMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_SupplierConcentrationRiskTwoMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_SupplierConcentrationRisk4Member_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_CustomerConcentrationRisk7Member_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_CustomerConcentrationRisk2Member_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_CustomerConcentrationRisk3Member_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_CustomerConcentrationRisk4Member_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1" xlink:to="loc_txmd_CustomerConcentrationRisk5Member_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_srt_MajorCustomersAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_14" xlink:to="loc_srt_NameOfMajorCustomerDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14" xlink:to="loc_txmd_FourMajorCustomersMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14" xlink:to="loc_txmd_OnerMajorCustomersMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14" xlink:to="loc_txmd_FiveMajorCustomersMember_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_14" xlink:to="loc_srt_NameOfMajorCustomerDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_20" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_20" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20" xlink:to="loc_us-gaap_SalesRevenueNetMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_20" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_srt_RangeAxis_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_24" xlink:to="loc_srt_RangeMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24" xlink:to="loc_srt_MinimumMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_24" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0" xlink:to="loc_us-gaap_Revenues_30" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmd_CapitalLeaseObligationsTerm_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ReimbursementFromLandlordTenantImprovements" xlink:label="loc_txmd_ReimbursementFromLandlordTenantImprovements_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum" xlink:label="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_11"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NewOperatingLeasesMember" xlink:label="loc_txmd_NewOperatingLeasesMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_CapitalLeaseObligationsTerm_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LeaseAndRentalExpense_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseExpense_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_VariableLeaseCost_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LeaseExpirationDate1_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_ReimbursementFromLandlordTenantImprovements_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_11" order="100" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_11" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_11" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_11" xlink:to="loc_txmd_NewOperatingLeasesMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_11" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15" xlink:to="loc_us-gaap_BuildingMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/THECOMPANY"/>
  <definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/THECOMPANYDetails"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>txmd-20190630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AccruedRebates" xlink:label="loc_txmd_AccruedRebates_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmd_AccruedResearchAndDevelopment_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_3"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AmortizationOfDeferredFinancingFees" xlink:label="loc_txmd_AmortizationOfDeferredFinancingFees_4"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnoveraMember" xlink:label="loc_txmd_AnnoveraMember_5"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualNetSalesMilestones" xlink:label="loc_txmd_AnnualNetSalesMilestones_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_8"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmd_CapitalLeaseObligationsTerm_11"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CashUpfrontPaymentDue" xlink:label="loc_txmd_CashUpfrontPaymentDue_12"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_13"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_14"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmd_CouncilLicenseAgreement1Member_15"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmd_CustomerConcentrationRisk2Member_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmd_CustomerConcentrationRisk3Member_17"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmd_CustomerConcentrationRisk4Member_18"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk5Member" xlink:label="loc_txmd_CustomerConcentrationRisk5Member_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk7Member" xlink:label="loc_txmd_CustomerConcentrationRisk7Member_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmd_DebtTrancheAxis_21"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_EnrolledPatients" xlink:label="loc_txmd_EnrolledPatients_22"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmd_FacilityFeePaidPercent_23"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmd_FinancingAgreementMember_24"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FiveMajorCustomersMember" xlink:label="loc_txmd_FiveMajorCustomersMember_25"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FourMajorCustomersMember" xlink:label="loc_txmd_FourMajorCustomersMember_26"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_27"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ImvexxyTmMember" xlink:label="loc_txmd_ImvexxyTmMember_28"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_IntangibleWrittenOfff" xlink:label="loc_txmd_IntangibleWrittenOfff_29"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_InterestonlyPeriodExtension" xlink:label="loc_txmd_InterestonlyPeriodExtension_30"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_KnightTherapeuticsIncMember" xlink:label="loc_txmd_KnightTherapeuticsIncMember_31"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:label="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_32"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LiborFloor" xlink:label="loc_txmd_LiborFloor_33"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LiborFloorRate" xlink:label="loc_txmd_LiborFloorRate_34"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LicenseRights" xlink:label="loc_txmd_LicenseRights_35"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmd_LongTermIncentiveCompensationPlan2009Member_36"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_37"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmd_MidCapAgreementMember_38"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_39"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MilestonePaymentsUponFDAApproval" xlink:label="loc_txmd_MilestonePaymentsUponFDAApproval_40"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_41"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_42"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmd_NetSalesAmountPerStepbasedRoyalty_43"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NewOperatingLeasesMember" xlink:label="loc_txmd_NewOperatingLeasesMember_44"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmd_NoncashOperatingLeaseExpense_45"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmd_NonQualified2012StockIncentivePlanMember_46"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_47"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmd_NumberOfInstallmentPayments_48"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmd_NumberOfIssuedPatents_49"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmd_NumberOfStockOptionsExercised_50"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_51"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfSubsidiares" xlink:label="loc_txmd_NumberOfSubsidiares_52"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmd_NumberOfTranchesUnderTermLoanFacility_53"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OnerMajorCustomersMember" xlink:label="loc_txmd_OnerMajorCustomersMember_54"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum" xlink:label="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_55"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OptionExercisePrices" xlink:label="loc_txmd_OptionExercisePrices_56"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmd_OutsideConsultant2Member_57"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents10Member" xlink:label="loc_txmd_Patents10Member_58"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents11Member" xlink:label="loc_txmd_Patents11Member_59"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents15Member" xlink:label="loc_txmd_Patents15Member_60"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents16Member" xlink:label="loc_txmd_Patents16Member_61"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents1Member" xlink:label="loc_txmd_Patents1Member_62"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents2Member" xlink:label="loc_txmd_Patents2Member_63"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents3Member" xlink:label="loc_txmd_Patents3Member_64"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents4Member" xlink:label="loc_txmd_Patents4Member_65"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents5Member" xlink:label="loc_txmd_Patents5Member_66"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents6Member" xlink:label="loc_txmd_Patents6Member_67"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents7Member" xlink:label="loc_txmd_Patents7Member_68"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents8Member" xlink:label="loc_txmd_Patents8Member_69"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents9Member" xlink:label="loc_txmd_Patents9Member_70"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Plan2019Member" xlink:label="loc_txmd_Plan2019Member_71"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmd_PlanAwardsNumberOfNewShares_72"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PlanAwardsNumberOfNewSharesUnallocated" xlink:label="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_73"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_74"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFee" xlink:label="loc_txmd_PrepaymentFee_75"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmd_PrepaymentFeeFifthYearFundingPercent_76"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_77"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmd_PrepaymentFeeFourthYearFundingPercent_78"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmd_PrepaymentFeeThirdYearFundingPercent_79"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentPercentOfDebt" xlink:label="loc_txmd_PrepaymentPercentOfDebt_80"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmd_PrescriptionVitaminsMember_81"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmd_PrimeRateFloor_82"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ProceedsFromIssuanceOfCommonStock1" xlink:label="loc_txmd_ProceedsFromIssuanceOfCommonStock1_83"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RegulatoryMilestonePaymentDue" xlink:label="loc_txmd_RegulatoryMilestonePaymentDue_84"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ReimbursementFromLandlordTenantImprovements" xlink:label="loc_txmd_ReimbursementFromLandlordTenantImprovements_85"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RepaymentFeePercent" xlink:label="loc_txmd_RepaymentFeePercent_86"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmd_RepaymentOfDebtWithNewCreditFacility_87"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_88"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RevenueRequirementToDrawOnTermLoan" xlink:label="loc_txmd_RevenueRequirementToDrawOnTermLoan_89"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmd_RoyaltyPercent_90"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyTierAxis" xlink:label="loc_txmd_RoyaltyTierAxis_91"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_92"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SalesMilestonePayments" xlink:label="loc_txmd_SalesMilestonePayments_93"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="loc_txmd_ScheduleOfIntangibleAssetsTableTextBlock_94"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation" xlink:label="loc_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_95"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_96"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_97"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_98"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmd_ShelfLifeOfPrescriptionProducts_99"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentOneMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentOneMember_100"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentThreeMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentThreeMember_101"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentTwoMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentTwoMember_102"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SubscriptionAgreementMember" xlink:label="loc_txmd_SubscriptionAgreementMember_103"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRisk4Member" xlink:label="loc_txmd_SupplierConcentrationRisk4Member_104"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRiskOneMember" xlink:label="loc_txmd_SupplierConcentrationRiskOneMember_105"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRiskTwoMember" xlink:label="loc_txmd_SupplierConcentrationRiskTwoMember_106"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_TotalMilestonesPayments" xlink:label="loc_txmd_TotalMilestonesPayments_107"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_TrancheOneMember" xlink:label="loc_txmd_TrancheOneMember_108"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_109"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_110"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_111"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_112"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_113"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_114"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_115"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_116"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_117"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_118"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_119"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_120"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_121"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_122"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_123"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_124"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_125"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_126"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_127"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_128"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_129"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_131"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_132"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_147"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_148"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_149"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_151"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_153"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_154"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_155"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_156"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_157"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_158"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_159"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_161"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_162"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_163"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_164"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_165"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_166"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_167"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_168"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_169"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_170"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_171"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_172"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_173"/>

    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_175"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BijuvaMember" xlink:label="loc_txmd_BijuvaMember_176"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DeferredFinancingFees" xlink:label="loc_txmd_DeferredFinancingFees_177"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmd_DocumentAndEntityInformationAbstract_178"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmd_OtherCurrentAssetsAbstract_179"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_180"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_181"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Tranche2Member" xlink:label="loc_txmd_Tranche2Member_182"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Tranche3Member" xlink:label="loc_txmd_Tranche3Member_183"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmd_WarrantsAbstract_184"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_185"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_186"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_187"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_188"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_189"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_190"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_191"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_192"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_193"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_194"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_195"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_196"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_197"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_200"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_202"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_203"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_204"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_205"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_206"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_207"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_208"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_209"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_210"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_211"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_212"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_213"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_214"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_215"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_216"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_217"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_218"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_219"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_220"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_221"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_222"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_223"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_224"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_225"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_226"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_228"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_229"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_230"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_231"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_232"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_233"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_234"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_235"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_236"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_237"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_238"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_239"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_240"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_241"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_242"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_243"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_244"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_245"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_246"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_247"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_248"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_249"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_250"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_251"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_252"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_253"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_254"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_255"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_256"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_257"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_258"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_259"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_260"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_261"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_262"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_263"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_264"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_265"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_266"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_267"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_268"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_269"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_270"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_271"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_272"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_273"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_274"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_275"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_276"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_278"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_279"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_280"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_281"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_282"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_283"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_284"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_285"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_286"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_287"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_288"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_289"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_290"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_291"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_292"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_293"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaap_IndefiniteLivedTrademarks_294"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_295"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_296"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_297"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_298"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings_299"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_300"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_301"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaap_InternetDomainNamesMember_302"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_303"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_304"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_305"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_306"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_307"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_308"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_309"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_310"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_311"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_312"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_313"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_314"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_315"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_316"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_317"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_318"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_319"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_320"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_321"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_322"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_323"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_324"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_325"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_326"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_327"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_328"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_329"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_330"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_331"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_332"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_333"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_334"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_335"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_336"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember" xlink:label="loc_us-gaap_MediumTermNotesMember_337"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_338"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_339"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_340"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_342"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_343"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_344"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_345"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="loc_us-gaap_NewAccountingPronouncementMember_346"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_347"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_348"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_349"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_350"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_351"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_352"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_353"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_354"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_355"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_356"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_357"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_358"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_359"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_360"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_361"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_362"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_363"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_364"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_365"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_366"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_367"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_368"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_369"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_370"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_371"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_372"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_373"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_374"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_375"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_376"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_377"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_378"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_379"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_380"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_381"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_382"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_383"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_384"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_385"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_386"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_387"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_388"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_389"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_390"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_391"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_392"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_393"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_394"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_395"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_396"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_397"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_398"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_399"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_400"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_401"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherShortTermDebt_402"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_403"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_404"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_405"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_406"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_407"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_408"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_409"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_410"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_411"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_412"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_413"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_414"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_415"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_416"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_417"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_418"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_419"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_420"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_421"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_422"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_423"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_424"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_426"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_427"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_428"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_429"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_430"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_431"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_432"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_433"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_434"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_435"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_436"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_437"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_438"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_439"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_440"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_441"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_442"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_443"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_444"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_445"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_446"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_447"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_448"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_449"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_450"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_451"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_452"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_453"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_454"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_455"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_456"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_457"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_458"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_459"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_460"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_461"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_462"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_463"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_464"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_465"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_466"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_467"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_468"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_469"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_470"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_471"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_472"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_473"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_474"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_475"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_476"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_477"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_478"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_479"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_480"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_481"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_482"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_483"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_484"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_485"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_486"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_487"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_488"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_489"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_490"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_491"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_492"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_493"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_494"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_495"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_496"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_497"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_498"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_499"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_500"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_501"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_502"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AccruedRebates_0" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AccruedRebates_1" xml:lang="en-US">Accrued rebates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AccruedResearchAndDevelopment_0" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AccruedResearchAndDevelopment_1" xml:lang="en-US">Accrued research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AllowanceForWholesaleDistributorFeesCurrent_0" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AllowanceForWholesaleDistributorFeesCurrent_1" xml:lang="en-US">Allowance for wholesale distributor fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AmortizationOfDeferredFinancingFees_0" xml:lang="en-US">This element represents the amortization of deferred financing fees incurred and amortized over the term of the debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AmortizationOfDeferredFinancingFees_1" xml:lang="en-US">Amortization of deferred financing fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AnnoveraMember_0" xml:lang="en-US">The drug name.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AnnoveraMember_1" xml:lang="en-US">ANNOVERA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AnnualNetSalesMilestones_0" xml:lang="en-US">Annual net sale milestones in the Territory per license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AnnualNetSalesMilestones_1" xml:lang="en-US">Annual net sales milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_0" xml:lang="en-US">The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_1" xml:lang="en-US">Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_0" xml:lang="en-US">The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_1" xml:lang="en-US">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_0" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_1" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_0" xml:lang="en-US">The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_1" xml:lang="en-US">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CapitalLeaseObligationsTerm_0" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CapitalLeaseObligationsTerm_1" xml:lang="en-US">Non-cancelable operating lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CashUpfrontPaymentDue_0" xml:lang="en-US">The amount of cash due as an upfront fee per signed agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CashUpfrontPaymentDue_1" xml:lang="en-US">Cash upfront payment due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_0" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_1" xml:lang="en-US">Expiration date of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_0" xml:lang="en-US">Date the warrants or rights are vesting date in CCYY-MM-DD format.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_1" xml:lang="en-US">Vesting date of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CouncilLicenseAgreement1Member_0" xml:lang="en-US">Information about agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CouncilLicenseAgreement1Member_1" xml:lang="en-US">Council License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CustomerConcentrationRisk2Member_0" xml:lang="en-US">Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CustomerConcentrationRisk2Member_1" xml:lang="en-US">Customer Concentration - Pillpack [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CustomerConcentrationRisk3Member_0" xml:lang="en-US">Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CustomerConcentrationRisk3Member_1" xml:lang="en-US">Customer Concentration - AmerisourceBergen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CustomerConcentrationRisk4Member_0" xml:lang="en-US">Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CustomerConcentrationRisk4Member_1" xml:lang="en-US">Customer Concentration - Cardinal Health [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CustomerConcentrationRisk5Member_0" xml:lang="en-US">Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CustomerConcentrationRisk5Member_1" xml:lang="en-US">Customer Concentration - McKesson Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_CustomerConcentrationRisk7Member_0" xml:lang="en-US">Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_CustomerConcentrationRisk7Member_1" xml:lang="en-US">Customer Concentration - PI Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_DebtTrancheAxis_0" xml:lang="en-US">Portions of the Credit and Security Agreement to draw funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_DebtTrancheAxis_1" xml:lang="en-US">Debt Tranche [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_txmd_DebtTrancheAxis_2" xml:lang="en-US">VitaMed Promissory Notes [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_EnrolledPatients_0" xml:lang="en-US">The maximum amount that enrolled patients will pay per prescription refill.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_EnrolledPatients_1" xml:lang="en-US">Enrolled patients</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_FacilityFeePaidPercent_0" xml:lang="en-US">The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_FacilityFeePaidPercent_1" xml:lang="en-US">Facility fee paid (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_FinancingAgreementMember_0" xml:lang="en-US">Represents member of financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_FinancingAgreementMember_1" xml:lang="en-US">Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_FiveMajorCustomersMember_0" xml:lang="en-US">Information by name or description of a single external customer or a group of external customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_FiveMajorCustomersMember_1" xml:lang="en-US">Five Major Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_FourMajorCustomersMember_0" xml:lang="en-US">Information by name or description of a single external customer or a group of external customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_FourMajorCustomersMember_1" xml:lang="en-US">Four Major Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_HormoneTherapyDrugCandidatePatentsMember_0" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_HormoneTherapyDrugCandidatePatentsMember_1" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ImvexxyTmMember_0" xml:lang="en-US">Information about ImvexxyTm.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ImvexxyTmMember_1" xml:lang="en-US">IMVEXXY [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_IntangibleWrittenOfff_0" xml:lang="en-US">THe amount of intangibles written off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_IntangibleWrittenOfff_1" xml:lang="en-US">Intangible written offf</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_InterestonlyPeriodExtension_0" xml:lang="en-US">The number of months extended of interest-only period .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_InterestonlyPeriodExtension_1" xml:lang="en-US">Interest-only period extension</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_KnightTherapeuticsIncMember_0" xml:lang="en-US">Information about Knight Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_KnightTherapeuticsIncMember_1" xml:lang="en-US">Knight Therapeutics Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_0" xml:lang="en-US">The amount of computed imputed interest for operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_1" xml:lang="en-US">Less: Imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_2" xml:lang="en-US">LesseeOperatingLeaseLiabilityImputedInterestAmount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_LiborFloor_0" xml:lang="en-US">The minimum LIBOR rate under credit and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_LiborFloor_1" xml:lang="en-US">LIBOR floor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_LiborFloorRate_0" xml:lang="en-US">Represents libor floor rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_LiborFloorRate_1" xml:lang="en-US">LIBOR floor rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_LicenseRights_0" xml:lang="en-US">The amount of license rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_LicenseRights_1" xml:lang="en-US">License rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_LongTermIncentiveCompensationPlan2009Member_0" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_LongTermIncentiveCompensationPlan2009Member_1" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_0" xml:lang="en-US">The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_1" xml:lang="en-US">Maximum costs and expenses for post approval study to be paid by the Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_MidCapAgreementMember_0" xml:lang="en-US">Represents member of Mid Cap agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_MidCapAgreementMember_1" xml:lang="en-US">Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_0" xml:lang="en-US">The amount of milestone payments payable after release of first commercial batch.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_1" xml:lang="en-US">Milestone payments (payment after release of first commercial batch)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_MilestonePaymentsUponFDAApproval_0" xml:lang="en-US">The amount of milestone payments payable upon FDA approval.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_MilestonePaymentsUponFDAApproval_1" xml:lang="en-US">Milestone payments upon FDA approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_0" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_1" xml:lang="en-US">Minimum cash balance requirement under credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_MultipleTrademarksForVitaminsSupplementsMember_0" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_MultipleTrademarksForVitaminsSupplementsMember_1" xml:lang="en-US">Multiple Trademarks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NetSalesAmountPerStepbasedRoyalty_0" xml:lang="en-US">The net sales amount as defined in license agreement for step-based royalty payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NetSalesAmountPerStepbasedRoyalty_1" xml:lang="en-US">Net sales amount per step-based royalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NewOperatingLeasesMember_0" xml:lang="en-US">Information about new operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NewOperatingLeasesMember_1" xml:lang="en-US">New Operating Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NoncashOperatingLeaseExpense_0" xml:lang="en-US">Amount of expense related to operating lease costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NoncashOperatingLeaseExpense_1" xml:lang="en-US">Non-cash operating lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NonQualified2012StockIncentivePlanMember_0" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NonQualified2012StockIncentivePlanMember_1" xml:lang="en-US">2012 Stock Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_0" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_1" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfInstallmentPayments_0" xml:lang="en-US">Number of principal installment payments under credit and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfInstallmentPayments_1" xml:lang="en-US">Number of quarterly principal installment payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfIssuedPatents_0" xml:lang="en-US">Number of issued patents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfIssuedPatents_1" xml:lang="en-US">Number of issued patents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfStockOptionsExercised_0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfStockOptionsExercised_1" xml:lang="en-US">Number of stock options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfStockOptionsExercisedInCashlessExercise_0" xml:lang="en-US">Number of options exercised in the cashless transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfStockOptionsExercisedInCashlessExercise_1" xml:lang="en-US">Number of stock options exercised in cashless exercise (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfSubsidiares_0" xml:lang="en-US">Number of subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfSubsidiares_1" xml:lang="en-US">Number of Subsidiares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_NumberOfTranchesUnderTermLoanFacility_0" xml:lang="en-US">The number of seperate tranches under terms of the Credit Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_NumberOfTranchesUnderTermLoanFacility_1" xml:lang="en-US">Number of tranches under term loan facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_txmd_NumberOfTranchesUnderTermLoanFacility_2" xml:lang="en-US">Number of tranches under term credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_OnerMajorCustomersMember_0" xml:lang="en-US">Represents member of one major customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_OnerMajorCustomersMember_1" xml:lang="en-US">One Major Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_0" xml:lang="en-US">Amount of estimated variable future minimum rental payments for operating lease over the term of the lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_1" xml:lang="en-US">Estimated variable future minimum rental commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_OptionExercisePrices_0" xml:lang="en-US">The exercise price of the option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_OptionExercisePrices_1" xml:lang="en-US">Option exercise prices (in dollars per shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_OutsideConsultant2Member_0" xml:lang="en-US">A person who provides consutling services to the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_OutsideConsultant2Member_1" xml:lang="en-US">Outside Consultants Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents10Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents10Member_1" xml:lang="en-US">Foreign Patents Progesterone - Only Candidate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents11Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents11Member_1" xml:lang="en-US">Domestic Utility Patents Topical - Cream Candidates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents15Member_0" xml:lang="en-US">Represents the information pertaining to patents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents15Member_1" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_txmd_Patents15Member_2" xml:lang="en-US">Domestic Patents - TX-009HR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents16Member_0" xml:lang="en-US">Represents the information pertaining to patents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents16Member_1" xml:lang="en-US">Domestic utility patent D-limonene [Member] [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_txmd_Patents16Member_2" xml:lang="en-US">Foreign Patents Progesterone - Only Candidate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents1Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents1Member_1" xml:lang="en-US">Domestic Utility Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents2Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents2Member_1" xml:lang="en-US">Domestic Utility Patent - Transdermal Patch Candidates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents3Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents3Member_1" xml:lang="en-US">Foreign Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents4Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents4Member_1" xml:lang="en-US">Domestic Patents - TX-004HR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents5Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents5Member_1" xml:lang="en-US">Domestic U.S. Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents6Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents6Member_1" xml:lang="en-US">Foreign Utility Patents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents7Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents7Member_1" xml:lang="en-US">Foreign Patents - TX-004HR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents8Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents8Member_1" xml:lang="en-US">Foreign Utility Patent - Transdermal Patch Candidates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Patents9Member_0" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Patents9Member_1" xml:lang="en-US">Domestic Patents - TX-009HR [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Plan2019Member_0" xml:lang="en-US">Plan 2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_Plan2019Member_1" xml:lang="en-US">New 2019 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PlanAwardsNumberOfNewShares_0" xml:lang="en-US">Number of new shares authorized for stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PlanAwardsNumberOfNewShares_1" xml:lang="en-US">Plan Awards Number of New Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PlanAwardsNumberOfNewSharesUnallocated_0" xml:lang="en-US">Unallocated shares previously available for issuance under the award plan that were not then subject to outstanding Awards as defined in the Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PlanAwardsNumberOfNewSharesUnallocated_1" xml:lang="en-US">Plan Awards Number Of New Shares Unallocated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaidSalesAndMarketingCostsCurrent_0" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaidSalesAndMarketingCostsCurrent_1" xml:lang="en-US">Prepaid sales and marketing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaymentFee_0" xml:lang="en-US">The prepayment fee, expressed as a percentage of the tranche funding being repaid,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaymentFee_1" xml:lang="en-US">Prepayment fee (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaymentFeeFifthYearFundingPercent_0" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaymentFeeFifthYearFundingPercent_1" xml:lang="en-US">Prepayment fee fifth year funding (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_0" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_1" xml:lang="en-US">Prepayment fee for first two years funding (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaymentFeeFourthYearFundingPercent_0" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaymentFeeFourthYearFundingPercent_1" xml:lang="en-US">Prepayment fee fourth year funding (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaymentFeeThirdYearFundingPercent_0" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaymentFeeThirdYearFundingPercent_1" xml:lang="en-US">Prepayment fee third year funding (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrepaymentPercentOfDebt_0" xml:lang="en-US">Percent of debt allowed to be prepaid per agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrepaymentPercentOfDebt_1" xml:lang="en-US">Prepayment percent of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrescriptionVitaminsMember_0" xml:lang="en-US">Information about Prescription Vitamins.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrescriptionVitaminsMember_1" xml:lang="en-US">Prescription Vitamins [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_PrimeRateFloor_0" xml:lang="en-US">The prime rate floor as defined in agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_PrimeRateFloor_1" xml:lang="en-US">Prime rate floor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ProceedsFromIssuanceOfCommonStock1_0" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ProceedsFromIssuanceOfCommonStock1_1" xml:lang="en-US">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_RegulatoryMilestonePaymentDue_0" xml:lang="en-US">Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_RegulatoryMilestonePaymentDue_1" xml:lang="en-US">Regulatory milestone payment due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ReimbursementFromLandlordTenantImprovements_0" xml:lang="en-US">The amount reimbursable from the landlord for tenant improvements per lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ReimbursementFromLandlordTenantImprovements_1" xml:lang="en-US">Reimbursement from landlord - tenant improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_RepaymentFeePercent_0" xml:lang="en-US">Represents repayment fee percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_RepaymentFeePercent_1" xml:lang="en-US">Repayment fee (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_RepaymentOfDebtWithNewCreditFacility_0" xml:lang="en-US">Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_RepaymentOfDebtWithNewCreditFacility_1" xml:lang="en-US">Repayment of debt with new credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_0" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_1" xml:lang="en-US">Return period of unsalable prescription products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_RevenueRequirementToDrawOnTermLoan_0" xml:lang="en-US">The amount of consolidated net revenue attributable to commercial sales of TX-001HR and TX-004HR during the twelve-month period ending immediately prior to the funding of Tranche 3.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_RevenueRequirementToDrawOnTermLoan_1" xml:lang="en-US">Revenue requirement to draw on term loan tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_RoyaltyPercent_0" xml:lang="en-US">The percent of the net sales to be paid as royalty per license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_RoyaltyPercent_1" xml:lang="en-US">Royalty (percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_RoyaltyTierAxis_0" xml:lang="en-US">Royalty Tier of step-based royalty payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_RoyaltyTierAxis_1" xml:lang="en-US">Royalty Tier [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_txmd_RoyaltyTierAxis_2" xml:lang="en-US">Number of stock options exercised (in shares) [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_SalesDiscountsReturnsAndAllowancesGoods1_0" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SalesDiscountsReturnsAndAllowancesGoods1_1" xml:lang="en-US">Allowance for coupons and returns</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_SalesMilestonePayments_0" xml:lang="en-US">Amount of sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Territory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SalesMilestonePayments_1" xml:lang="en-US">Sales milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ScheduleOfIntangibleAssetsTableTextBlock_0" xml:lang="en-US">Tabular disclosure of intangible assets, which may be broken down by major class.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ScheduleOfIntangibleAssetsTableTextBlock_1" xml:lang="en-US">Schedule of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_0" xml:lang="en-US">Disclosure of supplementary lease and cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_1" xml:lang="en-US">Schedule of supplemental lease information and cash flow information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_0" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_1" xml:lang="en-US">Unvested ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_0" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_1" xml:lang="en-US">Unvested ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_2" xml:lang="en-US">Warrants: [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Unvested ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member] [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_ShelfLifeOfPrescriptionProducts_0" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ShelfLifeOfPrescriptionProducts_1" xml:lang="en-US">Shelf life of prescription products following product expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_StepBasedRoyaltyPaymentOneMember_0" xml:lang="en-US">The step-based royalty payment information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_StepBasedRoyaltyPaymentOneMember_1" xml:lang="en-US">Step-based Royalty Payment One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_StepBasedRoyaltyPaymentThreeMember_0" xml:lang="en-US">The step-based royalty payment information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_StepBasedRoyaltyPaymentThreeMember_1" xml:lang="en-US">Step-based Royalty Payment Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_StepBasedRoyaltyPaymentTwoMember_0" xml:lang="en-US">The step-based royalty payment information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_StepBasedRoyaltyPaymentTwoMember_1" xml:lang="en-US">Step-based Royalty Payment Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_SubscriptionAgreementMember_0" xml:lang="en-US">Information by type of sale of the entity's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SubscriptionAgreementMember_1" xml:lang="en-US">Subscription Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_SupplierConcentrationRisk4Member_0" xml:lang="en-US">Represents member of supplier concentration risk.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SupplierConcentrationRisk4Member_1" xml:lang="en-US">Products Supplier #4 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_SupplierConcentrationRiskOneMember_0" xml:lang="en-US">Reflects the percentage that purchases in the period from one significant supplier is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SupplierConcentrationRiskOneMember_1" xml:lang="en-US">Products Supplier #2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_SupplierConcentrationRiskTwoMember_0" xml:lang="en-US">Reflects the percentage that purchases in the period from one significant supplier is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SupplierConcentrationRiskTwoMember_1" xml:lang="en-US">Products Supplier #3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_TotalMilestonesPayments_0" xml:lang="en-US">Amount of eligible milestone payments we may receive per agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_TotalMilestonesPayments_1" xml:lang="en-US">Total milestones payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_TrancheOneMember_0" xml:lang="en-US">Tranche of the Credit Facility Agreement to draw funds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_TrancheOneMember_1" xml:lang="en-US">Tranche 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_0" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_1" xml:lang="en-US">Weighted-average contractual remaining life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_0" xml:lang="en-US">Weighted average price at which warrant holders can acquire the shares reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0" xml:lang="en-US">Debt discount and financing fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0" xml:lang="en-US">Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_0" xml:lang="en-US">Payment of security deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_1" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense_1" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0" xml:lang="en-US">Patent costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Options Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Shares issued for exercise of options, net (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Shares issued for exercise of options, net (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash_0" xml:lang="en-US">Cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash_1" xml:lang="en-US">Cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Common stock, outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Vested and Exercisable ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xml:lang="en-US">Unvested ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Options Outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US">Options Outstanding beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Options Outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Options Outstanding beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Options outstanding, ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Options Outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options Outstanding beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Vested and Exercisable ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Vested and Exercisable ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport_0" xml:lang="en-US">Document Quarterly Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince_0" xml:lang="en-US">Entity Address, State or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity's Reporting Status Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis_0" xml:lang="en-US">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis_0" xml:lang="en-US">Customer [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis_0" xml:lang="en-US">Products and Services [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ProductOrServiceAxis_1" xml:lang="en-US">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
  <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_0" xml:lang="en-US">Basis Of Presentation And Recently Issued Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_BijuvaMember_0" xml:lang="en-US">BIJUVA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_DeferredFinancingFees_0" xml:lang="en-US">Deferred financing fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_OtherCurrentAssetsAbstract_0" xml:lang="en-US">Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_0" xml:lang="en-US">Options, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_0" xml:lang="en-US">Summary of Activity under 2009 and 2012 Plans:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Tranche2Member_0" xml:lang="en-US">Tranche 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_Tranche3Member_0" xml:lang="en-US">Tranche 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_txmd_WarrantsAbstract_0" xml:lang="en-US">Warrants:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0" xml:lang="en-US">OTHER CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xml:lang="en-US">Other accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0" xml:lang="en-US">Payable - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $764,102 and $596,602, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent_0" xml:lang="en-US">Accrued sales and marketing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_0" xml:lang="en-US">Accrued legal and accounting expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRentCurrent_0" xml:lang="en-US">Accrued rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent_0" xml:lang="en-US">Accrued payroll, bonuses and commission costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedVacationCurrent_0" xml:lang="en-US">Accrued compensated absences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0" xml:lang="en-US">Allowance for doubtful accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_0" xml:lang="en-US">Amortization of deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_1" xml:lang="en-US">Amortization of debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_0" xml:lang="en-US">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_1" xml:lang="en-US">Amortization expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Current Assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BaseRateMember_0" xml:lang="en-US">Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BuildingMember_0" xml:lang="en-US">New Corporate Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease_0" xml:lang="en-US">Increase in cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies - See Note 15</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common stock, authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common stock, issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computer hardware [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_0" xml:lang="en-US">Domestic Utilty Patent - Opera Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_0" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_0" xml:lang="en-US">BUSINESS CONCENTRATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_0" xml:lang="en-US">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0" xml:lang="en-US">Concentration Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTable_0" xml:lang="en-US">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_0" xml:lang="en-US">Years ending December 31,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_0" xml:lang="en-US">Cost of goods sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis_0" xml:lang="en-US">Credit Facility [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_0" xml:lang="en-US">Customer Concentration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0" xml:lang="en-US">Basis spread of loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_0" xml:lang="en-US">Borrowings outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_0" xml:lang="en-US">Description of Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_1" xml:lang="en-US">Description of rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0" xml:lang="en-US">Term Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0" xml:lang="en-US">Effective interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0" xml:lang="en-US">Maturity date of facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_0" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_0" xml:lang="en-US">Year Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_0" xml:lang="en-US">Year Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0" xml:lang="en-US">First Two Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_0" xml:lang="en-US">Year Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0" xml:lang="en-US">Debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet_0" xml:lang="en-US">Debt financing fees (Note 9)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent_0" xml:lang="en-US">Security deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization_0" xml:lang="en-US">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0" xml:lang="en-US">Schedule of disaggregated revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Loss per share, basic and diluted:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract_1" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_0" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">NET LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized estimated compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Unrecognized estimated compensation expense period recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Recognized weighted-average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Total unrecognized estimated compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember_0" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_0" xml:lang="en-US">Payment of milestone recorded as finite-lived intangible asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0" xml:lang="en-US">2019 (9 months)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0" xml:lang="en-US">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0" xml:lang="en-US">2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_0" xml:lang="en-US">Year Ending December 31,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0" xml:lang="en-US">Gross Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1" xml:lang="en-US">Net Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0" xml:lang="en-US">Finite-Lived Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0" xml:lang="en-US">Weighted average remaining amortization period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0" xml:lang="en-US">Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0" xml:lang="en-US">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">INCOME TAXES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0" xml:lang="en-US">Net Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0" xml:lang="en-US">Indefinite-Lived Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedTrademarks_0" xml:lang="en-US">Indefinite-Lived Trademarks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IndefiniteLivedTrademarks_1" xml:lang="en-US">Gross Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1" xml:lang="en-US">Gross Carrying Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0" xml:lang="en-US">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1" xml:lang="en-US">Net Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseBorrowings_0" xml:lang="en-US">Interest Expense, Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt_0" xml:lang="en-US">Interest expense - debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet_0" xml:lang="en-US">Interest paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternetDomainNamesMember_0" xml:lang="en-US">Development Costs Of Corporate Website [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_0" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_0" xml:lang="en-US">INVENTORY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoods_0" xml:lang="en-US">Finished product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet_0" xml:lang="en-US">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet_1" xml:lang="en-US">TOTAL INVENTORY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies_0" xml:lang="en-US">Raw material</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcess_0" xml:lang="en-US">Work in process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense_0" xml:lang="en-US">Rental expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_0" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1_0" xml:lang="en-US">Expiration date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Reconciliation of undiscounted cash flows for all operating leases to the operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total undiscounted lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0" xml:lang="en-US">Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0" xml:lang="en-US">Lease renewal term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0" xml:lang="en-US">Lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Current Liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0" xml:lang="en-US">Borrowing capacity under loan facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditMember_0" xml:lang="en-US">Line of Credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt_0" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_0" xml:lang="en-US">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_1" xml:lang="en-US">TOTAL LONG-TERM DEBT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_0" xml:lang="en-US">Long-Term Liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTextBlock_0" xml:lang="en-US">DEBT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_0" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_0" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MediumTermNotesMember_0" xml:lang="en-US">Medium-term Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations_0" xml:lang="en-US">THE COMPANY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementMember_0" xml:lang="en-US">ASU 2018-11, Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Total other (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments_0" xml:lang="en-US">Number of operating segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense_0" xml:lang="en-US">Operating lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Present value of lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating lease liability - short term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Short-term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Long-term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities for operating lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0" xml:lang="en-US">Estimated fixed future minimum rental commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Weighted average discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Weighted average remaining term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssets_0" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsAbstract_0" xml:lang="en-US">Other Assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock_0" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashExpense_0" xml:lang="en-US">Other Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome_0" xml:lang="en-US">Miscellaneous income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0" xml:lang="en-US">Other (expense) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_0" xml:lang="en-US">Other prepaid costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_0" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0" xml:lang="en-US">Debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_0" xml:lang="en-US">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0" xml:lang="en-US">Preferred stock, authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred stock, issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0" xml:lang="en-US">Preferred stock, outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue_0" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance_0" xml:lang="en-US">Prepaid insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrimeRateMember_0" xml:lang="en-US">Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from sale of common stock, net of costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0" xml:lang="en-US">Proceeds from term loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_0" xml:lang="en-US">Proceeds from Other Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">FIXED ASSETS, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">TOTAL FIXED ASSETS, GROSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Fixed assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">TOTAL FIXED ASSETS, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_0" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_0" xml:lang="en-US">Provision for doubtful accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_0" xml:lang="en-US">Manufacturing activities billed from related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt_0" xml:lang="en-US">Repayments of Other Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfOtherShortTermDebt_0" xml:lang="en-US">Repayments of Other Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember_0" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0" xml:lang="en-US">Revenues, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember_0" xml:lang="en-US">TSPP Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_0" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_0" xml:lang="en-US">Common stock sale price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember_0" xml:lang="en-US">Sales Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of accrued expenses and current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of potentially dilutive securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0" xml:lang="en-US">Schedule of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0" xml:lang="en-US">Schedule of estimated amortization expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0" xml:lang="en-US">Schedule of inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0" xml:lang="en-US">Schedule of other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Schedule of activity of 2009 and 2012 Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredDebtMember_0" xml:lang="en-US">Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0" xml:lang="en-US">Segment Reporting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0" xml:lang="en-US">Sales, general, and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Grant date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0" xml:lang="en-US">Volatility - maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0" xml:lang="en-US">Volatility - minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0" xml:lang="en-US">Risk-free interest rate - maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0" xml:lang="en-US">Risk-free interest rate - minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0" xml:lang="en-US">Warrants granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0" xml:lang="en-US">Number of shares authorized for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Number of shares available for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Options outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Vested and Exercisable ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Options Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">weighted average grant date (in dollars per shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Options, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Options Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Cancelled/Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_0" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_0" xml:lang="en-US">Expected term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_0" xml:lang="en-US">Volatility rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_0" xml:lang="en-US">Risk free rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0" xml:lang="en-US">Acounting System [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_0" xml:lang="en-US">Cash-Settled Stock Appreciation Rights (SARs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Stockholders' Equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issue of common stock shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0" xml:lang="en-US">Shares issued for exercise of options and warrants, net (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_1" xml:lang="en-US">Shares issued for exercise of options and warrants, net (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_0" xml:lang="en-US">Shares issued for exercise of options and warrants, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_1" xml:lang="en-US">Shares issued for exercise of options and warrants, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Shares issued for exercise of options, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Shares issued for exercise of options, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2" xml:lang="en-US">Value of common stock issued during period for stock options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember_0" xml:lang="en-US">Products Supplier #1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_0" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnsecuredDebtMember_0" xml:lang="en-US">Unsecured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost_0" xml:lang="en-US">Variable lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis_0" xml:lang="en-US">Variable Rate [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain_0" xml:lang="en-US">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis_0" xml:lang="en-US">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0" xml:lang="en-US">Warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryNetAbstract_0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AccruedRebates_1" xlink:to="lab_txmd_AccruedRebates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AccruedRebates_1" xlink:to="lab_txmd_AccruedRebates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AccruedResearchAndDevelopment_2" xlink:to="lab_txmd_AccruedResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AccruedResearchAndDevelopment_2" xlink:to="lab_txmd_AccruedResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_3" xlink:to="lab_txmd_AllowanceForWholesaleDistributorFeesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_3" xlink:to="lab_txmd_AllowanceForWholesaleDistributorFeesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AmortizationOfDeferredFinancingFees_4" xlink:to="lab_txmd_AmortizationOfDeferredFinancingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AmortizationOfDeferredFinancingFees_4" xlink:to="lab_txmd_AmortizationOfDeferredFinancingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnoveraMember_5" xlink:to="lab_txmd_AnnoveraMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnoveraMember_5" xlink:to="lab_txmd_AnnoveraMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnualNetSalesMilestones_6" xlink:to="lab_txmd_AnnualNetSalesMilestones_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnualNetSalesMilestones_6" xlink:to="lab_txmd_AnnualNetSalesMilestones_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_7" xlink:to="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_7" xlink:to="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_8" xlink:to="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_8" xlink:to="lab_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_9" xlink:to="lab_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_9" xlink:to="lab_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_10" xlink:to="lab_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_10" xlink:to="lab_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CapitalLeaseObligationsTerm_11" xlink:to="lab_txmd_CapitalLeaseObligationsTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CapitalLeaseObligationsTerm_11" xlink:to="lab_txmd_CapitalLeaseObligationsTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CashUpfrontPaymentDue_12" xlink:to="lab_txmd_CashUpfrontPaymentDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CashUpfrontPaymentDue_12" xlink:to="lab_txmd_CashUpfrontPaymentDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_13" xlink:to="lab_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_13" xlink:to="lab_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_14" xlink:to="lab_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_14" xlink:to="lab_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CouncilLicenseAgreement1Member_15" xlink:to="lab_txmd_CouncilLicenseAgreement1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CouncilLicenseAgreement1Member_15" xlink:to="lab_txmd_CouncilLicenseAgreement1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk2Member_16" xlink:to="lab_txmd_CustomerConcentrationRisk2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk2Member_16" xlink:to="lab_txmd_CustomerConcentrationRisk2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk3Member_17" xlink:to="lab_txmd_CustomerConcentrationRisk3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk3Member_17" xlink:to="lab_txmd_CustomerConcentrationRisk3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk4Member_18" xlink:to="lab_txmd_CustomerConcentrationRisk4Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk4Member_18" xlink:to="lab_txmd_CustomerConcentrationRisk4Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk5Member_19" xlink:to="lab_txmd_CustomerConcentrationRisk5Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk5Member_19" xlink:to="lab_txmd_CustomerConcentrationRisk5Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk7Member_20" xlink:to="lab_txmd_CustomerConcentrationRisk7Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_CustomerConcentrationRisk7Member_20" xlink:to="lab_txmd_CustomerConcentrationRisk7Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_DebtTrancheAxis_21" xlink:to="lab_txmd_DebtTrancheAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_DebtTrancheAxis_21" xlink:to="lab_txmd_DebtTrancheAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_DebtTrancheAxis_21" xlink:to="lab_txmd_DebtTrancheAxis_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_EnrolledPatients_22" xlink:to="lab_txmd_EnrolledPatients_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_EnrolledPatients_22" xlink:to="lab_txmd_EnrolledPatients_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FacilityFeePaidPercent_23" xlink:to="lab_txmd_FacilityFeePaidPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FacilityFeePaidPercent_23" xlink:to="lab_txmd_FacilityFeePaidPercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FinancingAgreementMember_24" xlink:to="lab_txmd_FinancingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FinancingAgreementMember_24" xlink:to="lab_txmd_FinancingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FiveMajorCustomersMember_25" xlink:to="lab_txmd_FiveMajorCustomersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FiveMajorCustomersMember_25" xlink:to="lab_txmd_FiveMajorCustomersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FourMajorCustomersMember_26" xlink:to="lab_txmd_FourMajorCustomersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_FourMajorCustomersMember_26" xlink:to="lab_txmd_FourMajorCustomersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_27" xlink:to="lab_txmd_HormoneTherapyDrugCandidatePatentsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_27" xlink:to="lab_txmd_HormoneTherapyDrugCandidatePatentsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ImvexxyTmMember_28" xlink:to="lab_txmd_ImvexxyTmMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ImvexxyTmMember_28" xlink:to="lab_txmd_ImvexxyTmMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_IntangibleWrittenOfff_29" xlink:to="lab_txmd_IntangibleWrittenOfff_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_IntangibleWrittenOfff_29" xlink:to="lab_txmd_IntangibleWrittenOfff_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_InterestonlyPeriodExtension_30" xlink:to="lab_txmd_InterestonlyPeriodExtension_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_InterestonlyPeriodExtension_30" xlink:to="lab_txmd_InterestonlyPeriodExtension_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_KnightTherapeuticsIncMember_31" xlink:to="lab_txmd_KnightTherapeuticsIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_KnightTherapeuticsIncMember_31" xlink:to="lab_txmd_KnightTherapeuticsIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_32" xlink:to="lab_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_32" xlink:to="lab_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_32" xlink:to="lab_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LiborFloor_33" xlink:to="lab_txmd_LiborFloor_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LiborFloor_33" xlink:to="lab_txmd_LiborFloor_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LiborFloorRate_34" xlink:to="lab_txmd_LiborFloorRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LiborFloorRate_34" xlink:to="lab_txmd_LiborFloorRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LicenseRights_35" xlink:to="lab_txmd_LicenseRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LicenseRights_35" xlink:to="lab_txmd_LicenseRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LongTermIncentiveCompensationPlan2009Member_36" xlink:to="lab_txmd_LongTermIncentiveCompensationPlan2009Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_LongTermIncentiveCompensationPlan2009Member_36" xlink:to="lab_txmd_LongTermIncentiveCompensationPlan2009Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_37" xlink:to="lab_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_37" xlink:to="lab_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MidCapAgreementMember_38" xlink:to="lab_txmd_MidCapAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MidCapAgreementMember_38" xlink:to="lab_txmd_MidCapAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_39" xlink:to="lab_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_39" xlink:to="lab_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MilestonePaymentsUponFDAApproval_40" xlink:to="lab_txmd_MilestonePaymentsUponFDAApproval_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MilestonePaymentsUponFDAApproval_40" xlink:to="lab_txmd_MilestonePaymentsUponFDAApproval_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_41" xlink:to="lab_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_41" xlink:to="lab_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_42" xlink:to="lab_txmd_MultipleTrademarksForVitaminsSupplementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_42" xlink:to="lab_txmd_MultipleTrademarksForVitaminsSupplementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NetSalesAmountPerStepbasedRoyalty_43" xlink:to="lab_txmd_NetSalesAmountPerStepbasedRoyalty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NetSalesAmountPerStepbasedRoyalty_43" xlink:to="lab_txmd_NetSalesAmountPerStepbasedRoyalty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NewOperatingLeasesMember_44" xlink:to="lab_txmd_NewOperatingLeasesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NewOperatingLeasesMember_44" xlink:to="lab_txmd_NewOperatingLeasesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NoncashOperatingLeaseExpense_45" xlink:to="lab_txmd_NoncashOperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NoncashOperatingLeaseExpense_45" xlink:to="lab_txmd_NoncashOperatingLeaseExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NonQualified2012StockIncentivePlanMember_46" xlink:to="lab_txmd_NonQualified2012StockIncentivePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NonQualified2012StockIncentivePlanMember_46" xlink:to="lab_txmd_NonQualified2012StockIncentivePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_47" xlink:to="lab_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_47" xlink:to="lab_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfInstallmentPayments_48" xlink:to="lab_txmd_NumberOfInstallmentPayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfInstallmentPayments_48" xlink:to="lab_txmd_NumberOfInstallmentPayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfIssuedPatents_49" xlink:to="lab_txmd_NumberOfIssuedPatents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfIssuedPatents_49" xlink:to="lab_txmd_NumberOfIssuedPatents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfStockOptionsExercised_50" xlink:to="lab_txmd_NumberOfStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfStockOptionsExercised_50" xlink:to="lab_txmd_NumberOfStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_51" xlink:to="lab_txmd_NumberOfStockOptionsExercisedInCashlessExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_51" xlink:to="lab_txmd_NumberOfStockOptionsExercisedInCashlessExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfSubsidiares_52" xlink:to="lab_txmd_NumberOfSubsidiares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfSubsidiares_52" xlink:to="lab_txmd_NumberOfSubsidiares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfTranchesUnderTermLoanFacility_53" xlink:to="lab_txmd_NumberOfTranchesUnderTermLoanFacility_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfTranchesUnderTermLoanFacility_53" xlink:to="lab_txmd_NumberOfTranchesUnderTermLoanFacility_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_NumberOfTranchesUnderTermLoanFacility_53" xlink:to="lab_txmd_NumberOfTranchesUnderTermLoanFacility_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OnerMajorCustomersMember_54" xlink:to="lab_txmd_OnerMajorCustomersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OnerMajorCustomersMember_54" xlink:to="lab_txmd_OnerMajorCustomersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_55" xlink:to="lab_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_55" xlink:to="lab_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OptionExercisePrices_56" xlink:to="lab_txmd_OptionExercisePrices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OptionExercisePrices_56" xlink:to="lab_txmd_OptionExercisePrices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OutsideConsultant2Member_57" xlink:to="lab_txmd_OutsideConsultant2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OutsideConsultant2Member_57" xlink:to="lab_txmd_OutsideConsultant2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents10Member_58" xlink:to="lab_txmd_Patents10Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents10Member_58" xlink:to="lab_txmd_Patents10Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents11Member_59" xlink:to="lab_txmd_Patents11Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents11Member_59" xlink:to="lab_txmd_Patents11Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents15Member_60" xlink:to="lab_txmd_Patents15Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents15Member_60" xlink:to="lab_txmd_Patents15Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents15Member_60" xlink:to="lab_txmd_Patents15Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents16Member_61" xlink:to="lab_txmd_Patents16Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents16Member_61" xlink:to="lab_txmd_Patents16Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents16Member_61" xlink:to="lab_txmd_Patents16Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents1Member_62" xlink:to="lab_txmd_Patents1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents1Member_62" xlink:to="lab_txmd_Patents1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents2Member_63" xlink:to="lab_txmd_Patents2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents2Member_63" xlink:to="lab_txmd_Patents2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents3Member_64" xlink:to="lab_txmd_Patents3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents3Member_64" xlink:to="lab_txmd_Patents3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents4Member_65" xlink:to="lab_txmd_Patents4Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents4Member_65" xlink:to="lab_txmd_Patents4Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents5Member_66" xlink:to="lab_txmd_Patents5Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents5Member_66" xlink:to="lab_txmd_Patents5Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents6Member_67" xlink:to="lab_txmd_Patents6Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents6Member_67" xlink:to="lab_txmd_Patents6Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents7Member_68" xlink:to="lab_txmd_Patents7Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents7Member_68" xlink:to="lab_txmd_Patents7Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents8Member_69" xlink:to="lab_txmd_Patents8Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents8Member_69" xlink:to="lab_txmd_Patents8Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents9Member_70" xlink:to="lab_txmd_Patents9Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Patents9Member_70" xlink:to="lab_txmd_Patents9Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Plan2019Member_71" xlink:to="lab_txmd_Plan2019Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Plan2019Member_71" xlink:to="lab_txmd_Plan2019Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PlanAwardsNumberOfNewShares_72" xlink:to="lab_txmd_PlanAwardsNumberOfNewShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PlanAwardsNumberOfNewShares_72" xlink:to="lab_txmd_PlanAwardsNumberOfNewShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_73" xlink:to="lab_txmd_PlanAwardsNumberOfNewSharesUnallocated_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_73" xlink:to="lab_txmd_PlanAwardsNumberOfNewSharesUnallocated_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_74" xlink:to="lab_txmd_PrepaidSalesAndMarketingCostsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_74" xlink:to="lab_txmd_PrepaidSalesAndMarketingCostsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFee_75" xlink:to="lab_txmd_PrepaymentFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFee_75" xlink:to="lab_txmd_PrepaymentFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeFifthYearFundingPercent_76" xlink:to="lab_txmd_PrepaymentFeeFifthYearFundingPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeFifthYearFundingPercent_76" xlink:to="lab_txmd_PrepaymentFeeFifthYearFundingPercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_77" xlink:to="lab_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_77" xlink:to="lab_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeFourthYearFundingPercent_78" xlink:to="lab_txmd_PrepaymentFeeFourthYearFundingPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeFourthYearFundingPercent_78" xlink:to="lab_txmd_PrepaymentFeeFourthYearFundingPercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeThirdYearFundingPercent_79" xlink:to="lab_txmd_PrepaymentFeeThirdYearFundingPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentFeeThirdYearFundingPercent_79" xlink:to="lab_txmd_PrepaymentFeeThirdYearFundingPercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentPercentOfDebt_80" xlink:to="lab_txmd_PrepaymentPercentOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrepaymentPercentOfDebt_80" xlink:to="lab_txmd_PrepaymentPercentOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrescriptionVitaminsMember_81" xlink:to="lab_txmd_PrescriptionVitaminsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrescriptionVitaminsMember_81" xlink:to="lab_txmd_PrescriptionVitaminsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrimeRateFloor_82" xlink:to="lab_txmd_PrimeRateFloor_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_PrimeRateFloor_82" xlink:to="lab_txmd_PrimeRateFloor_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ProceedsFromIssuanceOfCommonStock1_83" xlink:to="lab_txmd_ProceedsFromIssuanceOfCommonStock1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ProceedsFromIssuanceOfCommonStock1_83" xlink:to="lab_txmd_ProceedsFromIssuanceOfCommonStock1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RegulatoryMilestonePaymentDue_84" xlink:to="lab_txmd_RegulatoryMilestonePaymentDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RegulatoryMilestonePaymentDue_84" xlink:to="lab_txmd_RegulatoryMilestonePaymentDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ReimbursementFromLandlordTenantImprovements_85" xlink:to="lab_txmd_ReimbursementFromLandlordTenantImprovements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ReimbursementFromLandlordTenantImprovements_85" xlink:to="lab_txmd_ReimbursementFromLandlordTenantImprovements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RepaymentFeePercent_86" xlink:to="lab_txmd_RepaymentFeePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RepaymentFeePercent_86" xlink:to="lab_txmd_RepaymentFeePercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RepaymentOfDebtWithNewCreditFacility_87" xlink:to="lab_txmd_RepaymentOfDebtWithNewCreditFacility_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RepaymentOfDebtWithNewCreditFacility_87" xlink:to="lab_txmd_RepaymentOfDebtWithNewCreditFacility_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_88" xlink:to="lab_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_88" xlink:to="lab_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RevenueRequirementToDrawOnTermLoan_89" xlink:to="lab_txmd_RevenueRequirementToDrawOnTermLoan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RevenueRequirementToDrawOnTermLoan_89" xlink:to="lab_txmd_RevenueRequirementToDrawOnTermLoan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RoyaltyPercent_90" xlink:to="lab_txmd_RoyaltyPercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RoyaltyPercent_90" xlink:to="lab_txmd_RoyaltyPercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RoyaltyTierAxis_91" xlink:to="lab_txmd_RoyaltyTierAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RoyaltyTierAxis_91" xlink:to="lab_txmd_RoyaltyTierAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_RoyaltyTierAxis_91" xlink:to="lab_txmd_RoyaltyTierAxis_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_92" xlink:to="lab_txmd_SalesDiscountsReturnsAndAllowancesGoods1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_92" xlink:to="lab_txmd_SalesDiscountsReturnsAndAllowancesGoods1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SalesMilestonePayments_93" xlink:to="lab_txmd_SalesMilestonePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SalesMilestonePayments_93" xlink:to="lab_txmd_SalesMilestonePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ScheduleOfIntangibleAssetsTableTextBlock_94" xlink:to="lab_txmd_ScheduleOfIntangibleAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ScheduleOfIntangibleAssetsTableTextBlock_94" xlink:to="lab_txmd_ScheduleOfIntangibleAssetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_95" xlink:to="lab_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_95" xlink:to="lab_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_96" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_96" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_97" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_97" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_97" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_98" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_98" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_98" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShelfLifeOfPrescriptionProducts_99" xlink:to="lab_txmd_ShelfLifeOfPrescriptionProducts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShelfLifeOfPrescriptionProducts_99" xlink:to="lab_txmd_ShelfLifeOfPrescriptionProducts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_StepBasedRoyaltyPaymentOneMember_100" xlink:to="lab_txmd_StepBasedRoyaltyPaymentOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_StepBasedRoyaltyPaymentOneMember_100" xlink:to="lab_txmd_StepBasedRoyaltyPaymentOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_StepBasedRoyaltyPaymentThreeMember_101" xlink:to="lab_txmd_StepBasedRoyaltyPaymentThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_StepBasedRoyaltyPaymentThreeMember_101" xlink:to="lab_txmd_StepBasedRoyaltyPaymentThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_StepBasedRoyaltyPaymentTwoMember_102" xlink:to="lab_txmd_StepBasedRoyaltyPaymentTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_StepBasedRoyaltyPaymentTwoMember_102" xlink:to="lab_txmd_StepBasedRoyaltyPaymentTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SubscriptionAgreementMember_103" xlink:to="lab_txmd_SubscriptionAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SubscriptionAgreementMember_103" xlink:to="lab_txmd_SubscriptionAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SupplierConcentrationRisk4Member_104" xlink:to="lab_txmd_SupplierConcentrationRisk4Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SupplierConcentrationRisk4Member_104" xlink:to="lab_txmd_SupplierConcentrationRisk4Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SupplierConcentrationRiskOneMember_105" xlink:to="lab_txmd_SupplierConcentrationRiskOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SupplierConcentrationRiskOneMember_105" xlink:to="lab_txmd_SupplierConcentrationRiskOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SupplierConcentrationRiskTwoMember_106" xlink:to="lab_txmd_SupplierConcentrationRiskTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SupplierConcentrationRiskTwoMember_106" xlink:to="lab_txmd_SupplierConcentrationRiskTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_TotalMilestonesPayments_107" xlink:to="lab_txmd_TotalMilestonesPayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_TotalMilestonesPayments_107" xlink:to="lab_txmd_TotalMilestonesPayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_TrancheOneMember_108" xlink:to="lab_txmd_TrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_TrancheOneMember_108" xlink:to="lab_txmd_TrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_109" xlink:to="lab_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_109" xlink:to="lab_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_110" xlink:to="lab_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_110" xlink:to="lab_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_111" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_111" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_112" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_112" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_113" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_113" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_114" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_114" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_115" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_115" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_116" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_116" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_117" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_117" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash_118" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash_118" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_119" xlink:to="lab_us-gaap_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_119" xlink:to="lab_us-gaap_InterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_120" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_120" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_121" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_121" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_122" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_122" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_123" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_123" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_123" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_124" xlink:to="lab_us-gaap_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_124" xlink:to="lab_us-gaap_Cash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_124" xlink:to="lab_us-gaap_Cash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_125" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_125" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_125" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_126" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_126" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_127" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_127" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_128" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_128" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_128" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_129" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_129" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_129" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_131" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_131" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_132" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_132" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_133" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_133" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_133" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_133" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_134" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_135" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_136" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_137" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_138" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_139" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_140" xlink:to="lab_dei_DocumentQuarterlyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_141" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_142" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_143" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_144" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_145" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_146" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_147" xlink:to="lab_dei_EntityAddressStateOrProvince_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_148" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_149" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_150" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_151" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_152" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_153" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_154" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_155" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_156" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_157" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_158" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_159" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_160" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_161" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_162" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_163" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_164" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_165" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_166" xlink:to="lab_srt_CounterpartyNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_167" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_168" xlink:to="lab_srt_MajorCustomersAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_169" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_170" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_171" xlink:to="lab_srt_ProductOrServiceAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_171" xlink:to="lab_srt_ProductOrServiceAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_172" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_173" xlink:to="lab_srt_RangeMember_0"/>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_175" xlink:to="lab_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_BijuvaMember_176" xlink:to="lab_txmd_BijuvaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_DeferredFinancingFees_177" xlink:to="lab_txmd_DeferredFinancingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_178" xlink:to="lab_txmd_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_OtherCurrentAssetsAbstract_179" xlink:to="lab_txmd_OtherCurrentAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_180" xlink:to="lab_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_181" xlink:to="lab_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Tranche2Member_182" xlink:to="lab_txmd_Tranche2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_Tranche3Member_183" xlink:to="lab_txmd_Tranche3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txmd_WarrantsAbstract_184" xlink:to="lab_txmd_WarrantsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_185" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_186" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_187" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_188" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_189" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_190" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent_191" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_192" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent_193" xlink:to="lab_us-gaap_AccruedRentCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_194" xlink:to="lab_us-gaap_AccruedSalariesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent_195" xlink:to="lab_us-gaap_AccruedVacationCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_196" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_197" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_197" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_199" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_200" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_201" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_202" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_202" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_203" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_203" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_204" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_205" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_206" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_207" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_208" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_208" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_209" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_210" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_210" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_211" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember_212" xlink:to="lab_us-gaap_BaseRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_213" xlink:to="lab_us-gaap_BuildingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_214" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_215" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_216" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_217" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_218" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_219" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_220" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_220" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_221" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_222" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_223" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_224" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_225" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_226" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_227" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_228" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_229" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_230" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_231" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_232" xlink:to="lab_us-gaap_ConcentrationRiskTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_233" xlink:to="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_234" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_235" xlink:to="lab_us-gaap_CreditFacilityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_236" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_237" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_238" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_239" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_240" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_240" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_241" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_242" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_243" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_244" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_245" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_246" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_247" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_248" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_249" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_250" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_251" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_252" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet_253" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent_254" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_255" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_255" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_256" xlink:to="lab_us-gaap_DepreciationAndAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_257" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_258" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_258" xlink:to="lab_us-gaap_EarningsPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_259" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_260" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_261" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_262" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_262" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_263" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_264" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_265" xlink:to="lab_us-gaap_EquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_266" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_267" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_268" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_269" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_270" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_271" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_272" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_273" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_274" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_275" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_276" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_277" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_278" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_279" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_280" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_281" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_282" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_282" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_283" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_284" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_285" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_286" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_287" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_288" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_288" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_289" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_290" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_291" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_292" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_293" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedTrademarks_294" xlink:to="lab_us-gaap_IndefiniteLivedTrademarks_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedTrademarks_294" xlink:to="lab_us-gaap_IndefiniteLivedTrademarks_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_295" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_296" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_296" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_297" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_297" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_298" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings_299" xlink:to="lab_us-gaap_InterestExpenseBorrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_300" xlink:to="lab_us-gaap_InterestExpenseDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_301" xlink:to="lab_us-gaap_InterestPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternetDomainNamesMember_302" xlink:to="lab_us-gaap_InternetDomainNamesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_303" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_304" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_305" xlink:to="lab_us-gaap_InventoryFinishedGoods_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_306" xlink:to="lab_us-gaap_InventoryNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_306" xlink:to="lab_us-gaap_InventoryNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies_307" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_308" xlink:to="lab_us-gaap_InventoryWorkInProcess_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_309" xlink:to="lab_us-gaap_LeaseAndRentalExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_310" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1_311" xlink:to="lab_us-gaap_LeaseExpirationDate1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_312" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_313" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_314" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_314" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_315" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_316" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_317" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_317" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_318" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_318" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_319" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_319" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_320" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_320" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_321" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_322" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_323" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_323" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_324" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_324" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_325" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_326" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_326" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_327" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_328" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_329" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_330" xlink:to="lab_us-gaap_LineOfCreditMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_331" xlink:to="lab_us-gaap_LongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_332" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_332" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_333" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_334" xlink:to="lab_us-gaap_LongTermDebtTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_335" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_336" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember_337" xlink:to="lab_us-gaap_MediumTermNotesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_338" xlink:to="lab_us-gaap_NatureOfOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_339" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_339" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_340" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_341" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_342" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_343" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_343" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_344" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_345" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_345" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_345" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementMember_346" xlink:to="lab_us-gaap_NewAccountingPronouncementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_347" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_347" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_348" xlink:to="lab_us-gaap_NumberOfReportableSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_349" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_349" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_350" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_351" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_352" xlink:to="lab_us-gaap_OperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_353" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_353" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_354" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_354" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_355" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_355" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_356" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_357" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_358" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_359" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_360" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_361" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets_362" xlink:to="lab_us-gaap_OtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract_363" xlink:to="lab_us-gaap_OtherAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock_364" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_365" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_366" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_366" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense_367" xlink:to="lab_us-gaap_OtherNoncashExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome_368" xlink:to="lab_us-gaap_OtherNonoperatingIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_369" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent_370" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_371" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_372" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_373" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_374" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_375" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_376" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_377" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_378" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_379" xlink:to="lab_us-gaap_PreferredStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_380" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_380" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance_381" xlink:to="lab_us-gaap_PrepaidInsurance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_382" xlink:to="lab_us-gaap_PrimeRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_383" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_384" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_385" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_386" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_387" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_388" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_389" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_390" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_391" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_392" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_392" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_393" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_394" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_395" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_396" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_397" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_398" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_399" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_400" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt_401" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherShortTermDebt_402" xlink:to="lab_us-gaap_RepaymentsOfOtherShortTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_403" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_404" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_405" xlink:to="lab_us-gaap_RestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_406" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_407" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_408" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_408" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_409" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_410" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_411" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_412" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_413" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_414" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_415" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_416" xlink:to="lab_us-gaap_SalesRevenueNetMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_417" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_418" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_419" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_420" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_421" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_422" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_423" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_424" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_426" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_427" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_428" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_429" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_430" xlink:to="lab_us-gaap_SecuredDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_431" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_432" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_433" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_433" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_434" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_435" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_436" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_437" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_438" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_439" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_440" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_441" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_442" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_443" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_444" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_445" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_446" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_447" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_448" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_449" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_450" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_451" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_452" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_453" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_454" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_455" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_456" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_457" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_458" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_459" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_460" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_461" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_462" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_463" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_463" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_464" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_465" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_466" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_467" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_468" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_469" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_471" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_472" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_473" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_474" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_475" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_475" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_476" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_477" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_478" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_479" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_479" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_480" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_480" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_481" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_481" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_481" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_482" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_483" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_484" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_485" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_486" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_487" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_488" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_489" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember_490" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_491" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_492" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember_493" xlink:to="lab_us-gaap_UnsecuredDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_494" xlink:to="lab_us-gaap_VariableLeaseCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_495" xlink:to="lab_us-gaap_VariableRateAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_496" xlink:to="lab_us-gaap_VariableRateDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_497" xlink:to="lab_us-gaap_VestingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_498" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_499" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_500" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_501" xlink:to="lab_us-gaap_InventoryNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_502" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>txmd-20190630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DocumentAndEntityInformation" roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedBalanceSheets" roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#Company" roleURI="http://therapeuticsmd.com/role/Company"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#Inventory" roleURI="http://therapeuticsmd.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssets" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNet" roleURI="http://therapeuticsmd.com/role/FixedAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssets" roleURI="http://therapeuticsmd.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIES" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#Debt" roleURI="http://therapeuticsmd.com/role/Debt"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#NetLossPerShare" roleURI="http://therapeuticsmd.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquity" roleURI="http://therapeuticsmd.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IncomeTaxes" roleURI="http://therapeuticsmd.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#RelatedParties" roleURI="http://therapeuticsmd.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BusinessConcentrations" roleURI="http://therapeuticsmd.com/role/BusinessConcentrations"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingencies" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SubsequentEvents" roleURI="http://therapeuticsmd.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#InventoryTables" roleURI="http://therapeuticsmd.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssetsTables" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetTables" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsTables" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIESTables" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtTables" roleURI="http://therapeuticsmd.com/role/DebtTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#NetLossPerShareTables" roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityTables" roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesTables" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#InventoryDetails" roleURI="http://therapeuticsmd.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OtherCurrentAssetsDetails" roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetDetails" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#FixedAssetsNetDetailsNarrative" roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetails" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetails1" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#IntangibleAssetsDetailsNarrative" roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#OTHERCURRENTLIABILITIESDetails" roleURI="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtDetails" roleURI="http://therapeuticsmd.com/role/DebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#DebtDetailsNarrative" roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#NetLossPerShareDetails" roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetails" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetails1" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetailsNarrative1" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#StockholdersEquityDetailsNarrative2" roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#RelatedPartiesDetailsNarrative" roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#BusinessConcentrationsDetailsNarrative" roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#THECOMPANY" roleURI="http://therapeuticsmd.com/role/THECOMPANY"/>
  <roleRef xlink:type="simple" xlink:href="txmd-20190630.xsd#THECOMPANYDetails" roleURI="http://therapeuticsmd.com/role/THECOMPANYDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmd_DocumentAndEntityInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityPublicFloat_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentTransitionReport_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFileNumber_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CityAreaCode_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine2_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityShellCompany_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentQuarterlyReport_23" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_24" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_LocalPhoneNumber_25" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_SecurityExchangeName_26" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_27" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_Security12bTitle_28" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_29" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityAddressStateOrProvince_30" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_31" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_8"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LicenseRights" xlink:label="loc_txmd_LicenseRights_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_InventoryNet_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OtherAssetsAbstract_8" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_8" xlink:to="loc_txmd_LicenseRights_8" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_8" xlink:to="loc_us-gaap_OtherAssets_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_8" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_8" xlink:to="loc_us-gaap_AssetsNoncurrent_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_8" xlink:to="loc_us-gaap_Assets_13" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccountsPayableCurrent_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrent_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_20" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_20" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_20" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_20" xlink:to="loc_us-gaap_Liabilities_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_23" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_StockholdersEquityAbstract_25" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_PreferredStockValue_25" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommonStockValue_26" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquity_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="80" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_DepreciationAndAmortization_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_10" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_OtherNonoperatingIncome_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_InterestExpense_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_16" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_18" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_18" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_18" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_18" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_19" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmd_NoncashOperatingLeaseExpense_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherShortTermDebt_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_34"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_Depreciation_3" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_OtherNoncashExpense_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_txmd_NoncashOperatingLeaseExpense_7" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_8" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_9" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_10" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_16" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_24" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_RepaymentsOfOtherShortTermDebt_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_30" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_Cash_31" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_Cash_32" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_34" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_34" xlink:to="loc_us-gaap_InterestPaidNet_34" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_0" xlink:to="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermDebtTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6" order="50" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="loc_txmd_ScheduleOfIntangibleAssetsTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xlink:to="loc_txmd_ScheduleOfIntangibleAssetsTableTextBlock_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation" xlink:label="loc_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract" xlink:label="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:label="loc_us-gaap_NewAccountingPronouncementMember_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_OperatingLeaseLiability_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_4" xlink:to="loc_us-gaap_AccountingGuidanceMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_4" xlink:to="loc_us-gaap_NewAccountingPronouncementMember_4" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_BijuvaMember" xlink:label="loc_txmd_BijuvaMember_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmd_PrescriptionVitaminsMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ImvexxyTmMember" xlink:label="loc_txmd_ImvexxyTmMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_ProductOrServiceAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1" xlink:to="loc_srt_ProductsAndServicesDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_txmd_BijuvaMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_txmd_PrescriptionVitaminsMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1" xlink:to="loc_txmd_ImvexxyTmMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmd_ShelfLifeOfPrescriptionProducts_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_3"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_EnrolledPatients" xlink:label="loc_txmd_EnrolledPatients_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_10"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ImvexxyTmMember" xlink:label="loc_txmd_ImvexxyTmMember_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_ReturnPeriodOfUnsalablePrescriptionProducts_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_ShelfLifeOfPrescriptionProducts_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_NumberOfReportableSegments_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_EnrolledPatients_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_ProductOrServiceAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_10" xlink:to="loc_srt_ProductsAndServicesDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10" xlink:to="loc_txmd_ImvexxyTmMember_10" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryFinishedGoods_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryWorkInProcess_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryNet_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmd_OtherCurrentAssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_txmd_OtherCurrentAssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_OtherCurrentAssetsAbstract_1" xlink:to="loc_txmd_PrepaidSalesAndMarketingCostsCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_OtherCurrentAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_OtherCurrentAssetsAbstract_1" xlink:to="loc_us-gaap_PrepaidInsurance_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_OtherCurrentAssetsAbstract_1" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_OtherCurrentAssetsAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_EquipmentMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_ComputerEquipmentMember_8" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9" order="40" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_Depreciation_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaap_IndefiniteLivedTrademarks_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_12"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaap_InternetDomainNamesMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_17"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_17"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6" xlink:to="loc_us-gaap_IndefiniteLivedTrademarks_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12" xlink:to="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12" xlink:to="loc_us-gaap_InternetDomainNamesMember_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_17" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_17" xlink:to="loc_txmd_HormoneTherapyDrugCandidatePatentsMember_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_17" xlink:to="loc_txmd_MultipleTrademarksForVitaminsSupplementsMember_18" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5" order="40" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyTierAxis" xlink:label="loc_txmd_RoyaltyTierAxis_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyTierDomain" xlink:label="loc_txmd_RoyaltyTierDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentOneMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentOneMember_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentThreeMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentThreeMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_StepBasedRoyaltyPaymentTwoMember" xlink:label="loc_txmd_StepBasedRoyaltyPaymentTwoMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmd_CouncilLicenseAgreement1Member_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnoveraMember" xlink:label="loc_txmd_AnnoveraMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SubscriptionAgreementMember" xlink:label="loc_txmd_SubscriptionAgreementMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents5Member" xlink:label="loc_txmd_Patents5Member_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents3Member" xlink:label="loc_txmd_Patents3Member_21"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents1Member" xlink:label="loc_txmd_Patents1Member_22"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents6Member" xlink:label="loc_txmd_Patents6Member_23"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents4Member" xlink:label="loc_txmd_Patents4Member_24"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents7Member" xlink:label="loc_txmd_Patents7Member_25"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents2Member" xlink:label="loc_txmd_Patents2Member_26"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents8Member" xlink:label="loc_txmd_Patents8Member_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_28"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents11Member" xlink:label="loc_txmd_Patents11Member_29"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents9Member" xlink:label="loc_txmd_Patents9Member_30"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents10Member" xlink:label="loc_txmd_Patents10Member_31"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents15Member" xlink:label="loc_txmd_Patents15Member_32"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents16Member" xlink:label="loc_txmd_Patents16Member_33"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Patents16Member" xlink:label="loc_txmd_Patents16Member_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_37"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_KnightTherapeuticsIncMember" xlink:label="loc_txmd_KnightTherapeuticsIncMember_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_IntangibleWrittenOfff" xlink:label="loc_txmd_IntangibleWrittenOfff_40"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualNetSalesMilestones" xlink:label="loc_txmd_AnnualNetSalesMilestones_41"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SalesMilestonePayments" xlink:label="loc_txmd_SalesMilestonePayments_42"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RegulatoryMilestonePaymentDue" xlink:label="loc_txmd_RegulatoryMilestonePaymentDue_43"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_TotalMilestonesPayments" xlink:label="loc_txmd_TotalMilestonesPayments_44"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CashUpfrontPaymentDue" xlink:label="loc_txmd_CashUpfrontPaymentDue_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_46"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmd_NumberOfIssuedPatents_48"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MilestonePaymentsUponFDAApproval" xlink:label="loc_txmd_MilestonePaymentsUponFDAApproval_49"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_50"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_51"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmd_RoyaltyPercent_52"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ProceedsFromIssuanceOfCommonStock1" xlink:label="loc_txmd_ProceedsFromIssuanceOfCommonStock1_54"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_55"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmd_NetSalesAmountPerStepbasedRoyalty_56"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_57"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_58"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_59"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_txmd_RoyaltyTierAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_RoyaltyTierAxis_1" xlink:to="loc_txmd_RoyaltyTierDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_RoyaltyTierDomain_1" xlink:to="loc_txmd_StepBasedRoyaltyPaymentOneMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_RoyaltyTierDomain_1" xlink:to="loc_txmd_StepBasedRoyaltyPaymentThreeMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_RoyaltyTierDomain_1" xlink:to="loc_txmd_StepBasedRoyaltyPaymentTwoMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_txmd_CouncilLicenseAgreement1Member_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_srt_ProductOrServiceAxis_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9" xlink:to="loc_srt_ProductsAndServicesDomain_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9" xlink:to="loc_txmd_AnnoveraMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_srt_RangeAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_12" xlink:to="loc_srt_RangeMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12" xlink:to="loc_srt_MinimumMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12" xlink:to="loc_srt_MaximumMember_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_txmd_SubscriptionAgreementMember_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_19" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents5Member_20" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents3Member_21" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents1Member_22" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents6Member_23" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents4Member_24" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents7Member_25" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents2Member_26" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents8Member_27" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_28" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents11Member_29" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents9Member_30" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents10Member_31" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents15Member_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents16Member_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_txmd_Patents16Member_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_dei_LegalEntityAxis_37" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_37" xlink:to="loc_dei_EntityDomain_37" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_37" xlink:to="loc_txmd_KnightTherapeuticsIncMember_37" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_IntangibleWrittenOfff_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_AnnualNetSalesMilestones_41" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_SalesMilestonePayments_42" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_RegulatoryMilestonePaymentDue_43" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_TotalMilestonesPayments_44" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_CashUpfrontPaymentDue_45" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_46" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_NumberOfIssuedPatents_48" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_MilestonePaymentsUponFDAApproval_49" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_50" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_51" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_RoyaltyPercent_52" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_53" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_ProceedsFromIssuanceOfCommonStock1_54" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_55" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_NetSalesAmountPerStepbasedRoyalty_56" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_57" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_58" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_40" xlink:to="loc_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_59" order="190" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_4"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmd_AccruedResearchAndDevelopment_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AccruedRebates" xlink:label="loc_txmd_AccruedRebates_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedSalariesCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_txmd_SalesDiscountsReturnsAndAllowancesGoods1_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedVacationCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_txmd_AllowanceForWholesaleDistributorFeesCurrent_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_txmd_AccruedResearchAndDevelopment_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedRentCurrent_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_txmd_AccruedRebates_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_us-gaap_LineOfCreditMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1" xlink:to="loc_us-gaap_UnsecuredDebtMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentPercentOfDebt" xlink:label="loc_txmd_PrepaymentPercentOfDebt_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrimeRateFloor" xlink:label="loc_txmd_PrimeRateFloor_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_AmortizationOfDeferredFinancingFees" xlink:label="loc_txmd_AmortizationOfDeferredFinancingFees_3"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DeferredFinancingFees" xlink:label="loc_txmd_DeferredFinancingFees_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmd_NumberOfTranchesUnderTermLoanFacility_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_13"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LiborFloor" xlink:label="loc_txmd_LiborFloor_14"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LiborFloorRate" xlink:label="loc_txmd_LiborFloorRate_15"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_InterestonlyPeriodExtension" xlink:label="loc_txmd_InterestonlyPeriodExtension_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_18"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RepaymentFeePercent" xlink:label="loc_txmd_RepaymentFeePercent_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PrepaymentFee" xlink:label="loc_txmd_PrepaymentFee_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmd_FacilityFeePaidPercent_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmd_RepaymentOfDebtWithNewCreditFacility_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_41"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmd_MidCapAgreementMember_41"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmd_FinancingAgreementMember_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_48"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_48"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_48"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_49"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmd_DebtTrancheAxis_52"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmd_DebtTrancheDomain_52"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Tranche3Member" xlink:label="loc_txmd_Tranche3Member_52"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Tranche2Member" xlink:label="loc_txmd_Tranche2Member_53"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_TrancheOneMember" xlink:label="loc_txmd_TrancheOneMember_54"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_57"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_57"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_58"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_PrepaymentPercentOfDebt_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_PrimeRateFloor_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_AmortizationOfDeferredFinancingFees_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_DeferredFinancingFees_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_InterestExpenseBorrowings_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_Revenues_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_MinimumCashBalanceRequirementUnderCreditAgreement_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_NumberOfTranchesUnderTermLoanFacility_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_LiborFloor_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_LiborFloorRate_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_InterestonlyPeriodExtension_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_InterestExpenseDebt_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_RepaymentFeePercent_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_PrepaymentFee_20" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_FacilityFeePaidPercent_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_22" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_23" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_RepaymentOfDebtWithNewCreditFacility_25" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_26" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LongTermDebt_27" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_29" xlink:to="loc_srt_RangeMember_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_29" xlink:to="loc_srt_MaximumMember_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_32" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_32" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_VariableRateAxis_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_38" xlink:to="loc_us-gaap_VariableRateDomain_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_38" xlink:to="loc_us-gaap_BaseRateMember_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_41" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_41" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41" xlink:to="loc_txmd_MidCapAgreementMember_41" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_41" xlink:to="loc_txmd_FinancingAgreementMember_42" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_45" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_45" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_45" xlink:to="loc_us-gaap_SubsequentEventMember_45" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_CreditFacilityAxis_48" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_48" xlink:to="loc_us-gaap_CreditFacilityDomain_48" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_48" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_48" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_48" xlink:to="loc_us-gaap_SecuredDebtMember_49" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_txmd_DebtTrancheAxis_52" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DebtTrancheAxis_52" xlink:to="loc_txmd_DebtTrancheDomain_52" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DebtTrancheDomain_52" xlink:to="loc_txmd_Tranche3Member_52" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DebtTrancheDomain_52" xlink:to="loc_txmd_Tranche2Member_53" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_DebtTrancheDomain_52" xlink:to="loc_txmd_TrancheOneMember_54" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_57" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_57" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57" xlink:to="loc_us-gaap_LineOfCreditMember_57" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57" xlink:to="loc_us-gaap_UnsecuredDebtMember_58" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_13" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_4" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract_21" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_23" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_SummaryOfActivityUnder2009And2012PlansAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmd_NumberOfStockOptionsExercised_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_CommonStockSharesIssued_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_NumberOfStockOptionsExercised_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_NumberOfStockOptionsExercisedInCashlessExercise_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_CounterpartyNameAxis_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_14" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_18" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_18" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmd_WarrantsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_22"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmd_OutsideConsultant2Member_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_WarrantsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedCompensation_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmd_WarrantsAbstract_1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_22" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_22" xlink:to="loc_txmd_OutsideConsultant2Member_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_22" xlink:to="loc_us-gaap_WarrantMember_23" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_VestingAxis_26" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_26" xlink:to="loc_us-gaap_VestingDomain_26" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_28" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28" xlink:to="loc_srt_RangeMember_28" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_28" xlink:to="loc_srt_MinimumMember_28" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_28" xlink:to="loc_srt_MaximumMember_29" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_Plan2019Member" xlink:label="loc_txmd_Plan2019Member_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmd_NonQualified2012StockIncentivePlanMember_2"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmd_LongTermIncentiveCompensationPlan2009Member_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PlanAwardsNumberOfNewSharesUnallocated" xlink:label="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmd_PlanAwardsNumberOfNewShares_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OptionExercisePrices" xlink:label="loc_txmd_OptionExercisePrices_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_37"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_txmd_Plan2019Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_txmd_NonQualified2012StockIncentivePlanMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_txmd_LongTermIncentiveCompensationPlan2009Member_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_RestrictedStockMember_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_12" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_12" xlink:to="loc_srt_RangeMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12" xlink:to="loc_srt_MinimumMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12" xlink:to="loc_srt_MaximumMember_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_16" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_txmd_PlanAwardsNumberOfNewSharesUnallocated_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_txmd_PlanAwardsNumberOfNewShares_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_19" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_txmd_OptionExercisePrices_21" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_23" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_24" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_25" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_26" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_27" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_29" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensation_30" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_31" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_32" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_33" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_34" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_35" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_37" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_srt_DirectorMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_5" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_4"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRiskOneMember" xlink:label="loc_txmd_SupplierConcentrationRiskOneMember_5"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRiskTwoMember" xlink:label="loc_txmd_SupplierConcentrationRiskTwoMember_6"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_SupplierConcentrationRisk4Member" xlink:label="loc_txmd_SupplierConcentrationRisk4Member_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk7Member" xlink:label="loc_txmd_CustomerConcentrationRisk7Member_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmd_CustomerConcentrationRisk2Member_10"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmd_CustomerConcentrationRisk3Member_11"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmd_CustomerConcentrationRisk4Member_12"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CustomerConcentrationRisk5Member" xlink:label="loc_txmd_CustomerConcentrationRisk5Member_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FourMajorCustomersMember" xlink:label="loc_txmd_FourMajorCustomersMember_16"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OnerMajorCustomersMember" xlink:label="loc_txmd_OnerMajorCustomersMember_17"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_FiveMajorCustomersMember" xlink:label="loc_txmd_FiveMajorCustomersMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_24"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1" xlink:to="loc_us-gaap_Revenues_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_SupplierConcentrationRiskOneMember_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_SupplierConcentrationRiskTwoMember_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_SupplierConcentrationRisk4Member_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_CustomerConcentrationRisk7Member_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_CustomerConcentrationRisk2Member_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_CustomerConcentrationRisk3Member_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_CustomerConcentrationRisk4Member_12" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4" xlink:to="loc_txmd_CustomerConcentrationRisk5Member_13" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_srt_MajorCustomersAxis_16" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_16" xlink:to="loc_srt_NameOfMajorCustomerDomain_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_16" xlink:to="loc_txmd_FourMajorCustomersMember_16" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_16" xlink:to="loc_txmd_OnerMajorCustomersMember_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_16" xlink:to="loc_txmd_FiveMajorCustomersMember_18" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_21" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_21" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_21" xlink:to="loc_us-gaap_SalesRevenueNetMember_21" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_1" xlink:to="loc_srt_RangeAxis_24" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_24" xlink:to="loc_srt_RangeMember_24" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24" xlink:to="loc_srt_MinimumMember_24" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasePayments_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:label="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1" xlink:to="loc_us-gaap_OperatingLeaseLiability_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmd_CapitalLeaseObligationsTerm_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_ReimbursementFromLandlordTenantImprovements" xlink:label="loc_txmd_ReimbursementFromLandlordTenantImprovements_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum" xlink:label="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_12"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NewOperatingLeasesMember" xlink:label="loc_txmd_NewOperatingLeasesMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_CapitalLeaseObligationsTerm_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LeaseAndRentalExpense_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_OperatingLeaseExpense_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_VariableLeaseCost_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LeaseExpirationDate1_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_ReimbursementFromLandlordTenantImprovements_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1" xlink:to="loc_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_12" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_12" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_12" xlink:to="loc_txmd_NewOperatingLeasesMember_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15" xlink:to="loc_us-gaap_BuildingMember_15" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/THECOMPANY"/>
  <presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/THECOMPANYDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="txmd-20190630.xsd#txmd_NumberOfSubsidiares" xlink:label="loc_txmd_NumberOfSubsidiares_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_txmd_NumberOfSubsidiares_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>txmd-10q_063019_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:txmd="http://therapeuticsmd.com/20190630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20190630.xsd" xlink:type="simple"/>
    <context id="AsOf2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-01</instant>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:KnightTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-3120181231_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_InternetDomainNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_SubsequentEventMember_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="C_20180101to20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to2018063020180101to20180630_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630txmdPrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_0_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_0_1_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_txmd_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_us-gaap_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_us-gaap_EmployeeStockOptionMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_usgaapSupplierConcentrationRiskMember_srtMajorCustomersAxis_txmdOnerMajorCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:OnerMajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630txmdPrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180401to20180630usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180101to20180630_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_20180630_txmd_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="C_20181212to2018121320181212to20181213_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-12</startDate>
            <endDate>2018-12-13</endDate>
        </period>
    </context>
    <context id="C_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="C_20190101to20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to2019063020190101to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to2019063020190101to20190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentTwoMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630txmdImvexxyTmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyTmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630txmdPrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_0_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierConcentrationRisk4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_0_1_2_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_srtProductOrServiceAxis_txmdBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_txmd_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_us-gaap_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByBenchmarkAxis_usgaap_SalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaap_CustomerConcentrationRiskMember_srtRangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk2Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskOneMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierConcentrationRiskOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskTwoMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierConcentrationRiskTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_usgaap_SupplierConcentrationRiskMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">txmd:FourMajorCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190101to20190630_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630txmdImvexxyTmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyTmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630txmdPrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630usgaapRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630_srtProductOrServiceAxis_txmdBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190401to20190630_usgaapVariableRateAxis_usgaapBaseRateMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents16Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapLongtermDebtTypeAxis_usgaapLineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapPlanNameAxis_txmdNonQualified2012StockIncentivePlanMember_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_2019063020190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630txmdHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630txmdMultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapFurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630usgaapSoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_0_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_0_1_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmdDebtTrancheAxis_txmdTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_LongTermIncentiveCompensationPlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_Patents11Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents11Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_Patents1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_Patents6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_txmd_Patents9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapCreditFacilityAxis_usgaapSecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFiveMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFourMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodOneMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodThreeMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapPlanNameAxis_txmdPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:Tranche2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:Tranche3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_usgaapVariableRateAxis_usgaapBaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_20190802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-02</instant>
        </period>
    </context>
    <context id="From2018-01-01to2018-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-01to2018-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-01to2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-01to2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-04-29to2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-29</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2018-07-29to2018-07-30_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-29</startDate>
            <endDate>2018-07-30</endDate>
        </period>
    </context>
    <context id="From2018-08-04to2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:KnightTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-04</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentThreeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_20190101to20190630"
      id="Fdei_EntityCentralIndexKey_From2019-01-01to2019-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_20190101to20190630"
      id="Fdei_AmendmentFlag_From2019-01-01to2019-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20190101to20190630"
      id="Fdei_CurrentFiscalYearEndDate_From2019-01-01to2019-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20190101to20190630"
      id="Fdei_DocumentFiscalPeriodFocus_From2019-01-01to2019-03-31">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20190101to20190630"
      id="Fdei_DocumentFiscalYearFocus_From2019-01-01to2019-03-31">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentType
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154039407">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801162509962">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154344415">2019-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801172622096">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154207811">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154227247">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154257252">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154316019">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154409917">6800 Broken Sound Parkway NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154425351">Third Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154439559">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154504285">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154553567">33487</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154612345">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154628961">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154655095">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154711447">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801154731063">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190808000421567">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190808000456320">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190808000617327">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801155144509">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801155209319">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801155844967">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20190802"
      decimals="-3"
      id="Fxbrl_20190801155021947"
      unitRef="Shares">241221840000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="C_20190630"
      decimals="0"
      id="F486"
      unitRef="USD">182846301</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F490"
      unitRef="USD">161613077</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190801160142324"
      unitRef="USD">764102</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190801160154492"
      unitRef="USD">596602</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F496"
      unitRef="USD">18383012</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F500"
      unitRef="USD">11063821</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_20190630"
      decimals="0"
      id="F506"
      unitRef="USD">7494440</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F510"
      unitRef="USD">3267670</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F516"
      unitRef="USD">7739048</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F520"
      unitRef="USD">10834693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F526"
      unitRef="USD">216462801</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F530"
      unitRef="USD">186779261</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20190630"
      decimals="0"
      id="F546"
      unitRef="USD">1432137</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F550"
      unitRef="USD">472683</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:LicenseRights
      contextRef="C_20190630"
      decimals="0"
      id="F576"
      unitRef="USD">20000000</txmd:LicenseRights>
    <txmd:LicenseRights
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F580"
      unitRef="USD">20000000</txmd:LicenseRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804111216876"
      unitRef="USD">4688114</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F590"
      unitRef="USD">4092679</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssets
      contextRef="C_20190630"
      decimals="0"
      id="F596"
      unitRef="USD">3635227</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F600"
      unitRef="USD">324855</us-gaap:OtherAssets>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_20190630"
      decimals="0"
      id="F606"
      unitRef="USD">334866</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F610"
      unitRef="USD">314446</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20190630"
      decimals="0"
      id="F616"
      unitRef="USD">28658207</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F620"
      unitRef="USD">24731980</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20190630"
      decimals="0"
      id="F626"
      unitRef="USD">246553145</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F630"
      unitRef="USD">211983924</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F659"
      unitRef="USD">19499238</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F663"
      unitRef="USD">22743841</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F669"
      unitRef="USD">22376617</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F673"
      unitRef="USD">18334948</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F679"
      unitRef="USD">41875855</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F683"
      unitRef="USD">41078789</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_20190630"
      decimals="0"
      id="F709"
      unitRef="USD">194095220</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F713"
      unitRef="USD">73381014</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20190630"
      decimals="0"
      id="F719"
      unitRef="USD">2488101</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20190630"
      decimals="0"
      id="F729"
      unitRef="USD">238459176</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F733"
      unitRef="USD">114459803</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2018-12-31"
      decimals="3"
      id="Fxbrl_201908011602580120"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_20190630"
      decimals="3"
      id="Fxbrl_20190801160258012"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_201908011603370650"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190801160337065"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="C_20190630"
      id="Fxbrl_20190801180633653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2018-12-31"
      id="Fxbrl_20190801180647605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2018-12-31"
      decimals="INF"
      id="Fxbrl_201908011604407860"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20190630"
      decimals="INF"
      id="Fxbrl_20190801160440786"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_201908011605137050"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190801160513705"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_201908011606050430"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190801160605043"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_201908011607024580"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190801160702458"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190801160744089"
      unitRef="USD">241222</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190801160754449"
      unitRef="USD">240463</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20190630"
      decimals="0"
      id="F809"
      unitRef="USD">621871919</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F813"
      unitRef="USD">616559938</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20190630"
      decimals="0"
      id="F819"
      unitRef="USD">-614019172</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F823"
      unitRef="USD">-519276280</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20190630"
      decimals="0"
      id="F829"
      unitRef="USD">8093969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F833"
      unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20190630"
      decimals="0"
      id="F839"
      unitRef="USD">246553145</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F843"
      unitRef="USD">211983924</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F938"
      unitRef="USD">6078865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F942"
      unitRef="USD">3763010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F946"
      unitRef="USD">10025516</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F950"
      unitRef="USD">7536402</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F974"
      unitRef="USD">1248860</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F978"
      unitRef="USD">454161</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F982"
      unitRef="USD">2011687</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F986"
      unitRef="USD">1087784</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1010"
      unitRef="USD">4830005</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1014"
      unitRef="USD">3308849</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1018"
      unitRef="USD">8013829</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1022"
      unitRef="USD">6448618</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1064"
      unitRef="USD">41387451</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1068"
      unitRef="USD">29466770</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1072"
      unitRef="USD">76251533</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1076"
      unitRef="USD">50224007</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1082"
      unitRef="USD">4964368</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1086"
      unitRef="USD">6798380</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1090"
      unitRef="USD">11282250</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1094"
      unitRef="USD">13837677</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1100"
      unitRef="USD">115059</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1104"
      unitRef="USD">65603</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1108"
      unitRef="USD">221997</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1112"
      unitRef="USD">125224</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1118"
      unitRef="USD">46466878</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1122"
      unitRef="USD">36330753</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1126"
      unitRef="USD">87755780</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1130"
      unitRef="USD">64186908</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1154"
      unitRef="USD">-41636873</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1158"
      unitRef="USD">-33021904</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1162"
      unitRef="USD">-79741951</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1166"
      unitRef="USD">-57738290</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190801160938478"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801161417958"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1226"
      unitRef="USD">486597</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1230"
      unitRef="USD">334238</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1234"
      unitRef="USD">1175318</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1238"
      unitRef="USD">648795</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1244"
      unitRef="USD">4028609</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20180401to20180630"
      decimals="0"
      id="Fxbrl_20190801161549851"
      unitRef="USD">531382</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1252"
      unitRef="USD">6118627</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801161609705"
      unitRef="USD">531382</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1262"
      unitRef="USD">-13599644</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1266"
      unitRef="USD">-197144</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1270"
      unitRef="USD">-15000941</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1274"
      unitRef="USD">117413</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1298"
      unitRef="USD">-55236517</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1302"
      unitRef="USD">-33219048</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1306"
      unitRef="USD">-94742892</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1310"
      unitRef="USD">-57620877</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F1370"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1374"
      unitRef="USD">-33219048</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F1378"
      unitRef="USD">-94742892</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F1382"
      unitRef="USD">-57620877</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_20190401to20190630"
      decimals="2"
      id="Fxbrl_20190801161446762"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_20180401to20180630"
      decimals="2"
      id="Fxbrl_20190801161456274"
      unitRef="USDPShares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_20190101to20190630"
      decimals="2"
      id="Fxbrl_20190801161506216"
      unitRef="USDPShares">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_20180101to20180630"
      decimals="2"
      id="Fxbrl_20190801161526286"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_20190401to20190630"
      decimals="INF"
      id="F1478"
      unitRef="Shares">241221840</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_20180401to20180630"
      decimals="INF"
      id="F1482"
      unitRef="Shares">216640186</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_20190101to20190630"
      decimals="INF"
      id="F1486"
      unitRef="Shares">241114532</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_20180101to20180630"
      decimals="INF"
      id="F1490"
      unitRef="Shares">216583067</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="F1622"
      unitRef="Shares">216429642</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="F1626"
      unitRef="USD">216430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="F1630"
      unitRef="USD">516351405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="F1634"
      unitRef="USD">-386659120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31"
      decimals="0"
      id="F1638"
      unitRef="USD">129908715</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="F1644"
      unitRef="Shares">154632</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-01to2018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="F1648"
      unitRef="USD">154</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="F1652"
      unitRef="USD">43902</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-01to2018-03-31"
      decimals="0"
      id="Fxbrl_20190808232157473"
      unitRef="USD">44056</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-01to2018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190808225858347"
      unitRef="USD">1751358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-01to2018-03-31"
      decimals="0"
      id="Fxbrl_20190808225752717"
      unitRef="USD">1751358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-01to2018-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="F1700"
      unitRef="USD">-24401829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-01to2018-03-31"
      decimals="0"
      id="F1704"
      unitRef="USD">-24401829</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="F1732"
      unitRef="Shares">216584274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="F1736"
      unitRef="USD">216584</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="F1740"
      unitRef="USD">518146665</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="F1744"
      unitRef="USD">-411060949</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31"
      decimals="0"
      id="F1748"
      unitRef="USD">107302300</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20180401to20180630usgaapCommonStockMember"
      decimals="0"
      id="F1776"
      unitRef="Shares">249785</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20180401to20180630usgaapCommonStockMember"
      decimals="0"
      id="F1780"
      unitRef="USD">250</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20180401to20180630usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="F1784"
      unitRef="USD">1084689</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1792"
      unitRef="USD">1084939</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20180401to20180630usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="F1806"
      unitRef="USD">2377082</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1814"
      unitRef="USD">2377082</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_20180401to20180630usgaapRetainedEarningsMember"
      decimals="0"
      id="F1832"
      unitRef="USD">-33219048</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F1836"
      unitRef="USD">-33219048</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="F1864"
      unitRef="Shares">216834059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="0"
      id="F1868"
      unitRef="USD">216834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="F1872"
      unitRef="USD">521608436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2018063020180630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="F1876"
      unitRef="USD">-444279997</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20180630"
      decimals="0"
      id="F1880"
      unitRef="USD">77545273</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fxbrl_20190801163539302"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fxbrl_20190801163822002"
      unitRef="USD">240463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190801163851129"
      unitRef="USD">616559938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20190801164011931"
      unitRef="USD">-519276280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190801164029485"
      unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fxbrl_20190801165118177"
      unitRef="Shares">759401</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-01to2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fxbrl_20190801165149019"
      unitRef="USD">759</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190801165219477"
      unitRef="USD">99348</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-01to2019-03-31"
      decimals="0"
      id="Fxbrl_20190801165244147"
      unitRef="USD">100107</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190801164851065"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-03-31"
      decimals="0"
      id="Fxbrl_20190801164913277"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20190801164549687"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-03-31"
      decimals="0"
      id="Fxbrl_20190801164617937"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fxbrl_20190801163717618"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fxbrl_20190801164123338"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190801164215295"
      unitRef="USD">619234655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20190801164255203"
      unitRef="USD">-558782655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31"
      decimals="0"
      id="Fxbrl_20190801164326605"
      unitRef="USD">60693222</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190801164958800"
      unitRef="USD">2637264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190801165012723"
      unitRef="USD">2637264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_20190401to2019063020190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20190801164715597"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190801164733240"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20190630usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20190801163753847"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20190630usgaapCommonStockMember"
      decimals="0"
      id="Fxbrl_20190801164141732"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20190630usgaapAdditionalPaidInCapitalMember"
      decimals="0"
      id="Fxbrl_20190801164351020"
      unitRef="USD">621871919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20190630usgaapRetainedEarningsMember"
      decimals="0"
      id="Fxbrl_20190801164411546"
      unitRef="USD">-614019172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190801164441008"
      unitRef="USD">8093969</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801161859370"
      unitRef="USD">-94742892</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190809000639608"
      unitRef="USD">-57620877</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2217"
      unitRef="USD">133049</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2221"
      unitRef="USD">79201</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2227"
      unitRef="USD">88948</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2231"
      unitRef="USD">46023</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNoncashExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801163351469"
      unitRef="USD">78864</us-gaap:OtherNoncashExpense>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2247"
      unitRef="USD">443734</txmd:NoncashOperatingLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2257"
      unitRef="USD">167500</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2261"
      unitRef="USD">38024</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801162552686"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2277"
      unitRef="USD">5224212</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2281"
      unitRef="USD">4128440</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801162001756"
      unitRef="USD">316880</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801162013848"
      unitRef="USD">30155</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2307"
      unitRef="USD">7486691</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2311"
      unitRef="USD">1335209</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2317"
      unitRef="USD">4226770</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2321"
      unitRef="USD">395219</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2327"
      unitRef="USD">-1710697</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2331"
      unitRef="USD">-2539394</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2337"
      unitRef="USD">-3244603</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2341"
      unitRef="USD">7329560</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801162118384"
      unitRef="USD">2801717</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801162130810"
      unitRef="USD">561615</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2367"
      unitRef="USD">-88677723</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2371"
      unitRef="USD">-44598893</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2397"
      unitRef="USD">763247</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2401"
      unitRef="USD">434677</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2407"
      unitRef="USD">1092504</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2411"
      unitRef="USD">45720</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801162311377"
      unitRef="USD">20420</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2421"
      unitRef="USD">11486</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2437"
      unitRef="USD">-1876171</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2441"
      unitRef="USD">-491883</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801163205366"
      unitRef="USD">100107</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801162728552"
      unitRef="USD">1128996</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801162858927"
      unitRef="USD">-81660719</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801162939771"
      unitRef="USD">200000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801162949944"
      unitRef="USD">75000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801163043487"
      unitRef="USD">-6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801163056042"
      unitRef="USD">-3786918</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2517"
      unitRef="USD">111787118</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2521"
      unitRef="USD">72342078</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashPeriodIncreaseDecrease
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801163238216"
      unitRef="USD">21233224</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801163252494"
      unitRef="USD">27251302</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:Cash
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F2547"
      unitRef="USD">161613077</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2017-12-31"
      decimals="0"
      id="F2551"
      unitRef="USD">127135628</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20190630"
      decimals="0"
      id="F2557"
      unitRef="USD">182846301</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="C_20180630"
      decimals="0"
      id="F2561"
      unitRef="USD">154386930</us-gaap:Cash>
    <us-gaap:InterestPaidNet
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801161933980"
      unitRef="USD">6989570</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190709101414998">

&lt;div style="display: inline; text-decoration: underline; font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; THE COMPANY&lt;/b&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;TherapeuticsMD, Inc., a Nevada
corporation, or TherapeuticsMD or the Company, has three&#160;wholly
owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada
corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context
otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201c;our
company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us.&#x201d;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Nature of Business&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We are a women&#x2019;s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#x2019;s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt; and BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt; brands.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;With our SYMBODA&#x2122; technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During 2018 , U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our FDA-approved product, IMVEXXY&#xae; (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched BIJUVA&#xae;, our hormone therapy combination of bio-identical 17 &#xdf;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. We are also focused on commercialization activities necessary for launch of ANNOVERA&#x2122; (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In addition, on July 30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. On June 6, 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel.&lt;/div&gt;</us-gaap:NatureOfOperations>
    <txmd:NumberOfSubsidiares
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190802171029422"
      unitRef="Pure">3</txmd:NumberOfSubsidiares>
    <txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock
      contextRef="C_20190101to20190630"
      id="F599c2581-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Interim Financial Statements&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period in the future.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Recently Issued Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating the effect of this guidance on our disclosures.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In June 2018, the FASB issued ASU 2018 -07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In February 2016, the FASB issued ASU 2016 -02 , Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018 -11 , Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016 -02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018 -11 and we recorded a $3.8 million right of use asset and a $4.1 million liability related to adoption of this standard. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess ( 1 ) whether existing or expired contracts contain leases, ( 2 ) lease classification for any existing or expired leases, and ( 3 ) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.&lt;/div&gt;</txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20190101"
      decimals="-5"
      id="Fxbrl_20190801165600395"
      unitRef="USD">3800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20190101"
      decimals="-5"
      id="Fxbrl_20190801165629829"
      unitRef="USD">4100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20190101to20190630"
      id="F599c2582-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820,

&lt;div style="display:inline;font-style:italic"&gt;Fair Value Measurements.&lt;/div&gt;&#160;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.5in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Level 1&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.5in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Level 2&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.5in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Level 3&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0.5in"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#x2019;s impairment test on an annual basis.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display: inline; text-decoration:underline"&gt; Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;br/&gt;&lt;br/&gt;Trade accounts receivable are customer obligations due
under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an
allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and
existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#x201c;completed&#x201d; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;

&lt;div style="display:inline;font-style:italic"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Prescription Products&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on&#160;consignment,&#160;revenue&#160;is generally recognized when the prescription is filled.&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of
six&#160;months&#160;prior to and up to 12&#160;months
following product expiration. Our prescription products currently have a shelf life of 24&#160;months
from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use
history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for
which the right of return exists but for which we currently do not have history of product returns, we estimate returns based
on available industry data, our own sales information and our visibility into the inventory remaining in the distribution
channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information
from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current
liabilities on the consolidated balance sheet.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible&#160;enrolled patients do not pay more than $35&#160;for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;

&lt;div style="display:inline;font-style:italic"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Disaggregation of revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;For the Three Months&lt;/div&gt;&lt;/div&gt;
        &lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;For the Six Months&lt;br/&gt;Ended June 30&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prescription vitamins&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,822,872&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,763,010&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,758,844&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,536,402&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;IMVEXXY&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,121,711&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,132,390&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;BIJUVA&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;134,282&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;134,282&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Net revenue&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;6,078,865&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,763,010&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;10,025,516&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,536,402&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Share-Based Compensation&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Research and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;amp;D expenses include professional research and advice regarding R&amp;amp;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Segment Reporting&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801165719609">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820,

&lt;div style="display:inline;font-style:italic"&gt;Fair Value Measurements.&lt;/div&gt;&#160;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.5in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Level 1&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.5in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Level 2&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.5in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Level 3&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0.5in"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#x2019;s impairment test on an annual basis.&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801165757102">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display: inline; text-decoration:underline"&gt; Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;br/&gt;&lt;br/&gt;Trade accounts receivable are customer obligations due
under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an
allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and
existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.&lt;div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801165842808">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#x201c;completed&#x201d; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;

&lt;div style="display:inline;font-style:italic"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Prescription Products&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on&#160;consignment,&#160;revenue&#160;is generally recognized when the prescription is filled.&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of
six&#160;months&#160;prior to and up to 12&#160;months
following product expiration. Our prescription products currently have a shelf life of 24&#160;months
from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use
history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for
which the right of return exists but for which we currently do not have history of product returns, we estimate returns based
on available industry data, our own sales information and our visibility into the inventory remaining in the distribution
channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information
from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current
liabilities on the consolidated balance sheet.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible&#160;enrolled patients do not pay more than $35&#160;for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;

&lt;div style="display:inline;font-style:italic"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Disaggregation of revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;For the Three Months&lt;/div&gt;&lt;/div&gt;
        &lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;For the Six Months&lt;br/&gt;Ended June 30&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prescription vitamins&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,822,872&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,763,010&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,758,844&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,536,402&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;IMVEXXY&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,121,711&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,132,390&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;BIJUVA&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;134,282&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;134,282&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Net revenue&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;6,078,865&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,763,010&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;10,025,516&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,536,402&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts
      contextRef="C_20190101to20190630_srt_MinimumMember"
      id="Fxbrl_20190808010302031">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts
      contextRef="C_20190101to20190630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20190807122414745">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190807122517919">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:EnrolledPatients
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190807122651310"
      unitRef="USD">35</txmd:EnrolledPatients>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170017507">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;For the Three Months&lt;/div&gt;&lt;/div&gt;
        &lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;For the Six Months&lt;br/&gt;Ended June 30&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prescription vitamins&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,822,872&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,763,010&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,758,844&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,536,402&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;IMVEXXY&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,121,711&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,132,390&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;BIJUVA&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;134,282&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;134,282&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Net revenue&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;6,078,865&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,763,010&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;10,025,516&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,536,402&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190401to20190630txmdPrescriptionVitaminsMember"
      decimals="0"
      id="F2840"
      unitRef="USD">2822872</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20180401to20180630txmdPrescriptionVitaminsMember"
      decimals="0"
      id="F2844"
      unitRef="USD">3763010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190101to20190630txmdPrescriptionVitaminsMember"
      decimals="0"
      id="F2848"
      unitRef="USD">4758844</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20180101to20180630txmdPrescriptionVitaminsMember"
      decimals="0"
      id="F2852"
      unitRef="USD">7536402</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190401to20190630txmdImvexxyTmMember"
      decimals="0"
      id="F2858"
      unitRef="USD">3121711</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190101to20190630txmdImvexxyTmMember"
      decimals="0"
      id="F2866"
      unitRef="USD">5132390</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190401to20190630_srtProductOrServiceAxis_txmdBijuvaMember"
      decimals="0"
      id="Fxbrl_20190808142038661"
      unitRef="USD">134282</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190101to20190630_srtProductOrServiceAxis_txmdBijuvaMember"
      decimals="0"
      id="Fxbrl_20190808142112181"
      unitRef="USD">134282</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F2894"
      unitRef="USD">6078865</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F2898"
      unitRef="USD">3763010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20190101to20190630"
      decimals="0"
      id="F2902"
      unitRef="USD">10025516</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_20180101to20180630"
      decimals="0"
      id="F2906"
      unitRef="USD">7536402</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801165906669">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Share-Based Compensation&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801165929160">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Research and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;amp;D expenses include professional research and advice regarding R&amp;amp;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801165950011">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Segment Reporting&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c2583-9c46-11e9-a255-0d2e847c7ff2">
&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;
&lt;div style="display:inline;font-weight:bold"&gt;
&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 4 &#x2013; INVENTORY&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;


&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Inventory consists of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
	&lt;tbody&gt;
		&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;
			2019&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;
			2018&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;
			&lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			4,382,969
			&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			2,908,958
			&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Work in process&lt;/td&gt;
			&lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			439,993
			&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			339,312
			&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			2,671,478
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			19,400
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			7,494,440
			&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			3,267,670
			&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;

&lt;/table&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170052657">
&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Inventory consists of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
	&lt;tbody&gt;
		&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;
			2019&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;
			2018&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
			&lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;
			&lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			4,382,969
			&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			2,908,958
			&lt;/td&gt;
			&lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Work in process&lt;/td&gt;
			&lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			439,993
			&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			339,312
			&lt;/td&gt;
			&lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			2,671,478
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			19,400
			&lt;/td&gt;
			&lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
			&lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			7,494,440
			&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
			&lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
			3,267,670
			&lt;/td&gt;
			&lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_20190630"
      decimals="0"
      id="F2975"
      unitRef="USD">4382969</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F2979"
      unitRef="USD">2908958</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_20190630"
      decimals="0"
      id="F2985"
      unitRef="USD">439993</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F2989"
      unitRef="USD">339312</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="C_20190630"
      decimals="0"
      id="F2995"
      unitRef="USD">2671478</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F2999"
      unitRef="USD">19400</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryNet
      contextRef="C_20190630"
      decimals="0"
      id="F3005"
      unitRef="USD">7494440</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3009"
      unitRef="USD">3267670</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="C_20190101to20190630"
      id="F599c2584-9c46-11e9-a255-0d2e847c7ff2">&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 5 &#x2013; OTHER CURRENT ASSETS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Other current assets consist of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prepaid sales and marketing costs&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,568,100&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,148,789&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Deferred financing fees (Note 9)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;550,757&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,898,074&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;686,891&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;790,465&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,933,300&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,997,365&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,739,048&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;10,834,693&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170126948">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Other current assets consist of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prepaid sales and marketing costs&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,568,100&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,148,789&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Deferred financing fees (Note 9)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;550,757&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,898,074&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;686,891&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;790,465&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,933,300&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,997,365&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;7,739,048&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;10,834,693&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <txmd:PrepaidSalesAndMarketingCostsCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F3041"
      unitRef="USD">2568100</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:PrepaidSalesAndMarketingCostsCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3045"
      unitRef="USD">5148789</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190802171741106"
      unitRef="USD">550757</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190802171758580"
      unitRef="USD">1898074</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:PrepaidInsurance
      contextRef="C_20190630"
      decimals="0"
      id="F3061"
      unitRef="USD">686891</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3065"
      unitRef="USD">790465</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F3071"
      unitRef="USD">3933300</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3075"
      unitRef="USD">2997365</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F3081"
      unitRef="USD">7739048</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3085"
      unitRef="USD">10834693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170203300">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 6 &#x2013; FIXED ASSETS, NET&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Fixed assets, net consist of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Accounting system&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;581,150&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;490,576&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;940,963&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;116,542&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Computer hardware&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;220,820&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;80,211&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;74,788&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;37,888&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,118,817&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,026,313&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(686,680&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(553,630&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,432,137&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;472,683&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Depreciation expense for the three months ended June 30, 2019 and 2018 was $66,556&#160;and $40,777&#160;, respectively, and for the six months ended June 30, 2019 and 2018 was $133,049&#160;and $79,201&#160;, respectively.&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170246097">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Fixed assets, net consist of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Accounting system&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;301,096&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;581,150&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;490,576&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;940,963&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;116,542&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Computer hardware&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;220,820&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;80,211&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;74,788&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;37,888&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,118,817&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,026,313&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(686,680&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(553,630&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,432,137&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;472,683&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20190630usgaapSoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="F3117"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Fxbrl_20190802171912175"
      unitRef="USD">301096000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20190630usgaapEquipmentMember"
      decimals="0"
      id="F3127"
      unitRef="USD">581150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_EquipmentMember"
      decimals="0"
      id="F3131"
      unitRef="USD">490576</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20190630usgaapFurnitureAndFixturesMember"
      decimals="0"
      id="F3137"
      unitRef="USD">940963</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="F3141"
      unitRef="USD">116542</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20190630usgaapComputerEquipmentMember"
      decimals="0"
      id="F3147"
      unitRef="USD">220820</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="F3151"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20190630usgaapLeaseholdImprovementsMember"
      decimals="0"
      id="F3157"
      unitRef="USD">74788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="F3161"
      unitRef="USD">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190802171944119"
      unitRef="USD">2118817</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190802172038860"
      unitRef="USD">1026313</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20190630"
      decimals="0"
      id="F3177"
      unitRef="USD">686680</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3181"
      unitRef="USD">553630</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20190630"
      decimals="0"
      id="F3187"
      unitRef="USD">1432137</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3191"
      unitRef="USD">472683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190801170328497"
      unitRef="USD">66556</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20180401to20180630"
      decimals="0"
      id="Fxbrl_20190801170341018"
      unitRef="USD">40777</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190801170355146"
      unitRef="USD">133049</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190801170409094"
      unitRef="USD">79201</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c4c91-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 7 &#x2013; INTANGIBLE ASSETS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;&#160; &#160; &#160; &#160;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Gross Carrying Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Accumulated Amortization&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Net&lt;br/&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted-Average&lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,962,563&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(370,338&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,592,225&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;13.5&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,833,584&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,833,584&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;n/a&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Multiple trademarks&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;262,305&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;262,305&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;indefinite&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,058,452&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(370,338&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,688,114&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/div&gt;&#160;&#160; &#160; &#160; &#160;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Gross Carrying Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Accumulated Amortization&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Net&lt;br/&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted-Average&lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&#xae;&lt;/sup&gt; software patent&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(10,484&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;21,467&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;10.75&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;n/a&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,234,129&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;(282,485&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,951,644&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;14&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,855,279&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,855,279&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;n/a&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Multiple trademarks&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;264,289&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;264,289&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;indefinite&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,477,391&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(384,712&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,092,679&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately20&#160;years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30, 2019, we wrote off $78,864&#160;in costs related to trademarks and patents, including the net carrying amount of the OPERA patent.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As of June 30, 2019, we had&#160;26&#160;issued domestic, or U.S., patents and&#160;27&#160;issued foreign patents, including:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;12 domestic patents and&#160;five&#160;foreign patents that relate to BIJUVA as well as three domestic patents that relate to non-approved doses of BIJUVA. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Four foreign
    patents that relate to our progesterone-only candidate, which are owned by us. The foreign patents will expire no earlier
    than 2033. In addition, we have pending patent applications with respect to our progesterone-only candidate in the U.S.,
    Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Five&#160;
    domestic patents (three utility and two design) and 13&#160;foreign
    patents (three utility and ten design) that relate to IMVEXXY. These patents establish an important intellectual property
    foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents
    will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain
    jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent
    applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New
    Zealand, Russia, South Africa, and South Korea;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;One domestic
    utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035.
    We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil,
    Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;One domestic utility patent and&#160;five&#160;foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South Africa;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;One domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;One domestic
    utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031;
    and&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:0.25in;font-family:Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Two&#160;domestic utilitypatents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Amortization expense was $48,503&#160;and $24,826&#160;for the three months ended June 30, 2019 and 2018, respectively and $88,948&#160;and $46,023&#160;for the six months ended June 30, 2019 and 2018, respectively. Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;&#160;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:25%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Year Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Estimated Amortization&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2019(6 months)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;96,008&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2023&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;License Agreement with the Population Council&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On July 30, 2018, we entered into the Council License Agreement to commercialize in the U.S. ANNOVERA. We currently estimate that ANNOVERA will be commercially available as early as the third quarter of 2019 with a planned full commercial launch by the first quarter of 2020.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Under the terms of the Council License
Agreement, we paid the Population Council a milestone payment of $20,000,000&#160;within
30 days following approval by the FDA of the NDA for ANNOVERA and will be required to pay the Population Council
$20,000,000&#160;within
30 days following the release of the first commercial batch of ANNOVERA. The Population Council is also eligible to receive
milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for marketing expenses
related to the commercialization of ANNOVERA. The milestone payment of $20,000,000&#160;upon
the FDA&#x2019;s approval of ANNOVERA in the third quarter of 2018 was recorded as a finite-lived intangible asset in the
consolidated balance sheet and will be amortized on a straight-line basis once it becomes available for use which is expected
to be upon release of first commercial batch of ANNOVERA. In addition, we are required to pay the Population Council, on a
quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its
affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $50,000,000&#160;,
a royalty of 5&#160;%
of net sales; (ii) for annual net sales greater than $50,000,000&#160;and
less than or equal to $150,000,000&#160;,
a royalty of 10&#160;%
of such net sales; and (iii) for net sales greater than $150,000,000&#160;,
a royalty of 15&#160;%
of such net sales. The annual royalty rate will be reduced to 50&#160;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to 20&#160;%
of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will be offset against
royalties or other payments owed by us to the Population Council under the Council License Agreement. We and the Population
Council have agreed to form a joint product committee responsible for overseeing activities under the Council License
Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system,
subject to oversight and decisions made by the joint product committee. The Council License Agreement includes exclusive
rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the
Population Council.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We assess our intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;License Agreement with Knight Therapeutics Inc.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased3,921,568&#160;shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $5.10&#160;, for proceeds of $20,000,000&#160;, on August 6, 2018.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;License Agreement with Theramex&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On June 6, 2019, we entered into an
exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical
company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and
Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR14&#160;million
in cash as an upfront fee on August 5, 2019. Within thirty days of signing License Agreement, we are required to provide
Theramex the regulatory materials and clinical data that are necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. The revenue related to fees received by us will
be recognized once our performance obligations have been satisfied. We are eligible to receive additional milestone payments
comprised of (i) up to an aggregate of EUR 2&#160;million
in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii)
up to an aggregate of EUR 27.5&#160;million
in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net
sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR 25&#160;million
to EUR100&#160;million.
We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will
be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense
its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the
License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for
regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate
the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material
breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy
or other related matters.&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <txmd:ScheduleOfIntangibleAssetsTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190804141249795">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;&#160; &#160; &#160; &#160;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Gross Carrying Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Accumulated Amortization&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Net&lt;br/&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted-Average&lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,962,563&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(370,338&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,592,225&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;13.5&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,833,584&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,833,584&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;n/a&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Multiple trademarks&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;262,305&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;262,305&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;indefinite&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;5,058,452&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(370,338&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,688,114&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/div&gt;&#160;&#160; &#160; &#160; &#160;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Gross Carrying Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Accumulated Amortization&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Net&lt;br/&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted-Average&lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&#xae;&lt;/sup&gt; software patent&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(10,484&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;21,467&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;10.75&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;n/a&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,234,129&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;(282,485&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,951,644&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;14&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,855,279&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,855,279&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;n/a&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif"&gt;Multiple trademarks&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;264,289&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;264,289&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;indefinite&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,477,391&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(384,712&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,092,679&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</txmd:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3274"
      unitRef="USD">2962563</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3278"
      unitRef="USD">370338</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_20190630txmdApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3282"
      unitRef="USD">2592225</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="C_20190101to20190630_us-gaap_ComputerSoftwareIntangibleAssetMember"
      id="Fxbrl_20190802123211924">P13Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_20190630txmdHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3292"
      unitRef="USD">1833584</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_20190630txmdHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3300"
      unitRef="USD">1833584</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="C_20190630txmdMultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      id="F3329"
      unitRef="USD">262305</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="C_20190630txmdMultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      id="F3337"
      unitRef="USD">262305</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190802121900481"
      unitRef="USD">5058452</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190802121951031"
      unitRef="USD">370338</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190802121916123"
      unitRef="USD">4688114</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      id="F3426"
      unitRef="USD">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      id="F3430"
      unitRef="USD">10484</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      id="F3434"
      unitRef="USD">21467</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2018-01-01to2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      id="Fxbrl_20190807105637186">P10Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      decimals="0"
      id="F3444"
      unitRef="USD">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      decimals="0"
      id="F3448"
      unitRef="USD">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3463"
      unitRef="USD">2234129</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3467"
      unitRef="USD">282485</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3471"
      unitRef="USD">1951644</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2018-01-01to2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      id="Fxbrl_20190807105737177">P14Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3481"
      unitRef="USD">1855279</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      id="F3489"
      unitRef="USD">1855279</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      id="F3518"
      unitRef="USD">264289</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      id="F3526"
      unitRef="USD">264289</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190802122754480"
      unitRef="USD">4477391</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190802122828042"
      unitRef="USD">384712</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190802122809838"
      unitRef="USD">4092679</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_20190101to20190630_txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      id="Fxbrl_20190802123459138">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <txmd:IntangibleWrittenOfff
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190807192021078"
      unitRef="USD">78864</txmd:IntangibleWrittenOfff>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents5Member"
      decimals="INF"
      id="Fxbrl_20190717154044672"
      unitRef="Pure">26</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents3Member"
      decimals="INF"
      id="Fxbrl_20190717154636576"
      unitRef="Pure">27</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_txmd_Patents1Member"
      decimals="INF"
      id="Fxbrl_20190802124143640"
      unitRef="Pure">12</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_txmd_Patents6Member"
      decimals="INF"
      id="Fxbrl_20190802124306426"
      unitRef="Pure">5</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents10Member"
      decimals="INF"
      id="Fxbrl_20190804123843106"
      unitRef="Pure">4</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents4Member"
      decimals="0"
      id="Fxbrl_20190804124145396"
      unitRef="Pure">5</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents7Member"
      decimals="INF"
      id="Fxbrl_20190804124254828"
      unitRef="Pure">13</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_txmd_Patents11Member"
      decimals="INF"
      id="Fxbrl_20190804124529586"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents2Member"
      decimals="INF"
      id="Fxbrl_20190804124716143"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmd_Patents8Member"
      decimals="INF"
      id="Fxbrl_20190804124625652"
      unitRef="Pure">5</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_2019063020190630_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_txmdPatents16Member"
      decimals="INF"
      id="Fxbrl_20190804130031224"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="INF"
      id="Fxbrl_20190804125148646"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="C_20190630_txmd_Patents9Member"
      decimals="0"
      id="Fxbrl_20190808002720029"
      unitRef="Pure">2</txmd:NumberOfIssuedPatents>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F3596_40444"
      unitRef="USD">48503</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20180401to20180630"
      decimals="0"
      id="F3596_21197"
      unitRef="USD">24826</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190808133831216"
      unitRef="USD">88948</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190808133843387"
      unitRef="USD">46023</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170551044">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;&#160;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:25%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Year Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Estimated Amortization&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2019(6 months)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;96,008&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2023&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;196,017&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_20190630"
      decimals="0"
      id="F3647"
      unitRef="USD">96008</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_20190630"
      decimals="0"
      id="F3655"
      unitRef="USD">196017</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_20190630"
      decimals="0"
      id="F3663"
      unitRef="USD">196017</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_20190630"
      decimals="0"
      id="F3671"
      unitRef="USD">196017</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_20190630"
      decimals="0"
      id="F3679"
      unitRef="USD">196017</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <txmd:MilestonePaymentsUponFDAApproval
      contextRef="C_20190630_0_1"
      decimals="0"
      id="Fxbrl_20190804130506978"
      unitRef="USD">20000000</txmd:MilestonePaymentsUponFDAApproval>
    <txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch
      contextRef="C_20190630_0_1"
      decimals="-3"
      id="Fxbrl_20190804130557953"
      unitRef="USD">20000000000</txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2018-07-29to2018-07-30_custom_CouncilLicenseAgreement1Member"
      decimals="-3"
      id="Fxbrl_20190804130700619"
      unitRef="USD">20000000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="C_20190101to20190630_0_1_2_3"
      decimals="0"
      id="Fxbrl_20190804130903166"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="C_20190630_0_1_2"
      decimals="2"
      id="Fxbrl_20190804135026954"
      unitRef="Pure">0.05</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="C_20190101to2019063020190101to20190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentTwoMember_srtRangeAxis_srtMinimumMember"
      decimals="0"
      id="Fxbrl_20190804131343634"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember_srt_MaximumMember"
      decimals="0"
      id="Fxbrl_20190804131533195"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="AsOf2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentTwoMember"
      decimals="2"
      id="Fxbrl_20190804135436155"
      unitRef="Pure">0.10</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentThreeMember_srt_MinimumMember"
      decimals="0"
      id="Fxbrl_20190804142227168"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="C_2019063020190630_usgaapTypeOfArrangementAxis_txmdCouncilLicenseAgreement1Member_srtProductOrServiceAxis_txmdAnnoveraMember_txmdRoyaltyTierAxis_txmdStepBasedRoyaltyPaymentThreeMember"
      decimals="2"
      id="Fxbrl_20190804135254055"
      unitRef="Pure">0.15</txmd:RoyaltyPercent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="2"
      id="Fxbrl_20190804142328368"
      unitRef="Pure">0.50</txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2019-01-01to2019-03-31_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="2"
      id="Fxbrl_20190804142405118"
      unitRef="Pure">0.20</txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-08-04to2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember"
      decimals="INF"
      id="F3717_3921568"
      unitRef="Shares">3921568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember"
      decimals="INF"
      id="F3717_510"
      unitRef="USDPShares">5.10</us-gaap:SaleOfStockPricePerShare>
    <txmd:ProceedsFromIssuanceOfCommonStock1
      contextRef="From2018-08-04to2018-08-06_custom_SubscriptionAgreementMember_custom_KnightTherapeuticsIncMember"
      decimals="0"
      id="Fxbrl_20190804141542003"
      unitRef="USD">20000000</txmd:ProceedsFromIssuanceOfCommonStock1>
    <txmd:CashUpfrontPaymentDue
      contextRef="C_20190630"
      decimals="-6"
      id="Fxbrl_20190806103115224"
      unitRef="EUR">14000000</txmd:CashUpfrontPaymentDue>
    <txmd:RegulatoryMilestonePaymentDue
      contextRef="C_20190630"
      decimals="-6"
      id="Fxbrl_20190806103209638"
      unitRef="EUR">2000000</txmd:RegulatoryMilestonePaymentDue>
    <txmd:SalesMilestonePayments
      contextRef="C_20190630"
      decimals="-5"
      id="Fxbrl_20190806103247860"
      unitRef="EUR">27500000</txmd:SalesMilestonePayments>
    <txmd:AnnualNetSalesMilestones
      contextRef="C_2019063020190630_srtRangeAxis_srtMinimumMember"
      decimals="-6"
      id="Fxbrl_20190806103601794"
      unitRef="EUR">25000000</txmd:AnnualNetSalesMilestones>
    <txmd:AnnualNetSalesMilestones
      contextRef="C_2019063020190630_srtRangeAxis_srtMaximumMember"
      decimals="-6"
      id="Fxbrl_20190806103638864"
      unitRef="EUR">100000000</txmd:AnnualNetSalesMilestones>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190807231825954">

&lt;div&gt;

&lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 8 &#x2013; OTHER CURRENT LIABILITIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&#160;&lt;/div&gt;

&lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Other current liabilities consist of the following:&lt;/div&gt;&#160;

&lt;table cellpadding="5" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;border:Black 1pt solid;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:Black 1pt solid;text-align:center"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:Black 1pt solid;text-align:center"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued payroll, bonuses and commission costs&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5,115,082&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;6,854,002&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Allowance for coupons and returns&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;6,340,450&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5,294,120&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,107,696&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,288,028&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued compensated absences&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,492,131&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,178,110&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Allowance for wholesale distributor fees&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,077,444&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;792,891&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued legal and accounting expense&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;367,898&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;385,824&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued research and development&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,402,600&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;388,675&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Operating lease liability&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,187,029&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued rent&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;365,155&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued rebates&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,251,047&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;412,570&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;35,240&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;375,573&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.25in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;22,376,617&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;18,334,948&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190804122919023">

&lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Other current liabilities consist of the following:&lt;/div&gt;&#160;

&lt;table cellpadding="5" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;border:Black 1pt solid;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:Black 1pt solid;text-align:center"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:Black 1pt solid;text-align:center"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued payroll, bonuses and commission costs&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5,115,082&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;6,854,002&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Allowance for coupons and returns&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;6,340,450&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5,294,120&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued sales and marketing costs&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,107,696&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,288,028&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued compensated absences&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,492,131&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,178,110&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Allowance for wholesale distributor fees&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,077,444&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;792,891&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued legal and accounting expense&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;367,898&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;385,824&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued research and development&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,402,600&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;388,675&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Operating lease liability&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;1,187,029&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued rent&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;365,155&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Accrued rebates&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2,251,047&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;412,570&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;padding-left:0.125in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;35,240&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;375,573&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.25in"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;22,376,617&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;18,334,948&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804120835764"
      unitRef="USD">5115082</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804120758347"
      unitRef="USD">6854002</us-gaap:AccruedSalariesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804120937701"
      unitRef="USD">6340450</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804120951637"
      unitRef="USD">5294120</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121324224"
      unitRef="USD">2107696</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121342898"
      unitRef="USD">2288028</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121423708"
      unitRef="USD">1492131</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121443614"
      unitRef="USD">1178110</us-gaap:AccruedVacationCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121511313"
      unitRef="USD">2077444</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121522690"
      unitRef="USD">792891</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121550288"
      unitRef="USD">367898</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121603320"
      unitRef="USD">385824</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AccruedResearchAndDevelopment
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121632291"
      unitRef="USD">1402600</txmd:AccruedResearchAndDevelopment>
    <txmd:AccruedResearchAndDevelopment
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121647645"
      unitRef="USD">388675</txmd:AccruedResearchAndDevelopment>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121708681"
      unitRef="USD">1187029</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121736431"
      unitRef="USD">365155</us-gaap:AccruedRentCurrent>
    <txmd:AccruedRebates
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121800231"
      unitRef="USD">2251047</txmd:AccruedRebates>
    <txmd:AccruedRebates
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121811739"
      unitRef="USD">412570</txmd:AccruedRebates>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121848974"
      unitRef="USD">35240</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121915102"
      unitRef="USD">375573</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804121939658"
      unitRef="USD">22376617</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="Fxbrl_20190804121953819"
      unitRef="USD">18334948</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="C_20190101to20190630"
      id="F599c4c93-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 9 &#x2013; DEBT&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On April 24, 2019, we entered into a
Financing Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the
Administrative Agent, various lenders from time to time party thereto, and certain of the Company&#x2019;s subsidiaries party
thereto from time to time as guarantors, which provides us with a $300,000,000&#160;first
lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three&#160;tranches:
(i) $200,000,000&#160;was
drawn upon entering into the Financing Agreement; (ii) $50,000,000&#160;will
be available to us upon the designation of our ANNOVERA product as a new category of birth control by the FDA on or prior to
December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $50,000,000&#160;will
be available to us upon our achieving $11,000,000&#160;in
net revenues, as defined in the Financing Agreement, from our IMVEXXY, BIJUVA and ANNOVERA products for the fourth quarter of
2019 and satisfaction (or waiver) of other customary conditions precedent. Borrowings under the Facility accrue interest at
either (i)3-month
LIBOR plus7.75%,
subject to a LIBOR floor of 2.70%
or (ii) the
prime rate plus6.75%,
subject to a prime rate floor of 5.20%,
as selected by us. Interest on amounts borrowed under the Facility will be payable quarterly. The outstanding principal
amount of the Facility is payable in four equal quarterly installments beginning on June 30, 2023, with the Facility maturing
on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a
prepayment fee on the principal amount being prepaid of (i)30.0%
for the first two years following the initial funding date of the applicable borrowing, (ii)5.0%
for the third year following the initial funding date of the applicable borrowing, (iii)3.0%
for the fourth year following the initial funding date of the applicable borrowing and (iv)1.0%
for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection
with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to 2.5%
of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings
under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in
addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and
covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i)
maintain a minimum unrestricted cash balance of $50,000,000,
which will increase to $60,000,000&#160;if
we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts
attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending
December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default
that are customary for financings of this type, including an event of default relating to a change of control of the Company.
Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations
under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the
Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject
to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all
existing and after-acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be
guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $200,000,000, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in three separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) one-month LIBOR (subject to a LIBOR floor of1.50%) plus (ii)7.75% per annum.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On April 24, 2019, we terminated
the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of
approximately $81,661,000&#160;was
used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of 4%,
a repayment fee of 4%
and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the
Credit Agreement, we recorded $10,057,632&#160;in
loss on extinguishment of debt in the accompanying unaudited consolidated financial statements. Interest on amounts
borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the six months ending June 30, 2019
related to the Credit Agreement was $1,816,747.
During the six months ended June 30, 2019, and prior to the repayment of the Credit Agreement, we amortized $120,146&#160;of
deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As of June 30, 2019, we had
$200,000,000&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying unaudited
consolidated financial statements. We incurred $6,652,270&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees
related to Tranche 1 of $6,101,513&#160;have
been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred
financing fees associated with unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones have
been met. As of June 30, 2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in other current
assets in the accompanying consolidated financial statements. During both the three and six months ended June 30, 2019, we
amortized $196,734&#160;of
deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated financial
statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest
expense for both the three and six months ending June 30, 2019 was $3,985,000.
The overall effective interest rate under the Financing Agreement was approximately 11%
as of June 30, 2019. As of June 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Financing Agreement&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;200,000,000&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Credit Agreement&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;75,000,000&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Debt discount and financing fees&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(5,904,780&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(1,618,986&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;194,095,220&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;73,381,014&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid"&gt;

&lt;div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_SubsequentEventMember_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fxbrl_20190806115642913"
      unitRef="USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:NumberOfTranchesUnderTermLoanFacility
      contextRef="AsOf2019-04-24_us-gaap_SubsequentEventMember_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      id="Fxbrl_20190806115858351"
      unitRef="Pure">3</txmd:NumberOfTranchesUnderTermLoanFacility>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_20190630_usgaapCreditFacilityAxis_usgaapSecuredDebtMember"
      decimals="0"
      id="Fxbrl_20190806120120260"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche2Member"
      decimals="0"
      id="Fxbrl_20190806140245643"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_txmdDebtTrancheAxis_txmdTranche3Member"
      decimals="0"
      id="Fxbrl_20190806140552675"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:Revenues
      contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="0"
      id="Fxbrl_20190806140846968"
      unitRef="USD">11000000</us-gaap:Revenues>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      id="Fxbrl_20190806141031245">3-month
LIBOR plus7.75%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="4"
      id="Fxbrl_20190806141104317"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="4"
      id="Fxbrl_20190806141145183"
      unitRef="Pure">0.0270</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_20190401to20190630_usgaapVariableRateAxis_usgaapBaseRateMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      id="Fxbrl_20190806141606218">the
prime rate plus6.75</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_20190401to20190630_usgaapVariableRateAxis_usgaapBaseRateMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="4"
      id="Fxbrl_20190807100635497"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:PrimeRateFloor
      contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_usgaapVariableRateAxis_usgaapBaseRateMember"
      decimals="4"
      id="Fxbrl_20190806142027954"
      unitRef="Pure">0.0520</txmd:PrimeRateFloor>
    <txmd:PrepaymentPercentOfDebt
      contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodOneMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="3"
      id="Fxbrl_20190806142335695"
      unitRef="Pure">0.300</txmd:PrepaymentPercentOfDebt>
    <txmd:PrepaymentPercentOfDebt
      contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodThreeMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="3"
      id="Fxbrl_20190806143104358"
      unitRef="Pure">0.050</txmd:PrepaymentPercentOfDebt>
    <txmd:PrepaymentPercentOfDebt
      contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFourMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="3"
      id="Fxbrl_20190806143139553"
      unitRef="Pure">0.030</txmd:PrepaymentPercentOfDebt>
    <txmd:PrepaymentPercentOfDebt
      contextRef="C_20190630_usgaapDebtInstrumentRedemptionPeriodAxis_usgaapDebtInstrumentRedemptionPeriodFiveMember_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="3"
      id="Fxbrl_20190806143201185"
      unitRef="Pure">0.010</txmd:PrepaymentPercentOfDebt>
    <txmd:FacilityFeePaidPercent
      contextRef="C_20190401to20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="3"
      id="Fxbrl_20190806142419034"
      unitRef="Pure">0.025</txmd:FacilityFeePaidPercent>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember"
      decimals="0"
      id="Fxbrl_20190806143431403"
      unitRef="USD">50000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="C_20190630_usgaapTypeOfArrangementAxis_txmdFinancingAgreementMember_srtRangeAxis_srtMaximumMember"
      decimals="0"
      id="Fxbrl_20190806143639301"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      id="Fxbrl_20190806115307416"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="From2018-04-29to2018-05-01_us-gaap_SecuredDebtMember"
      id="Fxbrl_20190806115359973">ne-month LIBOR (subject to a LIBOR floor of1.50%) plus (ii)7.75% per annum</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <txmd:LiborFloor
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="4"
      id="Fxbrl_20190806115447900"
      unitRef="Pure">0.0150</txmd:LiborFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2018-04-29to2018-05-01_us-gaap_SecuredDebtMember"
      decimals="4"
      id="Fxbrl_20190806115537636"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:RepaymentOfDebtWithNewCreditFacility
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190806112625196"
      unitRef="USD">81661000</txmd:RepaymentOfDebtWithNewCreditFacility>
    <txmd:PrepaymentFee
      contextRef="C_20190401to20190630"
      decimals="2"
      id="Fxbrl_20190806111434846"
      unitRef="Pure">0.04</txmd:PrepaymentFee>
    <txmd:RepaymentFeePercent
      contextRef="C_20190401to20190630"
      decimals="2"
      id="Fxbrl_20190806111503891"
      unitRef="Pure">0.04</txmd:RepaymentFeePercent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190806111625974"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseBorrowings
      contextRef="C_20190101to20190630_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember"
      decimals="0"
      id="Fxbrl_20190806112448419"
      unitRef="USD">1816747</us-gaap:InterestExpenseBorrowings>
    <txmd:AmortizationOfDeferredFinancingFees
      contextRef="C_20190101to20190630_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember"
      decimals="0"
      id="Fxbrl_20190806112550757"
      unitRef="USD">120146</txmd:AmortizationOfDeferredFinancingFees>
    <us-gaap:LongTermDebt
      contextRef="C_2019063020190630_usgaapLongtermDebtTypeAxis_usgaapLineOfCreditMember"
      decimals="0"
      id="Fxbrl_20190806110409454"
      unitRef="USD">200000000</us-gaap:LongTermDebt>
    <txmd:DeferredFinancingFees
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190806110653599"
      unitRef="USD">6652270</txmd:DeferredFinancingFees>
    <txmd:DeferredFinancingFees
      contextRef="C_20190630_txmdDebtTrancheAxis_txmdTrancheOneMember"
      decimals="0"
      id="Fxbrl_20190806110801800"
      unitRef="USD">6101513</txmd:DeferredFinancingFees>
    <txmd:AmortizationOfDeferredFinancingFees
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_201908061111580110"
      unitRef="USD">196734</txmd:AmortizationOfDeferredFinancingFees>
    <txmd:AmortizationOfDeferredFinancingFees
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190806111158011"
      unitRef="USD">196734</txmd:AmortizationOfDeferredFinancingFees>
    <us-gaap:InterestExpenseBorrowings
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_201908061112342360"
      unitRef="USD">3985000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190806111234236"
      unitRef="USD">3985000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_20190630"
      decimals="2"
      id="Fxbrl_20190806111331861"
      unitRef="Pure">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190807102918456">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;br/&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;December 31,&lt;br/&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Financing Agreement&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;200,000,000&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Credit Agreement&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;75,000,000&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Debt discount and financing fees&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(5,904,780&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(1,618,986&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;194,095,220&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;73,381,014&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_2019063020190630_usgaapLongtermDebtTypeAxis_usgaapLineOfCreditMember"
      decimals="0"
      id="Fxbrl_20190805184215513"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2018-12-3120181231_usgaapLongtermDebtTypeAxis_usgaapUnsecuredDebtMember"
      decimals="0"
      id="Fxbrl_20190806112137771"
      unitRef="USD">75000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_20190630"
      decimals="0"
      id="F3932"
      unitRef="USD">5904780</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3936"
      unitRef="USD">1618986</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_20190630"
      decimals="0"
      id="F3942"
      unitRef="USD">194095220</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F3946"
      unitRef="USD">73381014</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20190101to20190630"
      id="F599c4c94-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 10&#x2013; NET LOSS PER SHARE&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been antidilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Three and Six months ended&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:30%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;22,072,469&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;25,210,899&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,832,571&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,007,571&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Restricted stock awards&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,040,000&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;24,945,040&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;28,218,470&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801170918904">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Three and Six months ended&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:30%;text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;22,072,469&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;25,210,899&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;font-family:Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,832,571&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,007,571&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;Restricted stock awards&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,040,000&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;TOTAL&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;24,945,040&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;28,218,470&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F39950"
      unitRef="Shares">22072469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190401to20190630_EmployeeStockOptionMember"
      decimals="INF"
      id="F3995"
      unitRef="Shares">22072469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20180401to20180630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F3999"
      unitRef="Shares">25210899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="F3999_1"
      unitRef="Shares">25210899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190101to20190630_us-gaap_WarrantMember"
      decimals="INF"
      id="F40050"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190401to20190630usgaapWarrantMember"
      decimals="INF"
      id="F4005"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20180101to20180630_WarrantMember"
      decimals="INF"
      id="F40090"
      unitRef="Shares">3007571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20180401to20180630usgaapWarrantMember"
      decimals="INF"
      id="F4009"
      unitRef="Shares">3007571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190101to20190630_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="F40150"
      unitRef="Shares">1040000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190401to20190630usgaapRestrictedStockMember"
      decimals="INF"
      id="F4015"
      unitRef="Shares">1040000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190401to20190630"
      decimals="INF"
      id="Fxbrl_20190804144547868"
      unitRef="Shares">24945040</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20190101to20190630"
      decimals="INF"
      id="Fxbrl_20190804144547868_1"
      unitRef="Shares">24945040</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20180101to20180630"
      decimals="INF"
      id="Fxbrl_201908041446067970"
      unitRef="Shares">28218470</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20180401to20180630"
      decimals="INF"
      id="Fxbrl_20190804144606797"
      unitRef="Shares">28218470</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c4c95-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 11 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Preferred Stock&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;At June 30, 2019, we had 10,000,000&#160;shares
of preferred stock, par value $0.001 per share, authorized for issuance, of which no shares of preferred stock were issued or
outstanding.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Common Stock&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;At June 30, 2019, we had 350,000,000&#160;shares
of Common Stock authorized for issuance, of which 241,221,840&#160;shares
of Common Stock were issued and outstanding.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-style:italic"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Issuances During the Three and Six Months Ended June 30, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During the three months ended June 30,
2019, no options to purchase shares of Common Stock were exercised. During the six months ended June 30, 2019, certain
individuals exercised stock options to purchase 276,383&#160;shares
of Common Stock for $100,107&#160;in
cash. Also, during the same period, stock options to purchase 12,097&#160;shares
of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 11,834&#160;shares
of Common Stock were issued.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-style:italic"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Issuances During the Three and Six Months Ended June 30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During the three months ended June
30, 2018, certain individuals exercised stock options to purchase 249,785&#160;shares
of Common Stock for $1,084,939&#160;in
cash. During the six months ended June 30, 2018, certain individuals exercised stock options to purchase 394,576&#160;shares
of Common Stock for $1,128,996&#160;in
cash. Also, during the six months ended June 30, 2018, stock options to purchase 10,000&#160;shares
of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 9,841&#160;shares
of Common Stock were issued.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Warrants to Purchase Common Stock&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As of June 30, 2019, we had
warrants outstanding to purchase an aggregate of 1,832,571&#160;shares
of Common Stock with a weighted-average contractual remaining life of approximately 2.5&#160;years,
and exercise prices ranging from $0.24&#160;to
$8.20&#160;per
share, resulting in a weighted average exercise price of $2.62&#160;per
share.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During the six months ended June
30, 2019, we granted warrants to purchase75,000&#160;shares
of Common Stock to outside consultants at an exercise price of $5.63&#160;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of 5&#160;years;
volatility of 60.8&#160;%;
risk free rate of 2.52&#160;%;
and dividend yield of 0&#160;%.
The grant date fair value of the warrants was $3.00&#160;per
share. The warrants are vesting ratably over a 12-month period and have an expiration date of February 12, 2024. During
the six months ended June 30, 2018, we granted warrants to purchase175,000&#160;shares
of Common Stock to outside consultants at an exercise price of $5.16&#160;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of 5&#160;years;
volatility of 62.1&#160;%;
risk free rate of 2.36&#160;%;
and dividend yield of 0&#160;%.
The grant date fair value of the warrants was $2.79&#160;per
share. The warrants vest ratably over a 12-month period and have an expiration date of March 15, 2023.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During the three months ended June 30, 2019 and 2018, we recorded $56,172&#160;and $164,840&#160;, respectively, and during the six months ended June 30, 2019 and 2018, we recorded $141,888&#160;and $256,315&#160;, respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants. As of June 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants was approximately $139,000&#160;, which is expected to be recognized over a weighted-average period of0.6&#160;years.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&lt;br/&gt;During the three months ended June 30, 2019 and 2018, no warrants to purchase shares of Common Stock were exercised.&lt;br/&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During the six months ended June
30, 2019, warrants to purchase 1,250,000&#160;shares
of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 471,184&#160;shares
of Common Stock were issued. During the six months ended June 30, 2018, no warrants were exercised.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Options to Purchase Common Stock&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In 2009, we adopted the 2009 Long Term
Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and
consultants of our company who are able to contribute towards the creation of or who have created stockholder value by
providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan
consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or
as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or
on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable
exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of
June 30, 2019, there were non-qualified stock options to purchase 15,116,995&#160;shares
of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive
Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In 2012, we adopted the 2012
Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to
serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants
and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as
described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors,
upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they
have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The
expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were non-qualified
stock options to purchase 6,317,974&#160;shares
of Common Stock outstanding and 1,040,000&#160;restricted
stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan on June 20, 2019, no future awards may be
made under the 2012 Plan.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were16,812,383&#160;shares of Common Stock authorized for issuance thereunder, consisting of (i)14,362,500&#160;new shares, (ii)2,393,833&#160;unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2012 Plan), and (iii)56,050&#160;unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#x201c;Awards&#x201d; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of June 30, 2019, there were non-qualified stock options to purchase&#160;637,500&#160;shares of Common Stock outstanding under the 2019 Plan.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2019 and 2018 are set forth in the table below.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:70%;border-collapse:collapse;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Six months ended&lt;/div&gt;&lt;/div&gt;
        &lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:38%;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:2%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2.19&#x2014;2.54&#160;%&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2.38&#x2014;2.63&#160;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;61.25&#x2014;61.85&#160;%&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;61.82&#x2014;64.04&#160;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5.5&#x2014;6.25&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5.1&#x2014;6.25&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;0.00%&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;0.00%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:95%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Number of Shares Underlying Stock Options&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted Average Exercise Price&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life in Years&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:39%;font-family:Times New Roman, Times, Serif"&gt;Balance at December 31, 2018&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;20,872,824&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.93&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.94&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;12,239,876&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,544,500&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;(288,480&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;0.35&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,315,238&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:1pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(56,375&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.77&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;Balance at June 30, 2019&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;22,072,469&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.95&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.80&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,945,665&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Vested and Exercisable at June 30, 2019&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;17,125,888&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.79&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.94&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,945,665&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;Unvested at June 30, 2019&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,946,581&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.48&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;8.79&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;0&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;At June 30, 2019, our outstanding stock options had exercise prices ranging from $0.10&#160;to $8.92&#160;per share. The weighted average grant date fair value per share of options granted was $2.57&#160;and $3.15&#160;during the six months ended June 30, 2019 and 2018, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended June 30, 2019 and 2018 ($2,230,829&#160;and $2,212,241&#160;, respectively) and for the six months ended June 30, 2019 and 2018 ($4,374,069&#160;and $3,872,125&#160;, respectively) is based on vested awards. At June 30, 2019, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $11,606,000&#160;which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of2.1&#160;years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Restricted Stock&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On December 13, 2018, we granted 1,040,000&#160;restricted
stock units to certain executive employees which will vest at the end of the third year. The grant date fair value
was $4.06&#160;per
unit. During the three and six months ended June 30, 2019 we recorded $350,263&#160;and
$696,676&#160;,
respectively, in share-based compensation expense related to restricted stock units. At June 30, 2019, total
unrecognized estimated compensation expense related to unvested restricted stock units was approximately $3,453,000&#160;,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of 2.5&#160;years.
At June 30, 2019,1,040,000&#160;restricted
stock awards remained outstanding.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;Cash-Settled Stock Appreciation Rights (SARs)&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Cash settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, &#x201c;Stock Compensation,&#x201d; the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded liability was reversed and no cash payment was made.&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805172810515"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805172836945"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_201908051729050280"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805172905028"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesIssued>
    <txmd:NumberOfStockOptionsExercised
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805183759077"
      unitRef="Shares">276383</txmd:NumberOfStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805183838429"
      unitRef="USD">100107</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805183945484"
      unitRef="Shares">12097</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805184045995"
      unitRef="Shares">11834</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <txmd:NumberOfStockOptionsExercised
      contextRef="C_20180401to20180630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="Fxbrl_20190805173113057"
      unitRef="Shares">249785</txmd:NumberOfStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20180401to20180630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="Fxbrl_20190805173020037"
      unitRef="USD">1084939</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercised
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="Fxbrl_20190805173204963"
      unitRef="Shares">394576</txmd:NumberOfStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="Fxbrl_20190805173243759"
      unitRef="USD">1128996</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190805173329995"
      unitRef="Shares">10000</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190805173356488"
      unitRef="Shares">9841</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805173454706"
      unitRef="USD">1832571</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190805173534925">P2Y6M</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20190805174114177"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2019063020190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="Fxbrl_20190805174204806"
      unitRef="USDPShares">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="C_20190630_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember"
      decimals="2"
      id="Fxbrl_20190808171425198"
      unitRef="Shares">2.62</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      decimals="0"
      id="Fxbrl_20190805174457582"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20190630_txmd_OutsideConsultant2Member"
      decimals="2"
      id="Fxbrl_20190805174556143"
      unitRef="USDPShares">5.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      id="Fxbrl_20190805175101963">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      decimals="3"
      id="Fxbrl_20190805175130289"
      unitRef="Pure">0.608</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      decimals="4"
      id="Fxbrl_20190805175244651"
      unitRef="Pure">0.0252</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      decimals="2"
      id="Fxbrl_20190805175314443"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      decimals="2"
      id="Fxbrl_20190805175853010"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      decimals="0"
      id="Fxbrl_20190805175348840"
      unitRef="Shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="C_20180630_txmd_OutsideConsultant2Member"
      decimals="2"
      id="Fxbrl_20190805175543966"
      unitRef="Shares">5.16</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      id="Fxbrl_20190805175613902">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      decimals="3"
      id="Fxbrl_20190805175644631"
      unitRef="Pure">0.621</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      decimals="4"
      id="Fxbrl_20190805175712301"
      unitRef="Pure">0.0236</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      decimals="2"
      id="Fxbrl_20190805175738498"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      decimals="2"
      id="Fxbrl_20190805175835321"
      unitRef="USDPShares">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20190401to20190630usgaapWarrantMember"
      decimals="0"
      id="Fxbrl_20190805175950990"
      unitRef="USD">56172</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20180401to20180630usgaapWarrantMember"
      decimals="0"
      id="Fxbrl_20190805180002541"
      unitRef="USD">164840</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20190101to20190630_us-gaap_WarrantMember"
      decimals="0"
      id="Fxbrl_20190805180015882"
      unitRef="USD">141888</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20180101to20180630_txmd_OutsideConsultant2Member"
      decimals="0"
      id="Fxbrl_20190805180027631"
      unitRef="USD">256315</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805180129948"
      unitRef="USD">139000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_20190101to20190630_us-gaap_WarrantMember"
      id="Fxbrl_20190805180158269">P0M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_20190101to20190630_txmd_OutsideConsultant2Member"
      decimals="0"
      id="Fxbrl_20190805180458308"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_20190101to20190630_us-gaap_WarrantMember"
      decimals="0"
      id="Fxbrl_20190805180631338"
      unitRef="Shares">471184</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20190630_txmd_LongTermIncentiveCompensationPlan2009Member"
      decimals="0"
      id="Fxbrl_20190805180744758"
      unitRef="Shares">15116995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20190630_txmd_NonQualified2012StockIncentivePlanMember"
      decimals="0"
      id="Fxbrl_20190805180835817"
      unitRef="Shares">6317974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2019063020190630_usgaapPlanNameAxis_txmdNonQualified2012StockIncentivePlanMember_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fxbrl_20190805181146886"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805181537818"
      unitRef="Shares">16812383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <txmd:PlanAwardsNumberOfNewShares
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805181808633"
      unitRef="Shares">14362500</txmd:PlanAwardsNumberOfNewShares>
    <txmd:PlanAwardsNumberOfNewSharesUnallocated
      contextRef="C_20190630_txmd_NonQualified2012StockIncentivePlanMember"
      decimals="0"
      id="Fxbrl_20190805182031607"
      unitRef="Shares">2393833</txmd:PlanAwardsNumberOfNewSharesUnallocated>
    <txmd:PlanAwardsNumberOfNewSharesUnallocated
      contextRef="C_20190630_txmd_LongTermIncentiveCompensationPlan2009Member"
      decimals="0"
      id="Fxbrl_20190805182049312"
      unitRef="Shares">56050</txmd:PlanAwardsNumberOfNewSharesUnallocated>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20190630_usgaapPlanNameAxis_txmdPlan2019Member"
      decimals="INF"
      id="Fxbrl_20190809044255788"
      unitRef="Shares">637500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801171005263">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:70%;border-collapse:collapse;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Six months ended&lt;/div&gt;&lt;/div&gt;
        &lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:38%;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:2%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2.19&#x2014;2.54&#160;%&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2.38&#x2014;2.63&#160;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;61.25&#x2014;61.85&#160;%&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;61.82&#x2014;64.04&#160;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5.5&#x2014;6.25&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5.1&#x2014;6.25&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;0.00%&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:center;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;0.00%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805170942669"
      unitRef="Pure">0.0219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171121781"
      unitRef="Pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171011725"
      unitRef="Pure">0.0238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171145883"
      unitRef="Pure">0.0263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171220687"
      unitRef="Pure">0.6125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171309803"
      unitRef="Pure">0.6185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171244247"
      unitRef="Pure">0.6182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171331971"
      unitRef="Pure">0.6404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20190101to2019063020190101to20190630_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20190805171411048">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20190101to20190630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20190805171817089">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20190805171725791">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20180101to20180630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20190805171856652">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171938465"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20180101to20180630_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20190805171957655"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801171035546">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:95%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Number of Shares Underlying Stock Options&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted Average Exercise Price&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life in Years&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:39%;font-family:Times New Roman, Times, Serif"&gt;Balance at December 31, 2018&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;20,872,824&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.93&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.94&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;12,239,876&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,544,500&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.40&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;(288,480&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;0.35&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,315,238&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:1pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(56,375&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.77&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;Balance at June 30, 2019&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;22,072,469&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.95&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.80&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,945,665&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif"&gt;Vested and Exercisable at June 30, 2019&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;17,125,888&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.79&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4.94&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,945,665&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;Unvested at June 30, 2019&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,946,581&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;5.48&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;8.79&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;0&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="F4205"
      unitRef="Shares">20872824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="F4209"
      unitRef="USDPShares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fxbrl_20190805172411252">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="F4217"
      unitRef="USD">12239876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4223"
      unitRef="Shares">1544500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4227"
      unitRef="USDPShares">4.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4241"
      unitRef="Shares">288480</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4245"
      unitRef="USDPShares">0.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="F4253"
      unitRef="USD">1315238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4259"
      unitRef="Shares">56375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4263"
      unitRef="USDPShares">5.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4277"
      unitRef="Shares">22072469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4281"
      unitRef="USDPShares">4.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      id="Fxbrl_20190805172435417">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="Fxbrl_20190805172516555"
      unitRef="USD">3945665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4295"
      unitRef="Shares">17125888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4299"
      unitRef="USDPShares">4.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      id="Fxbrl_20190805172621306">P4Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="0"
      id="Fxbrl_20190805172545599"
      unitRef="USD">3945665</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4313"
      unitRef="Shares">4946581</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice
      contextRef="C_20190630usgaapEmployeeStockOptionMember"
      decimals="INF"
      id="F4317"
      unitRef="USDPShares">5.48</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      id="Fxbrl_20190805172648875">P8Y9M14D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <txmd:OptionExercisePrices
      contextRef="C_2019063020190630_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20190805182252672"
      unitRef="USDPShares">0.10</txmd:OptionExercisePrices>
    <txmd:OptionExercisePrices
      contextRef="C_2019063020190630_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="Fxbrl_20190805182324264"
      unitRef="USDPShares">8.92</txmd:OptionExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20190101to20190630"
      decimals="2"
      id="Fxbrl_20190805182404023"
      unitRef="USDPShares">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20180101to20180630"
      decimals="2"
      id="Fxbrl_20190805182415728"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190805182448003"
      unitRef="USD">2230829</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20180401to20180630"
      decimals="0"
      id="Fxbrl_20190805182504198"
      unitRef="USD">2212241</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805182522661"
      unitRef="USD">4374069</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20180101to20180630"
      decimals="0"
      id="Fxbrl_20190805182537393"
      unitRef="USD">3872125</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805182616429"
      unitRef="USD">11606000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_20190101to20190630usgaapEmployeeStockOptionMember"
      id="Fxbrl_20190805182641826">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20181212to2018121320181212to20181213_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fxbrl_20190805183011909"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20181212to2018121320181212to20181213_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fxbrl_20190805183106717"
      unitRef="USDPShares">4.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20190401to20190630usgaapRestrictedStockMember"
      decimals="0"
      id="Fxbrl_20190805183224034"
      unitRef="USD">350263</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20190101to20190630_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fxbrl_20190805183245314"
      unitRef="USD">696676</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_2019063020190630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fxbrl_20190805183345174"
      unitRef="USD">3453000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_20190101to20190630_us-gaap_RestrictedStockMember"
      id="Fxbrl_20190805183446370">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_2019063020190630_usgaapAwardTypeAxis_usgaapRestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fxbrl_20190805183618631"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c73a0-9c46-11e9-a255-0d2e847c7ff2">
&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&lt;div style="display:inline;font-weight:bold"&gt;&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 12 &#x2013; INCOME TAXES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;Deferred income tax assets and liabilities
are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay
any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the six months ended June 30,
2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior years.
Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201c;more likely than
not&#x201d; that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2019, we maintain
a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has
been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.&lt;/div&gt;


</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c73a1-9c46-11e9-a255-0d2e847c7ff2">
&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;
&lt;div style="display:inline;font-weight:bold"&gt;
&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 13 &#x2013; RELATED PARTIES&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of our company since July 2015. During the three months ended June 30, 2019 and 2018, we were billed by Catalent approximately $
974,000
and $

1,266,000
, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. During the six months ended June 30, 2019 and 2018, we were billed by Catalent approximately $

2,371,000
and $

2,040,000
, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of June 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $

243,000
and $

88,000
, respectively.&lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190804145609173"
      unitRef="USD">974000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_20180401to20180630"
      decimals="0"
      id="Fxbrl_20190804145633765"
      unitRef="USD">1266000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_20190101to20190630_us-gaap_DirectorMember"
      decimals="0"
      id="Fxbrl_20190804145242309"
      unitRef="USD">2371000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_20180101to20180630_us-gaap_DirectorMember"
      decimals="0"
      id="Fxbrl_20190804145214901"
      unitRef="USD">2040000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190804145545029"
      unitRef="USD">243000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2018-12-31"
      decimals="0"
      id="F4824_88000"
      unitRef="USD">88000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c73a2-9c46-11e9-a255-0d2e847c7ff2">&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 14 &#x2013; BUSINESS CONCENTRATIONS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We purchase our prescription products
from several suppliers with approximately&#160;14%,18%,31%
and37%
of our purchases were supplied by four vendors each, respectively, during the six months ended June 30, 2019 and
approximately 100%
of our purchases were supplied from one vendor for the six months ended June 30, 2018.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We sell our prescription prenatal
vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that
generally sell products to retail pharmacies, hospitals, and other institutional customers. During the six months ended June
30, 2019, three customers each generated more than 10%
of our total revenues. During the six months ended June 30, 2018, four customers each generated more than 10%
of our total revenues. Revenue generated from the three customers combined accounted for approximately 60%
of our recognized revenue for the six months ended June 30, 2019 and revenue generated from the four customers combined
accounted for approximately71%
of our recognized revenue for the six months ended June 30, 2018.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;During the six months ended June 30, 2019, &#160; Pillpack, Inc. accounted for approximately $3,615,000of our revenue, AmerisourceBergen accounted for approximately $1,365,000of our revenue and Cardinal Health accounted for approximately $1,048,000of our revenue. During the six months ended June 30, 2018, PI Services generated approximately $981,000of our revenue, Pillpack, Inc. generated approximately $2,088,000of our revenue, AmerisourceBergen generated approximately $1,283,000of our revenue and Cardinal Health generated approximately $971,000of our &#160;revenue.&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_usgaap_SupplierConcentrationRiskMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember"
      decimals="2"
      id="Fxbrl_20190807094026692"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskOneMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember"
      decimals="2"
      id="Fxbrl_20190717170009193"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmd_SupplierConcentrationRiskTwoMember_srtMajorCustomersAxis_txmd_FourMajorCustomersMember"
      decimals="2"
      id="Fxbrl_20190717170114041"
      unitRef="Pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20190101to20190630_0_1"
      decimals="2"
      id="Fxbrl_20190717170311759"
      unitRef="Pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_usgaapSupplierConcentrationRiskMember_srtMajorCustomersAxis_txmdOnerMajorCustomersMember"
      decimals="2"
      id="Fxbrl_20190717170533812"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByBenchmarkAxis_usgaap_SalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaap_CustomerConcentrationRiskMember_srtRangeAxis_srt_MinimumMember"
      decimals="2"
      id="Fxbrl_20190806100553131"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20180101to20180630_0_1_2"
      decimals="2"
      id="Fxbrl_20190806100218357"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20190101to20190630"
      decimals="2"
      id="Fxbrl_20190717170949802"
      unitRef="Pure">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20180101to20180630"
      decimals="2"
      id="Fxbrl_20190717171256915"
      unitRef="Pure">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk2Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"
      decimals="0"
      id="Fxbrl_20190806103954046"
      unitRef="USD">3615000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"
      decimals="0"
      id="Fxbrl_20190806105704728"
      unitRef="USD">1365000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20190101to20190630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"
      decimals="0"
      id="Fxbrl_20190806110304552"
      unitRef="USD">1048000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20180101to2018063020180101to20180630_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk7Member"
      decimals="0"
      id="F4842_557000"
      unitRef="USD">981000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20180101to20180630_0_1"
      decimals="0"
      id="F4842_905000"
      unitRef="USD">2088000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk3Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"
      decimals="0"
      id="Fxbrl_20190806104425339"
      unitRef="USD">1283000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20180101to20180630_usgaapConcentrationRiskByTypeAxis_txmdCustomerConcentrationRisk4Member_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember"
      decimals="0"
      id="Fxbrl_20190806104817562"
      unitRef="USD">971000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_20190101to20190630"
      id="F599c73a3-9c46-11e9-a255-0d2e847c7ff2">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;

&lt;div style="display:inline;font-weight:bold"&gt;

&lt;div style="display:inline;text-decoration:underline"&gt;NOTE 15 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which lease on 7,561 square feet commenced in 2018 and the lease on the remaining 48,651 square feet will commence sometime in the third quarter of 2019, or the full premises commencement date. The lease will expire 11 years after full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In addition, we will be entitled to reimbursement from the landlord of up to $1,800,000&#160;for tenant improvements. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019.&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Supplemental lease information as of June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;Right-of-use asset (included in Other assets)&lt;/td&gt;
    &lt;td style="width:2%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,316,436&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,187,029&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;Long-term operating lease liability&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,488,101&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;Weighted average remaining term&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5Years&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;Weighted average discount rate&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;8.25&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Supplemental cash flow information&lt;br/&gt;for the six months ended June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;
    &lt;td style="width:2%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;564,092&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,760,171&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Years Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2019 (6 months)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;595,649&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,292,914&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,135,467&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;172,651&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2023&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;176,968&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,228,504&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Total undiscounted lease payments&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,602,153&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Less: imputed interest&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(927,023&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Present value of lease payments&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,675,130&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;As of June 30, 2019, we estimated undiscounted fixed future minimum rental commitments of approximately $13,300,000&#160;and estimated undiscounted variable future minimum rental commitments of approximately $6,400,000&#160;over the term of the lease related to the operating lease for the new corporate office that we entered into in October 2018 and an additional suite that we entered into in 2019 that had not commenced yet, as disclosed above. During the three and six months ended June 30, 2019, operating lease expense related to our real estate leases was approximately $295,000&#160;and $590,000&#160;, respectively, and variable lease expense was insignificant for the three and six months ended June 30, 2019. Rent expense totaled $257,000&#160;and $515,000&#160;during the three and six months ended June 30, 2018, respectively.&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <txmd:ReimbursementFromLandlordTenantImprovements
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805170823573"
      unitRef="USD">1800000</txmd:ReimbursementFromLandlordTenantImprovements>
    <txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801171136670">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Supplemental lease information as of June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;Right-of-use asset (included in Other assets)&lt;/td&gt;
    &lt;td style="width:2%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,316,436&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,187,029&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;Long-term operating lease liability&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;2,488,101&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;Weighted average remaining term&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;5Years&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;Weighted average discount rate&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;8.25&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Supplemental cash flow information&lt;br/&gt;for the six months ended June 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;
    &lt;td style="width:2%;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;564,092&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;
    &lt;td style="font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,760,171&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190808003742416"
      unitRef="USD">3316436</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20190630"
      decimals="0"
      id="F4427"
      unitRef="USD">1187029</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20190630"
      decimals="0"
      id="F4433"
      unitRef="USD">2488101</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20190630" id="Fxbrl_20190807110051339">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20190630"
      decimals="4"
      id="Fxbrl_20190805170615555"
      unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F4465"
      unitRef="USD">564092</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_20190401to20190630"
      decimals="0"
      id="F4471"
      unitRef="USD">3760171</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20190101to20190630"
      id="Fxbrl_20190801171204026">

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet:&lt;/div&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"&gt;
        &lt;tbody&gt;
&lt;tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;Years Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-weight:bold"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;2019 (6 months)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif"&gt;595,649&lt;/td&gt;
    &lt;td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,292,914&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2021&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,135,467&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2022&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;172,651&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;2023&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;176,968&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;1,228,504&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Total undiscounted lease payments&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align:right;font-family:Times New Roman, Times, Serif"&gt;4,602,153&lt;/td&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Less: imputed interest&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif"&gt;(927,023&lt;/td&gt;
    &lt;td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"&gt;
    &lt;td style="text-align:left;font-family:Times New Roman, Times, Serif"&gt;
        &lt;div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt"&gt;Present value of lease payments&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif"&gt;3,675,130&lt;/td&gt;
    &lt;td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
&lt;/table&gt;

&lt;div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"&gt;&#160;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20190630"
      decimals="0"
      id="F4492"
      unitRef="USD">595649</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20190630"
      decimals="0"
      id="F4498"
      unitRef="USD">1292914</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20190630"
      decimals="0"
      id="F4504"
      unitRef="USD">1135467</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20190630"
      decimals="0"
      id="F4510"
      unitRef="USD">172651</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_20190630"
      decimals="0"
      id="F4516"
      unitRef="USD">176968</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_20190630"
      decimals="0"
      id="F4523"
      unitRef="USD">1228504</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20190630"
      decimals="0"
      id="F4530"
      unitRef="USD">4602153</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <txmd:LesseeOperatingLeaseLiabilityImputedInterestAmount
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190808143103920"
      unitRef="USD">927023</txmd:LesseeOperatingLeaseLiabilityImputedInterestAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20190630"
      decimals="0"
      id="F4544"
      unitRef="USD">3675130</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805170238375"
      unitRef="USD">13300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <txmd:OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum
      contextRef="C_20190630"
      decimals="0"
      id="Fxbrl_20190805170320093"
      unitRef="USD">6400000</txmd:OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190805170357464"
      unitRef="USD">295000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805170408954"
      unitRef="USD">590000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_20190401to20190630"
      decimals="0"
      id="Fxbrl_20190805170527436"
      unitRef="USD">257000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_20190101to20190630"
      decimals="0"
      id="Fxbrl_20190805170544832"
      unitRef="USD">515000</us-gaap:LeaseAndRentalExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6783566832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Aug. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,221,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Third Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6800 Broken Sound Parkway NW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6777070624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 182,846,301<span></span>
</td>
<td class="nump">$ 161,613,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $764,102 and $596,602, respectively</a></td>
<td class="nump">18,383,012<span></span>
</td>
<td class="nump">11,063,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,494,440<span></span>
</td>
<td class="nump">3,267,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,739,048<span></span>
</td>
<td class="nump">10,834,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">216,462,801<span></span>
</td>
<td class="nump">186,779,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">1,432,137<span></span>
</td>
<td class="nump">472,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseRights', window );">License rights</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,688,114<span></span>
</td>
<td class="nump">4,092,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">3,635,227<span></span>
</td>
<td class="nump">324,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">334,866<span></span>
</td>
<td class="nump">314,446<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">28,658,207<span></span>
</td>
<td class="nump">24,731,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">246,553,145<span></span>
</td>
<td class="nump">211,983,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">19,499,238<span></span>
</td>
<td class="nump">22,743,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">22,376,617<span></span>
</td>
<td class="nump">18,334,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,875,855<span></span>
</td>
<td class="nump">41,078,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">194,095,220<span></span>
</td>
<td class="nump">73,381,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">2,488,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">238,459,176<span></span>
</td>
<td class="nump">114,459,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively</a></td>
<td class="nump">241,222<span></span>
</td>
<td class="nump">240,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">621,871,919<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(614,019,172)<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">8,093,969<span></span>
</td>
<td class="nump">97,524,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 246,553,145<span></span>
</td>
<td class="nump">$ 211,983,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6960655008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 764,102<span></span>
</td>
<td class="nump">$ 596,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6777165168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 6,078,865<span></span>
</td>
<td class="nump">$ 3,763,010<span></span>
</td>
<td class="nump">$ 10,025,516<span></span>
</td>
<td class="nump">$ 7,536,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,248,860<span></span>
</td>
<td class="nump">454,161<span></span>
</td>
<td class="nump">2,011,687<span></span>
</td>
<td class="nump">1,087,784<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,830,005<span></span>
</td>
<td class="nump">3,308,849<span></span>
</td>
<td class="nump">8,013,829<span></span>
</td>
<td class="nump">6,448,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">41,387,451<span></span>
</td>
<td class="nump">29,466,770<span></span>
</td>
<td class="nump">76,251,533<span></span>
</td>
<td class="nump">50,224,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,964,368<span></span>
</td>
<td class="nump">6,798,380<span></span>
</td>
<td class="nump">11,282,250<span></span>
</td>
<td class="nump">13,837,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">115,059<span></span>
</td>
<td class="nump">65,603<span></span>
</td>
<td class="nump">221,997<span></span>
</td>
<td class="nump">125,224<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">46,466,878<span></span>
</td>
<td class="nump">36,330,753<span></span>
</td>
<td class="nump">87,755,780<span></span>
</td>
<td class="nump">64,186,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(41,636,873)<span></span>
</td>
<td class="num">(33,021,904)<span></span>
</td>
<td class="num">(79,741,951)<span></span>
</td>
<td class="num">(57,738,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">486,597<span></span>
</td>
<td class="nump">334,238<span></span>
</td>
<td class="nump">1,175,318<span></span>
</td>
<td class="nump">648,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,028,609)<span></span>
</td>
<td class="num">(531,382)<span></span>
</td>
<td class="num">(6,118,627)<span></span>
</td>
<td class="num">(531,382)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(13,599,644)<span></span>
</td>
<td class="num">(197,144)<span></span>
</td>
<td class="num">(15,000,941)<span></span>
</td>
<td class="nump">117,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(55,236,517)<span></span>
</td>
<td class="num">(33,219,048)<span></span>
</td>
<td class="num">(94,742,892)<span></span>
</td>
<td class="num">(57,620,877)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,236,517)<span></span>
</td>
<td class="num">$ (33,219,048)<span></span>
</td>
<td class="num">$ (94,742,892)<span></span>
</td>
<td class="num">$ (57,620,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="nump">216,640,186<span></span>
</td>
<td class="nump">241,114,532<span></span>
</td>
<td class="nump">216,583,067<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6784408640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">$ 516,351,405<span></span>
</td>
<td class="num">$ (386,659,120)<span></span>
</td>
<td class="nump">$ 129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">43,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">154,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,751,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,751,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,401,829)<span></span>
</td>
<td class="num">(24,401,829)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">$ 216,584<span></span>
</td>
<td class="nump">518,146,665<span></span>
</td>
<td class="num">(411,060,949)<span></span>
</td>
<td class="nump">107,302,300<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">216,584,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">516,351,405<span></span>
</td>
<td class="num">(386,659,120)<span></span>
</td>
<td class="nump">129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,620,877)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">$ 216,834<span></span>
</td>
<td class="nump">521,608,436<span></span>
</td>
<td class="num">(444,279,997)<span></span>
</td>
<td class="nump">77,545,273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="nump">216,834,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">$ 216,584<span></span>
</td>
<td class="nump">518,146,665<span></span>
</td>
<td class="num">(411,060,949)<span></span>
</td>
<td class="nump">107,302,300<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">216,584,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">1,084,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">249,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,219,048)<span></span>
</td>
<td class="num">(33,219,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">$ 216,834<span></span>
</td>
<td class="nump">521,608,436<span></span>
</td>
<td class="num">(444,279,997)<span></span>
</td>
<td class="nump">77,545,273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="nump">216,834,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">99,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">759,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,742,892)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">621,871,919<span></span>
</td>
<td class="num">(614,019,172)<span></span>
</td>
<td class="nump">$ 8,093,969<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,221,840<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">$ 60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,236,517)<span></span>
</td>
<td class="num">(55,236,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">$ 621,871,919<span></span>
</td>
<td class="num">$ (614,019,172)<span></span>
</td>
<td class="nump">$ 8,093,969<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,221,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6785286448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (94,742,892)<span></span>
</td>
<td class="num">$ (57,620,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">133,049<span></span>
</td>
<td class="nump">79,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">10,057,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">88,948<span></span>
</td>
<td class="nump">46,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Other Noncash Expense</a></td>
<td class="nump">78,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">443,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">167,500<span></span>
</td>
<td class="nump">38,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">5,224,212<span></span>
</td>
<td class="nump">4,128,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">316,880<span></span>
</td>
<td class="nump">30,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,486,691)<span></span>
</td>
<td class="num">(1,335,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,226,770)<span></span>
</td>
<td class="num">(395,219)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">1,710,697<span></span>
</td>
<td class="nump">2,539,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,244,603)<span></span>
</td>
<td class="nump">7,329,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,801,717<span></span>
</td>
<td class="nump">561,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(88,677,723)<span></span>
</td>
<td class="num">(44,598,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(763,247)<span></span>
</td>
<td class="num">(434,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(1,092,504)<span></span>
</td>
<td class="num">(45,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Payment of security deposit</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(11,486)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,876,171)<span></span>
</td>
<td class="num">(491,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">100,107<span></span>
</td>
<td class="nump">1,128,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayments of Other Long-term Debt</a></td>
<td class="num">(81,660,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from Other Debt</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="num">(6,652,270)<span></span>
</td>
<td class="num">(3,786,918)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">111,787,118<span></span>
</td>
<td class="nump">72,342,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase in cash</a></td>
<td class="nump">21,233,224<span></span>
</td>
<td class="nump">27,251,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">161,613,077<span></span>
</td>
<td class="nump">127,135,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">182,846,301<span></span>
</td>
<td class="nump">$ 154,386,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 6,989,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773877024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">THE COMPANY</a></td>
<td class="text">

<div style="display: inline; text-decoration: underline; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; THE COMPANY</b></span></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">TherapeuticsMD, Inc., a Nevada
corporation, or TherapeuticsMD or the Company, has three&#160;wholly
owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada
corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context
otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#8220;our
company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Nature of Business</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We are a women&#8217;s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#8217;s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD<sup>&#174;</sup> and BocaGreenMD<sup>&#174;</sup> brands.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">With our SYMBODA&#8482; technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During 2018 , U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our FDA-approved product, IMVEXXY&#174; (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched BIJUVA&#174;, our hormone therapy combination of bio-identical 17 &#223;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. We are also focused on commercialization activities necessary for launch of ANNOVERA&#8482; (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In addition, on July 30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. On June 6, 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769836560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract', window );"><strong>Basis Of Presentation And Recently Issued Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock', window );">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Interim Financial Statements</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period in the future.</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Recently Issued Accounting Pronouncements</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating the effect of this guidance on our disclosures.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In June 2018, the FASB issued ASU 2018 -07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In February 2016, the FASB issued ASU 2016 -02 , Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018 -11 , Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016 -02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018 -11 and we recorded a $3.8 million right of use asset and a $4.1 million liability related to adoption of this standard. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess ( 1 ) whether existing or expired contracts contain leases, ( 2 ) lease classification for any existing or expired leases, and ( 3 ) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773868032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Fair Value of Financial Instruments</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820,

<div style="display:inline;font-style:italic">Fair Value Measurements.</div>&#160;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 1</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 2</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 3</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#8217;s impairment test on an annual basis.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display: inline; text-decoration:underline"> Trade Accounts Receivable and Allowance for Doubtful Accounts<br/><br/>Trade accounts receivable are customer obligations due
under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an
allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and
existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.<div>&#160;</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Revenue Recognition</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#8220;completed&#8221; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Prescription Products</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on&#160;consignment,&#160;revenue&#160;is generally recognized when the prescription is filled.&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of
six&#160;months&#160;prior to and up to 12&#160;months
following product expiration. Our prescription products currently have a shelf life of 24&#160;months
from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use
history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for
which the right of return exists but for which we currently do not have history of product returns, we estimate returns based
on available industry data, our own sales information and our visibility into the inventory remaining in the distribution
channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information
from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current
liabilities on the consolidated balance sheet.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible&#160;enrolled patients do not pay more than $35&#160;for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Disaggregation of revenue</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Three Months</div></div>
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Ended June 30,</div></div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Six Months<br/>Ended June 30</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif">Prescription vitamins</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,822,872</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">3,763,010</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">4,758,844</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">7,536,402</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">IMVEXXY</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,121,711</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5,132,390</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">BIJUVA</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">134,282</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">134,282</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Net revenue</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">6,078,865</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">3,763,010</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">10,025,516</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">7,536,402</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Share-Based Compensation</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Research and Development Expenses</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Research and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;D expenses include professional research and advice regarding R&amp;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">&#160;</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Segment Reporting</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769868880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">
<div style="display:inline;font-weight:bold">
<div style="display:inline;text-decoration:underline">NOTE 4 &#8211; INVENTORY</div>
</div>
</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>


<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Inventory consists of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
	<tbody>
		<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">June 30,<br/>
			2019</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">December 31,<br/>
			2018</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
			<td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Finished product</td>
			<td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">
			4,382,969
			</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">
			2,908,958
			</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;font-family:Times New Roman, Times, Serif">Work in process</td>
			<td style="font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:right;font-family:Times New Roman, Times, Serif">
			439,993
			</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:right;font-family:Times New Roman, Times, Serif">
			339,312
			</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Raw material</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">
			2,671,478
			</td>
			<td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">
			19,400
			</td>
			<td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
			<td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL INVENTORY</td>
			<td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">
			7,494,440
			</td>
			<td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">
			3,267,670
			</td>
			<td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
	</tbody>

</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769935872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 5 &#8211; OTHER CURRENT ASSETS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Other current assets consist of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Prepaid sales and marketing costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,568,100</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">5,148,789</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Deferred financing fees (Note 9)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">550,757</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,898,074</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Prepaid insurance</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">686,891</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">790,465</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Other prepaid costs</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">3,933,300</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">2,997,365</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">7,739,048</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">10,834,693</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769877264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS, NET</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 6 &#8211; FIXED ASSETS, NET</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Fixed assets, net consist of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Accounting system</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">301,096</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">301,096</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Equipment</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">581,150</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">490,576</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Furniture and fixtures</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">940,963</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">116,542</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Computer hardware</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">220,820</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">80,211</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Leasehold improvements</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">74,788</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">37,888</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,118,817</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,026,313</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Accumulated depreciation</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(686,680</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(553,630</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL FIXED ASSETS, NET</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">1,432,137</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">472,683</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Depreciation expense for the three months ended June 30, 2019 and 2018 was $66,556&#160;and $40,777&#160;, respectively, and for the six months ended June 30, 2019 and 2018 was $133,049&#160;and $79,201&#160;, respectively.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773907600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 7 &#8211; INTANGIBLE ASSETS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>&#160; &#160; &#160; &#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Gross Carrying Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Net<br/>Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted-Average<br/>Remaining Amortization Period (yrs.)</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,962,563</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(370,338</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,592,225</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">13.5</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,833,584</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,833,584</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Multiple trademarks</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">262,305</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">262,305</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">indefinite</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">5,058,452</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(370,338</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,688,114</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">&#160;</div>&#160;&#160; &#160; &#160; &#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Gross Carrying Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Net<br/>Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted-Average<br/>Remaining Amortization Period (yrs.)</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">31,951</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(10,484</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">21,467</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#160;10.75</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Development costs of corporate website</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">91,743</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(91,743</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,234,129</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(282,485</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,951,644</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">14</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,855,279</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,855,279</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Multiple trademarks</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">264,289</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">264,289</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">indefinite</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,477,391</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(384,712</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,092,679</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately20&#160;years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the six months ended June 30, 2019, we wrote off $78,864&#160;in costs related to trademarks and patents, including the net carrying amount of the OPERA patent.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we had&#160;26&#160;issued domestic, or U.S., patents and&#160;27&#160;issued foreign patents, including:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">12 domestic patents and&#160;five&#160;foreign patents that relate to BIJUVA as well as three domestic patents that relate to non-approved doses of BIJUVA. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Four foreign
    patents that relate to our progesterone-only candidate, which are owned by us. The foreign patents will expire no earlier
    than 2033. In addition, we have pending patent applications with respect to our progesterone-only candidate in the U.S.,
    Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Five&#160;
    domestic patents (three utility and two design) and 13&#160;foreign
    patents (three utility and ten design) that relate to IMVEXXY. These patents establish an important intellectual property
    foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents
    will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain
    jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent
    applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New
    Zealand, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">One domestic
    utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035.
    We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil,
    Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">One domestic utility patent and&#160;five&#160;foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Australia, Brazil, Canada, Europe, Mexico, Japan, and South Africa;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">One domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">One domestic
    utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031;
    and</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="width:100%;font:10pt Times New Roman, Times, Serif">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:0.25in;font-family:Times New Roman, Times, Serif">&#9679;</td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Two&#160;domestic utilitypatents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Amortization expense was $48,503&#160;and $24,826&#160;for the three months ended June 30, 2019 and 2018, respectively and $88,948&#160;and $46,023&#160;for the six months ended June 30, 2019 and 2018, respectively. Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>&#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:25%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Year Ending December 31,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Estimated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2019(6 months)</div></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">96,008</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2020</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2021</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2023</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">License Agreement with the Population Council</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On July 30, 2018, we entered into the Council License Agreement to commercialize in the U.S. ANNOVERA. We currently estimate that ANNOVERA will be commercially available as early as the third quarter of 2019 with a planned full commercial launch by the first quarter of 2020.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Under the terms of the Council License
Agreement, we paid the Population Council a milestone payment of $20,000,000&#160;within
30 days following approval by the FDA of the NDA for ANNOVERA and will be required to pay the Population Council
$20,000,000&#160;within
30 days following the release of the first commercial batch of ANNOVERA. The Population Council is also eligible to receive
milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for marketing expenses
related to the commercialization of ANNOVERA. The milestone payment of $20,000,000&#160;upon
the FDA&#8217;s approval of ANNOVERA in the third quarter of 2018 was recorded as a finite-lived intangible asset in the
consolidated balance sheet and will be amortized on a straight-line basis once it becomes available for use which is expected
to be upon release of first commercial batch of ANNOVERA. In addition, we are required to pay the Population Council, on a
quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its
affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $50,000,000&#160;,
a royalty of 5&#160;%
of net sales; (ii) for annual net sales greater than $50,000,000&#160;and
less than or equal to $150,000,000&#160;,
a royalty of 10&#160;%
of such net sales; and (iii) for net sales greater than $150,000,000&#160;,
a royalty of 15&#160;%
of such net sales. The annual royalty rate will be reduced to 50&#160;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to 20&#160;%
of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will be offset against
royalties or other payments owed by us to the Population Council under the Council License Agreement. We and the Population
Council have agreed to form a joint product committee responsible for overseeing activities under the Council License
Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs,
publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system,
subject to oversight and decisions made by the joint product committee. The Council License Agreement includes exclusive
rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the
Population Council.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We assess our intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">License Agreement with Knight Therapeutics Inc.</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased3,921,568&#160;shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $5.10&#160;, for proceeds of $20,000,000&#160;, on August 6, 2018.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">License Agreement with Theramex</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On June 6, 2019, we entered into an
exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical
company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and
Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR14&#160;million
in cash as an upfront fee on August 5, 2019. Within thirty days of signing License Agreement, we are required to provide
Theramex the regulatory materials and clinical data that are necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. The revenue related to fees received by us will
be recognized once our performance obligations have been satisfied. We are eligible to receive additional milestone payments
comprised of (i) up to an aggregate of EUR 2&#160;million
in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii)
up to an aggregate of EUR 27.5&#160;million
in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net
sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR 25&#160;million
to EUR100&#160;million.
We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will
be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense
its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the
License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for
regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate
the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material
breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy
or other related matters.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773877024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text">

<div>

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</div></div></div><br/>&#160;</div>

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other current liabilities consist of the following:</div>&#160;

<table cellpadding="5" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;border:Black 1pt solid;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></div></td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></div></td>
    <td style="padding-bottom:1pt">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued payroll, bonuses and commission costs</div></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="width:12%;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5,115,082</div></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="width:12%;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">6,854,002</div></td>
    <td style="width:1%;text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Allowance for coupons and returns</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">6,340,450</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5,294,120</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued sales and marketing costs</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,107,696</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,288,028</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued compensated absences</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,492,131</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,178,110</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Allowance for wholesale distributor fees</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,077,444</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">792,891</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued legal and accounting expense</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">367,898</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">385,824</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued research and development</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,402,600</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">388,675</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Operating lease liability</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,187,029</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued rent</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">365,155</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued rebates</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,251,047</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">412,570</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other accrued expenses</div></td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">35,240</div></td>
    <td style="padding-bottom:1pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">375,573</div></td>
    <td style="padding-bottom:1pt;text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">TOTAL OTHER CURRENT LIABILITIES</div></td>
    <td style="padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="border-bottom:Black 2pt double;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">22,376,617</div></td>
    <td style="padding-bottom:2pt;text-align:left">&#160;</td>
    <td style="padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="border-bottom:Black 2pt double;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">18,334,948</div></td>
    <td style="padding-bottom:2pt;text-align:left">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769889536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 9 &#8211; DEBT</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On April 24, 2019, we entered into a
Financing Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the
Administrative Agent, various lenders from time to time party thereto, and certain of the Company&#8217;s subsidiaries party
thereto from time to time as guarantors, which provides us with a $300,000,000&#160;first
lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three&#160;tranches:
(i) $200,000,000&#160;was
drawn upon entering into the Financing Agreement; (ii) $50,000,000&#160;will
be available to us upon the designation of our ANNOVERA product as a new category of birth control by the FDA on or prior to
December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $50,000,000&#160;will
be available to us upon our achieving $11,000,000&#160;in
net revenues, as defined in the Financing Agreement, from our IMVEXXY, BIJUVA and ANNOVERA products for the fourth quarter of
2019 and satisfaction (or waiver) of other customary conditions precedent. Borrowings under the Facility accrue interest at
either (i)3-month
LIBOR plus7.75%,
subject to a LIBOR floor of 2.70%
or (ii) the
prime rate plus6.75%,
subject to a prime rate floor of 5.20%,
as selected by us. Interest on amounts borrowed under the Facility will be payable quarterly. The outstanding principal
amount of the Facility is payable in four equal quarterly installments beginning on June 30, 2023, with the Facility maturing
on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a
prepayment fee on the principal amount being prepaid of (i)30.0%
for the first two years following the initial funding date of the applicable borrowing, (ii)5.0%
for the third year following the initial funding date of the applicable borrowing, (iii)3.0%
for the fourth year following the initial funding date of the applicable borrowing and (iv)1.0%
for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection
with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to 2.5%
of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings
under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in
addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and
covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i)
maintain a minimum unrestricted cash balance of $50,000,000,
which will increase to $60,000,000&#160;if
we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts
attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending
December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default
that are customary for financings of this type, including an event of default relating to a change of control of the Company.
Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations
under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the
Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject
to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all
existing and after-acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be
guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $200,000,000, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in three separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) one-month LIBOR (subject to a LIBOR floor of1.50%) plus (ii)7.75% per annum.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On April 24, 2019, we terminated
the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of
approximately $81,661,000&#160;was
used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of 4%,
a repayment fee of 4%
and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the
Credit Agreement, we recorded $10,057,632&#160;in
loss on extinguishment of debt in the accompanying unaudited consolidated financial statements. Interest on amounts
borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the six months ending June 30, 2019
related to the Credit Agreement was $1,816,747.
During the six months ended June 30, 2019, and prior to the repayment of the Credit Agreement, we amortized $120,146&#160;of
deferred financing fees as interest expense in the accompanying unaudited consolidated financial statements.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we had
$200,000,000&#160;in
borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying unaudited
consolidated financial statements. We incurred $6,652,270&#160;in
deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement
have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees
related to Tranche 1 of $6,101,513&#160;have
been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred
financing fees associated with unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones have
been met. As of June 30, 2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in other current
assets in the accompanying consolidated financial statements. During both the three and six months ended June 30, 2019, we
amortized $196,734&#160;of
deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated financial
statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest
expense for both the three and six months ending June 30, 2019 was $3,985,000.
The overall effective interest rate under the Financing Agreement was approximately 11%
as of June 30, 2019. As of June 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Financing Agreement</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">200,000,000</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Credit Agreement</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">75,000,000</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Debt discount and financing fees</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(5,904,780</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(1,618,986</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL LONG-TERM DEBT</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">194,095,220</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">73,381,014</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="margin-top:6pt;margin-bottom:6pt;border-bottom:Black 1pt solid">

<div style="margin-top:0pt;text-align:center;margin-bottom:0pt;font:normal 10pt Times New Roman, Times, Serif">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769880528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 10&#8211; NET LOSS PER SHARE</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been antidilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three and Six months ended</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:justify;font-family:Times New Roman, Times, Serif">Stock options</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">22,072,469</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">25,210,899</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Warrants</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,832,571</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,007,571</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Restricted stock awards</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">1,040,000</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">24,945,040</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">28,218,470</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769851584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Preferred Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019, we had 10,000,000&#160;shares
of preferred stock, par value $0.001 per share, authorized for issuance, of which no shares of preferred stock were issued or
outstanding.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Common Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019, we had 350,000,000&#160;shares
of Common Stock authorized for issuance, of which 241,221,840&#160;shares
of Common Stock were issued and outstanding.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Issuances During the Three and Six Months Ended June 30, 2019</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the three months ended June 30,
2019, no options to purchase shares of Common Stock were exercised. During the six months ended June 30, 2019, certain
individuals exercised stock options to purchase 276,383&#160;shares
of Common Stock for $100,107&#160;in
cash. Also, during the same period, stock options to purchase 12,097&#160;shares
of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein 11,834&#160;shares
of Common Stock were issued.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Issuances During the Three and Six Months Ended June 30, 2018</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the three months ended June
30, 2018, certain individuals exercised stock options to purchase 249,785&#160;shares
of Common Stock for $1,084,939&#160;in
cash. During the six months ended June 30, 2018, certain individuals exercised stock options to purchase 394,576&#160;shares
of Common Stock for $1,128,996&#160;in
cash. Also, during the six months ended June 30, 2018, stock options to purchase 10,000&#160;shares
of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein 9,841&#160;shares
of Common Stock were issued.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Warrants to Purchase Common Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we had
warrants outstanding to purchase an aggregate of 1,832,571&#160;shares
of Common Stock with a weighted-average contractual remaining life of approximately 2.5&#160;years,
and exercise prices ranging from $0.24&#160;to
$8.20&#160;per
share, resulting in a weighted average exercise price of $2.62&#160;per
share.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the six months ended June
30, 2019, we granted warrants to purchase75,000&#160;shares
of Common Stock to outside consultants at an exercise price of $5.63&#160;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of 5&#160;years;
volatility of 60.8&#160;%;
risk free rate of 2.52&#160;%;
and dividend yield of 0&#160;%.
The grant date fair value of the warrants was $3.00&#160;per
share. The warrants are vesting ratably over a 12-month period and have an expiration date of February 12, 2024. During
the six months ended June 30, 2018, we granted warrants to purchase175,000&#160;shares
of Common Stock to outside consultants at an exercise price of $5.16&#160;.
The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of 5&#160;years;
volatility of 62.1&#160;%;
risk free rate of 2.36&#160;%;
and dividend yield of 0&#160;%.
The grant date fair value of the warrants was $2.79&#160;per
share. The warrants vest ratably over a 12-month period and have an expiration date of March 15, 2023.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the three months ended June 30, 2019 and 2018, we recorded $56,172&#160;and $164,840&#160;, respectively, and during the six months ended June 30, 2019 and 2018, we recorded $141,888&#160;and $256,315&#160;, respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants. As of June 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants was approximately $139,000&#160;, which is expected to be recognized over a weighted-average period of0.6&#160;years.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"><br/>During the three months ended June 30, 2019 and 2018, no warrants to purchase shares of Common Stock were exercised.<br/>&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the six months ended June
30, 2019, warrants to purchase 1,250,000&#160;shares
of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein 471,184&#160;shares
of Common Stock were issued. During the six months ended June 30, 2018, no warrants were exercised.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Options to Purchase Common Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In 2009, we adopted the 2009 Long Term
Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and
consultants of our company who are able to contribute towards the creation of or who have created stockholder value by
providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan
consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or
as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or
on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable
exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of
June 30, 2019, there were non-qualified stock options to purchase 15,116,995&#160;shares
of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive
Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In 2012, we adopted the 2012
Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to
serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants
and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as
described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors,
upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they
have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The
expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were non-qualified
stock options to purchase 6,317,974&#160;shares
of Common Stock outstanding and 1,040,000&#160;restricted
stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan on June 20, 2019, no future awards may be
made under the 2012 Plan.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of June 30, 2019, there were16,812,383&#160;shares of Common Stock authorized for issuance thereunder, consisting of (i)14,362,500&#160;new shares, (ii)2,393,833&#160;unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii)56,050&#160;unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of June 30, 2019, there were non-qualified stock options to purchase&#160;637,500&#160;shares of Common Stock outstanding under the 2019 Plan.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the six months ended June 30, 2019 and 2018 are set forth in the table below.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:70%;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">
        <div style="display:inline;font-weight:bold">Six months ended</div></div>
        <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">
        <div style="display:inline;font-weight:bold">June 30,</div></div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:38%;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">2019</div></div></td>
    <td style="width:2%;text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">2018</div></div></td></tr>
<tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Risk-free interest rate</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2.19&#8212;2.54&#160;%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2.38&#8212;2.63&#160;%</div></td></tr>
<tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Volatility</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">61.25&#8212;61.85&#160;%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">61.82&#8212;64.04&#160;%</div></td></tr>
<tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Term (in years)</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5.5&#8212;6.25</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5.1&#8212;6.25</div></td></tr>
<tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Dividend yield</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">0.00%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">0.00%</div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:95%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Number of Shares Underlying Stock Options</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted Average Exercise Price</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Aggregate Intrinsic Value</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:39%;font-family:Times New Roman, Times, Serif">Balance at December 31, 2018</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">20,872,824</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">4.93</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">5.94</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">12,239,876</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Granted</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,544,500</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.40</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Exercised</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(288,480</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">0.35</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,315,238</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Expired/Forfeited</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(56,375</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.77</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">Balance at June 30, 2019</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">22,072,469</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.95</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.80</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,945,665</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Vested and Exercisable at June 30, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">17,125,888</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.79</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.94</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,945,665</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Unvested at June 30, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4,946,581</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.48</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">8.79</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">0</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019, our outstanding stock options had exercise prices ranging from $0.10&#160;to $8.92&#160;per share. The weighted average grant date fair value per share of options granted was $2.57&#160;and $3.15&#160;during the six months ended June 30, 2019 and 2018, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended June 30, 2019 and 2018 ($2,230,829&#160;and $2,212,241&#160;, respectively) and for the six months ended June 30, 2019 and 2018 ($4,374,069&#160;and $3,872,125&#160;, respectively) is based on vested awards. At June 30, 2019, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $11,606,000&#160;which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of2.1&#160;years. No tax benefit was realized due to a continued pattern of operating losses.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Restricted Stock</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On December 13, 2018, we granted 1,040,000&#160;restricted
stock units to certain executive employees which will vest at the end of the third year. The grant date fair value
was $4.06&#160;per
unit. During the three and six months ended June 30, 2019 we recorded $350,263&#160;and
$696,676&#160;,
respectively, in share-based compensation expense related to restricted stock units. At June 30, 2019, total
unrecognized estimated compensation expense related to unvested restricted stock units was approximately $3,453,000&#160;,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of 2.5&#160;years.
At June 30, 2019,1,040,000&#160;restricted
stock awards remained outstanding.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Cash-Settled Stock Appreciation Rights (SARs)</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Cash settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, &#8220;Stock Compensation,&#8221; the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded liability was reversed and no cash payment was made.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773869120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"><div style="display:inline;font-weight:bold"><div style="display:inline;text-decoration:underline">NOTE 12 &#8211; INCOME TAXES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Deferred income tax assets and liabilities
are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay
any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the six months ended June 30,
2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior years.
Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#8220;more likely than
not&#8221; that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2019, we maintain
a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has
been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</div>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773848704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">
<div style="display:inline;font-weight:bold">
<div style="display:inline;text-decoration:underline">NOTE 13 &#8211; RELATED PARTIES</div>
</div>
</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company or a committee consisting of independent directors of our company since July 2015. During the three months ended June 30, 2019 and 2018, we were billed by Catalent approximately $
974,000
and $

1,266,000
, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. During the six months ended June 30, 2019 and 2018, we were billed by Catalent approximately $

2,371,000
and $

2,040,000
, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of June 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $

243,000
and $

88,000
, respectively.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773869120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We purchase our prescription products
from several suppliers with approximately&#160;14%,18%,31%
and37%
of our purchases were supplied by four vendors each, respectively, during the six months ended June 30, 2019 and
approximately 100%
of our purchases were supplied from one vendor for the six months ended June 30, 2018.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We sell our prescription prenatal
vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that
generally sell products to retail pharmacies, hospitals, and other institutional customers. During the six months ended June
30, 2019, three customers each generated more than 10%
of our total revenues. During the six months ended June 30, 2018, four customers each generated more than 10%
of our total revenues. Revenue generated from the three customers combined accounted for approximately 60%
of our recognized revenue for the six months ended June 30, 2019 and revenue generated from the four customers combined
accounted for approximately71%
of our recognized revenue for the six months ended June 30, 2018.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During the six months ended June 30, 2019, &#160; Pillpack, Inc. accounted for approximately $3,615,000of our revenue, AmerisourceBergen accounted for approximately $1,365,000of our revenue and Cardinal Health accounted for approximately $1,048,000of our revenue. During the six months ended June 30, 2018, PI Services generated approximately $981,000of our revenue, Pillpack, Inc. generated approximately $2,088,000of our revenue, AmerisourceBergen generated approximately $1,283,000of our revenue and Cardinal Health generated approximately $971,000of our &#160;revenue.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773982192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;font-weight:bold">

<div style="display:inline;text-decoration:underline">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a 63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum is effective beginning November 1, 2016.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which lease on 7,561 square feet commenced in 2018 and the lease on the remaining 48,651 square feet will commence sometime in the third quarter of 2019, or the full premises commencement date. The lease will expire 11 years after full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In addition, we will be entitled to reimbursement from the landlord of up to $1,800,000&#160;for tenant improvements. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Supplemental lease information as of June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use asset (included in Other assets)</td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">3,316,436</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Short-term operating lease liability (included in Other current liabilities)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,187,029</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Long-term operating lease liability</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,488,101</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Weighted average remaining term</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5Years</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Weighted average discount rate</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">8.25</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Supplemental cash flow information<br/>for the six months ended June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">564,092</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,760,171</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Years Ending December 31,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2019 (6 months)</div></td>
    <td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">595,649</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2020</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,292,914</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2021</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,135,467</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">172,651</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2023</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">176,968</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Thereafter</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">1,228,504</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Total undiscounted lease payments</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4,602,153</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Less: imputed interest</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(927,023</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Present value of lease payments</div></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">3,675,130</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, we estimated undiscounted fixed future minimum rental commitments of approximately $13,300,000&#160;and estimated undiscounted variable future minimum rental commitments of approximately $6,400,000&#160;over the term of the lease related to the operating lease for the new corporate office that we entered into in October 2018 and an additional suite that we entered into in 2019 that had not commenced yet, as disclosed above. During the three and six months ended June 30, 2019, operating lease expense related to our real estate leases was approximately $295,000&#160;and $590,000&#160;, respectively, and variable lease expense was insignificant for the three and six months ended June 30, 2019. Rent expense totaled $257,000&#160;and $515,000&#160;during the three and six months ended June 30, 2018, respectively.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6958637136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Fair Value of Financial Instruments</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of June 30, 2019 (as disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820,

<div style="display:inline;font-style:italic">Fair Value Measurements.</div>&#160;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 1</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 2</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr></tbody>
</table>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;margin-top:0;margin-bottom:1;width:100%">
        <tbody>
<tr style="vertical-align:top;text-align:justify;font-family:Times New Roman, Times, Serif">
    <td style="width:0.5in;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1in;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Level 3</div></td>
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">At June 30, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#8217;s impairment test on an annual basis.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display: inline; text-decoration:underline"> Trade Accounts Receivable and Allowance for Doubtful Accounts<br/><br/>Trade accounts receivable are customer obligations due
under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an
allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and
existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received
as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately
reflect bad debts, adjustments to these reserves may be required.<div>&#160;</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Revenue Recognition</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We adopted ASC 606 on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#8220;completed&#8221; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Prescription Products</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As of June 30, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. In consignment arrangements, control of the product is transferred at the point in time when the goods are removed from consignment stock and sold to the end customer. We typically satisfy our performance obligations and recognize revenue at a point in time, generally when products are shipped to the customer, depending on the terms underlying each arrangement. In circumstances where our products are on&#160;consignment,&#160;revenue&#160;is generally recognized when the prescription is filled.&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We accept returns of unsalable
prescription products sold through wholesale distributors within a return period of
six&#160;months&#160;prior to and up to 12&#160;months
following product expiration. Our prescription products currently have a shelf life of 24&#160;months
from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a
patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a
reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use
history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for
which the right of return exists but for which we currently do not have history of product returns, we estimate returns based
on available industry data, our own sales information and our visibility into the inventory remaining in the distribution
channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information
from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products
currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the
amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return
asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of
revenue is deferred due to the anticipated return). Return estimates are recorded in the accrued expenses and other current
liabilities on the consolidated balance sheet.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">As part of the commercial launch for IMVEXXY during the third quarter of 2018 and for BIJUVA in the second quarter of 2019, we introduced a co-pay assistance program where eligible&#160;enrolled patients do not pay more than $35&#160;for prescription fills. This allows patients to access the product at a reasonable cost regardless of insurance coverage. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for IMVEXXY or BIJUVA positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of IMVEXXY and BIJUVA is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain revenue recognized for IMVEXXY and BIJUVA to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for IMVEXXY and BIJUVA is constrained by our estimates of the amount to be paid for the co-pay assistance program for IMVEXXY and BIJUVA which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate any constraint each reporting period.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">

<div style="display:inline;font-style:italic">

<div style="display:inline;text-decoration:underline">Disaggregation of revenue</div></div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-indent:0.5in">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Three Months</div></div>
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Ended June 30,</div></div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Six Months<br/>Ended June 30</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif">Prescription vitamins</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,822,872</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">3,763,010</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">4,758,844</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">7,536,402</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">IMVEXXY</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,121,711</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5,132,390</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">BIJUVA</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">134,282</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">134,282</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Net revenue</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">6,078,865</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">3,763,010</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">10,025,516</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">7,536,402</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">

<div style="display:inline;text-decoration:underline">Share-Based Compensation</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Research and Development Expenses</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Research and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;D expenses include professional research and advice regarding R&amp;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">

<div style="display:inline;text-decoration:underline">Segment Reporting</div></div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6768380240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregated revenue</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table provides information about disaggregated revenue by product mix for the three and six months ended June 30, 2019 and 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Three Months</div></div>
        <div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Ended June 30,</div></div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">For the Six Months<br/>Ended June 30</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:20%;text-align:justify;font-family:Times New Roman, Times, Serif">Prescription vitamins</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,822,872</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">3,763,010</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">4,758,844</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">7,536,402</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">IMVEXXY</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,121,711</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5,132,390</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">BIJUVA</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">134,282</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">134,282</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Net revenue</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">6,078,865</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">3,763,010</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">10,025,516</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">7,536,402</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773875680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text">
<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Inventory consists of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
	<tbody>
		<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">June 30,<br/>
			2019</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
			<td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">December 31,<br/>
			2018</div>
			</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
			<div style="display:inline;font-weight:bold">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
			<td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Finished product</td>
			<td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">
			4,382,969
			</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">
			2,908,958
			</td>
			<td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;font-family:Times New Roman, Times, Serif">Work in process</td>
			<td style="font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:right;font-family:Times New Roman, Times, Serif">
			439,993
			</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="text-align:right;font-family:Times New Roman, Times, Serif">
			339,312
			</td>
			<td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
			<td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Raw material</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">
			2,671,478
			</td>
			<td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">
			19,400
			</td>
			<td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
		<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
			<td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL INVENTORY</td>
			<td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">
			7,494,440
			</td>
			<td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
			<td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
			<td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">
			3,267,670
			</td>
			<td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
		</tr>
	</tbody>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769918272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Other current assets consist of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Prepaid sales and marketing costs</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,568,100</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">5,148,789</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Deferred financing fees (Note 9)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">550,757</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,898,074</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Prepaid insurance</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">686,891</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">790,465</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Other prepaid costs</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">3,933,300</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">2,997,365</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">7,739,048</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">10,834,693</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769813088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">Fixed assets, net consist of the following:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Accounting system</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">301,096</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">301,096</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Equipment</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">581,150</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">490,576</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Furniture and fixtures</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">940,963</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">116,542</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Computer hardware</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">220,820</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">80,211</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Leasehold improvements</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">74,788</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">37,888</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,118,817</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,026,313</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Accumulated depreciation</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(686,680</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(553,630</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL FIXED ASSETS, NET</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">1,432,137</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">472,683</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769852688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2019 and December 31, 2018:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>&#160; &#160; &#160; &#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Gross Carrying Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Net<br/>Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted-Average<br/>Remaining Amortization Period (yrs.)</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,962,563</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(370,338</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">2,592,225</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">13.5</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,833,584</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,833,584</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Multiple trademarks</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">262,305</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">262,305</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">indefinite</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">5,058,452</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(370,338</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,688,114</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="margin-top:0;margin-bottom:0;font-family:Times New Roman, Times, Serif">&#160;</div>&#160;&#160; &#160; &#160; &#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="14" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Gross Carrying Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Accumulated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Net<br/>Amount</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted-Average<br/>Remaining Amortization Period (yrs.)</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">OPERA<sup>&#174;</sup> software patent</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">31,951</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">(10,484</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">21,467</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#160;10.75</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Development costs of corporate website</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">91,743</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(91,743</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,234,129</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(282,485</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,951,644</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">14</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,855,279</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,855,279</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">n/a</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:1pt;text-indent:-0.125in;padding-left:0.25in;font-family:Times New Roman, Times, Serif">Multiple trademarks</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">264,289</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">264,289</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">indefinite</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;text-indent:-0.125in;padding-left:0.375in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,477,391</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">(384,712</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">4,092,679</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>&#160;

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:25%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Year Ending December 31,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Estimated Amortization</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2019(6 months)</div></td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:10%;text-align:right;font-family:Times New Roman, Times, Serif">96,008</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2020</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2021</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2023</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">196,017</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of intangible assets, which may be broken down by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773919568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text">

<div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other current liabilities consist of the following:</div>&#160;

<table cellpadding="5" style="border-collapse:collapse;width:90%;font:10pt Times New Roman, Times, Serif;border:Black 1pt solid;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></div></td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td colspan="2" style="border-bottom:Black 1pt solid;text-align:center">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></div></td>
    <td style="padding-bottom:1pt">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued payroll, bonuses and commission costs</div></td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="width:12%;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5,115,082</div></td>
    <td style="width:1%;text-align:left">&#160;</td>
    <td style="width:1%">&#160;</td>
    <td style="width:1%;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="width:12%;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">6,854,002</div></td>
    <td style="width:1%;text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Allowance for coupons and returns</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">6,340,450</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5,294,120</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued sales and marketing costs</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,107,696</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,288,028</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued compensated absences</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,492,131</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,178,110</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Allowance for wholesale distributor fees</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,077,444</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">792,891</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued legal and accounting expense</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">367,898</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">385,824</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued research and development</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,402,600</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">388,675</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Operating lease liability</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">1,187,029</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued rent</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">&#8212;</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">365,155</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Accrued rebates</div></td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2,251,047</div></td>
    <td style="text-align:left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align:left">&#160;</td>
    <td style="text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">412,570</div></td>
    <td style="text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:#cceeff;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;padding-left:0.125in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Other accrued expenses</div></td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">35,240</div></td>
    <td style="padding-bottom:1pt;text-align:left">&#160;</td>
    <td style="padding-bottom:1pt">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">375,573</div></td>
    <td style="padding-bottom:1pt;text-align:left">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font:10pt Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.25in">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">TOTAL OTHER CURRENT LIABILITIES</div></td>
    <td style="padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="border-bottom:Black 2pt double;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">22,376,617</div></td>
    <td style="padding-bottom:2pt;text-align:left">&#160;</td>
    <td style="padding-bottom:2pt">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">$</div></td>
    <td style="border-bottom:Black 2pt double;text-align:right">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">18,334,948</div></td>
    <td style="padding-bottom:2pt;text-align:left">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773900816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Financing Agreement</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">200,000,000</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Credit Agreement</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">75,000,000</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Debt discount and financing fees</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(5,904,780</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(1,618,986</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL LONG-TERM DEBT</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">194,095,220</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">73,381,014</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6959066880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="6" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Three and Six months ended</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30, 2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:30%;text-align:justify;font-family:Times New Roman, Times, Serif">Stock options</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">22,072,469</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">25,210,899</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Warrants</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,832,571</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,007,571</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Restricted stock awards</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">1,040,000</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">24,945,040</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">28,218,470</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769851008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font:10pt Times New Roman, Times, Serif;width:70%;border-collapse:collapse;margin:auto">
        <tbody>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="3" style="border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">
        <div style="display:inline;font-weight:bold">Six months ended</div></div>
        <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">
        <div style="display:inline;font-weight:bold">June 30,</div></div></td></tr>
<tr style="vertical-align:top;font-family:Times New Roman, Times, Serif">
    <td style="width:38%;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">2019</div></div></td>
    <td style="width:2%;text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="width:15%;border-bottom:Black 1pt solid;text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">
        <div style="display:inline;font-weight:bold">2018</div></div></td></tr>
<tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Risk-free interest rate</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2.19&#8212;2.54&#160;%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2.38&#8212;2.63&#160;%</div></td></tr>
<tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Volatility</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">61.25&#8212;61.85&#160;%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">61.82&#8212;64.04&#160;%</div></td></tr>
<tr style="vertical-align:top;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Term (in years)</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5.5&#8212;6.25</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5.1&#8212;6.25</div></td></tr>
<tr style="vertical-align:top;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Dividend yield</div></td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">0.00%</div></td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:center;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">0.00%</div></td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of activity of 2009 and 2012 Plans</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:95%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Number of Shares Underlying Stock Options</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted Average Exercise Price</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Aggregate Intrinsic Value</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:39%;font-family:Times New Roman, Times, Serif">Balance at December 31, 2018</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">20,872,824</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">4.93</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">5.94</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:11%;text-align:right;font-family:Times New Roman, Times, Serif">12,239,876</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Granted</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,544,500</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.40</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-left:0.125in;font-family:Times New Roman, Times, Serif">Exercised</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">(288,480</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">0.35</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,315,238</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:1pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Expired/Forfeited</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(56,375</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.77</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">Balance at June 30, 2019</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">22,072,469</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.95</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.80</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,945,665</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-indent:-0.125in;padding-left:0.125in;font-family:Times New Roman, Times, Serif">Vested and Exercisable at June 30, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">17,125,888</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.79</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4.94</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,945,665</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Unvested at June 30, 2019</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4,946,581</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">5.48</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">8.79</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">0</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769862816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation', window );">Schedule of supplemental lease information and cash flow information</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Supplemental lease information as of June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use asset (included in Other assets)</td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">3,316,436</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Short-term operating lease liability (included in Other current liabilities)</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,187,029</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Long-term operating lease liability</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,488,101</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Weighted average remaining term</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5Years</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="font-family:Times New Roman, Times, Serif">Weighted average discount rate</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">8.25</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Supplemental cash flow information<br/>for the six months ended June 30, 2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td>
    <td style="width:2%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">564,092</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligation</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,760,171</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Reconciliation of undiscounted cash flows for all operating leases to the operating lease liabilities</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">The following table reconciles the undiscounted cash flows for all operating leases at June 30, 2019 to the operating lease liabilities recorded on the balance sheet:</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">Years Ending December 31,</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">2019 (6 months)</div></td>
    <td style="width:2%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">595,649</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2020</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,292,914</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2021</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,135,467</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2022</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">172,651</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">2023</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">176,968</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Thereafter</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">1,228,504</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Total undiscounted lease payments</div></td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">4,602,153</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Less: imputed interest</div></td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(927,023</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">Present value of lease payments</div></td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">3,675,130</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplementary lease and cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6773999536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>THE COMPANY (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSubsidiares', window );">Number of Subsidiares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSubsidiares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSubsidiares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769877552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 3,316,436<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 3,675,130<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6784890656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 6,078,865<span></span>
</td>
<td class="nump">$ 3,763,010<span></span>
</td>
<td class="nump">$ 10,025,516<span></span>
</td>
<td class="nump">$ 7,536,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">134,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember', window );">Prescription Vitamins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">2,822,872<span></span>
</td>
<td class="nump">$ 3,763,010<span></span>
</td>
<td class="nump">4,758,844<span></span>
</td>
<td class="nump">$ 7,536,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyTmMember', window );">IMVEXXY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 3,121,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,132,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyTmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyTmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6765892016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EnrolledPatients', window );">Enrolled patients</a></td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EnrolledPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount that enrolled patients will pay per prescription refill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EnrolledPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6958976208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 4,382,969<span></span>
</td>
<td class="nump">$ 2,908,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">439,993<span></span>
</td>
<td class="nump">339,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw material</a></td>
<td class="nump">2,671,478<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 7,494,440<span></span>
</td>
<td class="nump">$ 3,267,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6958705792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 2,568,100<span></span>
</td>
<td class="nump">$ 5,148,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing fees (Note 9)</a></td>
<td class="nump">550,757<span></span>
</td>
<td class="nump">1,898,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">686,891<span></span>
</td>
<td class="nump">790,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">3,933,300<span></span>
</td>
<td class="nump">2,997,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 7,739,048<span></span>
</td>
<td class="nump">$ 10,834,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6784765056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS, GROSS</a></td>
<td class="nump">$ 2,118,817<span></span>
</td>
<td class="nump">$ 1,026,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(686,680)<span></span>
</td>
<td class="num">(553,630)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS, NET</a></td>
<td class="nump">1,432,137<span></span>
</td>
<td class="nump">472,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Acounting System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS, GROSS</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS, GROSS</a></td>
<td class="nump">581,150<span></span>
</td>
<td class="nump">490,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS, GROSS</a></td>
<td class="nump">940,963<span></span>
</td>
<td class="nump">116,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS, GROSS</a></td>
<td class="nump">220,820<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS, GROSS</a></td>
<td class="nump">$ 74,788<span></span>
</td>
<td class="nump">$ 37,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769902016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 66,556<span></span>
</td>
<td class="nump">$ 40,777<span></span>
</td>
<td class="nump">$ 133,049<span></span>
</td>
<td class="nump">$ 79,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6784356816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (370,338)<span></span>
</td>
<td class="num">$ (384,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">5,058,452<span></span>
</td>
<td class="nump">4,477,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
<td class="nump">4,688,114<span></span>
</td>
<td class="nump">4,092,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,855,279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">1,833,584<span></span>
</td>
<td class="nump">1,855,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTrademarks', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 262,305<span></span>
</td>
<td class="nump">264,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Domestic Utilty Patent - Opera Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,484)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">10 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,962,563<span></span>
</td>
<td class="nump">$ 2,234,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(370,338)<span></span>
</td>
<td class="num">(282,485)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 2,592,225<span></span>
</td>
<td class="nump">$ 1,951,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development Costs Of Corporate Website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (91,743)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6949178080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Year Ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2019 (9 months)</a></td>
<td class="nump">$ 96,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2020</a></td>
<td class="nump">196,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2021</a></td>
<td class="nump">196,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2022</a></td>
<td class="nump">196,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2023</a></td>
<td class="nump">$ 196,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6789803328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative)<br> $ / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 06, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IntangibleWrittenOfff', window );">Intangible written offf</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesMilestonePayments', window );">Sales milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RegulatoryMilestonePaymentDue', window );">Regulatory milestone payment due | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CashUpfrontPaymentDue', window );">Cash upfront payment due | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,826<span></span>
</td>
<td class="nump">$ 88,948<span></span>
</td>
<td class="nump">$ 46,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member', window );">Domestic U.S. Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member', window );">Foreign Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member', window );">Domestic Utility Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents6Member', window );">Foreign Utility Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member', window );">Domestic Patents - TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents7Member', window );">Foreign Patents - TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member', window );">Domestic Utility Patent - Transdermal Patch Candidates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents8Member', window );">Foreign Utility Patent - Transdermal Patch Candidates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Domestic Utilty Patent - Opera Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents11Member', window );">Domestic Utility Patents Topical - Cream Candidates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member', window );">Domestic Patents - TX-009HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents10Member', window );">Foreign Patents Progesterone - Only Candidate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents16Member', window );">Domestic utility patent D-limonene [Member] [Default Label]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementMember', window );">Subscription Agreement [Member] | Knight Therapeutics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of common stock shares (in shares) | shares</a></td>
<td class="nump">3,921,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuanceOfCommonStock1', window );">Gross proceeds</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock sale price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestones', window );">Annual net sales milestones | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestones', window );">Annual net sales milestones | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Payment of milestone recorded as finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member] | ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsUponFDAApproval', window );">Milestone payments upon FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch', window );">Milestone payments (payment after release of first commercial batch)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember', window );">Step-based Royalty Payment One [Member] | Council License Agreement [Member] | ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember', window );">Step-based Royalty Payment One [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember', window );">Step-based Royalty Payment Three [Member] | Council License Agreement [Member] | ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember', window );">Step-based Royalty Payment Three [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember', window );">Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember', window );">Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember', window );">Step-based Royalty Payment Two [Member] | Council License Agreement [Member] | ANNOVERA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualNetSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual net sale milestones in the Territory per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualNetSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CashUpfrontPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash due as an upfront fee per signed agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CashUpfrontPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IntangibleWrittenOfff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>THe amount of intangibles written off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IntangibleWrittenOfff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable after release of first commercial batch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable upon FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetSalesAmountPerStepbasedRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net sales amount as defined in license agreement for step-based royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetSalesAmountPerStepbasedRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromIssuanceOfCommonStock1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromIssuanceOfCommonStock1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RegulatoryMilestonePaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RegulatoryMilestonePaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of the net sales to be paid as royalty per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Territory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6789833440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">$ 5,115,082<span></span>
</td>
<td class="nump">$ 6,854,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">6,340,450<span></span>
</td>
<td class="nump">5,294,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">2,107,696<span></span>
</td>
<td class="nump">2,288,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">1,492,131<span></span>
</td>
<td class="nump">1,178,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">2,077,444<span></span>
</td>
<td class="nump">792,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - short term</a></td>
<td class="nump">1,187,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">367,898<span></span>
</td>
<td class="nump">385,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,402,600<span></span>
</td>
<td class="nump">388,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">2,251,047<span></span>
</td>
<td class="nump">412,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">35,240<span></span>
</td>
<td class="nump">375,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 22,376,617<span></span>
</td>
<td class="nump">$ 18,334,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6770055856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text">

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:80%;font:10pt Times New Roman, Times, Serif;margin:auto">
        <tbody>
<tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">June 30,<br/>2019</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td>
    <td colspan="2" style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">December 31,<br/>2018</div></td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">
        <div style="display:inline;font-weight:bold">&#160;</div></td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="width:50%;text-align:justify;font-family:Times New Roman, Times, Serif">Financing Agreement</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">200,000,000</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;font-family:Times New Roman, Times, Serif">Credit Agreement</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">&#8212;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align:right;font-family:Times New Roman, Times, Serif">75,000,000</td>
    <td style="text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif">
    <td style="text-align:justify;padding-bottom:1pt;font-family:Times New Roman, Times, Serif">Debt discount and financing fees</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(5,904,780</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td>
    <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 1pt solid;text-align:right;font-family:Times New Roman, Times, Serif">(1,618,986</td>
    <td style="padding-bottom:1pt;text-align:left;font-family:Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif">
    <td style="text-align:left;padding-bottom:2pt;padding-left:0.125in;font-family:Times New Roman, Times, Serif">TOTAL LONG-TERM DEBT</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">194,095,220</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-bottom:2pt;font-family:Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom:Black 2pt double;text-align:left;font-family:Times New Roman, Times, Serif">$</td>
    <td style="border-bottom:Black 2pt double;text-align:right;font-family:Times New Roman, Times, Serif">73,381,014</td>
    <td style="padding-bottom:2pt;text-align:left;font-family:Times New Roman, Times, Serif">&#160;</td></tr></tbody>
</table>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div>

<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">&#160;</div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and financing fees</a></td>
<td class="num">$ (5,904,780)<span></span>
</td>
<td class="num">$ (1,618,986)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">TOTAL LONG-TERM DEBT</a></td>
<td class="nump">194,095,220<span></span>
</td>
<td class="nump">73,381,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowings outstanding</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowings outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6789686720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationOfDeferredFinancingFees', window );">Amortization of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,734<span></span>
</td>
<td class="nump">$ 196,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DeferredFinancingFees', window );">Deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,652,270<span></span>
</td>
<td class="nump">6,652,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,985,000<span></span>
</td>
<td class="nump">3,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 316,880<span></span>
</td>
<td class="nump">$ 30,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentFeePercent', window );">Repayment fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFee', window );">Prepayment fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentOfDebtWithNewCreditFacility', window );">Repayment of debt with new credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowings outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationOfDeferredFinancingFees', window );">Amortization of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowings outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,816,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtTrancheAxis=txmd_TrancheOneMember', window );">Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DeferredFinancingFees', window );">Deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,101,513<span></span>
</td>
<td class="nump">6,101,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowings outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity under loan facility</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of Interest Rate</a></td>
<td class="text">ne-month LIBOR (subject to a LIBOR floor of1.50%) plus (ii)7.75% per annum<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread of loan</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloor', window );">LIBOR floor</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3-month
LIBOR plus7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FacilityFeePaidPercent', window );">Facility fee paid (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of Credit Facility, Current Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of Credit Facility, Current Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Subsequent Event [Member] | TSPP Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity under loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfTranchesUnderTermLoanFacility', window );">Number of tranches under term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Rate [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrimeRateFloor', window );">Prime rate floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the
prime rate plus6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">First Two Years [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentPercentOfDebt', window );">Prepayment percent of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Year Three [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentPercentOfDebt', window );">Prepayment percent of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Year Four [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentPercentOfDebt', window );">Prepayment percent of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Year Five [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentPercentOfDebt', window );">Prepayment percent of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmortizationOfDeferredFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amortization of deferred financing fees incurred and amortized over the term of the debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AmortizationOfDeferredFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FacilityFeePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FacilityFeePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum LIBOR rate under credit and security agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents libor floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfTranchesUnderTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seperate tranches under terms of the Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfTranchesUnderTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentPercentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of debt allowed to be prepaid per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentPercentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrimeRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prime rate floor as defined in agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrimeRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents repayment fee percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentOfDebtWithNewCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentOfDebtWithNewCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_Tranche3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_Tranche3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_Tranche2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_Tranche2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6772501408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">24,945,040<span></span>
</td>
<td class="nump">28,218,470<span></span>
</td>
<td class="nump">24,945,040<span></span>
</td>
<td class="nump">28,218,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">22,072,469<span></span>
</td>
<td class="nump">25,210,899<span></span>
</td>
<td class="nump">22,072,469<span></span>
</td>
<td class="nump">25,210,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6777119952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - minimum</a></td>
<td class="nump">2.19%<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - maximum</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility - minimum</a></td>
<td class="nump">61.25%<span></span>
</td>
<td class="nump">61.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility - maximum</a></td>
<td class="nump">61.85%<span></span>
</td>
<td class="nump">64.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6959532320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options, Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding beginning</a></td>
<td class="nump">20,872,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,544,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(288,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="num">(56,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding ending</a></td>
<td class="nump">22,072,469<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Exercisable ending</a></td>
<td class="nump">17,125,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested ending</a></td>
<td class="nump">4,946,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding beginning</a></td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">4.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="nump">5.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding ending</a></td>
<td class="nump">4.95<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Exercisable ending</a></td>
<td class="nump">4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Unvested ending</a></td>
<td class="nump">$ 5.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Options, Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Exercisable ending</a></td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Unvested ending</a></td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options outstanding, Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding beginning</a></td>
<td class="nump">$ 12,239,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">1,315,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding ending</a></td>
<td class="nump">3,945,665<span></span>
</td>
<td class="nump">$ 12,239,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and Exercisable ending</a></td>
<td class="nump">$ 3,945,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6784825520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="nump">$ 1,084,939<span></span>
</td>
<td class="nump">$ 44,056<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercised', window );">Number of stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,097<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">9,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="nump">$ 1,084,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,128,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercised', window );">Number of stock options exercised (in shares)</a></td>
<td class="nump">249,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6772845632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,224,212<span></span>
</td>
<td class="nump">$ 4,128,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized estimated compensation expense</a></td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.80%<span></span>
</td>
<td class="nump">62.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="nump">2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">$ 56,172<span></span>
</td>
<td class="nump">$ 164,840<span></span>
</td>
<td class="nump">$ 141,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized estimated compensation expense period recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6783863056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PlanAwardsNumberOfNewShares', window );">Plan Awards Number of New Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,362,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,362,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,812,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,812,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">weighted average grant date (in dollars per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,230,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,212,241<span></span>
</td>
<td class="nump">$ 4,374,069<span></span>
</td>
<td class="nump">$ 3,872,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,224,212<span></span>
</td>
<td class="nump">$ 4,128,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized estimated compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OptionExercisePrices', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OptionExercisePrices', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,072,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,072,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,544,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized estimated compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PlanAwardsNumberOfNewSharesUnallocated', window );">Plan Awards Number Of New Shares Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,393,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,393,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,317,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PlanAwardsNumberOfNewSharesUnallocated', window );">Plan Awards Number Of New Shares Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,116,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,116,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OptionExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OptionExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PlanAwardsNumberOfNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares authorized for stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PlanAwardsNumberOfNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PlanAwardsNumberOfNewSharesUnallocated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unallocated shares previously available for issuance under the award plan that were not then subject to outstanding Awards as defined in the Plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PlanAwardsNumberOfNewSharesUnallocated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6772823648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Manufacturing activities billed from related party</a></td>
<td class="nump">$ 974,000<span></span>
</td>
<td class="nump">$ 1,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable - related party</a></td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Manufacturing activities billed from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,371,000<span></span>
</td>
<td class="nump">$ 2,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6772837856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Products Supplier #1 [Member] | Four Major Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Products Supplier #1 [Member] | One Major Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRiskOneMember', window );">Products Supplier #2 [Member] | Four Major Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRiskTwoMember', window );">Products Supplier #3 [Member] | Four Major Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRisk4Member', window );">Products Supplier #4 [Member] | Four Major Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration [Member] | Sales Revenue [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk7Member', window );">Customer Concentration - PI Services [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 981,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member', window );">Customer Concentration - Pillpack [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,615,000<span></span>
</td>
<td class="nump">2,088,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member', window );">Customer Concentration - AmerisourceBergen [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,365,000<span></span>
</td>
<td class="nump">1,283,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member', window );">Customer Concentration - Cardinal Health [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,048,000<span></span>
</td>
<td class="nump">$ 971,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=txmd_FourMajorCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=txmd_FourMajorCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=txmd_OnerMajorCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=txmd_OnerMajorCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRiskOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRiskOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRiskTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRiskTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRisk4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierConcentrationRisk4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6788895056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 3,316,436<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability</a></td>
<td class="nump">1,187,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">$ 2,488,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities for operating lease</a></td>
<td class="nump">$ 564,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">$ 3,760,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6769960016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Years ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 595,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,292,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">1,135,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">172,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">176,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,228,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">4,602,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount', window );">Less: Imputed interest</a></td>
<td class="num">(927,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 3,675,130<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of computed imputed interest for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6768343360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="nump">$ 515,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">295,000<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReimbursementFromLandlordTenantImprovements', window );">Reimbursement from landlord - tenant improvements</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Estimated fixed future minimum rental commitment</a></td>
<td class="nump">13,300,000<span></span>
</td>
<td class="nump">13,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum', window );">Estimated variable future minimum rental commitment</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated variable future minimum rental payments for operating lease over the term of the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReimbursementFromLandlordTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount reimbursable from the landlord for tenant improvements per lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReimbursementFromLandlordTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^%V'KM=F:?VQ\%NQ:^'47W1=02P,$%     @ #'@)3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M%]"Y#X+X#'[8 29X8MB^0G(5\E4X)JB"72ZXB<G/+X0)))C 5A?<R>2EV'K
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M7'.TT]HHNY3TSEKW8/OE\:%2.]/?3NU]>VT:KP]&'X>&.!F[\M4?4$L#!!0
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MP"Q.C+QBX)I9,LR92#"#<QJ22V,AH^;RNH,L)D 09OG+**N/HUPEJMAZJ3Z
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M=<AKH;S=@F.$.BK4,5-'F13M1%.E')HZH."2!0WN4E(=O94QBCGJT?>)WQ<
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MMS.SVTW?7*;SP.)^*+GY#U!+ P04    "  ,> E/@XW0,[$!  #2 P  &
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MC<>7C?VOC?& 4C97.$(M?K#9D%#[<-SCV8YC-AK>=-,/8O,W+GX#4$L#!!0
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MV/_&& \H97>%(]3A!UL,"8T/QUL\VVG,)L.;?OY!;/G&Y2]02P,$%     @
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M/]AB**A].-[BV4YC-AG>]/,/8LLW+MX!4$L#!!0    (  QX"4\AWQ,#M $
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M!4V(QWL\NVG,)B/8?OY!;/G&Y6]02P,$%     @ #'@)3QC\L-VS 0  T0,
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MX6RG*9L,C_W\@=CRB\O?4$L#!!0    (  QX"4]W<?CTLP$  -(#   9
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M4!JW/=B]&N?+:!C93:.3S/,[^P-02P,$%     @ #'@)3]4J8TNW 0  T@,
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MZ<+QUI_-,&:#X; =?Q";OG'V 5!+ P04    "  ,> E/]/[*?+@!  #2 P
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M%XY?_-E,8S893O?S#R++-R[_ 5!+ P04    "  ,> E/ _(*<+<!  #2 P
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M4[*#LR%VT%J8/R=0..8TH:^.)]FT+CA8D?6B@>_@?O1GXRVVJ%120V<E=L1
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MXP=_-M.838;#?OY!;/G&Q5]02P,$%     @ #'@)3VE <JK& 0  -P0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL;51A;]L@$/TKB!]0'!*W:61;
M:CI-F[1)4:=MGXE]ME'!N(#C]M\7L.MY*5\,=[Q[[^[@G(U*/YL6P*)7*3J3
MX];:_D"(*5N0S-RH'CIW4BLMF76F;HCI-; J!$E!:)+<$LEXAXLL^$ZZR-1@
M!>_@I)$9I&3Z[0A"C3G>X _'$V]:ZQVDR'K6P"^PO_N3=A996"HNH3-<=4A#
MG>.'S>&8>GP _.$PFM4>^4K.2CU[XWN5X\0G! )*ZQF86R[P"$)X(I?&R\R)
M%TD?N-Y_L'\-M;M:SLS HQ)_>67;'.\QJJ!F@[!/:OP&<STI1G/Q/^ "PL%]
M)DZC5,*$+RH'8Y6<65PJDKU.*^_".DXG:3J'Q0/H'$"7@'W0(9-0R/P+LZS(
MM!J1GGK?,W_%FP-UO2F],[0BG+GDC?->"KJ[R\C%$\V8XX2A*\QF01#'ODC0
MF,21?@JG\?!M-,-M"-^NU>_W<8)=E& 7"';_E;B_*C&&N8^+I%&1]#-!FER)
MQ##7G22KBY.@F_!D#2K5T(5Q67F7J7B@X>+_P:>1^LETPSN#SLJZYQ,NN5;*
M@DLEN7&YM&Z*%T- ;?WVSNWU])8GPZI^'E.R_"N*=U!+ P04    "  ,> E/
MKA,^P[<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6QU4]MN
MW" 0_17$!P0OZVVCE6TIFRIJI59:I6KSS-IC&P4\+N!U^O<%[#ANZKX ,YQS
MYL*0C6B>;0O@R(M6G<UIZUQ_9,R6+6AA;["'SM_4:+1PWC0-L[T!44625HPG
MR0>FA>QHD47?V109#D[)#LZ&V$%K87Z?0.&8TQU]=3S*IG7!P8JL%PU\!_>C
M/QMOL46EDAHZ*[$C!NJ<WNV.IS3@(^"GA-&NSB14<D%\#L:7*J=)2 @4E"XH
M"+]=X1Z4"D(^C5^S)EU"!N+Z_*K^$&OWM5R$A7M43[)R;4YO*:F@%H-RCSA^
MAKF> R5S\5_A"LK#0R8^1HG*QI64@W6H9Q6?BA8OTRZ[N(_337J8:=L$/A/X
M0KB-<=@4*&;^23A19 9'8J;>]R(\\>[(?6_*X(RMB'<^>>N]UX(?>,:N06C&
MG"8,7V%V"X)Y]24$WPIQXO_0^39]OYGA/M+W:WKRG_CIID :!=*_2MR_*W$+
MD[X+PE8]U6":.$V6E#AT<9)7WF5@[WA\DS?X-.W?A&ED9\D%G7_9V/\:T8%/
M);GQ(]3Z#[88"FH7CA_]V4QC-AD.^_D'L>4;%W\ 4$L#!!0    (  QX"4_!
M_869MP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;&U3VV[<
M(!#]%<0'!"_KS48KVU(V5=5*K;1*U?:9M<<7A8L+>)W^?0?LN&[J%V"&<\Y<
M&++1V!?7 GCRJJ1V.6V][T^,N;(%)=R=Z4'C36VL$AY-VS#76Q!5)"G)>)+<
M,R4Z38LL^BZVR,S@9:?A8HD;E!+V]QFD&7.ZHV^.YZYI?7"P(NM% ]_ ?^\O
M%BVVJ%2= NTZHXF%.J>/N],Y#?@(^-'!Z%9G$BJY&O,2C,]53I.0$$@H?5 0
MN-W@":0,0IC&KUF3+B$#<7U^4_\8:\=:KL+!DY$_N\JW.7V@I():#-(_F_$3
MS/4<*)F+_P(WD @/F6",TD@75U(.SALUJV J2KQ.>Z?C/DXW_#C3M@E\)O"%
M\!#CL"E0S/R#\*+(K!F)G7K?B_#$NQ/'WI3!&5L1[S!YA]Y;P0^'C-V"T(PY
M3QB^PNP6!$/U)03?"G'F_]'Y-GV_F>$^TO=K>I)N"Z2; FD42/\I\?Y=B5N8
MX[L@;-53!;:)T^1(:08=)WGE70;VD<<W^0N?IOVKL$VG';D:CR\;^U\;XP%3
M2>YPA%K\8(LAH?;A>,2SG<9L,KSIYQ_$EF]<_ %02P,$%     @ #'@)3WT+
M9/*W 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&UL;5/;;MP@
M$/T5Q <$+^NDVY5M*9NH:J566J5J^\S:8QL%/"[@=?KW!>RX;N(78(9SSEP8
MLA'-LVT!''G1JK,Y;9WKCXS9L@4M[ WVT/F;&HT6SINF8;8W(*I(THKQ)+EC
M6LB.%EGTG4V1X>"4[.!LB!VT%N;/"12..=W15\>3;%H7'*S(>M' =W _^K/Q
M%EM4*JFALQ([8J#.Z?WN>$H#/@)^2ACMZDQ")1?$YV!\J7*:A(1 0>F"@O#;
M%1Y J2#DT_@]:](E9""NSZ_JGV+MOI:+L/" ZI>L7)O3 R45U&)0[@G'SS#7
M<TO)7/Q7N(+R\)")CU&BLG$EY6 =ZEG%IZ+%R[3++N[C=).F,VV;P&<"7PB'
M&(=-@6+FC\*)(C,X$C/UOA?AB7='[GM3!F=L1;SSR5OOO1;\]I"Q:Q":,:<)
MPU>8W8)@7GT)P;="G/@[.M^F[S<SW$?Z?AV=)]L"Z:9 &@72_TK\^*;$#<S=
MVR!LU5,-IHG39$F)0Q<G>>5=!O:>QS?Y!Y^F_9LPC>PLN:#S+QO[7R,Z\*DD
M-WZ$6O_!%D-![<+Q@S^;:<PFPV$__R"V?./B+U!+ P04    "  ,> E/H_GE
M;\4!   V!   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6QU5-MNVS ,
M_15!'U E<MP&@6V@Z3!TP 8$+;8]*S9]075Q)3GN_KZ2[+I>IKU8(G4.#RF*
MSD:E7TP+8-&;X-+DN+6V/Q!BRA8$,S>J!^E.:J4%L\[4#3&]!E8%DN"$;C:W
M1+!.XB(+OI,N,C58WDDX:60&(9C^<P2NQAQO\8?CJ6M:ZQVDR'K6P#/8G_U)
M.XLL4:I.@#2=DDA#G>/[[>&8>GP _.I@-*L]\I6<E7KQQK<JQQN?$' HK8_
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M,S(N>&UL;53M;ML@%'T5Q ,4AWQUD6VIZ31UTB9%G=;^)O:UC0K&!1QW;S_
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M"KH0MW>X=]-53T&PP_R*V?(KU9]02P,$%     @ #'@)3R @K7'" 0  *00
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M@3NX=^+FJ!4WX1W5%V.5F%2<%4'?QY'), Z3_HVV3D@G0CH3DNR_!#(1R(*
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M7II+K>T$*C<]N\!WT#_ZO30C-+N<FA8ZU8@ND'#>AA_BYXI:O1/\;&!0=_W
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MZ<OQN1H'6O332XSFST'Y%U!+ P04    "  ,> E/$PVDG;8"  !M"@  &0
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M-YMM;4>O6T;8.K@ZH@YSWV+H $/?(G93!"<])+ ">A4454&;>/9&18@3,)2
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M0MSWANR_R:,L-+QCHF.L5-&87V]U:%I5#EXTE3)[Z9]Y99ZG_A_Q:H8;P&
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MJ"\CO1)W)(!?0?"K0 \7@#PQ8N\J 'EBR-Y5$/M2/R-]$G<DZ#:6X%>!U5D
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M]3!58S[VO7$B63^U=&_^7ZE^ 5!+ P04    "  ,> E/8"'\9*@$  !!&@
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MD$32I*$HE#1FB !XD(%V4 1^$H'*E[0A'$43EN<4I6L+TT0 4,C0;ST,"@%
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M965T<R]S:&5E=#0W+GAM;)56[8[:,!!\E2@/<+$=YP,4D(!0M5(KH:NN_6W
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M8M</KYEZ;\<+R3CHY=%<MJ++C6_Y%U!+ P04    "  ,> E/*Z+9$>@"  #
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M(=>L/_[[C:"MN=G <+UF_P!02P,$%     @ #'@)3RB8U<\@ P  4PX  !D
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MK.^KMLUI!TJ670OG]7WD\A]02P,$%     @ #'@)3XNEVYQ& @  Q@8  !D
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ME6E!X2SU-%%S/G3682%9-]X:WG1U%?\ 4$L#!!0    (  QX"4]<^#NM2 (
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M;N\$_M_MUK '7SP#T@6@6=3P931NP97P;+$ T)61_A&^AR,,[Q[SVF5Y2 L
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M_6?80EO;%S48[5G53V%_V(OZ_5XT'79I0?UA-QJ.^]%P<-JRSOVW&:@AR3(
M\DV<+DY K9G'FQ2.H 'M=NO=BH2Z10*,OPWW2^]\$CJ?9P^95GW(FWLI,/ /
M0.6'9 MBR6H/%2;N01(#T,!W:09$,D6NGHM@UZY(G>VGJ<^@H<M-CP#4BWRU
MBHO2LM3:2FL#6&38AUHOG\A_^]!9&.7V/]-^9_S#O+V#?SY<7,%!7K\+KV]
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M5 E^,I0*\1H09I'#D,!"5S[QRC-<$ZZF:#&TXO;PE+VW?(PP2^D 6P'5$>;
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M;^KM)[;FG'0G9-^%HUSA@I2]R#5&^)5.&(IQ5Z$#&716>"M_2A)")!"?[^E
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M9MP<E" \+GO.%2J$)O&3[=-&/1D%GJEU>:_,$3BD_?";2-OX_E=1>-2>&]@
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M<CON<N05&#Q<V0_SF$6R2>?&<D]J])(S?.L69;*I,6292:Y5AB2HZ"!BNSX
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M8[1H<_,HWPM1/EE4SXB8?<+9Z>Q-(S52["HKLIHD,=U+ T^&=5J E(>GA5+
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M7]8+;E/5CG5*:Z_48!1>& 6A$70Q;B-<N+==?;LJ<A&Y07)/^"&704B,7MF
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M)D6N2CA5F+LKZ+8_A;,<2SP\4@"KR732LC>2- 6[HPNLA-G)X;"9&U9-7#B
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M98A6+#A3 P$=A:U$4HO$J)M4_U0]!"@-^^]TPG,%/WD_6ABXV EMM+U'^Q^
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MVW<5*_Q0S%0S;51E% 2@*G9%6IH-ZD!^8&]PF["Z]M%X**2B*^LD#$^^($R
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M:[45P<A3X)X6V]@<8&@@"M<XSY%*JQPOXM)WA9!;9)K->Z;_#X"E<.J98=!
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MMQB9P.%S("!M.+RFVNL.,\KBRFJK>/3B0 </)36GGPNQ+.0V^D09TC^I,XS
M#$$MVB;QB0B@NY4(9/\TQDH*Z#HB52Y"A^,+Z".A#3FIT#9NMK^R7"1F?16N
MV%#)5^9CH:(2W'U'#MPF]F,>=(WJ4872KA*57I<:?P0ZKMRFR(\TA1@3]=UW
MR;) VH9PG* K2>Z,2MR+>S%?BV@//)%?F99&@9>4N_)GE>\(. 9#*[%(!_ZJ
M;$[=H RF)2(X]&IN0J#F/A'+VD@HMUP:&3;/37GL1JZ%;.G%E#AB5X_N4T%'
M*M2':O8QR12I0,O60_RN IJP\"YMS^3ZRTFKH3):9N#NFFMFLQ.F5B[5ZT$2
M+%P?>8"T)H@=FFNU0+'6$)" ;N\1J ^<!&]^6X%YXWQW@KS(=LEY,7/_D$-\
MHXU )VOUKJS,7$&++D4PD%!$.0%\(B#_<B<G*!JJ88\- WO)E,*)<*H<?$"D
M[62J$=L =J(8Q\)06Y'P7X,:/6P6S\)'A/&C@KTHB 0+Z5"@.%P/RL+Z!<[5
MCKE="3$*T^%V"M%/Y4AK8T-1&DMQ?5J5NBJW+^>/;-F8+TE&7:)3A>+5!2)X
M(?R="IG,YZIB65%3(8J3HZE?/E12K):L@FN) FE!/)-A5;;EOIHT1WFIZ@W+
M,2B Y$!5V!$0-$*Y;)<RVE(@7VG*MYC$!HL*,PU]0-H<KMA7TG3HY.HU',06
MLY6K9?[>,6+YID1H,XH --*@31%D_+RB@VIUT[7+//.G/_#_M3]P=/UQ>#T;
M RFUH1,)+3&KPPK,"8?IJHK.@CA^\N0.5-)]7F""70WO[K_QDDZ<1YVB7WA8
M;ZX(\DZ1YM[/*. LI8CI)7'1*8K8B^'_.(R\R?Q%FG;@M7X6=I(L]T W38+
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MW15%L'I1X.=!)PI#CXIQ?$;8JYYEV\^ H>6Y'V>=/ >^V E#8#,A[GL0]>'
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M1N]?BV*]K$GW<5S"#,)N?6+[4!2QWI>4\TKTK^QTUSB]"_7I7U!+ P04
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MO>&>*%W&55(X/R\.X7GJ1T3X](>4Q[]02P,$%     @ #'@)3]<FG)W< 0
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M'_/9\/^1Q1M02P$"% ,4    "  ,> E/'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    "  ,> E/)^B'#H(   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   (  QX"4]1=\L\[P   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    (  QX"4^97)PC$ 8  )PG   3
M      "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ #'@)
M3Y5MTAU' P  H0\  !@              ( !^ @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    (  QX"4^1_[]<(@0   H2   8
M      "  74,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  ,> E/^3_%^C,"   Y!P  &               @ '-$   >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ #'@)3P2Q%(N2!   J1,  !@
M             ( !-A,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    (  QX"4^IR3J G@4  -\=   8              "  ?X7  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  ,> E/^4=S%*D$  "@
M%   &               @ '2'0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ #'@)3X.-T#.Q 0  T@,  !@              ( !L2(
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (  QX"4^+/@[C
MM $  -(#   8              "  9@D  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  ,> E/L# =K[4!  #2 P  &
M@ &")@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ #'@)
M3\7'([BV 0  T@,  !D              ( !;2@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  ,> E/E#V\+;4!  #2 P  &0
M        @ %:*@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   (  QX"4\.H6S>M $  -(#   9              "  48L  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ #'@)3PTCA(.U 0  T@,
M !D              ( !,2X  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  ,> E/7TW4\+,!  #2 P  &0              @ $=,
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  QX"4_A,K[6
MM0$  -(#   9              "  0<R  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ #'@)3R'?$P.T 0  T@,  !D
M ( !\S,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  ,
M> E/&/RPW;,!  #1 P  &0              @ '>-0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  QX"4]W<?CTLP$  -(#   9
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M970R,BYX;6Q02P$"% ,4    "  ,> E/U2IC2[<!  #2 P  &0
M    @ &E00  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M  QX"4_T_LI\N $  -(#   9              "  9-#  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ #'@)3P/R"G"W 0  T@,  !D
M             ( !@D4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  ,> E/6F72=;<!  #2 P  &0              @ %P1P  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (  QX"4]I0'*JQ@$
M #<$   9              "  5Y)  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ #'@)3ZX3/L.W 0  T@,  !D              ( !
M6TL  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  ,> E/
MP?V%F;<!  #2 P  &0              @ %)30  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    (  QX"4]]"V3RMP$  -(#   9
M      "  3=/  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ #'@)3Z/YY6_% 0  -@0  !D              ( !)5$  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  ,> E/58C!0,(!   W!
M&0              @ $A4P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    (  QX"4]J'Y)LF0$  %8#   9              "  1I5  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ #'@)3R @K7'"
M 0  *00  !D              ( !ZE8  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  ,> E/!/>2@GL"   C"   &0
M@ 'C6   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  QX
M"4]S+7ROZP$  $,%   9              "  95;  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ #'@)3_(?$SP' @  A@4  !D
M         ( !MUT  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    "  ,> E/49AH/2<"   :!@  &0              @ 'U7P  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  QX"4\3#:2=M@(  &T*
M   9              "  5-B  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ #'@)3\X>OMT7 @  F 4  !D              ( !0&4
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  ,> E/".ZW
M@'$#   [#P  &0              @ &.9P  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    (  QX"4_ZJ@? V@$  /P$   9
M  "  39K  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M#'@)3[L]D#[&!0  S"0  !D              ( !1VT  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  ,> E/4KSRG,<"  #0"0  &0
M            @ %$<P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    (  QX"4\>-S7=, (  &,&   9              "  4)V  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ #'@)3V A_&2H!
M01H  !D              ( !J7@  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    "  ,> E/?<N^3Y@"  "/"0  &0              @ &(
M?0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (  QX"4\J
MPL3G<P(  /,(   9              "  5>   !X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ #'@)3QBF_4A7 P  _0T  !D
M     ( ! 8,  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  QX"4\HF-7/( ,  %,.   9              "
M <>4  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ #'@)
M3XNEVYQ& @  Q@8  !D              ( !'I@  'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    "  ,> E/7/@[K4@"   E!P  &0
M        @ &;F@  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   (  QX"4^)T-0$)P(  'H&   9              "  1J=  !X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ #'@)3S4C-P5FAP  F/4!
M !0              ( !>)\  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ #'@)3[]$U2ED @  @ P   T              ( !$"<! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  ,> E/TDDG]X0$  "/)0  #P
M    @ &?*0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ #'@)3\VC$6(#
M @  H"(  !H              ( !4"X! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ #'@)3]<FG)W< 0  1R(  !,
M ( !BS ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $( 0@  $@  F#(!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>166</ContextCount>
  <ElementCount>353</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNet</Role>
      <ShortName>FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0025 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0026 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0027 - Disclosure - FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetTables</Role>
      <ShortName>FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0028 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0030 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0031 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0032 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0034 - Disclosure - THE COMPANY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/THECOMPANYDetails</Role>
      <ShortName>THE COMPANY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Company</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0035 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0038 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/InventoryTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0039 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0040 - Disclosure - FIXED ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetails</Role>
      <ShortName>FIXED ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0041 - Disclosure - FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative</Role>
      <ShortName>FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0042 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0043 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0044 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0045 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0046 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/DebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0047 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/DebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0048 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0049 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0050 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0053 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0054 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0055 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0056 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-10q_063019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="txmd-10q_063019.htm">txmd-10q_063019.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex10-3.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>txmd-20190630.xsd</File>
    <File>txmd-20190630_cal.xml</File>
    <File>txmd-20190630_def.xml</File>
    <File>txmd-20190630_lab.xml</File>
    <File>txmd-20190630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-10q_063019.htm": {
   "axisCustom": 2,
   "axisStandard": 21,
   "contextCount": 166,
   "dts": {
    "calculationLink": {
     "local": [
      "txmd-20190630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20190630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "txmd-10q_063019.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20190630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20190630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20190630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 512,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 52,
   "keyStandard": 301,
   "memberCustom": 42,
   "memberStandard": 30,
   "nsprefix": "txmd",
   "nsuri": "http://therapeuticsmd.com/20190630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "role": "http://therapeuticsmd.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - INVENTORY",
     "role": "http://therapeuticsmd.com/role/Inventory",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - OTHER CURRENT ASSETS",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssets",
     "shortName": "OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - FIXED ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNet",
     "shortName": "FIXED ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - INTANGIBLE ASSETS",
     "role": "http://therapeuticsmd.com/role/IntangibleAssets",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - OTHER CURRENT LIABILITIES",
     "role": "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES",
     "shortName": "OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - DEBT",
     "role": "http://therapeuticsmd.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - NET LOSS PER SHARE",
     "role": "http://therapeuticsmd.com/role/NetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://therapeuticsmd.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - INCOME TAXES",
     "role": "http://therapeuticsmd.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - RELATED PARTIES",
     "role": "http://therapeuticsmd.com/role/RelatedParties",
     "shortName": "RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - BUSINESS CONCENTRATIONS",
     "role": "http://therapeuticsmd.com/role/BusinessConcentrations",
     "shortName": "BUSINESS CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0025 - Disclosure - INVENTORY (Tables)",
     "role": "http://therapeuticsmd.com/role/InventoryTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0026 - Disclosure - OTHER CURRENT ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsTables",
     "shortName": "OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0027 - Disclosure - FIXED ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetTables",
     "shortName": "FIXED ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0028 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables",
     "shortName": "OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0030 - Disclosure - DEBT (Tables)",
     "role": "http://therapeuticsmd.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0031 - Disclosure - NET LOSS PER SHARE (Tables)",
     "role": "http://therapeuticsmd.com/role/NetLossPerShareTables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0032 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0034 - Disclosure - THE COMPANY (Details)",
     "role": "http://therapeuticsmd.com/role/THECOMPANYDetails",
     "shortName": "THE COMPANY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0035 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
     "shortName": "BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630_srtProductOrServiceAxis_txmdBijuvaMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ShelfLifeOfPrescriptionProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ShelfLifeOfPrescriptionProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0038 - Disclosure - INVENTORY (Details)",
     "role": "http://therapeuticsmd.com/role/InventoryDetails",
     "shortName": "INVENTORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0039 - Disclosure - OTHER CURRENT ASSETS (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails",
     "shortName": "OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0040 - Disclosure - FIXED ASSETS, NET (Details)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetDetails",
     "shortName": "FIXED ASSETS, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0041 - Disclosure - FIXED ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative",
     "shortName": "FIXED ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0042 - Disclosure - INTANGIBLE ASSETS (Details)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0043 - Disclosure - INTANGIBLE ASSETS (Details 1)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsDetails1",
     "shortName": "INTANGIBLE ASSETS (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:IntangibleWrittenOfff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0044 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:IntangibleWrittenOfff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0045 - Disclosure - OTHER CURRENT LIABILITIES (Details)",
     "role": "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails",
     "shortName": "OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0046 - Disclosure - DEBT (Details)",
     "role": "http://therapeuticsmd.com/role/DebtDetails",
     "shortName": "DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "txmd:AmortizationOfDeferredFinancingFees",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:AmortizationOfDeferredFinancingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0047 - Disclosure - DEBT (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/DebtDetailsNarrative",
     "shortName": "DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "txmd:AmortizationOfDeferredFinancingFees",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:AmortizationOfDeferredFinancingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0048 - Disclosure - NET LOSS PER SHARE (Details)",
     "role": "http://therapeuticsmd.com/role/NetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630_srtRangeAxis_srtMaximumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0049 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630_srtRangeAxis_srtMaximumMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0050 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
     "shortName": "STOCKHOLDERS' EQUITY (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630usgaapEmployeeStockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "AsOf2017-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "From2018-01-01to2018-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS' EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "0",
      "lang": null,
      "name": "txmd:NumberOfStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0053 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
     "shortName": "STOCKHOLDERS' EQUITY (Details Narrative 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "lang": "en-US",
      "name": "txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PlanAwardsNumberOfNewShares",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0054 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
     "shortName": "STOCKHOLDERS' EQUITY (Details Narrative 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0055 - Disclosure - RELATED PARTIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative",
     "shortName": "RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0056 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
     "shortName": "BUSINESS CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0057 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0058 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0059 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190401to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherNoncashExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - THE COMPANY",
     "role": "http://therapeuticsmd.com/role/Company",
     "shortName": "THE COMPANY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "role": "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements",
     "shortName": "BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_063019.htm",
      "contextRef": "C_20190101to20190630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity's Reporting Status Current"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r115",
      "r171",
      "r174",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r114",
      "r171",
      "r173",
      "r284",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products and Services [Axis]",
        "verboseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 90.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 60.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AllowanceForWholesaleDistributorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 100.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Allowance for wholesale distributor fees"
       }
      }
     },
     "localname": "AllowanceForWholesaleDistributorFeesCurrent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AmortizationOfDeferredFinancingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amortization of deferred financing fees incurred and amortized over the term of the debt.",
        "label": "Amortization of deferred financing fees"
       }
      }
     },
     "localname": "AmortizationOfDeferredFinancingFees",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The drug name.",
        "label": "ANNOVERA [Member]"
       }
      }
     },
     "localname": "AnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AnnualNetSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual net sale milestones in the Territory per license agreement.",
        "label": "Annual net sales milestones"
       }
      }
     },
     "localname": "AnnualNetSalesMilestones",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Approved Hormone Therapy Drug Candidate Patents [Member]"
       }
      }
     },
     "localname": "ApprovedHormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis Of Presentation And Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "xbrltype": "stringItemType"
    },
    "txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract": {
     "auth_ref": [],
     "localname": "BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrativeAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "xbrltype": "stringItemType"
    },
    "txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_BijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BIJUVA [Member]"
       }
      }
     },
     "localname": "BijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CapitalLeaseObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total term (in months) of the company's outstanding lease obligation.",
        "label": "Non-cancelable operating lease term"
       }
      }
     },
     "localname": "CapitalLeaseObligationsTerm",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_CashUpfrontPaymentDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash due as an upfront fee per signed agreement.",
        "label": "Cash upfront payment due"
       }
      }
     },
     "localname": "CashUpfrontPaymentDue",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date the warrants or rights are expired in CCYY-MM-DD format.",
        "label": "Expiration date of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "dateItemType"
    },
    "txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date the warrants or rights are vesting date in CCYY-MM-DD format.",
        "label": "Vesting date of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightVestingDateOfWarrantsOrRights",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "dateItemType"
    },
    "txmd_CouncilLicenseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "Council License Agreement [Member]"
       }
      }
     },
     "localname": "CouncilLicenseAgreement1Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationRisk2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration - Pillpack [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRisk2Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationRisk3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration - AmerisourceBergen [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRisk3Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationRisk4Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration - Cardinal Health [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRisk4Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationRisk5Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration - McKesson Corp [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRisk5Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationRisk7Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration - PI Services [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRisk7Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DebtTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portions of the Credit and Security Agreement to draw funds.",
        "label": "Debt Tranche [Axis]",
        "verboseLabel": "VitaMed Promissory Notes [Axis]"
       }
      }
     },
     "localname": "DebtTrancheAxis",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_DebtTrancheDomain": {
     "auth_ref": [],
     "localname": "DebtTrancheDomain",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DeferredFinancingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred financing fees"
       }
      }
     },
     "localname": "DeferredFinancingFees",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "xbrltype": "stringItemType"
    },
    "txmd_EnrolledPatients": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount that enrolled patients will pay per prescription refill.",
        "label": "Enrolled patients"
       }
      }
     },
     "localname": "EnrolledPatients",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_FacilityFeePaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.",
        "label": "Facility fee paid (percent)"
       }
      }
     },
     "localname": "FacilityFeePaidPercent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_FinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of financing agreement.",
        "label": "Financing Agreement [Member]"
       }
      }
     },
     "localname": "FinancingAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FiveMajorCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Five Major Customers [Member]"
       }
      }
     },
     "localname": "FiveMajorCustomersMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FourMajorCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Four Major Customers [Member]"
       }
      }
     },
     "localname": "FourMajorCustomersMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_HormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Hormone Therapy Drug Candidate Patents - (Pending) [Member]"
       }
      }
     },
     "localname": "HormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyTmMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about ImvexxyTm.",
        "label": "IMVEXXY [Member]"
       }
      }
     },
     "localname": "ImvexxyTmMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_IntangibleWrittenOfff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "THe amount of intangibles written off.",
        "label": "Intangible written offf"
       }
      }
     },
     "localname": "IntangibleWrittenOfff",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_InterestonlyPeriodExtension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of months extended of interest-only period .",
        "label": "Interest-only period extension"
       }
      }
     },
     "localname": "InterestonlyPeriodExtension",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_KnightTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about Knight Therapeutics Inc.",
        "label": "Knight Therapeutics Inc. [Member]"
       }
      }
     },
     "localname": "KnightTherapeuticsIncMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of computed imputed interest for operating lease liability.",
        "label": "LesseeOperatingLeaseLiabilityImputedInterestAmount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityImputedInterestAmount",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LiborFloor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum LIBOR rate under credit and security agreement.",
        "label": "LIBOR floor"
       }
      }
     },
     "localname": "LiborFloor",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LiborFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents libor floor rate.",
        "label": "LIBOR floor rate"
       }
      }
     },
     "localname": "LiborFloorRate",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of license rights.",
        "label": "License rights"
       }
      }
     },
     "localname": "LicenseRights",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LongTermIncentiveCompensationPlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Incentive Compensation Plan 2009 Member.",
        "label": "2009 Long Term Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2009Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.",
        "label": "Maximum costs and expenses for post approval study to be paid by the Company"
       }
      }
     },
     "localname": "MaximumCostsAndExpensesForPostApprovalStudyToBePaid",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MidCapAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of Mid Cap agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "MidCapAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments payable after release of first commercial batch.",
        "label": "Milestone payments (payment after release of first commercial batch)"
       }
      }
     },
     "localname": "MilestonePaymentsAfterReleaseOfFirstCommercialBatch",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsUponFDAApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments payable upon FDA approval.",
        "label": "Milestone payments upon FDA approval"
       }
      }
     },
     "localname": "MilestonePaymentsUponFDAApproval",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.",
        "label": "Minimum cash balance requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MultipleTrademarksForVitaminsSupplementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multiple Trademarks For Vitamins Supplements Member.",
        "label": "Multiple Trademarks [Member]"
       }
      }
     },
     "localname": "MultipleTrademarksForVitaminsSupplementsMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NetSalesAmountPerStepbasedRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net sales amount as defined in license agreement for step-based royalty payments.",
        "label": "Net sales amount per step-based royalty"
       }
      }
     },
     "localname": "NetSalesAmountPerStepbasedRoyalty",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NewOperatingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about new operating leases.",
        "label": "New Operating Leases [Member]"
       }
      }
     },
     "localname": "NewOperatingLeasesMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NonQualified2012StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Qualified 2012 Stock Incentive Plan Member.",
        "label": "2012 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "NonQualified2012StockIncentivePlanMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to operating lease costs.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to stock options exercised in cashless transaction.",
        "label": "Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfIssuedPatents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents.",
        "label": "Number of issued patents"
       }
      }
     },
     "localname": "NumberOfIssuedPatents",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfStockOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Number of stock options exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercised",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfStockOptionsExercisedInCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options exercised in the cashless transaction.",
        "label": "Number of stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercisedInCashlessExercise",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfSubsidiares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of subsidiaries.",
        "label": "Number of Subsidiares"
       }
      }
     },
     "localname": "NumberOfSubsidiares",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/THECOMPANYDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfTranchesUnderTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of seperate tranches under terms of the Credit Agreement.",
        "label": "Number of tranches under term loan facility",
        "verboseLabel": "Number of tranches under term credit facility"
       }
      }
     },
     "localname": "NumberOfTranchesUnderTermLoanFacility",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "txmd_OnerMajorCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of one major customers.",
        "label": "One Major Customers [Member]"
       }
      }
     },
     "localname": "OnerMajorCustomersMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of estimated variable future minimum rental payments for operating lease over the term of the lease.",
        "label": "Estimated variable future minimum rental commitment"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_OptionExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exercise price of the option.",
        "label": "Option exercise prices (in dollars per shares)"
       }
      }
     },
     "localname": "OptionExercisePrices",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_OtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_OutsideConsultant2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A person who provides consutling services to the Company.",
        "label": "Outside Consultants Warrants [Member]"
       }
      }
     },
     "localname": "OutsideConsultant2Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents10Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Foreign Patents Progesterone - Only Candidate [Member]"
       }
      }
     },
     "localname": "Patents10Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents11Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Domestic Utility Patents Topical - Cream Candidates [Member]"
       }
      }
     },
     "localname": "Patents11Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents15Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to patents.",
        "label": "Multiple Advance Revolving Credit Note (Plato Warrant) [Member]",
        "verboseLabel": "Domestic Patents - TX-009HR [Member]"
       }
      }
     },
     "localname": "Patents15Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents16Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to patents.",
        "label": "Domestic utility patent D-limonene [Member] [Default Label]",
        "verboseLabel": "Foreign Patents Progesterone - Only Candidate [Member]"
       }
      }
     },
     "localname": "Patents16Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Domestic Utility Patents [Member]"
       }
      }
     },
     "localname": "Patents1Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Domestic Utility Patent - Transdermal Patch Candidates [Member]"
       }
      }
     },
     "localname": "Patents2Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Foreign Patents [Member]"
       }
      }
     },
     "localname": "Patents3Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents4Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Domestic Patents - TX-004HR [Member]"
       }
      }
     },
     "localname": "Patents4Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents5Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Domestic U.S. Patents [Member]"
       }
      }
     },
     "localname": "Patents5Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents6Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Foreign Utility Patents [Member]"
       }
      }
     },
     "localname": "Patents6Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents7Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Foreign Patents - TX-004HR [Member]"
       }
      }
     },
     "localname": "Patents7Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents8Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Foreign Utility Patent - Transdermal Patch Candidates [Member]"
       }
      }
     },
     "localname": "Patents8Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Patents9Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Domestic Patents - TX-009HR [Member]"
       }
      }
     },
     "localname": "Patents9Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New 2019 Plan.",
        "label": "Plan 2019 [Member]"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PlanAwardsNumberOfNewShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new shares authorized for stock awards.",
        "label": "Plan Awards Number of New Shares"
       }
      }
     },
     "localname": "PlanAwardsNumberOfNewShares",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_PlanAwardsNumberOfNewSharesUnallocated": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unallocated shares previously available for issuance under the award plan that were not then subject to outstanding Awards as defined in the Plan.",
        "label": "Plan Awards Number Of New Shares Unallocated"
       }
      }
     },
     "localname": "PlanAwardsNumberOfNewSharesUnallocated",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_PrepaidSalesAndMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It refers to the amount of prepaid sales and marketing costs incurred.",
        "label": "Prepaid sales and marketing costs"
       }
      }
     },
     "localname": "PrepaidSalesAndMarketingCostsCurrent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaymentFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "Prepayment fee (percent)"
       }
      }
     },
     "localname": "PrepaymentFee",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentPercentOfDebt": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of debt allowed to be prepaid per agreement.",
        "label": "Prepayment percent of debt"
       }
      }
     },
     "localname": "PrepaymentPercentOfDebt",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrescriptionVitaminsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about Prescription Vitamins.",
        "label": "Prescription Vitamins [Member]"
       }
      }
     },
     "localname": "PrescriptionVitaminsMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PrimeRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prime rate floor as defined in agreement.",
        "label": "Prime rate floor"
       }
      }
     },
     "localname": "PrimeRateFloor",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ProceedsFromIssuanceOfCommonStock1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock1",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RegulatoryMilestonePaymentDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.",
        "label": "Regulatory milestone payment due"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentDue",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ReimbursementFromLandlordTenantImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount reimbursable from the landlord for tenant improvements per lease agreement.",
        "label": "Reimbursement from landlord - tenant improvements"
       }
      }
     },
     "localname": "ReimbursementFromLandlordTenantImprovements",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents repayment fee percent.",
        "label": "Repayment fee (percent)"
       }
      }
     },
     "localname": "RepaymentFeePercent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RepaymentOfDebtWithNewCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.",
        "label": "Repayment of debt with new credit facility"
       }
      }
     },
     "localname": "RepaymentOfDebtWithNewCreditFacility",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ReturnPeriodOfUnsalablePrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the company accepts returns of unsalable prescription products from customers following product expiration.",
        "label": "Return period of unsalable prescription products"
       }
      }
     },
     "localname": "ReturnPeriodOfUnsalablePrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_RoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of the net sales to be paid as royalty per license agreement.",
        "label": "Royalty (percent)"
       }
      }
     },
     "localname": "RoyaltyPercent",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RoyaltyTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Tier of step-based royalty payment.",
        "label": "Royalty Tier [Axis]",
        "verboseLabel": "Number of stock options exercised (in shares) [Axis]"
       }
      }
     },
     "localname": "RoyaltyTierAxis",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_RoyaltyTierDomain": {
     "auth_ref": [],
     "localname": "RoyaltyTierDomain",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SalesDiscountsReturnsAndAllowancesGoods1": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.",
        "label": "Allowance for coupons and returns"
       }
      }
     },
     "localname": "SalesDiscountsReturnsAndAllowancesGoods1",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Territory.",
        "label": "Sales milestone payments"
       }
      }
     },
     "localname": "SalesMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of intangible assets, which may be broken down by major class.",
        "label": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of supplementary lease and cash flow information.",
        "label": "Schedule of supplemental lease information and cash flow information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationAndCashFlowInformation",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Options, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLifeAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire unvested shares reserved for issuance.",
        "label": "Multiple Advance Revolving Credit Note (Plato Warrant) [Member] [Default Label]",
        "periodEndLabel": "Unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.",
        "label": "Warrants: [Default Label]",
        "periodEndLabel": "Unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ShelfLifeOfPrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period shelf life of prescription products from date of manufacture.",
        "label": "Shelf life of prescription products following product expiration"
       }
      }
     },
     "localname": "ShelfLifeOfPrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_StepBasedRoyaltyPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The step-based royalty payment information.",
        "label": "Step-based Royalty Payment One [Member]"
       }
      }
     },
     "localname": "StepBasedRoyaltyPaymentOneMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_StepBasedRoyaltyPaymentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The step-based royalty payment information.",
        "label": "Step-based Royalty Payment Three [Member]"
       }
      }
     },
     "localname": "StepBasedRoyaltyPaymentThreeMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_StepBasedRoyaltyPaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The step-based royalty payment information.",
        "label": "Step-based Royalty Payment Two [Member]"
       }
      }
     },
     "localname": "StepBasedRoyaltyPaymentTwoMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subscription Agreement [Member]"
       }
      }
     },
     "localname": "SubscriptionAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SummaryOfActivityUnder2009And2012PlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Summary of Activity under 2009 and 2012 Plans:"
       }
      }
     },
     "localname": "SummaryOfActivityUnder2009And2012PlansAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_SupplierConcentrationRisk4Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of supplier concentration risk.",
        "label": "Products Supplier #4 [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRisk4Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierConcentrationRiskOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one significant supplier is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services.",
        "label": "Products Supplier #2 [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskOneMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierConcentrationRiskTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one significant supplier is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services.",
        "label": "Products Supplier #3 [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskTwoMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TotalMilestonesPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of eligible milestone payments we may receive per agreement.",
        "label": "Total milestones payments"
       }
      }
     },
     "localname": "TotalMilestonesPayments",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_Tranche2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Tranche 2 [Member]"
       }
      }
     },
     "localname": "Tranche2Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_Tranche3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Tranche 3 [Member]"
       }
      }
     },
     "localname": "Tranche3Member",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche of the Credit Facility Agreement to draw funds.",
        "label": "Tranche 1 [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrants:"
       }
      }
     },
     "localname": "WarrantsAbstract",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item provides the weighted-average contractual remaining life of warrants.",
        "label": "Weighted-average contractual remaining life"
       }
      }
     },
     "localname": "WarrantsAndRightsWeightedAverageContractualRemainingLife",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which warrant holders can acquire the shares reserved for issuance.",
        "label": "Weighted average exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20190630",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AccountingGuidanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Previous accounting guidance and the new accounting guidance."
       }
      }
     },
     "localname": "AccountingGuidanceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 80.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r38",
      "r94",
      "r242",
      "r243",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payable - related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r1",
      "r22",
      "r117",
      "r118",
      "r172"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance for doubtful accounts of $764,102 and $596,602, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued sales and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r42"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 50.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued legal and accounting expense"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r42"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 70.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rent"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r42"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll, bonuses and commission costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r8",
      "r42",
      "r175"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensated absences"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r150"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid in Capital [Member]",
        "verboseLabel": "Additional Paid in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r177",
      "r179",
      "r210",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r179",
      "r204",
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r28",
      "r123",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r63",
      "r82",
      "r226"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 60.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing costs",
        "verboseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r82",
      "r135",
      "r143"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Anti-dilutive shares excluded from earnings per share calculation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r265",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r54"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r180",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "New Corporate Office [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r34",
      "r288",
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.",
        "label": "Increase in cash"
       }
      }
     },
     "localname": "CashPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r93",
      "r168",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r154",
      "r268",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - See Note 15"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r153",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer hardware [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r136",
      "r141",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Domestic Utilty Patent - Opera Software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r220",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r220",
      "r221",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "verboseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r104",
      "r105",
      "r220",
      "r221",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "BUSINESS CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r104",
      "r105",
      "r220",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r102",
      "r104",
      "r105",
      "r106",
      "r220",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r220",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Years ending December 31,"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Basis spread of loan"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r157",
      "r266",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Borrowings outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Description of Interest Rate",
        "verboseLabel": "Description of rate"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r225",
      "r227"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/DebtDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Term Loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r44",
      "r160",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Year Five [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Year Four [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "First Two Years [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Year Three [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r224",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r158",
      "r226"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/DebtDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Debt discount and financing fees"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r53",
      "r226"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt financing fees (Note 9)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r82",
      "r148"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation of fixed assets",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r82",
      "r148"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 20.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Schedule of disaggregated revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss per share, basic and diluted:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized estimated compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized estimated compensation expense period recognition",
        "verboseLabel": "Recognized weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Total unrecognized estimated compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r85",
      "r218",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2019 (9 months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r136",
      "r139",
      "r142",
      "r146",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Year Ending December 31,"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r142",
      "r250"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Payment of milestone recorded as finite-lived intangible asset"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r82",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r96",
      "r263",
      "r269",
      "r283"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r111",
      "r213"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 70.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 80.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 90.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestrictedCash": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.",
        "label": "Increase (Decrease) in Restricted Cash",
        "negatedLabel": "Payment of security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r138",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Net Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r138",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedTrademarks": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trademarks",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedTrademarks",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r134",
      "r140"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Net Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r110",
      "r223",
      "r226",
      "r272"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 20.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r68",
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest expense - debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternetDomainNamesMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.",
        "label": "Development Costs Of Corporate Website [Member]"
       }
      }
     },
     "localname": "InternetDomainNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished product"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r0",
      "r52",
      "r130"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "totalLabel": "TOTAL INVENTORY"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw material"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Rental expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms."
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Reconciliation of undiscounted cash flows for all operating leases to the operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 50.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 40.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 30.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 20.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": 10.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r267",
      "r279"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Borrowing capacity under loan facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r159",
      "r266",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/DebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt",
        "totalLabel": "TOTAL LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r101",
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "THE COMPANY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_CashPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r56",
      "r57",
      "r61",
      "r83",
      "r99",
      "r270",
      "r282"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "ASU 2018-11, Leases [Member]"
       }
      }
     },
     "localname": "NewAccountingPronouncementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Lease liability",
        "totalLabel": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": 40.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability - short term",
        "verboseLabel": "Short-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails",
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability",
        "verboseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails",
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r233",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for amounts included in the measurement of lease liabilities for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r239",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r238",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Estimated fixed future minimum rental commitment"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r18",
      "r264",
      "r275"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r42"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "TOTAL OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid costs"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r180",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "totalLabel": "TOTAL OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r132",
      "r133"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from debt classified as other.",
        "label": "Proceeds from Other Debt"
       }
      }
     },
     "localname": "ProceedsFromOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r207"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r149"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "TOTAL FIXED ASSETS, GROSS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r151",
      "r280"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "totalLabel": "TOTAL FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to prospectively adopted accounting guidance.",
        "label": "Prospective Adoption of New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "ProspectiveAdoptionOfNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r62",
      "r128"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Manufacturing activities billed from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r176",
      "r242",
      "r243",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-term Debt"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherShortTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.",
        "label": "Repayments of Other Short-term Debt"
       }
      }
     },
     "localname": "RepaymentsOfOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r212",
      "r290"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r167",
      "r278"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenues, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r59",
      "r108",
      "r109",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "TSPP Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r237",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Common stock sale price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of potentially dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetails",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r90",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r180",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r185",
      "r193",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of activity of 2009 and 2012 Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of assumptions used in the Black-Scholes Model of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of estimated amortization expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Term Loan [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66",
      "r129"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Sales, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based compensation",
        "verboseLabel": "Share based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period of warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r186",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "weighted average grant date (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Options Outstanding ending",
        "periodStartLabel": "Options Outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r187",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding, ending",
        "periodEndLabel": "Options Outstanding ending",
        "periodStartLabel": "Options Outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Options, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Options outstanding",
        "periodEndLabel": "Options Outstanding ending",
        "periodStartLabel": "Options Outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Vested and Exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Vested and Exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r178",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Cancelled/Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r85",
      "r180",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Volatility rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r199",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Vested and Exercisable ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Vested and Exercisable ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Unvested ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Acounting System [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Cash-Settled Stock Appreciation Rights (SARs) [Member]"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r165",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issue of common stock shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued for exercise of options and warrants, net (in shares)",
        "terseLabel": "Shares issued for exercise of options and warrants, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r165",
      "r167",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares issued for exercise of options, net (in shares)",
        "negatedLabel": "Options Exercised",
        "terseLabel": "Shares issued for exercise of options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued for exercise of options and warrants, net",
        "terseLabel": "Shares issued for exercise of options and warrants, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r165",
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued for exercise of options, net",
        "terseLabel": "Shares issued for exercise of options, net",
        "verboseLabel": "Value of common stock issued during period for stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r125"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity:",
        "verboseLabel": "Stockholders' Equity Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Products Supplier #1 [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r124",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r235",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/NetLossPerShareDetails",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r291": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r292": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r293": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r294": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r295": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r296": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001387131-19-005935-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-19-005935-xbrl.zip
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M)4I^WNFI?IS [&5X)R>I??7<Z;*U.NOA*888Q<E(AN+M5P_4]8M6NT270'E
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MG4LQ#I4/EAT\'5X"BF2?;V0IKY&XX$NB?ST$5WL\0KUR#4A@#6FYT..GA?*
M?U$LS&*'EF&'+0O :9NC3"?+H> "N"5(W.-\#B\T&]_&#.)^7I@9Q@QC #$O
MCS/$0XPQ,QZ72VH#8X4F<G[Q&W 'VMZ==Q=7'3K>/2#> &B=+5*]U^-$C8!X
MN#P#OY FW M/!Q7@-DB)Z,FRCF]5)+'*'_F&GXBFMO+9B!XS71?&,CX*I7<?
M"#&^2[^S:;,V%&+<O:5Y["US'OK9&>9W@\@8_23R\5@EJ/L=81^?./E)_#][
MH!_N[3W[I8VQHE"!M6JFO<3D4W+FT[^GG7?=\^Y-]^+\6K3/3T7W_*9S=7G5
MN6GC=T]]Q?].V;+DKG>S%*+U_F8#K-C9)GCS_A7+)Z>/OYS"88M6%\BL73*H
M;T PL?PAW15-[V:##!@68NYYJ,]-D(ERU M5"XXZ-O1;8#8-@UZ@ 4Y2;ZC\
M/+2BKC7M"+ O;#:,(^!O$7Y+[W>X-D0,4W%<I_A*;!)RUCV^N!)7%'.TKE/R
MY:2LT:'2V"5?-ZAM>)TX54A30<2G*H7A[P+0P;26A$HE&.7VGDL83>SSLT3Q
M.JJ1A!,;B0=.3=3:\(1&/P(YELB<)S4URD>@S?*QBZJH']P&1+Q;P;;8:E=>
MK_[(T0L1TV\T%(^R;PGJ4G2^>$,9@19XK")O"!OSN=EP=5J8UEGF[XHMX[\B
ME1-GDL;(,!(F*3^CD_U6L<XKRW?#1.@^'-6V.VG'*]X]Z? O)=\XZ!"I&.>@
M?*=#GJX4O-+ ;A-DSW@0D9LN5<EMX"E^$=R$PSB-[\2_X@A&]@$F!=KQM;YH
MZT:%BD;3$E<J1^@+ 9,[#N-XU%/)P$Y5J]<@\$8C6+2 WBIO91!*D \BC?/$
M4ZPFT1[ J+/"RK!SP@&-Y 1=)["WL&IP]P2])T#O%%>!B>& JRP)L)>G8Q(P
M:B(?#ZV8A$;"X_54FL)?M/LDXN !J/[#R[1H&_%"D"MR$OD47O>=Z6E/$FTJ
M^@=Z2H%8=P8MQSC;^X=LE,T\Y,5@AL"K30Q&;%F"8-718<80M@-7Q27'*8[$
MH$G&0_D2C. W&-C^_D][>T+NCG9;P$R1CZ2):Q9'!=7?P[3,WJ=H,26P,^,X
M16&_A5_Z*H2I)1,@!GX6&VT^;*BA["GVWN892W;. ?<%MS+$A4$+L^)ZW+ZM
MXVT1.(R"437TUUEJ U[(M/\8YV6D$>]-JXKM?3W+!W8+(W:JN!_>0NZ^8A5@
M.WEAX.1T%T0LNA[XA%3"H/&:/AC<J:%'9P^-DU(;)E.R$8;(QZGT8:]8?.6*
M5LZCH@(*3\+9_,B5OXOST,?YQ_T^13#API'\'1[;D]%G.TZFJ&8CP-OQ%Z'R
M)/:97#13H1S4!O(?.;[B'AH56PZ-;B],I,T&;.16$)!W6:^7%>XH_$':M03<
MDZ=$4+3GXW$(?(Y2XDJAF,3_PL(D9.5QS!2]R@>[K_=^**AG5[2!NFC-?'<@
MY#[CS6&EIX>13E2A4O)0]%)<;CB @S[.1 '#)W^+:V #=)\%,[2F1GQ/UM/K
M(W$QIO/K)WR>UNO7+Q6*M_+^A*@VG*R!-YL,M7]/,E2=!O4WT/?J\>4WVR0S
M#ZQ('RB?Y:"RFXP/O1+&>AEJ;5@;H@+-DJ ?V'BV-7>U,5L+ZU6;RK<2Q8])
MB@^P:*P51$(F+BD5? GI+J0"39DIE1KD;-847'F7!%F&UD-$=9WXDU7_ WY1
MXF/1'*ML;B[$WNX^6+[DOM'$:X9%^66LGK):!D/6X12MCHS %*5@QEA.R(T]
M-T8C./*3#4'3MD5.U@_.AA^]P 9/:M98M:D\BC6P]!AXXI(3&T 6WL,(8.D2
M,;9 !0ZRELF&($?+W5 1<92S]EHP:3"HT8@&Z\&&Y<!6'5@8642M#P@L2$<3
MR9!/>H%QE=AGP_=H_8USS"$$W@O)VNHIH/&^F\THM!E8$;;>1B8.Y1U>@MD=
MH/-GDQ;E4;("@C]0KN9$O'>&*-IY-J1X9$OX\0@'Z^&E> ML+N8AV@ BW%KJ
MFR).0AF,X-5F"< 8&N2AS&(P%WNQ/Z'7XVTC6$S\VEV!.&D)LP!C19 ' K_3
MGJO/47QGXY4++  :Q>1+B_BP0XE$1J0<R" "XV2!9YB?QKK/P(*OKB7%JDWE
M,9*BWX>3B/S!E/#U6*6JE FU_Q:,:WQ"31*K-I6O(PETD-8445.$04F;I04.
M^J6<V8_>-W8KXE'!09,6'QMN&,4/$B 0/.7QL+:?T-&9Q&'( 9[2N3M2&*LP
M[M)414&,KL@(C'<NWA\D<3ZV+EE^SW;+/I+T>8HDL!Z,08 X,C^34M[B0 #?
MNBO>Z90F4DI2KJH@[=FW05=;D: ?8U>D&'R+]7W0_A,5RE*R-'NQ.3VZ_!Q<
M@)9AM:F?:"+F-U3?]>_NM)H-=U[EVHOJ'6)%D*8;8U?UE&97O4TMFTW#P0V,
MVL7B-LX4$-8/<"U0!.E;9J]L?XRAO&4E!U9&@HH$]^!G?HY)(5.AEAUP/[\2
M\]W*&TL;B6Y<>#%?0ZYQF7,V;[/!7SJ9/P6IT**-XQ"45[.I=M<+A0QTJ3@?
ML-T5FY:E>+4>LS,KUBMIQ24-Q$E3VT6<']R$-).1(6:@(OA#9Q5I;8]O3R:4
MNQ3%0MWB4-G(JS3GM#;&9[:CFY%3'DQAP[ TOBND/=CU=Q2-8!\V94=1&,&0
MD+W'D!<FRN$[C-TYJ67XJDWE,3+<I,H#=8RX?\UI7B'0'W.X']8G^RI.Y>NH
MXE+[D+Z!)%YS+41-$:LVE4=1A(5 FJ/KL1[T#@[QR$-J*/L3R9T41>J+FI])
M)K-,X@?MA4?-),A,UH@<X:'FHS,*M!5Z,,>^[;&*&H;/]#?KC:UPM]++\][O
M.D6IT+LXT1=.9IO&4G:0UH2\:E.939UI-FSNS$PRVXS<FJX:*)1YJO76N7%.
M/D9- :LVE8("H@@=N;)4-\\"RJ02ML_/+SYUKMIB*U4#!5N;Q!'&5U0&6_M<
MH28^"85"W=H/P%ZZE3 [&8IT M>.MM$1ZN=>5B2"]6,W/R[XDQW9FI@^[E[O
M4A*?*2W1#:<H3])DGA3&</EEG/,#!'FKPGALDGV*-Q5Y3;;N4FO]!81YQ@6U
MF%D)-@T(LI+5Z-ZLL^H*?R[80RI*%=L+("MWBB^VHMBXU2D!*L_R1&VCA<ZF
M"]90&OO,WD6N[])S6IC\@(E!TQFC>LHC;=;,+B^8X&DN.:^IJ-@H$NW,@I1F
MU&R4PP.T)+J& PN59\@!=^@Y/&*6*K9P[Z9FZX5D;7+MJV\_X@;W@%):&/IP
M'1A5!45@@ 6W9-1A^4D<3L!N'@]3Q)B(80FX)L5/<O05C&",/;!:,SI5<>BX
MH#+41RM3%%8W<.[N",,0>*:UN)(6;A_&7-YJ$]HTM9"7Y*OH3"Q 9C8$\IWH
M;.8QE61&8='O0V=342@J2T9W !A8B=GV9N,N3D)?F.H[4',2W)5(.KF- 6>H
MPD#J,^>)9)"]J9/%W&2Q@SI9;+5(>?58<(EJ'^;[.)9J.:>!3WL-CG3&9T-A
MUAF$IW_E<$X<[A&TTYL6:&#9G5*1E?.$?P1R_S(>Z^,4?LK!Y@U;HAMYNURQ
MH<W5Q2S1PO3D([06]:LVE0HZN\2L"O:+35,9*_U$*29C9,Q7<YQ!YW7P=QQ]
MX3,^I;""S_J.T5Y(?9K1,D"5G,GUJ%*5= "+ DU(A*V2S\1X5T!-[>>AKEJ)
MM-_.Q+\(U4?)Q(-/CKK4PE*$*.]+C]\#SZ"'@_Y)*IE9JIJ:5VTJ#C5GP<Y)
MG"3YF L;SN1=!45CO,DIF""# :ZDH@>51!R^8Q+3Z"@]Q,1))JQ1F\<[=:8<
M 8WS#'3V4< U4KKV[V,4H!1&3&J8U3O-/WJ0XA+#:0'V3VQ[5"BS__;U:PYB
M&@>A+>/'R9F!L \2OBB&@XEAS) Z00L94$.CQ, :O^=)D(+VS8R)R5/529<^
M3#<'DUZE=<[3RDWE,2YN)(\;JM8)TE'!"W/3(QV6,!SA\D!F'H5<,(HC-0&*
M(V./&. A7C#>J@]TYYF]4YSH,+YE@#>OQ-;/W5^"7?1+=G]IB?TW= "=[(H?
M4Y#E1_PO7/GR%=$[_/$:#'R*E:,%FR<)H@[3;YKAF@VW\QU,%7,PR:T/;]TZ
MW*]\P<O#_?V=EX>'>_R6@^I1O-E_LX4@+/MO#O;8]T4CVM^!?]Z"9>\60RZR
M;PAAWVQ<*R]1, <8W^RFX60]GNS'ZS9P;I8$<8;7P@\^_X#2H.6* AI8YXOR
M<L:_20CXS&2\4IA<^S589,$86&:=*H0!,62!%]Q@B6*>3&P:^D6_CPGA\+,1
M<&W&M3&;N_68%;AXUSZIFC00D=JV3HI$#4&=P*ET86O%->B?[ PR2?%@OX64
M\HH3/PU,0T]#:* .\\8&(QV 07IP%ZRT'%J"-QOSEP,6O\^^3\S1'2<QA87T
M<<+9&IB+H%-5#3]EE)=\:_,LN/[2A)WP%147PE( BZC=P?TL<G!X^+9-D\2_
MCMDANC7@0:; GECL2.>&BB2-SGAY2Z>6T=+(_U8Z1] #Z!PD!B^&XD^E)'S,
MM:6B7)DZKD+2)P<Q3I1&@>I;1>F!$RX#SE9W^ =#],%?Y'Q+U#B4GBX8)> C
M3CE&34^'[%A_%*$:@*6<3!W_\S.F=:XW"3;I^PGF#>'?1C2BUXW]S%FF1F,C
M+14*OXBKH=W]8S:D/Q"%3R8VG.A2'M#.* \'9+\5#KNZFF<UIU+HG[8PM]GX
M0..:53[Q')R!DQ W6-Q,:IAQ-\]B28C7NZ]?_F!C+ \]!%@3GW*,'F7G(:_P
M(34-K=I4*FFHHKJ[ L4$"[M ?J"H+"!-9HB'$P2_!*-\I%$:U!<4CQKX4X(I
M[ 5P K<L7 "B1-#[4S&=ZSFEW;&W7Z:!IY<2'T/I,_2'S7# 3_!',B#US"DH
MX=? L90H(YI]"F?T<-"!QB2;(GF35J'/4[V$G3R)/:,!A@$K 7 FF47;@LE:
MS%YA4EWYY+NR(EB<;C<;',EPY7*0IGFE%TRK"L>Q3'P4['R6Z*1._.6=\@FV
MSVSI-<=#[1K(HJ8?:_3H8+&%-B:IE"*TXX3"4^XQO"M^<S>%CB#,,J44]YFC
MMK4 B !G9>(0^IBJZAS_EB;,/HF9;>IIE &=S\RP"]/BBH.*$X%X)8.8HTC.
M=AD29,)#L]1@5_3PJ$1DAXA+$ OMPUG#BB2'LA83&& &0LA #8 E9Y#J^110
M&ZQAF+"V.U[205*350,*NQ]DSI:R"LSCT_.8YLMT5[1G@#$L"H./RA,S B:S
M9D&6PS7S*)PU"4W=4\]P,X/T#I9U(,/5&MS2F1 CA #A)9K9&:J29XW9ZGV:
M)IU;)KG)XNG,<HI.37+VBM-[=\D+;7;#;@]Y<:;6K)B<--LL\PSD+'5 XKHZ
MO1::]ID3*!QMMANWDD&2M,I[/T/4)^83"5>^K<.5;KCRL Y7KA8IKQX++D]I
M9:=[YW9.M)(SB6)/'UY:#@NZ'O\^57V9AYFU<$J5,O.0"K3'Y,IJC0;2W\\3
MHPAI<"FIWTD'Y,Q;Z62DA_!99M &.,;E0.<[(,P]98N-C)E.IW6Y@.!@JU]7
M!Z[D5![C3D=MKMFXEF%5.8GVHE.PL"5"16E<E+2E/Z#9$3*8'W_/'[9;'%]$
M&J,+>W#0H)/,=.QM,1C:!&D7(TJ$[XLMCW0TU3Q-?W(K"K'>:X2(';ZXU"F>
MCA/<*>CW@Y1T:R17U,QC71TF(_8K%+513JJ;,AB3P!&VE)Y#K&[178#HY\!1
MQ8L9Z1 4+%.:YCCF6Q:W7-?HPTMG*[2,V[G9,($J@EYG=9MU51R.?C[>"_:4
M7]2]P:D&ANB81HA_83PC^&+0YDQQ'$PNT$",:-GPI^(A47P':V'"VVB+RCYB
M?$J/!=%#$1'V8T_CLD^5HE&!IEN<Z84RX1Z*'%4Q56TX=X&T:0B2561C=9C@
M"\>RJ_8==?Q;U)NL<JQK_=*6-7W<ZYU=QS@G%Q)*8X2/0ZEK&QEMW(S*X+.H
MHJ?6&2X)&FK:D"ER ]J>K0!T<#%=2J+'8>YGR9E=!$>43, :<#'W*'3EVQ6<
MGBS:1G 6.,C!B?)4  )*HVH4>\,VHR=3,%+U45&L;!F8':$Z#+?8ED%4_,CA
M&AJ_SC+0L#BI34BE/I^I]794>&*:C6E7C+DGUHYE& LB"IIAP@FJY*C2F[*]
M7373I$C,*,-ET$FMMGD+DG@B0[@<8X.923=UMVO:!:"%5EJ68=9H0QLPQ..?
MQF[1.@S+%?FXA*&X6.ZJBPW=R[E_3J@I$ $E9<CO-W/AI<) FOZB%V-U:9&-
MK+_''B@Z9(/)N9,(?D20%7,;A^5ARW-5V+:NY*,KAI->$OAS%[".QZ_:5*8*
MGSGCPW&T17CV6?^;@2P':ANAQZ7DH&&OD]214Y+EZPPP3LU^Q4GG[.RR?8KM
M%O_Y;.\9?;Z^;)^8S_K]=X&?#?%Y>S\L;C>7#=6]N8;J$GMH.VV:]9!I-1_5
M?)E:(B_A.4O;OZU@N]2NN1A;)3']'4.4$?L%%OH_].$;2["L?Q$8>?FD<T\5
M[;ET#ADZ8.D<>,3[BX.UU+*<VF OT 2[FHY7HO%ZS=I/CK57G[=SK(1>F+F0
M*;6)S/R=#O$[^F_'8H=S8T7$2XG8T,T,-KM)VBF2H71_D<5',%U>;3Q45?"3
MM02H)<#?+0%67P10<>'"#,AFI,ZZLV:ESJ73=0LME!*^PG)Z^!M1*'>&7&Q0
M1(=G3,_'B2'=J,/Q':6Z:L%WC?FB16M+.'ZW"N?=(UY?<O-I1X8%I/+B/.$B
M4^,],]TA8A*!V-D@X;XH9*EBJ)U,]T<,8.J%$3D?M3IEWSJE7MV#V(FYCMR2
M!8W]A4>!J9$DW+6_4C<TL)Y32PY\!-@@,:.TZ7 [>G6=(^61BV!V7-?&3$?E
M*XR^[7)OTOI<J,^%O^5<N%VW8T&1C"TB*S8.HTON=>L=BCV8V$#A=MRJ%LZ/
M&$!E#&89POD18[#EF<L3SKOK*:J>IJOM<?%,S0A3-<;S^@@4-Y"O&C[F(RX\
M*TP=X"?TA6:&0DWBX0@I!U[:8:0L<5*'PU=Q*D4^AT,<9PH$7?) ];E#'-<!
MICG23:8$O4C$H_0[K@IO8;LKT,I-,*DUIUD>$IO.Z:@I9M6F\AB!PQ4U?^*A
MR?5B53#L"^$L(XK,+<<TAW'HFS0?-SCM#64 K[;8N#W*S-X*\)S'HEAZ/Z("
M#0.%B;RF+$[_TJ+2H< W45T.X^#91^TF[8\<IZ58L].9SF(.,2:?A?0M$A?X
MM3IFB#H'OY;]5U1-QA]8ZRB+53<8'F1AC=[VM^;S/2(U=7^OSDUU<U-?U+FI
MJT7+J\>#?\G)A!77"*+@39J-D]B?G]]W@^)6[.^;0Z5<)8NW"BPCSA C3@^@
M>+8%NY<I(9M0PH=-&T-/(/F?B@R[HOTO"']T1=6"?M6F8A5FK+*<:6H\W6;<
MEUB,?F\K;^X4GF9NJ_#+!$;!Y2^62K#$A3NYXC-ULG2S8:K,& ._8ZM>YM^,
M5MDXS D90OS83Z2W?T"@^/L_%'ET5=546^R7H,D8MR;H-3+T<G9Y]B26%N9C
M*L:9[8^,' 1F(R8[94-.?YHNO*(Z'A@D[ U5%Z;;I='B""D!S=\6+W</]GYH
M-J9ZW98+?(IU;)5*\BH72VMU53.W3MRBJHB[_38;;IU1T3OYNPRCY8!LAG73
M@I6;2H5HH.!O!1R1:8<M$TX\U9Q"#1N)O\IMOTO5CU1U:DJ\:RI8M:D\1@NA
MRDL/,X_F@])7EL"@$*0PHJZD7(^E6S\J@#T.?L]O[\/R/N[^Z^.GMM@J<)EU
M]9%%<OX:O&Y1#==-QV>S40;L-D]_&*G;-#-"AX7%P[F5:3R*L68]G8S&8'.E
M#R(M4];LHE#+WP71&S/H'P6UO&1$;\Z?KX1:+B-ZSR>+K\+O+I+A[0BRIX+?
M78E!+>9#4-=2<=6F,B45:PC2!R%(>:%V:U)>M:D\1LT+8^\SQD X)' O(B-?
MLLYE(-\Z%?IW'[-D%IC2<B<$IRK/:9%_+2#7F!(2,3B.@^+V3EO!MO8@B%$,
MAA_7QV-A&CN"-'E=,Z 2W'NJ,-I*7I9SDG(R9#FHB4L3CL4\HI>F0UTIA_"*
M#'"+,2PZR>'C0$9TKJ(J,Y0) 4*2\!D2.A3!ZY7R4BB%VAZ_"<'<!=05W,&:
MH7>E!IJ17)MJU(,=C$E[221!(&$>.NJH3O8U <?X,=?IF4P8HSF5_:Y%42DY
MF2*](J)CD:8Z((+C4> !TV&D.66D3(9NE'1P_&8>W8G4:,*_E_""RFBJ"(ZZ
M3K2\?LS9^QKFK*@M-1UUZ<B'WU/GY[3X!:'V/*H;[G.%/R)6J*$,^X(R':PP
MA^,^]1#$F3380D$'#1A5\G7:@_4C*N\11*7QRYS^M4&%@%,RU)GJA0*IH@$V
MS1H8$\<MH=;%V172J)0U_/37>OV(Q_\:B22-DX3$DDS3V.-/W/+Q'J%"/B4.
M#>$)ZVF;?^FVP]K1R.I;$)C*1,#^IZ9U^/Q$JDJX6?*;)&.+Z%<D2$WW(V?T
M)'NI@\=!^<^.[\['-C/2YGC1>SC4:,]!CH;1BUIS(&P1\$4W(G]H6+K !M$W
MZ![;L=U]!-+][%L,XD-H,4<\=@88F-2(!; &L$30$/HK+>9O>]AC'WJ]&-0E
MO7*\' 9T"H<1BR4.E?.&JA=G-E-2ASDK=E(W8K?Y<<ZB)<(96JFW/,+O,**H
M!4[IYZRDU\Z%IY)-ME]GD[G99"_K;++5HN75X\&_Z'CF?/:J(.Z]+>;I\$*X
M(<SLK;'^5W,J1=!">Z6:C5,YJ8;YUSE?7'I*;J9KF>4)I6Q=YQ'^9)H_X-\:
M*!J];=RD8H@2&'XH'%S4)$/K.>3]HK %#O\_<?*9(A4$Y2X) YD?J.'$1: K
M6BDH$L:>U.T^5*!SS!$UFGL$)\K5Y,A5J+&^>]S;Q&:F#YR>&6#L>@9#T OC
M5+7F]RH(0RQGP\97+9O=HF.!J(G@8NG(CD'AG VD5&1&Z3R;:@S\M&4!'6QV
MIG$MPAZ6D?-P%ZMVQKVC;'8!3;#E1;V.*$.-\03-O6$:Z[WI,TP%HY Q$9BV
MC R6'B!&1(AJF84]UP+B+(Y\"N[#-/!:Y(G/JH:G7KFI/.+$T"A$6&HET[G9
MQP\5Q90*68NZU6K02XMYN<T9%C+3S^)&71JL5#$4;DLS'X;L XWR*=ZWVY=X
M72FK]%1Y;+D<[IM^HP&G5 SC//2IV)T!#G7^",46/(W"1#, >X8IO2=#@FE*
MATKI^E0[2F$ ^>TX'18M88TB2&,&>B.90G$$-BJB/43\8KU)!5P?C<">UEO8
M@JPU]43C[J6L%]T[(]+MC:B/$6T#S8UG2G%I ^&)F(/3PI"';@4=H@]RX5O"
M6('4>)5S8YV7NM>/DR#R@K'DM! '.Q^/$LPMQ.'T=9XI7!J/E+B17^RPMFOQ
ML6I3^1KQ02AF]P:437<L..,2RM&!8SV;6(K!;W2HC%MY(5$5G1Y(CB@'16EK
M"(KN+2+)VH#D-CFF#$>G%M>V['!RQ^(4SF'\A1PWQ8@XS*BYOER$[SQQVT7;
M;3:JX'8=MY#S=$X[(M].Z8>6U<S,,.]D E( ?]'HJK@BN@T&,">PDC<D 9P8
MC\Q=@JX7&"G>.#"]QA(7G96Q@BL;HM4LN6I3>11+IL/Y2;S4/+,E; \7 L36
MW6/,J:=C/XA1%)$*?LJ*H&EN6)/'JDWED>31;#AX=/?K?)DV1+AS3<E<8@<_
MVP!4$9PJ("MN!X1I);IAE>T_&;) RR/$_0@X42*<-!N#7*)T4ZQ;@&@JJA H
MT=3H%U4M,9W&B2V;S:%?K..54G?\JBJ;H\*9N >;98Z:OE:)4 %"//PB#;B?
M@R3N2XI]84*K[KA4\5C262VV%N*F<#L(/!HT)OU$8?=%K+YK-G0Y5*:.2*]T
M%I373;@#+,\MU79XQ=2P:_@(Z,63%M >LV,1;@B39 PZ.AV9NN+/V.#F>DH7
M(ML]R=G,Q@/;!@8>,4EAY\BEA]12#+N],6IQ!N1M9D'GDFD(8&,00FNX.-B,
M]%R01F*?(]G7/\K1^.B2&V'J'R_-CQ_BV+>H_4<4E"FR>3& @W5;=O11#!*2
MNW X<^!.4L.B@Y.'NK SPJE9B4=-BK?@VV8%MA3"83"XO-)IS"RT8^Z"!EJ&
MOAZ- S7.4-2G=N:LN#RT<05+\S,*2M1Y!OBRB0W3\2+3ZYTLKTJ74K/Q$/DR
M;9H%UU&K4ZQ'"1A#Z"0.\U$OD&PFL00JED[+2.ECS6-&.&NL*.*8"K-+EIKR
M<;9LT8-/I\F#3!HA@)$IGS-N+MLT3\,OD#1"O^M- #/>MZKIU%MHC9W7L!Z+
MD$MH8#(M_F-_;Z^UQ_\[,MCW6I<VAC<WQF;Y(48Y 0BB0ZM8D"&U:',!'5"]
MU+/232R""+L58[Z>;ET3YVD!J(/V+*]#9)H:IUP5IMOQN=XH<D5:;Q1\#?*-
M/W()@%V?" 9L>F@4,T?A@%-_64S=KJN^$8<TA#-.=],C$='#>H6B YSV,3KL
M5&*>6IE9M:D\1IDI9!YV+!W(A/R:YW&T@\7O)$SR>SK/NT)S80"ITQI :A6G
M8J,C)U3R3#)4MX!_J'%MR08VG1**7F%IG07_;5/9_QNSWRE-I?#<:C(9)'$^
MMFUYM>KC1D>!'*YRQ,W=/_3%(9TZ^-=+1WOIF+XZ;2_;IN.5PS>@!RK;BDDW
M-65EL_ QP>-?[NWN_\!-@1+%_E(T,;#549AK$(/ 1MQNXZQ4H*V'.]/$R;;'
M,<90,2:T='277$:LPLNLCSY.Z-Q57U!I2]$Y3YWDJ0$O[/COW)!>C\:F)/%'
MVWK8)H51I:5)[[%=[)N-'IR\V^XXUX$>5XVQEI_N<U"G^[CI/J_J=)]5HN15
MX[^_IG*$6V$W&Z52[U*X<&QAW,F%Y3:&:!4'!1\0'H4.*=)GSJN0&IZQLXOU
MJ%;AR:/"5/.IU6P@5/:#AY@-\. S%SW1&%VBHG'-T]WG]2'8QU2ED)=G6I-(
ME20@RR*X=BL]I&;ZP=8F+JIAB!D%PZ5LT(! J1\'S!&Z4%'<#6/C)$ E[@Y[
M#CRLX)1TK:@"W\(H8/0\)'N*47)'>[>S\,//;TUI8##@$3_62?2>'0*. "Y-
MG4;&&"#40S&--^UO=U0$J6X#]O=8A _J3.6^GEV"YLU'\- UH.3U8<G'U/J0
M<:1-HJ*EKI;VQCQR^(P:A^H3@^QC-H=TQ+KDU,2[5(8DE@V-;/=-[R%X$-8@
M>^S]=OBW12QXOV43]#DTI1NF3D.=%1.8&;ESZ@6I32RDKMDC^5E1#<C$H,G\
MXZ5Q.A9&FBD7CB:B"Q/O 4/;>N3(A09VLF)&&#*=]\ [71?MFFT/@MT_7>)<
M0W_30FY*ELJ8KIO-1_@L DPF?9;KR@/T2(H;3!VE5%**38ZD3PVA=>99&P@N
M% <O*//M;>V<7+6I?"VQ",?#?8\;NW3LGWR%3[M3^[17<2J/(1O,V<XP'#DW
M^0=QK*BS&,%VMDSLCX.<I0Q=2DVCMO1%,F_1O+I\-&L@2%@(/#@+F[, PD*I
M!>2L#_]MF]96I,)15#>(#+*8IY2?VE OX2#-;W9O L[:QTN@KSJ'0YP%*D+Q
M.* $$Y]T#4H\33*;UZI_P\>X58JN6<V(:69]BQ:*J(;HI)>)A:2[*+(U:H9:
MM:E\%4,U&VU"PQ8+]*HA%M-T(ODNB[^'\I=D+[=F(,GL$>\AU_5 0*= -RE"
M<"&4#1!>&7(3F^6H.OUN]:;RE51EY<B]*N%EJ/P!I]]<&UGC^/'PD@\@SP9R
MH'25D2.JI@D7<],H6:3%\" Z0.H^T$AGTXW29']AM50A^/"B E=20R8ZZ4#6
M7S<E2%TGI$6;UX=059=:-B4IY!:SJ)[E"X:B;5D)S"Y,LKEHQ1"4"C/*<7WT
MF4# X&#[SJE,*8X]4_OA3.@!H5].C"-3E<Z5J@,$_6&$V"='7&I11O.+?2[0
MY/PSS"?#-:20-1Z6G@<K0R+DSF0E.O!7IMXL-1Y<SKE,19&R9A$4:I&R:E,I
MLAD(1L$<.E/9W 0C9@Q#45Q:[^>J3>511\0(.1^;_KHI!O<>$O:>4E:"V'I-
MV*4GN^)'$%G9D=@7"EWK?^QNLP]-BYT* 4/BH6X%\B2F\CCB0B"8&B"@IH-Q
M&*#RT&PLZ&.R=WR5A^FX]C"MXE0</<, '#0;75NFJRH0L2](32^NY^M83::Z
MX1$6]E(''4*OHHZ"9!E@FK<N 7;*-VUL=-M 6G+]<1^T?6^(BC"_ &L+Z"O4
MSOL8'J'O:YKZ/E-9?A;989U%YF:1O:ZSR%:+EE>/!_\B52#*$H3]1Y]4X<CX
M6BP03!NATD)3EF2]5D7MXA2<AKZ05P.[#X!]JUU:"-&CN&5; DO7XMB^1(QL
MW5"AQ9&&3'[FZCOK;;6P 84/JX"\<$= R!UC\NUP_9K&S^7B.2<<K[U"6. *
M]_3BG,NC[4,?N$$[9^H#:]6F\EAFB<.%^M;;/!19>%>_,02@79W-!G>-QI)I
M>%#)_5I*)1'ON;@:_K:Y))/J;N?L^:5J56YA,E723=&ZD:(G-!M;L\BFU\6U
M&BA@VQ2?BHK+IT %:AR8E9N*:QL >:%,?X[T'T2Y9$/!Y+/,.J3<;I1<,\WL
M8.[54/;ZL72FV.Y1[!-GS_ET"IE#FW-'=4[H;C4]K=I4'J8GWKFJ-I5S;A%\
MQ\)>B/;.0>V'6,6IN+2AVU^@'\+4F!<=^ZIJ.=,J/=2%IM85\')[7@$#JF<,
M-,>)HPAOD7(%?+D71V!ZOC"FF[V#NVNY"20&?[+4X68ZR82 !+#'L DD:E@T
M)-L1:;1PU#-0%N*HJ%Y6*KS7> TFG911OC%75+PSF2ZITEGL@4[/#1B[Q63]
M3N7Z]@O$*UI=!N@8<QKZO,7#CH0:J@06AMJ*4#(C?:<M 8LQSLHY9?J P>X%
MJD IUR\V)8F]B=7V*51L(Z,U^Z[:5 KV)5B<^S2#0A_@:T4',\?2&OY]!:<R
MLZUVKZKWED46[RZ&I.L=7;6I/,+4/873!@N&KL"Z5'UL]'-O"!H!-Y)\G'F8
M5>0K"V+(YW 8P"GF2SY[0*JG*KE%I!QNE=&S]^)ICGB.=$CT\?53&3V,NQ5C
M=]<1(C#&29"/L"&] W6('SV%)C$_/HC2.+Q%&##\19_&>BQ.C8A/$\;FFCA?
MPIKN\_NGL(F,8\DQ1GX'TS?U S[N9L+I!5)MS1&K-I5'<8078GU3LW&IDY3O
MY8BB].<<S%ASBZ%-OPI67(K?9'!+%/4!&$B2%^@R4:8NJ4\U?=S=RV!N8=R>
MJOC8'WLGT>I&[R.!?1) :/& BKPQF-BU'L/![OZ^QFBJ"775IO(H0NW+/*QP
M39K$,5DD!*(XX[H^QMOF[/J([6KX+91CMD=(D%&;(31U[@A4&R4Y(?NCO!>=
M6UT[I]]?T]"J3>7Q-$1):"J]!R:TJL67OAF50992+5TD@H^R.<C6\)NYW*"S
MH=2DQ@I27"/6G054' P2-2!+(L_0\\,MN"NJ+IVZ.51+PU"_(15;G@P]Q-QC
MX-& ?YT9"IC ;GEZ]7@1C<XGL#WE.W4UY7;V^BYL&('CV198];K(=$#8V_G@
MP\MSJAY1S7NK-I6OX;U+>%CL+X7WQO0HQN6DRFN#&6 ,\BGW^CMNA0*F/#\/
M1?]M$(?2>'0<O>'M[LLMC]2&(CI,3^&@DF)ZUN\#31T4[-1BYQ:0:SB2]"?R
MTYF!44L&7<X%E%^D.',9K(=J#/GGN NTSB3"MSZ?3<VG6WQ0XF3"=_04)2,%
M(XIK$2JHGRO3_(4FT&R4T_F_(?'>N.&<8@MT$,[6_9H:^"D1/+/;U9SOPI#U
ML*\+3#;W6#G\4R5Q@?EED8TCTPZF^HD6)'A*@LV7/CJ0CD^/R,\9(SRG-)21
M.>D!MW$(HDUR(^^157H+G36EUW,#&GSIM^U 2=M]2VBD\-ZR#KQGOB;L"R"1
MGD;,L 43+L#KP[M0Q&=A<#H#E^ZOBL/"&PUZ/Y8Z]@.0"GJ],"6! [&1:78T
MC"-TQB)PJD/G.$AV4T^3#%[I,!%WJ9REP!/3D[*R HW&?F7Z,IGSE T/G+06
M'691[J,3V$R<+?6#U(TF@_D7IVCV5"QU'!K6I=#R(F)J=LZ5F^'L(LT/D^+A
M"_N&:9HJ7C&?G9Q)UZ?T4TE>?%$G+[K)BV_JY,75HN75X\&_4E-&N8S:086F
M?&]92_G<?UT[OE9Q*H\G![);^+"M*:*F"+*AKNXM;XJ*3F3&]"M5KI?(XE5-
M%:LX%1NM/E6AG."1<)K(.]'>V1</DXKUJ=FUJ IP%\76QM='WO(9Z$5#.H0M
M5Q8I6W(;S<::A%9Q*O>0$&W]PW0T58E_+S5Y]C*=,L'FH8$CM.W\" U"=W)!
MKQ -3=#("H)$\UF/OW2%'?O4R-+R>!A"T7&OL:]9MZ<R-K[)PC7^ZEUQ4PIT
M,EAOV86_T&B*F$#@9OVBRP5VHST>HP_Q"]Q^:'PSLPG![2)SP'&Q.7XA<KM0
MTV93($*N,09+GL)[LOXCR@(L8V?H65NG?3'_F?V9N_KH)]4WE"0'3/\?+VV_
MFUI"K-I4YDJ(@]4[9.I39C6G<@\-/=U3YF"E3IGJT2Q\RKQX:J?,G-6O3YFG
M.94Y$F())\PT".@#&HNN"<0H\#QZJZEGU:8RAWJ6>[8\CI":C>*)MM!T(1E6
MD]>J3>4^\IK:/%$DL,PJ)I10.#<MI71>9<,DS@<<Z"^ B!T:NF\,-T7/:GI:
M35&K-I4Y%'7/'LZI.C:I1:!><7\*4'[<=**YB(F<&X3HU3*"CR%A@Y;39N;D
MG<SU$N\?F':WG& "WQQR[D$YZZ=O-4$S0=,2N7J@CQO'F]U]_5)OVR1*:*66
MBJWO<UIP3*VD/_]+1CGFZAP<8JN!@SUNPX/*.X&;ZE;1J:[AYDJ/R(!M<T+0
M3.((#R?@/ [A!ZF7*!S[-@(0<D[(P@.?I_=_D F,\7#_<:,FR_K1PZ[ERU-)
MZGA9)W6X21UOZZ2.U:+EU>/!ORAF2] PA+N//H][('9\A2FC+0U:F\I;T MA
M%&.9IKTX_DP%+ &V=N(GF2HK+#BTE]/Q&9*UFZ:Q%TA=I:AK7O-(5\G0@Z:J
M!XO" !G9E^CN5J9Y6J0&<1:0\\CM-PX'F,\3K0^,59M*H9 &Z3C/2C"8%4BY
M+DJ-HWN]V#TX!.VE=L*OXE0>(X^"](\<AH<Y0LU&J?W-O1DE4XURJ+P.) +F
M8+/C=ZM(D^<O=$Z\[2]@2XU+C\*:!!=T+D@UEE(6H)"!FVR=J/Y9:51P%$+;
M5/1,?7+PQ4.);F]3M@\OYV) QF?R-5H(VE CB=A\*04,@M2FZB-Z"4A*!8*8
M"C[*_6C!A"=( (HK%"GJI48'+8.34CQ&R(Q;0HQ=_)!A'.KFZ^@?Y]*,NV',
M4X:_$<./#1T"(?1AL 97)?6&8,YAH8BI*B#Y&Y"D]JFFV\?<[Z"7LP\>BW-E
M.N0^GO[V]!KC!A HB;NR]#8LWB@U!W2[!E9L)F/3S)13NC17OL$VF&@VC"'D
MA0BZDFI3EUTE,.@6EI Q0*%C $NBB+?[\'F2.K'%PG#Z@#N-Y%=[2U9Q*N[A
MY,BEKJ:=2G0.I RG2Q:P!@Q99E.0@=16TX3W7 )TGFV>BSB9NDZ%BX6;C5*=
M2V4Y18D>2QX^7:E3\A94E\=HYW$$QHM?X$)QE1!%!LM80E0ZAJ5B(7J'0/KB
MML"L6,SHD*26A;9;=?$<^P(;:<07&Q\.0C7I/L)8&Z01L!&'266!Z>,[U1!'
M0X06>(Q6H+%[,TMGYE;N*3/5<LU,:+J5Z+P]<$IN'K<=>-&]R)'-QO3 Q1+W
MY)[M(!GK;7/#BA+P%SRLH.YY%5=<Y#/*$0(76Q]C6'=.TL41ZG?Z=/%-)1%B
MBWW9YA4P7:6!PSPX333, \EGHAG9B^&]_$;@&^W-5BYS&A&M(D3 I0>,-+HM
M'*YPW*3T-YZ&=&P[1RD>B0@/QIW5V:N>8#-WLF_8TK$M<0V63UK@JA@/6YS
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M>IGNZDTG"CK]@>A3K;S!?Y,\Q(^)=:^DA1J68G,^+U%X 69.!_B-[LK'QU7
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M>72H[A^^?1E%V\QA?;,(-U?=D_95QPQ0;.WOE=\#*PQ6HP)F4'_LZKN]X#8
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MVVM=1="J+,GCJ!1VJ#-)T=&[10M?BSJ2,N'1#?*&:>^0NHJ84A$11:VC]V#
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M825R'L_:M/A<;0_\^S7L5&6ZPES]/YL<86RB>N4A9(6^:!'NNUYR_;3'U;;
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M4 H0W2#9S3!@:(,=6X9:N/>+F[I_6V117@PIEG6DOC\&\:<Y-[:NW M+&/E
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M(FM6AG+5?-=LYR9]$9-$15?P:SL,L'>1!86O4UK W?0RFVA M7X8]9%_/4.
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M]@:MW=@A!<*'OF/\02(=7XPYTB%>I4V3"(WTUA)4_-DKB6N7-KIU(0,$N(Y
MJ[JL^4J*#SDI1'DBG?.YDBQT?-]PD+ #UY7#ZN*!E/*X'7CTQ&A=&% 6W89D
MTVAH$MLHE3$FW"KQSTH=!O>Y0AZ1,).B:(PIQ=6M1Q9_9B.85"QI JOS&?Q[
MDS:;5NWE0K,:HI?I[D>:];(I,F>@U3#KA!+\0B#;H/D,]GT<ICJ5#4@N234(
M7*BRDI6@>A[E;\MF6Z\0Z!LG3O]=+*JY!H:Z6ICXM.5\1GMO/K.PEK0"C^C1
M?^$[@V?GS:9M(+;!,,[)T<E[MA-7_NMC88:TDS<5%+^.VFN/!+0=83<].==
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MI_#20M_#G1Y^97A'QZQ)Q=5O&.;%"TPNZ&G"Y<5BH4U2VB 56U1^.^@;M5N
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M8-H(UEPRXX$&.QY$-2L:V+;MBCG3&B4-'[PNK(DIDB2M1!<V0PDUW%,"R+I
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M4XY X"O_S)N:>Q#Q42[K<LU-%4N7Z]/G,UZY5+**@:QD6\LN:SLHXH62T])
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MS:Y!I:=G]VU%UVY0/5,[:)JI9SH@BC4V+WG6E 4O-S):NASSWY=%B.%T@9N
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M"&O?VNUF'2M"W#W-^@AA![2I8B$@>2:P:+2AJ(;S-^E7!GM+G<KCT6M: Y/
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M+9"6B3F%-M\!8!=I)[R*^'F$UO'/$0ED#(WPOI2,'H[%^\;V[FQ/BT9OV"_
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MY:FCX.L07.89TOOC5WXI\JH5\B=XKN@#>CQ21V9Q,P.Z?Q+IGI8)Y5<#]NZ
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M@2$RB]MV@Q!XX)?S-CC@!/53^1= ;Z1H?6Q,G162NQ(?4,$R:8"4,>@E9#'
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M/(2?,\)?!;P=JE2I\7R$B)%7.HT94:)^X\47.C[  C'0-.@2!P87)[#L8.8
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MYC.*<P<Y7)*@I8GJE.0/Q^C>H*<VH]?V0H''VSU$K['VL[86QYU9>^3^8(
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MHRP@-Q(*00+G#V?UDGFTUJA&:1WOSHP2J(E)L^C=8WL=?&J]A)4BM&YKXE^
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M#9?<UR@Y4T92;GA",_T2EX(X+@LD[BQ+?0U*]+^BH%!!@O*+:C%W94Z'V:Q
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M&DI&P>?TZIC/D,L&J8#%!0MKS^T)3JYL?>1.R4BSM@P5@:->AYI 2:4VE1N
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MB8ZUDFNN=(8^??3D,9@;.,UTFN:P)@CLQE.B\U3:+\G M3>%#:;WKO=^*WK
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MK/55,<SW>7T1.DX'I:WK:E-Z/(H1P*(D*7,_D$10C:.]>K0P7'+SH-##[<B
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M()#Z0B%FV+@%<SPD417ZM?N!BP1&.H)!<Y(("WM"A&JV*X]NM4_Y&W7W)M:
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MR<?W=?C^[SX/>1N]4SYXVL*,X9VRV<_H3Y)*S!#B2>NR05A"78&O2L!.C;S
M>BB&.;._3-B6]V$9GNVZ9UW!0(\*9LF0S<6%RD2GT9?AU5*]Q^5+0N>:AH@4
ML":*6O*"/A3ER71-%G6M-94JIJ0P->AH4R&,$ER@_#KEM3XRN4>*O1G.V%IP
M/R:QU2(646ID$8!$I?,,E6(8&LPJGZI3Z1 C*U>XB,SD\SD&!1$$Q^6/J=M'
M&7'"0\25C4/:PHA\9XPI1K;F2,H8GYO76(_DB^:]-Y8F*D<LHC.D<96NVG+E
M(/1H#L^@(FJ>,&O^RK=EJEXD0@[J,\<^E:Q%)/XKOW=6K5&A%T<$ VP]2Z^M
MM5KDS>KAY=#+/'O/<1W40!(Z.5-6HJWQ$WGU^[K:UW>#)V+-J,K4:;^F?H2Q
MGL*^4GW-\$:&!4Y%(G>&&5G.\0YF"(D!DPX: 9>BL2]+4W%U#I:V#/L4#KP%
MPX:G><?/N7$X4^<[M-Z8ODG5F@Z<):4'--Y2+$K0.^ PWMZ@&8G4:=!K4@RW
M6N&7>4E'.6,N>3Z:7#KMDC9J8=!UZ\P":H?H:LV9HYI])=X'Z!&9$E]3#!OW
MS0]Y/2P::RXP-(06,AA/2[9O.HWS(!$#"&%[1P: D 7D%%-V'(%CK9L0XPQ:
M7YY\@^[K4'!6"PM;+41@'. QJ#8WYFY'L-Q@:,@.RZHA_,FTV]#='<NB1(6Q
M-6N1@:U6D"06>9S3;]S?.)#=%#T"=1 B:SDK^4DX[@4QATQPO#,6&U,-RI1W
M!"R_2' U75R&'BS!1[C6G<\H5G7&#6^!Q+0.%XL/[0!I#<S6TZ6T7G($==?C
MH'<VJKX50O2:5[!?]DTQF+!765&R""?Q>!H$!97F._[^K8+7I^G(&LB"[[;(
M@A!9\.,66?"5K9+/YYR--RCIV!-G;F%1;07%0%PNKD!4AZMD RB(N]B2G<#?
MVMVYM<.E42\^+@.:]5L! /:-22 JF:U,5%>CO@O""XY([C-909?9R+BN[\'V
M*_/11>O&L+1)7 >M3P>(A7N#'4Z2+#A<39/7<^/1)@HNT.,\+P4G2O&FR"]2
M-1,)6TJ?8W2<ND/6YTA\,M0NF?-G%J JD%_G7[I ISO(_;/$I&>SG?&)WG.W
M%3O@E"K%B%H<>PZP*[5"?:=_*D#DU,"0;0-O8[EW7$?1VS*^8ZIN3;LJ)W!+
MZ)T2=VR/X[:.ATTS@?PNF@#B>H'3Y65OU.5R95!CY^^@<2Q5JB/,X<QQ/F'
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M@#&!\-^+:9Y'*4,Y4ZUU.'#\EAD593<<KD >\U@B/!66$'#V:+HR;U,?QWO
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M3QGFL, L?Q ;>'16DH%'I5AT^N)<YC\C1J^P2'24J@I/U>[XK/PS\X":Z*)
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M\\FLK);(X 4?;V?O)G4D,GNG=SQ[M72(U+W UANJ1W8NQK1(5.ONZ4J-]/(
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M9T=^EK,-:W8N= 37>92\ )YU!1(#(XE'T5#RAW@\&/3HJ4::BEBHYHP((/.
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M[@3_<_CF#/]S_+]P.?P^V3MY??CRW=')ZU_@JW?PT<ODA0[^T<D9-9ONL)]
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M8YCMJ9OD;UZ]PI'&C1KF &_6\-K/W-EV8G:5=Z_/3UYR&Z+WA]7GQBPR;V%
M8.K"QH8G#,U<6K!G\#>V87?G]/C_OH-^\A;/,SP\9?O?@=W]=;;_8><Z3W7=
M[W6:_Z&3W,]Q6 LXQWF*NQG>GN"\BQX>GYWY148MUMG<,B!P8$^/W[SXF5Z"
M&1H<,?R.AP@'!)XO(V).0UCC1[BMT5S\K./$1^,Z Y6L,TY'QV>'L ="PV4]
M4,?/WNB?)Z_PG '[""RKMV#W'!_1J:1#L$VX?+E\^+?;?'B8#_]AFP__"I?*
MEW")?U@_=/=9)!+.%L-AWC15O(ASF^G>L$C1IF6ZXQA#!-75.29<@CSC8(F5
M08S+*S"(.(*=4,PD7V'47%8U!CMG\,B*Z/%<IH5"H[T@^7VDC+%Q0ZD?T&I,
M4SV,\5 !\SU*WFGEG2TZ(#(13AD1]+R3/VD!5 F;"B83E?&-<0$]5R#CD>FE
M-JG2QS-[.-.8DY;SJN4(OLD8\<#^*M,*K.W;W6DJ0XK>5TW@4_><PB7\(V*.
M);&M//T4DV5%%'Q=>]\^WJ=W9L+16(9)*;;X3,!*L,:,*1==F'&=HS#SBAOY
MFH(T3+3;:H[(^/74)G! ?5()-E2SRHD3*Q4!:%,'9,<CZRFF\5 )*MN^J15:
MXK+B5<O[X3KE&3.M(AN2I@U%'$PJG!E3P->W%69H58C$C*5.5NSXJG'WN.;5
MKT>R"3"XLWFYI#00"Y=@;F)>R<)>W6&\0[- HBD+,6ZG$CP^MYCGS.%^6)68
MV4">LTLP?@QQK/\&7%I/V!GRNN)SZQQK:RSZUU.937-L=<889<JTPGAB\J6'
M8BR@U1H;"+(#P=PP$'UBA*G/&#&/G>CI<IH[N6F8'2,V+7*XX\@)#0B@",MM
M#/\;O7I7IR/B=4,!R/G:I5N,#['@6AZA-:>&CAO/BZ6KU6E<M43LG=N1N]9U
M)*FR=:8SU64UPTLX\.$)M'/@]F4J VPAA2F#.&!-)0+&K-H='4.$V1'#DH;X
MFFQQ7_5SO6L-B9 R8.N%ZYTH8*5.3=YIET.#P07\,=5(H])KF=,_;MP)MUFY
MC>G(IB%U7H=L>$0I$K NM^CS>DJ$J'2#]A(V*WQUD"[1O@44X%U2+@B1'027
MA,^<X]HZ/WNY5FZ:H =Q [1*7>F(5M&RX1'4:\+4@D5+MH%>W=:IQ2YS&2-^
M@7N?;.<T#+W[6=]B)1(=A@%@F5C#(X%=Z12(KO,8Z4C3[7]OAY29Q)\)JAS?
M^IC_]B^&M[;UC*)^R;V5L\5*>:Q+2[_=];X,Y]QWVPAE&*'\<1NA_,J6R0/%
M$_9'E%1G(M ]&[=M<E?KV[()I&)8M^^V[%=;3378UI666O4LZ+(I ><GB+9O
M%H-OA+,N"+[$8SB]&DLN!N7N9_O=$GR[;<?#'D ?BUHQ^M0*!Q;DHO3<\_ZE
M5)$RF3+G-\6M VHEXX<8;I^?'GWK""C\9]\SX(_K@M5K\5__8-P6M-"6ZJ.(
M!^A;V2LA:8);[@Z=WJ++<\41AAXOOEER!;8INY%ZC7$V% T6HJCF"@6TI%1T
M!>R?')_>V,?TF& P&_AEVL"-^&CR^KRQTJ+;RRTU(]7.A*_)O)O]S_IR<,ZB
M7ZV35AC'PA<6<*RX:]/;OBX,!_L'4>UW[/'FN5P7GDT<._>CI.6 )#?Z'^V*
M%L+DFR?JHJ>-(NYS8$RLM;A]7#OI$TJ+;E<=LIE2['.90*@Q<^,,,K.'KI(=
M \,$X33:[X2+UYZQS-/8USFE-N W$)2]M8G6<,B9"3SHZ!HK97?'=M1*&/7W
MEQEN2GGOZO<Y3Z]._E$53(EDA;T98 X36HC@V-N#E>F'RRI*MEVAE"-[M^Q>
M<E/OL.ZMU;V EF=2C9@X&UW!"<L517L]CJY<:'/?O"8=*ZZ(L7&R/OD&$5]R
MPAT.:IX: JJ.>$)'CC!Z]>Z.7!Y+VC@>6JX,1"H-??VK-0R-+JI_Z^%0;-W!
M#4H"K\S#_WC'[$'15 5-[U\6&1;0;/64-FUI;%HNOI>#BHV(6&*D.\$"@4BA
MI!HO:D[^W* 1V5+M&9& AC"L.859=]Q)=D$(L"082=J"GHOA*K<UU3$Y%FU\
MVD[^L/QD3T+H$=:8_T-N$R$D]2>_]KT3[_7#D7F"(->Y?B_6I^Z6)LE(!X^3
M6S(Y-6@?%]65N=9IO2R@'?D4?CK@ZE:JFY[GDU8RE"OV&Z[/:J2_9) U&?/?
M2:JS:(CT25R=K&ERK"E'(G)* WD!)-(J*6!^W)H?=G<G3FJMP]E/#2NBF(Y)
MR1704KR=;"8[.#(?+&NX3A%PUQ9UL\BF[;?^PZ,G3\FWJ>K.'/O(_L8YO*E.
M\6/[N[4E-J8CFY90"PK<3G,8B']1&7>X'2;'XD*%&WY$Q6JE7M=-VE:[.P[:
MU&OHY]U#AK!=O&?MW<S![0GO.&102Z<YQ6\:;X9 ".5E$,+#HT!G" >!%F8S
MKQ!YIL6X0GY"F;)UY(MW=V03T)#<2,7'>Z,#40Z1'K+NCF!QMV$<#W(M6XV.
M2&[=6H=#$3;'7&E7,^++%_&GWF"("CQU7Y'=H#/X"_S&H:15KRCK)P<7!9+H
MWYU;D"(&RA3L[OAN/\^F[^O%;#Y<PJ6CO&=F5H$$EXP*I7RE3-I[_+5&0>@0
ML.ML;D-BV,0^(A5V+V\P?<X0\@)O1(,&Q*N+;G*H%69F3#%7G;>BQE/7!=&Z
M')$\-2C1VP-O],<0+T^X/QI"L%#V??0J%XK3U&L8<CZ9PC^#8B01GI$RTH!]
M ==[(3''C&W'&M_Y,'<I:GDW*$)I0K)FX&'.CNSHR^SAET#6YJ+)E7&#= O<
M!+2UZ^3R*S//M,VL'6L<23;X&9PMB42C,_4=_Z;&"*!9VR-]@_S2E>&!G^ZL
M<OV V('9E7J;UV-NTPH"_+[SE6/4C>63D2O</D08BJPH\SRZE&?N\7UP/-&<
M+\%#86KAV.[,_@49UE'!%@6Q_:2K[MWA(5@5PVQ*C/C<"(Q83OF,,NQ7GM:#
M+'36T8BV51PAV5XYND=/C]\-%KV@RTD;YDK.E?AMISRZP<WW^PFU^EZ8IQ%B
M-A#2>;F$;2X@_&(ZK<!?\*0G[=,IXH\'..HF;#2XR> $ER-SVF PER1EX^-D
MDSS^N6E [.+BSTC*WX./%A@221DY6#$;=RNUMM#MPM= =R F-.5^9Y!L>T!6
MB G'9N9*%&>H,6255%>A3+.RJ7Q$>N:(\+R*58A.$Z@[&Q@RT4SZ.0[+==ZH
MI+D]V1,!?I,RNPYG$7+72;J]G686^[E *U/,X%A@IN5[](&:->#DF64(:=IX
MJ6X+<EZZS*3+AC%F#8G3V5%V#HH7ZGT A],FG+/KX+*>;7%9(2[KIRTNZRM<
M*E_")'WR^.[8E'+TPR3*\(;.H!//V_DS[/U>\AE.L)]1HGE89O#L6I1#GR\9
MK$N>H9A?$0TA8Q;][0&\SX<< +W3U%<!<[&E]266H ;OXOCW10V?70;6:4\-
MDC%#N?B1(H8(-P>SZ I\)BDE0%;A&9DI-'?'N*F"+2=$O_D'Z* 4^M2TB#JV
MDU6\Z/ V[]%-LUMQ=/%B[7)R\>K%T 4'B!#P</O[-A&R+]35A"7-&$CF&N82
M0K;-.\ ],:1OY!P&0UG?F/67O,JG-"F]]^OK(6\4=YHIR3]@A+4I$3')/)OD
M:[5=[?@L'%5<RTP)"L<37@?: 91#9,I3DDD29\2R7^./>*:FO 89^&5162QX
M[>*+EA2[DZ616]W[J?*0Y_R=(NK7G?-,%4 [:)*)EA)2M-?Y)4H"8/X-S[&F
M=9 UZ8HEXT &9.+M[AAM)D*SQPY&TFPLIGPB4I!/M)N&P4( [SZK*;6P4D"
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MC*A\LQ_W4*8A+,G]QI^ &O$$!XQ'17YSMGU/%T4FQKM;#ONIX!G6>]P/,L'
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MNP8]-O,31K9-&/TA32#6K\2C+J*UZ7!<+Q ;Y"9XWA-368,GIN]-#RYN;GB
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MH<%/3MAG7&,(&Y5\ $CPAPE3%>_QD7\#9EXJ$6#N%JQQ0%D]+ 6+IC7]'+>
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M9G"!SQ[T6L?0XO/629M)<8$OO6SWX#WG])[\)^D%9:-$>6&65%=D(Z&RXGP
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M0T00+\K?9KQ\R81@DRZ9KV:6J\U8HCM$$X1"3!#,G^^1W9U)'$6>TR.9R;!
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M\C>_:NXO(NB0*$=8>Z)%#>)T:;-I,FKWHL2/V"])9-=IKGLL12/:STN"\E>
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ME-7KR>NT=GE7RG&K1U6&^L>]SB45=^"%E_I_W7)9[:*W"?,YL5P>,"MV<GN
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M-R>&:U)@X7?[]14Z;(/2.F:U;FO%W4#%7;&SV5F3XLK18'@&LK3VHCG,3T[
M$ YGP^DLE(CY"JK*A0_PU(&<F]([?'+I2,T"1VI>SJ['_G#\Q%K]U1O/'T:H
M-<9%BMI$7&<M_J_)R(WN/AL9#9Y37@4'O&@QG7K0=<SG7].#S0P)?45+<J)(
M>[.Q=R""#2GHL776^=+]QZ>S]NG@4]ZCRSF[@C+92%+(I-QV*8 TWQSD=J,#
M&\V/ZRV,L^1_RG&6*?G7-K)R0,_N3HMRS<_=<'AGE&T3CS2:BQ/+4]%KZXU
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M-=(IA73'FMMVF50JM9'.=AI5JU&!YQ9*+ UU2D'=ZT/F582ZS64G7%4^?_W
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M6E0415M@ &B*1^1GZ"F:&M<TKFV+7$K34]04#\J/L[D=S1160,A2+)M;FV*
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MA>=0N*GP% KW>>?Z93?IC$0/:/PCPQ,F";R!MS8,Q008-C&< <,AM:3F,J+
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MDW"?H^+ME1R8.E>3I*)F0W&R:R79<U5^I\WMK*1E.@F>WX=)=BN3,5=W91U
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MM MM(7=]$[G5I[,XH@N7YC>*JQT]Y:5\Y]PWY;,F*F1$$B6-^524@I+9$:Q
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MGJO83+X^.RNB@8FO*YY>SG@QJ3U,!PSW<!(G1EL2&FWBV5X(Z_2D-(H9_=W
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MG,S1=^(^R5OUH :CQJE0N'0;\+;3W:#=:VA:0V=[AYHN-B*J6$;TH.8VB1"
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M^/<_SKV/[[SC#V>?AH?GQQ\_> <?CKQWGT_/_QB>>@=G9Y]/#S[ Q2!GT.3
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M?& #\*^+UG"A(@ XI& BQ<^4#:0(\4G2[GSSO8$HA34&_O1^[0M;^A46.#^
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MJNCK$:=?O2KY59!!NBHU<REEAM/'NB?T:R-K4S#V0U>01"3Y?)<[[B61AN#
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M\49.QI\>1OVY;Z7/EI=-0.#)3P%:X27_. +^2M@:?[H3V?)!]KU!=74 CQ[
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M?+>SW=T5'W,IJ5XKS)/*@J@L>FPBV.OQ]@:=A@&/.S).+/.=,7!>0Z$?R,=
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M)-KQT6+9W+_Z3Z Z<;  MRO&_7FZHH+W2?5N9DGG1,;D1N5A;"<DGP; ^NQ
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MTF(LT&E?%N2H9:PM#E1#P6X^J<T0DTBZ=G'_\BKMXZ/E%W!:[!/9>12#W7V
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MGBF9^+,QE^@S2Q+3F,EJS?FXE<@%4^3\2+OB5!=.1&ZGZD_+$P]C@X/3A[R
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MYX)2\SZ-0MZ[[O-7R4P%_,[[_$7F;Q;*CG;>Z.\VCT3[NV][ERD;>/?B-9&
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MZ$?(I3=R_8L\\5N==CV3XZU:LT6F(D%7+D2BY/CMH$NC['C0N"S3K.G3:8E
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M;P5:&F6EB^J^NFFV3+-)1B(A5RY$HH*_[9!+IVSU4LNNERI5TK8(LW(A$M4
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M[)N?\5DGB@*TSX/?HZSY&C,]SE3H27@>O%\MX%U?%V>JI&\]#]Y&<\63];;
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MIXIN4*>JI&DPIV0SA!6H9[P+^=DZ%B7O"F^:5E6CMH-#?U/2YS2M;'R[^*9
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M;D<!#B/8EB'Y)/Q9\&Y!58#PG=?1!(X)74%["\W20_&Q@H-/"^J*$FQT_V0
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MTB!GYD<.-6B2$-L.RH8#])W%;&Y7XPK_&-VV@AV*5,NPS5/.(,"VMC)WM9#
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M4$W9YW#GTJY!L-$5^,:K@H! >9%O.>8S!7)-_M0!CDMQF@<%P#:%E'/\M4C
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M&K5.B;[/N6W,Y9#DQ"3BE_:,:F-+4HD O+!^U"#;KR7;;4AI#XF;JO-U*6J
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M0A9AO1CN_%;!F4(_03M'NM53A"!59YG=_40W<E"YSF66!MDI K)CFJ\=RB!
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M^$KW495&)C%<B\C^FD49;=G?\0[R24WBOQ3V/TOD)U@0%R&"L!9P,)L0R<5
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MYMRP@2(!^&NI,K6,:"36@=R8K((8J82VS)2X^'6\9+*RT^7IL$TZ$Q'.&PW
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MG"'Y)<%XI0_I1+$L 9^;BHP)'NRT6</+^E^/.H-ARQ4L6TDK/3\X;T53B^K
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M<OOK/Q^/;QMP"O+>-KDY HDKXOY5@64VIM51IX8]6*:$8PO^=K+7L3Q=5XO
M]X(2MXX7RGDQR<4VE@H_DOK<?.=*F@.\KQ8 FX->?%>I"_)A5\0/L:]B12#Y
M'8X*4 %AMP?]U$S'J[2L:F=LP4F$855K\:.I"_^78\Y_$B%7K0;M4:P"/X5A
M9FFN!$*HK/H*B.9.G9I^]O2NV(]!:JODM9M%7) #Y8W2*;<-$E5'U",+'! ,
M<G @)4+HUA^,Z-= 8^R;4IY&N3/)%6QC@HIA0ZU/B%H(HF295AC%742Y0FCQ
M1[7"LBN*9Q,"'=E<3LD+=+X-"TP83 4O$@FF#28"') Y7LEOF\;C$<)-<VK=
M8KW&"E:2ZSU,<XI!\7ZF>W ;N9'N?XVC@/+&]1'VL?]LI7T#>WHD_Q'K=!Q#
M:M$-E3![+A#%% -T'4*BHA5JH),'&UR^Q+V",N[GD^O?J"O=O*B=GE1<$*E[
M^V#X!YM4.<D OV88#RO=TGC$5!TJ_BU&R86<9EUJ>CO8K73ID5-+2<[QVFRV
M%\AHAV+<:> $MWDA#,V8"$&X=E*P+E?EIZC%Q7T'&0"B(*T$ILJSQF?:Z5/?
MTX5V/.+;<L@AAEU<S+&JB9+YG /UW_JY8?Q!*RU."9P];;(IYB\HDE!2>98K
M)5TZ1$,MH)LHEQ1IA3&DBQ1-_K5/=O;BM"EIU[C;+ZU-I&=:(C?IAO4IXHBR
M2*V%<*>=!M$3$:-./'2_3?L:7?4GD[R2("*,.7-U*K?P79AYYEX_-DB<2[(;
M=.]\@>&M!ORV\[7L^OUZZ(3<>E)4WF;K?6D,.5(GO,HNJ+Q\_PJZ:V8+P"]Q
M/%@(!*V%@EDXY\AX$J"@ KS0!+!UM0UN"!ZW@$/P6UZB ;OLG>9JZ(]\]<&Q
M6[5UIC!DJ;TKU&2WD1:[V&R6?\YW=C^\Z$> $C;4)Z4:<(.?[S(]O?40V5&I
MM@X^"8OSX1$;,9C7.P_QZYKG)J_2 V#PB.U"2W-&29HFP[]AXS2\'=8QF6)
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MW>QEBGVV_0RQV]W5MP<>H3>3E)'8]_0<W>M#?I4"UF=#+L/-93P=<AE?]]D
M\7/GL<9VI][GP4N6=D&K-Z]1B*!0I$@%A30KEB1:=91+\ :U%Z@^!1-'N6L=
ML!N/^M4;Q>AR\?O7*3FIG:'R+;SI9RFO\:BKO5(B=[%/+[A/L<M-Y,9*)A2
MC$"S9Q^#D[]_@%=;J@Q>MRP^@I.%T1'*?]!+;DU66_0#QT)"FWMH%F!/>GJ-
MILV$V\!.P.X<](J.[^)?C8R-,/6@_P.K#]LKZVG#\4B^Z!L&[>\X81/9%5X<
MKY7E;^E_J0Y28I*D#,&G:= [H'-[M),0)KC$NC&PL/[?[[?HRC^YFKZS,^V+
MM1G1:<VQ/\N4]I+^T"G8DI<P(;HH69)M[X#O86,L,BRK2KP&TV2\N4PE]'K2
MRP8[SQ#[4&*BWV[*;3PZ*Y&IBF##1/BQ83&2$QZ5<+_3\['G@3CS:+ELLC?<
M62Z]JTHU%UBT=])XNF%X2.7CS;E9"#-]'OZ$.YKT-3/A"8;E)5K')=)^<GS3
MM-:)TJ1G?G65PY4FV VYM\[]8)Q]E@+Z\9YX8-;R/OADY!TL;:\2<LLW)4A6
MP1;GODQYW_<<K4#I$=F<G 9W=V=?VDBZBZYX/UH.W74<<X3#:V<%VD!LOO=X
M)/+2):@*-E(*$V]RO63?^SC"#3$ 0AS,>3DO5RBB2 +2.F'H0Q%@Z.H3U]U,
M^Q_F =TRO%(<871=5[H(M4]0A>UYD %A+3S3KC&CEX8F=(;G/?RBD0Y"X+.$
MP$\W+@3&H\L( *?+NUGB8\J)"!>L#PW>#O#XW]-9O'NTX$6+?.L\*;L9.- Y
M(W2.2K"S)5<*<K) VW7ELXZS;'_I8'TXRG_)?"IWGD.21$.]@=7PJ!4PQ;BE
M3$0N<L:UD'%M[!X=NK;')H[T>Z3T,(/=D.I$87[$+U#J80J&5C53!!9 B;6)
M!*HNFWJ+3MC\[F>03;);&X:1R5VT(%":#<[2!U0%<<D6F%Z5R*(_!#'.U[8$
ME$[F<,V\#?CH17GTYL U&EN#KXDLI46><2A(#$D#FZQTY$Y^:0:D/YZ?@PLW
M);7F-2<J5U,LI(6O%SERRN1&F1L868T]T1U2#H<!_?]O[TV;&L>V=.'OCO!_
M4)SW/1UPPH!MYJKJBG"",]/=)$DSG*KJCOX@;!E4)4L^D@5)__J[U[ G23:C
ML654]W:>3+"E/:R]]AJ>]2PB"$DHZX;9 I/P)C>@J;,"5H:WGU8>$8=3R6,S
MQ)\Q][)_QFRH1,PTV D'P[ _$#>BF,CV:X*;/8G2N&_(3!R-X'ZWCMS(;G4Y
M412H9'ME_2*)A*$S@H+/X(0"V@Q9)PU@31@*XA<,RPKCS*I<<MJH*NC<*VZ9
M]V:H*+Y9SMS^7^Z-0L_9DEK _2MO#UGSD$-)):D_D1X"O*]>6X.6%U#23BA?
M?4\(>1:2/98CP%_[XNWBHEKG'X-.MC%*H? P)A1,DL**AK"O.WH4P'7%<\!^
M+[B%'&2G#XE+=<1X G= ;=> LKOD0K[08K_]Q==.6HOT'4.5R[QB2^P!43IG
MX]X#ST-F=6"/EZ-FDO]G=I)-J$%QV]T"\:^4A0*&'@Z%KX$&T/SZ;!S9</)Z
MC3Z\;@3.[5=D W/7*E!"<0$KP,KV(D<-3H#L&E:,Z!-14T%@6_;04,E>X)0R
M&!/L 13WB]?FLZY)1"/:B!]W[%^9\6-'-@.!?MYC)'H&N\IZ,<5>,P_1\*6A
M'X\*XD:9. C_TN29R]:48'Q(K97!K"8N!L .#W3=0.Q!K\R![O&>X WF =$>
MMWO"J%05()ES"GN_2F&;*>S=*H6]VF=C?Z'=>NREN?KU6S10SJT0EB-N/0:4
M-P77XY(NZ9+[>&+'WS>2^/S2"A->W9\J QE0&MRMG-N!C*@$,>?R%6@H"<>*
M"W6@Y"42>GDS]WB^K(5*# =8#$D]ZT<I=>LTHWM&[*;D;MEBY?)=8P_BBB/A
MDL#.C'UL5XF8B3^?&BKJY :*$?097YZDUI)+Q%/D85EJ021Y4::,DZLH@1P9
MW+ +&>U!U(^"SA3EAXM]!>UO8*&&4& >1NTGMY@WQ1J4C -E8V6 '=TN,Y5E
MV^31X3!1MWK@4Q04BDI6%7$:("RE:KDS)P.[2<D)0XE:T23)$4ND^^@ZXR!%
MDO61'Z82MS0&+GST[@@EM$Y-:Q%?HECRC&+![ )@E]+K]:RC3+K:KD\<NP\J
M<^..H#;0JH[$8C9H\BQ]8.01E36<NM:L(X//<J"P.47SU\ZT?(Z^D&!?Q.>Q
M>;0#AC)P_PTS!35J *4V=!8:M3I8ECB?M53'?,Y_YG:4*,7'GDQOL@ M\[HN
M]<7Q/HGRI[HT<K,1Y"9\FHM)%(.3^ME39(](FUA4\F]'F@HJ]YDDPVIQW_W]
MMWJM=WKT_;)[_NW":3=;30*C N& V<:!GBY>&R9#\7C5P$/IW:FL7EH;RF?)
MM(RA/9G 7FA[?Y2.Q-N\8"C,\"%:4!:J48,=U\R8)#]@^A?7'2[:AZ@90AIY
MK2&A"[G;3^X$6X\ZB,3D4%OQK- QL F6TS$F;N\C>HX0&[RM)'#WP7/%!31U
ML)BVM*:96R,GLT1Z':;/V:ZB[*=Q+(X%DMU(X+.$EFTTFRTJO,:_[W#))5PU
MS&4PXRU+>K277.\L4RCEW .H/NXLBR]I&_OT@W_;!Y/0#7W9T@J:85$4!K_=
M"=W@(?$)TN4*:\WZ[<AD'C+9#AJ.A8>&:+:+;1/1%@00CM!&^F$*:J@Y(NSV
M)6[B6/9P80USO6:0,/42H !@(N;9LWK-.\VNB\JL2R#SH39 :B)+==H-3.QL
M-B5^C2<8>1KJS8&M@):#3K?DQ_8YV8&#*CM@9@?VJNS :I^-@X7&8/)7&GA+
M/[.KA+&$"^#.&XJ;+%&5!8@.N_7',C8[W1_G.PD"&#GO"QD$F*:O7M,\?4.#
M[B,?19"<-2J2,\5 9<A?)FH1$N<3C@UB.2KQ[L? BK&VW>3\NF[ 8S!CR1 )
M&[V,#!RX(R'TT"$$)H@][M0T^FZ(!D#2IRX,.AWM_8 (/5T].D1?KPU\R62'
M%?3>#R$*H2O;FN@0:6B.CUB+>$>03@<B-M;D'#TW:FT&!0@1KB!/,'&!,O>)
ML^*8_Y,GYCQM7L*DGSXQZ)HDV0*IW0,6C% EG<F.E$PX];!>U(%)-P63'H4+
M\3HF'JK7<H+*,C^P>0DSN1$LH'-])IPK>HVNF('SDS\.:T)6-  #:GS&Q.QT
MBE^T(!AD*/+ \00!XO4A*ZAX**@MH1$OI9(9D@S%C.8(1=1@H$3@W0&Q$XJY
M3/*@5^6-C##GM8<0$AAFQC^&,RHV(R'R2F01(=2O;F4/2T B)M29DBQ4."1Q
MB57#),Z%)$U+%).<Q>XYI HBL\!2M?4ITE5KZ(,7EF+R4]0Z"%D*T-<,J&FD
MZD("SQUC@2W;M,DZ6=@^AF75D#EX;!(->3]\*I RM)?XUCT63!5 A#A62Z29
MCVDV,0& ^""P$LJ-R,Y6A_$!6SZ!)9PK/>*6FVO^NKCL_O+000?5P/RI/R/S
MVYKO0Q=,?W2= CV?&H@=^A6^/)0U#BW-831\(3^Y#]:W6T![&(U5FQA;AP$C
M""EH5 ZAV4G5!58_DT -0-WF,F;C^>8P&FSWT[2C6$]1TQ1> _^@3$) ,!]Q
MZ'0?4#$T10^ DFK !!]%O(_&H<N5")/$,F&M.GRD>(3Z2X1P@.M3\(*AV>A&
M/8*PM8X8<ZJ:T5IM;@N?)3[2(%6=)?.QR=Y0;>2+U\0+IP7=LY1[N1%7/M:+
M[,A%$DOE0K)2U4V@1$ULM&$\@AX<8UXFQC;#)N>:C+IQJ0Y03 :N#[<.71;Z
M?@ ),PQ)-T%:3'5VI!&9,TUET$3;,$(2H^!.&S"ZA$C2H86@>MJ&:>C2L,2W
MR1:9X,6!V223!)(ICLTVQA)"X<<&(RK1M\&,Y-+@L(RFH$"I.?#&'LH#D@/%
MX@JC"HTD\VNQ$!!CA;995/PDKN!U,4BTMS@"-059(5:R@58,7AV:VH[I6CFT
M5)!7U8@3L:O7_H3(PH2:2@-/5:+V0JXE0=5\=.N.KH%T=RCI*SQY&TJ,2:8'
M-/ 3]6]Y8=Q ZT8HJ UTZI$[7""'M@>V8."+FQJJ%&Z)@Y7*EPT30ADCQ?;N
M&H@CS!(N*XJVK9ORE_=[S#!4O79%!<&H;>_!-+9*@\WUUS=WPRBQ<I,DZONX
M>5QH 9$NWF0J6\ D5Y[ $P:#-KU1*E7DB@D!C/WK="++I"VV<V&@44:EH2R>
M1H9K5C8W+V3Y!H"PV-FHWX?6IHK*1'EP=O!-7]4PLXQ9J2^MOA\+FPOHW_M0
M]IJQAHB%/4; +[3^E>80LY/G%\!*3"3@Q/33B=[0!ARS>P_R]@F'#JUO0#T?
M]/^2A3%X3T?A6K)>768ONLP627N7#XJP?22K-S<ZYG$I2"OS5:>[N:N@=>'I
MXU8$W^Q _U3.?,/:<FW*%&DUD];\"4,<XAH.W#X9D/E7$P"0'6FC<ZDP<S./
MADM'G+"?971!W.\#?T)V\C -[8*&G!L@2R3,\XRN :BRW+ :X&?()@YPTB+P
MG,'%ICM;6 OPU ;<XGTO,#\E[.^O7>?[IY/>E\YE[_NI<_G=.>^>G72.ND['
M.>Y^[AY=]O[9=<[.OQ]?'5TZW\^=H_/N<0__=M[]?'5Z[)QU_OC6/;V\J->^
M=8Z[SJ<_G)/>4??THMMU/HM/%3VF<WEYWOMT==GY=-*%5W;/S[^?7\ SZ;,7
M3N_4^=8YO?K<.;J\.N^=?H''BE^+$7[J?NV<?':^?Z8ENA#_.A$_5"_E+1##
MN?@NGMX1(^S^?G1R=0$#..]^ZQ[_(2;=NW Z7\Z[71@Y#O/BZNAKT4C%UWLX
MG)->]PK>VCD5(Q&K=N[\UCD_[YQ>_M$0+S@[[U[@!'K?SL0GC\6>X K!ZRJE
M]B*EMA@JLV*E=@)9.HF<((WU&]I#AJ6@[9J LMZRD0GZPH#V<AVA%-Q &+9@
MT]Y!XGZBN#3_+@V_.TCHH#F&YAE52<M?4H$G&>5V^".0W$;H1Q(W&'W."]PQ
MN0X/$9. 1;%_@_=RIJ1H/%;=,XL*E9#9J0^?&A!7&5*4J63]WS?E&F78.DT"
M+D(Q%&'O"'*W[GP2UD H3,!Z[1B+MR3\PQYK400*C;YL;=5%%AS'//$#SKRJ
MQQ;!X0"U,=4U7P4X7!FRG(=5EM/,<NY76<X5/QN??CU<%J"H;*C+FOS<ZPLE
M"=D5RV9'R C\1JMC3>4B ZT44L\$Y-%7S-'().0GWD8!MH5D\WT P#1@2$"W
MU.BA1>H?WE_0&X%C_7CMH3-L!/S'XFX93X*'AHS[:CYM#FA%H;@#UEKKXNJC
M6PFI23DIR"D+XI;#"Y%&0>M!4.^&T;,-[A6(XZI(4&0$NV+OQJ4&;MB^2/CC
M<$'U(XBI)YA1<;DK3\9]Q_R2>"P1CVJJ- <2EBJ,@U0Q(5D/8JA61(#:Y<@X
MFUS+V9VR"XNE<5N@#0W>M7;.S\BH*(Z]@B[W6/C"8D7C '93G<MT]=)B<$Y\
MO*!C#X7GK+8K=F\;R)B9S2UR^R<&)78;B4"@3WDF!$\V 5DY5G,6LVL,=CT7
MZ^W&,23.O 1Y+6D3<GW8S-A=@X9C2#'R:V916<1Q8Q+I($./RO9@/"PS3XS'
MTBPI:&967)@I#;%B1N_TQ*,UX#-NX ORM$U&JRFFWDLH$IGY<K8G3JYU!U:F
M)QBHE?A=1>'N$/T6]Y,%\\R8AU5T@9$F#WSVOD?\0S<N< N2VLB< SP:U$'/
M. APPF 'O%#%OTMM]"T4J]]J+O)NXY4!M#O*SIG[@+GH95ZQI396Q':^7WF#
M607WS0^\9 )D(["9/RNU<A;[?1GJ/X\>A+]==8%_35$F;/";;O'T3:3(RM4X
M8G:7_BV4NLK4&P4VU!>L (!X5/?'K7_M3YPV/"7'VH[-4F5@%>XR2>LB5/]$
M9=HE9[S]8LPZJO=*(G4CSV3/8FHNU*"AP0N9[DJL 9%%'/^5BCN?;53BAD^M
M24-&B@8WX(4R\%^X0 0.D).RXM],U^.&8$]1E-@,0RM$RM2)0>B] )=!$I)C
MLX=/(]>?^R S90RXD=V*=5I4/:JUN;V9?:W5.X7BYR[B<1#7AI%U12P(X1NC
M;WSB33:BX1!;YWICW&--V6Y0+!^(UR[M"2R#@GC+4A.;C4]K]46J\<7M$_T)
M[W^S@:ZYZTL27IBV[5W5F.KH^Q?G3&B<J]!7=SO=$Z<%#:YR/4.*^U%-YU%7
M'+.>.8(+++5+80AC$$0=:%<8/:%9%'P"7%.7&Y9/,CU(J+4X#'3,@6KNZCZ)
M4ZS]$XH),5]CH8<W)K=QE-[<*B0H%-ILI&/"S1$Y:?#(4-TI'0ES<X#+1>A+
ML0+46\RX4[?G<O#F(-GE.8+7RW4$+9W+/I$DP96)KZT,D4@Q*2!DNLC_?](I
MXI+A>HVE,"E"31GF0;L2P[<4P_YRB6%>&#O4\ODR3KV-JS'G7LG 3OP?8%_O
MY>QKB;(#8A%.GA;<"F#N8OS6U1E6JTDM=_/@V*T;]-- $B_&P,[;]ZF>P#D#
MT(:^LJ0^1>,5NK*GA(CK4.+1^C48R0K:0<4'#716T$W@H"!"%O,&.R#59KSY
M'A+4B*7#"[+H[5Q"FP6G\(/KM5E/%LND;]^"AW_<<_JVEO5;5KS9C=K,V(AS
M_$C;,U#KL?P*9?]CSJ KZAR;.4><J5-O@CW6DIFY!&<-_FDV&GM E(2.S1F-
MQI9VLY9<EIZ1<-]N5@EW,^%^4"7<E_9\?$COF*.$P0,K5QWJAF0HY ,3RU#*
M%;7:EA('(FT3248B,T'+XA::\MO3\H*YVV28QM!>P" #_Y>:DXS,QC@3J"S0
MKR^Z4$"?6-CW1H9[7(9L_1AZ-@?\J41UMS;NM8$.$L/]A5:9>B<4)V1"KI0D
MQ'':#WM0!B-6<FH@( 6B#8M.AEVSMYX1;67WIUXC@T![[MG=>D8,=I:/M<TP
M"CD5FJ'$8<@>=? 0LV;9F[A^X*Q1Y".50?R!.W$)\N'>B=_+4<B]6G>F;JLN
M8%:5L/5:X OGDQ>50('P6<KZ9A&!^JD#;XC!DBA<5_MD[ ^\-;?\1OTTT1KU
M'X!/!OIJ)$S&4MBM#]9O7=GU5FVLXFIB8?^X)O('BZAHY<S2JIH?NX#P"2?Q
M W3TY;\J%B_XF0HP_BD,]&3@X]?A%^:_N0NP%'R$>G AD>M\\4(QR[XZ5S?(
M,3&M=1<(K0'\,!IZ044!8B!N ,X"$& X.$,?KP&[_!?#._4:]IU4L)MU";!B
M< K.%;Q.:R;YJV,BNU$I=81*W3QRI!:EDD.]A.@PC.9J-: R7 :!9X8I8]JP
ME$:-80L)>V3#EJ7_H]M3^PRBIE;!N9N50&3J8N2\5"*I#]35& Y,[%22XI+#
MFVQRJ.+=KM=NB'#B^?O-X6, H]UA"=?S-N[C*K>W]?_?LE(YDUG#+*GX\!WD
MUGX68D!EI$QS3SJJ0T0$UD<-0M];,7&"56%S<J1FH+;50KB%0"6DFFR#@\%<
MS'X(N#J0RW/QE89AFJ837\FC+,57)H0<TED4!<Y7 $EFHPB903/ P&I97O"0
M080I9&(DA(IJ-[GED@RL5E2%T(01BT # B>;+N\<%F3*#1:XCN);"!X:6(:=
M94EA PWK/W$(U&LOED5E"=:"PPIA:81>:9-=V(?@)\$:X!&XHU;>"U49Z^P!
MM8_7H$&<JWQ=E@;"8G$9Q]X&J0AO,.T!5<SFI<BJ]R9P-/7#I?O#U $SQ=H!
MV*DBW)"%P] 53HPH1;80IG5%)(8//^%#-1B@)3&@TP.43C%B-^#M(/2]D'^"
MXW$,/A%P\M:X?X)V]KC^;QW?;KH3&-[67$E2E:U!WU-*B^*!U J$%T!K#/:N
ML-22;8U&MHR<G"W?KL5>,XE\%"1%N2X($A:? +@[>KJ(4$U,I2++0V$#%(A8
M#,B NC :^,Y/N+J<G%A0G!:B7/J=T&P0N5WAT.)<-XTL^#0"*/&3"*MKQ>&6
M7J\>IJS!LBT3$Z\M]A6F6PS9S@\ "68X_$QNF32+"L50KO.TI:6B9!0D!@05
MZ%_DM6+:M"F/\6T0>N#>(SD.0Y)MCC4>.3&UBW=;:OJ:G&_D X8+E+:Y7I.F
MK"E%A3/6E#?B=4!6E)6]7$FT KD9,G$#I0(A[EC@N+PA<!I@>Z>$;K1,4+8M
M)GCZ@.LJ2$IX\@J2+K:_830>4TMA]J[T*)[ 9 B1(KBP70SD-E';0Y$8M92T
MCLB[ %>THI(P&[GX>)QLL=,,3T@Z@:_O1Y$P[;&D,W("[\;%-M! D2QT-5OG
MX!+0!$TI88U%[6ZI0$*(  %.7"E6TX\*RJ%8, 2SRCVI0*SS+3;<;E6Y#S/W
M<5CE/CY"349K"6HR>FB82.@^QV&7>=666N>UWA:T_USO@3:38VY&;PD#>)E-
MA&2QZ$4.O,VD9/LD$&RS;".RYF(//?H,IAQLT&S$GW'[H1]ZD"T[M"E@,Y#]
M;"R?0:;UFH';5TX& F:4%QWQR*^]O@N4HVSK%<<++@U.%U5%"B2R6,<G/"K4
MQT:[\=PRR(1'+HHC%\)83![+IEP49;CY<C^5P3ER!UY!'DF3'6(B:4E/Q[(?
MW44Z_M;1M5B:GGEZ*8N'C4S(X[A.9+6K*5,87^JGP&MMID4AM@4V>F%_E/7\
M*04V$4"KTFG-=9=6V0LD>!I88\0*=2?IWPI#/H!HF$4U\H(SF N/R"-HCRE,
M@=0O=]A4><[CI\VI#MOK#]M[<\H78*VI&Q-W1-'2X)M',5L5A=5<$&TQ"ZGM
MFBRF-3 >PI=>O:9NO2<\9SLCAV9\839O>@XJ0?$A'I+% 6I-/ VQW3BQ/G/L
MBT)9)FQ" 4!F3T&H4PM,@/")'T@'SB$.&3?*H@N>#%^70TG6G[]4$'PO@.-@
MU2'2.*EB0)/?#7(JH(,'UKIIRD>M0M3BB+%8]*IRI/4:#G7:3EIC@<'9PY4\
M2DJ;IT3@J<TT&03"-I)HD"FH1J6R7J:RWIN^V*K9]5SBBF"Y^]DY8GR,SA:8
MX5KC*(#R(MGC(*1)@#(SOLDR*N3S:O-BTSD6(NC&B60]O7;#OX3\ GV);!\'
M% ^2+"(P,X> <$^(G$(<*7P:?AUNUI3*@#DZ.? 2L5&LL#0M*C:E0L5VAR20
M.'AB*8.0+\Q,_"]3F_/A\'YP:U]:CY2H5C$>F3(Q+1+E>.*%"FX$'S9G:W07
MP,60!,#9=XQ3587VX'P*H@BLC!LPL[P[IBL&O #M0. F$T6YYAR[#_9Y'\-$
M!WS6Q2;8"@E'/3LQU._':452_L)C_M[$KN8Q1\Y##<%GEE8CH(\)>6HY([8<
M,@A""CC'#">(L $.4&''2%!-7@!_4,7H-;]?"ITK6)CE>\1'_,"Z9YB^CS_0
MR)Z"*<4(<'63\#[&8;BDTK#LHOK>=)UV0VQ@"<*\Y[E_<ZLYA5$6"X!5!O4N
M]+689!O2N$0L)30:4<P/BA.PF?P8/  Z7!A/(&JB= ($0T1?10=FAJT5JLXW
MV2\WH":8")"E](-&)G)\X)OP^ZIW_.3>"^X\9ZW57I>:G(O+-#&I.*0(&90M
M0&12/88UQ+8"8PT^=EI[FSO \B!<D#$D 2E=+YN.#V6("0UR.K7R#/L)WE>_
M](Q-\0(D;\/^0_IYW$_6 JJDB<F8'SPX9@,H;PC-$)G ;$,L5#QQ]) 483OZ
M(IGAF*:Y./2]7)9H2<[64A_\YV36VE5FS<BL;3>KS-I'R*RUER"S]BF*_N(J
M(0_"AT)8.BF4_.)M67&?O6)S%YEC^^;ZH6XG"%=F+DP_XH\@% :)#95'+K_;
MP*!13()AT%XB]$7#9>!#FD*S7@,.31G8)TBX;D5$SN$4Q+F1<C)18 PS3XQV
M>;+.P.Q6"*_+M'[0%_W/.L>6!:G>^5&:B+F$W'XHU_O-[*TE%X/1.)P=)(\W
M]BC- "Y-["-N$"LM0K.J +WVP+VOG(F7G:I%IK_L4R7EJ)#J1!XBR35!<# 7
M6O> -RK%2,9EAVA=JZ UEJ1P3SVH+*.RBD)*515.TP2R6(ZA2T&H^ X\#Z"T
MF"BDGVJK*)OM#'TH[D\1/XZ.A1N+(<-M4*^-(<\&0>-&!NDM3&;2!=@82J'G
M5)?2ON:$*6A27I * \\;R(+UD5'9C7I-45/D,O1*<TAW#(XC]14S&Z=0#-(Z
MRD;D3&TOIOTF#C0U%^,%X/+:[GJ]]N!!9%'BX8,HO 'G@?J"%D 7KQ\RU,+5
MH7_9H5]D&LXTAZ@0QB2C-*I<J2$7^>@-+GHVDBF(5[8$3P>>F84LQDLO5H3B
M]=HM5IY0$IKE#/WI&*#CV^L.":2*DQ7Q1B*AC4T:*1;?%W=AZNK+'6$H?>1M
M&>@T&!/@8#(N&Y,7IW"+(?8FL_4=++ZLIH.&<D8;.6"\45EPC[5A_T&G +$^
M7<*(C9P=%\-DRF7DG8PJ"AO-P3H#H@>8S@-X)]S;1Z#9, $OYMO3$-M&,=";
MX-WT@)3ZVBG+!\=!DWCB## C0 MF=74U ID4.1(?]"?3"H-4.!4#_=%]R*9:
M= ^O2.%[J.24*L-_38LD*7'AA5.MJ6CX#6K!HH*S:XK?",*B5+>(EUA6G1M9
MU=UU_1;=42;U&#5A3,A1\]'6'<2![?D0^Q!(A!@:@"!X;&:$=^I8&B]="4K4
MT.[UW3A&R<5:<_4=-427=G>8!MPM5T;IZ&.<^31^(F44VT[BOLLH5,%AL]JX
M ^D\1KHAE 428) 8&M<FO@:63.D-'1 L#H4WM)[ %HUJEI#%=BW&>5?6KROU
MEY]TJ6^[Q88&MI<@-'!N]RMH.+_I;@5@@AV)8QJZ%4'ZJ[9YH4&"%--EF7W&
MO=5;3;:.T3H%_(SK!WWGBQ%Q&PNF3>E+N<!^KT:1ORIIM<R(:1RD\*@<.ZLK
M"6J2GY9T3Q<H<$^J&]^>%V5[CYOB@C>( )\8*K_&$;4P%EL)MU5\XX9B- .L
M\?0'XD?>#RHV5'UV;J)HX*BDF#2( (UPKT3%9!= TCBZM'P<@A_*]\H6.YC"
MHXN9?^&,Q<5)G6]4_92"8F(E%Z6ZL$;LGD@/9*T76+Q0'^>Q%0RDO,+V8"ZA
MB"P%2&G#!U5O(#$$&EX8W;-?*EQN</>YR-5-$#KJ"5^:<259.W!IA:H,,C\7
M%O(>I8>YRO'YHH69)K"T<VUN,+3CQ4A #7)D]K!1D9Y*(EXC$7-ASY02(9Q]
MZK*MH^9:0KC--ZN(,62FS<I?%IO_\]@MA1;:DGG%;/9MBPPA#K#4F^3&94!]
M)3YS$9^YD*]<VEI 52;@[:F:J1N"0$SRNHP;O2_N%,9A7:-E-JH?OGNY+[P?
M$K& EA#[,8R#2?)]LA*$QQ04'H# $:"W,,"B'N0'H!K%HQ%;#<45C->,T_&D
MCP 4[*@%>$<([XA/070,#0&7C$6X19&B.(HEO8/"J&#Y-74<KR3]':AAMRL0
MAPGB:%4@CM4_'W@3O"44U[@)'KW(9Z#B0VI5/12N]T0K97:_7"*94OP2E7I\
MU?:_);PU:T?"/J(F0X=P$IDM8S'1H0,D<.,6="HP?0QPRR4G&-&8J-QIGTLI
M$^:&O(_28$ D)$6"](@45@+U&H':GY- ,7$3>Y7%-1F9.(<*7T@D@Z_-/!OV
M0YUSEW9AEST.O$A8B\)R/"/B;T%>BF+!F5 PPR^JJ.U+U<+;X@G5]EM@N!?'
ML<"+)'V@F=4)<(2J!NX=S3JF[XYZ;<UV#?D+E#=''U0_L.KO\2KIF4O\,P-Z
M$Q:)U=,>0:4%A/LFU3Z:,6#8K/GKSM#'7ITR::18B$& IF!&Z[59F%$+( I/
MR7 @_RQ>*]XK^^TI%!E2PKE]ZGNOP9\46> Z&GZ4:D\&4VL4L09J"KD^-[<W
MG@8="1Q%J3@:3X('9P H&D(V),*M5!SW@%;],QUPI1*,@9Z!:R!C'093+.#1
M %7Q,\Q+3%3,=*29,GAE92$V93-R*U2=NM><NKG$F&<VLX ?V:TLUMQU174D
M :(@7S+<QW"3[K>.3:%40,3Y4-"A:8ATB]=N++D7?3K3;!* .,-OP8-90^2D
MHB7%<\5!O;&P$P("22GXM Z10\#\#GE UQ46S1@O5<--';0\L$^E)[>H(FP+
M5WQ7#2!.98,5PNTQ@GWXS-&1QER[7B< %"P=59"+!9/]3KCP#^!*A#V:X^0!
MD@S;@>G7@9_\*Q5G82BU\:WG$K1^3;Z>-Y!_ <\'SAX/*\/75?HU1&ILB&2K
M)[Y"(!  )24B(\!OO!Y0E]C( 1'JM6F'L*$.T3!W%O&.$VZ4ESSA(!+-YV-G
M\5E;2SA2?5A=Q6";V^?L]A9OA[AX<@>T05>JG^AS;[V M_TEAQ^S^R, DP[6
M&W@4Z5+SPAOWQDOTUH:2UIF_RUF,/@8U L\=2&F3N+IKX:ALP)J(]P*@+KL<
MEHYSN:O,6H1EOB]08OD>] 8?!=:A:(YFL "J2_BE?O5"D>-"G#:.HAC26:JQ
MBX&D>IK;K %3,Z%2#+FNUT _H;A7OO9+[;:WA>4ID? GK_>3H*D$4.6/H4!?
MTE^CHL-,*VBC:^@[!<E3H)YF*H"__/Y?UY!) X))MP^95U)LFBO#BBMCL8*J
M"Y1.@G@]L:ZCY@0JG<B@<(J8PUK5%D 1@3@"<%/)@@"C%L /AP&DQ)#Z0&C7
M/K'3RT]>"S=DZ"MZ, ,R2+WK%">7O)=OP&]Q,:7,WX'TV4T$V#)Q5?+:FQ,5
M"YO&BN@AM_HPF\M;/Y;89QDBC^)$/LNL@H0W0B=Z<7U<3!#!]9E)>U@%@*/(
M1530%-?L(D;@,"X?$OH>H.[KV:XEGX_..G;/ 3E*5UP[T4V4)@R2BRV+5"+L
M"FQWOH<- T)\L;C5$@: PY!A]2H38*:HBHL73DUB,9N\/WS0\L>?HHX."!5$
M4:)_-0B]'GH/1IT7@NY@8'(5H1 "A)?A!+),56PS0Q#%";W#CB8$^[?S).+3
MFNL>!3L2PB0,@("=8]G0*FG0N5;_)FF>B*_*S!K2+/6M?)L8:1\PC5  D="!
MD)^"YW@-6GVKD 8>3).5<7AB916+GB!2EQ 0%@#$L&JT_#M&3D<C0NJU.S_2
M;>[@FT)^&NC89(2H,D#> 4"Q4P$H3 !%NP)0K/[Y0&MK+K%IZ]X!8<TYZG:8
MC.P./Y8- L&Z/L_H8Q?$">)IT"&'H'>@:+^C!@<=RE=^O=8A2#@R%$>!JBM;
MT]?Y]\^=(_,ZES?]!1!@8FW7L289/)4W"USYGX*H_Q>49.$U(%S)9,(/,9]_
M<7P*48ID8KW$"G!G0R_B%B>@Z0":F"0$.[A^<&"HYJ.1PZ K+I)H).ZO"_Y:
MDGW1VO5ZO1;=(Y%$GQ8BH >R9YZYNQI3;W^T%'"V#38I<;^,^]K>$#%W7!:=
M'"B:;_$T=%XS']HI[!$\4V3J-175LRULBEE,F;&BZ@+*2H[2&!&,<32A<E;Q
M2;K"O1S%A)Q7O:;V1]AB$=1!WJC: E4EB:=0I2&P2:B1L<L>'?B)Y9N@0<5A
M%[+$&#9 M.\OW;Z9TEJ\>P7Y%XJ8JJ 0@UO5$ <1.U=R)9>A9']5-/M<\A\=
MTNE*J1KD>L*4(/JVB=GR+%&X*%/@C5;8X ,(5TJ#H\" @#!R%DY52<-+ W&+
MI"7&4.HSP2WXG:=%Z'1^-Q^@J]<P0E?%XUZC1W;F$X_#+68+C< O^),S=X*H
M2'TG=7_<^M?^Q&GI.SR?$M*4/_Q(==683ZT4R&O$8"Z. B3E<(LD!$K!FI!E
MS#[A 3$.L^E#RH ;7!(X!*JKH TU)G5]\]%@8^C^Z _U&C^DP2]$"Y!Y+8"6
M#8*]L5$ :PDG-*N$?_]G&-UO?(WNI55D!BPQ2,>F*?Q>]8O7S%* ><E^#&^\
M?H"17YA!0UJCPHO.!)(,6'!U3[Z=F,_%:KHDP_@O(3#""[OQ9--/I/UEGIO(
M@9 GIZ,E!L H]I+L7-Z-Q!DAU9#N$9^H:*)J,J^X5\S LQ\.07O"R$?B2[K?
M:&+;_&R3T[F$TX$->9'D6U9@\[E#V((A_94$OD8"YU+<>(8$6>R@V2G,AJTF
M%0 &U8X%@FF :O)'E)$?N41XE=5\**)T.TO_;P!<[M&88OT&"HZ;4(O'S1)C
M+;#83"HCLH\))Q)15M+Y9M(YEX(K, -"Z$+")KQUW?I)-OP@M2.&#9$W#>-<
ML;=A$*<)N1J/H\2GO^/M+EN"B>]I70O\BA(SE6C3@4'SRM%5NIM:$%&3'WN@
M /3#\EY\BE&SN[Q;NN02]YP,SFZ5P3$S.-M5!F?USP=JY+G40%ZB74K09=G;
M!;/?W/*"^7:FJ4CX$IJJ@ZR2=@=W7IQ('@XQEB3U(<2#ED72P*S!D,Z&CE&+
M?UAP34H9)=YD$N@RRC_3P<V(XD70]"R@-E!L0W#B@\UIPO=96%$=84>L!H!
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M2,24#9XV*5@<PD;X8V0TIEC_* JI7RAV^N27XBB ""/Q5#]FZ/S4OXVB!)>
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M'<,'/IWCY'GM3\0^",D3>T2[" O8,#XCOO\9Y4V()>Z/&OY%J?778E$"NTN
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MH>=/5 MK2=.G<[I1C@<07F[%C#$A2"W=DUM_+"/[4^IW,59KOA/ 8,(<2\P
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MX5SB9^LU8-OPQ'H/"]ZQZ70 88WDXHGCC<9!]"!K>TT$.]0)TB^]+.$G(%U
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MK&+T4^70E;]G#QCT"BIFZ?9<>Z$W](F/%;]H+.HZM/(5*Y]?>G*HZ/0+T=[
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M9O.PV3PH*9B_TFFEU6G/A\2NL+56P?O?_'#L'.RU#YN[FR5-!E2:K;2:[?F
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M7!_^_Z%#!IKB?_[QCW_\+R@5_,M[^#CSF3F9'C@)&OB:F)/P1\3<_5 8$T%
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M"4]IQEYA,P@  +(N   *    97@S,2TQ+FAT;>U::V_;.!;]/L#\!ZX7.T@
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M),E'<HF<RN X,P29J=0V=$%*Q%8/%<:KH%<.G*D(N65=GLFMF%//@RI]E B
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M\N[;P]5)^]W__?S7O_S\_YV<]&X>+G_M_4MXG J7_SWYUY?[ZY.3SS\//6@
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M:E[<XQ"9^KT6_A_NIUC-2'98RB\<KL:%PS6##3]C/RZF\PL7]WCA8OU@PFM
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MW+$F8[Q<_> 52+>Y#)?#*^^RGE(SK&0EUO9^W>J5@JDI<+%0.@=N1N!&Q.+
MW3=P9Q??<-RN>S:'RW X;/.!;2R_C -W[;-9LO$X=-=!=].2"Z&OJ":G'5O[
MB@[CU&,W'JL'SN-U=WH> X^U ^>QQGGL-@Z<QPW.8[=UX#QN<1Z[[0/G<?N
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M0^%.Q]W66=*C'=+_&LD?*HC34B+S10V3\7D5Z?JBC$4;*=FI>'"Z8;F)2OS
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M8E,J(5OEZ/3()9#0-C"BET,B_U1.454Z8J-YM&>IR^X<+4!4.A.JAYD$_FF
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M+05V^DN\6:8H/.1Z\ 7+%COU*1C_=^5XV 34SO>"WZP\[4Y2.#Z+^560/H]
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MZ/D_(+>8H(W4UW!XZX>%BI<?C((F*06-+A@):QQ'T[4L-)KO*7,[0R]7H(R
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MH'R1A40(/??A9@@_Z_[8H,-N_UQH*Q)N?6%<J0&_/#HVGI/&&W]")]&K[?Q
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MF5CV(Y[K,4P:UGCB12^I'\"P2F\V\IH&40*KPO7F>,L$0(01?;;*2(PN&-[
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M@;T^&0="F0V,I31Y+%;!KT<4#@]>'!HP92<H1N&/$L\M9^$V[*#LKW^)@DV
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MH*HRTQ&,_$6BN.?;<??5/-4STY323?(5-?\N ?IQL[B-F><YTH;',8<9=J[
MCD (I,1)FUE>S'LT3,&F]88+@!ZN:. 0>V"6N4G[= $/(SO#Q[+SD,0;55%0
M<G AXM[AT] '-N.(J0JH5T*W^$N<(4+Q2D0L0I]P**BKQ?;E?37M0#NGMA4)
M-G5VMS@4:H88LB$0B24_1"DM(7@$TDFC%.)]"#F%. HK1TMXI+Y^$?6)Y[/'
MYBT52Z"6*:5+X,@WV37E.ASE>3UAE R;Y%9&4MF5)XS]6R#&Y/BRP-&RK;L
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MF927R,5($/C?F'E(QCCI-_4D.@IU[4@;!]TU.M#=#G2W]LPOMP3=W06<[3;
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M_&'9>%I>&PHTN@4$:6$Z "%@MWQE]7)_^%FW)0'+%C1U[]G17<3</X_N&/
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M]K9T$?PK9V;FI7$9V5B0D&U!6%]\_NW\?_[GG]M8C_SU"R:D&'<[&Q(C"US
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MG(H3&EXL^AH&O\8Q9=4YF,'P(?R5-P^Y\;Y351=LJQ>.\(2DWC2>K:OQKRS
M4.@YV,O@9A2VOIU#U8CUM%Q4H<7M<7+P+1CENJD<$5G0Y@:ZP,[<>P'=JP^Y
MW4[7[7,^O!M-XB.@SST\M>!74XL=Y9X3\O" ):24(R#\)M;#*]]<> ^U& K
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MYXCD ?&[T13]5W9/3S NQ7'G<,5PUFDSJ!,T0Q1IT5"+=U9(VNK*7J"HLI0
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M>AJFFC8_2T8'\E!S.!!-@?*9+H1P.]RP"""=6IQ0(QAJ1T=]8ACVP;Q;:A7
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MBG?I:K!6TY*Z;ZJFHZN:7E8^L%/NJNB/\XIRA0L7CE[!Y?KB/7=:9/;^\ZL
M$4#9VX$(;'>9O ,1V F(@/%#R1E<TD3,6J>)V+D;(0)1_(5%-P]NM$\5"SO%
M+-AU1S!=DQW!+L]OP>J_N5&^G%\K-_\XN3Y_;?W!?L>Z(G\X]^GBN6 XNK8;
M(\O1A?WS+S<J%?H-\68; <Q1F>_)S:EB]#15D8RJ *<J-_PY7N$O8.QB7L 4
M3J9SCG-%P32,K/EAC+ ]6+KT&.*;9'7B!^7.C>'T\"_Z\QD"-/PN!V'B4WP
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MZ5?@+FU>/'R57O'92>WP\]'H(@!>T'A]C#N"D\IXR1#^4?D4 B-A!/;PX"+
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MKMF$ TWP7T_A673MYJ[/__ );]]X@?)/S+:\I(W9TVF]"'XYN;^/V#U>AKU
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M35'2? RBV/=<S,=(,JQ()8AET"I/!EB)&-#&+TH^VN)<F!31>IHL+(&=H8<
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MJ7_$+(?+&R11,:O2'/:;K%7+96L6P1W7\0C#]R6%'HB202:C'>A%U>Y#TW6
MG_EA&-VX[+72_BCLM$MN/W;F^$.!F'?DS<;W\D!C=S(%,J*!T491CKB54_.3
M),.E21-I@ YIFV3>%"QZ=*S-\5\8 N!&P.I3&U[F!U[?CY'-A5F<P$OI^Q-X
M531%%SES4_UGS3I+ETRX&6U/'XX <XY!)N*DLYBB\E,_]D$H:;<-A7A27PVL
M_>N!<-&SB!QUK:M9^DM P<\,GYT(24AA^(.R1]R8.X/3_I!W%3>O9EV"W,E_
M&C/(,'IH7._&I43H1?_S=.R"[C^@Q;*6I,]2^CQ/9, A$)YM!=@C"8.BU),;
M/G<I@G7#+=!)&\I]4DLNIC[,R).^WA$F2/D#Y6=ELQ%WUL4<?#1I)WYHMOS6
M5NZ2MYU=5KD)N_P O;B25H>QJM]4>M*W__O\[O*]UOE!S1]SC-M63FQYCU8Q
MJ;M0O;QJG@B JF/2V_I^=.+C%M'#<BR\F>2= JZ*6>""574O2EQ&]IY(*\-H
M9 X4#C]),2OBLBQF0TD,B*6+L+H93P<+)O :@C8>"-F6ANY/',UHEXIA'AGS
MBD=@5,A!EQR_[) >\*!+#FM=$\$IR7CU?JE]PT!HQ#?W/8:LS@K+(B7RX_LS
M6P[''GA\#\:W@)N[9!R%*B)OVEG,H.#F>Q$,R441IA1BYSA.:*4K'&,NH2C^
MJD@)>BJRASV\@Y<W0TLA"[&1,CT$BUC:$EO[QE\*7+'G1\"A7+A8L$Y@4L#P
MDU=YAC^*3=4,81)YF$LE3M+H),'C \J:@U",11;ZKO52C3*E@%&21 .?DO$H
MFI*('VBYRAR4^2O4W\&ZFJ81E>+<9 $0GBQ#X&%<8-33L73N_0K'X644HS'D
M&RS_;!K[05Y7MKC^D\7U2YO<+@U@LF3449'B77&Z__U?C4;S[4F^;R05"P_!
M6T;PO8AQ6-P&"^5T(' 5*&*C83H2V&%EFF3XZ:8;?>,FT21*T9[A34MX7SY_
M6]X7?"_K*+3SK@6W-,ZT4:[+=FYDO@V\'BDE,DJ63CEGD 5A+(7A"I+D[<J3
MBXRP+O4$H!/!92F_A_4R$?DF >?"T/MK >9Z.*<:HP6J3.;P[.25+?,U8QE.
MBT(@_#*Y#DL#/@DB^V0(,A2C3A@&\Y$3%@1T0>;+N)D;*O4+2RJ489_K9KBB
MC-0>EZQV2KG<8&?/LA%(*<NIJXV]E#<WKY=8K )SJ;E"D%$02(:^\ABC3L[\
M&DUE(,@ZCS*$.+<^R8?/\H=U1'/Y<>767CF>O<QU]5'*[ ABJH44O>CV]>6+
M(A_ %".O>GT\XW^$Y.(PE=A\MORES=%?F:8L#T* 2'&I/E*.4+J92\M:#AOB
M L_=$&,'^.%%$KLBD*<'Q-LQ2UIO/[R2=>I]7W5HM/:)^&']_$_KEW_ 8Q0$
MH9^IKTH.2,Z>YBP79:3>J".S>9*4J;NT2CVS:Q&#71#%\TKG/(A5*74,D\_3
M:/#=1@^7Q%?XJ5ZKUQU,Z+(2T!N%/N1S_L$W_H$O_;^Z=<$7-_'</ZR_!U$?
M./(W0=G6GV5VS) RM>4C-(+ZBD)X\@W\O6U80>Q=U9'*?WU^7U,AR-]$G@8U
M$WW0M=!;F=[=NS.;S6JIP48F7@WVB ]=NN;S_%K4@:,LT3J#F@&GI)=GZ4><
M]:4G2ZN6(@4S3"CYA;+;6=,N/.Q%*#>IRC<$PDK1P$2WY&8YBM6]W$/GV]:>
M2Y685SD>]Y0J0>A_=A<T&C<,44FB>^VF6N/#HGVM">*'+>!RO7;G+1NV3EW_
M"38VYW7NI5FVPNY"+M@Z44M ;JA41F,AY%M,9%D!*$'1#$-<!9L,%T_6GYRB
M85FIW+^CY6T'EDK16[>B*I7BF1&QLEY[=HGK23$ 4$T4B]!5FF MP\^,VA%T
MF( 1PQ9U"ELAD#<E[F0:B%4IS:12_GS^E3)EC:PZ:8<B=V(G#A!O[G[ [XTI
M*=ZC9ML7(]#4?&VJ\[I4;F9KY>]RCQ-FBDU3KKITFLK0_^;C,G-77.Y._ *?
M(4>7(]$FCMT;K,(5H>EM$3_$($N5ZT^N"-VKO-;O8FY4C^EDV?PQE=;RQGKI
MOY+;B*/UX\@U'<U22;6D((L%J+8!>6K9U46G:#P^=>=T&B]]&%96*A1#8>0T
MAF4+E#E2/E 2L@HQ&?GHUE!@8[FB-'3!*!G!:?!IPXO@39X@,!+I)/;$-(CF
M:G-@SX!U<,T0?H;",>!C?.G?O#*=["I5/ ZIY;%10_ 23T7\(!JTE8O#Q=51
M30SEO\,7XPPN"CIR821*#YP(CQ<U'+H^;DRAQ-KP^'MNZG)%-IHBMG+AP[F,
M?&X1A_,98(JC# 5,.>7ZE1F7+)9*G"0INM-UPL]ODIBH\HEN&1X(=NQT]7U(
MF'A4D>& %_GFN7&KYV!.G.?7[HQNZ;U.Z>G7L^),MFI2N*RV+&@ZF\+8R:93
M]?J++3L4PHON!<O)+Z[7&NJB[*R7V5W&['6ZO=N1GDT:V@\(T7>1=&[G4IJM
MK).55A:5PJ+X0U^LKC,"[CAQ?\=D#&;(<\SPP,B]X>:VS4)LK=>\N[@\N?C[
MEXOK#RK"B^Z;D,3C#5AAE$^*M3(G^/D<K*&1GY [6]6*Z=0"BIW*'VOKYQ90
MRNK:5-?F+HE4I"&X(](-"*@+3,@,XR6+6AY5PG&\/N&RWB4]T!(3U,24.S<4
M,_1(R$+&/K8(UA6RJ%_!]Y@&H+1GSFJQLC %E9-RAGG0"99<N_GK56VO+&3/
MINR@]@U=#FNQ80MDXC$Z<&O6&=Y9*Q'B.V?IRJI:@H/)2&-'Y&'2G^E5', K
MT77]%)WC!< &6?:&H&;T;WI+%B*\=>Q3-K>>O8DXD:">"(8\75VI>5,BF"S/
MK.Y^=?<?L,D,1R&6D7G!.F"0A7(*EE[#&Z%M.3A0BX \EA@".Q"-&FF&4BC<
M%=@>2@74 5$I5.40=+40MU4*[AH?8S'6[):!#*>SR)PAHA5^)OL,R[LPM/)^
MU31GZ$)UO=\S+C8&4U&]O+J1U8U\,"46#/"0O1JI%(LV0_'(@* '8E"Y2@10
MJJNKZY4<X:)([5&CBGK.OX/_6 (63DDP(N1,F0(0 .;0H2S3"G)*!19N$G$.
M(58@UZS?L.+?U7%17P4M26+*NG4Y13^A(I\HY,P;RL&=ZVH7& *K051 @STG
M?)LYA0/#I@;F+*H*F/F0[X'.KC9!%MRY3++H)^*/C+)X0)\P"MT+2L%O.7;<
M"?T4E*"$T1;D)MKK=DV6R> O)Q%5.L&<?VJV:55N,=<H-STV92++_OM[LXC*
MQ;+^!L94G5=P7IYY$1U@Y6VI!%4EJ!:1^!1V'<4J,%+A^3$F!B6"8&DX&QH?
M6,[DSJ,='-T@\:9J*B99 .<.[#3$R(.^D -W,G5181S*^(_*(F>\TY&?NH$-
M/#D\F8)>1^$?X..32 O*WV$NE%KL$64E*H; 9G" V)Q8)^J213I!W!957,F&
MW@S!0. W]&Y44Z5?"-5'K/H<1;$$C]%1);4BS(@=J0PBN5_#/ ;A2G0I^C$-
MK^ P.6CC8WHK2"U#&^69^Z,QH;0IL,TLG("YK2(1",[#BH#Z$<I5$,!#K$0=
M$F0?%JEBMO"Z.,YBV$8&,-;&;E34!0<E0D.(A_\4MH\A4^00*JPA*T43,S96
ML]XIW+H\BLA$Q6@X<#HT4956;QLBN5=_@=.BM])>L%[BY<T-DBR^$?-$5^_F
MV1QSI@T-H.0Q*!<5QA: E?1$2SN>Y)-QFHBSSI/!+)&$X6_T^12T!@J*:E\D
MJ14IH?.G5",@=Z[2*/95['Z5I'U64-!9KQAS&;GUE37-*IY3:1B5AJ$=TQJ(
MW+ HW:5;Y.I;).VU'!:."GYE>>;4#R+Z-[77DSA=:RHU\TI78OY%-#8&(,#\
M-3VQ/#Y?S.>@6+S$HY!0 \K'5*(X4,B^4+^TQ<+-%^/KQB*8YI8JP[=B!<!)
M-#R91@-TR:-%GU@OUQBX:-F&T8)Q.Q7%W7O%R)9R2W+'1"Q&;DQI)K\N%"+H
M6I11Q,DPALJAEZP76$R 8"$8JO=Y1BIDGE2T0@CWFB^4SD4M:/2$4!F29\WN
M IFTJ343]P;FEF@BHY.BQ!K8:95G$_L2QTXJHE(7QA@()G5C-S>CO-$\KAQA
M-")=-!CB-+EQSJK^:3K!5/=>ZM;M+B@6^O!FXXB7)#T[WJ+NX'OE2@?N!C^=
MZQ['K6(<5BHFMD]\JE3,1SKN1\J\?'H*/5?I;)\QCZU2$2L5L5(1B9;6RD7I
M&0#NANT9*:>8W!D%>=D 89G*RD:"+*,HQO)SS;8VV.V%A%/7&L_[L:^ "BC7
M5.'O$L1*0JJ*RDO@ITSP% &*FZS1QJ#(',96#@A9G)P6UQ)9B!BCW" ZV34+
M?4+Z!7U!XS0'\]S%MCP+>K6L3T/E!T:$%>J8"GTSI%<5 =MUAK:Q=7FN*96)
M\_Y(%?8?8H[YBMBL5#8EBT'G_,?9Y^05 U2,=%!Y?1K5<6L@^\S6+\)A["(Z
M&\'D5#*JDE&5C%)N##/51>%DK:X[R#%O-+LO8)#I4A;M;%:,5[L-D+,NU@CD
M3%5S4P5GKR?7S_S 6S,U8\@^9MN:H9S$;/AEF.H@18?<?@;D CMBE)<&_\#*
M XHC:,<_X7Q(X2.+?:CO\$D*V\S/JH0!<YMP,%QW)2+VE:M>,5A]%,\K\5")
MATH\*!,FAWB@"L$\I<FH%%RJ#L0\2S^5K=E5NPT7^YND)_D/^QA&=56O^33S
M*$%*( J(FPH)'YQ\IU83H0=6!/7HP/#P0%#[-AI/U7S#-R6(4N1CI-9,6-U]
M0I619BEW-()?9"%VSTDXH=I5 %GX%<?"N5P^8=O!3;Y+WZN"[<VQAI=&-I'N
MZ-<$Y"M;TDFG:LD^$% 1[%LH%KIOECQKFTUB=.<M"ORR>-*%=8PNK=N*2M@G
M1,#C-E!]-_%E]-]$>U/X'GQ"OL2()-!HF2TKL\SR@(BK^K@DJAMF7^CV5@LH
M3&HJO*^475X@$[- D?9!XG(3:<EF-7F#/BY8(=1EW@4CFT[3KD8VE:J!1F1*
MLGY.MS"I2ESOJY3;&KI$=@ZKD$OVM #V<AG:S^ -"HU#8H:]+.(;FHB&KQ1P
M(;S)L2:CUZ!\P']*D?D*0!]]/UH"'5V%NKCZ]26 BG(^.\!1M%XR9A9,_7L8
MS1 J!6::6L/ 3<:"NP<'&?[SU<:0B\SOM< J6X_<=!UH3EPP=<"4F^CR^$D4
MB$&&_3RUDP7GA@\;\*VR>UJ(:5CH_)-\F1L8$E:VFP-2(YL]6F"5PUJ5F1,@
M:252J*>.;,.MB$[U?96.Z"CW$]P!)F*/P2$4N&$)-H3X,94-Z?''1GHHI0W^
M0!4&G12WH$1H<.+=8T1L!@FQ#O:AZ KBO:@N\T&LZE+G2H.FS_(2R  OYN6[
MUW__OR\RO)+8TI1!KA]@T4R42,V_D*GL8G%"#KACLY>1L+ZEB1 ;MVDB4Y#-
M^G5EQIA4*8-+VV1=D=6A78[# L;RT!>!)SUU")#+-Y2M@+41N0539J%PD(=9
M\F_JVB<-"V0R2.JS$_-O$TZPG5'[ =PMZG4SE,]CG1.WB/UQ FQ&%21R'3-I
M&PH?-LF[6&,VD#],C_8R'EB>C%-!EAT19-E]DRL53U-*5JY>V4^9<+E<$?I4
MZ96GW87T2LDAM\^N7)W<<2,6LS-L9]ND1SFMS7,>G\L->+;W>LDW*EN-@[A?
M#IH66Y)H33^W#63BC5&A5 [<(V.IMP#X4 >%4+NE-?> _U(7$)4DO8RR@I#R
M^LYYQ;*R1P)AF>=^B8B4NRR4E=9WAF6I63]',]QT>['3_/)1J#U1!X(!!.!%
MM%^,XD(=A94YB/V<\D/CIC FU*1FC!I:9H[G :QO.%>N;"0;-)?O@XZQ@#RQ
M&AOC\[?=8&-(&W!C: QDA9M#8YBSI X7)C)&97X>T*I^4Q? C"\JO4:Y@W64
M:S&DR'%'U:-HF,44E3.[O\%3OH=<CMTF)S=^&D?(%U4;-[!!P98E0RD91S,+
M_W]N1\4")37&J;!LF Q8Z=VE7JKYB(E(=1'%'YDK6X%3 QCJK)HD=%E61]OD
M-(PYD^(D9._ 0*C*H<68%=XGO4$^&\IJ@ZI+L(?QG*U#6:JS317,VE>RO&_G
MI'6]D)8;Z9@-C@ZL@=7NNU8]-U)ZGA=$DRF>["! 5*.A7SQ;/'+#1L@#CABC
M3>>VLA& ;KZ<?U PZ!DW/QPBM2$%D7X8Z]P^?>E0'N==?JC%XE>">SH'X2I2
M7^-Q?'6IW_FUB"?6%68%R<:29P.2U4[OM&5S]L_,1ZQJ%9?%87]VT\'XY#?W
M!P98S@CC43<EP]7!U3S!25I8TW&2C-UI7E4A;TSQ?E(@^/Q7XYZK&X(: Z)H
MZS ;\!2\^0+VEN)(MNH#E%@EG %[:CB]DY":_!K17]@@7[8=IO0EO;POM!7P
MB&I*C\?PX1L?PQ*;H:\_?*C!_Z>5A_EMEK EL ' &QF5*V3#D2U"W4W4Z!M:
M ZHJ74(9G?!6<W&T6AQQ3%>#@\DY1!R5!O.8?B/Q5 A.3';?)/Z-6+D(X$+!
M?>XORNWAJ2L3'Q<>*$;2)ABT3&55#G7DA!V=Z/.$E<"F$<42H+[*?2/%K>WD
M@1',O:+TZT$<)8G$1=<]4U56,AU^[IEK=.QNKV4-YH. @Y)@:$8)\.R*21[$
MJC2SD/VYN,>.5/MC,3&E(25/6&.LL J&1 BJWP3Z$^'LW;(V%3@2=CL+_.]"
M)JN8W(<33R[/X;]Z+KH-F+0Q+,_U$:"ZV'87T03ZE)K'03Z3I3$:#K"P88K)
M/@Z,,"?RI/;@^6)XA4G^:E01&-83?T&/QJ(_-[I%N)+58Q!,".FT2M&Y8[WT
M:Z+&_0J]V)VYP>L$_4D9^E35PZ_8'*/\%N"RU&(.KS]H.7KOR?NL*]A@^J^[
M)[0 /WP-6VX7%!EV,J.8:*IK^!)9%C+]5X8TD&9E(C=3<1$-"4[U#$N<$@9#
M[H'4\.&#G#O(4B I3XUHQ63KP@3:NI_3:YBNI7[H-.E/!4+._%F&27/J A:$
M@5ZB/>E&*KR >YZC2@O<\2;B)('$3PHM5:E5".Y.OAD4)9!YM867<B$%CIH_
M3&$"B\UK^?:*D1W$JGX3O"Z=&\[N8LJ=D1 5IE-1)8R#<7 B?>-&ZUZDH)P;
M<>OL%=@4MAE4/TF BH693!1*>LQ-GC\R:F'(OV_4R3.>(VD54FZT!]@OU!::
M=48YJARE%JSI48M?C00YJQ:<PV;'\)+6K[E&E&O4F&XMFR%C&,%(V5OJB,Q9
M6*!]+ ]]M%?KP#($&E6&P!%E"%0%.55!SF*(X#@K<I[+C3X*/F7R)D/G,6[R
MRI!>&5,"TIV*&(F0Z6("MD 6%QD4F(G8'ANS+"?]2& 7;S^9@)Z$M)=&@RA@
MVJ+B[[QF6]6XR>H)-<5"S\6>@2:"'GN^W#PAF1 ^-VX;><1^3-'#GRPUMZ6+
M7%RQ9"*26TB<5W^XZ8CDBBH9$5V?.->?&G4+3C2@JZZT9?H1/I!([A -AXD
M$3%"CR$8^]'<#4C]AHV2.('NG./]T8SY=*8964G0(O>UEGSY2<8_SE3\HV;]
M'=%R2S@L%8_HU("<WZYG>.;C2]ROC.<^M_OX;+G,2H2E1A>N<9*Q !.8IC(E
M3S[?GD9'?8MJ#(HH(&Q;-D^3#VK7ND2YMIQV_C2E":9S/:@$;0Y(3XITQ@+%
M(3;]4:ZUT7OA-VX?F-989CN"JN"2>SP500#B-F./.#">%,-G<,/X5A7P/<F)
M7_Y^\_6)Q''VIP+/I."JGF(4HU (LLV@G&LYI=)^S/&<H+KH40Y&LO7T9$\/
M/8**:1"X^DG@8Z59*+:?X.57$$@<R5A1_8(.@Y08O$)OG8$8048T7 #'+/@0
MG)Y,DPLC"W._$ A+]O12$1V*#,RBC:GD^E\G]7KOYRM;@L0:T1J2"SJTZV%0
M2V]5Q=+V,/MAZ]2/37Y 7[U!?%=_@+@FC#9/Q/'>L"(^2 5B.8OD4'?SF0HY
M"SF_K#VDIGY3K!A&EJ=U0"RJ0O:0M^8&H97%,@,L-DG -"1SKZI*S+Q:]:A^
ME61$T]B'S<1@A=3Y8+V4Z3E?^JF<=I$=Z3=BO9G&LF9_)*K? E[G47.DJ4(2
MY*[1RE,L$VR5+V/5&LW7K-P'O3A$00:#U5@=1TWY6[VGK,PNIKQJ.$3]G@4$
M*HS=7UW*8# !+@<HT1.%Q\@KD=#?BZ'?MS)M6H@394NKB2TH*NAS=F,%UM4'
M@3CT50@:X]8#%U2*!.QS<<*9T+BS,!!-\ZW6FG'I"ZW(*;0.\@54 *#;;.BB
MRUL5LLKLH*10@ZK62E;+@J'"9D1^*+F+G^.;.F=#V3%)S;I<^,W"0?*+ HS4
MX\K1^ZV.%%;#W^I37'1=+!"H4<S(X4Y9K7$1WJ"<'BF+!.\QY8_ - -?M3Q3
MII?.$SUFW\6!N=2;E4O]B%SJW.P((V4D4F23;<:X360D;KW<L#@' 6$+M",)
M*SHBSVC7<R]4N7W<MUW@S#&BVFG]Q:;K4>QB  ?F3A/Q1OU#WK<W;I9&6T+-
M\17='G7- '&32ST)Q! /R"&$N%O.\40]M_6+-X%[*U@-Q:,J0Z%3"U#L2K+-
M)YL6'"N02_@_?^EH6EDK*$H$P<//_WH,"J#U&4OO$^L# @;\M1];K_^F'%*'
MM.%[.JV#H(-O6)QVP%1 R':/Q"&-E59,\Z$N2V./+POZ1 ]I4_=T6H=RUJ>'
MM*E[.JU#.>OJ7A_/61_ O:[4FN=Q);:]!KCQ>W*)VWM\B5_6Z_7DU9:$L%?;
M7-%K1:_[3Z_+8J@/FSFB/K_HQXSB-_\U& @Q'+Y]),<D>UV;C1</(9:N_V75
MZ\[)SU?62TZ">K6NF8;S8INQ;V_.X;RXSY'_M&[H7F'H&(]\F[%[]?;#37RC
MC3F2C6[8]4ZCVNK'V>J64U'UHVQU^]&V>@-Y-1O[J7@L:?50,JH%,NJES)-=
M(:-V1%L/= 7N14[=[J/.]?GNI&-WVZ?57NYH+YNM%:*[VLLM][)I.P]+E_MG
MUSR I,BA]HZ+>DY;]>H>[F0GJ<2U\;CS?;Z["=+6:55[>2B4N0>VQ!-$9M8G
MJ3^$$WL=B3R8'WHG+[V#SZ&S2D?<K?]WW?*JT]KXM'K=7G5:!W):;?O4<:K3
M.IC3:G16N 0?[+3VPNB3JVH\HDB_1B#'C?:Z\;#T"L-;7I3U _$ GNK-7[@U
ML;;L7F>%XEZR@8_#6JJC*GTCH@9O)K.KHWKBHW(<NW&ZF39<G=53GU73/FVN
M\,@^V%F1O(;_445PKZD\[V^/6'^XOS6O=RM[7(^0X/G< 9HPIDQ,6X+OEH7G
MC BCNA)I; 0%OF/G/T0$(-E\3##:[$(_((F-@+^'&9<V.F)8&C>>&S7[U/5Z
M&HLI@H$;E?8Y(IKL]A7%WU6=?%Z.GZ7C*.9*_2C,@7"-'Q]MI?MAK>K:!$C3
M@!,$ZLFMYVZ0;+#'&V$S$AIQI#HW!_Y0,+"\JGV6%=2(U'2# !0(2P7D%LD6
M@P@V(:&3"U@BC$FZ\'8D+-BX28[$@*3*>!62Z(VV>1+X2#Y.F N(M,$M;,@;
M1_T1&>P3VS9O=HM5,?<B,D3Q=KN$8T^=ZA@.5;;GXM]'X<DHHNN1F@U< [>/
MG43P/LFK;9=?1 F&0="F@BYDS?J(&/2$N)+Q,Q+?+M3@> ([QB+H1Y**:6*
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M']7-/7 CX"/8PBXUM<TH75>A;(4NF*WD'Y+&D@VO%E/EJ%^*B\2K:442)XX
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M&,82V");9['_34D<]4T5&]TF-KH#G/LJ-KI7KNXJ-EI1P2U1I.K^5,'N_3V
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MZUQ51^XG/TY2*_"!EY$9)GD@W$M4THM>]'Q?Y0<UZ]KX2[V+&;-[ V)+%<S
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M5(':EA;WF$-+#GG;TN(M<QA4F^K-P9JPSISUG?/$/+6\=R\":,(^L1=*C.=
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M(WSG3BPH44XCBC$[$2U4ZX-+,\N_$*VE/:^\L"OV7B(P/;DH%Z/DPO0VI"2
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M4ZAZ#<T)2>'&)&\ '1U8FET4JJ>3 DB!Q12J:V@;A#M[*M1P+24;1@.;*M0
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M?]\97DW.O@[_YMP].6?_O?^WX_&%L[\O?^91P,9L[@CZ_IP\K=E_?1?[JW6
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M:T!A<\<H\A[\P-37:-NA@&<J:Z<=H8U6\'9#@@RH[)02P=B7BF%":XLYG>,
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M?,PJ!K'S=.&$[HI1R+Y,HE',5U>C;V?C@?-W"?3_2 6:N@%8\:+ER*4/_Y'
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M:&&8*JXJK[#1*<,G7 2X'F'1B*@=;4P L.LL>)2N$?#9[Q3G;:4 S#J\9XZ
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MT!Y8"$:.GW(0M7N)*-TSN-PE3UA?FXNOQ*K [&UXCV4CO%\8IGPP;P"VJ+N
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M6(A7+S_^[?CI&([,)4:;6++)"D@.8CD9$F%"3&.>S$?1,YZHKY(&/JP7X+?
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M#*]Y-&,5+]8(@;Z8M80A(?<"W2RB03/8&X&M%X:$((USE,3FW66M)9,$L%.
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M4"P:ZE5OUGV1;0S0E9,FCM.5_%M;$>286<TTS# _#MS9;_L &>'5XS+R@'4
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MZ!CX/%BO.0/YH>1$(G!\,QC?6'8?G$#[-RQ)@JQ.1'$,1P[B? _#Q#]0;TU
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M<HE^-E$H[](;5-M:$#PCG+KI !+D>[[+GPKUJ*K)5YU25(U+2K+7ZT"X4=Q
M>\*&(6S<*[?>AU3 %1V>Y;U3G WH(9O#6(Z?#T;'H,\XW/#PJ9(K)TUL*T)Z
MS2,OG<'6HY&=?SN@W4(GW/7REDVJPM:8S9A_C^O5\O J,'5)>"P6IG%D?\8
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M>))A"55M</,WUX-W1C%T,SC99'@#LB&;-R?NVL?6UOBP,,I:)L68334],+N
M;"AD.NZ8#T)]Q,O;-?PQ3%2JZVG*I@=F+Y 9F% '+Z:=3NZ!&\,R5D\ (RY>
M# IYYEBF(_LY5K_#C<CLWMER-#K-]8'[?NE>/;15T6IV$&TQ4K]T_EI<T^D:
M3U\_N/!G^(0^6' FCN(#;;^9/5$U6'0ZW 4W=+I1W4^?!1,=:LK,_JI:/#K]
M[(JC_NGH2%-F=O[4XO5/1R_EJ'\Z>J\I,_L_:O'ZIZ.7<M0_'7W0E)D]$K5X
M_=/12SGJGXX^*<H.S2Z!6KS^Z>BE')'I2/3V!-MRMI3AB(?FN_XF&)D&MJ3W
MK<GWD(K>LQ!  ZP3EOCH8IL>FMT/S^#(9L36%)/-"=UC_IRQ:]?WKAF?B4@E
MLS>@ II,WIU03R=['6R27=OTSFV^FU?"T\F_*PX(=7#/+MU_1%P?B_KUY]!\
MWZZ$)]1!1QS0Z2!*N9D#\XVZ$IY.!UUQ0*:#QJ^BA^8;=/^?D5^-0S(=#E?W
M[/'Q:;+2C)@OTIM@9!K9DEXZ^69]YW_A?@(J'\WG\^FA^2IL!J:3]<MIIY2[
MJ!X9A<&3#-$Y>P2BL"+1],A\R;6A4.J@2S[(]/&7$!]^Y$;(TL2?Q<-PIA;G
MD?E.:4,ATT?'?)#IXX+%,6.C-4-?3K@001 7OGLG+CO#U1J3OO1$&JPP>F5Z
M9+Z7;C$2F?9(N?[7U#69)^C"OXOX>1!%L##-=_L"!-V,;$,EW0S*:!#5F(_,
M-_4-J![(M 6UA+(5S_ J,.+(? $O Q%*MC6M='*-P@7&\F5-%(J-$;"A HSX
M19_<YBMWFR'H=/*Z?)+I4W50%J7'!Z$HB@^S#%NA7,.?9*2V&]PDJ?<TB8Z%
MMW9Z9+Z6;S,4F7Z)^:;3M^^=N.M-I^^1^;YO!J;3V<MI)Y2[RO=38;FQ2,@:
M,U%[!@NA\SC)4UV.W62VG!Z9?0+;#$6H,U*^^Z/OVW44GI\.]'8P?6]V,]3B
M]4>377%$J"/1]!YCYH_= .L&C-D_4Y^+#>,V]!@_X<SSDVP3F;XW^R+:#T2H
M13*>Z?2<!HF_#I@H*[=R^6]X-G_S$W?EAW%>$%"_&KPWW]);CD*G80INR72K
M\^FE7^2:\9N$K47W,I5Q.GUO=@#4(Y)I<(<\$>KIH>S@RN:?V8]0"4^HE8XX
MH-,!P,!V7:9*75>F[\UN!RL.G2ZZYH12)W]-W<"?^\P[?'=P*.N=:X\!>@GT
M+#,[&1KC4^KJ=3BDTZ&J)'@B2O]55*R'X]-8KWX8H@D%FW;V)UF8?_K>[&W8
MS<?H9L?;EQWYO!N&<>(& =IC^HXU?6_VBMA0R.= 1WS0ZT/,*16*-'UO]F:8
M@>EUL#WMY'(W]P/Y8'9+V)'(]= A+_W4R_/M=/K![&EH.TP_=;<[?NGUJ]M(
MP&'XP>Q.,('2ZVD[NLGEK5*"8N%EPQ?&B\@-=4K%]$.%;Z 1,KE.=LC;[UEO
M9/% HY"9X^<_F+TBE?!D,Z\S#LCFUX:;Z3Q-4LZ4?UXW8=#6\6G*2K]//YB]
M)2\:DTZ7?9,$X9Q NT';"-?<G^$A9_:P&&$)=?A"RNEDGB9@)+ 3L-?2(''#
M1-<5^6!V1U3"T\F^*P[(=* NHP?O-.%F_\$F&)G$MZ277+ZZK-$'LX=@$XQ<
MOBWI)9>O+M/QT7SCWP0CEV]+>M^:?,GL:TW(1TVOV6>P"48^'UK22SX?6M)+
M/A\TN6:WQ084^6QH12WU7- VS$?SA7P#BEJV[:BEEJVNXO;1?+?>@**6;3MJ
MJ66KJZ]]--]C-Z"H9=N.6FK99N:"^1ZZ 44MVW;44LLV.WK-=\P-*&K9MJ.6
M6K:ZDMQ'Z[62O(+>5M12R_:SIM9ZI?S<$]FVHY9:MCHO[I/U>D:>);@5M2A;
MQZ&A5V0='F3T5EQVRE!TTMV&6KJ9"W0,'ESNQ?K)[HH]J!"Q3Q47'PL*J=0[
MY*./^K@-W0#@7&SO_*GBWM0,NX]:ZHX[.MUQMG9]3R8SA-ZERW]C^ 0G<FQU
M!]=/%;>R)KAT>MLU9[0Z$\^@YXQ-/U5<ZTI M%IH1VL_Y'KNSY/EK\SEYZEH
M*J\KIWZJN.DUP>V'%G;!64]T%G&1FSQYB)#&>)/!BHMDBR%ZHL&=\]D7?:;<
M/%4KKJV-D/NBPUWPU@^]398^]TRL5=R(F^#V0VN[X*P'.E.D8$_XNV3ZN>)R
M70'> \V\B'Y*^<<S[HO(*IWPK>[6GRMNX-48E%KHC@M"7?@KAH749*6ZSQ77
M[S(4H<RWH)90MM&,,2\^AS]C(A.6L"BE!AY,/U?<GNLQ"76P0Z[(=#5FBS1P
MDX@_;5:3P?:FG\W793L2F89VP NA7OS57<IC40L$)\Z%&WI!Q+T)"]TP&:Y$
MHV^9EOG9?,MN,P2ASEZ53T)]YH:A-@0_FR_@)E!"_;R(;GIY2Z/O%S]97K$'
M63@IR^WY;+XX-\*EU\BN."/469+R4-8*&,UOP]@-1 I(P7R$H]1+9[@7F&_-
M;88@U."K\DFHSWL6IL7J99/HE+L/HU!GV4T_F^_1#3 )M;=#KNAT)<M8Z7W[
MB_E*O0%%IX-MJ*66[<1G7#0;_&*^)F^"44NW+;UO3;YDD>;BF?'4CV=82RZ6
M6SD^._[_[5UM;^,XDOY%AYO$Z9D)<#C 23J-X+KC7)+NP=V70)%HF]NRZ*4D
M)]Y?OU74JRV6++^E*/< BYUTPJ+J*;X5R6(]PS!4;[@YC+\H%<1G+Y?V?7YG
M>;8>]&$(V?J<T;"1@/7ETGX"0)3F;9]]M>>SO3\501H*3%)4D#@-XU@D\3,Z
M0<_B/;F"PC]?+NU;_L[R?.WS40@=:,,JY:D7FH?@=]%8Z9G)Y0]#'I.RW,*H
MK_WVY=)^$+!7G0ZTM2.6X.L3&"9UA4E5ZWP.0ZVA!QL(5\NJ2#X-F5BKS^!0
M)TO,6*93,S?EN7V^1PN8LT3PET!N#Q$,%T)[$W# 9YZ,3'@/<H/[2>J%Z('#
M!&@_V>!7C*]WLD-WMDWZ-T[6D&*.@<0S=]/#R42+B9? ])!H&<72_^&%J7BY
MM)\C?: &_>OY?;3RWWWY(S3@VW$>!&,-X=HDN9(GYN72?F;YL4KT?-[HE:U[
M/GOTRM:,<X@(QU_E&#85UFN&2_NA]R8QQG%Z%#Q\8R$1\ZL:(T7>TT:1*&*M
M?K,?DV\4Y&NBHT%RK96>IUI4H.SGUQU$76NI \%RKK7>5 F*.,#>).A<2^T/
MB:^5TM=R'F[0$OY&G&FWR/"US8&!,+;(?!Y*H:^Q+!Z;H':/,OY99AWYC3BX
MWB3(V#;'@N1>*]476.* >;.H>RUU$%CNM59]ZB;.2C>+NM=:!X'%UEK/*O'"
M\LXTKBY-?[.?0E'EV=KE4 #X6B!+ZUX?]/;]>Z,@G\UW5IG-RG]Y>,YAZ+D?
M\=0B7CN\J-V:E#<IN'L&:/;]]<X5LK6:.R9@[P6U0ZQ1,A7Z>>I%^2E7^P'B
MF7T?OV^]['W"-8-P]) T_H^)Y\U?AKZ?SO"MC0ANQ%P+7YH%&WX.11Z.,)PI
MG<A_>?F)VEQHV&>& !C^AO>V\YD)Y#QKG"0<_!L</:>7AN+L4?B&H;K(_QYY
MF<8 *0\=?-!B)M,9*&R*YF_O3%:7>X'V:1QU'*IJSO[CL%DX>\LM+)2)^"H7
MR/6U&A57&PWU7@^6:!RZ[%$;9Y]@!\_9\E_ 1XJ_*M O'D6?WS&S4RKC:?40
M"K V#F^Z"W.VZY&A<;;:7>1KC%B\$=E_[R+H6WE N"_D B-9 5WC)&<K><ZV
M^Q" ;K7@7;2 SJ6TQ/R%9XUCG6Z";K7902"YU4IF2Y&GO<MF=4#6./;92MZM
M-CL"0+=:\%& CR9]6(0QPAO -<Z1.LNZU7('!,;;8HG0H,[G=PP8PEF^<11$
M%>5MCYW5YK1V<1C]K(:^>7N[[K2^G)TWSENZ"W.VR)&A.=5J+8<0Y^1!QQ:U
M.-6.QP;+V;+[1DS"G"*SV[[X+D^" %8A#RV.\3G.OG("YF/M?9AR"T^F1'"3
MZBPQ(^B4)>FV4L.#=<BCD!UJ8^T[W.!_Z9;G"-XNU,U\WG/R,(C=V>^D(&?W
MZ:0@:Q-7*06S7EB[)@3%R8.D5CG6+G$,0*Q=Z!B .+N<T>9ULW/P2CH'9F[$
MH\K5QW)G8 [R,.V(7V5W[$[)F.R;C#U@W:O\86=!Y%+0[IR3!X7'^F2?^Z1#
M9F3OC7MLHFKS_?K3[7/R"/1X'V7OD:=CRK][Y<$^RNX('095-FV!"<G#]<-_
M[$0&-(?I3F0 <YCN1 9L>\CM@+Q_^2@53F1PNV[F$YD(7#=SGR>-'V9?@A=Q
M[W.!D0C/ZL=J\H]B&AZ0EWP?ID.?IXU>&;K/$\=FD!OFDZ/=.^ZIV6GW_IXV
M"OOMX52%@=!QED02#-5^.[A:FOW>=Q_E>VUY5I=A7^4'#,H'0KX,8>P&.'YO
M0V\".C?N/9N%.'HX:G$-=AIJX5VK &>OQC5:HPR;HEG,\*V,?2]$;M#/47#C
M):ATXWZFM3P7@!OEFZ=?F499Q,,M_"X&!(T#_78!-R 8@M8<0./(LJTXM_J9
M*:O^TSBVH0MSJ_Z_J:<3H</EHY@KG;R<730VE6W%N=7'[ NQ-,E&"OT;>XC6
M\NP X"N@=,/):Y3A4O1SE.!L'01:Q''^GZ\RPAOEB\;2V2[@&H1S@&!=26D!
M)R#@\CG2S^HM @#6!98J[H3Z#PKV%^'_RWGF(EQ85]L6"2= /"4P>X_T@U8+
M&>%NZ,*ZY+;*\ *Y%IBZ)+R+ O'^/P(\X0OKFFLOS*QZ:^C6A77Y[2#)#"KS
M+[-U"=3!WH*NT"?K@MPJPPOD\TSH"2CS1:NW9(IG$UX$W>N3=6%N$^&%<2M#
M41P*?K*NSXUR_ KK:YAB)DJCO5M6Y]6BO&K?1;[2T'_-Z969(J_QX;1>9LO#
MIY85NEV4&Q;XR9Z?R(4 1]_+1RK@:5FP"1E>( _I:RC]VU!YJ'W+8ETOR*OR
MHYC(.,'L3/?>#/M0R]J\5I97<<QH'E8S9LN"O%*26>F9%X97:0P.<HSK5<OR
MNUJ45^UG[_TN@.$EQ](W$T@QV?_>LN!20EQ0OHJ)%^9.IB'^_-VZRJX78U-7
MX<'35$7EROJ[=65ME.-2^$GXJ0:KG9V_/LL$<WC\;EU6&^6X%?[\[D_Q'BB;
M '^W+J+6LER*/VL/G?"GY>Q5A:"Q=9E<+<2A:JR3%^-D"#WW=+)$F^4CK[$T
MDF6Y%+^16OB)TD6FTM\;ZZ*E%)>RW[Q_*'V=QHF"S4&<V[BQ(A(E^91^E[-T
M5AJXL18V"[&I*J.ZJG\T5KUF(2Y5<T:7D7X2>B']?,#]T5CJR+*]59SCJA>5
M><3U(->VL4*O%N"RK=&@[+V-57F]2*$F2P[:*R^6<<92!,YCP?B*J<&B)%QF
M#Y?SA&'X>%FK"'[T31!'/'R-38IA &G/E'^0RMG2\U[)?Z0+KVQ'>WKYE4)L
MJMZ(L8 =>7 K(R_RP9:W I\R_6'/PFXOS:=\?IF$\3[Y84/%/EQU,7N2\T["
M;-":*<!J@.QYO5M$>LM62 =NV8AS,4MY9:8_"?(N/I4863!F,T\O1^,A'L1!
M7_\>!4)#-9?0^\]_.SO'!#ZU'O8GP:6U737<1 ?GQ0S\IYUR:JT8M[J#4ET[
M%=-:,?;D\[7N8J<F:A1DSGI>> LJE+X4=?W)Q @M4@Z 01H4?!</_]3@$'V5
MWJL,98):1H%9#FJ_PA3:H8I3+?(UXEF\)U=0ZT\P /EZ_\!?<LEH4=!$4UYI
M_$D^']^F&H?@5LC(E[.$A$,@'H7)_/W@Z=7&(M\4=I)W 6"54OE>)"6P2_(U
M5*L<,R <#-\\_5,DQA>*DZJE+ML8(V@Y!P#!'G,LXA@\0"_$74\%B7S,L$'2
M 5"/H$<%A(P:MY1V0/DG+_1T?1JX)%-G$1(.@/CA97=N%8@V7\0FP0HB"$S@
MJ1<^>#*XBZZ]N4R\L!:1!(!HWV*SM(/@"B_]DO806@5/$!(K[5/PCS1.BK2T
M=C7M&7\>Q3]3&<M$Y(?361 [+*AJ$IE:\E0CE[3#=.QO\_:5$S:L,ST6-8M\
M:=PW#/V:"21,>5:8[-$$U08BN%I^CY$)9S07&!863?+CEY4]["7M Q_C>ZP]
M,X1_H1]O/\HK4L)#U:1)NM7 #?(-R:UNE;Y1Z6LR3L.FTU\X >>_T8[U5A6Q
M0JX1.HW&Y1V#V0D 0MK/;I,[.4"L4]>*8HUT_N=-$OF.DNZTT@%!L;94E,A
MABG&W>8Q43!]?W[WPQ1F^%LHCQ->FN2Z?_8T7ES$L%R:*1&0I69:H;=4!_D
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MR\QJW['Z;C3M3!=QWI:RG,;:)IL6[[13#;\$2)<ZZKU(;!!;//,.\BZUXE$
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MR%Y?:)116*)^5VLIV%PB-T;%$GF1 B+LJQ6-:'17R&T'K9!# X]_7O$$MDZ
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M'T%/2WC^0"2^#ZV.'O'^W>SJ%LS7&845A8D\3+T!2>D?R]HFM@:#H6#2TPM
M-1HIP^<J#L#:AI1AUC4-$W3I5N8(3XT!UD[$)9J.4UJ] 75+:V 6J3_ [FL-
MK'P-"5@KKP92FCJ%O5-'>Y)UX4Q-9P/6Z*M^5DMK<L!B5H# N,%EE#[,,WQ,
M)6",L8RC78)[ W0%35%-=1?WON3+(D ;8N"%<4QV9117$S;!>T7YU.U920;6
M+4>3451-&E@W'&60+<4;V^'F]6P1GEI/X)IC#R67:#F<%*T?U.>C!EI]Y9]
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M).AK"=,"/>P.B?DZ3X9=2:+*P</M9ZER8(NFFWO\2M,!4^MHJ:I@=<5D1 E
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M>6X_6\7*RO)\WQ!)$\5SXFZVM94>9^7E9P,Y/BZ"G05"2#ZWGYTJ:PN4N%Z
M5D6.+R$&>@<[26P:B_@TW&+2.+13VUNJN59L1'QIH"S-H\RN+1O;J=Q%N8)X
M1#<; ZDR;Z"^N95 KXR6O%CK:1IA,O+'4%:K5S5$4GDL2^ENZ&3F$V((,V<P
M.VER>'.3*:PTYS7K:REA#I?WFJ JG2U5.ZLY,#(N]XS*NZ9;Y@+A$S'V$K0K
MEY(C(CZ0FR ;)9LQKBC1[Z=MU6/3RY%H1?KH>AO:2:K3QW582:5C7Q7"?5>R
M="+-)]VDJ@"TT0FXP'@<3I,I++ ,E2+E!6J*+Y!<#S79(WKA&C/J3H!7S)>T
M,>/M!)C$>K)/RUBK?$)7%0'3<I2@0V2Q@Z)B,'4:0[.,J3!&H+PPMF+&S",=
M%8BYJH]XQ0([E_59QM>@F/.+G!+/ZAH98SXTD^)10\%CSC]FE$P:0N/#=J*9
M@N0IP>267LE<B:91+CJZVFKJ_C1=):Q*/.*7/E@TH"_*]L$-;#B:S*.-&^RB
M]?<>,5Y6H/>Z@K/T2,6'7^DL(^&(8F1\2\63W"2-T'R]+R+(4Y2W&E=<)FS5
MG33$>]893H,,Q+F+%#R+Y^LJ2@R:9"$($O\E%X%VT<U$#(K" /^XS)$K[4)&
M.9<NW^?L*F-CJ^ZH'F#>XHD]QA_[T0?.<G![N]#D7#5VH%'V -FQ-^EVZT8O
M\_6-AZ7EM;<D :E[\O'9M22):2T8GUM$R%1:8W:RY'3)8RIO)ZH-8/_.XS*>
M)7S+8@.R58J<,#;DQ?+;IUZ\],,XW9<IY:P>3B\[^X%"D,PNX'6SO_;Y7&8L
M?@$D($N>4FK)1M')_#V9A>3M-$'>OQ&1I1]<;X5OWXS,G#ZE_=%Q9#M[J#TG
M,EN(T\O^#NH^#XQ=QD<-9).=>\]89,RH(^G%K92'H&<CD=A"PKYV-@F3++6+
M1V48^]M(9BX8&T41*)"=TRK.9:4X0(T$O(//GI=^2A2E7\-P]>3Y<L4RY8>Q
M);K5*525X(2][>\?Q4E@2G8R4('LH/GM/\X6)]\7B[.KV\N+H^.+RXO;B[,;
M&Y=0GNPPQH</?@U&J>O+//@YO>QLDT;NQHPHM*JD(2R$F<JO]BMD)ZK(["BS
M'[*_^?@SR3(:FV9"#S[ @^WEK*B7C>?97:+XZJ)UL+-=JUF99'8=M;W]S<-D
M*6/?L&  N97PQ4L<%*Y)YB>,W\*B+IR6"Q(DEC6KBYV%W:1&9G$S^]A?X!SF
M,I8X#PR090XDY856G@MHR2V:]%R%"5)[HDB/87\WZ,6 R<,#LC]R5[5;]]F*
M ;+\NJ+)A=G+UKN]19#<@YW=S?X&X'.9^3#G0@*RZ!?()ZF1KMTHL6-XKQ#P
M<ANY08R92KR,)!:_J*N='<"B2FU#*(QB?W](3 1CDZC!!+)GCM/8"U <GX0!
M<<,IW 8M+#4O_D%T#M\Q'1$)?Y2L6\_M9V?7U'A)Z%/;+C+= >P3 =\9FT02
M')#=07RYO3RR D/%M!,_&Q18\NOB4*,D:"F-8VL+29 HMYE4!K*_K53GAKG-
M%&$#V7 WZ5V,_DSQH&>/RI[-AA[$#1*DBK#3NUAZT3>HD7K!L_K8WQ$<YK+>
MZQPP8-:YC._PFP]Q-Q#GKA?EX;3[>)&+ %.49B=C1B0O-9-4?SN)1O$#8X5*
M[ZY6S4HA-*G^MA*/XEV;HDH4:DZ-W%-3T-=..E)Z!=X\)!Y/PD4F$WN/B/@0
MB9>EQFAV4IDN\+&)#_M[3-0IGA@_S/RB=E6LA3 E>CN?K<PFVA!*%NB!U W>
M'78O\HM4JG\E)>J( A-D3TRHA8QT,,L>I>S<*B,$+7/0@BT=K15RHW7H@BUU
MJ3?G,@<RV')M6K,N>50+ZF$ >U=DN<3>7A6Z7EM>[&XV$:EMF86B[X["C*DR
MU[]4?_OO;IWM(@L-R"N\C"2SMB$F$IQXL[Q'J]3'4E])6N$A*KLK9(>POS&T
M@A85X '9')0 ,%N[Y"V,D;';&'.DMM]$@]C?<;T%.2HQ <B^K,<\6MN3KRGR
ML5.\(Z!]U$>4(\ =T@PCLRC=@8]P9*1)JHHK%&8*,R')]K=4(V]'74B4E%Z"
M+KU'4DJT3NAY2I*%'6W)PS_/2+;3="A?L28^4S'%C#+$4W550%40FPET-;PR
M!)IEVR&Q]F24:03&5F732C2F]#DDU1^ =*(3QBJ+;>S1J1;?WB..4=U?."4/
MU=[&[6[V]XEJQ*H #1"AO1&X:FV]CSY\=3_=1T'BK3P_)6;)&[1,H^QHS,45
MM#K'"XN8,M,BI:Y.W*OYC]G?7^H!L[UP <B^; <_6MN:TXBW+=?*WJ, 2SZ9
M%N;)C5;58BG$DR9?_7&<;O/?:5QB)CYD]Z%>Q5!UOZAB.%KB35<L3UT&J0UN
M_U&N%<YL>F% ?:N;8H[RHH#R'N=$@5@[Q$<1Q"34BMZD#P]^EIG<]2\17B07
MP3J,MD5.\Q,WOC_WPZ?*;\6:4O4Q[1S*ERB.$=K54 @V&:G%T_OE&RFQH'(*
M:XQF_]CM&*5E8N*A'KJ& MCTE@64@[=+I8-34OS5CZ_<B$!_5$OAU$/5BR8]
M?1;[8'W+5FJ<:NU5[ANC4:35)K&718DJ&8++QG:(KN_OA;>Y3^;K[W%N .%I
MM'G]($ ICRII$&4/.T%7>!_&#VB9;;I5?FK.UU?HB5GJY=GC+3"=X>S$*.TI
M^IIZ*Q<3E%?;EG)(KG>Q X#-52$04=<*H+&5(N+<)*R77_,0ARIA=2@)/@)0
M-6(9-C_!Z3\]C-7+ 6P8F>RZU+P;P.+6Q4/G#N=R@;JN>23304I</%#,'U(!
M5;O;YBVB:GP/K3A**H3B?S6)Q+\B6WR5+I-YM*N3S9!^64T')Y2H7G;?CT_#
MK>O1U(_<]JHDLQ0/WK_21Y<IB+;:&/HL$1F7D9<=&;][B;OU@IA/!+N'ZGN,
M0=+%]A$]/[_<;OET-)I92E?149?PBPVB=[&&N8T]R$ZS/[SD_B2-DW"+HM)+
MDTB)^#^K6_>9@TICM'%F;)C,LX=S^$*#Q".5"8IZ1@-&1J>78@AIG/\]>&J.
M@P_<*PC<ZT<'8?MR YLBI(.2Y1=XD\6GEHY,[P8<X[--S]3V]GX#\7Z#;BAC
M/ <6*$FCX!I%7KB:K[\'L>MGR:(J=T!QNK*>"@I#&"+ZYA[YZTMOC7*EO"RA
M@FYV#%Y7*;F"2(H2DMJ',&Z7ZX>W'-B=5!]J# Z?!?CX\HD_7N(Q:*&V,V)Z
MDM(P+-Q@P]-_E'\W\@J4)XGYK&ZT&(ZL;U[@;5/V>[_59D#2W&<Q:=4VSJ^C
M4;69N &'UK69<4_45#%5OOZFMP#UDA@!J$NV*5-#2!D]7+&H,Z:W(7.M<N4@
M^&]ZT2Q2I"NPB3QEU*)5F0S<^FL1R*"_E)&@'1(4"ML0FH+>.$$T1$)P:ZF[
MK> CO..+2ZR2N> CR&7')UA"C2S$-7Q"47L.(1/)*%H2=(5D,LK1FMM1+Y:4
MD,P^\3U:D:Q /)T2O8-EXO\(HQ\71&S%FU&*^%H'.QJ]DI:%^_0-G_^11S+(
MX$.%A%>1*CH2,!A=[;AA5!>UY-JWY[$M=Y(PWA.,[6O*%/R(HKLP1I<V+<(B
MJ +&- \':!=Y1WC-XP.L9*F)CWVN@!,W.R+-#R'V<UEQZR8A"8JUD'2KG1#8
MGDPWF?S7#,5UF]>B(%-V#W,>I(0!-VZ>D.Z;&_U 1$&=,RK_,(LXF;YVY+MB
MNO/:3*A*$%_&X'>T%;*8L?DBP"N2$,4AO]G4CCR7+=H=*;M4GNR5).YD)]RP
M3DK]@!"CD>A=J>DVE73SXB,+FC@G03$%HN3!-WJPTJ<B.#%6&RKE! 4GN6J#
MXYZQX"P_7>=0</BRZ[>-172O5\BP)[9/L$3&/FD1NR"$R =4<@@[$C*3IDL)
M;U%Q9V"@OD8A5[W+[V@'S-%RF6Y3WTW0ZA3APV/I94<'_ME'NQ01U9SY3 @<
MV*8^82V5"YT<_A./U\W.>XE)T?'++?ZV. 6-J+>=\M'L8P]_F>E!J-#;4E7L
M<)T\D73)P:KXL5(E-I.-A0EII,>P ['DM1!(HZ6=B-CS- J\K(9(@)\HS^0G
M\12P.QGQ 58&D>?+1I$\[QD]G-_L),MT8T1RT%YL'Z+P,<\ (H3 Z>5\L:T>
MZ5!%3$'V@Z8DT(' >H9)2(E0X<L1KPB\D":G"-J@+,G6)LF^S+_D#^2 %&C>
MM1TS;P4B*UM!U5&3,<G3IR86@U-<*I*OB+TF.X_N%*I3S[AY%23K23*@+9&/
M;XW+X.3*[^!4]D8@LP5^<+I[(WCYKP.V_AZ %MYFJH4)JN.K$B77>V/?S'Y]
MK0[OQP:0_OQ#K=6JMADX +Y8M6D;%J?XKKP52S2('2L)ARH92Y9,=W# Y$)%
MY 8 !TYDJA-U!0>HHABI*D#T(#(&LV. XZ\P[:5IQPC'H6F!B)Q*4H!5%5A9
MJ/],#R5O1#ONCA?X1E^S"=:[(?6&M&-$:E![&[DK/$G1#WXX%:,/" A"AAN<
M.SLV,^H%H 939H"**0J8G-I1/C631,CD47O\\LW]5QB=^&XL*KVC,(HS@W8_
M[NF[<K=B9PC%D2SA+?13A>*U0:JT09O;7QD;(_#EZ"'3*:W^$4;;,$"WV;OU
MY31*-R=NL/)66,2ZQO_E6;&UQG%FEF)L,6,#E.0+A"P5L76>V<>90911%,X.
MQ9&<F:7KC4NEXAFB,9HR;L9>Z[K'Y/>6&7J_I7[B/?AH+]"=AU&1JGI?Q51
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M_'N'D87KWQPI#UM:@MLP<?W!V"GS>>=@[.\V"*O3WMO,S,U;QS/0==_XJ',
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M<7;:AH BW;%\S3;CWQI;-%Z[0F]_H7>L;SDS*T6;3,W]H^OYY/E^'D:9@^0
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M5S?3"$)I6K$36]IIIGA)O5ZH@'LH,4S;P'_]0 BZPY?:W_\/4$L! A0#%
M  @ #'@)3Q50PO((5 ( M)(6  H              ( !     &5X,3 M,2YH
M=&U02P$"% ,4    "  ,> E/) =#H/_E  !SOPP "@              @ $P
M5 ( 97@Q,"TR+FAT;5!+ 0(4 Q0    (  QX"4^,V%?EUN<  +JZ!P *
M          "  5<Z P!E>#$P+3,N:'1M4$L! A0#%     @ #'@)3VG&7F$S
M"   LBX   H              ( !52($ &5X,S$M,2YH=&U02P$"% ,4
M"  ,> E/6V]3RBX(  #R+0  "@              @ &P*@0 97@S,2TR+FAT
M;5!+ 0(4 Q0    (  QX"4]LXCA[! 4  (02   *              "  08S
M! !E>#,R+3$N:'1M4$L! A0#%     @ #'@)3_7^1H$)!0  FQ(   H
M         ( !,C@$ &5X,S(M,BYH=&U02P$"% ,4    "  ,> E/1B1RGU%,
M 0!-N X $P              @ %C/00 ='AM9"TQ,'%?,#8S,#$Y+FAT;5!+
M 0(4 Q0    (  QX"4\@OF13IA,  /[?   1              "  >6)!0!T
M>&UD+3(P,3DP-C,P+GAS9%!+ 0(4 Q0    (  QX"4]GI!>X$@T  #VT   5
M              "  ;J=!0!T>&UD+3(P,3DP-C,P7V-A;"YX;6Q02P$"% ,4
M    "  ,> E/*!]R8A$O  !\90, %0              @ '_J@4 ='AM9"TR
M,#$Y,#8S,%]D968N>&UL4$L! A0#%     @ #'@)3^TLD^. C0   F<& !4
M             ( !0]H% '1X;60M,C Q.3 V,S!?;&%B+GAM;%!+ 0(4 Q0
M   (  QX"4]1;?T4"4<  (?\!  5              "  ?9G!@!T>&UD+3(P
D,3DP-C,P7W!R92YX;6Q02P4&      T #0 4 P  ,J\&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
